source	gene	environment	description	evidence	publication_url	_idpmkb	SMO	NA	Some studies have demonstrated activity of sonic hedgehog pathway inhibitors in a subset of medulloblastomas harboring alterations in this pathway.	1	http://www.ncbi.nlm.nih.gov/pubmed/24951114	AVv-QfaaSS-TIFzzUKzXpmkb	PTCH1	NA	The W844C mutation is associated with resistance to Vismodegib in basal cell carcinoma.	1	http://www.ncbi.nlm.nih.gov/pubmed/23662017	AVv-QP_cSS-TIFzzUKxApmkb	KIT	NA	"The V654A c-KIT kinase domain mutation has been associated with imatinib-resistant GIST relapse, representing  about 47% of all GIST secondary mutations. GIST harboring KIT V654A is still sensitive to Sunitinib and Sorafenib. "	1	http://www.ncbi.nlm.nih.gov/pubmed/17363509	AVv-PNnsSS-TIFzzUKpSpmkb	ERBB2	NA	The ERBB2 p.V842I mutation has been previously reported in several cancer types and has been reported to be an activating mutation. The potential for these mutations to be used for selection of patients to targeted therapies continues to be evaluated.	2	http://www.ncbi.nlm.nih.gov/pubmed/26320869	AVv-Op7oSS-TIFzzUKkApmkb	DNMT3A	NA	"In AML, mutations in DNMT3A are associated with an overall poor survival outcome and a shortened event-free survival. p.R882 is a highly recurrent mutation in DNMT3A."	1	http://www.ncbi.nlm.nih.gov/pubmed/26234722	AVv-Oa_nSS-TIFzzUKiNoncokb	TSC2	Everolimus	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://www.ncbi.nlm.nih.gov/pubmed/16981987	AVv-M3S-SS-TIFzzUJ7ioncokb	TSC1	Everolimus	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://www.ncbi.nlm.nih.gov/pubmed/26831717	AVv-M3ZySS-TIFzzUJ7joncokb	TSC1	Everolimus	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://www.ncbi.nlm.nih.gov/pubmed/16981987	AVv-M3acSS-TIFzzUJ7koncokb	ROS1	Crizotinib	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/25264305	AVv-M7zKSS-TIFzzUJ8aoncokb	ROS1	Cabozantinib	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/26673800	AVv-M7ygSS-TIFzzUJ8Zoncokb	RET	Vandetanib	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/23578175	AVv-NSy9SS-TIFzzUKCDoncokb	RET	Cabozantinib	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://meetinglibrary.asco.org/content/147349-156	AVv-NSyUSS-TIFzzUKCConcokb	RAF1	Sorafenib	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://www.ncbi.nlm.nih.gov/pubmed/24569458	AVv-NTDMSS-TIFzzUKCEoncokb	PTEN	Olaparib	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://www.ncbi.nlm.nih.gov/pubmed/20944090	AVv-M0SRSS-TIFzzUJ7Uoncokb	PTEN	LY3023414 + Enzalutamide	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://www.ncbi.nlm.nih.gov/pubmed/21575859	AVv-M0RwSS-TIFzzUJ7Toncokb	PTEN	"GSK2636771,AZD8186,AZD5363 + Olaparib"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2514	AVv-M0RESS-TIFzzUJ7Soncokb	PTCH1	"Sonidegib,Vismodegib"	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/24900187	AVv-NGB2SS-TIFzzUJ-Goncokb	PTCH1	Sonidegib	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/24900187	AVv-NGA7SS-TIFzzUJ-Foncokb	PIK3CA	"Serabelisib + MLN0128,Alpelisib + LJM716 + Trastuzumab,Buparlisib + Olaparib,AZD5363 + Fulvestrant,AZD8835 + Fulvestrant,Alpelisib + Olaparib,Alpelisib + Everolimus,Alpelisib + Letrozole,Ribociclib + Alpelisib + Letrozole"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://cancerres.aacrjournals.org/content/76/4_Supplement/P3-14-01	AVv-My77SS-TIFzzUJ7Boncokb	PIK3CA	"Buparlisib,Serabelisib,Alpelisib + Fulvestrant,Copanlisib,Fulvestrant + Taselisib,Alpelisib,GDC0077,Buparlisib + Fulvestrant,Taselisib"	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://cancerres.aacrjournals.org/content/75/9_Supplement/PD5-5	AVv-My_QSS-TIFzzUJ7Foncokb	PIK3CA	"Alpelisib + Fulvestrant,Fulvestrant + Taselisib,Buparlisib + Fulvestrant"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	https://www.sabcs.org/Portals/SABCS2016/Documents/SABCS-2016-Abstracts.pdf?v=1	AVv-My9eSS-TIFzzUJ7Concokb	PIK3CA	"Alpelisib + Fulvestrant,Fulvestrant + Taselisib,Buparlisib + Fulvestrant"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://cancerres.aacrjournals.org/content/75/9_Supplement/PD5-5	AVv-My-HSS-TIFzzUJ7Doncokb	PIK3CA	"ARQ 751,AZD5363 + Olaparib"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=d60a28c6-91a3-4a37-a419-d79f96801b30&cKey=edbea616-0ae5-4520-936b-897b8d25b2d6&mKey=%7b19573A54-AE8F-4E00-9C23-BD6D62268424%7d	AVv-My-tSS-TIFzzUJ7Eoncokb	PDGFRB	Imatinib	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/20439456	AVv-M-5OSS-TIFzzUJ8qoncokb	PDGFRB	Imatinib	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/16960151	AVv-M-52SS-TIFzzUJ8roncokb	PDGFRA	Imatinib	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://www.ncbi.nlm.nih.gov/pubmed/24963404	AVv-M_BNSS-TIFzzUJ8uoncokb	PDGFRA	Imatinib	NCCN-compendium listed biomarker for resistance to a FDA-approved drug	NCCN-compendium listed biomarker for resistance to a FDA-approved drug	http://www.ncbi.nlm.nih.gov/pubmed/25905001	AVv-M_EGSS-TIFzzUJ8zoncokb	PDGFRA	Imatinib	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/16754777	AVv-M_YHSS-TIFzzUJ9Soncokb	PDGFRA	Imatinib	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/12944919	AVv-M_IBSS-TIFzzUJ85oncokb	PDGFRA	Dasatinib	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://meetinglibrary.asco.org/content/79120-102	AVv-M_XdSS-TIFzzUJ9Roncokb	NTRK3	"LOXO-101,Entrectinib"	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/26565381	AVv-NSTwSS-TIFzzUKCBoncokb	NTRK2	"LOXO-101,Entrectinib"	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/26565381	AVv-NPznSS-TIFzzUKBtoncokb	NTRK1	LOXO-101	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/26216294	AVv-NNOOSS-TIFzzUKBaoncokb	NTRK1	Entrectinib	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/26565381	AVv-NNO9SS-TIFzzUKBboncokb	NRAS	Selumetinib + Radioiodine Uptake Therapy	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/22105174	AVv-NZKtSS-TIFzzUKDIoncokb	NRAS	Radiation Therapy + Trametinib + Fluorouracil	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://cancerres.aacrjournals.org/content/75/15_Supplement/4693	AVv-NZMKSS-TIFzzUKDKoncokb	NRAS	"Panitumumab,Cetuximab"	NCCN-compendium listed biomarker for resistance to a FDA-approved drug	NCCN-compendium listed biomarker for resistance to a FDA-approved drug	http://www.ncbi.nlm.nih.gov/pubmed/20619739	AVv-NZLdSS-TIFzzUKDJoncokb	NRAS	Cobimetinib + Atezolizumab	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://meetinglibrary.asco.org/content/171295-176	AVv-NZKBSS-TIFzzUKDHoncokb	NRAS	"Binimetinib,Binimetinib + Ribociclib"	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://meetinglibrary.asco.org/content/130034-144	AVv-NZJLSS-TIFzzUKDGoncokb	NF1	Trametinib	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://www.ncbi.nlm.nih.gov/pubmed/26936308	AVv-NHPeSS-TIFzzUJ-concokb	NF1	Trametinib	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://www.ncbi.nlm.nih.gov/pubmed/25243813	AVv-NHQJSS-TIFzzUJ-doncokb	NF1	"Binimetinib,PLX3397"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://www.ncbi.nlm.nih.gov/pubmed/26925841	AVv-NHOdSS-TIFzzUJ-boncokb	MTOR	"Temsirolimus,Rapamycin,Everolimus"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://www.ncbi.nlm.nih.gov/pubmed/27482884	AVv-NBO9SS-TIFzzUJ9moncokb	MTOR	Everolimus	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/24625776	AVv-NBP7SS-TIFzzUJ9noncokb	MET	Crizotinib	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://www.ncbi.nlm.nih.gov/pubmed/25971939	AVv-NYOvSS-TIFzzUKCooncokb	MET	Crizotinib	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://meetinglibrary.asco.org/content/132030-144	AVv-NYZ-SS-TIFzzUKDEoncokb	MET	"Cabozatinib,Capmatinib"	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/21918175	AVv-NYQaSS-TIFzzUKCroncokb	MET	Cabozantinib	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://www.ncbi.nlm.nih.gov/pubmed/27279544	AVv-NYOMSS-TIFzzUKCnoncokb	MDM2	SAR405838	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://www.ncbi.nlm.nih.gov/pubmed/26475335	AVv-NH6qSS-TIFzzUJ-5oncokb	MDM2	"DS-3032b,RG7112"	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://meetinglibrary.asco.org/content/166204-176	AVv-NH6DSS-TIFzzUJ-4oncokb	MAP2K1	"Cobimetinib,Selumetinib,Trametinib"	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/23846731	AVv-NPidSS-TIFzzUKBroncokb	KRAS	"Regorafenib,Panitumumab,Cetuximab"	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/20921462	AVv-NTJdSS-TIFzzUKCHoncokb	KRAS	Radiation Therapy + Trametinib + Fluorouracil	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://cancerres.aacrjournals.org/content/75/15_Supplement/4693	AVv-NTI5SS-TIFzzUKCGoncokb	KRAS	"Panitumumab,Cetuximab"	NCCN-compendium listed biomarker for resistance to a FDA-approved drug	NCCN-compendium listed biomarker for resistance to a FDA-approved drug	http://www.ncbi.nlm.nih.gov/pubmed/21228335	AVv-NTIMSS-TIFzzUKCFoncokb	KRAS	Cobimetinib + Atezolizumab	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://meetinglibrary.asco.org/content/171295-176	AVv-NTKzSS-TIFzzUKCJoncokb	KRAS	"Cabozantinib + Panitumumab,Pembrolizumab,Regorafenib + Panitumumab"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://meetinglibrary.asco.org/content/166423-176	AVv-NTKKSS-TIFzzUKCIoncokb	KIT	"Sunitinib,Sorafenib"	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://www.ncbi.nlm.nih.gov/pubmed/19461405	AVv-NJXwSS-TIFzzUKAFoncokb	KIT	"Sunitinib,Imatinib"	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://meetinglibrary.asco.org/content/82574-102	AVv-NJUBSS-TIFzzUJ__oncokb	KIT	Sunitinib	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://www.ncbi.nlm.nih.gov/pubmed/25592632	AVv-NJftSS-TIFzzUKAToncokb	KIT	Sunitinib	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/17046465	AVv-NJx1SS-TIFzzUKA6oncokb	KIT	Sorafenib	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://www.ncbi.nlm.nih.gov/pubmed/19461405	AVv-NJbySS-TIFzzUKAMoncokb	KIT	Sorafenib	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://meetinglibrary.asco.org/content/80567-102	AVv-NJSLSS-TIFzzUJ_8oncokb	KIT	"Regorafenib,Sunitinib,Imatinib"	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://meetinglibrary.asco.org/content/82574-102	AVv-NI9aSS-TIFzzUJ_concokb	KIT	"Regorafenib,Sunitinib"	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/17046465	AVv-NI8qSS-TIFzzUJ_boncokb	KIT	Regorafenib	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/23177515	AVv-NJc2SS-TIFzzUKAOoncokb	KIT	"Nilotinib,Sorafenib"	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://meetinglibrary.asco.org/content/80567-102	AVv-NJptSS-TIFzzUKAjoncokb	KIT	"Nilotinib,Dasatinib,Sorafenib"	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://meetinglibrary.asco.org/content/80567-102	AVv-NJd6SS-TIFzzUKAQoncokb	KIT	"Nilotinib,Dasatinib,Sorafenib"	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://meetinglibrary.asco.org/content/79120-102	AVv-NJKuSS-TIFzzUJ_woncokb	KIT	"Nilotinib,Dasatinib"	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://meetinglibrary.asco.org/content/79120-102	AVv-NJitSS-TIFzzUKAYoncokb	KIT	Nilotinib	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://www.ncbi.nlm.nih.gov/pubmed/22357255	AVv-NJuxSS-TIFzzUKA1oncokb	KIT	Imatinib	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://www.ncbi.nlm.nih.gov/pubmed/23775962	AVv-NJjbSS-TIFzzUKAZoncokb	KIT	Imatinib	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://meetinglibrary.asco.org/content/82574-102	AVv-NJq6SS-TIFzzUKAwoncokb	KIT	Dasatinib	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://meetinglibrary.asco.org/content/79120-102	AVv-NJEfSS-TIFzzUJ_moncokb	JAK2	Ruxolitinib	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/22899477	AVv-M1T1SS-TIFzzUJ7Voncokb	IDH2	AG-221	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.bloodjournal.org/content/124/21/115?sso-checked=true	AVv-NHd2SS-TIFzzUJ-goncokb	IDH1	AG-120	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://www.aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=789#.WGVjHrYrKjR	AVv-NHn4SS-TIFzzUJ-poncokb	IDH1	AG-120	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/23393090	AVv-NHk3SS-TIFzzUJ-koncokb	IDH1	AG-120	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=789#.WGVjHrYrKjR	AVv-NHu2SS-TIFzzUJ-1oncokb	FLT3	Sorafenib	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/18230792	AVv-M_8jSS-TIFzzUJ9koncokb	FGFR3	"JNJ-42756493,Debio1347"	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://meetinglibrary.asco.org/content/127043-144	AVv-NIeCSS-TIFzzUJ_Woncokb	FGFR3	Debio1347	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://meetinglibrary.asco.org/content/127043-144	AVv-NISdSS-TIFzzUJ_Foncokb	FGFR2	"JNJ-42756493,Debio1347"	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://meetinglibrary.asco.org/content/127043-144	AVv-NIHdSS-TIFzzUJ-7oncokb	FGFR2	"BGJ398,Debio1347"	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://meetinglibrary.asco.org/content/159420-173	AVv-NIGzSS-TIFzzUJ-6oncokb	FGFR1	Ponatinib	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://www.ncbi.nlm.nih.gov/pubmed/22781593	AVv-NImcSS-TIFzzUJ_aoncokb	FGFR1	"AZD4547,Debio1347"	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://meetinglibrary.asco.org/content/128825-144	AVv-NIlwSS-TIFzzUJ_Zoncokb	EZH2	"Tazemetostat,GSK126"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://www.bloodjournal.org/content/126/23/473?sso-checked=true	AVv-NCw7SS-TIFzzUJ94oncokb	ESR1	GDC-0810	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://www.ncbi.nlm.nih.gov/pubmed/24185512	AVv-NMfQSS-TIFzzUKBZoncokb	ESR1	"AZD9496,Fulvestrant"	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/27986707	AVv-NMekSS-TIFzzUKBYoncokb	ERCC2	Cisplatin	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/12208738	AVv-NN3QSS-TIFzzUKBconcokb	ERBB2	Trastuzumab	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/20728210	AVv-NG9gSS-TIFzzUJ-Joncokb	ERBB2	Neratinib	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/20142587	AVv-NG-xSS-TIFzzUJ-Loncokb	ERBB2	Neratinib	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://cancerres.aacrjournals.org/content/76/4_Supplement/PD5-05	AVv-NG85SS-TIFzzUJ-Ioncokb	ERBB2	"Lapatinib + Trastuzumab,Pertuzumab + Trastuzumab,Ado-trastuzumab emtansine,Lapatinib,Trastuzumab"	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/10561337	AVv-NG_aSS-TIFzzUJ-Moncokb	ERBB2	Lapatinib	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/23950206	AVv-NG-HSS-TIFzzUJ-Koncokb	ERBB2	AP32788	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://cancerres.aacrjournals.org/content/76/14_Supplement/2644	AVv-NG8OSS-TIFzzUJ-Honcokb	EGFR	Osimertinib	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-M46mSS-TIFzzUJ8Aoncokb	EGFR	"Gefitnib,Afatinib,Erlotinib"	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/17285735	AVv-M42bSS-TIFzzUJ75oncokb	EGFR	"Erlotinib,Afatinib,Gefitinib"	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/15638953	AVv-M4zRSS-TIFzzUJ70oncokb	EGFR	"Afatinib,Erlotinib,Gefitinib"	NCCN-compendium listed biomarker for resistance to a FDA-approved drug	NCCN-compendium listed biomarker for resistance to a FDA-approved drug	http://library.iaslc.org/search-speaker?search_speaker=17991	AVv-M45YSS-TIFzzUJ7-oncokb	EGFR	"Afatinib,Erlotinib,Gefitinib"	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/23566546	AVv-M49RSS-TIFzzUJ8Eoncokb	EGFR	"Afatinib,Erlotinib,Gefitinib"	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/22190593	AVv-M47OSS-TIFzzUJ8Boncokb	EGFR	"Afatinib,Erlotinib,Gefitinib"	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/21949883	AVv-M48aSS-TIFzzUJ8Doncokb	EGFR	"Afatinib,Erlotinib,Gefitinib"	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/21531810	AVv-M47ySS-TIFzzUJ8Concokb	EGFR	"Afatinib,Erlotinib,Gefitinib"	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/19625781	AVv-M43DSS-TIFzzUJ76oncokb	EGFR	AP32788	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://cancerres.aacrjournals.org/content/76/14_Supplement/2644	AVv-M40hSS-TIFzzUJ72oncokb	CDKN2A	Palbociclib + Letrozole	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://www.ncbi.nlm.nih.gov/pubmed/26715889	AVv-M8dhSS-TIFzzUJ8concokb	CDKN2A	Palbociclib	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://www.ncbi.nlm.nih.gov/pubmed/26380006	AVv-M8cwSS-TIFzzUJ8boncokb	CDK4	"Abemaciclib,Palbociclib"	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://www.ncbi.nlm.nih.gov/pubmed/23569312	AVv-NLb0SS-TIFzzUKBKoncokb	BRCA2	"Rucaparib,Niraparib"	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://meetinglibrary.asco.org/content/150121-156	AVv-NHHzSS-TIFzzUJ-Ooncokb	BRCA2	Olaparib	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://www.ncbi.nlm.nih.gov/pubmed/19553641	AVv-NHKDSS-TIFzzUJ-Poncokb	BRCA1	"Rucaparib,Niraparib"	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://meetinglibrary.asco.org/content/150121-156	AVv-M4jOSS-TIFzzUJ7loncokb	BRCA1	Olaparib	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://www.ncbi.nlm.nih.gov/pubmed/19553641	AVv-M4kWSS-TIFzzUJ7moncokb	BRAF	"Vemurafenib,Dabrafenib,Dabrafenib + Trametinib,Vemurafenib + Cobimetinib,Trametinib"	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/23846731	AVv-Na0OSS-TIFzzUKDXoncokb	BRAF	"Vemurafenib,Dabrafenib,Dabrafenib + Trametinib,Vemurafenib + Cobimetinib"	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/23846731	AVv-Na_WSS-TIFzzUKDqoncokb	BRAF	"Vemurafenib,Dabrafenib,Dabrafenib + Trametinib"	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://www.ncbi.nlm.nih.gov/pubmed/27080216	AVv-Na-2SS-TIFzzUKDponcokb	BRAF	"Vemurafenib + Panitumumab,Encorafenib + Binimetinib + Cetuximab"	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/19884556	AVv-NbJOSS-TIFzzUKD5oncokb	BRAF	Vemurafenib	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://www.ncbi.nlm.nih.gov/pubmed/20818844	AVv-Na9JSS-TIFzzUKDmoncokb	BRAF	Trametinib	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/11091	AVv-Na_3SS-TIFzzUKDroncokb	BRAF	Trametinib	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/22663011	AVv-NbFwSS-TIFzzUKD0oncokb	BRAF	Sorafenib + Temsirolimus	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://www.ncbi.nlm.nih.gov/pubmed/23152448	AVv-NbMvSS-TIFzzUKD-oncokb	BRAF	Selumetinib + Paclitaxel	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/26324360	AVv-Na8lSS-TIFzzUKDloncokb	BRAF	Radiation + Trametinib + Fluorouracil	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://www.ncbi.nlm.nih.gov/pubmed/23438367	AVv-NbA6SS-TIFzzUKDtoncokb	BRAF	BGB659	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://www.ncbi.nlm.nih.gov/pubmed/26343582	AVv-Na02SS-TIFzzUKDYoncokb	ATM	Olaparib	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://www.ncbi.nlm.nih.gov/pubmed/26510020	AVv-M_hcSS-TIFzzUJ9Yoncokb	ARAF	Sorafenib	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://www.ncbi.nlm.nih.gov/pubmed/24569458	AVv-M7nDSS-TIFzzUJ8Xoncokb	ALK	"Crizotinib,Ceritinib"	Standard-of-care biomarker and drug in this indication but not FDA-approved	Standard-of-care biomarker and drug in this indication but not FDA-approved	http://www.ncbi.nlm.nih.gov/pubmed/24670165	AVv-NQEvSS-TIFzzUKBvoncokb	ALK	"Crizotinib,Alectinib,Ceritinib"	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/24670165	AVv-NQD9SS-TIFzzUKBuoncokb	ALK	Crizotinib	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	"Preclinical evidence associates this biomarker to drug response, where the biomarker and drug are NOT FDA-approved or NCCN compendium-listed"	http://www.ncbi.nlm.nih.gov/pubmed/22072639	AVv-NQFdSS-TIFzzUKBwoncokb	AKT1	AZD5363	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	Clinical evidence links biomarker to drug response in this indication but neither biomarker or drug are FDA-approved or NCCN compendium-listed	http://mct.aacrjournals.org/content/14/12_Supplement_2/B109	AVv-NRtoSS-TIFzzUKB_oncokb	ABL1	"Nilotinib,Imatinib,Dasatnib"	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/11287973	AVv-NWnXSS-TIFzzUKCioncokb	ABL1	"Dasatinib,Imatinib"	FDA-approved biomarker and drug in this indication	FDA-approved biomarker and drug in this indication	http://www.ncbi.nlm.nih.gov/pubmed/17496201	AVv-NWoFSS-TIFzzUKCjmolecularmatch	YES1	Trastuzumab	YES1 Increased Expression confers resistance to Trastuzumab in patients with Neoplasm of lung	YES1 Increased Expression confers resistance to Trastuzumab in patients with Neoplasm of lung	http://cancerres.aacrjournals.org/content/76/14_supplement/4392.short	AVv-NnOOSS-TIFzzUKUSmolecularmatch	YES1	Enmd-2076	YES1 confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	YES1 confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20406842	AVv-No61SS-TIFzzUKW6molecularmatch	Wild-Type RB1	Pd-0332991	Wild-Type RB1 confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	Wild-Type RB1 confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24765199	AVv-NqDnSS-TIFzzUKY1molecularmatch	Wild-Type RB1	Ly2835219	Wild-Type RB1 confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	Wild-Type RB1 confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24919854	AVv-Nq02SS-TIFzzUKaCmolecularmatch	Wild-Type NRAS	Cetuximab	Wild-Type NRAS confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	Wild-Type NRAS confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NpUZSS-TIFzzUKXhmolecularmatch	Wild-Type KRAS	Panitumumab	Wild-Type KRAS confers sensitivity to Panitumumab in patients with Neoplasm of colorectum	Wild-Type KRAS confers sensitivity to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NqOfSS-TIFzzUKZHmolecularmatch	Wild-Type KRAS	Cetuximab	Wild-Type KRAS confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	Wild-Type KRAS confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NpVKSS-TIFzzUKXimolecularmatch	VEGFR	Nintedanib	VEGFR confers sensitivity to Nintedanib in patients with Neoplasm of colorectum	VEGFR confers sensitivity to Nintedanib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25015210	AVv-NqaLSS-TIFzzUKZZmolecularmatch	VEGFR	Famitinib	VEGFR confers sensitivity to Famitinib in patients with Neoplasm of colorectum	VEGFR confers sensitivity to Famitinib in patients with Neoplasm of colorectum	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.513	AVv-NorHSS-TIFzzUKWimolecularmatch	VEGFR	Enmd-2076	VEGFR confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	VEGFR confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20406842	AVv-No8FSS-TIFzzUKW8molecularmatch	VEGFR	Cabozantinib	VEGFR confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	VEGFR confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NqJmSS-TIFzzUKY_molecularmatch	VEGFD	Nintedanib	VEGFD confers sensitivity to Nintedanib in patients with Neoplasm of colorectum	VEGFD confers sensitivity to Nintedanib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25015210	AVv-Nqa7SS-TIFzzUKZamolecularmatch	VEGFD	Famitinib	VEGFD confers sensitivity to Famitinib in patients with Neoplasm of colorectum	VEGFD confers sensitivity to Famitinib in patients with Neoplasm of colorectum	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.513	AVv-NoruSS-TIFzzUKWjmolecularmatch	VEGFC	Nintedanib	VEGFC confers sensitivity to Nintedanib in patients with Neoplasm of colorectum	VEGFC confers sensitivity to Nintedanib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25015210	AVv-NqblSS-TIFzzUKZbmolecularmatch	VEGFC	Famitinib	VEGFC confers sensitivity to Famitinib in patients with Neoplasm of colorectum	VEGFC confers sensitivity to Famitinib in patients with Neoplasm of colorectum	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.513	AVv-NosTSS-TIFzzUKWkmolecularmatch	VEGFB	Nintedanib	VEGFB confers sensitivity to Nintedanib in patients with Neoplasm of colorectum	VEGFB confers sensitivity to Nintedanib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25015210	AVv-NqcNSS-TIFzzUKZcmolecularmatch	VEGFB	Famitinib	VEGFB confers sensitivity to Famitinib in patients with Neoplasm of colorectum	VEGFB confers sensitivity to Famitinib in patients with Neoplasm of colorectum	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.513	AVv-NotrSS-TIFzzUKWmmolecularmatch	VEGFA	RO5520985	VEGFA confers sensitivity to RO5520985 in patients with Neoplasm of colorectum	VEGFA confers sensitivity to RO5520985 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/27529514	AVv-NposSS-TIFzzUKYMmolecularmatch	VEGFA	Nintedanib	VEGFA confers sensitivity to Nintedanib in patients with Neoplasm of colorectum	VEGFA confers sensitivity to Nintedanib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25015210	AVv-NqczSS-TIFzzUKZdmolecularmatch	VEGFA	Famitinib	VEGFA confers sensitivity to Famitinib in patients with Neoplasm of colorectum	VEGFA confers sensitivity to Famitinib in patients with Neoplasm of colorectum	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.513	AVv-NoudSS-TIFzzUKWnmolecularmatch	VEGF	RO5520985	VEGF confers sensitivity to RO5520985 in patients with Neoplasm of colorectum	VEGF confers sensitivity to RO5520985 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/27529514	AVv-NppTSS-TIFzzUKYNmolecularmatch	VEGF	Nintedanib	VEGF confers sensitivity to Nintedanib in patients with Neoplasm of colorectum	VEGF confers sensitivity to Nintedanib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25015210	AVv-NqdcSS-TIFzzUKZemolecularmatch	VEGF	Famitinib	VEGF confers sensitivity to Famitinib in patients with Neoplasm of colorectum	VEGF confers sensitivity to Famitinib in patients with Neoplasm of colorectum	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.513	AVv-NovISS-TIFzzUKWomolecularmatch	UGT1A1*93	Irinotecan hydrochloride	UGT1A1*93 confers resistance to Irinotecan hydrochloride in patients with Neoplasm of colorectum	UGT1A1*93 confers resistance to Irinotecan hydrochloride in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19364970	AVv-NsGUSS-TIFzzUKcEmolecularmatch	UGT1A1*60	Irinotecan hydrochloride	UGT1A1*60 confers resistance to Irinotecan hydrochloride in patients with Neoplasm of colorectum	UGT1A1*60 confers resistance to Irinotecan hydrochloride in patients with Neoplasm of colorectum	http://emedicine.medscape.com/article/1790367-overview#a3	AVv-NsHlSS-TIFzzUKcGmolecularmatch	UGT1A1*6	Irinotecan hydrochloride	UGT1A1*6 G71R confers resistance to Irinotecan hydrochloride in patients with Neoplasm of colorectum	UGT1A1*6 G71R confers resistance to Irinotecan hydrochloride in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19364970	AVv-NsFpSS-TIFzzUKcDmolecularmatch	UGT1A1*27	Irinotecan hydrochloride	UGT1A1*27 P229Q confers resistance to Irinotecan hydrochloride in patients with Neoplasm of colorectum	UGT1A1*27 P229Q confers resistance to Irinotecan hydrochloride in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19364970	AVv-NsFESS-TIFzzUKcCmolecularmatch	UGT1A1	Irinotecan hydrochloride	UGT1A1 D103Y and UGT1A1 UGT1A1*28 confers an unfavorable response to Irinotecan hydrochloride in patients with Neoplasm of colorectum	UGT1A1 D103Y and UGT1A1 UGT1A1*28 confers an unfavorable response to Irinotecan hydrochloride in patients with Neoplasm of colorectum		AVv-NsYXSS-TIFzzUKchmolecularmatch	TYMS	Trifluridine	TYMS confers sensitivity to Trifluridine and Tipiracil in patients with Neoplasm of colorectum	TYMS confers sensitivity to Trifluridine and Tipiracil in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/15010854	AVv-NsXKSS-TIFzzUKcfmolecularmatch	TSC2	Everolimus	TSC2 Loss confers sensitivity to Everolimus in patients with Neoplasm of lung	TSC2 Loss confers sensitivity to Everolimus in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23332287	AVv-NnOxSS-TIFzzUKUTmolecularmatch	TRIM33–RET	Cabozantinib	TRIM33–RET confers sensitivity to Cabozantinib in patients with Neoplasm of lung	TRIM33–RET confers sensitivity to Cabozantinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23533264	AVv-NnPWSS-TIFzzUKUUmolecularmatch	TPM3-ROS1	Pf-06463922	TPM3-ROS1 confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	TPM3-ROS1 confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25733882	AVv-NnQYSS-TIFzzUKUWmolecularmatch	TPM3-ROS1	Crizotinib	TPM3-ROS1 confers sensitivity to Crizotinib in patients with Neoplasm of lung	TPM3-ROS1 confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25264305	AVv-NnR5SS-TIFzzUKUZmolecularmatch	TPM3-ROS1	Ceritinib	TPM3-ROS1 confers sensitivity to Ceritinib in patients with Neoplasm of lung	TPM3-ROS1 confers sensitivity to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26917690	AVv-NnQ9SS-TIFzzUKUYmolecularmatch	TPM3-ROS1	Alectinib	TPM3-ROS1 confers sensitivity to Alectinib in patients with Neoplasm of lung	TPM3-ROS1 confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25349307	AVv-NnP2SS-TIFzzUKUVmolecularmatch	TOP1	Sgi-110	TOP1 confers sensitivity to Sgi-110 in patients with Neoplasm of colorectum	TOP1 confers sensitivity to Sgi-110 in patients with Neoplasm of colorectum	http://cancerres.aacrjournals.org/content/76/14_supplement/ct017.short	AVv-NsXySS-TIFzzUKcgmolecularmatch	TNFRSF4	MEDI6469	TNFRSF4 confers sensitivity to MEDI6469 in patients with Neoplasm of colorectum	TNFRSF4 confers sensitivity to MEDI6469 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24177180	AVv-NqksSS-TIFzzUKZpmolecularmatch	TIE1	Cabozantinib	TIE1 confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	TIE1 confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NqP6SS-TIFzzUKZJmolecularmatch	TGFB1	Fluorouracil	TGFB1 Increased Expression confers an unfavorable response to Fluorouracil in patients with Neoplasm of colorectum	TGFB1 Increased Expression confers an unfavorable response to Fluorouracil in patients with Neoplasm of colorectum		AVv-NomJSS-TIFzzUKWamolecularmatch	TFG-ALK	X-976	TFG-ALK confers sensitivity to X-976 in patients with Neoplasm of lung	TFG-ALK confers sensitivity to X-976 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-NnTjSS-TIFzzUKUcmolecularmatch	TFG-ALK	X-396	TFG-ALK confers sensitivity to X-396 in patients with Neoplasm of lung	TFG-ALK confers sensitivity to X-396 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-NnSbSS-TIFzzUKUamolecularmatch	TFG-ALK	X-376	TFG-ALK confers sensitivity to X-376 in patients with Neoplasm of lung	TFG-ALK confers sensitivity to X-376 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-NnUwSS-TIFzzUKUemolecularmatch	TFG-ALK	Pf-06463922	TFG-ALK confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	TFG-ALK confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-NnVtSS-TIFzzUKUfmolecularmatch	TFG-ALK	Crizotinib	TFG-ALK confers sensitivity to Crizotinib in patients with Neoplasm of lung	TFG-ALK confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23401436	AVv-NnWdSS-TIFzzUKUgmolecularmatch	TFG-ALK	Ceritinib	TFG-ALK confers sensitivity to Ceritinib in patients with Neoplasm of lung	TFG-ALK confers sensitivity to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25979929	AVv-NnXuSS-TIFzzUKUimolecularmatch	TFG-ALK	Ap-26113	TFG-ALK confers sensitivity to Ap-26113 in patients with Neoplasm of lung	TFG-ALK confers sensitivity to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21502504	AVv-NnXCSS-TIFzzUKUhmolecularmatch	TFG-ALK	Alectinib	TFG-ALK confers sensitivity to Alectinib in patients with Neoplasm of lung	TFG-ALK confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27413075	AVv-NnTBSS-TIFzzUKUbmolecularmatch	TEK	Cabozantinib	TEK confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	TEK confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NqW7SS-TIFzzUKZUmolecularmatch	STK11	Everolimus	STK11 Loss confers sensitivity to Everolimus in patients with Neoplasm of lung	STK11 Loss confers sensitivity to Everolimus in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23332287	AVv-NnYaSS-TIFzzUKUjmolecularmatch	SRC	Enmd-2076	SRC confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	SRC confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20406842	AVv-No8uSS-TIFzzUKW9molecularmatch	SLC34A2-ROS1	Pf-06463922	SLC34A2-ROS1 confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	SLC34A2-ROS1 confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25733882	AVv-NnZ1SS-TIFzzUKUlmolecularmatch	SLC34A2-ROS1	Crizotinib	SLC34A2-ROS1 confers sensitivity to Crizotinib in patients with Neoplasm of lung	SLC34A2-ROS1 confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25264305	AVv-NnbOSS-TIFzzUKUnmolecularmatch	SLC34A2-ROS1	Ceritinib	SLC34A2-ROS1 confers sensitivity to Ceritinib in patients with Neoplasm of lung	SLC34A2-ROS1 confers sensitivity to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26917690	AVv-NnaiSS-TIFzzUKUmmolecularmatch	SLC34A2-ROS1	Cabozantinib	SLC34A2-ROS1 confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	SLC34A2-ROS1 confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-Np7NSS-TIFzzUKYomolecularmatch	SLC34A2-ROS1	Alectinib	SLC34A2-ROS1 confers sensitivity to Alectinib in patients with Neoplasm of lung	SLC34A2-ROS1 confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25349307	AVv-NnZLSS-TIFzzUKUkmolecularmatch	SDC4-ROS1	Pf-06463922	SDC4-ROS1 confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	SDC4-ROS1 confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25733882	AVv-NndwSS-TIFzzUKUrmolecularmatch	SDC4-ROS1	Crizotinib	SDC4-ROS1 confers sensitivity to Crizotinib in patients with Neoplasm of lung	SDC4-ROS1 confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25264305	AVv-NnfGSS-TIFzzUKUtmolecularmatch	SDC4-ROS1	Ceritinib	SDC4-ROS1 confers sensitivity to Ceritinib in patients with Neoplasm of lung	SDC4-ROS1 confers sensitivity to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26917690	AVv-NnebSS-TIFzzUKUsmolecularmatch	SDC4-ROS1	Alectinib	SDC4-ROS1 confers sensitivity to Alectinib in patients with Neoplasm of lung	SDC4-ROS1 confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25349307	AVv-NndGSS-TIFzzUKUqmolecularmatch	RSPO3	vantictumab	RSPO3 confers sensitivity to vantictumab in patients with Neoplasm of colorectum	RSPO3 confers sensitivity to vantictumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/22753465	AVv-NpgQSS-TIFzzUKX-molecularmatch	RSPO3	Pri-724	RSPO3 confers sensitivity to Pri-724 in patients with Neoplasm of colorectum	RSPO3 confers sensitivity to Pri-724 in patients with Neoplasm of colorectum	http://meetinglibrary.asco.org/content/115980-132	AVv-NpxoSS-TIFzzUKYamolecularmatch	RSPO3	OMP-54F28	RSPO3 confers sensitivity to OMP-54F28 in patients with Neoplasm of colorectum	RSPO3 confers sensitivity to OMP-54F28 in patients with Neoplasm of colorectum	http://mct.aacrjournals.org/content/12/11_supplement/b48.short	AVv-NqR8SS-TIFzzUKZMmolecularmatch	RSPO3	Lgk-974	RSPO3 confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	RSPO3 confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/28100566	AVv-Nq48SS-TIFzzUKaImolecularmatch	RSPO3	ETC159	RSPO3 confers sensitivity to ETC159 in patients with Neoplasm of colorectum	RSPO3 confers sensitivity to ETC159 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26257057	AVv-No2cSS-TIFzzUKWzmolecularmatch	RSPO2	vantictumab	RSPO2 confers sensitivity to vantictumab in patients with Neoplasm of colorectum	RSPO2 confers sensitivity to vantictumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/22753465	AVv-Npg1SS-TIFzzUKX_molecularmatch	RSPO2	Pri-724	RSPO2 confers sensitivity to Pri-724 in patients with Neoplasm of colorectum	RSPO2 confers sensitivity to Pri-724 in patients with Neoplasm of colorectum	http://meetinglibrary.asco.org/content/115980-132	AVv-NpyXSS-TIFzzUKYbmolecularmatch	RSPO2	OMP-54F28	RSPO2 confers sensitivity to OMP-54F28 in patients with Neoplasm of colorectum	RSPO2 confers sensitivity to OMP-54F28 in patients with Neoplasm of colorectum	http://mct.aacrjournals.org/content/12/11_supplement/b48.short	AVv-NqShSS-TIFzzUKZNmolecularmatch	RSPO2	Lgk-974	RSPO2 confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	RSPO2 confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24277854	AVv-Nq6RSS-TIFzzUKaKmolecularmatch	RSPO2	ETC159	RSPO2 confers sensitivity to ETC159 in patients with Neoplasm of colorectum	RSPO2 confers sensitivity to ETC159 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26257057	AVv-No3FSS-TIFzzUKW0molecularmatch	ROS1	Pf-06463922	ROS1 S1986Y confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	ROS1 S1986Y confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27401242	AVv-NnfySS-TIFzzUKUumolecularmatch	ROS1	Pf-06463922	ROS1 S1986F confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	ROS1 S1986F confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27401242	AVv-NnhFSS-TIFzzUKUwmolecularmatch	ROS1	Pf-06463922	ROS1 G2032R confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	ROS1 G2032R confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25733882	AVv-NnkgSS-TIFzzUKU1molecularmatch	ROS1	Crizotinib	ROS1 S1986Y confers resistance to Crizotinib in patients with Neoplasm of lung	ROS1 S1986Y confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27401242	AVv-NngaSS-TIFzzUKUvmolecularmatch	ROS1	Crizotinib	ROS1 S1986F confers resistance to Crizotinib in patients with Neoplasm of lung	ROS1 S1986F confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27401242	AVv-NnhwSS-TIFzzUKUxmolecularmatch	ROS1	Crizotinib	ROS1 G2032R confers resistance to Crizotinib in patients with Neoplasm of lung	ROS1 G2032R confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23724914	AVv-NnjNSS-TIFzzUKUzmolecularmatch	ROS1	Crizotinib	ROS1 D2033N confers resistance to Crizotinib in patients with Neoplasm of lung	ROS1 D2033N confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26673800	AVv-NnlJSS-TIFzzUKU2molecularmatch	ROS1	Cabozantinib	ROS1 exon 38 mutation confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	ROS1 exon 38 mutation confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NpWjSS-TIFzzUKXkmolecularmatch	ROS1	Cabozantinib	ROS1 confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	ROS1 confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NqeOSS-TIFzzUKZfmolecularmatch	ROS1	Cabozantinib	ROS1 Pkinase_Tyr domain confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	ROS1 Pkinase_Tyr domain confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NpXKSS-TIFzzUKXlmolecularmatch	ROS1	Cabozantinib	ROS1 G2032R confers sensitivity to Cabozantinib in patients with Neoplasm of lung	ROS1 G2032R confers sensitivity to Cabozantinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27370605	AVv-NnicSS-TIFzzUKUymolecularmatch	ROS1	Cabozantinib	ROS1 G2032R confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	ROS1 G2032R confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NpX3SS-TIFzzUKXmmolecularmatch	RNF43	vantictumab	RNF43 confers sensitivity to vantictumab in patients with Neoplasm of colorectum	RNF43 confers sensitivity to vantictumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/22753465	AVv-NphpSS-TIFzzUKYAmolecularmatch	RNF43	Pri-724	RNF43 confers sensitivity to Pri-724 in patients with Neoplasm of colorectum	RNF43 confers sensitivity to Pri-724 in patients with Neoplasm of colorectum	http://meetinglibrary.asco.org/content/115980-132	AVv-Npy9SS-TIFzzUKYcmolecularmatch	RNF43	OMP-54F28	RNF43 confers sensitivity to OMP-54F28 in patients with Neoplasm of colorectum	RNF43 confers sensitivity to OMP-54F28 in patients with Neoplasm of colorectum	http://mct.aacrjournals.org/content/12/11_supplement/b48.short	AVv-NqTHSS-TIFzzUKZOmolecularmatch	RNF43	Lgk-974	RNF43 confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	RNF43 confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24277854	AVv-Nq7mSS-TIFzzUKaMmolecularmatch	RNF43	ETC159	RNF43 confers sensitivity to ETC159 in patients with Neoplasm of colorectum	RNF43 confers sensitivity to ETC159 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26257057	AVv-No3oSS-TIFzzUKW1molecularmatch	RICTOR	cc223	RICTOR Amplification confers sensitivity to cc223 in patients with Neoplasm of lung	RICTOR Amplification confers sensitivity to cc223 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26370156	AVv-NnmmSS-TIFzzUKU4molecularmatch	RICTOR	Mln0128	RICTOR Amplification confers sensitivity to Mln0128 in patients with Neoplasm of lung	RICTOR Amplification confers sensitivity to Mln0128 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26370156	AVv-Nnl4SS-TIFzzUKU3molecularmatch	RET	Enmd-2076	RET confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	RET confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20406842	AVv-No9TSS-TIFzzUKW-molecularmatch	RET	Cabozantinib	RET fusion confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	RET fusion confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NpZKSS-TIFzzUKXomolecularmatch	RET	Cabozantinib	RET exon 16 mutation confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	RET exon 16 mutation confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NpZvSS-TIFzzUKXpmolecularmatch	RET	Cabozantinib	RET confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	RET confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NqlRSS-TIFzzUKZqmolecularmatch	RET	Cabozantinib	RET Pkinase_Tyr domain confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	RET Pkinase_Tyr domain confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NpaXSS-TIFzzUKX1molecularmatch	RET	Cabozantinib	RET M918T confers sensitivity to Cabozantinib in patients with Neoplasm of lung	RET M918T confers sensitivity to Cabozantinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21606412	AVv-NnnPSS-TIFzzUKU5molecularmatch	RET	Cabozantinib	RET M918T confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	RET M918T confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NpbTSS-TIFzzUKX2molecularmatch	RB1	Pd-0332991	RB1 confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	RB1 confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24765199	AVv-NqEPSS-TIFzzUKY2molecularmatch	RB1	Pd-0332991	RB1 Loss confers resistance to Pd-0332991 in patients with Neoplasm of colorectum	RB1 Loss confers resistance to Pd-0332991 in patients with Neoplasm of colorectum	http://cancerres.aacrjournals.org/content/75/15_supplement/3104.short	AVv-NsIzSS-TIFzzUKcImolecularmatch	RB1	Ly2835219	RB1 confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	RB1 confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24919854	AVv-Nq1kSS-TIFzzUKaDmolecularmatch	RB1	Ly2835219	RB1 Loss confers resistance to Ly2835219 in patients with Neoplasm of colorectum	RB1 Loss confers resistance to Ly2835219 in patients with Neoplasm of colorectum	http://cancerres.aacrjournals.org/content/75/15_supplement/3104.short	AVv-NsIKSS-TIFzzUKcHmolecularmatch	PTPRK-RSPO3	Lgk-974	PTPRK-RSPO3 confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	PTPRK-RSPO3 confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/28100566	AVv-Nq5jSS-TIFzzUKaJmolecularmatch	PTPRK-RSPO3	ETC159	PTPRK-RSPO3 confers sensitivity to ETC159 in patients with Neoplasm of colorectum	PTPRK-RSPO3 confers sensitivity to ETC159 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26257057	AVv-No10SS-TIFzzUKWymolecularmatch	PTK2	Enmd-2076	PTK2 confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	PTK2 confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20406842	AVv-No92SS-TIFzzUKW_molecularmatch	PTEN	Panitumumab	PTEN Loss confers resistance to Panitumumab in patients with Neoplasm of colorectum	PTEN Loss confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20619739	AVv-NsJcSS-TIFzzUKcKmolecularmatch	PTEN	Mk-2206	PTEN Loss confers sensitivity to Mk-2206 in patients with Neoplasm of lung	PTEN Loss confers sensitivity to Mk-2206 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20571069	AVv-NnoeSS-TIFzzUKU7molecularmatch	PTEN	Everolimus	PTEN Loss confers sensitivity to Everolimus in patients with Neoplasm of lung	PTEN Loss confers sensitivity to Everolimus in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23332287	AVv-NnpFSS-TIFzzUKU8molecularmatch	PTEN	Cetuximab	PTEN Loss confers resistance to Cetuximab in patients with Neoplasm of colorectum	PTEN Loss confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20619739	AVv-NrfoSS-TIFzzUKbCmolecularmatch	PTEN	At13148	PTEN Loss confers sensitivity to At13148 in patients with Neoplasm of lung	PTEN Loss confers sensitivity to At13148 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19351834	AVv-Nnn5SS-TIFzzUKU6molecularmatch	PORCN	Lgk-974	PORCN confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	PORCN confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24277854	AVv-Nq8QSS-TIFzzUKaNmolecularmatch	PORCN	ETC159	PORCN confers sensitivity to ETC159 in patients with Neoplasm of colorectum	PORCN confers sensitivity to ETC159 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26257057	AVv-No4USS-TIFzzUKW2molecularmatch	PMS2	Pembrolizumab	PMS2 confers sensitivity to Pembrolizumab in patients with Neoplasm of colorectum	PMS2 confers sensitivity to Pembrolizumab in patients with Neoplasm of colorectum	http://ascopubs.org/doi/abs/10.1200/jco.2016.34.4_suppl.tps787	AVv-Np3MSS-TIFzzUKYimolecularmatch	PIK3CA	Xl147	PIK3CA H1047R confers sensitivity to Xl147 in patients with Neoplasm of lung	PIK3CA H1047R confers sensitivity to Xl147 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25637314	AVv-NnrzSS-TIFzzUKVAmolecularmatch	PIK3CA	Xl147	PIK3CA H1047L confers sensitivity to Xl147 in patients with Neoplasm of lung	PIK3CA H1047L confers sensitivity to Xl147 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25637314	AVv-NnvNSS-TIFzzUKVFmolecularmatch	PIK3CA	Xl147	PIK3CA E545K confers sensitivity to Xl147 in patients with Neoplasm of lung	PIK3CA E545K confers sensitivity to Xl147 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25637314	AVv-NnyqSS-TIFzzUKVLmolecularmatch	PIK3CA	Xl147	PIK3CA E545G confers sensitivity to Xl147 in patients with Neoplasm of lung	PIK3CA E545G confers sensitivity to Xl147 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25637314	AVv-Nn0_SS-TIFzzUKVPmolecularmatch	PIK3CA	Xl147	PIK3CA E545A confers sensitivity to Xl147 in patients with Neoplasm of lung	PIK3CA E545A confers sensitivity to Xl147 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25637314	AVv-Nn4XSS-TIFzzUKVUmolecularmatch	PIK3CA	Pf-04691502	PIK3CA H1047R confers sensitivity to Pf-04691502 in patients with Neoplasm of lung	PIK3CA H1047R confers sensitivity to Pf-04691502 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21750219	AVv-Nnp0SS-TIFzzUKU9molecularmatch	PIK3CA	Pf-04691502	PIK3CA H1047L confers sensitivity to Pf-04691502 in patients with Neoplasm of lung	PIK3CA H1047L confers sensitivity to Pf-04691502 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21750219	AVv-Nnt3SS-TIFzzUKVDmolecularmatch	PIK3CA	Pf-04691502	PIK3CA E545K confers sensitivity to Pf-04691502 in patients with Neoplasm of lung	PIK3CA E545K confers sensitivity to Pf-04691502 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21750219	AVv-NnxCSS-TIFzzUKVImolecularmatch	PIK3CA	Pf-04691502	PIK3CA E545G confers sensitivity to Pf-04691502 in patients with Neoplasm of lung	PIK3CA E545G confers sensitivity to Pf-04691502 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21750219	AVv-Nnz3SS-TIFzzUKVNmolecularmatch	PIK3CA	Pf-04691502	PIK3CA E545A confers sensitivity to Pf-04691502 in patients with Neoplasm of lung	PIK3CA E545A confers sensitivity to Pf-04691502 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21750219	AVv-Nn2-SS-TIFzzUKVSmolecularmatch	PIK3CA	Panitumumab	PIK3CA H1047R confers resistance to Panitumumab in patients with Neoplasm of colorectum	PIK3CA H1047R confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19223544	AVv-NsKdSS-TIFzzUKcLmolecularmatch	PIK3CA	Panitumumab	PIK3CA E545K confers resistance to Panitumumab in patients with Neoplasm of colorectum	PIK3CA E545K confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20619739	AVv-NsLNSS-TIFzzUKcMmolecularmatch	PIK3CA	Panitumumab	PIK3CA E542K confers resistance to Panitumumab in patients with Neoplasm of colorectum	PIK3CA E542K confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20619739	AVv-NsL3SS-TIFzzUKcNmolecularmatch	PIK3CA	P7170	PIK3CA H1047R confers sensitivity to P7170 in patients with Neoplasm of lung	PIK3CA H1047R confers sensitivity to P7170 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25466244	AVv-NnqeSS-TIFzzUKU-molecularmatch	PIK3CA	P7170	PIK3CA H1047L confers sensitivity to P7170 in patients with Neoplasm of lung	PIK3CA H1047L confers sensitivity to P7170 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25466244	AVv-NnuiSS-TIFzzUKVEmolecularmatch	PIK3CA	P7170	PIK3CA E545K confers sensitivity to P7170 in patients with Neoplasm of lung	PIK3CA E545K confers sensitivity to P7170 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25466244	AVv-NnxlSS-TIFzzUKVJmolecularmatch	PIK3CA	P7170	PIK3CA E545G confers sensitivity to P7170 in patients with Neoplasm of lung	PIK3CA E545G confers sensitivity to P7170 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25466244	AVv-Nn0aSS-TIFzzUKVOmolecularmatch	PIK3CA	P7170	PIK3CA E545A confers sensitivity to P7170 in patients with Neoplasm of lung	PIK3CA E545A confers sensitivity to P7170 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25466244	AVv-Nn3rSS-TIFzzUKVTmolecularmatch	PIK3CA	Mk-2206	PIK3CA H1047R confers sensitivity to Mk-2206 in patients with Neoplasm of lung	PIK3CA H1047R confers sensitivity to Mk-2206 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22648207	AVv-NnshSS-TIFzzUKVBmolecularmatch	PIK3CA	Mk-2206	PIK3CA E545V confers sensitivity to Mk-2206 in patients with Neoplasm of lung	PIK3CA E545V confers sensitivity to Mk-2206 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22648207	AVv-Nnv4SS-TIFzzUKVGmolecularmatch	PIK3CA	Mk-2206	PIK3CA E545Q confers sensitivity to Mk-2206 in patients with Neoplasm of lung	PIK3CA E545Q confers sensitivity to Mk-2206 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22648207	AVv-NnwfSS-TIFzzUKVHmolecularmatch	PIK3CA	Mk-2206	PIK3CA E545K confers sensitivity to Mk-2206 in patients with Neoplasm of lung	PIK3CA E545K confers sensitivity to Mk-2206 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22648207	AVv-NnzRSS-TIFzzUKVMmolecularmatch	PIK3CA	Mk-2206	PIK3CA E545G confers sensitivity to Mk-2206 in patients with Neoplasm of lung	PIK3CA E545G confers sensitivity to Mk-2206 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22648207	AVv-Nn1nSS-TIFzzUKVQmolecularmatch	PIK3CA	Mk-2206	PIK3CA E545D confers sensitivity to Mk-2206 in patients with Neoplasm of lung	PIK3CA E545D confers sensitivity to Mk-2206 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22648207	AVv-Nn2TSS-TIFzzUKVRmolecularmatch	PIK3CA	Mk-2206	PIK3CA E545A confers sensitivity to Mk-2206 in patients with Neoplasm of lung	PIK3CA E545A confers sensitivity to Mk-2206 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22648207	AVv-Nn5uSS-TIFzzUKVWmolecularmatch	PIK3CA	Everolimus	PIK3CA H1047R confers sensitivity to Everolimus in patients with Neoplasm of lung	PIK3CA H1047R confers sensitivity to Everolimus in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25701455	AVv-NntLSS-TIFzzUKVCmolecularmatch	PIK3CA	Everolimus	PIK3CA Amplification confers sensitivity to Everolimus in patients with Neoplasm of lung	PIK3CA Amplification confers sensitivity to Everolimus in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23332287	AVv-Nn6ZSS-TIFzzUKVXmolecularmatch	PIK3CA	Cetuximab	PIK3CA H1047R confers resistance to Cetuximab in patients with Neoplasm of colorectum	PIK3CA H1047R confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19223544	AVv-Nrg_SS-TIFzzUKbEmolecularmatch	PIK3CA	Cetuximab	PIK3CA E545K confers resistance to Cetuximab in patients with Neoplasm of colorectum	PIK3CA E545K confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20619739	AVv-NrhoSS-TIFzzUKbFmolecularmatch	PIK3CA	Cetuximab	PIK3CA E542K confers resistance to Cetuximab in patients with Neoplasm of colorectum	PIK3CA E542K confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20619739	AVv-NriUSS-TIFzzUKbGmolecularmatch	PGF	Famitinib	PGF confers sensitivity to Famitinib in patients with Neoplasm of colorectum	PGF confers sensitivity to Famitinib in patients with Neoplasm of colorectum	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.513	AVv-Nov6SS-TIFzzUKWpmolecularmatch	PDGFRB	Famitinib	PDGFRB confers sensitivity to Famitinib in patients with Neoplasm of colorectum	PDGFRB confers sensitivity to Famitinib in patients with Neoplasm of colorectum	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.513	AVv-NowmSS-TIFzzUKWqmolecularmatch	PDGFRB	Cabozantinib	PDGFRB confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	PDGFRB confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NqslSS-TIFzzUKZ1molecularmatch	PDGFRA	Enmd-2076	PDGFRA confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	PDGFRA confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20406842	AVv-No-cSS-TIFzzUKXAmolecularmatch	PDGFRA	Dasatinib	PDGFRA D842V confers sensitivity to Dasatinib in patients with Neoplasm of lung	PDGFRA D842V confers sensitivity to Dasatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/18794084	AVv-Nn7mSS-TIFzzUKVZmolecularmatch	PDGFRA	Crenolanib	PDGFRA D842V confers sensitivity to Crenolanib in patients with Neoplasm of lung	PDGFRA D842V confers sensitivity to Crenolanib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22745105	AVv-Nn6-SS-TIFzzUKVYmolecularmatch	PDGFRA	Crenolanib	PDGFRA D842I confers sensitivity to Crenolanib in patients with Neoplasm of lung	PDGFRA D842I confers sensitivity to Crenolanib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22745105	AVv-Nn8VSS-TIFzzUKVamolecularmatch	PDGFR	Famitinib	PDGFR confers sensitivity to Famitinib in patients with Neoplasm of colorectum	PDGFR confers sensitivity to Famitinib in patients with Neoplasm of colorectum	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.513	AVv-NoxUSS-TIFzzUKWrmolecularmatch	PDGFR	Enmd-2076	PDGFR confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	PDGFR confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20406842	AVv-No_DSS-TIFzzUKXBmolecularmatch	PDGFR	Cabozantinib	PDGFR confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	PDGFR confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NqzjSS-TIFzzUKaAmolecularmatch	PDCD1LG2	RG7446	PDCD1LG2 confers sensitivity to RG7446 in patients with Neoplasm of colorectum	PDCD1LG2 confers sensitivity to RG7446 in patients with Neoplasm of colorectum	http://cancerres.aacrjournals.org/content/76/14_supplement/2651.short	AVv-NptNSS-TIFzzUKYUmolecularmatch	PDCD1LG2	Pembrolizumab	PDCD1LG2 confers sensitivity to Pembrolizumab in patients with Neoplasm of colorectum	PDCD1LG2 confers sensitivity to Pembrolizumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26994146	AVv-Np9NSS-TIFzzUKYrmolecularmatch	PDCD1LG2	MEDI6469	PDCD1LG2 confers sensitivity to MEDI6469 in patients with Neoplasm of colorectum	PDCD1LG2 confers sensitivity to MEDI6469 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24177180	AVv-Nql9SS-TIFzzUKZrmolecularmatch	PDCD1LG2	MEDI-4736	PDCD1LG2 confers sensitivity to MEDI-4736 in patients with Neoplasm of colorectum	PDCD1LG2 confers sensitivity to MEDI-4736 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25943534	AVv-NqqFSS-TIFzzUKZxmolecularmatch	PDCD1	nivolumab	PDCD1 confers sensitivity to nivolumab and Ipilimumab in patients with Neoplasm of colorectum	PDCD1 confers sensitivity to nivolumab and Ipilimumab in patients with Neoplasm of colorectum	https://doi.org/10.1093/annonc/mdw370.27	AVv-NqY1SS-TIFzzUKZXmolecularmatch	PDCD1	RG7446	PDCD1 confers sensitivity to RG7446 in patients with Neoplasm of colorectum	PDCD1 confers sensitivity to RG7446 in patients with Neoplasm of colorectum	http://cancerres.aacrjournals.org/content/76/14_supplement/2651.short	AVv-NpuSSS-TIFzzUKYVmolecularmatch	PDCD1	Pembrolizumab	PDCD1 confers sensitivity to Pembrolizumab in patients with Neoplasm of colorectum	PDCD1 confers sensitivity to Pembrolizumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26994146	AVv-Np9zSS-TIFzzUKYsmolecularmatch	PDCD1	MEDI6469	PDCD1 confers sensitivity to MEDI6469 in patients with Neoplasm of colorectum	PDCD1 confers sensitivity to MEDI6469 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24177180	AVv-NqmrSS-TIFzzUKZsmolecularmatch	PDCD1	MEDI-4736	PDCD1 confers sensitivity to MEDI-4736 in patients with Neoplasm of colorectum	PDCD1 confers sensitivity to MEDI-4736 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25943534	AVv-NqqrSS-TIFzzUKZymolecularmatch	NTRK2	Cabozantinib	NTRK2 confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	NTRK2 confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-Nq69SS-TIFzzUKaLmolecularmatch	NTRK1	Enmd-2076	NTRK1 confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	NTRK1 confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20406842	AVv-No_rSS-TIFzzUKXCmolecularmatch	NRAS	Selumetinib	NRAS Q61R confers sensitivity to Selumetinib in patients with Neoplasm of lung	NRAS Q61R confers sensitivity to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23200175	AVv-Nn8-SS-TIFzzUKVbmolecularmatch	NRAS	Selumetinib	NRAS Q61Q confers sensitivity to Selumetinib in patients with Neoplasm of lung	NRAS Q61Q confers sensitivity to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23200175	AVv-Nn9sSS-TIFzzUKVcmolecularmatch	NRAS	Selumetinib	NRAS Q61P confers sensitivity to Selumetinib in patients with Neoplasm of lung	NRAS Q61P confers sensitivity to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23200175	AVv-Nn-jSS-TIFzzUKVdmolecularmatch	NRAS	Selumetinib	NRAS Q61L confers sensitivity to Selumetinib in patients with Neoplasm of lung	NRAS Q61L confers sensitivity to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23200175	AVv-Nn_TSS-TIFzzUKVemolecularmatch	NRAS	Selumetinib	NRAS Q61K confers sensitivity to Selumetinib in patients with Neoplasm of lung	NRAS Q61K confers sensitivity to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23200175	AVv-Nn_9SS-TIFzzUKVfmolecularmatch	NRAS	Selumetinib	NRAS Q61H confers sensitivity to Selumetinib in patients with Neoplasm of lung	NRAS Q61H confers sensitivity to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23200175	AVv-NoBQSS-TIFzzUKVhmolecularmatch	NRAS	Selumetinib	NRAS Q61E confers sensitivity to Selumetinib in patients with Neoplasm of lung	NRAS Q61E confers sensitivity to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23200175	AVv-NoB9SS-TIFzzUKVimolecularmatch	NOTCH1	OMP-52M51	NOTCH1 confers sensitivity to OMP-52M51 in patients with Neoplasm of colorectum	NOTCH1 confers sensitivity to OMP-52M51 in patients with Neoplasm of colorectum	http://mct.aacrjournals.org/content/12/11_supplement/b48.short	AVv-NqVrSS-TIFzzUKZSmolecularmatch	NOTCH	OMP-52M51	NOTCH confers sensitivity to OMP-52M51 in patients with Neoplasm of colorectum	NOTCH confers sensitivity to OMP-52M51 in patients with Neoplasm of colorectum	http://mct.aacrjournals.org/content/12/11_supplement/b48.short	AVv-NqWWSS-TIFzzUKZTmolecularmatch	Microsatellite	nivolumab	Microsatellite instability confers sensitivity to nivolumab and Ipilimumab in patients with Neoplasm of colorectum	Microsatellite instability confers sensitivity to nivolumab and Ipilimumab in patients with Neoplasm of colorectum	https://doi.org/10.1093/annonc/mdw370.27	AVv-NqYNSS-TIFzzUKZWmolecularmatch	Microsatellite	RG7446	Microsatellite instability confers sensitivity to RG7446 in patients with Neoplasm of colorectum	Microsatellite instability confers sensitivity to RG7446 in patients with Neoplasm of colorectum	http://cancerres.aacrjournals.org/content/76/14_supplement/2651.short	AVv-NpqaSS-TIFzzUKYPmolecularmatch	Microsatellite	Pembrolizumab	Microsatellite instability confers sensitivity to Pembrolizumab in patients with Neoplasm of colorectum	Microsatellite instability confers sensitivity to Pembrolizumab in patients with Neoplasm of colorectum	http://ascopubs.org/doi/abs/10.1200/jco.2016.34.4_suppl.tps787	AVv-Np51SS-TIFzzUKYmmolecularmatch	Microsatellite	MEDI-4736	Microsatellite instability confers sensitivity to MEDI-4736 in patients with Neoplasm of colorectum	Microsatellite instability confers sensitivity to MEDI-4736 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25943534	AVv-NqoCSS-TIFzzUKZumolecularmatch	MUC5AC	ensituximab	MUC5AC confers sensitivity to ensituximab in patients with Neoplasm of colorectum	MUC5AC confers sensitivity to ensituximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26257057	AVv-No6OSS-TIFzzUKW5molecularmatch	MTOR	Everolimus	MTOR I1973F confers sensitivity to Everolimus in patients with Neoplasm of lung	MTOR I1973F confers sensitivity to Everolimus in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25701455	AVv-NoCpSS-TIFzzUKVjmolecularmatch	MTHFR	Fluorouracil				AVv-NsWhSS-TIFzzUKcemolecularmatch	MST1R	Cabozantinib	MST1R confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	MST1R confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NrCISS-TIFzzUKaWmolecularmatch	MSH6	Pembrolizumab	MSH6 confers sensitivity to Pembrolizumab in patients with Neoplasm of colorectum	MSH6 confers sensitivity to Pembrolizumab in patients with Neoplasm of colorectum	http://ascopubs.org/doi/abs/10.1200/jco.2016.34.4_suppl.tps787	AVv-Np31SS-TIFzzUKYjmolecularmatch	MSH2	Pembrolizumab	MSH2 confers sensitivity to Pembrolizumab in patients with Neoplasm of colorectum	MSH2 confers sensitivity to Pembrolizumab in patients with Neoplasm of colorectum	http://ascopubs.org/doi/abs/10.1200/jco.2016.34.4_suppl.tps787	AVv-Np4cSS-TIFzzUKYkmolecularmatch	MLH1	Pembrolizumab	MLH1 confers sensitivity to Pembrolizumab in patients with Neoplasm of colorectum	MLH1 confers sensitivity to Pembrolizumab in patients with Neoplasm of colorectum	http://ascopubs.org/doi/abs/10.1200/jco.2016.34.4_suppl.tps787	AVv-Np5GSS-TIFzzUKYlmolecularmatch	MET	Panitumumab	MET Amplification confers resistance to Panitumumab in patients with Neoplasm of colorectum	MET Amplification confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/23729478	AVv-NsMbSS-TIFzzUKcOmolecularmatch	MET	Mgcd-265	MET Y971C confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET Y971C confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoDPSS-TIFzzUKVkmolecularmatch	MET	Mgcd-265	MET Y971* confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET Y971* confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoD3SS-TIFzzUKVlmolecularmatch	MET	Mgcd-265	MET Y1021N confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET Y1021N confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoEkSS-TIFzzUKVmmolecularmatch	MET	Mgcd-265	MET Y1021F confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET Y1021F confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoFLSS-TIFzzUKVnmolecularmatch	MET	Mgcd-265	MET Y1021* confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET Y1021* confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoF2SS-TIFzzUKVomolecularmatch	MET	Mgcd-265	MET Y1003N confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET Y1003N confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoGgSS-TIFzzUKVpmolecularmatch	MET	Mgcd-265	MET Y1003F confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET Y1003F confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoHNSS-TIFzzUKVqmolecularmatch	MET	Mgcd-265	MET Y1003* confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET Y1003* confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoIpSS-TIFzzUKVsmolecularmatch	MET	Mgcd-265	MET V989I confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET V989I confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoJSSS-TIFzzUKVtmolecularmatch	MET	Mgcd-265	MET V1014I confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET V1014I confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoJ9SS-TIFzzUKVumolecularmatch	MET	Mgcd-265	MET T1011A confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET T1011A confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoK0SS-TIFzzUKVvmolecularmatch	MET	Mgcd-265	MET T1010I confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET T1010I confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoLfSS-TIFzzUKVwmolecularmatch	MET	Mgcd-265	MET S1018F confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET S1018F confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoMOSS-TIFzzUKVxmolecularmatch	MET	Mgcd-265	MET S1000F confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET S1000F confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoM-SS-TIFzzUKVymolecularmatch	MET	Mgcd-265	MET R992T confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET R992T confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoNnSS-TIFzzUKVzmolecularmatch	MET	Mgcd-265	MET R988H confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET R988H confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoOWSS-TIFzzUKV0molecularmatch	MET	Mgcd-265	MET R988C confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET R988C confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoO_SS-TIFzzUKV1molecularmatch	MET	Mgcd-265	MET R974T confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET R974T confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoQOSS-TIFzzUKV3molecularmatch	MET	Mgcd-265	MET R1005G confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET R1005G confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoQ6SS-TIFzzUKV4molecularmatch	MET	Mgcd-265	MET R1000S confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET R1000S confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoRhSS-TIFzzUKV5molecularmatch	MET	Mgcd-265	MET P996S confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET P996S confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoSOSS-TIFzzUKV6molecularmatch	MET	Mgcd-265	MET P991S confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET P991S confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoS0SS-TIFzzUKV7molecularmatch	MET	Mgcd-265	MET P978L confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET P978L confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoTbSS-TIFzzUKV8molecularmatch	MET	Mgcd-265	MET M1013I confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET M1013I confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoUnSS-TIFzzUKV-molecularmatch	MET	Mgcd-265	MET L986* confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET L986* confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoVMSS-TIFzzUKV_molecularmatch	MET	Mgcd-265	MET L1001H confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET L1001H confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoVzSS-TIFzzUKWAmolecularmatch	MET	Mgcd-265	MET G983V confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET G983V confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoW-SS-TIFzzUKWCmolecularmatch	MET	Mgcd-265	MET G983S confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET G983S confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoXgSS-TIFzzUKWDmolecularmatch	MET	Mgcd-265	MET E994* confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET E994* confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoYFSS-TIFzzUKWEmolecularmatch	MET	Mgcd-265	MET E1012K confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET E1012K confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoYqSS-TIFzzUKWFmolecularmatch	MET	Mgcd-265	MET E1012* confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET E1012* confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoZSSS-TIFzzUKWGmolecularmatch	MET	Mgcd-265	MET D1020G confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	MET D1020G confers sensitivity to Mgcd-265 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/170636-176	AVv-NoZ7SS-TIFzzUKWHmolecularmatch	MET	Gefitinib	MET Amplification confers resistance to Gefitinib in patients with Neoplasm of lung	MET Amplification confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/17463250	AVv-NeRaSS-TIFzzUKFxmolecularmatch	MET	Erlotinib hydrochloride	MET Amplification confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	MET Amplification confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/17463250	AVv-NeQ1SS-TIFzzUKFwmolecularmatch	MET	Crizotinib	MET exon 14 deletion confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET exon 14 deletion confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NodvSS-TIFzzUKWNmolecularmatch	MET	Crizotinib	MET c.3028_3028+5delGGTATA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3028_3028+5delGGTATA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdWoSS-TIFzzUKESmolecularmatch	MET	Crizotinib	MET c.3028_3028+3delGGTAinsCC confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3028_3028+3delGGTAinsCC confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdX6SS-TIFzzUKEUmolecularmatch	MET	Crizotinib	MET c.3028+3A>T confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3028+3A>T confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NoeaSS-TIFzzUKWOmolecularmatch	MET	Crizotinib	MET c.3028+3A>G confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3028+3A>G confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Noe_SS-TIFzzUKWPmolecularmatch	MET	Crizotinib	MET c.3028+3A>C confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3028+3A>C confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NofjSS-TIFzzUKWQmolecularmatch	MET	Crizotinib	MET c.3028+2_3028+4delTATinsACC confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3028+2_3028+4delTATinsACC confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NoiSSS-TIFzzUKWUmolecularmatch	MET	Crizotinib	MET c.3028+2T>G confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3028+2T>G confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NogRSS-TIFzzUKWRmolecularmatch	MET	Crizotinib	MET c.3028+2T>C confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3028+2T>C confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Nog-SS-TIFzzUKWSmolecularmatch	MET	Crizotinib	MET c.3028+2T>A confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3028+2T>A confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NohoSS-TIFzzUKWTmolecularmatch	MET	Crizotinib	MET c.3028+1delG confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3028+1delG confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdVSSS-TIFzzUKEQmolecularmatch	MET	Crizotinib	MET c.3028+1_3028+2delGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3028+1_3028+2delGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdV8SS-TIFzzUKERmolecularmatch	MET	Crizotinib	MET c.3028+1G>T confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3028+1G>T confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Noi7SS-TIFzzUKWVmolecularmatch	MET	Crizotinib	MET c.3028+1G>C confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3028+1G>C confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NojoSS-TIFzzUKWWmolecularmatch	MET	Crizotinib	MET c.3028+1G>A confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3028+1G>A confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdTSSS-TIFzzUKEPmolecularmatch	MET	Crizotinib	MET c.3027_3028+3delAGGTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3027_3028+3delAGGTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdYmSS-TIFzzUKEVmolecularmatch	MET	Crizotinib	MET c.3026_3028+11delAAGGTATATTTCAG confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3026_3028+11delAAGGTATATTTCAG confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdZZSS-TIFzzUKEWmolecularmatch	MET	Crizotinib	MET c.3025_3028+3delGAAGGTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3025_3028+3delGAAGGTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdaFSS-TIFzzUKEXmolecularmatch	MET	Crizotinib	MET c.3025_3028+11delGAAGGTATATTTCAG confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3025_3028+11delGAAGGTATATTTCAG confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdavSS-TIFzzUKEYmolecularmatch	MET	Crizotinib	MET c.3024_3028+20delAGAAGGTATATTTCAGTTTATTGTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3024_3028+20delAGAAGGTATATTTCAGTTTATTGTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdcESS-TIFzzUKEamolecularmatch	MET	Crizotinib	MET c.3024_3028+13delAGAAGGTATATTTCAGTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3024_3028+13delAGAAGGTATATTTCAGTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdcySS-TIFzzUKEbmolecularmatch	MET	Crizotinib	MET c.3022_3028+5delCCAGAAGGTATAinsG confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3022_3028+5delCCAGAAGGTATAinsG confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NddaSS-TIFzzUKEcmolecularmatch	MET	Crizotinib	MET c.3022_3028+1delCCAGAAGG confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3022_3028+1delCCAGAAGG confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Ndd_SS-TIFzzUKEdmolecularmatch	MET	Crizotinib	MET c.3022_3028+14delCCAGAAGGTATATTTCAGTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3022_3028+14delCCAGAAGGTATATTTCAGTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdetSS-TIFzzUKEemolecularmatch	MET	Crizotinib	MET c.3022_3028+13delCCAGAAGGTATATTTCAGTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3022_3028+13delCCAGAAGGTATATTTCAGTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdfWSS-TIFzzUKEfmolecularmatch	MET	Crizotinib	MET c.3021_3028+9delTCCAGAAGGTATATTTCinsGGTATATTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3021_3028+9delTCCAGAAGGTATATTTCinsGGTATATTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Ndf-SS-TIFzzUKEhmolecularmatch	MET	Crizotinib	MET c.3021_3028+9delTCCAGAAGGTATATTTC confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3021_3028+9delTCCAGAAGGTATATTTC confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdgvSS-TIFzzUKEimolecularmatch	MET	Crizotinib	MET c.3021_3028+4delTCCAGAAGGTAT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3021_3028+4delTCCAGAAGGTAT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdhTSS-TIFzzUKEjmolecularmatch	MET	Crizotinib	MET c.3020_3028+2delTTCCAGAAGGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3020_3028+2delTTCCAGAAGGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Ndh0SS-TIFzzUKEkmolecularmatch	MET	Crizotinib	MET c.3017_3028+4delCTTTTCCAGAAGGTAT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3017_3028+4delCTTTTCCAGAAGGTAT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Ndi9SS-TIFzzUKEmmolecularmatch	MET	Crizotinib	MET c.3012_3028+7delAGCTACTTTTCCAGAAGGTATATT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3012_3028+7delAGCTACTTTTCCAGAAGGTATATT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdjiSS-TIFzzUKEnmolecularmatch	MET	Crizotinib	MET c.3009_3028+7delCCGAGCTACTTTTCCAGAAGGTATATT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3009_3028+7delCCGAGCTACTTTTCCAGAAGGTATATT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdkESS-TIFzzUKEomolecularmatch	MET	Crizotinib	MET c.3009_3028+10delCCGAGCTACTTTTCCAGAAGGTATATTTCA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3009_3028+10delCCGAGCTACTTTTCCAGAAGGTATATTTCA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdkkSS-TIFzzUKEpmolecularmatch	MET	Crizotinib	MET c.3005_3028+1delACTACCGAGCTACTTTTCCAGAAGG confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3005_3028+1delACTACCGAGCTACTTTTCCAGAAGG confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdlESS-TIFzzUKEqmolecularmatch	MET	Crizotinib	MET c.3004_3028+3delGACTACCGAGCTACTTTTCCAGAAGGTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.3004_3028+3delGACTACCGAGCTACTTTTCCAGAAGGTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdlmSS-TIFzzUKErmolecularmatch	MET	Crizotinib	MET c.2888-9_2951delTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-9_2951delTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdnuSS-TIFzzUKEvmolecularmatch	MET	Crizotinib	MET c.2888-9_2908delTGTTTTAAGATCTGGGCAGTGAATTAGTTC confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-9_2908delTGTTTTAAGATCTGGGCAGTGAATTAGTTC confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Ndo8SS-TIFzzUKExmolecularmatch	MET	Crizotinib	MET c.2888-6_2888-2delTTTAAinsG confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-6_2888-2delTTTAAinsG confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdqqSS-TIFzzUKE0molecularmatch	MET	Crizotinib	MET c.2888-5_2944delTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-5_2944delTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdsWSS-TIFzzUKE3molecularmatch	MET	Crizotinib	MET c.2888-5_2909delTTAAGATCTGGGCAGTGAATTAGTTCG confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-5_2909delTTAAGATCTGGGCAGTGAATTAGTTCG confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Nds-SS-TIFzzUKE4molecularmatch	MET	Crizotinib	MET c.2888-5_2907delTTAAGATCTGGGCAGTGAATTAGTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-5_2907delTTAAGATCTGGGCAGTGAATTAGTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdtmSS-TIFzzUKE5molecularmatch	MET	Crizotinib	MET c.2888-5_2890delTTAAGATCinsATA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-5_2890delTTAAGATCinsATA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NduISS-TIFzzUKE6molecularmatch	MET	Crizotinib	MET c.2888-52_2927delGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACAinsCC confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-52_2927delGGGGCCCATGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACAinsCC confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdrwSS-TIFzzUKE2molecularmatch	MET	Crizotinib	MET c.2888-44_2891delTGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-44_2891delTGATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdvWSS-TIFzzUKE8molecularmatch	MET	Crizotinib	MET c.2888-42_2888-2delATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-42_2888-2delATAGCCGTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Ndv4SS-TIFzzUKE9molecularmatch	MET	Crizotinib	MET c.2888-3_2888-2insAC confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-3_2888-2insAC confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdzJSS-TIFzzUKFCmolecularmatch	MET	Crizotinib	MET c.2888-35_3011delTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCG confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-35_3011delTCTTTAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAAGTGCCCGAAGTGTAAGCCCAACTACAGAAATGGTTTCAAATGAATCTGTAGACTACCG confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdweSS-TIFzzUKE-molecularmatch	MET	Crizotinib	MET c.2888-33_2888-7delTTTAACAAGCTCTTTCTTTCTCTCTGTinsTTAAAACTG confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-33_2888-7delTTTAACAAGCTCTTTCTTTCTCTCTGTinsTTAAAACTG confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdxCSS-TIFzzUKE_molecularmatch	MET	Crizotinib	MET c.2888-30_2898delAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-30_2898delAACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdxrSS-TIFzzUKFAmolecularmatch	MET	Crizotinib	MET c.2888-30_2888-5delAACAAGCTCTTTCTTTCTCTCTGTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-30_2888-5delAACAAGCTCTTTCTTTCTCTCTGTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NdyWSS-TIFzzUKFBmolecularmatch	MET	Crizotinib	MET c.2888-29_2891delACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-29_2891delACAAGCTCTTTCTTTCTCTCTGTTTTAAGATCT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Ndz4SS-TIFzzUKFDmolecularmatch	MET	Crizotinib	MET c.2888-28_2896delCAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-28_2896delCAAGCTCTTTCTTTCTCTCTGTTTTAAGATCTGGGCA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Nd1TSS-TIFzzUKFFmolecularmatch	MET	Crizotinib	MET c.2888-28_2888-7delCAAGCTCTTTCTTTCTCTCTGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-28_2888-7delCAAGCTCTTTCTTTCTCTCTGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Nd2uSS-TIFzzUKFHmolecularmatch	MET	Crizotinib	MET c.2888-28_2888-3delCAAGCTCTTTCTTTCTCTCTGTTTTAinsAAAC confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-28_2888-3delCAAGCTCTTTCTTTCTCTCTGTTTTAinsAAAC confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Nd3aSS-TIFzzUKFImolecularmatch	MET	Crizotinib	MET c.2888-28_2888-3delCAAGCTCTTTCTTTCTCTCTGTTTTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-28_2888-3delCAAGCTCTTTCTTTCTCTCTGTTTTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Nd4GSS-TIFzzUKFJmolecularmatch	MET	Crizotinib	MET c.2888-28_2888-2delCAAGCTCTTTCTTTCTCTCTGTTTTAA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-28_2888-2delCAAGCTCTTTCTTTCTCTCTGTTTTAA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Nd41SS-TIFzzUKFKmolecularmatch	MET	Crizotinib	MET c.2888-27_2890delAAGCTCTTTCTTTCTCTCTGTTTTAAGATC confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-27_2890delAAGCTCTTTCTTTCTCTCTGTTTTAAGATC confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Nd5jSS-TIFzzUKFLmolecularmatch	MET	Crizotinib	MET c.2888-26_2888-5delAGCTCTTTCTTTCTCTCTGTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-26_2888-5delAGCTCTTTCTTTCTCTCTGTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Nd6RSS-TIFzzUKFMmolecularmatch	MET	Crizotinib	MET c.2888-24_2888-1delCTCTTTCTTTCTCTCTGTTTTAAG confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-24_2888-1delCTCTTTCTTTCTCTCTGTTTTAAG confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Nd67SS-TIFzzUKFNmolecularmatch	MET	Crizotinib	MET c.2888-23_2891delTCTTTCTTTCTCTCTGTTTTAAGATCT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-23_2891delTCTTTCTTTCTCTCTGTTTTAAGATCT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Nd7oSS-TIFzzUKFOmolecularmatch	MET	Crizotinib	MET c.2888-23_2889delTCTTTCTTTCTCTCTGTTTTAAGAT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-23_2889delTCTTTCTTTCTCTCTGTTTTAAGAT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Nd8SSS-TIFzzUKFPmolecularmatch	MET	Crizotinib	MET c.2888-22_2911delCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-22_2911delCTTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Nd9ASS-TIFzzUKFQmolecularmatch	MET	Crizotinib	MET c.2888-22_2888-3delCTTTCTTTCTCTCTGTTTTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-22_2888-3delCTTTCTTTCTCTCTGTTTTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Nd-VSS-TIFzzUKFSmolecularmatch	MET	Crizotinib	MET c.2888-20_2899delTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTG confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-20_2899delTTCTTTCTCTCTGTTTTAAGATCTGGGCAGTG confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Nd_ESS-TIFzzUKFTmolecularmatch	MET	Crizotinib	MET c.2888-20_2898delTTCTTTCTCTCTGTTTTAAGATCTGGGCAGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-20_2898delTTCTTTCTCTCTGTTTTAAGATCTGGGCAGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Nd_tSS-TIFzzUKFUmolecularmatch	MET	Crizotinib	MET c.2888-20_2888-3delTTCTTTCTCTCTGTTTTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-20_2888-3delTTCTTTCTCTCTGTTTTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeAZSS-TIFzzUKFVmolecularmatch	MET	Crizotinib	MET c.2888-20_2888-2delTTCTTTCTCTCTGTTTTAA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-20_2888-2delTTCTTTCTCTCTGTTTTAA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeBMSS-TIFzzUKFWmolecularmatch	MET	Crizotinib	MET c.2888-1G>T confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-1G>T confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeB-SS-TIFzzUKFXmolecularmatch	MET	Crizotinib	MET c.2888-1G>A confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-1G>A confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeCtSS-TIFzzUKFYmolecularmatch	MET	Crizotinib	MET c.2888-18_2888-7delCTTTCTCTCTGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-18_2888-7delCTTTCTCTCTGT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeDdSS-TIFzzUKFZmolecularmatch	MET	Crizotinib	MET c.2888-18_2888-4delCTTTCTCTCTGTTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-18_2888-4delCTTTCTCTCTGTTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeEKSS-TIFzzUKFamolecularmatch	MET	Crizotinib	MET c.2888-17_2953delTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-17_2953delTTTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGATGCAAGAGTACACACTCCTCATTTGGATAGGCTTGTAA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeE5SS-TIFzzUKFbmolecularmatch	MET	Crizotinib	MET c.2888-17_2888-4delTTTCTCTCTGTTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-17_2888-4delTTTCTCTCTGTTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeGPSS-TIFzzUKFdmolecularmatch	MET	Crizotinib	MET c.2888-17_2888-1delTTTCTCTCTGTTTTAAGinsAA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-17_2888-1delTTTCTCTCTGTTTTAAGinsAA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeG3SS-TIFzzUKFemolecularmatch	MET	Crizotinib	MET c.2888-17_2888-1delTTTCTCTCTGTTTTAAG confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-17_2888-1delTTTCTCTCTGTTTTAAG confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeHeSS-TIFzzUKFfmolecularmatch	MET	Crizotinib	MET c.2888-16_2889delTTCTCTCTGTTTTAAGAT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-16_2889delTTCTCTCTGTTTTAAGAT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeIESS-TIFzzUKFgmolecularmatch	MET	Crizotinib	MET c.2888-16_2888-4delTTCTCTCTGTTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-16_2888-4delTTCTCTCTGTTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeIoSS-TIFzzUKFhmolecularmatch	MET	Crizotinib	MET c.2888-16_2888-3delTTCTCTCTGTTTTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-16_2888-3delTTCTCTCTGTTTTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeJMSS-TIFzzUKFimolecularmatch	MET	Crizotinib	MET c.2888-15_2915delTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGAinsT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-15_2915delTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCTACGAinsT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeJvSS-TIFzzUKFjmolecularmatch	MET	Crizotinib	MET c.2888-15_2911delTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-15_2911delTCTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTCGCT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeKRSS-TIFzzUKFkmolecularmatch	MET	Crizotinib	MET c.2888-15_2900delTCTCTCTGTTTTAAGATCTGGGCAGTGA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-15_2900delTCTCTCTGTTTTAAGATCTGGGCAGTGA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeKxSS-TIFzzUKFlmolecularmatch	MET	Crizotinib	MET c.2888-14_2905delCTCTCTGTTTTAAGATCTGGGCAGTGAATTAG confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-14_2905delCTCTCTGTTTTAAGATCTGGGCAGTGAATTAG confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeLYSS-TIFzzUKFmmolecularmatch	MET	Crizotinib	MET c.2888-14_2890delCTCTCTGTTTTAAGATC confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-14_2890delCTCTCTGTTTTAAGATC confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeMfSS-TIFzzUKFomolecularmatch	MET	Crizotinib	MET c.2888-14_2888-4delCTCTCTGTTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-14_2888-4delCTCTCTGTTTT confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeNDSS-TIFzzUKFpmolecularmatch	MET	Crizotinib	MET c.2888-14_2888-3delCTCTCTGTTTTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-14_2888-3delCTCTCTGTTTTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeNjSS-TIFzzUKFqmolecularmatch	MET	Crizotinib	MET c.2888-13_2908delTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTC confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-13_2908delTCTCTGTTTTAAGATCTGGGCAGTGAATTAGTTC confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeOFSS-TIFzzUKFrmolecularmatch	MET	Crizotinib	MET c.2888-13_2888-2delTCTCTGTTTTAA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-13_2888-2delTCTCTGTTTTAA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NeOnSS-TIFzzUKFsmolecularmatch	MET	Crizotinib	MET c.2888-11_2904delTCTGTTTTAAGATCTGGGCAGTGAATTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET c.2888-11_2904delTCTGTTTTAAGATCTGGGCAGTGAATTA confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NePHSS-TIFzzUKFtmolecularmatch	MET	Crizotinib	MET M995Ifs*19 confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET M995Ifs*19 confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NoT-SS-TIFzzUKV9molecularmatch	MET	Crizotinib	MET D1010Y confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET D1010Y confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NoarSS-TIFzzUKWImolecularmatch	MET	Crizotinib	MET D1010N confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET D1010N confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NobUSS-TIFzzUKWJmolecularmatch	MET	Crizotinib	MET D1010H confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET D1010H confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-Nob6SS-TIFzzUKWKmolecularmatch	MET	Crizotinib	MET D1010* confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET D1010* confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-NocjSS-TIFzzUKWLmolecularmatch	MET	Crizotinib	MET Amplification confers sensitivity to Crizotinib in patients with Neoplasm of lung	MET Amplification confers sensitivity to Crizotinib in patients with Neoplasm of lung		AVv-NeSrSS-TIFzzUKFzmolecularmatch	MET	Cetuximab	MET Amplification confers resistance to Cetuximab in patients with Neoplasm of colorectum	MET Amplification confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/23729478	AVv-NrjBSS-TIFzzUKbHmolecularmatch	MET	Cabozantinib	MET confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	MET confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-Nos7SS-TIFzzUKWlmolecularmatch	MET	Cabozantinib	MET Amplification confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	MET Amplification confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-Npb9SS-TIFzzUKX3molecularmatch	MCPH1	Enmd-2076	MCPH1 confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	MCPH1 confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20406842	AVv-NpAQSS-TIFzzUKXDmolecularmatch	MAP2K1	Trametinib	MAP2K1 V211D confers resistance to Trametinib in patients with Neoplasm of lung	MAP2K1 V211D confers resistance to Trametinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23614898	AVv-NeTTSS-TIFzzUKF0molecularmatch	MAP2K1	Trametinib	MAP2K1 Q56P confers sensitivity to Trametinib in patients with Neoplasm of lung	MAP2K1 Q56P confers sensitivity to Trametinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26582713	AVv-NeV8SS-TIFzzUKF4molecularmatch	MAP2K1	Trametinib	MAP2K1 P124L confers resistance to Trametinib in patients with Neoplasm of lung	MAP2K1 P124L confers resistance to Trametinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23614898	AVv-NegdSS-TIFzzUKGHmolecularmatch	MAP2K1	Trametinib	MAP2K1 L115P confers resistance to Trametinib in patients with Neoplasm of lung	MAP2K1 L115P confers resistance to Trametinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27922010	AVv-NelGSS-TIFzzUKGOmolecularmatch	MAP2K1	Selumetinib	MAP2K1 V211D confers resistance to Selumetinib in patients with Neoplasm of lung	MAP2K1 V211D confers resistance to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-NeT7SS-TIFzzUKF1molecularmatch	MAP2K1	Selumetinib	MAP2K1 Q56P confers sensitivity to Selumetinib in patients with Neoplasm of lung	MAP2K1 Q56P confers sensitivity to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26582713	AVv-NeWtSS-TIFzzUKF5molecularmatch	MAP2K1	Selumetinib	MAP2K1 Q56P confers resistance to Selumetinib in patients with Neoplasm of lung	MAP2K1 Q56P confers resistance to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NeY3SS-TIFzzUKF8molecularmatch	MAP2K1	Selumetinib	MAP2K1 P124S confers resistance to Selumetinib in patients with Neoplasm of lung	MAP2K1 P124S confers resistance to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NebtSS-TIFzzUKGAmolecularmatch	MAP2K1	Selumetinib	MAP2K1 P124Q confers resistance to Selumetinib in patients with Neoplasm of lung	MAP2K1 P124Q confers resistance to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NedxSS-TIFzzUKGDmolecularmatch	MAP2K1	Selumetinib	MAP2K1 P124L confers resistance to Selumetinib in patients with Neoplasm of lung	MAP2K1 P124L confers resistance to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NehCSS-TIFzzUKGImolecularmatch	MAP2K1	Selumetinib	MAP2K1 L215P confers resistance to Selumetinib in patients with Neoplasm of lung	MAP2K1 L215P confers resistance to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NejCSS-TIFzzUKGLmolecularmatch	MAP2K1	Selumetinib	MAP2K1 L115P confers resistance to Selumetinib in patients with Neoplasm of lung	MAP2K1 L115P confers resistance to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NeluSS-TIFzzUKGPmolecularmatch	MAP2K1	Selumetinib	MAP2K1 K57N confers sensitivity to Selumetinib in patients with Neoplasm of lung	MAP2K1 K57N confers sensitivity to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25351745	AVv-NeobSS-TIFzzUKGTmolecularmatch	MAP2K1	Selumetinib	MAP2K1 I99T confers resistance to Selumetinib in patients with Neoplasm of lung	MAP2K1 I99T confers resistance to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NeqeSS-TIFzzUKGWmolecularmatch	MAP2K1	Selumetinib	MAP2K1 I111N confers resistance to Selumetinib in patients with Neoplasm of lung	MAP2K1 I111N confers resistance to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NesYSS-TIFzzUKGZmolecularmatch	MAP2K1	Selumetinib	MAP2K1 I103N confers resistance to Selumetinib in patients with Neoplasm of lung	MAP2K1 I103N confers resistance to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-Neu2SS-TIFzzUKGdmolecularmatch	MAP2K1	Selumetinib	MAP2K1 H119P confers resistance to Selumetinib in patients with Neoplasm of lung	MAP2K1 H119P confers resistance to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NewjSS-TIFzzUKGgmolecularmatch	MAP2K1	Selumetinib	MAP2K1 G128D confers resistance to Selumetinib in patients with Neoplasm of lung	MAP2K1 G128D confers resistance to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NeyNSS-TIFzzUKGjmolecularmatch	MAP2K1	Selumetinib	MAP2K1 F129L confers resistance to Selumetinib in patients with Neoplasm of lung	MAP2K1 F129L confers resistance to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-Nez1SS-TIFzzUKGmmolecularmatch	MAP2K1	Selumetinib	MAP2K1 E120D confers resistance to Selumetinib in patients with Neoplasm of lung	MAP2K1 E120D confers resistance to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-Ne2PSS-TIFzzUKGqmolecularmatch	MAP2K1	Selumetinib	MAP2K1 D67N confers sensitivity to Selumetinib in patients with Neoplasm of lung	MAP2K1 D67N confers sensitivity to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25351745	AVv-Ne4GSS-TIFzzUKGtmolecularmatch	MAP2K1	Pd-0325901	MAP2K1 V211D confers resistance to Pd-0325901 in patients with Neoplasm of lung	MAP2K1 V211D confers resistance to Pd-0325901 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NeVMSS-TIFzzUKF3molecularmatch	MAP2K1	Pd-0325901	MAP2K1 Q56P confers resistance to Pd-0325901 in patients with Neoplasm of lung	MAP2K1 Q56P confers resistance to Pd-0325901 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26582713	AVv-Nea8SS-TIFzzUKF_molecularmatch	MAP2K1	Pd-0325901	MAP2K1 P124S confers resistance to Pd-0325901 in patients with Neoplasm of lung	MAP2K1 P124S confers resistance to Pd-0325901 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NedCSS-TIFzzUKGCmolecularmatch	MAP2K1	Pd-0325901	MAP2K1 P124Q confers resistance to Pd-0325901 in patients with Neoplasm of lung	MAP2K1 P124Q confers resistance to Pd-0325901 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NefKSS-TIFzzUKGFmolecularmatch	MAP2K1	Pd-0325901	MAP2K1 P124L confers resistance to Pd-0325901 in patients with Neoplasm of lung	MAP2K1 P124L confers resistance to Pd-0325901 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NeiYSS-TIFzzUKGKmolecularmatch	MAP2K1	Pd-0325901	MAP2K1 L215P confers resistance to Pd-0325901 in patients with Neoplasm of lung	MAP2K1 L215P confers resistance to Pd-0325901 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NekaSS-TIFzzUKGNmolecularmatch	MAP2K1	Pd-0325901	MAP2K1 L115P confers resistance to Pd-0325901 in patients with Neoplasm of lung	MAP2K1 L115P confers resistance to Pd-0325901 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23221341	AVv-NenxSS-TIFzzUKGSmolecularmatch	MAP2K1	Pd-0325901	MAP2K1 K57N confers resistance to Pd-0325901 in patients with Neoplasm of lung	MAP2K1 K57N confers resistance to Pd-0325901 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25351745	AVv-Nep0SS-TIFzzUKGVmolecularmatch	MAP2K1	Pd-0325901	MAP2K1 I99T confers resistance to Pd-0325901 in patients with Neoplasm of lung	MAP2K1 I99T confers resistance to Pd-0325901 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NerxSS-TIFzzUKGYmolecularmatch	MAP2K1	Pd-0325901	MAP2K1 I111N confers resistance to Pd-0325901 in patients with Neoplasm of lung	MAP2K1 I111N confers resistance to Pd-0325901 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22402123	AVv-NettSS-TIFzzUKGbmolecularmatch	MAP2K1	Pd-0325901	MAP2K1 I103N confers resistance to Pd-0325901 in patients with Neoplasm of lung	MAP2K1 I103N confers resistance to Pd-0325901 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NewBSS-TIFzzUKGfmolecularmatch	MAP2K1	Pd-0325901	MAP2K1 H119P confers resistance to Pd-0325901 in patients with Neoplasm of lung	MAP2K1 H119P confers resistance to Pd-0325901 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NexqSS-TIFzzUKGimolecularmatch	MAP2K1	Pd-0325901	MAP2K1 G128D confers resistance to Pd-0325901 in patients with Neoplasm of lung	MAP2K1 G128D confers resistance to Pd-0325901 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NezSSS-TIFzzUKGlmolecularmatch	MAP2K1	Pd-0325901	MAP2K1 F129L confers resistance to Pd-0325901 in patients with Neoplasm of lung	MAP2K1 F129L confers resistance to Pd-0325901 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22402123	AVv-Ne1nSS-TIFzzUKGpmolecularmatch	MAP2K1	Pd-0325901	MAP2K1 E120D confers resistance to Pd-0325901 in patients with Neoplasm of lung	MAP2K1 E120D confers resistance to Pd-0325901 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-Ne3gSS-TIFzzUKGsmolecularmatch	MAP2K1	Pd-0325901	MAP2K1 D67N confers resistance to Pd-0325901 in patients with Neoplasm of lung	MAP2K1 D67N confers resistance to Pd-0325901 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25351745	AVv-Ne5fSS-TIFzzUKGvmolecularmatch	MAP2K1	Mek-162	MAP2K1 V211D confers resistance to Mek-162 in patients with Neoplasm of lung	MAP2K1 V211D confers resistance to Mek-162 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-NeUiSS-TIFzzUKF2molecularmatch	MAP2K1	Mek-162	MAP2K1 Q56P confers sensitivity to Mek-162 in patients with Neoplasm of lung	MAP2K1 Q56P confers sensitivity to Mek-162 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26582713	AVv-NeZjSS-TIFzzUKF9molecularmatch	MAP2K1	Mek-162	MAP2K1 Q56P confers resistance to Mek-162 in patients with Neoplasm of lung	MAP2K1 Q56P confers resistance to Mek-162 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NeaOSS-TIFzzUKF-molecularmatch	MAP2K1	Mek-162	MAP2K1 P124S confers resistance to Mek-162 in patients with Neoplasm of lung	MAP2K1 P124S confers resistance to Mek-162 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NecaSS-TIFzzUKGBmolecularmatch	MAP2K1	Mek-162	MAP2K1 P124Q confers resistance to Mek-162 in patients with Neoplasm of lung	MAP2K1 P124Q confers resistance to Mek-162 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NeefSS-TIFzzUKGEmolecularmatch	MAP2K1	Mek-162	MAP2K1 P124L confers resistance to Mek-162 in patients with Neoplasm of lung	MAP2K1 P124L confers resistance to Mek-162 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NehnSS-TIFzzUKGJmolecularmatch	MAP2K1	Mek-162	MAP2K1 L215P confers resistance to Mek-162 in patients with Neoplasm of lung	MAP2K1 L215P confers resistance to Mek-162 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NejtSS-TIFzzUKGMmolecularmatch	MAP2K1	Mek-162	MAP2K1 L115P confers resistance to Mek-162 in patients with Neoplasm of lung	MAP2K1 L115P confers resistance to Mek-162 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NemYSS-TIFzzUKGQmolecularmatch	MAP2K1	Mek-162	MAP2K1 K57N confers sensitivity to Mek-162 in patients with Neoplasm of lung	MAP2K1 K57N confers sensitivity to Mek-162 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25351745	AVv-NepGSS-TIFzzUKGUmolecularmatch	MAP2K1	Mek-162	MAP2K1 I99T confers resistance to Mek-162 in patients with Neoplasm of lung	MAP2K1 I99T confers resistance to Mek-162 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NerKSS-TIFzzUKGXmolecularmatch	MAP2K1	Mek-162	MAP2K1 I111N confers resistance to Mek-162 in patients with Neoplasm of lung	MAP2K1 I111N confers resistance to Mek-162 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-Nes8SS-TIFzzUKGamolecularmatch	MAP2K1	Mek-162	MAP2K1 I103N confers resistance to Mek-162 in patients with Neoplasm of lung	MAP2K1 I103N confers resistance to Mek-162 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NeveSS-TIFzzUKGemolecularmatch	MAP2K1	Mek-162	MAP2K1 H119P confers resistance to Mek-162 in patients with Neoplasm of lung	MAP2K1 H119P confers resistance to Mek-162 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NexGSS-TIFzzUKGhmolecularmatch	MAP2K1	Mek-162	MAP2K1 G128D confers resistance to Mek-162 in patients with Neoplasm of lung	MAP2K1 G128D confers resistance to Mek-162 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-NeyxSS-TIFzzUKGkmolecularmatch	MAP2K1	Mek-162	MAP2K1 F129L confers resistance to Mek-162 in patients with Neoplasm of lung	MAP2K1 F129L confers resistance to Mek-162 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-Ne1ASS-TIFzzUKGomolecularmatch	MAP2K1	Mek-162	MAP2K1 E120D confers resistance to Mek-162 in patients with Neoplasm of lung	MAP2K1 E120D confers resistance to Mek-162 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-Ne22SS-TIFzzUKGrmolecularmatch	MAP2K1	Mek-162	MAP2K1 D67N confers sensitivity to Mek-162 in patients with Neoplasm of lung	MAP2K1 D67N confers sensitivity to Mek-162 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25351745	AVv-Ne42SS-TIFzzUKGumolecularmatch	LRIG3-ROS1	Pf-06463922	LRIG3-ROS1 confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	LRIG3-ROS1 confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25733882	AVv-Ne65SS-TIFzzUKGxmolecularmatch	LRIG3-ROS1	Crizotinib	LRIG3-ROS1 confers sensitivity to Crizotinib in patients with Neoplasm of lung	LRIG3-ROS1 confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25264305	AVv-Ne8-SS-TIFzzUKG0molecularmatch	LRIG3-ROS1	Ceritinib	LRIG3-ROS1 confers sensitivity to Ceritinib in patients with Neoplasm of lung	LRIG3-ROS1 confers sensitivity to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26917690	AVv-Ne8QSS-TIFzzUKGzmolecularmatch	LRIG3-ROS1	Alectinib	LRIG3-ROS1 confers sensitivity to Alectinib in patients with Neoplasm of lung	LRIG3-ROS1 confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25349307	AVv-Ne6RSS-TIFzzUKGwmolecularmatch	LGR5	BNC101	LGR5 confers sensitivity to BNC101 in patients with Neoplasm of colorectum	LGR5 confers sensitivity to BNC101 in patients with Neoplasm of colorectum	http://cancerres.aacrjournals.org/content/75/15_supplement/2639.short	AVv-NrCwSS-TIFzzUKaXmolecularmatch	LCK	Enmd-2076	LCK confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	LCK confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20406842	AVv-NpA5SS-TIFzzUKXEmolecularmatch	KRAS	Selumetinib	KRAS G13D confers sensitivity to Selumetinib in patients with Neoplasm of lung	KRAS G13D confers sensitivity to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23200175	AVv-NgWVSS-TIFzzUKI_molecularmatch	KRAS	Selumetinib	KRAS G12V confers sensitivity to Selumetinib in patients with Neoplasm of lung	KRAS G12V confers sensitivity to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23200175	AVv-Ng9sSS-TIFzzUKJ5molecularmatch	KRAS	Selumetinib	KRAS G12D confers sensitivity to Selumetinib in patients with Neoplasm of lung	KRAS G12D confers sensitivity to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23200175	AVv-Nh21SS-TIFzzUKLPmolecularmatch	KRAS	Selumetinib	KRAS G12C confers sensitivity to Selumetinib in patients with Neoplasm of lung	KRAS G12C confers sensitivity to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23200175	AVv-Nh9WSS-TIFzzUKLZmolecularmatch	KRAS	Panitumumab	KRAS confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-Nr_hSS-TIFzzUKb6molecularmatch	KRAS	Panitumumab	KRAS Q61R confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS Q61R confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NsNESS-TIFzzUKcPmolecularmatch	KRAS	Panitumumab	KRAS Q61P confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS Q61P confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NsOZSS-TIFzzUKcRmolecularmatch	KRAS	Panitumumab	KRAS Q61L confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS Q61L confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NsPCSS-TIFzzUKcSmolecularmatch	KRAS	Panitumumab	KRAS Q61K confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS Q61K confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NsPqSS-TIFzzUKcTmolecularmatch	KRAS	Panitumumab	KRAS Q61H confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS Q61H confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NsQVSS-TIFzzUKcUmolecularmatch	KRAS	Panitumumab	KRAS Q61E confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS Q61E confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NsRASS-TIFzzUKcVmolecularmatch	KRAS	Panitumumab	KRAS Q61 confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS Q61 confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NsRjSS-TIFzzUKcWmolecularmatch	KRAS	Panitumumab	KRAS G13_V14insG confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G13_V14insG confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NsSISS-TIFzzUKcXmolecularmatch	KRAS	Panitumumab	KRAS G13_V14>DI confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G13_V14>DI confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NsSwSS-TIFzzUKcYmolecularmatch	KRAS	Panitumumab	KRAS G13Y confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G13Y confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NsTcSS-TIFzzUKcZmolecularmatch	KRAS	Panitumumab	KRAS G13V confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G13V confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NsUESS-TIFzzUKcamolecularmatch	KRAS	Panitumumab	KRAS G13S confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G13S confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrDbSS-TIFzzUKaYmolecularmatch	KRAS	Panitumumab	KRAS G13R confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G13R confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrEDSS-TIFzzUKaZmolecularmatch	KRAS	Panitumumab	KRAS G13P confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G13P confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrEuSS-TIFzzUKaamolecularmatch	KRAS	Panitumumab	KRAS G13N confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G13N confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrFTSS-TIFzzUKabmolecularmatch	KRAS	Panitumumab	KRAS G13M confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G13M confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrF5SS-TIFzzUKacmolecularmatch	KRAS	Panitumumab	KRAS G13I confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G13I confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrGgSS-TIFzzUKadmolecularmatch	KRAS	Panitumumab	KRAS G13G confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G13G confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrHKSS-TIFzzUKaemolecularmatch	KRAS	Panitumumab	KRAS G13F confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G13F confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrH2SS-TIFzzUKafmolecularmatch	KRAS	Panitumumab	KRAS G13E confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G13E confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrIgSS-TIFzzUKagmolecularmatch	KRAS	Panitumumab	KRAS G13D confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G13D confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrJLSS-TIFzzUKahmolecularmatch	KRAS	Panitumumab	KRAS G13C confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G13C confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrKbSS-TIFzzUKajmolecularmatch	KRAS	Panitumumab	KRAS G13A confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G13A confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrLNSS-TIFzzUKakmolecularmatch	KRAS	Panitumumab	KRAS G13 confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G13 confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrL3SS-TIFzzUKalmolecularmatch	KRAS	Panitumumab	KRAS G12fs*3 confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G12fs*3 confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrMjSS-TIFzzUKammolecularmatch	KRAS	Panitumumab	KRAS G12_G13insG confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G12_G13insG confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrNMSS-TIFzzUKanmolecularmatch	KRAS	Panitumumab	KRAS G12_G13insAG confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G12_G13insAG confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrN6SS-TIFzzUKaomolecularmatch	KRAS	Panitumumab	KRAS G12_G13insA confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G12_G13insA confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrOwSS-TIFzzUKapmolecularmatch	KRAS	Panitumumab	KRAS G12Y confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G12Y confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrPjSS-TIFzzUKaqmolecularmatch	KRAS	Panitumumab	KRAS G12W confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G12W confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrQRSS-TIFzzUKarmolecularmatch	KRAS	Panitumumab	KRAS G12V confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G12V confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrQ9SS-TIFzzUKasmolecularmatch	KRAS	Panitumumab	KRAS G12T confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G12T confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrSSSS-TIFzzUKaumolecularmatch	KRAS	Panitumumab	KRAS G12S confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G12S confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrS-SS-TIFzzUKavmolecularmatch	KRAS	Panitumumab	KRAS G12R confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G12R confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrTmSS-TIFzzUKawmolecularmatch	KRAS	Panitumumab	KRAS G12N confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G12N confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrUNSS-TIFzzUKaxmolecularmatch	KRAS	Panitumumab	KRAS G12L confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G12L confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrU1SS-TIFzzUKaymolecularmatch	KRAS	Panitumumab	KRAS G12I confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G12I confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrVfSS-TIFzzUKazmolecularmatch	KRAS	Panitumumab	KRAS G12G confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G12G confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrWJSS-TIFzzUKa0molecularmatch	KRAS	Panitumumab	KRAS G12F confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G12F confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrW4SS-TIFzzUKa1molecularmatch	KRAS	Panitumumab	KRAS G12E confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G12E confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrXeSS-TIFzzUKa2molecularmatch	KRAS	Panitumumab	KRAS G12D confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G12D confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrYESS-TIFzzUKa3molecularmatch	KRAS	Panitumumab	KRAS G12C confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G12C confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NrZfSS-TIFzzUKa5molecularmatch	KRAS	Panitumumab	KRAS G12A confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G12A confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NraKSS-TIFzzUKa6molecularmatch	KRAS	Panitumumab	KRAS G12 confers resistance to Panitumumab in patients with Neoplasm of colorectum	KRAS G12 confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-NraxSS-TIFzzUKa7molecularmatch	KRAS	Necitumumab	KRAS Q61R confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS Q61R confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-Ne9uSS-TIFzzUKG1molecularmatch	KRAS	Necitumumab	KRAS Q61P confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS Q61P confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NfCPSS-TIFzzUKG7molecularmatch	KRAS	Necitumumab	KRAS Q61L confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS Q61L confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NfHYSS-TIFzzUKHCmolecularmatch	KRAS	Necitumumab	KRAS Q61K confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS Q61K confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NfMRSS-TIFzzUKHJmolecularmatch	KRAS	Necitumumab	KRAS Q61H confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS Q61H confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NfQ3SS-TIFzzUKHPmolecularmatch	KRAS	Necitumumab	KRAS Q61E confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS Q61E confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NfVcSS-TIFzzUKHWmolecularmatch	KRAS	Necitumumab	KRAS Q61 confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS Q61 confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NfZCSS-TIFzzUKHcmolecularmatch	KRAS	Necitumumab	KRAS G13_V14insG confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G13_V14insG confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-Ngf4SS-TIFzzUKJNmolecularmatch	KRAS	Necitumumab	KRAS G13_V14>DI confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G13_V14>DI confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NgkdSS-TIFzzUKJUmolecularmatch	KRAS	Necitumumab	KRAS G13Y confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G13Y confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NfdrSS-TIFzzUKHjmolecularmatch	KRAS	Necitumumab	KRAS G13V confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G13V confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NfjMSS-TIFzzUKHrmolecularmatch	KRAS	Necitumumab	KRAS G13S confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G13S confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NfnqSS-TIFzzUKHxmolecularmatch	KRAS	Necitumumab	KRAS G13R confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G13R confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-Nfs7SS-TIFzzUKIDmolecularmatch	KRAS	Necitumumab	KRAS G13P confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G13P confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NfxqSS-TIFzzUKIJmolecularmatch	KRAS	Necitumumab	KRAS G13N confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G13N confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-Nf2pSS-TIFzzUKIQmolecularmatch	KRAS	Necitumumab	KRAS G13M confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G13M confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-Nf7cSS-TIFzzUKIXmolecularmatch	KRAS	Necitumumab	KRAS G13I confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G13I confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-Nf_kSS-TIFzzUKIemolecularmatch	KRAS	Necitumumab	KRAS G13G confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G13G confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NgESSS-TIFzzUKIlmolecularmatch	KRAS	Necitumumab	KRAS G13F confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G13F confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NgIbSS-TIFzzUKIrmolecularmatch	KRAS	Necitumumab	KRAS G13E confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G13E confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NgNBSS-TIFzzUKIymolecularmatch	KRAS	Necitumumab	KRAS G13D confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G13D confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NgSESS-TIFzzUKI5molecularmatch	KRAS	Necitumumab	KRAS G13C confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G13C confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NgXESS-TIFzzUKJAmolecularmatch	KRAS	Necitumumab	KRAS G13A confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G13A confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NgbtSS-TIFzzUKJHmolecularmatch	KRAS	Necitumumab	KRAS G13 confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G13 confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NgpLSS-TIFzzUKJbmolecularmatch	KRAS	Necitumumab	KRAS G12fs*3 confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G12fs*3 confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NhiASS-TIFzzUKKwmolecularmatch	KRAS	Necitumumab	KRAS G12_G13insG confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G12_G13insG confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NiFESS-TIFzzUKLimolecularmatch	KRAS	Necitumumab	KRAS G12_G13insAG confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G12_G13insAG confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NiJ8SS-TIFzzUKL0molecularmatch	KRAS	Necitumumab	KRAS G12_G13insA confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G12_G13insA confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NiO8SS-TIFzzUKL8molecularmatch	KRAS	Necitumumab	KRAS G12Y confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G12Y confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NgtGSS-TIFzzUKJhmolecularmatch	KRAS	Necitumumab	KRAS G12W confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G12W confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NgzDSS-TIFzzUKJqmolecularmatch	KRAS	Necitumumab	KRAS G12V confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G12V confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-Ng4sSS-TIFzzUKJymolecularmatch	KRAS	Necitumumab	KRAS G12T confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G12T confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-Ng-VSS-TIFzzUKJ6molecularmatch	KRAS	Necitumumab	KRAS G12S confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G12S confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NhDtSS-TIFzzUKKCmolecularmatch	KRAS	Necitumumab	KRAS G12R confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G12R confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NhJKSS-TIFzzUKKKmolecularmatch	KRAS	Necitumumab	KRAS G12N confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G12N confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NhOVSS-TIFzzUKKSmolecularmatch	KRAS	Necitumumab	KRAS G12L confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G12L confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NhTRSS-TIFzzUKKZmolecularmatch	KRAS	Necitumumab	KRAS G12I confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G12I confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NhYuSS-TIFzzUKKhmolecularmatch	KRAS	Necitumumab	KRAS G12G confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G12G confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NhdeSS-TIFzzUKKpmolecularmatch	KRAS	Necitumumab	KRAS G12F confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G12F confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NhnfSS-TIFzzUKK4molecularmatch	KRAS	Necitumumab	KRAS G12E confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G12E confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-Nhs0SS-TIFzzUKLAmolecularmatch	KRAS	Necitumumab	KRAS G12D confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G12D confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NhxhSS-TIFzzUKLHmolecularmatch	KRAS	Necitumumab	KRAS G12C confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G12C confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-Nh3fSS-TIFzzUKLQmolecularmatch	KRAS	Necitumumab	KRAS G12A confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G12A confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-Nh99SS-TIFzzUKLamolecularmatch	KRAS	Necitumumab	KRAS G12 confers resistance to Necitumumab in patients with Neoplasm of lung	KRAS G12 confers resistance to Necitumumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26766738	AVv-NiT7SS-TIFzzUKMEmolecularmatch	KRAS	Ly2835219	KRAS exon 2 mutation confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	KRAS exon 2 mutation confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/27217383	AVv-Nqt7SS-TIFzzUKZ3molecularmatch	KRAS	Ly2835219	KRAS Ras domain confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	KRAS Ras domain confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/27217383	AVv-NquhSS-TIFzzUKZ4molecularmatch	KRAS	Ly2835219	KRAS G12C confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	KRAS G12C confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/27217383	AVv-NqvGSS-TIFzzUKZ5molecularmatch	KRAS	Ly2835219	KRAS G12 confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	KRAS G12 confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/27217383	AVv-NqvxSS-TIFzzUKZ6molecularmatch	KRAS	Icotinib	KRAS Q61R confers resistance to Icotinib in patients with Neoplasm of lung	KRAS Q61R confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-Ne-fSS-TIFzzUKG2molecularmatch	KRAS	Icotinib	KRAS Q61P confers resistance to Icotinib in patients with Neoplasm of lung	KRAS Q61P confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NfDBSS-TIFzzUKG8molecularmatch	KRAS	Icotinib	KRAS Q61L confers resistance to Icotinib in patients with Neoplasm of lung	KRAS Q61L confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NfIFSS-TIFzzUKHDmolecularmatch	KRAS	Icotinib	KRAS Q61K confers resistance to Icotinib in patients with Neoplasm of lung	KRAS Q61K confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NfM-SS-TIFzzUKHKmolecularmatch	KRAS	Icotinib	KRAS Q61H confers resistance to Icotinib in patients with Neoplasm of lung	KRAS Q61H confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NfRjSS-TIFzzUKHQmolecularmatch	KRAS	Icotinib	KRAS Q61E confers resistance to Icotinib in patients with Neoplasm of lung	KRAS Q61E confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NfWFSS-TIFzzUKHXmolecularmatch	KRAS	Icotinib	KRAS Q61 confers resistance to Icotinib in patients with Neoplasm of lung	KRAS Q61 confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NfZuSS-TIFzzUKHdmolecularmatch	KRAS	Icotinib	KRAS G13_V14insG confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G13_V14insG confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NghMSS-TIFzzUKJPmolecularmatch	KRAS	Icotinib	KRAS G13_V14>DI confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G13_V14>DI confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NglDSS-TIFzzUKJVmolecularmatch	KRAS	Icotinib	KRAS G13Y confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G13Y confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NfeYSS-TIFzzUKHkmolecularmatch	KRAS	Icotinib	KRAS G13V confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G13V confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-Nfj8SS-TIFzzUKHsmolecularmatch	KRAS	Icotinib	KRAS G13S confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G13S confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NfoTSS-TIFzzUKHymolecularmatch	KRAS	Icotinib	KRAS G13R confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G13R confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NftvSS-TIFzzUKIEmolecularmatch	KRAS	Icotinib	KRAS G13P confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G13P confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NfydSS-TIFzzUKIKmolecularmatch	KRAS	Icotinib	KRAS G13N confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G13N confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-Nf3VSS-TIFzzUKIRmolecularmatch	KRAS	Icotinib	KRAS G13M confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G13M confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-Nf8CSS-TIFzzUKIZmolecularmatch	KRAS	Icotinib	KRAS G13I confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G13I confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NgAQSS-TIFzzUKIfmolecularmatch	KRAS	Icotinib	KRAS G13G confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G13G confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NgFASS-TIFzzUKImmolecularmatch	KRAS	Icotinib	KRAS G13F confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G13F confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NgJESS-TIFzzUKIsmolecularmatch	KRAS	Icotinib	KRAS G13E confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G13E confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NgNxSS-TIFzzUKIzmolecularmatch	KRAS	Icotinib	KRAS G13D confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G13D confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NgSySS-TIFzzUKI6molecularmatch	KRAS	Icotinib	KRAS G13C confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G13C confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NgXuSS-TIFzzUKJBmolecularmatch	KRAS	Icotinib	KRAS G13A confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G13A confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NgcZSS-TIFzzUKJImolecularmatch	KRAS	Icotinib	KRAS G13 confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G13 confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NgpwSS-TIFzzUKJcmolecularmatch	KRAS	Icotinib	KRAS G12fs*3 confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G12fs*3 confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NhisSS-TIFzzUKKxmolecularmatch	KRAS	Icotinib	KRAS G12_G13insG confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G12_G13insG confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NiFqSS-TIFzzUKLumolecularmatch	KRAS	Icotinib	KRAS G12_G13insAG confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G12_G13insAG confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NiLTSS-TIFzzUKL2molecularmatch	KRAS	Icotinib	KRAS G12_G13insA confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G12_G13insA confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NiPnSS-TIFzzUKL9molecularmatch	KRAS	Icotinib	KRAS G12Y confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G12Y confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NgtuSS-TIFzzUKJimolecularmatch	KRAS	Icotinib	KRAS G12W confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G12W confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NgzuSS-TIFzzUKJrmolecularmatch	KRAS	Icotinib	KRAS G12V confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G12V confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-Ng5ZSS-TIFzzUKJzmolecularmatch	KRAS	Icotinib	KRAS G12T confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G12T confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-Ng_qSS-TIFzzUKJ8molecularmatch	KRAS	Icotinib	KRAS G12S confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G12S confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NhEcSS-TIFzzUKKDmolecularmatch	KRAS	Icotinib	KRAS G12R confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G12R confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NhJxSS-TIFzzUKKLmolecularmatch	KRAS	Icotinib	KRAS G12N confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G12N confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NhO9SS-TIFzzUKKTmolecularmatch	KRAS	Icotinib	KRAS G12L confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G12L confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NhT-SS-TIFzzUKKamolecularmatch	KRAS	Icotinib	KRAS G12I confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G12I confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NhZVSS-TIFzzUKKimolecularmatch	KRAS	Icotinib	KRAS G12G confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G12G confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NheGSS-TIFzzUKKqmolecularmatch	KRAS	Icotinib	KRAS G12F confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G12F confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NhoJSS-TIFzzUKK5molecularmatch	KRAS	Icotinib	KRAS G12E confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G12E confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NhtgSS-TIFzzUKLBmolecularmatch	KRAS	Icotinib	KRAS G12D confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G12D confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-Nhy1SS-TIFzzUKLJmolecularmatch	KRAS	Icotinib	KRAS G12C confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G12C confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-Nh4GSS-TIFzzUKLRmolecularmatch	KRAS	Icotinib	KRAS G12A confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G12A confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-Nh-pSS-TIFzzUKLbmolecularmatch	KRAS	Icotinib	KRAS G12 confers resistance to Icotinib in patients with Neoplasm of lung	KRAS G12 confers resistance to Icotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NiUnSS-TIFzzUKMFmolecularmatch	KRAS	Gefitinib	KRAS Q61R confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS Q61R confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NfBkSS-TIFzzUKG6molecularmatch	KRAS	Gefitinib	KRAS Q61P confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS Q61P confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NfGoSS-TIFzzUKHBmolecularmatch	KRAS	Gefitinib	KRAS Q61L confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS Q61L confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NfK3SS-TIFzzUKHHmolecularmatch	KRAS	Gefitinib	KRAS Q61K confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS Q61K confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NfQFSS-TIFzzUKHOmolecularmatch	KRAS	Gefitinib	KRAS Q61H confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS Q61H confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NfU1SS-TIFzzUKHVmolecularmatch	KRAS	Gefitinib	KRAS Q61E confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS Q61E confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NfYaSS-TIFzzUKHbmolecularmatch	KRAS	Gefitinib	KRAS Q61 confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS Q61 confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NfdASS-TIFzzUKHimolecularmatch	KRAS	Gefitinib	KRAS G13_V14insG confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G13_V14insG confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgjvSS-TIFzzUKJTmolecularmatch	KRAS	Gefitinib	KRAS G13_V14>DI confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G13_V14>DI confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgogSS-TIFzzUKJamolecularmatch	KRAS	Gefitinib	KRAS G13Y confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G13Y confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NfhOSS-TIFzzUKHomolecularmatch	KRAS	Gefitinib	KRAS G13V confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G13V confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-Nfm3SS-TIFzzUKHwmolecularmatch	KRAS	Gefitinib	KRAS G13S confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G13S confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NfsJSS-TIFzzUKICmolecularmatch	KRAS	Gefitinib	KRAS G13R confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G13R confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-Nfw8SS-TIFzzUKIImolecularmatch	KRAS	Gefitinib	KRAS G13P confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G13P confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-Nf1_SS-TIFzzUKIPmolecularmatch	KRAS	Gefitinib	KRAS G13N confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G13N confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-Nf6ISS-TIFzzUKIVmolecularmatch	KRAS	Gefitinib	KRAS G13M confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G13M confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-Nf-6SS-TIFzzUKIdmolecularmatch	KRAS	Gefitinib	KRAS G13I confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G13I confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgDlSS-TIFzzUKIkmolecularmatch	KRAS	Gefitinib	KRAS G13G confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G13G confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgHvSS-TIFzzUKIqmolecularmatch	KRAS	Gefitinib	KRAS G13F confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G13F confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgMYSS-TIFzzUKIxmolecularmatch	KRAS	Gefitinib	KRAS G13E confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G13E confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgQlSS-TIFzzUKI3molecularmatch	KRAS	Gefitinib	KRAS G13D confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G13D confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgVpSS-TIFzzUKI-molecularmatch	KRAS	Gefitinib	KRAS G13C confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G13C confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgbDSS-TIFzzUKJGmolecularmatch	KRAS	Gefitinib	KRAS G13A confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G13A confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgfQSS-TIFzzUKJMmolecularmatch	KRAS	Gefitinib	KRAS G13 confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G13 confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgsdSS-TIFzzUKJgmolecularmatch	KRAS	Gefitinib	KRAS G12fs*3 confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G12fs*3 confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-Nhm1SS-TIFzzUKK3molecularmatch	KRAS	Gefitinib	KRAS G12_G13insG confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G12_G13insG confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NiJUSS-TIFzzUKLzmolecularmatch	KRAS	Gefitinib	KRAS G12_G13insAG confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G12_G13insAG confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NiOUSS-TIFzzUKL7molecularmatch	KRAS	Gefitinib	KRAS G12_G13insA confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G12_G13insA confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NiTMSS-TIFzzUKMDmolecularmatch	KRAS	Gefitinib	KRAS G12Y confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G12Y confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgyaSS-TIFzzUKJpmolecularmatch	KRAS	Gefitinib	KRAS G12W confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G12W confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-Ng37SS-TIFzzUKJxmolecularmatch	KRAS	Gefitinib	KRAS G12V confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G12V confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-Ng80SS-TIFzzUKJ4molecularmatch	KRAS	Gefitinib	KRAS G12T confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G12T confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NhDGSS-TIFzzUKKBmolecularmatch	KRAS	Gefitinib	KRAS G12S confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G12S confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NhIkSS-TIFzzUKKJmolecularmatch	KRAS	Gefitinib	KRAS G12R confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G12R confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NhNASS-TIFzzUKKQmolecularmatch	KRAS	Gefitinib	KRAS G12N confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G12N confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NhSiSS-TIFzzUKKYmolecularmatch	KRAS	Gefitinib	KRAS G12L confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G12L confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NhYFSS-TIFzzUKKgmolecularmatch	KRAS	Gefitinib	KRAS G12I confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G12I confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NhczSS-TIFzzUKKomolecularmatch	KRAS	Gefitinib	KRAS G12G confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G12G confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NhhZSS-TIFzzUKKvmolecularmatch	KRAS	Gefitinib	KRAS G12F confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G12F confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NhsKSS-TIFzzUKK_molecularmatch	KRAS	Gefitinib	KRAS G12E confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G12E confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-Nhw4SS-TIFzzUKLGmolecularmatch	KRAS	Gefitinib	KRAS G12D confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G12D confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-Nh2MSS-TIFzzUKLOmolecularmatch	KRAS	Gefitinib	KRAS G12C confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G12C confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-Nh8qSS-TIFzzUKLYmolecularmatch	KRAS	Gefitinib	KRAS G12A confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G12A confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NiEXSS-TIFzzUKLhmolecularmatch	KRAS	Gefitinib	KRAS G12 confers resistance to Gefitinib in patients with Neoplasm of lung	KRAS G12 confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NiX2SS-TIFzzUKMKmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS Q61R confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS Q61R confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NfA2SS-TIFzzUKG5molecularmatch	KRAS	Erlotinib hydrochloride	KRAS Q61P confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS Q61P confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NfF4SS-TIFzzUKHAmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS Q61L confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS Q61L confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NfKKSS-TIFzzUKHGmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS Q61K confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS Q61K confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NfPaSS-TIFzzUKHNmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS Q61H confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS Q61H confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NfULSS-TIFzzUKHUmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS Q61E confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS Q61E confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NfX2SS-TIFzzUKHamolecularmatch	KRAS	Erlotinib hydrochloride	KRAS Q61 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS Q61 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NfcZSS-TIFzzUKHhmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G13_V14insG confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G13_V14insG confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgjCSS-TIFzzUKJSmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G13_V14>DI confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G13_V14>DI confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgnDSS-TIFzzUKJYmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G13Y confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G13Y confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NfgkSS-TIFzzUKHnmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G13V confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G13V confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NfmISS-TIFzzUKHvmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G13S confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G13S confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NfraSS-TIFzzUKIBmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G13R confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G13R confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NfwJSS-TIFzzUKIHmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G13P confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G13P confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-Nf1QSS-TIFzzUKIOmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G13N confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G13N confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-Nf5cSS-TIFzzUKIUmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G13M confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G13M confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-Nf-USS-TIFzzUKIcmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G13I confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G13I confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgC6SS-TIFzzUKIjmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G13G confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G13G confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgHESS-TIFzzUKIpmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G13F confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G13F confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgLtSS-TIFzzUKIwmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G13E confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G13E confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgP3SS-TIFzzUKI2molecularmatch	KRAS	Erlotinib hydrochloride	KRAS G13D confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G13D confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgU9SS-TIFzzUKI9molecularmatch	KRAS	Erlotinib hydrochloride	KRAS G13C confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G13C confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgabSS-TIFzzUKJFmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G13A confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G13A confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgelSS-TIFzzUKJLmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G13 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G13 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgrsSS-TIFzzUKJfmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G12fs*3 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G12fs*3 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NhmKSS-TIFzzUKK2molecularmatch	KRAS	Erlotinib hydrochloride	KRAS G12_G13insG confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G12_G13insG confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NiIqSS-TIFzzUKLymolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G12_G13insAG confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G12_G13insAG confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NiNuSS-TIFzzUKL6molecularmatch	KRAS	Erlotinib hydrochloride	KRAS G12_G13insA confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G12_G13insA confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NiSlSS-TIFzzUKMCmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G12Y confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G12Y confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NgxxSS-TIFzzUKJomolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G12W confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G12W confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-Ng2fSS-TIFzzUKJvmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G12V confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G12V confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-Ng8ISS-TIFzzUKJ3molecularmatch	KRAS	Erlotinib hydrochloride	KRAS G12T confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G12T confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NhCaSS-TIFzzUKKAmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G12S confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G12S confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NhH8SS-TIFzzUKKImolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G12R confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G12R confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NhMXSS-TIFzzUKKPmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G12N confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G12N confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NhR6SS-TIFzzUKKXmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G12L confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G12L confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NhXaSS-TIFzzUKKfmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G12I confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G12I confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NhbpSS-TIFzzUKKmmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G12G confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G12G confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NhgtSS-TIFzzUKKumolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G12F confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G12F confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NhrfSS-TIFzzUKK-molecularmatch	KRAS	Erlotinib hydrochloride	KRAS G12E confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G12E confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NhwPSS-TIFzzUKLFmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G12D confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G12D confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-Nh1fSS-TIFzzUKLNmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G12C confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G12C confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-Nh7-SS-TIFzzUKLXmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G12A confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G12A confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NiDuSS-TIFzzUKLgmolecularmatch	KRAS	Erlotinib hydrochloride	KRAS G12 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	KRAS G12 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-NiXLSS-TIFzzUKMJmolecularmatch	KRAS	Cetuximab	KRAS confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NsVTSS-TIFzzUKccmolecularmatch	KRAS	Cetuximab	KRAS Q61R confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS Q61R confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NrjxSS-TIFzzUKbImolecularmatch	KRAS	Cetuximab	KRAS Q61P confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS Q61P confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NrkeSS-TIFzzUKbJmolecularmatch	KRAS	Cetuximab	KRAS Q61L confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS Q61L confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NrlMSS-TIFzzUKbKmolecularmatch	KRAS	Cetuximab	KRAS Q61K confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS Q61K confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-Nrl6SS-TIFzzUKbLmolecularmatch	KRAS	Cetuximab	KRAS Q61H confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS Q61H confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NrmjSS-TIFzzUKbMmolecularmatch	KRAS	Cetuximab	KRAS Q61E confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS Q61E confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NrnTSS-TIFzzUKbNmolecularmatch	KRAS	Cetuximab	KRAS Q61 confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS Q61 confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NroiSS-TIFzzUKbPmolecularmatch	KRAS	Cetuximab	KRAS G13_V14insG confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G13_V14insG confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NrpSSS-TIFzzUKbQmolecularmatch	KRAS	Cetuximab	KRAS G13_V14>DI confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G13_V14>DI confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NrqCSS-TIFzzUKbRmolecularmatch	KRAS	Cetuximab	KRAS G13Y confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G13Y confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NrqwSS-TIFzzUKbSmolecularmatch	KRAS	Cetuximab	KRAS G13V confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G13V confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NrrdSS-TIFzzUKbTmolecularmatch	KRAS	Cetuximab	KRAS G13S confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G13S confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NrsESS-TIFzzUKbUmolecularmatch	KRAS	Cetuximab	KRAS G13R confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G13R confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NrssSS-TIFzzUKbVmolecularmatch	KRAS	Cetuximab	KRAS G13P confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G13P confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NrtWSS-TIFzzUKbWmolecularmatch	KRAS	Cetuximab	KRAS G13N confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G13N confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-Nrt6SS-TIFzzUKbXmolecularmatch	KRAS	Cetuximab	KRAS G13M confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G13M confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NrujSS-TIFzzUKbYmolecularmatch	KRAS	Cetuximab	KRAS G13I confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G13I confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NrvzSS-TIFzzUKbamolecularmatch	KRAS	Cetuximab	KRAS G13G confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G13G confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NrwuSS-TIFzzUKbbmolecularmatch	KRAS	Cetuximab	KRAS G13F confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G13F confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NrxeSS-TIFzzUKbcmolecularmatch	KRAS	Cetuximab	KRAS G13E confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G13E confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NryKSS-TIFzzUKbdmolecularmatch	KRAS	Cetuximab	KRAS G13D confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G13D confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-Nry6SS-TIFzzUKbemolecularmatch	KRAS	Cetuximab	KRAS G13C confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G13C confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NrzoSS-TIFzzUKbfmolecularmatch	KRAS	Cetuximab	KRAS G13A confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G13A confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-Nr0RSS-TIFzzUKbgmolecularmatch	KRAS	Cetuximab	KRAS G13 confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G13 confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-Nr08SS-TIFzzUKbhmolecularmatch	KRAS	Cetuximab	KRAS G12fs*3 confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G12fs*3 confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-Nr1tSS-TIFzzUKbimolecularmatch	KRAS	Cetuximab	KRAS G12_G13insG confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G12_G13insG confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-Nr2fSS-TIFzzUKbumolecularmatch	KRAS	Cetuximab	KRAS G12_G13insAG confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G12_G13insAG confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-Nr4NSS-TIFzzUKbwmolecularmatch	KRAS	Cetuximab	KRAS G12_G13insA confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G12_G13insA confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-Nr5nSS-TIFzzUKbxmolecularmatch	KRAS	Cetuximab	KRAS G12Y confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G12Y confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-Nr6RSS-TIFzzUKbymolecularmatch	KRAS	Cetuximab	KRAS G12W confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G12W confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-Nr67SS-TIFzzUKbzmolecularmatch	KRAS	Cetuximab	KRAS G12V confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G12V confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-Nr7oSS-TIFzzUKb0molecularmatch	KRAS	Cetuximab	KRAS G12T confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G12T confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-Nr8RSS-TIFzzUKb1molecularmatch	KRAS	Cetuximab	KRAS G12S confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G12S confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-Nr86SS-TIFzzUKb2molecularmatch	KRAS	Cetuximab	KRAS G12R confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G12R confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-Nr9kSS-TIFzzUKb3molecularmatch	KRAS	Cetuximab	KRAS G12N confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G12N confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-Nr-LSS-TIFzzUKb4molecularmatch	KRAS	Cetuximab	KRAS G12L confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G12L confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-Nr-0SS-TIFzzUKb5molecularmatch	KRAS	Cetuximab	KRAS G12I confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G12I confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NsAJSS-TIFzzUKb7molecularmatch	KRAS	Cetuximab	KRAS G12G confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G12G confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NsAxSS-TIFzzUKb8molecularmatch	KRAS	Cetuximab	KRAS G12F confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G12F confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NsBbSS-TIFzzUKb9molecularmatch	KRAS	Cetuximab	KRAS G12E confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G12E confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NsCCSS-TIFzzUKb-molecularmatch	KRAS	Cetuximab	KRAS G12D confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G12D confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NsC2SS-TIFzzUKb_molecularmatch	KRAS	Cetuximab	KRAS G12C confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G12C confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NsDlSS-TIFzzUKcAmolecularmatch	KRAS	Cetuximab	KRAS G12A confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G12A confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NsEOSS-TIFzzUKcBmolecularmatch	KRAS	Cetuximab	KRAS G12 confers resistance to Cetuximab in patients with Neoplasm of colorectum	KRAS G12 confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NsG8SS-TIFzzUKcFmolecularmatch	KRAS	Azd-9291	KRAS G12fs*3 confers resistance to Azd-9291 in patients with Neoplasm of lung	KRAS G12fs*3 confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NhkGSS-TIFzzUKKzmolecularmatch	KRAS	Azd-9291	KRAS G12_G13insG confers resistance to Azd-9291 in patients with Neoplasm of lung	KRAS G12_G13insG confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NiGwSS-TIFzzUKLvmolecularmatch	KRAS	Azd-9291	KRAS G12_G13insAG confers resistance to Azd-9291 in patients with Neoplasm of lung	KRAS G12_G13insAG confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NiL5SS-TIFzzUKL3molecularmatch	KRAS	Azd-9291	KRAS G12_G13insA confers resistance to Azd-9291 in patients with Neoplasm of lung	KRAS G12_G13insA confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NiQKSS-TIFzzUKL-molecularmatch	KRAS	Azd-9291	KRAS G12Y confers resistance to Azd-9291 in patients with Neoplasm of lung	KRAS G12Y confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NgumSS-TIFzzUKJjmolecularmatch	KRAS	Azd-9291	KRAS G12W confers resistance to Azd-9291 in patients with Neoplasm of lung	KRAS G12W confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-Ng0dSS-TIFzzUKJsmolecularmatch	KRAS	Azd-9291	KRAS G12V confers resistance to Azd-9291 in patients with Neoplasm of lung	KRAS G12V confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-Ng6GSS-TIFzzUKJ0molecularmatch	KRAS	Azd-9291	KRAS G12T confers resistance to Azd-9291 in patients with Neoplasm of lung	KRAS G12T confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NhAUSS-TIFzzUKJ9molecularmatch	KRAS	Azd-9291	KRAS G12S confers resistance to Azd-9291 in patients with Neoplasm of lung	KRAS G12S confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NhFKSS-TIFzzUKKEmolecularmatch	KRAS	Azd-9291	KRAS G12R confers resistance to Azd-9291 in patients with Neoplasm of lung	KRAS G12R confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NhKaSS-TIFzzUKKMmolecularmatch	KRAS	Azd-9291	KRAS G12N confers resistance to Azd-9291 in patients with Neoplasm of lung	KRAS G12N confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NhPqSS-TIFzzUKKUmolecularmatch	KRAS	Azd-9291	KRAS G12L confers resistance to Azd-9291 in patients with Neoplasm of lung	KRAS G12L confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NhUrSS-TIFzzUKKbmolecularmatch	KRAS	Azd-9291	KRAS G12I confers resistance to Azd-9291 in patients with Neoplasm of lung	KRAS G12I confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NhZ7SS-TIFzzUKKjmolecularmatch	KRAS	Azd-9291	KRAS G12G confers resistance to Azd-9291 in patients with Neoplasm of lung	KRAS G12G confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NhewSS-TIFzzUKKrmolecularmatch	KRAS	Azd-9291	KRAS G12F confers resistance to Azd-9291 in patients with Neoplasm of lung	KRAS G12F confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-Nho0SS-TIFzzUKK6molecularmatch	KRAS	Azd-9291	KRAS G12E confers resistance to Azd-9291 in patients with Neoplasm of lung	KRAS G12E confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NhuLSS-TIFzzUKLCmolecularmatch	KRAS	Azd-9291	KRAS G12D confers resistance to Azd-9291 in patients with Neoplasm of lung	KRAS G12D confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NhzfSS-TIFzzUKLKmolecularmatch	KRAS	Azd-9291	KRAS G12C confers resistance to Azd-9291 in patients with Neoplasm of lung	KRAS G12C confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-Nh4uSS-TIFzzUKLSmolecularmatch	KRAS	Azd-9291	KRAS G12A confers resistance to Azd-9291 in patients with Neoplasm of lung	KRAS G12A confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-Nh_WSS-TIFzzUKLcmolecularmatch	KRAS	Azd-9291	KRAS G12 confers resistance to Azd-9291 in patients with Neoplasm of lung	KRAS G12 confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/20921461	AVv-NiVPSS-TIFzzUKMGmolecularmatch	KRAS	Afatinib	KRAS Q61R confers resistance to Afatinib in patients with Neoplasm of lung	KRAS Q61R confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NfAISS-TIFzzUKG4molecularmatch	KRAS	Afatinib	KRAS Q61R confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS Q61R confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Ne_eSS-TIFzzUKG3molecularmatch	KRAS	Afatinib	KRAS Q61P confers resistance to Afatinib in patients with Neoplasm of lung	KRAS Q61P confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NfFISS-TIFzzUKG_molecularmatch	KRAS	Afatinib	KRAS Q61P confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS Q61P confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NfEeSS-TIFzzUKG-molecularmatch	KRAS	Afatinib	KRAS Q61L confers resistance to Afatinib in patients with Neoplasm of lung	KRAS Q61L confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NfJhSS-TIFzzUKHFmolecularmatch	KRAS	Afatinib	KRAS Q61L confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS Q61L confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NfIzSS-TIFzzUKHEmolecularmatch	KRAS	Afatinib	KRAS Q61K confers resistance to Afatinib in patients with Neoplasm of lung	KRAS Q61K confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NfOfSS-TIFzzUKHMmolecularmatch	KRAS	Afatinib	KRAS Q61K confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS Q61K confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NfNuSS-TIFzzUKHLmolecularmatch	KRAS	Afatinib	KRAS Q61H confers resistance to Afatinib in patients with Neoplasm of lung	KRAS Q61H confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NfS6SS-TIFzzUKHSmolecularmatch	KRAS	Afatinib	KRAS Q61H confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS Q61H confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NfSRSS-TIFzzUKHRmolecularmatch	KRAS	Afatinib	KRAS Q61E confers resistance to Afatinib in patients with Neoplasm of lung	KRAS Q61E confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NfXSSS-TIFzzUKHZmolecularmatch	KRAS	Afatinib	KRAS Q61E confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS Q61E confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NfWtSS-TIFzzUKHYmolecularmatch	KRAS	Afatinib	KRAS Q61 confers resistance to Afatinib in patients with Neoplasm of lung	KRAS Q61 confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NfbtSS-TIFzzUKHgmolecularmatch	KRAS	Afatinib	KRAS Q61 confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS Q61 confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NfbDSS-TIFzzUKHfmolecularmatch	KRAS	Afatinib	KRAS G13_V14insG confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G13_V14insG confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NgibSS-TIFzzUKJRmolecularmatch	KRAS	Afatinib	KRAS G13_V14insG confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G13_V14insG confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Ngh2SS-TIFzzUKJQmolecularmatch	KRAS	Afatinib	KRAS G13_V14>DI confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G13_V14>DI confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NgmVSS-TIFzzUKJXmolecularmatch	KRAS	Afatinib	KRAS G13_V14>DI confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G13_V14>DI confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NglvSS-TIFzzUKJWmolecularmatch	KRAS	Afatinib	KRAS G13Y confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G13Y confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NffzSS-TIFzzUKHmmolecularmatch	KRAS	Afatinib	KRAS G13Y confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G13Y confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NffESS-TIFzzUKHlmolecularmatch	KRAS	Afatinib	KRAS G13V confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G13V confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NflXSS-TIFzzUKHumolecularmatch	KRAS	Afatinib	KRAS G13V confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G13V confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NfkoSS-TIFzzUKHtmolecularmatch	KRAS	Afatinib	KRAS G13S confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G13S confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NfqJSS-TIFzzUKH_molecularmatch	KRAS	Afatinib	KRAS G13S confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G13S confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NfpGSS-TIFzzUKH-molecularmatch	KRAS	Afatinib	KRAS G13R confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G13R confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NfvVSS-TIFzzUKIGmolecularmatch	KRAS	Afatinib	KRAS G13R confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G13R confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NfueSS-TIFzzUKIFmolecularmatch	KRAS	Afatinib	KRAS G13P confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G13P confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Nf0jSS-TIFzzUKINmolecularmatch	KRAS	Afatinib	KRAS G13P confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G13P confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Nfz6SS-TIFzzUKIMmolecularmatch	KRAS	Afatinib	KRAS G13N confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G13N confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Nf4sSS-TIFzzUKITmolecularmatch	KRAS	Afatinib	KRAS G13N confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G13N confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Nf4BSS-TIFzzUKISmolecularmatch	KRAS	Afatinib	KRAS G13M confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G13M confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Nf9nSS-TIFzzUKIbmolecularmatch	KRAS	Afatinib	KRAS G13M confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G13M confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Nf9ASS-TIFzzUKIamolecularmatch	KRAS	Afatinib	KRAS G13I confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G13I confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NgBlSS-TIFzzUKIhmolecularmatch	KRAS	Afatinib	KRAS G13I confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G13I confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NgA7SS-TIFzzUKIgmolecularmatch	KRAS	Afatinib	KRAS G13G confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G13G confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NgGWSS-TIFzzUKIomolecularmatch	KRAS	Afatinib	KRAS G13G confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G13G confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NgFtSS-TIFzzUKInmolecularmatch	KRAS	Afatinib	KRAS G13F confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G13F confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NgLBSS-TIFzzUKIvmolecularmatch	KRAS	Afatinib	KRAS G13F confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G13F confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NgKZSS-TIFzzUKIumolecularmatch	KRAS	Afatinib	KRAS G13E confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G13E confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NgPMSS-TIFzzUKI1molecularmatch	KRAS	Afatinib	KRAS G13E confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G13E confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NgOjSS-TIFzzUKI0molecularmatch	KRAS	Afatinib	KRAS G13D confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G13D confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NgUSSS-TIFzzUKI8molecularmatch	KRAS	Afatinib	KRAS G13D confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G13D confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NgTlSS-TIFzzUKI7molecularmatch	KRAS	Afatinib	KRAS G13C confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G13C confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NgZwSS-TIFzzUKJEmolecularmatch	KRAS	Afatinib	KRAS G13C confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G13C confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NgYZSS-TIFzzUKJCmolecularmatch	KRAS	Afatinib	KRAS G13A confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G13A confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Ngd7SS-TIFzzUKJKmolecularmatch	KRAS	Afatinib	KRAS G13A confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G13A confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NgdKSS-TIFzzUKJJmolecularmatch	KRAS	Afatinib	KRAS G13 confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G13 confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NgrCSS-TIFzzUKJemolecularmatch	KRAS	Afatinib	KRAS G13 confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G13 confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NgqZSS-TIFzzUKJdmolecularmatch	KRAS	Afatinib	KRAS G12fs*3 confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G12fs*3 confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NhlbSS-TIFzzUKK1molecularmatch	KRAS	Afatinib	KRAS G12fs*3 confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G12fs*3 confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NhkwSS-TIFzzUKK0molecularmatch	KRAS	Afatinib	KRAS G12_G13insG confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G12_G13insG confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NiH-SS-TIFzzUKLxmolecularmatch	KRAS	Afatinib	KRAS G12_G13insG confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G12_G13insG confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NiHWSS-TIFzzUKLwmolecularmatch	KRAS	Afatinib	KRAS G12_G13insAG confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G12_G13insAG confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NiNGSS-TIFzzUKL5molecularmatch	KRAS	Afatinib	KRAS G12_G13insAG confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G12_G13insAG confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NiMfSS-TIFzzUKL4molecularmatch	KRAS	Afatinib	KRAS G12_G13insA confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G12_G13insA confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NiR_SS-TIFzzUKMBmolecularmatch	KRAS	Afatinib	KRAS G12_G13insA confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G12_G13insA confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NiQxSS-TIFzzUKL_molecularmatch	KRAS	Afatinib	KRAS G12Y confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G12Y confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NgxJSS-TIFzzUKJnmolecularmatch	KRAS	Afatinib	KRAS G12Y confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G12Y confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NgwiSS-TIFzzUKJmmolecularmatch	KRAS	Afatinib	KRAS G12W confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G12W confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Ng13SS-TIFzzUKJumolecularmatch	KRAS	Afatinib	KRAS G12W confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G12W confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Ng1LSS-TIFzzUKJtmolecularmatch	KRAS	Afatinib	KRAS G12V confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G12V confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Ng7cSS-TIFzzUKJ2molecularmatch	KRAS	Afatinib	KRAS G12V confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G12V confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Ng6ySS-TIFzzUKJ1molecularmatch	KRAS	Afatinib	KRAS G12T confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G12T confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NhBpSS-TIFzzUKJ_molecularmatch	KRAS	Afatinib	KRAS G12T confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G12T confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NhA-SS-TIFzzUKJ-molecularmatch	KRAS	Afatinib	KRAS G12S confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G12S confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NhHSSS-TIFzzUKKHmolecularmatch	KRAS	Afatinib	KRAS G12S confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G12S confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NhF5SS-TIFzzUKKFmolecularmatch	KRAS	Afatinib	KRAS G12R confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G12R confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NhLuSS-TIFzzUKKOmolecularmatch	KRAS	Afatinib	KRAS G12R confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G12R confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NhLGSS-TIFzzUKKNmolecularmatch	KRAS	Afatinib	KRAS G12N confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G12N confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NhRHSS-TIFzzUKKWmolecularmatch	KRAS	Afatinib	KRAS G12N confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G12N confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NhQbSS-TIFzzUKKVmolecularmatch	KRAS	Afatinib	KRAS G12L confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G12L confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NhWxSS-TIFzzUKKemolecularmatch	KRAS	Afatinib	KRAS G12L confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G12L confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NhWHSS-TIFzzUKKdmolecularmatch	KRAS	Afatinib	KRAS G12I confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G12I confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NhbFSS-TIFzzUKKlmolecularmatch	KRAS	Afatinib	KRAS G12I confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G12I confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NhaeSS-TIFzzUKKkmolecularmatch	KRAS	Afatinib	KRAS G12G confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G12G confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Nhf_SS-TIFzzUKKtmolecularmatch	KRAS	Afatinib	KRAS G12G confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G12G confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NhfYSS-TIFzzUKKsmolecularmatch	KRAS	Afatinib	KRAS G12F confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G12F confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NhqKSS-TIFzzUKK8molecularmatch	KRAS	Afatinib	KRAS G12F confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G12F confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NhpfSS-TIFzzUKK7molecularmatch	KRAS	Afatinib	KRAS G12E confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G12E confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NhvhSS-TIFzzUKLEmolecularmatch	KRAS	Afatinib	KRAS G12E confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G12E confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Nhu6SS-TIFzzUKLDmolecularmatch	KRAS	Afatinib	KRAS G12D confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G12D confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Nh04SS-TIFzzUKLMmolecularmatch	KRAS	Afatinib	KRAS G12D confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G12D confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Nh0PSS-TIFzzUKLLmolecularmatch	KRAS	Afatinib	KRAS G12C confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G12C confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Nh7NSS-TIFzzUKLWmolecularmatch	KRAS	Afatinib	KRAS G12C confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G12C confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Nh6hSS-TIFzzUKLVmolecularmatch	KRAS	Afatinib	KRAS G12A confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G12A confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NiCWSS-TIFzzUKLemolecularmatch	KRAS	Afatinib	KRAS G12A confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G12A confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NiBoSS-TIFzzUKLdmolecularmatch	KRAS	Afatinib	KRAS G12 confers resistance to Afatinib in patients with Neoplasm of lung	KRAS G12 confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NiWeSS-TIFzzUKMImolecularmatch	KRAS	Afatinib	KRAS G12 confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	KRAS G12 confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-NiV6SS-TIFzzUKMHmolecularmatch	KLC1-ALK	X-976	KLC1-ALK confers sensitivity to X-976 in patients with Neoplasm of lung	KLC1-ALK confers sensitivity to X-976 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-Nia7SS-TIFzzUKMPmolecularmatch	KLC1-ALK	X-396	KLC1-ALK confers sensitivity to X-396 in patients with Neoplasm of lung	KLC1-ALK confers sensitivity to X-396 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-NiZvSS-TIFzzUKMNmolecularmatch	KLC1-ALK	X-376	KLC1-ALK confers sensitivity to X-376 in patients with Neoplasm of lung	KLC1-ALK confers sensitivity to X-376 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-NibfSS-TIFzzUKMQmolecularmatch	KLC1-ALK	Pf-06463922	KLC1-ALK confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	KLC1-ALK confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-NicJSS-TIFzzUKMRmolecularmatch	KLC1-ALK	Crizotinib	KLC1-ALK confers sensitivity to Crizotinib in patients with Neoplasm of lung	KLC1-ALK confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23401436	AVv-NicvSS-TIFzzUKMSmolecularmatch	KLC1-ALK	Ceritinib	KLC1-ALK confers sensitivity to Ceritinib in patients with Neoplasm of lung	KLC1-ALK confers sensitivity to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25979929	AVv-NieBSS-TIFzzUKMUmolecularmatch	KLC1-ALK	Ap-26113	KLC1-ALK confers sensitivity to Ap-26113 in patients with Neoplasm of lung	KLC1-ALK confers sensitivity to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21502504	AVv-NidVSS-TIFzzUKMTmolecularmatch	KLC1-ALK	Alectinib	KLC1-ALK confers sensitivity to Alectinib in patients with Neoplasm of lung	KLC1-ALK confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27413075	AVv-NiaXSS-TIFzzUKMOmolecularmatch	KIT	Famitinib	KIT confers sensitivity to Famitinib in patients with Neoplasm of colorectum	KIT confers sensitivity to Famitinib in patients with Neoplasm of colorectum	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.513	AVv-Nox9SS-TIFzzUKWsmolecularmatch	KIT	Cabozantinib	KIT confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	KIT confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-No0lSS-TIFzzUKWwmolecularmatch	KIF5B-RET	Vandetanib	KIF5B-RET fusion confers sensitivity to Vandetanib in patients with Neoplasm of lung	KIF5B-RET fusion confers sensitivity to Vandetanib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23584301	AVv-Nig-SS-TIFzzUKMZmolecularmatch	KIF5B-RET	Sunitinib malate	KIF5B-RET fusion confers sensitivity to Sunitinib malate in patients with Neoplasm of lung	KIF5B-RET fusion confers sensitivity to Sunitinib malate in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22327622	AVv-NiejSS-TIFzzUKMVmolecularmatch	KIF5B-RET	Lenvatinib	KIF5B-RET fusion confers sensitivity to Lenvatinib in patients with Neoplasm of lung	KIF5B-RET fusion confers sensitivity to Lenvatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23856031	AVv-NifJSS-TIFzzUKMWmolecularmatch	KIF5B-RET	Cabozantinib	KIF5B-RET fusion confers sensitivity to Cabozantinib in patients with Neoplasm of lung	KIF5B-RET fusion confers sensitivity to Cabozantinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23533264	AVv-NihuSS-TIFzzUKMamolecularmatch	KIF5B-RET	Cabozantinib	KIF5B-RET fusion confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	KIF5B-RET fusion confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NpeZSS-TIFzzUKX7molecularmatch	KIF5B-RET	Alectinib	KIF5B-RET fusion confers sensitivity to Alectinib in patients with Neoplasm of lung	KIF5B-RET fusion confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25349307	AVv-NigPSS-TIFzzUKMYmolecularmatch	KIF5B-ALK	X-976	KIF5B-ALK confers sensitivity to X-976 in patients with Neoplasm of lung	KIF5B-ALK confers sensitivity to X-976 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-NijlSS-TIFzzUKMdmolecularmatch	KIF5B-ALK	X-396	KIF5B-ALK confers sensitivity to X-396 in patients with Neoplasm of lung	KIF5B-ALK confers sensitivity to X-396 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-NiiVSS-TIFzzUKMbmolecularmatch	KIF5B-ALK	X-376	KIF5B-ALK confers sensitivity to X-376 in patients with Neoplasm of lung	KIF5B-ALK confers sensitivity to X-376 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-NikQSS-TIFzzUKMemolecularmatch	KIF5B-ALK	Pf-06463922	KIF5B-ALK confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	KIF5B-ALK confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-Nik6SS-TIFzzUKMfmolecularmatch	KIF5B-ALK	Crizotinib	KIF5B-ALK confers sensitivity to Crizotinib in patients with Neoplasm of lung	KIF5B-ALK confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23401436	AVv-NilhSS-TIFzzUKMgmolecularmatch	KIF5B-ALK	Ceritinib	KIF5B-ALK confers sensitivity to Ceritinib in patients with Neoplasm of lung	KIF5B-ALK confers sensitivity to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25979929	AVv-NinZSS-TIFzzUKMjmolecularmatch	KIF5B-ALK	Ap-26113	KIF5B-ALK confers sensitivity to Ap-26113 in patients with Neoplasm of lung	KIF5B-ALK confers sensitivity to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21502504	AVv-NimHSS-TIFzzUKMhmolecularmatch	KIF5B-ALK	Alectinib	KIF5B-ALK confers sensitivity to Alectinib in patients with Neoplasm of lung	KIF5B-ALK confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27413075	AVv-Nii8SS-TIFzzUKMcmolecularmatch	KIF5B	Cabozantinib	KIF5B confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	KIF5B confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-No7eSS-TIFzzUKW7molecularmatch	KDR	Famitinib	KDR confers sensitivity to Famitinib in patients with Neoplasm of colorectum	KDR confers sensitivity to Famitinib in patients with Neoplasm of colorectum	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.513	AVv-NoysSS-TIFzzUKWtmolecularmatch	KDR	Enmd-2076	KDR confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	KDR confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20406842	AVv-NpBfSS-TIFzzUKXFmolecularmatch	KDR	Cabozantinib	KDR confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	KDR confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NpCKSS-TIFzzUKXGmolecularmatch	IGF1R	Gefitinib	IGF1R Amplification confers resistance to Gefitinib in patients with Neoplasm of lung	IGF1R Amplification confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/17473213	AVv-NioGSS-TIFzzUKMkmolecularmatch	IGF1R	Erlotinib hydrochloride	IGF1R Amplification confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	IGF1R Amplification confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22237261	AVv-NioxSS-TIFzzUKMlmolecularmatch	GPA33	MGD-007	GPA33 confers sensitivity to MGD-007 in patients with Neoplasm of colorectum	GPA33 confers sensitivity to MGD-007 in patients with Neoplasm of colorectum	http://cancerres.aacrjournals.org/content/74/19_supplement/669.short	AVv-Nqj_SS-TIFzzUKZomolecularmatch	GOPC-ROS1	Pf-06463922	GOPC-ROS1 confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	GOPC-ROS1 confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25733882	AVv-NiuxSS-TIFzzUKMumolecularmatch	GOPC-ROS1	Crizotinib	GOPC-ROS1 confers sensitivity to Crizotinib in patients with Neoplasm of lung	GOPC-ROS1 confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25264305	AVv-Niv-SS-TIFzzUKMwmolecularmatch	GOPC-ROS1	Ceritinib	GOPC-ROS1 confers sensitivity to Ceritinib in patients with Neoplasm of lung	GOPC-ROS1 confers sensitivity to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26917690	AVv-NivWSS-TIFzzUKMvmolecularmatch	GOPC-ROS1	Alectinib	GOPC-ROS1 confers sensitivity to Alectinib in patients with Neoplasm of lung	GOPC-ROS1 confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25349307	AVv-NitgSS-TIFzzUKMsmolecularmatch	GNAQ	Selumetinib	GNAQ Q209Y confers sensitivity to Selumetinib in patients with Neoplasm of lung	GNAQ Q209Y confers sensitivity to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22805292	AVv-NipcSS-TIFzzUKMmmolecularmatch	GNAQ	Selumetinib	GNAQ Q209R confers sensitivity to Selumetinib in patients with Neoplasm of lung	GNAQ Q209R confers sensitivity to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22805292	AVv-NiqISS-TIFzzUKMnmolecularmatch	GNAQ	Selumetinib	GNAQ Q209P confers sensitivity to Selumetinib in patients with Neoplasm of lung	GNAQ Q209P confers sensitivity to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22805292	AVv-NiqwSS-TIFzzUKMomolecularmatch	GNAQ	Selumetinib	GNAQ Q209L confers sensitivity to Selumetinib in patients with Neoplasm of lung	GNAQ Q209L confers sensitivity to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22805292	AVv-NircSS-TIFzzUKMpmolecularmatch	GNAQ	Selumetinib	GNAQ Q209K confers sensitivity to Selumetinib in patients with Neoplasm of lung	GNAQ Q209K confers sensitivity to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22805292	AVv-NisISS-TIFzzUKMqmolecularmatch	GNAQ	Selumetinib	GNAQ Q209H confers sensitivity to Selumetinib in patients with Neoplasm of lung	GNAQ Q209H confers sensitivity to Selumetinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22805292	AVv-Nis0SS-TIFzzUKMrmolecularmatch	FZD8	OMP-54F28	FZD8 confers sensitivity to OMP-54F28 in patients with Neoplasm of colorectum	FZD8 confers sensitivity to OMP-54F28 in patients with Neoplasm of colorectum	http://mct.aacrjournals.org/content/12/11_supplement/b48.short	AVv-NqTrSS-TIFzzUKZPmolecularmatch	FZD7	vantictumab	FZD7 confers sensitivity to vantictumab in patients with Neoplasm of colorectum	FZD7 confers sensitivity to vantictumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/22753465	AVv-NpiNSS-TIFzzUKYBmolecularmatch	FN1	L19-TNFalpha	FN1 confers sensitivity to L19-TNFalpha in patients with Neoplasm of colorectum	FN1 confers sensitivity to L19-TNFalpha in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/23160853	AVv-NoqhSS-TIFzzUKWhmolecularmatch	FLT4	Famitinib	FLT4 confers sensitivity to Famitinib in patients with Neoplasm of colorectum	FLT4 confers sensitivity to Famitinib in patients with Neoplasm of colorectum	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.513	AVv-NozUSS-TIFzzUKWumolecularmatch	FLT4	Enmd-2076	FLT4 confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	FLT4 confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20406842	AVv-NpC1SS-TIFzzUKXHmolecularmatch	FLT4	Cabozantinib	FLT4 confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	FLT4 confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NpJnSS-TIFzzUKXRmolecularmatch	FLT3	Sorafenib	FLT3 Amplification confers sensitivity to Sorafenib in patients with Neoplasm of colorectum	FLT3 Amplification confers sensitivity to Sorafenib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25848357	AVv-NpoGSS-TIFzzUKYLmolecularmatch	FLT3	Regorafenib	FLT3 Amplification confers sensitivity to Regorafenib in patients with Neoplasm of colorectum	FLT3 Amplification confers sensitivity to Regorafenib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/27906677	AVv-NpxBSS-TIFzzUKYZmolecularmatch	FLT3	Famitinib	FLT3 confers sensitivity to Famitinib in patients with Neoplasm of colorectum	FLT3 confers sensitivity to Famitinib in patients with Neoplasm of colorectum	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.513	AVv-Noz5SS-TIFzzUKWvmolecularmatch	FLT3	Enmd-2076	FLT3 confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	FLT3 confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20406842	AVv-NpDfSS-TIFzzUKXImolecularmatch	FLT3	Cabozantinib	FLT3 confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	FLT3 confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NpQ5SS-TIFzzUKXcmolecularmatch	FLT1	Famitinib	FLT1 confers sensitivity to Famitinib in patients with Neoplasm of colorectum	FLT1 confers sensitivity to Famitinib in patients with Neoplasm of colorectum	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.513	AVv-No1NSS-TIFzzUKWxmolecularmatch	FLT1	Cabozantinib	FLT1 confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	FLT1 confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NpYiSS-TIFzzUKXnmolecularmatch	FGFR3	Enmd-2076	FGFR3 confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	FGFR3 confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20406842	AVv-NpEESS-TIFzzUKXJmolecularmatch	FGFR2	Sunitinib malate	FGFR2 N549H confers sensitivity to Sunitinib malate in patients with Neoplasm of lung	FGFR2 N549H confers sensitivity to Sunitinib malate in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25732163	AVv-NiwoSS-TIFzzUKMxmolecularmatch	FGFR2	Enmd-2076	FGFR2 confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	FGFR2 confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20406842	AVv-NpEoSS-TIFzzUKXKmolecularmatch	FGFR1	Enmd-2076	FGFR1 confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	FGFR1 confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20406842	AVv-NpFTSS-TIFzzUKXLmolecularmatch	FGFR1	Azd-4547	FGFR1 Amplification confers sensitivity to Azd-4547 in patients with Neoplasm of lung	FGFR1 Amplification confers sensitivity to Azd-4547 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23082000	AVv-NixNSS-TIFzzUKMymolecularmatch	EZR-ROS1	Pf-06463922	EZR-ROS1 confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	EZR-ROS1 confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25733882	AVv-NiybSS-TIFzzUKM0molecularmatch	EZR-ROS1	Crizotinib	EZR-ROS1 confers sensitivity to Crizotinib in patients with Neoplasm of lung	EZR-ROS1 confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25264305	AVv-NizrSS-TIFzzUKM2molecularmatch	EZR-ROS1	Ceritinib	EZR-ROS1 confers sensitivity to Ceritinib in patients with Neoplasm of lung	EZR-ROS1 confers sensitivity to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26917690	AVv-NizGSS-TIFzzUKM1molecularmatch	EZR-ROS1	Alectinib	EZR-ROS1 confers sensitivity to Alectinib in patients with Neoplasm of lung	EZR-ROS1 confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25349307	AVv-Nix0SS-TIFzzUKMzmolecularmatch	ERBB3	Trastuzumab	ERBB3 Q809R confers sensitivity to Trastuzumab in patients with Neoplasm of lung	ERBB3 Q809R confers sensitivity to Trastuzumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25480824	AVv-Ni1dSS-TIFzzUKM5molecularmatch	ERBB3	MCLA-128	ERBB3 confers sensitivity to MCLA-128 in patients with Neoplasm of colorectum	ERBB3 confers sensitivity to MCLA-128 in patients with Neoplasm of colorectum	http://cancerres.aacrjournals.org/content/76/14_supplement/ct050.short	AVv-Nqr-SS-TIFzzUKZ0molecularmatch	ERBB3	Afatinib	ERBB3 Q809R confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB3 Q809R confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23630663	AVv-Ni0TSS-TIFzzUKM3molecularmatch	ERBB3	Afatinib	ERBB3 G284R confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB3 G284R confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23630663	AVv-Ni1_SS-TIFzzUKM6molecularmatch	ERBB2	Trastuzumab	ERBB2 Y772_V773insRDGE confers sensitivity to Trastuzumab in patients with Neoplasm of lung	ERBB2 Y772_V773insRDGE confers sensitivity to Trastuzumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26598547	AVv-Ni3OSS-TIFzzUKM8molecularmatch	ERBB2	Trastuzumab	ERBB2 Y772_A775dup confers sensitivity to Trastuzumab in patients with Neoplasm of lung	ERBB2 Y772_A775dup confers sensitivity to Trastuzumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26598547	AVv-Ni4YSS-TIFzzUKM-molecularmatch	ERBB2	Trastuzumab	ERBB2 V842I confers sensitivity to Trastuzumab in patients with Neoplasm of lung	ERBB2 V842I confers sensitivity to Trastuzumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25480824	AVv-Ni5uSS-TIFzzUKNAmolecularmatch	ERBB2	Trastuzumab	ERBB2 V777_G778insCG confers sensitivity to Trastuzumab in patients with Neoplasm of lung	ERBB2 V777_G778insCG confers sensitivity to Trastuzumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26598547	AVv-Ni8vSS-TIFzzUKNFmolecularmatch	ERBB2	Trastuzumab	ERBB2 V777L confers sensitivity to Trastuzumab in patients with Neoplasm of lung	ERBB2 V777L confers sensitivity to Trastuzumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26598547	AVv-Ni67SS-TIFzzUKNCmolecularmatch	ERBB2	Trastuzumab	ERBB2 S310Y confers sensitivity to Trastuzumab in patients with Neoplasm of lung	ERBB2 S310Y confers sensitivity to Trastuzumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22908275	AVv-Ni98SS-TIFzzUKNHmolecularmatch	ERBB2	Trastuzumab	ERBB2 S310F confers sensitivity to Trastuzumab in patients with Neoplasm of lung	ERBB2 S310F confers sensitivity to Trastuzumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26358791	AVv-Ni_KSS-TIFzzUKNJmolecularmatch	ERBB2	Trastuzumab	ERBB2 R896C confers sensitivity to Trastuzumab in patients with Neoplasm of lung	ERBB2 R896C confers sensitivity to Trastuzumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-NjATSS-TIFzzUKNLmolecularmatch	ERBB2	Trastuzumab	ERBB2 G778_S779insLPS confers sensitivity to Trastuzumab in patients with Neoplasm of lung	ERBB2 G778_S779insLPS confers sensitivity to Trastuzumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26598547	AVv-NjBYSS-TIFzzUKNNmolecularmatch	ERBB2	Trastuzumab	ERBB2 G776delinsVC confers sensitivity to Trastuzumab in patients with Neoplasm of lung	ERBB2 G776delinsVC confers sensitivity to Trastuzumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26598547	AVv-NjEYSS-TIFzzUKNSmolecularmatch	ERBB2	Trastuzumab	ERBB2 G776L confers sensitivity to Trastuzumab in patients with Neoplasm of lung	ERBB2 G776L confers sensitivity to Trastuzumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26598547	AVv-NjDwSS-TIFzzUKNRmolecularmatch	ERBB2	Trastuzumab	ERBB2 G776>VC confers sensitivity to Trastuzumab in patients with Neoplasm of lung	ERBB2 G776>VC confers sensitivity to Trastuzumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26598547	AVv-NjFvSS-TIFzzUKNUmolecularmatch	ERBB2	Trastuzumab	ERBB2 G776>LC confers sensitivity to Trastuzumab in patients with Neoplasm of lung	ERBB2 G776>LC confers sensitivity to Trastuzumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26598547	AVv-NjG9SS-TIFzzUKNWmolecularmatch	ERBB2	Trastuzumab	ERBB2 G309E confers sensitivity to Trastuzumab in patients with Neoplasm of lung	ERBB2 G309E confers sensitivity to Trastuzumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22908275	AVv-NjKPSS-TIFzzUKNbmolecularmatch	ERBB2	Trastuzumab	ERBB2 G309A confers sensitivity to Trastuzumab in patients with Neoplasm of lung	ERBB2 G309A confers sensitivity to Trastuzumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22908275	AVv-NjLhSS-TIFzzUKNdmolecularmatch	ERBB2	Trastuzumab	ERBB2 E770_A771insGIRD confers sensitivity to Trastuzumab in patients with Neoplasm of lung	ERBB2 E770_A771insGIRD confers sensitivity to Trastuzumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26598547	AVv-NjMwSS-TIFzzUKNfmolecularmatch	ERBB2	Trastuzumab	ERBB2 D769Y confers sensitivity to Trastuzumab in patients with Neoplasm of lung	ERBB2 D769Y confers sensitivity to Trastuzumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-NjOlSS-TIFzzUKNimolecularmatch	ERBB2	Trastuzumab	ERBB2 D769H confers sensitivity to Trastuzumab in patients with Neoplasm of lung	ERBB2 D769H confers sensitivity to Trastuzumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-NjP7SS-TIFzzUKNkmolecularmatch	ERBB2	Neratinib	ERBB2 G746delinsVC confers sensitivity to Neratinib in patients with Neoplasm of lung	ERBB2 G746delinsVC confers sensitivity to Neratinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/17311002	AVv-NjIPSS-TIFzzUKNYmolecularmatch	ERBB2	Neratinib	ERBB2 A745_G746insSVMA confers sensitivity to Neratinib in patients with Neoplasm of lung	ERBB2 A745_G746insSVMA confers sensitivity to Neratinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/17311002	AVv-NjSsSS-TIFzzUKNomolecularmatch	ERBB2	MCLA-128	ERBB2 confers sensitivity to MCLA-128 in patients with Neoplasm of colorectum	ERBB2 confers sensitivity to MCLA-128 in patients with Neoplasm of colorectum	http://cancerres.aacrjournals.org/content/76/14_supplement/ct050.short	AVv-NqtNSS-TIFzzUKZ2molecularmatch	ERBB2	Afatinib	ERBB2 Y772_V773insRDGE confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 Y772_V773insRDGE confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22325357	AVv-Ni2nSS-TIFzzUKM7molecularmatch	ERBB2	Afatinib	ERBB2 Y772_A775dup confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 Y772_A775dup confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22325357	AVv-Ni3wSS-TIFzzUKM9molecularmatch	ERBB2	Afatinib	ERBB2 V842I confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 V842I confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25480824	AVv-Ni5ESS-TIFzzUKM_molecularmatch	ERBB2	Afatinib	ERBB2 V777_G778insCG confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 V777_G778insCG confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26964772	AVv-Ni8HSS-TIFzzUKNEmolecularmatch	ERBB2	Afatinib	ERBB2 V777L confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 V777L confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27565914	AVv-Ni6USS-TIFzzUKNBmolecularmatch	ERBB2	Afatinib	ERBB2 S310Y confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 S310Y confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22908275	AVv-Ni9USS-TIFzzUKNGmolecularmatch	ERBB2	Afatinib	ERBB2 S310F confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 S310F confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24835218	AVv-Ni-jSS-TIFzzUKNImolecularmatch	ERBB2	Afatinib	ERBB2 R896C confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 R896C confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25480824	AVv-Ni_tSS-TIFzzUKNKmolecularmatch	ERBB2	Afatinib	ERBB2 G778_S779insLPS confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 G778_S779insLPS confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22325357	AVv-NjA2SS-TIFzzUKNMmolecularmatch	ERBB2	Afatinib	ERBB2 G776L confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 G776L confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22325357	AVv-NjDJSS-TIFzzUKNQmolecularmatch	ERBB2	Afatinib	ERBB2 G776>VC confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 G776>VC confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26545934	AVv-NjFGSS-TIFzzUKNTmolecularmatch	ERBB2	Afatinib	ERBB2 G776>LC confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 G776>LC confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26545934	AVv-NjGWSS-TIFzzUKNVmolecularmatch	ERBB2	Afatinib	ERBB2 G746delinsVC confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 G746delinsVC confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25480824	AVv-NjHoSS-TIFzzUKNXmolecularmatch	ERBB2	Afatinib	ERBB2 G309E confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 G309E confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22908275	AVv-NjI1SS-TIFzzUKNZmolecularmatch	ERBB2	Afatinib	ERBB2 G309A confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 G309A confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22908275	AVv-NjK3SS-TIFzzUKNcmolecularmatch	ERBB2	Afatinib	ERBB2 E770_A771insGIRD confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 E770_A771insGIRD confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26964772	AVv-NjMFSS-TIFzzUKNemolecularmatch	ERBB2	Afatinib	ERBB2 E321G confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 E321G confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22908275	AVv-NjNXSS-TIFzzUKNgmolecularmatch	ERBB2	Afatinib	ERBB2 D769Y confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 D769Y confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25480824	AVv-NjN-SS-TIFzzUKNhmolecularmatch	ERBB2	Afatinib	ERBB2 D769H confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 D769H confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25480824	AVv-NjPTSS-TIFzzUKNjmolecularmatch	ERBB2	Afatinib	ERBB2 A775_G776insYVMA confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 A775_G776insYVMA confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26545934	AVv-NjRQSS-TIFzzUKNmmolecularmatch	ERBB2	Afatinib	ERBB2 A745_G746insSVMA confers sensitivity to Afatinib in patients with Neoplasm of lung	ERBB2 A745_G746insSVMA confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/18408761	AVv-NjR3SS-TIFzzUKNnmolecularmatch	EML4-ALK	X-976	EML4-ALK confers sensitivity to X-976 in patients with Neoplasm of lung	EML4-ALK confers sensitivity to X-976 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-NjUoSS-TIFzzUKNrmolecularmatch	EML4-ALK	X-396	EML4-ALK confers sensitivity to X-396 in patients with Neoplasm of lung	EML4-ALK confers sensitivity to X-396 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-NjTVSS-TIFzzUKNpmolecularmatch	EML4-ALK	X-376	EML4-ALK confers sensitivity to X-376 in patients with Neoplasm of lung	EML4-ALK confers sensitivity to X-376 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-NjVXSS-TIFzzUKNsmolecularmatch	EML4-ALK	Pf-06463922	EML4-ALK confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	EML4-ALK confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-NjWCSS-TIFzzUKNtmolecularmatch	EML4-ALK	Crizotinib	EML4-ALK confers sensitivity to Crizotinib in patients with Neoplasm of lung	EML4-ALK confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23401436	AVv-NjWoSS-TIFzzUKNumolecularmatch	EML4-ALK	Ceritinib	EML4-ALK confers sensitivity to Ceritinib in patients with Neoplasm of lung	EML4-ALK confers sensitivity to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25979929	AVv-NjYvSS-TIFzzUKNxmolecularmatch	EML4-ALK	Cabozantinib	EML4-ALK confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	EML4-ALK confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NqC6SS-TIFzzUKY0molecularmatch	EML4-ALK	Ap-26113	EML4-ALK confers sensitivity to Ap-26113 in patients with Neoplasm of lung	EML4-ALK confers sensitivity to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21502504	AVv-NjXWSS-TIFzzUKNvmolecularmatch	EML4-ALK	Alectinib	EML4-ALK confers sensitivity to Alectinib in patients with Neoplasm of lung	EML4-ALK confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27413075	AVv-NjT9SS-TIFzzUKNqmolecularmatch	EGFR	Sym004	EGFR confers sensitivity to Sym004 in patients with Neoplasm of colorectum	EGFR confers sensitivity to Sym004 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25962717	AVv-NpnZSS-TIFzzUKYKmolecularmatch	EGFR	Sym004	EGFR S492R confers sensitivity to Sym004 in patients with Neoplasm of colorectum	EGFR S492R confers sensitivity to Sym004 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25962717	AVv-NpkjSS-TIFzzUKYFmolecularmatch	EGFR	Sym004	EGFR R451C confers sensitivity to Sym004 in patients with Neoplasm of colorectum	EGFR R451C confers sensitivity to Sym004 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26888827	AVv-Npm0SS-TIFzzUKYJmolecularmatch	EGFR	Sym004	EGFR K467T confers sensitivity to Sym004 in patients with Neoplasm of colorectum	EGFR K467T confers sensitivity to Sym004 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26888827	AVv-NplsSS-TIFzzUKYHmolecularmatch	EGFR	Sym004	EGFR G465R confers sensitivity to Sym004 in patients with Neoplasm of colorectum	EGFR G465R confers sensitivity to Sym004 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26888827	AVv-NpmQSS-TIFzzUKYImolecularmatch	EGFR	Panitumumab	EGFR confers sensitivity to Panitumumab in patients with Neoplasm of colorectum	EGFR confers sensitivity to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20921465	AVv-NqPJSS-TIFzzUKZImolecularmatch	EGFR	Panitumumab	EGFR S492R confers sensitivity to Panitumumab in patients with Neoplasm of colorectum	EGFR S492R confers sensitivity to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/22270724	AVv-NqL0SS-TIFzzUKZDmolecularmatch	EGFR	Panitumumab	EGFR S464L confers resistance to Panitumumab in patients with Neoplasm of colorectum	EGFR S464L confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-NreTSS-TIFzzUKbAmolecularmatch	EGFR	Panitumumab	EGFR R451C confers sensitivity to Panitumumab in patients with Neoplasm of colorectum	EGFR R451C confers sensitivity to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-NqMpSS-TIFzzUKZEmolecularmatch	EGFR	Panitumumab	EGFR R451C confers resistance to Panitumumab in patients with Neoplasm of colorectum	EGFR R451C confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-NrbXSS-TIFzzUKa8molecularmatch	EGFR	Panitumumab	EGFR K467T confers sensitivity to Panitumumab in patients with Neoplasm of colorectum	EGFR K467T confers sensitivity to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-NqLQSS-TIFzzUKZCmolecularmatch	EGFR	Panitumumab	EGFR I491M confers resistance to Panitumumab in patients with Neoplasm of colorectum	EGFR I491M confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-NrdqSS-TIFzzUKa_molecularmatch	EGFR	Panitumumab	EGFR G465R confers resistance to Panitumumab in patients with Neoplasm of colorectum	EGFR G465R confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26059438	AVv-NrcKSS-TIFzzUKa9molecularmatch	EGFR	Panitumumab	EGFR G465E confers resistance to Panitumumab in patients with Neoplasm of colorectum	EGFR G465E confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-Nrc8SS-TIFzzUKa-molecularmatch	EGFR	Panitumumab	EGFR Amplification confers sensitivity to Panitumumab in patients with Neoplasm of colorectum	EGFR Amplification confers sensitivity to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20921465	AVv-NqNVSS-TIFzzUKZFmolecularmatch	EGFR	MM-151	EGFR confers sensitivity to MM-151 in patients with Neoplasm of colorectum	EGFR confers sensitivity to MM-151 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-NqjVSS-TIFzzUKZnmolecularmatch	EGFR	MM-151	EGFR S492R confers sensitivity to MM-151 in patients with Neoplasm of colorectum	EGFR S492R confers sensitivity to MM-151 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-Nqe0SS-TIFzzUKZgmolecularmatch	EGFR	MM-151	EGFR S464L confers sensitivity to MM-151 in patients with Neoplasm of colorectum	EGFR S464L confers sensitivity to MM-151 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-NqiCSS-TIFzzUKZlmolecularmatch	EGFR	MM-151	EGFR R451C confers sensitivity to MM-151 in patients with Neoplasm of colorectum	EGFR R451C confers sensitivity to MM-151 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-NqiqSS-TIFzzUKZmmolecularmatch	EGFR	MM-151	EGFR K467T confers sensitivity to MM-151 in patients with Neoplasm of colorectum	EGFR K467T confers sensitivity to MM-151 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-NqgHSS-TIFzzUKZimolecularmatch	EGFR	MM-151	EGFR I491M confers sensitivity to MM-151 in patients with Neoplasm of colorectum	EGFR I491M confers sensitivity to MM-151 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-NqfcSS-TIFzzUKZhmolecularmatch	EGFR	MM-151	EGFR G465R confers sensitivity to MM-151 in patients with Neoplasm of colorectum	EGFR G465R confers sensitivity to MM-151 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-NqhcSS-TIFzzUKZkmolecularmatch	EGFR	MM-151	EGFR G465E confers sensitivity to MM-151 in patients with Neoplasm of colorectum	EGFR G465E confers sensitivity to MM-151 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-NqgwSS-TIFzzUKZjmolecularmatch	EGFR	Gefitinib	EGFR exon 20 insertion confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR exon 20 insertion confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-Nlb1SS-TIFzzUKRQmolecularmatch	EGFR	Gefitinib	EGFR Y801fs*1 confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR Y801fs*1 confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NjaCSS-TIFzzUKNzmolecularmatch	EGFR	Gefitinib	EGFR Y270* confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR Y270* confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-Njb0SS-TIFzzUKN2molecularmatch	EGFR	Gefitinib	EGFR W200* confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR W200* confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NjdrSS-TIFzzUKN5molecularmatch	EGFR	Gefitinib	EGFR V774_C775insHV confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR V774_C775insHV confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-Njh0SS-TIFzzUKOAmolecularmatch	EGFR	Gefitinib	EGFR V769_D770insMASVD confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR V769_D770insMASVD confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NjjFSS-TIFzzUKOCmolecularmatch	EGFR	Gefitinib	EGFR V769_D770insGVV confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR V769_D770insGVV confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NjkSSS-TIFzzUKOEmolecularmatch	EGFR	Gefitinib	EGFR V769_D770insGSV confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR V769_D770insGSV confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NjmuSS-TIFzzUKOImolecularmatch	EGFR	Gefitinib	EGFR V769_D770insERG confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR V769_D770insERG confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NjoASS-TIFzzUKOKmolecularmatch	EGFR	Gefitinib	EGFR V769_D770insCV confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR V769_D770insCV confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-Njp7SS-TIFzzUKONmolecularmatch	EGFR	Gefitinib	EGFR V769_D770insASV confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR V769_D770insASV confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NjrwSS-TIFzzUKOQmolecularmatch	EGFR	Gefitinib	EGFR V769_D770insANV confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR V769_D770insANV confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NjtnSS-TIFzzUKOTmolecularmatch	EGFR	Gefitinib	EGFR T790M confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR T790M confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23470965	AVv-Nju1SS-TIFzzUKOVmolecularmatch	EGFR	Gefitinib	EGFR T751_E758del confers sensitivity to Gefitinib in patients with Neoplasm of lung	EGFR T751_E758del confers sensitivity to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26980062	AVv-Nj2RSS-TIFzzUKOhmolecularmatch	EGFR	Gefitinib	EGFR S380Pfs*16 confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR S380Pfs*16 confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-Nj76SS-TIFzzUKOqmolecularmatch	EGFR	Gefitinib	EGFR R832H confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR R832H confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/17062680	AVv-Nj9KSS-TIFzzUKOsmolecularmatch	EGFR	Gefitinib	EGFR R669* confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR R669* confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-Nj-aSS-TIFzzUKOumolecularmatch	EGFR	Gefitinib	EGFR R531* confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR R531* confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NkA-SS-TIFzzUKOymolecularmatch	EGFR	Gefitinib	EGFR R255* confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR R255* confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NkDDSS-TIFzzUKO1molecularmatch	EGFR	Gefitinib	EGFR Q71* confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR Q71* confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NkE-SS-TIFzzUKO4molecularmatch	EGFR	Gefitinib	EGFR Q701* confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR Q701* confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NkG_SS-TIFzzUKO7molecularmatch	EGFR	Gefitinib	EGFR Q486* confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR Q486* confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NkKHSS-TIFzzUKPAmolecularmatch	EGFR	Gefitinib	EGFR Q276* confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR Q276* confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NkL9SS-TIFzzUKPDmolecularmatch	EGFR	Gefitinib	EGFR P772_H773insX confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR P772_H773insX confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkNzSS-TIFzzUKPGmolecularmatch	EGFR	Gefitinib	EGFR P772_H773insV confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR P772_H773insV confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkQLSS-TIFzzUKPKmolecularmatch	EGFR	Gefitinib	EGFR P772_H773insTP confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR P772_H773insTP confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkSCSS-TIFzzUKPNmolecularmatch	EGFR	Gefitinib	EGFR P772_H773insTHP confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR P772_H773insTHP confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkTrSS-TIFzzUKPQmolecularmatch	EGFR	Gefitinib	EGFR P772_H773insDNP confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR P772_H773insDNP confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkWoSS-TIFzzUKPVmolecularmatch	EGFR	Gefitinib	EGFR N771_P772insVDN confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR N771_P772insVDN confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkbHSS-TIFzzUKPdmolecularmatch	EGFR	Gefitinib	EGFR N771_P772insRH confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR N771_P772insRH confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkdsSS-TIFzzUKPimolecularmatch	EGFR	Gefitinib	EGFR N771_P772insN confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR N771_P772insN confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkfNSS-TIFzzUKPlmolecularmatch	EGFR	Gefitinib	EGFR N771_P772insH confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR N771_P772insH confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkgxSS-TIFzzUKPomolecularmatch	EGFR	Gefitinib	EGFR N771>TH confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR N771>TH confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkXuSS-TIFzzUKPXmolecularmatch	EGFR	Gefitinib	EGFR N771>SH confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR N771>SH confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkY4SS-TIFzzUKPZmolecularmatch	EGFR	Gefitinib	EGFR N771>SGH confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR N771>SGH confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkaISS-TIFzzUKPbmolecularmatch	EGFR	Gefitinib	EGFR Loss confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR Loss confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-Nkj3SS-TIFzzUKP3molecularmatch	EGFR	Gefitinib	EGFR L858R confers sensitivity to Gefitinib in patients with Neoplasm of lung	EGFR L858R confers sensitivity to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26980062	AVv-NkrISS-TIFzzUKQCmolecularmatch	EGFR	Gefitinib	EGFR L747_T751del confers sensitivity to Gefitinib in patients with Neoplasm of lung	EGFR L747_T751del confers sensitivity to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26980062	AVv-NkwJSS-TIFzzUKQJmolecularmatch	EGFR	Gefitinib	EGFR L747_S752del confers sensitivity to Gefitinib in patients with Neoplasm of lung	EGFR L747_S752del confers sensitivity to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26980062	AVv-Nk1oSS-TIFzzUKQSmolecularmatch	EGFR	Gefitinib	EGFR L747_E749delLRE confers sensitivity to Gefitinib in patients with Neoplasm of lung	EGFR L747_E749delLRE confers sensitivity to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26980062	AVv-Nk5kSS-TIFzzUKQYmolecularmatch	EGFR	Gefitinib	EGFR L707* confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR L707* confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-Nk8oSS-TIFzzUKQdmolecularmatch	EGFR	Gefitinib	EGFR H773_V774insTQPP confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR H773_V774insTQPP confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NlACSS-TIFzzUKQjmolecularmatch	EGFR	Gefitinib	EGFR H773_V774insQ confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR H773_V774insQ confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NlBqSS-TIFzzUKQmmolecularmatch	EGFR	Gefitinib	EGFR H773_V774insPH confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR H773_V774insPH confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NlC1SS-TIFzzUKQomolecularmatch	EGFR	Gefitinib	EGFR H773_V774insNPH confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR H773_V774insNPH confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NlEcSS-TIFzzUKQrmolecularmatch	EGFR	Gefitinib	EGFR H773_V774insH confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR H773_V774insH confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NlHaSS-TIFzzUKQwmolecularmatch	EGFR	Gefitinib	EGFR H773_V774insGNPH confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR H773_V774insGNPH confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NlItSS-TIFzzUKQymolecularmatch	EGFR	Gefitinib	EGFR H773_V774insAH confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR H773_V774insAH confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NlLBSS-TIFzzUKQ2molecularmatch	EGFR	Gefitinib	EGFR H773>PNPY confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR H773>PNPY confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-Nk-YSS-TIFzzUKQgmolecularmatch	EGFR	Gefitinib	EGFR G719A confers sensitivity to Gefitinib in patients with Neoplasm of lung	EGFR G719A confers sensitivity to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26980062	AVv-NlQ7SS-TIFzzUKRAmolecularmatch	EGFR	Gefitinib	EGFR G598* confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR G598* confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NlTwSS-TIFzzUKREmolecularmatch	EGFR	Gefitinib	EGFR G573* confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR G573* confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NlVGSS-TIFzzUKRGmolecularmatch	EGFR	Gefitinib	EGFR G339* confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR G339* confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NlXDSS-TIFzzUKRJmolecularmatch	EGFR	Gefitinib	EGFR G225Afs*55 confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR G225Afs*55 confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NlZLSS-TIFzzUKRMmolecularmatch	EGFR	Gefitinib	EGFR E746delE confers sensitivity to Gefitinib in patients with Neoplasm of lung	EGFR E746delE confers sensitivity to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26980062	AVv-NlfySS-TIFzzUKRWmolecularmatch	EGFR	Gefitinib	EGFR E746_T751delinsA confers sensitivity to Gefitinib in patients with Neoplasm of lung	EGFR E746_T751delinsA confers sensitivity to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26980062	AVv-NllPSS-TIFzzUKRemolecularmatch	EGFR	Gefitinib	EGFR E746_S752delinsA confers sensitivity to Gefitinib in patients with Neoplasm of lung	EGFR E746_S752delinsA confers sensitivity to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26980062	AVv-Nls6SS-TIFzzUKRqmolecularmatch	EGFR	Gefitinib	EGFR E746_A750del confers sensitivity to Gefitinib in patients with Neoplasm of lung	EGFR E746_A750del confers sensitivity to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26980062	AVv-Nl3GSS-TIFzzUKR7molecularmatch	EGFR	Gefitinib	EGFR E709fs*1 confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR E709fs*1 confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-Nl96SS-TIFzzUKSHmolecularmatch	EGFR	Gefitinib	EGFR D770fs*61 confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR D770fs*61 confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-Nl_DSS-TIFzzUKSJmolecularmatch	EGFR	Gefitinib	EGFR D770_N771insY confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR D770_N771insY confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmCUSS-TIFzzUKSOmolecularmatch	EGFR	Gefitinib	EGFR D770_N771insSVE confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR D770_N771insSVE confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmFCSS-TIFzzUKSSmolecularmatch	EGFR	Gefitinib	EGFR D770_N771insSVD confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR D770_N771insSVD confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmG6SS-TIFzzUKSVmolecularmatch	EGFR	Gefitinib	EGFR D770_N771insMATP confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR D770_N771insMATP confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmI5SS-TIFzzUKSYmolecularmatch	EGFR	Gefitinib	EGFR D770_N771insGT confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR D770_N771insGT confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmLhSS-TIFzzUKScmolecularmatch	EGFR	Gefitinib	EGFR D770_N771insGL confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR D770_N771insGL confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmNdSS-TIFzzUKSfmolecularmatch	EGFR	Gefitinib	EGFR D770_N771insGF confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR D770_N771insGF confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmPVSS-TIFzzUKSimolecularmatch	EGFR	Gefitinib	EGFR D770_N771insGD confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR D770_N771insGD confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmReSS-TIFzzUKSlmolecularmatch	EGFR	Gefitinib	EGFR D770_N771insG confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR D770_N771insG confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmUySS-TIFzzUKSqmolecularmatch	EGFR	Gefitinib	EGFR D770_N771insAPW confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR D770_N771insAPW confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmWqSS-TIFzzUKStmolecularmatch	EGFR	Gefitinib	EGFR D770>GY confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR D770>GY confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmAPSS-TIFzzUKSLmolecularmatch	EGFR	Gefitinib	EGFR Amplification confers sensitivity to Gefitinib in patients with Neoplasm of lung	EGFR Amplification confers sensitivity to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/15998907	AVv-NmhxSS-TIFzzUKTBmolecularmatch	EGFR	Gefitinib	EGFR A767_S768insTLA confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR A767_S768insTLA confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmkPSS-TIFzzUKTFmolecularmatch	EGFR	Gefitinib	EGFR A767_S768insSVG confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR A767_S768insSVG confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmmFSS-TIFzzUKTImolecularmatch	EGFR	Gefitinib	EGFR A767_S768insIA confers resistance to Gefitinib in patients with Neoplasm of lung	EGFR A767_S768insIA confers resistance to Gefitinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-Nmn9SS-TIFzzUKTLmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR Y801fs*1 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR Y801fs*1 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19724844	AVv-NjZYSS-TIFzzUKNymolecularmatch	EGFR	Erlotinib hydrochloride	EGFR Y270* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR Y270* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NjbNSS-TIFzzUKN1molecularmatch	EGFR	Erlotinib hydrochloride	EGFR W200* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR W200* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NjdFSS-TIFzzUKN4molecularmatch	EGFR	Erlotinib hydrochloride	EGFR V774_C775insHV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR V774_C775insHV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NjhLSS-TIFzzUKN_molecularmatch	EGFR	Erlotinib hydrochloride	EGFR V769_D770insMASVD confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR V769_D770insMASVD confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NjicSS-TIFzzUKOBmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR V769_D770insGVV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR V769_D770insGVV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NjjsSS-TIFzzUKODmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR V769_D770insGSV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR V769_D770insGSV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NjmFSS-TIFzzUKOHmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR V769_D770insERG confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR V769_D770insERG confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NjnXSS-TIFzzUKOJmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR V769_D770insCV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR V769_D770insCV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NjpUSS-TIFzzUKOMmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR V769_D770insASV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR V769_D770insASV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NjrKSS-TIFzzUKOPmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR V769_D770insANV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR V769_D770insANV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-Njs_SS-TIFzzUKOSmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR T790M confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR T790M confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23470965	AVv-NjuLSS-TIFzzUKOUmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR T751fs*4 confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR T751fs*4 confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24868098	AVv-NjzpSS-TIFzzUKOdmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR T751_E758del confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR T751_E758del confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24868098	AVv-Nj0OSS-TIFzzUKOemolecularmatch	EGFR	Erlotinib hydrochloride	EGFR S768I confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR S768I confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26773740	AVv-Nj3mSS-TIFzzUKOjmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR S380Pfs*16 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR S380Pfs*16 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-Nj7TSS-TIFzzUKOpmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR R832H confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR R832H confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/17062680	AVv-Nj8jSS-TIFzzUKOrmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR R669* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR R669* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-Nj9xSS-TIFzzUKOtmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR R531* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR R531* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-Nj_mSS-TIFzzUKOwmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR R255* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR R255* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NkCaSS-TIFzzUKO0molecularmatch	EGFR	Erlotinib hydrochloride	EGFR Q71* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR Q71* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NkEQSS-TIFzzUKO3molecularmatch	EGFR	Erlotinib hydrochloride	EGFR Q701* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR Q701* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NkGUSS-TIFzzUKO6molecularmatch	EGFR	Erlotinib hydrochloride	EGFR Q486* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR Q486* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NkJlSS-TIFzzUKO_molecularmatch	EGFR	Erlotinib hydrochloride	EGFR Q276* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR Q276* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NkLZSS-TIFzzUKPCmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR P772_H773insX confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR P772_H773insX confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkNISS-TIFzzUKPFmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR P772_H773insV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR P772_H773insV confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkPlSS-TIFzzUKPJmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR P772_H773insTP confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR P772_H773insTP confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkRbSS-TIFzzUKPMmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR P772_H773insTHP confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR P772_H773insTHP confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkTHSS-TIFzzUKPPmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR P772_H773insDNP confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR P772_H773insDNP confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkWDSS-TIFzzUKPUmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR N771_P772insVDN confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR N771_P772insVDN confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkanSS-TIFzzUKPcmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR N771_P772insRH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR N771_P772insRH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkdOSS-TIFzzUKPhmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR N771_P772insN confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR N771_P772insN confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkerSS-TIFzzUKPkmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR N771_P772insH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR N771_P772insH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkgQSS-TIFzzUKPnmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR N771>TH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR N771>TH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkXLSS-TIFzzUKPWmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR N771>SH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR N771>SH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkYSSS-TIFzzUKPYmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR N771>SGH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR N771>SGH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NkZlSS-TIFzzUKPamolecularmatch	EGFR	Erlotinib hydrochloride	EGFR Loss confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR Loss confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NkjISS-TIFzzUKP2molecularmatch	EGFR	Erlotinib hydrochloride	EGFR L861R confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR L861R confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21531810	AVv-NkkgSS-TIFzzUKP4molecularmatch	EGFR	Erlotinib hydrochloride	EGFR L861Q confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR L861Q confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21531810	AVv-NklzSS-TIFzzUKP6molecularmatch	EGFR	Erlotinib hydrochloride	EGFR L861P confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR L861P confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21531810	AVv-NknFSS-TIFzzUKP8molecularmatch	EGFR	Erlotinib hydrochloride	EGFR L858R confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR L858R confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24868098	AVv-NkoZSS-TIFzzUKP-molecularmatch	EGFR	Erlotinib hydrochloride	EGFR L747_T751del confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR L747_T751del confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24868098	AVv-Nkt9SS-TIFzzUKQGmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR L747_S752del confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR L747_S752del confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24868098	AVv-NkzUSS-TIFzzUKQOmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR L747_E749delLRE confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR L747_E749delLRE confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24868098	AVv-Nk2_SS-TIFzzUKQUmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR L747S confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR L747S confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/18309959	AVv-NksmSS-TIFzzUKQEmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR L707* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR L707* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-Nk8GSS-TIFzzUKQcmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR H773_V774insTQPP confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR H773_V774insTQPP confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-Nk_eSS-TIFzzUKQimolecularmatch	EGFR	Erlotinib hydrochloride	EGFR H773_V774insQ confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR H773_V774insQ confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NlBHSS-TIFzzUKQlmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR H773_V774insPH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR H773_V774insPH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NlCPSS-TIFzzUKQnmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR H773_V774insNPH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR H773_V774insNPH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NlD7SS-TIFzzUKQqmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR H773_V774insH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR H773_V774insH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NlG4SS-TIFzzUKQvmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR H773_V774insGNPH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR H773_V774insGNPH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NlIKSS-TIFzzUKQxmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR H773_V774insAH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR H773_V774insAH confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NlKdSS-TIFzzUKQ1molecularmatch	EGFR	Erlotinib hydrochloride	EGFR H773>PNPY confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR H773>PNPY confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-Nk9zSS-TIFzzUKQfmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR G719S confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR G719S confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21531810	AVv-NlMvSS-TIFzzUKQ5molecularmatch	EGFR	Erlotinib hydrochloride	EGFR G719D confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR G719D confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21531810	AVv-NlN6SS-TIFzzUKQ7molecularmatch	EGFR	Erlotinib hydrochloride	EGFR G719C confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR G719C confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21531810	AVv-NlPHSS-TIFzzUKQ9molecularmatch	EGFR	Erlotinib hydrochloride	EGFR G719A confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR G719A confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21531810	AVv-NlQSSS-TIFzzUKQ_molecularmatch	EGFR	Erlotinib hydrochloride	EGFR G598* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR G598* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NlSTSS-TIFzzUKRCmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR G573* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR G573* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NlUeSS-TIFzzUKRFmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR G339* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR G339* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NlWeSS-TIFzzUKRImolecularmatch	EGFR	Erlotinib hydrochloride	EGFR G225Afs*55 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR G225Afs*55 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NlYaSS-TIFzzUKRLmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR E746fs*15 confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR E746fs*15 confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24868098	AVv-NlcgSS-TIFzzUKRRmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR E746delE confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR E746delE confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24868098	AVv-Nld4SS-TIFzzUKRTmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR E746_T751delinsA confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR E746_T751delinsA confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24868098	AVv-NljLSS-TIFzzUKRbmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR E746_S752delinsA confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR E746_S752delinsA confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24868098	AVv-NlrISS-TIFzzUKRnmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR E746_A750del confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR E746_A750del confers sensitivity to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24868098	AVv-Nl0bSS-TIFzzUKR3molecularmatch	EGFR	Erlotinib hydrochloride	EGFR E709fs*1 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR E709fs*1 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-Nl9XSS-TIFzzUKSGmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR D770fs*61 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR D770fs*61 confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-Nl-dSS-TIFzzUKSImolecularmatch	EGFR	Erlotinib hydrochloride	EGFR D770_N771insY confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR D770_N771insY confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmBlSS-TIFzzUKSNmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR D770_N771insSVE confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR D770_N771insSVE confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmEaSS-TIFzzUKSRmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR D770_N771insSVD confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR D770_N771insSVD confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmGRSS-TIFzzUKSUmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR D770_N771insMATP confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR D770_N771insMATP confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmIQSS-TIFzzUKSXmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR D770_N771insGT confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR D770_N771insGT confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmKPSS-TIFzzUKSamolecularmatch	EGFR	Erlotinib hydrochloride	EGFR D770_N771insGL confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR D770_N771insGL confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmMwSS-TIFzzUKSemolecularmatch	EGFR	Erlotinib hydrochloride	EGFR D770_N771insGF confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR D770_N771insGF confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmOvSS-TIFzzUKShmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR D770_N771insGD confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR D770_N771insGD confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmQnSS-TIFzzUKSkmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR D770_N771insG confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR D770_N771insG confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmULSS-TIFzzUKSpmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR D770_N771insAPW confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR D770_N771insAPW confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmWASS-TIFzzUKSsmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR D770>GY confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR D770>GY confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-Nl_mSS-TIFzzUKSKmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR C311* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR C311* confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26711932	AVv-NmgKSS-TIFzzUKS-molecularmatch	EGFR	Erlotinib hydrochloride	EGFR A767_S768insTLA confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR A767_S768insTLA confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmjpSS-TIFzzUKTEmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR A767_S768insSVG confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR A767_S768insSVG confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-Nmk3SS-TIFzzUKTGmolecularmatch	EGFR	Erlotinib hydrochloride	EGFR A767_S768insIA confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	EGFR A767_S768insIA confers resistance to Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NmnQSS-TIFzzUKTKmolecularmatch	EGFR	Co-1686	EGFR T790M confers sensitivity to Co-1686 in patients with Neoplasm of lung	EGFR T790M confers sensitivity to Co-1686 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923550	AVv-NjwASS-TIFzzUKOXmolecularmatch	EGFR	Co-1686	EGFR C797Y confers resistance to Co-1686 in patients with Neoplasm of lung	EGFR C797Y confers resistance to Co-1686 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24723450	AVv-NmXPSS-TIFzzUKSumolecularmatch	EGFR	Co-1686	EGFR C797S confers resistance to Co-1686 in patients with Neoplasm of lung	EGFR C797S confers resistance to Co-1686 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24723450	AVv-NmZFSS-TIFzzUKSxmolecularmatch	EGFR	Co-1686	EGFR C797R confers resistance to Co-1686 in patients with Neoplasm of lung	EGFR C797R confers resistance to Co-1686 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24723450	AVv-NmaxSS-TIFzzUKS0molecularmatch	EGFR	Co-1686	EGFR C797G confers resistance to Co-1686 in patients with Neoplasm of lung	EGFR C797G confers resistance to Co-1686 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24723450	AVv-NmcWSS-TIFzzUKS3molecularmatch	EGFR	Co-1686	EGFR C797 confers resistance to Co-1686 in patients with Neoplasm of lung	EGFR C797 confers resistance to Co-1686 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24723450	AVv-Nmd_SS-TIFzzUKS6molecularmatch	EGFR	Cetuximab	EGFR exon 14 mutation confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	EGFR exon 14 mutation confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19339720	AVv-NpQJSS-TIFzzUKXbmolecularmatch	EGFR	Cetuximab	EGFR confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	EGFR confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19114683	AVv-NpV3SS-TIFzzUKXjmolecularmatch	EGFR	Cetuximab	EGFR S492R confers resistance to Cetuximab in patients with Neoplasm of colorectum	EGFR S492R confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/22270724	AVv-NsUtSS-TIFzzUKcbmolecularmatch	EGFR	Cetuximab	EGFR S464L confers resistance to Cetuximab in patients with Neoplasm of colorectum	EGFR S464L confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25623215	AVv-NrvMSS-TIFzzUKbZmolecularmatch	EGFR	Cetuximab	EGFR R705G confers resistance to Cetuximab in patients with Neoplasm of colorectum	EGFR R705G confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/23578570	AVv-NsNvSS-TIFzzUKcQmolecularmatch	EGFR	Cetuximab	EGFR R451C confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	EGFR R451C confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-NpTCSS-TIFzzUKXfmolecularmatch	EGFR	Cetuximab	EGFR R451C confers resistance to Cetuximab in patients with Neoplasm of colorectum	EGFR R451C confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26888827	AVv-NrJ0SS-TIFzzUKaimolecularmatch	EGFR	Cetuximab	EGFR P546S confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	EGFR P546S confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/23578570	AVv-NpRpSS-TIFzzUKXdmolecularmatch	EGFR	Cetuximab	EGFR K467T confers resistance to Cetuximab in patients with Neoplasm of colorectum	EGFR K467T confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26888827	AVv-NrRkSS-TIFzzUKatmolecularmatch	EGFR	Cetuximab	EGFR I491M confers resistance to Cetuximab in patients with Neoplasm of colorectum	EGFR I491M confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25623215	AVv-Nrn5SS-TIFzzUKbOmolecularmatch	EGFR	Cetuximab	EGFR G465R confers resistance to Cetuximab in patients with Neoplasm of colorectum	EGFR G465R confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25623215	AVv-NrYxSS-TIFzzUKa4molecularmatch	EGFR	Cetuximab	EGFR G465E confers resistance to Cetuximab in patients with Neoplasm of colorectum	EGFR G465E confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-NrgUSS-TIFzzUKbDmolecularmatch	EGFR	Cetuximab	EGFR Amplification confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	EGFR Amplification confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19884556	AVv-NpSWSS-TIFzzUKXemolecularmatch	EGFR	Azd-9291	EGFR T790M confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR T790M confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27821604	AVv-NjxSSS-TIFzzUKOZmolecularmatch	EGFR	Azd-9291	EGFR T751_E758del confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR T751_E758del confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-Nj1jSS-TIFzzUKOgmolecularmatch	EGFR	Azd-9291	EGFR S752_I759del confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR S752_I759del confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-Nj6tSS-TIFzzUKOomolecularmatch	EGFR	Azd-9291	EGFR L858R confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR L858R confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-NkqWSS-TIFzzUKQBmolecularmatch	EGFR	Azd-9291	EGFR L747_T751del confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR L747_T751del confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-NkvbSS-TIFzzUKQImolecularmatch	EGFR	Azd-9291	EGFR L747_S752del confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR L747_S752del confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-Nk0rSS-TIFzzUKQRmolecularmatch	EGFR	Azd-9291	EGFR L747_E749delLRE confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR L747_E749delLRE confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-Nk47SS-TIFzzUKQXmolecularmatch	EGFR	Azd-9291	EGFR L747_E749del confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR L747_E749del confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-Nk7dSS-TIFzzUKQbmolecularmatch	EGFR	Azd-9291	EGFR E746delE confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR E746delE confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-NlfLSS-TIFzzUKRVmolecularmatch	EGFR	Azd-9291	EGFR E746_T751delinsVP confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR E746_T751delinsVP confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-NlihSS-TIFzzUKRamolecularmatch	EGFR	Azd-9291	EGFR E746_T751delinsA confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR E746_T751delinsA confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-NlkoSS-TIFzzUKRdmolecularmatch	EGFR	Azd-9291	EGFR E746_S752delinsV confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR E746_S752delinsV confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-NlnaSS-TIFzzUKRhmolecularmatch	EGFR	Azd-9291	EGFR E746_S752delinsA confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR E746_S752delinsA confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-NlopSS-TIFzzUKRjmolecularmatch	EGFR	Azd-9291	EGFR E746_S752>I confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR E746_S752>I confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-NlqeSS-TIFzzUKRmmolecularmatch	EGFR	Azd-9291	EGFR E746_P753delinsVS confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR E746_P753delinsVS confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-NluqSS-TIFzzUKRtmolecularmatch	EGFR	Azd-9291	EGFR E746_P753>IS confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR E746_P753>IS confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-NlweSS-TIFzzUKRwmolecularmatch	EGFR	Azd-9291	EGFR E746_E749delinsA confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR E746_E749delinsA confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-NlxmSS-TIFzzUKRymolecularmatch	EGFR	Azd-9291	EGFR E746_A750delinsIP confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR E746_A750delinsIP confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-NlyqSS-TIFzzUKR0molecularmatch	EGFR	Azd-9291	EGFR E746_A750delinsAP confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR E746_A750delinsAP confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-Nlz3SS-TIFzzUKR2molecularmatch	EGFR	Azd-9291	EGFR E746_A750del confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR E746_A750del confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-Nl1zSS-TIFzzUKR5molecularmatch	EGFR	Azd-9291	EGFR E746_A750>VP confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR E746_A750>VP confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-Nl41SS-TIFzzUKR-molecularmatch	EGFR	Azd-9291	EGFR E746_A750>RP confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR E746_A750>RP confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-Nl6BSS-TIFzzUKSAmolecularmatch	EGFR	Azd-9291	EGFR E746_A750>QP confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR E746_A750>QP confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-Nl7ISS-TIFzzUKSCmolecularmatch	EGFR	Azd-9291	EGFR E746_A750>DP confers sensitivity to Azd-9291 in patients with Neoplasm of lung	EGFR E746_A750>DP confers sensitivity to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-Nl8QSS-TIFzzUKSEmolecularmatch	EGFR	Azd-9291	EGFR C797Y confers resistance to Azd-9291 in patients with Neoplasm of lung	EGFR C797Y confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24893891	AVv-NmYZSS-TIFzzUKSwmolecularmatch	EGFR	Azd-9291	EGFR C797S confers resistance to Azd-9291 in patients with Neoplasm of lung	EGFR C797S confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24893891	AVv-NmaNSS-TIFzzUKSzmolecularmatch	EGFR	Azd-9291	EGFR C797R confers resistance to Azd-9291 in patients with Neoplasm of lung	EGFR C797R confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24893891	AVv-Nmb0SS-TIFzzUKS2molecularmatch	EGFR	Azd-9291	EGFR C797G confers resistance to Azd-9291 in patients with Neoplasm of lung	EGFR C797G confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24893891	AVv-NmdbSS-TIFzzUKS5molecularmatch	EGFR	Azd-9291	EGFR C797 confers resistance to Azd-9291 in patients with Neoplasm of lung	EGFR C797 confers resistance to Azd-9291 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24893891	AVv-NmfmSS-TIFzzUKS9molecularmatch	EGFR	Asp8273	EGFR T790M confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR T790M confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-NjwtSS-TIFzzUKOYmolecularmatch	EGFR	Asp8273	EGFR T751_E758del confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR T751_E758del confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-Nj07SS-TIFzzUKOfmolecularmatch	EGFR	Asp8273	EGFR S752_I759del confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR S752_I759del confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-Nj6ASS-TIFzzUKOnmolecularmatch	EGFR	Asp8273	EGFR L858R confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR L858R confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-NkpvSS-TIFzzUKQAmolecularmatch	EGFR	Asp8273	EGFR L747_T751del confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR L747_T751del confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-NkurSS-TIFzzUKQHmolecularmatch	EGFR	Asp8273	EGFR L747_S752del confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR L747_S752del confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-Nk0ASS-TIFzzUKQPmolecularmatch	EGFR	Asp8273	EGFR L747_E749delLRE confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR L747_E749delLRE confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-Nk3kSS-TIFzzUKQVmolecularmatch	EGFR	Asp8273	EGFR L747_E749del confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR L747_E749del confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-Nk6wSS-TIFzzUKQamolecularmatch	EGFR	Asp8273	EGFR E746delE confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR E746delE confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-NleiSS-TIFzzUKRUmolecularmatch	EGFR	Asp8273	EGFR E746_T751delinsVP confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR E746_T751delinsVP confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-NlhESS-TIFzzUKRYmolecularmatch	EGFR	Asp8273	EGFR E746_T751delinsA confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR E746_T751delinsA confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-Nlj5SS-TIFzzUKRcmolecularmatch	EGFR	Asp8273	EGFR E746_S752delinsV confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR E746_S752delinsV confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-NlmrSS-TIFzzUKRgmolecularmatch	EGFR	Asp8273	EGFR E746_S752delinsA confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR E746_S752delinsA confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-NlruSS-TIFzzUKRomolecularmatch	EGFR	Asp8273	EGFR E746_S752>I confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR E746_S752>I confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-Nlp0SS-TIFzzUKRlmolecularmatch	EGFR	Asp8273	EGFR E746_P753delinsVS confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR E746_P753delinsVS confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-NluGSS-TIFzzUKRsmolecularmatch	EGFR	Asp8273	EGFR E746_P753>IS confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR E746_P753>IS confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-NlvRSS-TIFzzUKRumolecularmatch	EGFR	Asp8273	EGFR E746_E749delinsA confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR E746_E749delinsA confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-NlxESS-TIFzzUKRxmolecularmatch	EGFR	Asp8273	EGFR E746_A750delinsIP confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR E746_A750delinsIP confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-NlyISS-TIFzzUKRzmolecularmatch	EGFR	Asp8273	EGFR E746_A750delinsAP confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR E746_A750delinsAP confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-NlzPSS-TIFzzUKR1molecularmatch	EGFR	Asp8273	EGFR E746_A750del confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR E746_A750del confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-Nl0_SS-TIFzzUKR4molecularmatch	EGFR	Asp8273	EGFR E746_A750>VP confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR E746_A750>VP confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-Nl4USS-TIFzzUKR9molecularmatch	EGFR	Asp8273	EGFR E746_A750>RP confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR E746_A750>RP confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-Nl5aSS-TIFzzUKR_molecularmatch	EGFR	Asp8273	EGFR E746_A750>QP confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR E746_A750>QP confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-Nl6jSS-TIFzzUKSBmolecularmatch	EGFR	Asp8273	EGFR E746_A750>DP confers sensitivity to Asp8273 in patients with Neoplasm of lung	EGFR E746_A750>DP confers sensitivity to Asp8273 in patients with Neoplasm of lung	http://meetinglibrary.asco.org/content/162561-176	AVv-Nl7rSS-TIFzzUKSDmolecularmatch	EGFR	Asp8273	EGFR C797Y confers resistance to Asp8273 in patients with Neoplasm of lung	EGFR C797Y confers resistance to Asp8273 in patients with Neoplasm of lung	http://cancerres.aacrjournals.org/content/74/19_supplement/1728.short	AVv-NmX2SS-TIFzzUKSvmolecularmatch	EGFR	Asp8273	EGFR C797S confers resistance to Asp8273 in patients with Neoplasm of lung	EGFR C797S confers resistance to Asp8273 in patients with Neoplasm of lung	http://cancerres.aacrjournals.org/content/74/19_supplement/1728.short	AVv-NmZrSS-TIFzzUKSymolecularmatch	EGFR	Asp8273	EGFR C797R confers resistance to Asp8273 in patients with Neoplasm of lung	EGFR C797R confers resistance to Asp8273 in patients with Neoplasm of lung	http://cancerres.aacrjournals.org/content/74/19_supplement/1728.short	AVv-NmbRSS-TIFzzUKS1molecularmatch	EGFR	Asp8273	EGFR C797G confers resistance to Asp8273 in patients with Neoplasm of lung	EGFR C797G confers resistance to Asp8273 in patients with Neoplasm of lung	http://cancerres.aacrjournals.org/content/74/19_supplement/1728.short	AVv-Nmc5SS-TIFzzUKS4molecularmatch	EGFR	Asp8273	EGFR C797 confers resistance to Asp8273 in patients with Neoplasm of lung	EGFR C797 confers resistance to Asp8273 in patients with Neoplasm of lung	http://cancerres.aacrjournals.org/content/74/19_supplement/1728.short	AVv-NmefSS-TIFzzUKS7molecularmatch	EGFR	Ap-26113	EGFR T790M confers sensitivity to Ap-26113 in patients with Neoplasm of lung	EGFR T790M confers sensitivity to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27836716	AVv-NjydSS-TIFzzUKObmolecularmatch	EGFR	Afatinib	EGFR exon 20 insertion confers resistance to Afatinib in patients with Neoplasm of lung	EGFR exon 20 insertion confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21764376	AVv-NlbNSS-TIFzzUKRPmolecularmatch	EGFR	Afatinib	EGFR Y764_V765insHH confers resistance to Afatinib in patients with Neoplasm of lung	EGFR Y764_V765insHH confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NjanSS-TIFzzUKN0molecularmatch	EGFR	Afatinib	EGFR Y270* confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR Y270* confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25826094	AVv-NjchSS-TIFzzUKN3molecularmatch	EGFR	Afatinib	EGFR W200* confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR W200* confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25826094	AVv-NjeQSS-TIFzzUKN6molecularmatch	EGFR	Afatinib	EGFR V774_C775insPR confers resistance to Afatinib in patients with Neoplasm of lung	EGFR V774_C775insPR confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NjfZSS-TIFzzUKN8molecularmatch	EGFR	Afatinib	EGFR V774_C775insPHV confers resistance to Afatinib in patients with Neoplasm of lung	EGFR V774_C775insPHV confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-Njf6SS-TIFzzUKN9molecularmatch	EGFR	Afatinib	EGFR V774_C775insHV confers resistance to Afatinib in patients with Neoplasm of lung	EGFR V774_C775insHV confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NjgiSS-TIFzzUKN-molecularmatch	EGFR	Afatinib	EGFR V769_D770insGSV confers resistance to Afatinib in patients with Neoplasm of lung	EGFR V769_D770insGSV confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-Njk0SS-TIFzzUKOFmolecularmatch	EGFR	Afatinib	EGFR V769_D770insCV confers resistance to Afatinib in patients with Neoplasm of lung	EGFR V769_D770insCV confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NjotSS-TIFzzUKOLmolecularmatch	EGFR	Afatinib	EGFR V769_D770insASV confers resistance to Afatinib in patients with Neoplasm of lung	EGFR V769_D770insASV confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NjqkSS-TIFzzUKOOmolecularmatch	EGFR	Afatinib	EGFR T790M confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR T790M confers sensitivity to Afatinib in patients with Neoplasm of lung		AVv-Njx3SS-TIFzzUKOamolecularmatch	EGFR	Afatinib	EGFR T790M confers sensitivity to Afatinib and Cetuximab in patients with Neoplasm of lung	EGFR T790M confers sensitivity to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25074459	AVv-NjvaSS-TIFzzUKOWmolecularmatch	EGFR	Afatinib	EGFR T751_E758del confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR T751_E758del confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23982599	AVv-Nj26SS-TIFzzUKOimolecularmatch	EGFR	Afatinib	EGFR S768_D770dup confers resistance to Afatinib in patients with Neoplasm of lung	EGFR S768_D770dup confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-Nj40SS-TIFzzUKOlmolecularmatch	EGFR	Afatinib	EGFR S768I confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR S768I confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27413714	AVv-Nj4LSS-TIFzzUKOkmolecularmatch	EGFR	Afatinib	EGFR R669* confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR R669* confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25826094	AVv-Nj-9SS-TIFzzUKOvmolecularmatch	EGFR	Afatinib	EGFR R531* confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR R531* confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25826094	AVv-NkBvSS-TIFzzUKOzmolecularmatch	EGFR	Afatinib	EGFR R255* confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR R255* confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25826094	AVv-NkDoSS-TIFzzUKO2molecularmatch	EGFR	Afatinib	EGFR Q71* confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR Q71* confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25826094	AVv-NkFpSS-TIFzzUKO5molecularmatch	EGFR	Afatinib	EGFR Q701* confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR Q701* confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27413714	AVv-NkI5SS-TIFzzUKO-molecularmatch	EGFR	Afatinib	EGFR Q486* confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR Q486* confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25826094	AVv-NkKtSS-TIFzzUKPBmolecularmatch	EGFR	Afatinib	EGFR Q276* confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR Q276* confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25826094	AVv-NkMjSS-TIFzzUKPEmolecularmatch	EGFR	Afatinib	EGFR P772_H773insV confers resistance to Afatinib in patients with Neoplasm of lung	EGFR P772_H773insV confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NkOZSS-TIFzzUKPHmolecularmatch	EGFR	Afatinib	EGFR P772_H773insTP confers resistance to Afatinib in patients with Neoplasm of lung	EGFR P772_H773insTP confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NkQwSS-TIFzzUKPLmolecularmatch	EGFR	Afatinib	EGFR P772_H773insTHP confers resistance to Afatinib in patients with Neoplasm of lung	EGFR P772_H773insTHP confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NkSlSS-TIFzzUKPOmolecularmatch	EGFR	Afatinib	EGFR P772_H773insPNP confers resistance to Afatinib in patients with Neoplasm of lung	EGFR P772_H773insPNP confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NkURSS-TIFzzUKPRmolecularmatch	EGFR	Afatinib	EGFR P772_H773insDNP confers resistance to Afatinib in patients with Neoplasm of lung	EGFR P772_H773insDNP confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NkU3SS-TIFzzUKPSmolecularmatch	EGFR	Afatinib	EGFR N771_P772insV confers resistance to Afatinib in patients with Neoplasm of lung	EGFR N771_P772insV confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NkcNSS-TIFzzUKPfmolecularmatch	EGFR	Afatinib	EGFR N771_P772insRH confers resistance to Afatinib in patients with Neoplasm of lung	EGFR N771_P772insRH confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NkcvSS-TIFzzUKPgmolecularmatch	EGFR	Afatinib	EGFR N771_P772insPHN confers resistance to Afatinib in patients with Neoplasm of lung	EGFR N771_P772insPHN confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NkeLSS-TIFzzUKPjmolecularmatch	EGFR	Afatinib	EGFR N771_P772insH confers resistance to Afatinib in patients with Neoplasm of lung	EGFR N771_P772insH confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NkfvSS-TIFzzUKPmmolecularmatch	EGFR	Afatinib	EGFR N771_H773dup confers resistance to Afatinib in patients with Neoplasm of lung	EGFR N771_H773dup confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NkiSSS-TIFzzUKP1molecularmatch	EGFR	Afatinib	EGFR L861R confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR L861R confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27413714	AVv-NklKSS-TIFzzUKP5molecularmatch	EGFR	Afatinib	EGFR L861Q confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR L861Q confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27413714	AVv-NkmdSS-TIFzzUKP7molecularmatch	EGFR	Afatinib	EGFR L861P confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR L861P confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27413714	AVv-NkntSS-TIFzzUKP9molecularmatch	EGFR	Afatinib	EGFR L858R confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR L858R confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23982599	AVv-Nkr7SS-TIFzzUKQDmolecularmatch	EGFR	Afatinib	EGFR L747_T751del confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR L747_T751del confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23982599	AVv-NkxaSS-TIFzzUKQLmolecularmatch	EGFR	Afatinib	EGFR L747_S752del confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR L747_S752del confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23982599	AVv-Nk2VSS-TIFzzUKQTmolecularmatch	EGFR	Afatinib	EGFR L747_E749delLRE confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR L747_E749delLRE confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23982599	AVv-Nk6LSS-TIFzzUKQZmolecularmatch	EGFR	Afatinib	EGFR L747S confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR L747S confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19632948	AVv-NktUSS-TIFzzUKQFmolecularmatch	EGFR	Afatinib	EGFR H773dup confers resistance to Afatinib in patients with Neoplasm of lung	EGFR H773dup confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-Nk9QSS-TIFzzUKQemolecularmatch	EGFR	Afatinib	EGFR H773_V774insQ confers resistance to Afatinib in patients with Neoplasm of lung	EGFR H773_V774insQ confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NlAlSS-TIFzzUKQkmolecularmatch	EGFR	Afatinib	EGFR H773_V774insNPH confers resistance to Afatinib in patients with Neoplasm of lung	EGFR H773_V774insNPH confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NlDaSS-TIFzzUKQpmolecularmatch	EGFR	Afatinib	EGFR H773_V774insNH confers resistance to Afatinib in patients with Neoplasm of lung	EGFR H773_V774insNH confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NlFoSS-TIFzzUKQtmolecularmatch	EGFR	Afatinib	EGFR H773_V774insH confers resistance to Afatinib in patients with Neoplasm of lung	EGFR H773_V774insH confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NlGSSS-TIFzzUKQumolecularmatch	EGFR	Afatinib	EGFR H773_V774insGH confers resistance to Afatinib in patients with Neoplasm of lung	EGFR H773_V774insGH confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NlJRSS-TIFzzUKQzmolecularmatch	EGFR	Afatinib	EGFR H773_V774insAH confers resistance to Afatinib in patients with Neoplasm of lung	EGFR H773_V774insAH confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NlJ3SS-TIFzzUKQ0molecularmatch	EGFR	Afatinib	EGFR G719S confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR G719S confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/28004883	AVv-NlNVSS-TIFzzUKQ6molecularmatch	EGFR	Afatinib	EGFR G719D confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR G719D confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27413714	AVv-NlOfSS-TIFzzUKQ8molecularmatch	EGFR	Afatinib	EGFR G719C confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR G719C confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27413714	AVv-NlPtSS-TIFzzUKQ-molecularmatch	EGFR	Afatinib	EGFR G719A confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR G719A confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27413714	AVv-NlRpSS-TIFzzUKRBmolecularmatch	EGFR	Afatinib	EGFR G573* confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR G573* confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25826094	AVv-NlVuSS-TIFzzUKRHmolecularmatch	EGFR	Afatinib	EGFR G339* confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR G339* confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25826094	AVv-NlXpSS-TIFzzUKRKmolecularmatch	EGFR	Afatinib	EGFR G225Afs*55 confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR G225Afs*55 confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25826094	AVv-NlZ3SS-TIFzzUKRNmolecularmatch	EGFR	Afatinib	EGFR E746fs*15 confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR E746fs*15 confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23982599	AVv-NldLSS-TIFzzUKRSmolecularmatch	EGFR	Afatinib	EGFR E746delE confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR E746delE confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23982599	AVv-NlgZSS-TIFzzUKRXmolecularmatch	EGFR	Afatinib	EGFR E746_T751delinsA confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR E746_T751delinsA confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23982599	AVv-Nll7SS-TIFzzUKRfmolecularmatch	EGFR	Afatinib	EGFR E746_S752delinsA confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR E746_S752delinsA confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23982599	AVv-NlteSS-TIFzzUKRrmolecularmatch	EGFR	Afatinib	EGFR E746_A750del confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR E746_A750del confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23982599	AVv-Nl3tSS-TIFzzUKR8molecularmatch	EGFR	Afatinib	EGFR D770_N771insY confers resistance to Afatinib in patients with Neoplasm of lung	EGFR D770_N771insY confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NmA8SS-TIFzzUKSMmolecularmatch	EGFR	Afatinib	EGFR D770_N771insT confers resistance to Afatinib in patients with Neoplasm of lung	EGFR D770_N771insT confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NmC-SS-TIFzzUKSPmolecularmatch	EGFR	Afatinib	EGFR D770_N771insSVD confers resistance to Afatinib in patients with Neoplasm of lung	EGFR D770_N771insSVD confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NmFsSS-TIFzzUKSTmolecularmatch	EGFR	Afatinib	EGFR D770_N771insQRG confers resistance to Afatinib in patients with Neoplasm of lung	EGFR D770_N771insQRG confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NmHnSS-TIFzzUKSWmolecularmatch	EGFR	Afatinib	EGFR D770_N771insGT confers resistance to Afatinib in patients with Neoplasm of lung	EGFR D770_N771insGT confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NmJkSS-TIFzzUKSZmolecularmatch	EGFR	Afatinib	EGFR D770_N771insGL confers resistance to Afatinib in patients with Neoplasm of lung	EGFR D770_N771insGL confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NmMKSS-TIFzzUKSdmolecularmatch	EGFR	Afatinib	EGFR D770_N771insGF confers resistance to Afatinib in patients with Neoplasm of lung	EGFR D770_N771insGF confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NmOHSS-TIFzzUKSgmolecularmatch	EGFR	Afatinib	EGFR D770_N771insGD confers resistance to Afatinib in patients with Neoplasm of lung	EGFR D770_N771insGD confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NmP9SS-TIFzzUKSjmolecularmatch	EGFR	Afatinib	EGFR D770_N771insG confers resistance to Afatinib in patients with Neoplasm of lung	EGFR D770_N771insG confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NmTfSS-TIFzzUKSomolecularmatch	EGFR	Afatinib	EGFR D770_N771insAPW confers resistance to Afatinib in patients with Neoplasm of lung	EGFR D770_N771insAPW confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NmVcSS-TIFzzUKSrmolecularmatch	EGFR	Afatinib	EGFR C311* confers sensitivity to Afatinib in patients with Neoplasm of lung	EGFR C311* confers sensitivity to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25826094	AVv-NmgtSS-TIFzzUKS_molecularmatch	EGFR	Afatinib	EGFR Amplification confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	EGFR Amplification confers resistance to Afatinib and Cetuximab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/17085664	AVv-NmhPSS-TIFzzUKTAmolecularmatch	EGFR	Afatinib	EGFR A767_V769dup confers resistance to Afatinib in patients with Neoplasm of lung	EGFR A767_V769dup confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NmicSS-TIFzzUKTCmolecularmatch	EGFR	Afatinib	EGFR A767_S768insTLA confers resistance to Afatinib in patients with Neoplasm of lung	EGFR A767_S768insTLA confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NmjASS-TIFzzUKTDmolecularmatch	EGFR	Afatinib	EGFR A767_S768insIA confers resistance to Afatinib in patients with Neoplasm of lung	EGFR A767_S768insIA confers resistance to Afatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-NmmsSS-TIFzzUKTJmolecularmatch	EGF	Panitumumab	EGF confers sensitivity to Panitumumab in patients with Neoplasm of colorectum	EGF confers sensitivity to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20921465	AVv-NqQjSS-TIFzzUKZKmolecularmatch	DDR2	Dasatinib	DDR2 S768R confers sensitivity to Dasatinib and Erlotinib hydrochloride in patients with Neoplasm of lung	DDR2 S768R confers sensitivity to Dasatinib and Erlotinib hydrochloride in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22328973	AVv-NmonSS-TIFzzUKTMmolecularmatch	DDR2	Dasatinib	DDR2 L63V confers sensitivity to Dasatinib in patients with Neoplasm of lung	DDR2 L63V confers sensitivity to Dasatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22328973	AVv-NmpLSS-TIFzzUKTNmolecularmatch	DDR2	Dasatinib	DDR2 L239R confers sensitivity to Dasatinib in patients with Neoplasm of lung	DDR2 L239R confers sensitivity to Dasatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22328973	AVv-NmpwSS-TIFzzUKTOmolecularmatch	DDR2	Dasatinib	DDR2 I638F confers sensitivity to Dasatinib in patients with Neoplasm of lung	DDR2 I638F confers sensitivity to Dasatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22328973	AVv-NmqXSS-TIFzzUKTPmolecularmatch	DDR2	Dasatinib	DDR2 G774V confers sensitivity to Dasatinib in patients with Neoplasm of lung	DDR2 G774V confers sensitivity to Dasatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22328973	AVv-NmrBSS-TIFzzUKTQmolecularmatch	DDR2	Dasatinib	DDR2 G505S confers sensitivity to Dasatinib in patients with Neoplasm of lung	DDR2 G505S confers sensitivity to Dasatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22328973	AVv-NmrqSS-TIFzzUKTRmolecularmatch	DDR2	Dasatinib	DDR2 G253C confers sensitivity to Dasatinib in patients with Neoplasm of lung	DDR2 G253C confers sensitivity to Dasatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22328973	AVv-Nms3SS-TIFzzUKTTmolecularmatch	DACH1	Oxaliplatin	DACH1 confers sensitivity to Oxaliplatin in patients with Neoplasm of colorectum	DACH1 confers sensitivity to Oxaliplatin in patients with Neoplasm of colorectum	http://mct.aacrjournals.org/content/12/11_supplement/b48.short	AVv-NqRMSS-TIFzzUKZLmolecularmatch	Cetuximab	Panitumumab	Cetuximab resistance mutations confers sensitivity to Panitumumab in patients with Neoplasm of colorectum	Cetuximab resistance mutations confers sensitivity to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20921465	AVv-NqN7SS-TIFzzUKZGmolecularmatch	CTNNB1	vantictumab	CTNNB1 confers sensitivity to vantictumab in patients with Neoplasm of colorectum	CTNNB1 confers sensitivity to vantictumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/22753465	AVv-NpiySS-TIFzzUKYCmolecularmatch	CTNNB1	Pri-724	CTNNB1 confers sensitivity to Pri-724 in patients with Neoplasm of colorectum	CTNNB1 confers sensitivity to Pri-724 in patients with Neoplasm of colorectum	http://meetinglibrary.asco.org/content/115980-132	AVv-Np0XSS-TIFzzUKYemolecularmatch	CTNNB1	OMP-54F28	CTNNB1 confers sensitivity to OMP-54F28 in patients with Neoplasm of colorectum	CTNNB1 confers sensitivity to OMP-54F28 in patients with Neoplasm of colorectum	http://mct.aacrjournals.org/content/12/11_supplement/b48.short	AVv-NqURSS-TIFzzUKZQmolecularmatch	CTNNB1	Lgk-974	CTNNB1 confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	CTNNB1 confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24277854	AVv-NomvSS-TIFzzUKWbmolecularmatch	CTNNB1	Lgk-974	CTNNB1 W383R confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	CTNNB1 W383R confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24735922	AVv-Nq9lSS-TIFzzUKaPmolecularmatch	CTNNB1	Lgk-974	CTNNB1 T41A confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	CTNNB1 T41A confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/10698519	AVv-Nq_dSS-TIFzzUKaSmolecularmatch	CTNNB1	Lgk-974	CTNNB1 S45P confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	CTNNB1 S45P confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/9065403	AVv-Nq-QSS-TIFzzUKaQmolecularmatch	CTNNB1	Lgk-974	CTNNB1 S45F confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	CTNNB1 S45F confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18282277	AVv-Nq-3SS-TIFzzUKaRmolecularmatch	CTNNB1	Lgk-974	CTNNB1 S37Y confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	CTNNB1 S37Y confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/10347231	AVv-NrAHSS-TIFzzUKaTmolecularmatch	CTNNB1	Lgk-974	CTNNB1 S37F confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	CTNNB1 S37F confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/10347231	AVv-NrA0SS-TIFzzUKaUmolecularmatch	CTNNB1	Lgk-974	CTNNB1 S33C confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	CTNNB1 S33C confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/15064718	AVv-NrBiSS-TIFzzUKaVmolecularmatch	CTNNB1	Lgk-974	CTNNB1 N387K confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	CTNNB1 N387K confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/27177928	AVv-Nq84SS-TIFzzUKaOmolecularmatch	CTNNB1	ETC159	CTNNB1 confers sensitivity to ETC159 in patients with Neoplasm of colorectum	CTNNB1 confers sensitivity to ETC159 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26257057	AVv-No48SS-TIFzzUKW3molecularmatch	CSF1R	Enmd-2076	CSF1R confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	CSF1R confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20406842	AVv-NpF-SS-TIFzzUKXMmolecularmatch	CREBBP	Pri-724	CREBBP confers sensitivity to Pri-724 in patients with Neoplasm of colorectum	CREBBP confers sensitivity to Pri-724 in patients with Neoplasm of colorectum	http://meetinglibrary.asco.org/content/115980-132	AVv-Np1ESS-TIFzzUKYfmolecularmatch	CREB1	Pri-724	CREB1 confers sensitivity to Pri-724 in patients with Neoplasm of colorectum	CREB1 confers sensitivity to Pri-724 in patients with Neoplasm of colorectum	http://meetinglibrary.asco.org/content/115980-132	AVv-Np11SS-TIFzzUKYgmolecularmatch	CDKN2C	Pd-0332991	CDKN2C Loss confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	CDKN2C Loss confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24765199	AVv-Np_ASS-TIFzzUKYumolecularmatch	CDKN2C	Ly2835219	CDKN2C Loss confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	CDKN2C Loss confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24919854	AVv-NqwWSS-TIFzzUKZ7molecularmatch	CDKN2B	Pd-0332991	CDKN2B confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	CDKN2B confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24765199	AVv-NqE4SS-TIFzzUKY3molecularmatch	CDKN2B	Pd-0332991	CDKN2B Loss confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	CDKN2B Loss confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24765199	AVv-Np_sSS-TIFzzUKYvmolecularmatch	CDKN2B	Ly2835219	CDKN2B confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	CDKN2B confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24919854	AVv-Nq2PSS-TIFzzUKaEmolecularmatch	CDKN2B	Ly2835219	CDKN2B Loss confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	CDKN2B Loss confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24919854	AVv-Nqw8SS-TIFzzUKZ8molecularmatch	CDKN2A	Pd-0332991	CDKN2A confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	CDKN2A confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24765199	AVv-NqFbSS-TIFzzUKY4molecularmatch	CDKN2A	Pd-0332991	CDKN2A Loss confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	CDKN2A Loss confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24765199	AVv-NqAXSS-TIFzzUKYwmolecularmatch	CDKN2A	Ly2835219	CDKN2A confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	CDKN2A confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24919854	AVv-Nq28SS-TIFzzUKaFmolecularmatch	CDKN2A	Ly2835219	CDKN2A Loss confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	CDKN2A Loss confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24919854	AVv-NqxmSS-TIFzzUKZ9molecularmatch	CDK6	Pd-0332991	CDK6 confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	CDK6 confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24765199	AVv-NqGFSS-TIFzzUKY5molecularmatch	CDK6	Ly2835219	CDK6 confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	CDK6 confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24919854	AVv-Nq3lSS-TIFzzUKaGmolecularmatch	CDK4	Pd-0332991	CDK4 confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	CDK4 confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24765199	AVv-NqGrSS-TIFzzUKY6molecularmatch	CDK4	Ly2835219	CDK4 confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	CDK4 confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24919854	AVv-Nq4TSS-TIFzzUKaHmolecularmatch	CD74-ROS1	Pf-06463922	CD74-ROS1 L2026M confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	CD74-ROS1 L2026M confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25733882	AVv-NmuESS-TIFzzUKTVmolecularmatch	CD74-ROS1	Crizotinib	CD74-ROS1 L2026M confers sensitivity to Crizotinib in patients with Neoplasm of lung	CD74-ROS1 L2026M confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25264305	AVv-NmvgSS-TIFzzUKTXmolecularmatch	CD74-ROS1	Ceritinib	CD74-ROS1 L2026M confers sensitivity to Ceritinib in patients with Neoplasm of lung	CD74-ROS1 L2026M confers sensitivity to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26917690	AVv-Nmu0SS-TIFzzUKTWmolecularmatch	CD74-ROS1	Cabozantinib	CD74-ROS1 G2032R confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	CD74-ROS1 G2032R confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NplHSS-TIFzzUKYGmolecularmatch	CD74-ROS1	Alectinib	CD74-ROS1 L2026M confers sensitivity to Alectinib in patients with Neoplasm of lung	CD74-ROS1 L2026M confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25349307	AVv-NmteSS-TIFzzUKTUmolecularmatch	CD274	nivolumab	CD274 confers sensitivity to nivolumab and Ipilimumab in patients with Neoplasm of colorectum	CD274 confers sensitivity to nivolumab and Ipilimumab in patients with Neoplasm of colorectum	https://doi.org/10.1093/annonc/mdw370.27	AVv-NqZgSS-TIFzzUKZYmolecularmatch	CD274	nivolumab	CD274 Amplification confers sensitivity to nivolumab in patients with Neoplasm of lung	CD274 Amplification confers sensitivity to nivolumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27718847	AVv-NmxZSS-TIFzzUKTamolecularmatch	CD274	nivolumab	CD274 Amplification confers sensitivity to nivolumab and Ipilimumab in patients with Neoplasm of colorectum	CD274 Amplification confers sensitivity to nivolumab and Ipilimumab in patients with Neoplasm of colorectum	https://doi.org/10.1093/annonc/mdw370.27	AVv-NqXiSS-TIFzzUKZVmolecularmatch	CD274	RG7446	CD274 confers sensitivity to RG7446 in patients with Neoplasm of colorectum	CD274 confers sensitivity to RG7446 in patients with Neoplasm of colorectum	http://cancerres.aacrjournals.org/content/76/14_supplement/2651.short	AVv-Npu5SS-TIFzzUKYWmolecularmatch	CD274	RG7446	CD274 Amplification confers sensitivity to RG7446 in patients with Neoplasm of colorectum	CD274 Amplification confers sensitivity to RG7446 in patients with Neoplasm of colorectum	http://cancerres.aacrjournals.org/content/76/14_supplement/2651.short	AVv-NprISS-TIFzzUKYQmolecularmatch	CD274	Pembrolizumab	CD274 confers sensitivity to Pembrolizumab in patients with Neoplasm of colorectum	CD274 confers sensitivity to Pembrolizumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26994146	AVv-Np-XSS-TIFzzUKYtmolecularmatch	CD274	Pembrolizumab	CD274 Amplification confers sensitivity to Pembrolizumab in patients with Neoplasm of lung	CD274 Amplification confers sensitivity to Pembrolizumab in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26412456	AVv-NmwvSS-TIFzzUKTZmolecularmatch	CD274	Pembrolizumab	CD274 Amplification confers sensitivity to Pembrolizumab in patients with Neoplasm of colorectum	CD274 Amplification confers sensitivity to Pembrolizumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26994146	AVv-Np6gSS-TIFzzUKYnmolecularmatch	CD274	MEDI6469	CD274 confers sensitivity to MEDI6469 in patients with Neoplasm of colorectum	CD274 confers sensitivity to MEDI6469 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24177180	AVv-NqnVSS-TIFzzUKZtmolecularmatch	CD274	MEDI-4736	CD274 confers sensitivity to MEDI-4736 in patients with Neoplasm of colorectum	CD274 confers sensitivity to MEDI-4736 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25943534	AVv-NqrXSS-TIFzzUKZzmolecularmatch	CD274	MEDI-4736	CD274 Amplification confers sensitivity to MEDI-4736 in patients with Neoplasm of lung	CD274 Amplification confers sensitivity to MEDI-4736 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25943534	AVv-NmwHSS-TIFzzUKTYmolecularmatch	CD274	MEDI-4736	CD274 Amplification confers sensitivity to MEDI-4736 in patients with Neoplasm of colorectum	CD274 Amplification confers sensitivity to MEDI-4736 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25943534	AVv-NqouSS-TIFzzUKZvmolecularmatch	CCND3	Pd-0332991	CCND3 Amplification confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	CCND3 Amplification confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24765199	AVv-NqA_SS-TIFzzUKYxmolecularmatch	CCND3	Ly2835219	CCND3 Amplification confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	CCND3 Amplification confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24919854	AVv-NqyOSS-TIFzzUKZ-molecularmatch	CCND2	Pd-0332991	CCND2 Amplification confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	CCND2 Amplification confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24765199	AVv-NqBoSS-TIFzzUKYymolecularmatch	CCND2	Ly2835219	CCND2 Amplification confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	CCND2 Amplification confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24919854	AVv-Nqy3SS-TIFzzUKZ_molecularmatch	CCND1	Pd-0332991	CCND1 confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	CCND1 confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24765199	AVv-NqHPSS-TIFzzUKY7molecularmatch	CCND1	Pd-0332991	CCND1 Amplification confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	CCND1 Amplification confers sensitivity to Pd-0332991 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24765199	AVv-NqCRSS-TIFzzUKYzmolecularmatch	CCND1	Ly2835219	CCND1 Amplification confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	CCND1 Amplification confers sensitivity to Ly2835219 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24919854	AVv-Nq0PSS-TIFzzUKaBmolecularmatch	CCDC6-RET	Vandetanib	CCDC6-RET confers sensitivity to Vandetanib in patients with Neoplasm of lung	CCDC6-RET confers sensitivity to Vandetanib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25366691	AVv-Nm0nSS-TIFzzUKTfmolecularmatch	CCDC6-RET	Vandetanib	CCDC6-RET confers sensitivity to Vandetanib in patients with Neoplasm of colorectum	CCDC6-RET confers sensitivity to Vandetanib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26078337	AVv-Npj_SS-TIFzzUKYEmolecularmatch	CCDC6-RET	Sunitinib malate	CCDC6-RET confers sensitivity to Sunitinib malate in patients with Neoplasm of lung	CCDC6-RET confers sensitivity to Sunitinib malate in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23578175	AVv-NmypSS-TIFzzUKTcmolecularmatch	CCDC6-RET	Regorafenib	CCDC6-RET confers sensitivity to Regorafenib in patients with Neoplasm of colorectum	CCDC6-RET confers sensitivity to Regorafenib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26078337	AVv-NpvgSS-TIFzzUKYXmolecularmatch	CCDC6-RET	Lenvatinib	CCDC6-RET confers sensitivity to Lenvatinib in patients with Neoplasm of lung	CCDC6-RET confers sensitivity to Lenvatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23856031	AVv-Nmz8SS-TIFzzUKTemolecularmatch	CCDC6-RET	Lenvatinib	CCDC6-RET confers sensitivity to Lenvatinib in patients with Neoplasm of colorectum	CCDC6-RET confers sensitivity to Lenvatinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26078337	AVv-Nop7SS-TIFzzUKWgmolecularmatch	CCDC6-RET	Cabozantinib	CCDC6-RET confers sensitivity to Cabozantinib in patients with Neoplasm of lung	CCDC6-RET confers sensitivity to Cabozantinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27825637	AVv-Nm1LSS-TIFzzUKTgmolecularmatch	CCDC6-RET	Cabozantinib	CCDC6-RET confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	CCDC6-RET confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NprySS-TIFzzUKYRmolecularmatch	CCDC6-RET	Alectinib	CCDC6-RET confers sensitivity to Alectinib in patients with Neoplasm of lung	CCDC6-RET confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25349307	AVv-NmyCSS-TIFzzUKTbmolecularmatch	CBL	Dasatinib	CBL Y371H confers sensitivity to Dasatinib in patients with Neoplasm of lung	CBL Y371H confers sensitivity to Dasatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23696637	AVv-Nm13SS-TIFzzUKThmolecularmatch	CBL	Dasatinib	CBL C384R confers sensitivity to Dasatinib in patients with Neoplasm of lung	CBL C384R confers sensitivity to Dasatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23696637	AVv-Nm2fSS-TIFzzUKTimolecularmatch	C2orf44–ALK	Cabozantinib	C2orf44–ALK confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	C2orf44–ALK confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-NpzqSS-TIFzzUKYdmolecularmatch	BRAF	Vemurafenib	"BRAF exon 15 mutation confers sensitivity to Vemurafenib, Irinotecan hydrochloride and Cetuximab in patients with Neoplasm of colorectum"	"BRAF exon 15 mutation confers sensitivity to Vemurafenib, Irinotecan hydrochloride and Cetuximab in patients with Neoplasm of colorectum"	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.3511	AVv-NpciSS-TIFzzUKX4molecularmatch	BRAF	Vemurafenib	"BRAF confers sensitivity to Vemurafenib, Irinotecan hydrochloride and Cetuximab in patients with Neoplasm of colorectum"	"BRAF confers sensitivity to Vemurafenib, Irinotecan hydrochloride and Cetuximab in patients with Neoplasm of colorectum"	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.3511	AVv-NpfsSS-TIFzzUKX9molecularmatch	BRAF	Vemurafenib	BRAF V600_K601delinsE confers resistance to Vemurafenib in patients with Neoplasm of lung	BRAF V600_K601delinsE confers resistance to Vemurafenib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26045855	AVv-NnBkSS-TIFzzUKT9molecularmatch	BRAF	Vemurafenib	BRAF V600Q confers sensitivity to Vemurafenib in patients with Neoplasm of lung	BRAF V600Q confers sensitivity to Vemurafenib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26287849	AVv-Nm4gSS-TIFzzUKTlmolecularmatch	BRAF	Vemurafenib	BRAF V600M confers sensitivity to Vemurafenib in patients with Neoplasm of lung	BRAF V600M confers sensitivity to Vemurafenib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26287849	AVv-Nm5NSS-TIFzzUKTmmolecularmatch	BRAF	Vemurafenib	BRAF V600L confers sensitivity to Vemurafenib in patients with Neoplasm of lung	BRAF V600L confers sensitivity to Vemurafenib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26287849	AVv-Nm50SS-TIFzzUKTnmolecularmatch	BRAF	Vemurafenib	BRAF V600K confers sensitivity to Vemurafenib in patients with Neoplasm of lung	BRAF V600K confers sensitivity to Vemurafenib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26287849	AVv-Nm7LSS-TIFzzUKTpmolecularmatch	BRAF	Vemurafenib	BRAF V600G confers sensitivity to Vemurafenib in patients with Neoplasm of lung	BRAF V600G confers sensitivity to Vemurafenib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26287849	AVv-Nm8fSS-TIFzzUKTrmolecularmatch	BRAF	Vemurafenib	"BRAF V600E confers sensitivity to Vemurafenib, Irinotecan hydrochloride and Cetuximab in patients with Neoplasm of colorectum"	"BRAF V600E confers sensitivity to Vemurafenib, Irinotecan hydrochloride and Cetuximab in patients with Neoplasm of colorectum"	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.3511	AVv-NpdOSS-TIFzzUKX5molecularmatch	BRAF	Vemurafenib	BRAF V600E confers sensitivity to Vemurafenib in patients with Neoplasm of lung	BRAF V600E confers sensitivity to Vemurafenib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26287849	AVv-Nm_mSS-TIFzzUKT6molecularmatch	BRAF	Vemurafenib	BRAF V600D confers sensitivity to Vemurafenib in patients with Neoplasm of lung	BRAF V600D confers sensitivity to Vemurafenib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26287849	AVv-NnATSS-TIFzzUKT7molecularmatch	BRAF	Vemurafenib	BRAF V600A confers sensitivity to Vemurafenib in patients with Neoplasm of lung	BRAF V600A confers sensitivity to Vemurafenib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26287849	AVv-NnBBSS-TIFzzUKT8molecularmatch	BRAF	Vemurafenib	"BRAF V600 confers sensitivity to Vemurafenib, Irinotecan hydrochloride and Cetuximab in patients with Neoplasm of colorectum"	"BRAF V600 confers sensitivity to Vemurafenib, Irinotecan hydrochloride and Cetuximab in patients with Neoplasm of colorectum"	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.3511	AVv-NpdxSS-TIFzzUKX6molecularmatch	BRAF	Vemurafenib	"BRAF Pkinase_Tyr domain confers sensitivity to Vemurafenib, Irinotecan hydrochloride and Cetuximab in patients with Neoplasm of colorectum"	"BRAF Pkinase_Tyr domain confers sensitivity to Vemurafenib, Irinotecan hydrochloride and Cetuximab in patients with Neoplasm of colorectum"	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.3511	AVv-Npe_SS-TIFzzUKX8molecularmatch	BRAF	Vemurafenib	BRAF G469L confers resistance to Vemurafenib in patients with Neoplasm of lung	BRAF G469L confers resistance to Vemurafenib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24035431	AVv-NnFvSS-TIFzzUKUEmolecularmatch	BRAF	Sorafenib	BRAF G469R confers sensitivity to Sorafenib in patients with Neoplasm of lung	BRAF G469R confers sensitivity to Sorafenib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26237499	AVv-NnFHSS-TIFzzUKUDmolecularmatch	BRAF	Regorafenib	BRAF WILD TYPE confers sensitivity to Regorafenib in patients with Neoplasm of colorectum	BRAF WILD TYPE confers sensitivity to Regorafenib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25981818	AVv-NpwXSS-TIFzzUKYYmolecularmatch	BRAF	Plx8394	BRAF V600E confers sensitivity to Plx8394 in patients with Neoplasm of lung	BRAF V600E confers sensitivity to Plx8394 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27834212	AVv-Nm9NSS-TIFzzUKTsmolecularmatch	BRAF	Plx8394	BRAF G469A confers sensitivity to Plx8394 in patients with Neoplasm of lung	BRAF G469A confers sensitivity to Plx8394 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27834212	AVv-NnG8SS-TIFzzUKUGmolecularmatch	BRAF	Plx8394	BRAF G466V confers sensitivity to Plx8394 in patients with Neoplasm of lung	BRAF G466V confers sensitivity to Plx8394 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27834212	AVv-NnKOSS-TIFzzUKULmolecularmatch	BRAF	Panitumumab	BRAF exon 15 mutation confers sensitivity to Panitumumab and Vemurafenib in patients with Neoplasm of colorectum	BRAF exon 15 mutation confers sensitivity to Panitumumab and Vemurafenib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24755613	AVv-NqHzSS-TIFzzUKY8molecularmatch	BRAF	Panitumumab	BRAF confers sensitivity to Panitumumab and Vemurafenib in patients with Neoplasm of colorectum	BRAF confers sensitivity to Panitumumab and Vemurafenib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24755613	AVv-NqKuSS-TIFzzUKZBmolecularmatch	BRAF	Panitumumab	BRAF V600E confers sensitivity to Panitumumab and Vemurafenib in patients with Neoplasm of colorectum	BRAF V600E confers sensitivity to Panitumumab and Vemurafenib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24755613	AVv-NqIaSS-TIFzzUKY9molecularmatch	BRAF	Panitumumab	BRAF V600E confers resistance to Panitumumab in patients with Neoplasm of colorectum	BRAF V600E confers resistance to Panitumumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19001320	AVv-NrfCSS-TIFzzUKbBmolecularmatch	BRAF	Panitumumab	BRAF V600 confers sensitivity to Panitumumab and Vemurafenib in patients with Neoplasm of colorectum	BRAF V600 confers sensitivity to Panitumumab and Vemurafenib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24755613	AVv-NqJASS-TIFzzUKY-molecularmatch	BRAF	Panitumumab	BRAF Pkinase_Tyr domain confers sensitivity to Panitumumab and Vemurafenib in patients with Neoplasm of colorectum	BRAF Pkinase_Tyr domain confers sensitivity to Panitumumab and Vemurafenib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24755613	AVv-NqKKSS-TIFzzUKZAmolecularmatch	BRAF	Dasatinib	BRAF Y472C confers sensitivity to Dasatinib in patients with Neoplasm of lung	BRAF Y472C confers sensitivity to Dasatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22649091	AVv-Nm3JSS-TIFzzUKTjmolecularmatch	BRAF	Dasatinib	BRAF G469A confers resistance to Dasatinib in patients with Neoplasm of lung	BRAF G469A confers resistance to Dasatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22649091	AVv-NnGZSS-TIFzzUKUFmolecularmatch	BRAF	Dasatinib	BRAF G466V confers sensitivity to Dasatinib in patients with Neoplasm of lung	BRAF G466V confers sensitivity to Dasatinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22649091	AVv-NnJpSS-TIFzzUKUKmolecularmatch	BRAF	Dabrafenib	"BRAF exon 15 mutation confers sensitivity to Dabrafenib, Panitumumab and Trametinib in patients with Neoplasm of colorectum"	"BRAF exon 15 mutation confers sensitivity to Dabrafenib, Panitumumab and Trametinib in patients with Neoplasm of colorectum"	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.103	AVv-NpIBSS-TIFzzUKXPmolecularmatch	BRAF	Dabrafenib	"BRAF confers sensitivity to Dabrafenib, Panitumumab and Trametinib in patients with Neoplasm of colorectum"	"BRAF confers sensitivity to Dabrafenib, Panitumumab and Trametinib in patients with Neoplasm of colorectum"	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.103	AVv-NpMHSS-TIFzzUKXVmolecularmatch	BRAF	Dabrafenib	BRAF V600R confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	BRAF V600R confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27577079	AVv-Nm3ySS-TIFzzUKTkmolecularmatch	BRAF	Dabrafenib	"BRAF V600K confers sensitivity to Dabrafenib, Panitumumab and Trametinib in patients with Neoplasm of colorectum"	"BRAF V600K confers sensitivity to Dabrafenib, Panitumumab and Trametinib in patients with Neoplasm of colorectum"	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.103	AVv-NpIsSS-TIFzzUKXQmolecularmatch	BRAF	Dabrafenib	BRAF V600K confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	BRAF V600K confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27577079	AVv-Nm72SS-TIFzzUKTqmolecularmatch	BRAF	Dabrafenib	"BRAF V600E confers sensitivity to Dabrafenib, Panitumumab and Trametinib in patients with Neoplasm of colorectum"	"BRAF V600E confers sensitivity to Dabrafenib, Panitumumab and Trametinib in patients with Neoplasm of colorectum"	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.103	AVv-NpKOSS-TIFzzUKXSmolecularmatch	BRAF	Dabrafenib	BRAF V600E confers sensitivity to Dabrafenib in patients with Neoplasm of lung	BRAF V600E confers sensitivity to Dabrafenib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27080216	AVv-Nm-9SS-TIFzzUKT5molecularmatch	BRAF	Dabrafenib	BRAF V600E confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	BRAF V600E confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27283860	AVv-Nm99SS-TIFzzUKT4molecularmatch	BRAF	Dabrafenib	"BRAF V600 confers sensitivity to Dabrafenib, Panitumumab and Trametinib in patients with Neoplasm of colorectum"	"BRAF V600 confers sensitivity to Dabrafenib, Panitumumab and Trametinib in patients with Neoplasm of colorectum"	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.103	AVv-NpKzSS-TIFzzUKXTmolecularmatch	BRAF	Dabrafenib	"BRAF Pkinase_Tyr domain confers sensitivity to Dabrafenib, Panitumumab and Trametinib in patients with Neoplasm of colorectum"	"BRAF Pkinase_Tyr domain confers sensitivity to Dabrafenib, Panitumumab and Trametinib in patients with Neoplasm of colorectum"	http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.103	AVv-NpLcSS-TIFzzUKXUmolecularmatch	BRAF	Dabrafenib	BRAF L597V confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	BRAF L597V confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27577079	AVv-NnC4SS-TIFzzUKT_molecularmatch	BRAF	Dabrafenib	BRAF G596C confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	BRAF G596C confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27577079	AVv-NnDbSS-TIFzzUKUAmolecularmatch	BRAF	Dabrafenib	BRAF G469V confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	BRAF G469V confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27577079	AVv-NnD-SS-TIFzzUKUBmolecularmatch	BRAF	Dabrafenib	BRAF G469S confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	BRAF G469S confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27577079	AVv-NnEhSS-TIFzzUKUCmolecularmatch	BRAF	Dabrafenib	BRAF G469A confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	BRAF G469A confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27577079	AVv-NnHnSS-TIFzzUKUHmolecularmatch	BRAF	Dabrafenib	BRAF G469A confers resistance to Dabrafenib in patients with Neoplasm of lung	BRAF G469A confers resistance to Dabrafenib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26200454	AVv-NnIRSS-TIFzzUKUImolecularmatch	BRAF	Dabrafenib	BRAF G466V confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	BRAF G466V confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27577079	AVv-NnKwSS-TIFzzUKUMmolecularmatch	BRAF	Dabrafenib	BRAF D594V confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	BRAF D594V confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27577079	AVv-NnLXSS-TIFzzUKUNmolecularmatch	BRAF	Dabrafenib	BRAF D594N confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	BRAF D594N confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27577079	AVv-NnL8SS-TIFzzUKUOmolecularmatch	BRAF	Dabrafenib	BRAF D594G confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	BRAF D594G confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27577079	AVv-NnMhSS-TIFzzUKUPmolecularmatch	BRAF	Dabrafenib	BRAF D594E confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	BRAF D594E confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27577079	AVv-NnNGSS-TIFzzUKUQmolecularmatch	BRAF	Dabrafenib	BRAF D594A confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	BRAF D594A confers sensitivity to Dabrafenib and Trametinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27577079	AVv-NnNpSS-TIFzzUKURmolecularmatch	BRAF	Cetuximab	BRAF exon 15 mutation confers sensitivity to Cetuximab and Vemurafenib in patients with Neoplasm of colorectum	BRAF exon 15 mutation confers sensitivity to Cetuximab and Vemurafenib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/22281684	AVv-NpMzSS-TIFzzUKXWmolecularmatch	BRAF	Cetuximab	BRAF confers sensitivity to Cetuximab and Vemurafenib in patients with Neoplasm of colorectum	BRAF confers sensitivity to Cetuximab and Vemurafenib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/22281684	AVv-NpPeSS-TIFzzUKXamolecularmatch	BRAF	Cetuximab	BRAF V600E confers sensitivity to Cetuximab and Vemurafenib in patients with Neoplasm of colorectum	BRAF V600E confers sensitivity to Cetuximab and Vemurafenib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/22281684	AVv-NpNhSS-TIFzzUKXXmolecularmatch	BRAF	Cetuximab	BRAF V600E confers resistance to Cetuximab in patients with Neoplasm of colorectum	BRAF V600E confers resistance to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/19001320	AVv-Nr3hSS-TIFzzUKbvmolecularmatch	BRAF	Cetuximab	BRAF V600 confers sensitivity to Cetuximab and Vemurafenib in patients with Neoplasm of colorectum	BRAF V600 confers sensitivity to Cetuximab and Vemurafenib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/22281684	AVv-NpOLSS-TIFzzUKXYmolecularmatch	BRAF	Cetuximab	BRAF Pkinase_Tyr domain confers sensitivity to Cetuximab and Vemurafenib in patients with Neoplasm of colorectum	BRAF Pkinase_Tyr domain confers sensitivity to Cetuximab and Vemurafenib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/22281684	AVv-NpO1SS-TIFzzUKXZmolecularmatch	BRAF	Cetuximab	BRAF D594G confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	BRAF D594G confers sensitivity to Cetuximab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20619739	AVv-NpTsSS-TIFzzUKXgmolecularmatch	BLK	Enmd-2076	BLK confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	BLK confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20406842	AVv-NpGqSS-TIFzzUKXNmolecularmatch	AXL	Cabozantinib	AXL confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	AXL confers sensitivity to Cabozantinib in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25242168	AVv-Np75SS-TIFzzUKYpmolecularmatch	AURKA	Enmd-2076	AURKA confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	AURKA confers sensitivity to Enmd-2076 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/20406842	AVv-NpHYSS-TIFzzUKXOmolecularmatch	APC	vantictumab	APC confers sensitivity to vantictumab in patients with Neoplasm of colorectum	APC confers sensitivity to vantictumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/22753465	AVv-NpjYSS-TIFzzUKYDmolecularmatch	APC	Pri-724	APC confers sensitivity to Pri-724 in patients with Neoplasm of colorectum	APC confers sensitivity to Pri-724 in patients with Neoplasm of colorectum	http://meetinglibrary.asco.org/content/115980-132	AVv-Np2iSS-TIFzzUKYhmolecularmatch	APC	OMP-54F28	APC confers sensitivity to OMP-54F28 in patients with Neoplasm of colorectum	APC confers sensitivity to OMP-54F28 in patients with Neoplasm of colorectum	http://mct.aacrjournals.org/content/12/11_supplement/b48.short	AVv-NqU-SS-TIFzzUKZRmolecularmatch	APC	Lgk-974	APC confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	APC confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/24277854	AVv-NopWSS-TIFzzUKWfmolecularmatch	APC	Lgk-974	APC N1026S confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	APC N1026S confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/18166348	AVv-NonYSS-TIFzzUKWcmolecularmatch	APC	Lgk-974	APC K716* confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	APC K716* confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/11900252	AVv-NooASS-TIFzzUKWdmolecularmatch	APC	Lgk-974	APC E1309Afs*3 confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	APC E1309Afs*3 confers sensitivity to Lgk-974 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/10213492	AVv-NoowSS-TIFzzUKWemolecularmatch	APC	ETC159	APC confers sensitivity to ETC159 in patients with Neoplasm of colorectum	APC confers sensitivity to ETC159 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26257057	AVv-No5mSS-TIFzzUKW4molecularmatch	ANGPT2	RO5520985	ANGPT2 confers sensitivity to RO5520985 in patients with Neoplasm of colorectum	ANGPT2 confers sensitivity to RO5520985 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/27529514	AVv-Npp2SS-TIFzzUKYOmolecularmatch	ALK	X-976	ALK L1196M confers sensitivity to X-976 in patients with Neoplasm of lung	ALK L1196M confers sensitivity to X-976 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-NfzJSS-TIFzzUKILmolecularmatch	ALK	X-976	ALK C1156Y confers sensitivity to X-976 in patients with Neoplasm of lung	ALK C1156Y confers sensitivity to X-976 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-NmzQSS-TIFzzUKTdmolecularmatch	ALK	X-376	ALK L1196M confers sensitivity to X-376 in patients with Neoplasm of lung	ALK L1196M confers sensitivity to X-376 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-Nf6xSS-TIFzzUKIWmolecularmatch	ALK	X-376	ALK C1156Y confers sensitivity to X-376 in patients with Neoplasm of lung	ALK C1156Y confers sensitivity to X-376 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-Nm6hSS-TIFzzUKTomolecularmatch	ALK	Pf-06463922	ALK V1180L confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	ALK V1180L confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-Nnj1SS-TIFzzUKU0molecularmatch	ALK	Pf-06463922	ALK T1151_L1152insT confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	ALK T1151_L1152insT confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-NoH5SS-TIFzzUKVrmolecularmatch	ALK	Pf-06463922	ALK S1206Y confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	ALK S1206Y confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-NokSSS-TIFzzUKWXmolecularmatch	ALK	Pf-06463922	ALK R1275Q confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	ALK R1275Q confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26554404	AVv-NdibSS-TIFzzUKElmolecularmatch	ALK	Pf-06463922	ALK L1198F confers resistance to Pf-06463922 in patients with Neoplasm of lung	ALK L1198F confers resistance to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-NenHSS-TIFzzUKGRmolecularmatch	ALK	Pf-06463922	ALK L1196M confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	ALK L1196M confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-NgCRSS-TIFzzUKIimolecularmatch	ALK	Pf-06463922	ALK L1152R confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	ALK L1152R confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-NgvSSS-TIFzzUKJkmolecularmatch	ALK	Pf-06463922	ALK I1171T confers resistance to Pf-06463922 in patients with Neoplasm of lung	ALK I1171T confers resistance to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-NhGlSS-TIFzzUKKGmolecularmatch	ALK	Pf-06463922	ALK G1269A confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	ALK G1269A confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-NimuSS-TIFzzUKMimolecularmatch	ALK	Pf-06463922	ALK G1202R confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	ALK G1202R confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-NjQlSS-TIFzzUKNlmolecularmatch	ALK	Pf-06463922	ALK G1128S confers resistance to Pf-06463922 in patients with Neoplasm of lung	ALK G1128S confers resistance to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-NjzDSS-TIFzzUKOcmolecularmatch	ALK	Pf-06463922	ALK F1245C confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	ALK F1245C confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26554404	AVv-NkbpSS-TIFzzUKPemolecularmatch	ALK	Pf-06463922	ALK F1174V confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	ALK F1174V confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-NlFESS-TIFzzUKQsmolecularmatch	ALK	Pf-06463922	ALK F1174L confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	ALK F1174L confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-NlpOSS-TIFzzUKRkmolecularmatch	ALK	Pf-06463922	ALK F1174C confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	ALK F1174C confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-NmK1SS-TIFzzUKSbmolecularmatch	ALK	Pf-06463922	ALK E1210K confers resistance to Pf-06463922 in patients with Neoplasm of lung	ALK E1210K confers resistance to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-NduzSS-TIFzzUKE7molecularmatch	ALK	Pf-06463922	ALK C1156Y confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	ALK C1156Y confers sensitivity to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-NnCNSS-TIFzzUKT-molecularmatch	ALK	Pf-06463922	ALK C1156F confers resistance to Pf-06463922 in patients with Neoplasm of lung	ALK C1156F confers resistance to Pf-06463922 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-NfiiSS-TIFzzUKHqmolecularmatch	ALK	Crizotinib	ALK V1180L confers resistance to Crizotinib in patients with Neoplasm of lung	ALK V1180L confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-Nnb1SS-TIFzzUKUomolecularmatch	ALK	Crizotinib	ALK T1151_L1152insT confers resistance to Crizotinib in patients with Neoplasm of lung	ALK T1151_L1152insT confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-NoAoSS-TIFzzUKVgmolecularmatch	ALK	Crizotinib	ALK S1206Y confers resistance to Crizotinib in patients with Neoplasm of lung	ALK S1206Y confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22277784	AVv-NoWXSS-TIFzzUKWBmolecularmatch	ALK	Crizotinib	ALK R1275Q confers resistance to Crizotinib in patients with Neoplasm of lung	ALK R1275Q confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26554404	AVv-NdoVSS-TIFzzUKEwmolecularmatch	ALK	Crizotinib	ALK R1192P confers sensitivity to Crizotinib in patients with Neoplasm of lung	ALK R1192P confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21838707	AVv-NefxSS-TIFzzUKGGmolecularmatch	ALK	Crizotinib	ALK L1198F confers sensitivity to Crizotinib in patients with Neoplasm of lung	ALK L1198F confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-NfDtSS-TIFzzUKG9molecularmatch	ALK	Crizotinib	ALK L1196Q confers resistance to Crizotinib in patients with Neoplasm of lung	ALK L1196Q confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23239810	AVv-NfLjSS-TIFzzUKHImolecularmatch	ALK	Crizotinib	ALK L1196M confers resistance to Crizotinib in patients with Neoplasm of lung	ALK L1196M confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22277784	AVv-Nfh5SS-TIFzzUKHpmolecularmatch	ALK	Crizotinib	ALK L1152R confers resistance to Crizotinib in patients with Neoplasm of lung	ALK L1152R confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21791641	AVv-NggjSS-TIFzzUKJOmolecularmatch	ALK	Crizotinib	ALK L1152P confers resistance to Crizotinib in patients with Neoplasm of lung	ALK L1152P confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-Ng-_SS-TIFzzUKJ7molecularmatch	ALK	Crizotinib	ALK I1171T confers resistance to Crizotinib in patients with Neoplasm of lung	ALK I1171T confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-NhVYSS-TIFzzUKKcmolecularmatch	ALK	Crizotinib	ALK I1171S confers resistance to Crizotinib in patients with Neoplasm of lung	ALK I1171S confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-NhyOSS-TIFzzUKLImolecularmatch	ALK	Crizotinib	ALK I1171N confers resistance to Crizotinib in patients with Neoplasm of lung	ALK I1171N confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-NiKnSS-TIFzzUKL1molecularmatch	ALK	Crizotinib	ALK G1269A confers resistance to Crizotinib in patients with Neoplasm of lung	ALK G1269A confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-NiYeSS-TIFzzUKMMmolecularmatch	ALK	Crizotinib	ALK G1202R confers resistance to Crizotinib in patients with Neoplasm of lung	ALK G1202R confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-NjJjSS-TIFzzUKNamolecularmatch	ALK	Crizotinib	ALK G1128A confers sensitivity to Crizotinib in patients with Neoplasm of lung	ALK G1128A confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21838707	AVv-Nj5bSS-TIFzzUKOmmolecularmatch	ALK	Crizotinib	ALK G1123S confers resistance to Crizotinib in patients with Neoplasm of lung	ALK G1123S confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26134233	AVv-NkHpSS-TIFzzUKO8molecularmatch	ALK	Crizotinib	ALK F1245C confers resistance to Crizotinib in patients with Neoplasm of lung	ALK F1245C confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26775591	AVv-NkVeSS-TIFzzUKPTmolecularmatch	ALK	Crizotinib	ALK F1174V confers resistance to Crizotinib in patients with Neoplasm of lung	ALK F1174V confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24736079	AVv-Nk4NSS-TIFzzUKQWmolecularmatch	ALK	Crizotinib	ALK F1174L confers resistance to Crizotinib in patients with Neoplasm of lung	ALK F1174L confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/21791641	AVv-NlakSS-TIFzzUKROmolecularmatch	ALK	Crizotinib	ALK F1174C confers resistance to Crizotinib in patients with Neoplasm of lung	ALK F1174C confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-Nl80SS-TIFzzUKSFmolecularmatch	ALK	Crizotinib	ALK E1210K confers sensitivity to Crizotinib in patients with Neoplasm of lung	ALK E1210K confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-NeL9SS-TIFzzUKFnmolecularmatch	ALK	Crizotinib	ALK E1210K confers resistance to Crizotinib in patients with Neoplasm of lung	ALK E1210K confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22034911	AVv-NeSCSS-TIFzzUKFymolecularmatch	ALK	Crizotinib	ALK C1156Y confers resistance to Crizotinib in patients with Neoplasm of lung	ALK C1156Y confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-NmldSS-TIFzzUKTHmolecularmatch	ALK	Crizotinib	ALK C1156F confers sensitivity to Crizotinib in patients with Neoplasm of lung	ALK C1156F confers sensitivity to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-Nok3SS-TIFzzUKWYmolecularmatch	ALK	Crizotinib	ALK Amplification confers resistance to Crizotinib in patients with Neoplasm of lung	ALK Amplification confers resistance to Crizotinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22277784	AVv-Nh55SS-TIFzzUKLUmolecularmatch	ALK	Ceritinib	ALK V1180L confers sensitivity to Ceritinib in patients with Neoplasm of lung	ALK V1180L confers sensitivity to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25736571	AVv-NnrFSS-TIFzzUKU_molecularmatch	ALK	Ceritinib	ALK T1151_L1152insT confers resistance to Ceritinib in patients with Neoplasm of lung	ALK T1151_L1152insT confers resistance to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-Nn4_SS-TIFzzUKVVmolecularmatch	ALK	Ceritinib	ALK S1206Y confers sensitivity to Ceritinib in patients with Neoplasm of lung	ALK S1206Y confers sensitivity to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24670165	AVv-NdbaSS-TIFzzUKEZmolecularmatch	ALK	Ceritinib	ALK L1198F confers resistance to Ceritinib in patients with Neoplasm of lung	ALK L1198F confers resistance to Ceritinib in patients with Neoplasm of lung	http://mct.aacrjournals.org/content/14/12_supplement_2/pr03.short	AVv-Ne7nSS-TIFzzUKGymolecularmatch	ALK	Ceritinib	ALK L1196Q confers sensitivity to Ceritinib in patients with Neoplasm of lung	ALK L1196Q confers sensitivity to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23239810	AVv-NfaZSS-TIFzzUKHemolecularmatch	ALK	Ceritinib	ALK L1196M confers sensitivity to Ceritinib in patients with Neoplasm of lung	ALK L1196M confers sensitivity to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24670165	AVv-NgRUSS-TIFzzUKI4molecularmatch	ALK	Ceritinib	ALK L1152R confers resistance to Ceritinib in patients with Neoplasm of lung	ALK L1152R confers resistance to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-NgZFSS-TIFzzUKJDmolecularmatch	ALK	Ceritinib	ALK L1152P confers resistance to Ceritinib in patients with Neoplasm of lung	ALK L1152P confers resistance to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-Ng3OSS-TIFzzUKJwmolecularmatch	ALK	Ceritinib	ALK I1171T confers sensitivity to Ceritinib in patients with Neoplasm of lung	ALK I1171T confers sensitivity to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-NhjcSS-TIFzzUKKymolecularmatch	ALK	Ceritinib	ALK I1171S confers sensitivity to Ceritinib in patients with Neoplasm of lung	ALK I1171S confers sensitivity to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27609840	AVv-Nh5SSS-TIFzzUKLTmolecularmatch	ALK	Ceritinib	ALK I1171N confers sensitivity to Ceritinib in patients with Neoplasm of lung	ALK I1171N confers sensitivity to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25736571	AVv-NiRaSS-TIFzzUKMAmolecularmatch	ALK	Ceritinib	ALK G1269A confers sensitivity to Ceritinib in patients with Neoplasm of lung	ALK G1269A confers sensitivity to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24670165	AVv-Ni03SS-TIFzzUKM4molecularmatch	ALK	Ceritinib	ALK G1202R confers resistance to Ceritinib in patients with Neoplasm of lung	ALK G1202R confers resistance to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22277784	AVv-NjCBSS-TIFzzUKNOmolecularmatch	ALK	Ceritinib	ALK G1128S confers resistance to Ceritinib in patients with Neoplasm of lung	ALK G1128S confers resistance to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-NjsWSS-TIFzzUKORmolecularmatch	ALK	Ceritinib	ALK G1123S confers resistance to Ceritinib in patients with Neoplasm of lung	ALK G1123S confers resistance to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26134233	AVv-NkAOSS-TIFzzUKOxmolecularmatch	ALK	Ceritinib	ALK F1245C confers sensitivity to Ceritinib in patients with Neoplasm of lung	ALK F1245C confers sensitivity to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26775591	AVv-NkpHSS-TIFzzUKP_molecularmatch	ALK	Ceritinib	ALK F1174V confers resistance to Ceritinib in patients with Neoplasm of lung	ALK F1174V confers resistance to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-NkwzSS-TIFzzUKQKmolecularmatch	ALK	Ceritinib	ALK F1174L confers resistance to Ceritinib in patients with Neoplasm of lung	ALK F1174L confers resistance to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-NlTDSS-TIFzzUKRDmolecularmatch	ALK	Ceritinib	ALK F1174C confers resistance to Ceritinib in patients with Neoplasm of lung	ALK F1174C confers resistance to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-Nl2cSS-TIFzzUKR6molecularmatch	ALK	Ceritinib	ALK E1210K confers resistance to Ceritinib in patients with Neoplasm of lung	ALK E1210K confers resistance to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-NeFkSS-TIFzzUKFcmolecularmatch	ALK	Ceritinib	ALK D1203N confers resistance to Ceritinib in patients with Neoplasm of lung	ALK D1203N confers resistance to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26084268	AVv-NeXcSS-TIFzzUKF6molecularmatch	ALK	Ceritinib	ALK C1156Y confers resistance to Ceritinib in patients with Neoplasm of lung	ALK C1156Y confers resistance to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-NmfDSS-TIFzzUKS8molecularmatch	ALK	Ceritinib	ALK C1156F confers resistance to Ceritinib in patients with Neoplasm of lung	ALK C1156F confers resistance to Ceritinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-NncfSS-TIFzzUKUpmolecularmatch	ALK	Ap-26113	ALK S1206Y confers resistance to Ap-26113 in patients with Neoplasm of lung	ALK S1206Y confers resistance to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-NoPlSS-TIFzzUKV2molecularmatch	ALK	Ap-26113	ALK L1198F confers sensitivity to Ap-26113 in patients with Neoplasm of lung	ALK L1198F confers sensitivity to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-NeuRSS-TIFzzUKGcmolecularmatch	ALK	Ap-26113	ALK L1196Q confers sensitivity to Ap-26113 in patients with Neoplasm of lung	ALK L1196Q confers sensitivity to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/23239810	AVv-NfTiSS-TIFzzUKHTmolecularmatch	ALK	Ap-26113	ALK L1196M confers sensitivity to Ap-26113 in patients with Neoplasm of lung	ALK L1196M confers sensitivity to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27867609	AVv-NgJxSS-TIFzzUKItmolecularmatch	ALK	Ap-26113	ALK I1171T confers sensitivity to Ap-26113 in patients with Neoplasm of lung	ALK I1171T confers sensitivity to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27867609	AVv-NhcOSS-TIFzzUKKnmolecularmatch	ALK	Ap-26113	ALK G1269A confers sensitivity to Ap-26113 in patients with Neoplasm of lung	ALK G1269A confers sensitivity to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27867609	AVv-NiuISS-TIFzzUKMtmolecularmatch	ALK	Ap-26113	ALK G1202R confers sensitivity to Ap-26113 in patients with Neoplasm of lung	ALK G1202R confers sensitivity to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-Nje1SS-TIFzzUKN7molecularmatch	ALK	Ap-26113	ALK G1202R confers resistance to Ap-26113 in patients with Neoplasm of lung	ALK G1202R confers resistance to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-NjYDSS-TIFzzUKNwmolecularmatch	ALK	Ap-26113	ALK G1128S confers sensitivity to Ap-26113 in patients with Neoplasm of lung	ALK G1128S confers sensitivity to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-NjlgSS-TIFzzUKOGmolecularmatch	ALK	Ap-26113	ALK F1245C confers sensitivity to Ap-26113 in patients with Neoplasm of lung	ALK F1245C confers sensitivity to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27867609	AVv-NkheSS-TIFzzUKPpmolecularmatch	ALK	Ap-26113	ALK F1174V confers sensitivity to Ap-26113 in patients with Neoplasm of lung	ALK F1174V confers sensitivity to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27867609	AVv-NlLkSS-TIFzzUKQ3molecularmatch	ALK	Ap-26113	ALK F1174L confers sensitivity to Ap-26113 in patients with Neoplasm of lung	ALK F1174L confers sensitivity to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27867609	AVv-Nlv4SS-TIFzzUKRvmolecularmatch	ALK	Ap-26113	ALK F1174C confers sensitivity to Ap-26113 in patients with Neoplasm of lung	ALK F1174C confers sensitivity to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27867609	AVv-NmSKSS-TIFzzUKSmmolecularmatch	ALK	Ap-26113	ALK E1210K confers resistance to Ap-26113 in patients with Neoplasm of lung	ALK E1210K confers resistance to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-Nd2CSS-TIFzzUKFGmolecularmatch	ALK	Ap-26113	ALK C1156Y confers sensitivity to Ap-26113 in patients with Neoplasm of lung	ALK C1156Y confers sensitivity to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27867609	AVv-NnI-SS-TIFzzUKUJmolecularmatch	ALK	Ap-26113	ALK C1156F confers resistance to Ap-26113 in patients with Neoplasm of lung	ALK C1156F confers resistance to Ap-26113 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-Ngv5SS-TIFzzUKJlmolecularmatch	ALK	Alectinib	ALK V1180L confers resistance to Alectinib in patients with Neoplasm of lung	ALK V1180L confers resistance to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-NnUHSS-TIFzzUKUdmolecularmatch	ALK	Alectinib	ALK T1151_L1152insT confers sensitivity to Alectinib in patients with Neoplasm of lung	ALK T1151_L1152insT confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24887559	AVv-NnyISS-TIFzzUKVKmolecularmatch	ALK	Alectinib	ALK S1206Y confers sensitivity to Alectinib in patients with Neoplasm of lung	ALK S1206Y confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25727400	AVv-NodHSS-TIFzzUKWMmolecularmatch	ALK	Alectinib	ALK L1198F confers resistance to Alectinib in patients with Neoplasm of lung	ALK L1198F confers resistance to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-Ne0aSS-TIFzzUKGnmolecularmatch	ALK	Alectinib	ALK L1196M confers sensitivity to Alectinib in patients with Neoplasm of lung	ALK L1196M confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27609840	AVv-NfqzSS-TIFzzUKIAmolecularmatch	ALK	Alectinib	ALK L1152R confers sensitivity to Alectinib in patients with Neoplasm of lung	ALK L1152R confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27091190	AVv-NgnzSS-TIFzzUKJZmolecularmatch	ALK	Alectinib	ALK I1171T confers resistance to Alectinib in patients with Neoplasm of lung	ALK I1171T confers resistance to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-NhNrSS-TIFzzUKKRmolecularmatch	ALK	Alectinib	ALK I1171S confers resistance to Alectinib in patients with Neoplasm of lung	ALK I1171S confers resistance to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-Nhq1SS-TIFzzUKK9molecularmatch	ALK	Alectinib	ALK I1171N confers resistance to Alectinib in patients with Neoplasm of lung	ALK I1171N confers resistance to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-NiDBSS-TIFzzUKLfmolecularmatch	ALK	Alectinib	ALK G1269A confers sensitivity to Alectinib in patients with Neoplasm of lung	ALK G1269A confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26849637	AVv-NifuSS-TIFzzUKMXmolecularmatch	ALK	Alectinib	ALK G1202R confers resistance to Alectinib in patients with Neoplasm of lung	ALK G1202R confers resistance to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/24736079	AVv-Ni7fSS-TIFzzUKNDmolecularmatch	ALK	Alectinib	ALK G1123S confers sensitivity to Alectinib in patients with Neoplasm of lung	ALK G1123S confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26134233	AVv-NkPBSS-TIFzzUKPImolecularmatch	ALK	Alectinib	ALK F1174V confers sensitivity to Alectinib in patients with Neoplasm of lung	ALK F1174V confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/26464158	AVv-Nk-5SS-TIFzzUKQhmolecularmatch	ALK	Alectinib	ALK F1174L confers sensitivity to Alectinib in patients with Neoplasm of lung	ALK F1174L confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27609840	AVv-NlhvSS-TIFzzUKRZmolecularmatch	ALK	Alectinib	ALK F1174C confers sensitivity to Alectinib in patients with Neoplasm of lung	ALK F1174C confers sensitivity to Alectinib in patients with Neoplasm of lung		AVv-NmDsSS-TIFzzUKSQmolecularmatch	ALK	Alectinib	ALK E1210K confers resistance to Alectinib in patients with Neoplasm of lung	ALK E1210K confers resistance to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-Nd9rSS-TIFzzUKFRmolecularmatch	ALK	Alectinib	ALK C1156Y confers sensitivity to Alectinib in patients with Neoplasm of lung	ALK C1156Y confers sensitivity to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/27609840	AVv-NmsSSS-TIFzzUKTSmolecularmatch	ALK	Alectinib	ALK C1156F confers resistance to Alectinib in patients with Neoplasm of lung	ALK C1156F confers resistance to Alectinib in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-NeYLSS-TIFzzUKF7molecularmatch	AKT2	Mk-2206	AKT2 Amplification confers sensitivity to Mk-2206 in patients with Neoplasm of lung	AKT2 Amplification confers sensitivity to Mk-2206 in patients with Neoplasm of lung	http://cancerres.aacrjournals.org/content/69/9_supplement/3714.short	AVv-NkIVSS-TIFzzUKO9molecularmatch	AKT2	At13148	AKT2 Amplification confers sensitivity to At13148 in patients with Neoplasm of lung	AKT2 Amplification confers sensitivity to At13148 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/19351834	AVv-NjClSS-TIFzzUKNPmolecularmatch	AKT1	Mk-2206	AKT1 E17K confers sensitivity to Mk-2206 in patients with Neoplasm of lung	AKT1 E17K confers sensitivity to Mk-2206 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22648207	AVv-NmSvSS-TIFzzUKSnmolecularmatch	AKT1	Everolimus	AKT1 E17K confers sensitivity to Everolimus in patients with Neoplasm of lung	AKT1 E17K confers sensitivity to Everolimus in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/25701455	AVv-NoliSS-TIFzzUKWZmolecularmatch	AKT1	At13148	AKT1 E17K confers sensitivity to At13148 in patients with Neoplasm of lung	AKT1 E17K confers sensitivity to At13148 in patients with Neoplasm of lung	https://www.ncbi.nlm.nih.gov/pubmed/22648207	AVv-NlMKSS-TIFzzUKQ4molecularmatch	9p24.1	RG7446	9p24.1 amplification confers sensitivity to RG7446 in patients with Neoplasm of colorectum	9p24.1 amplification confers sensitivity to RG7446 in patients with Neoplasm of colorectum	http://cancerres.aacrjournals.org/content/76/14_supplement/2651.short	AVv-NpseSS-TIFzzUKYSmolecularmatch	9p24.1	Pembrolizumab	9p24.1 amplification confers sensitivity to Pembrolizumab in patients with Neoplasm of colorectum	9p24.1 amplification confers sensitivity to Pembrolizumab in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/26994146	AVv-Np8lSS-TIFzzUKYqmolecularmatch	9p24.1	MEDI-4736	9p24.1 amplification confers sensitivity to MEDI-4736 in patients with Neoplasm of colorectum	9p24.1 amplification confers sensitivity to MEDI-4736 in patients with Neoplasm of colorectum	https://www.ncbi.nlm.nih.gov/pubmed/25943534	AVv-NqpYSS-TIFzzUKZwjax	VHL	Sunitinib + Trametinib	"In a preclinical study, combination of Mekinist (trametinib) and Sutent (sunitinib) inhibited tumor growth in patient-derived xenograft models of renal cancer harboring VHL V155fs*4 (PMID: 26487278)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26487278	AVv-LP_aSS-TIFzzUJSzjax	VHL	Sunitinib	"In a Phase I study, 33% (6/18) of renal cell carcinoma archived patient samples with VHL mutations demonstrated partial response when treated with Sutent (sunitinib) (PMID: 22105611)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22105611	AVv-LP-XSS-TIFzzUJSxjax	VHL	STF-62247	"In a preclinical study, STF-62247 induced selective cytotoxicity and inhibited tumor growth of renal cell carcinoma cells lacking VHL (PMID: 18769110, PMID: 18598947)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18769110	AVv-LP7GSS-TIFzzUJSrjax	VHL	Regorafenib	"In a preclinical study, Stivarga (regorafenib) inhibited angiogenesis and tumor growth in cell line xenograft models of renal cell carcinoma harboring VHL gene deletion (PMID: 21170960)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21170960	AVv-LP7nSS-TIFzzUJSsjax	VHL	PT2399	"In a preclinical study, TP53 R248W was associated with resistance to PT2399 in VHL-defective clear cell renal cell carcinoma cell lines in culture (PMID: 27595393)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27595393	AVv-LP4BSS-TIFzzUJSmjax	VHL	PF-05212384	"In a preclinical study, human renal carcinoma cells with PTEN loss and VHL loss had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-LP8vSS-TIFzzUJSujax	VHL	ELR510444	"In a preclinical study, renal cell carcinoma cells deficient for VHL were sensitive to ELR510444 both in culture and in cell line xenograft models (PMID: 22295124)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22295124	AVv-LP9RSS-TIFzzUJSvjax	VHL	Cediranib + Saracatinib	"In a Phase II clinical study, baseline expression of VHL was not predictive for response to Saracatinib (AZD0530) and Recentin (cediranib) relative to Recentin (cediranib) in patients with metastatic clear-cell renal cell carcinoma (PMID: 26802156)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26802156	AVv-LP8ISS-TIFzzUJStjax	VHL	Bevacizumab	"In a preclinical study, clear cell renal cell carcinoma xenograft models with VHL loss demonstrated sensitivity to Avastin (bevacizumab) (PMID: 22931246)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22931246	AVv-LP90SS-TIFzzUJSwjax	TP53	p53-SLP vaccine	"In a Phase II trial, p53-SLP vaccine was demonstrated to be safe, well tolerated and to induce p53-specific T-cell responses in ovarian cancer patients; however clinical impact was lacking (PMID: 19621448, PMID: 21328579)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/21328579	AVv-LNhfSS-TIFzzUJPAjax	TP53	epirubicin	"In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations, who were also hormone receptor negative, demonstrated a favorable response to Ellence (epirubicin) in combination with other chemotherapeutic agents (PMID: 22903472)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22903472	AVv-LORsSS-TIFzzUJQTjax	TP53	YW3-56	"In a preclinical study, YW3-56 inhibited proliferation of a human triple-negative breast cancer (TNBC) cell line harboring TP53 R280K in culture and inhibited tumor growth in TP53 R280K-mutant TNBC cell line xenograft models (PMID: 25612620)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25612620	AVv-LOLzSS-TIFzzUJQJjax	TP53	Vorinostat	"In a preclinical study, Zolinza (vorinostat) inhibited tumor growth in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26009011	AVv-LNLfSS-TIFzzUJOcjax	TP53	Vemurafenib	"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of human melanoma cells TP53 D259Y in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-LOEVSS-TIFzzUJP9jax	TP53	Trifluridine	"In a preclinical study, treatment with Trifluridine (FTD) resulted in Tp53-dependent cell-cycle arrest and decreased expression of CyclinB1 and Cdk1 in a Tp53-proficient colon cancer cancer cell line in culture (PMID: 25700705)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25700705	AVv-LNUTSS-TIFzzUJOqjax	TP53	Tanespimycin + Vorinostat	"In a preclinical study, Tanespimycin (17-AAG) and Zolinza (vorinostat) were synergistic towards tumor growth inhibition in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26009011	AVv-LNKSSS-TIFzzUJOajax	TP53	Tanespimycin	"In a preclinical study, Tanespimycin (17-AAG) inhibited tumor growth in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26009011	AVv-LNK-SS-TIFzzUJObjax	TP53	TC-A2317	"In a preclinical study, MK-8745 treatment resulted in polyploidy in TP53-null colorectal cancer cells in culture (PMID: 22293494)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22293494	AVv-LONtSS-TIFzzUJQMjax	TP53	Serdemetan	"In a Phase I trial, Serdemetan (JNJ-26854165) treatment induced a 102% increase of Tp53 expression in tumor tissue, resulted in partial response in a patient with breast cancer (PMID: 21831953)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21831953	AVv-LNPwSS-TIFzzUJOjjax	TP53	Serdemetan	"In a Phase I trial, Serdemetan (JNJ-26854165) treatment increased Tp53 expression in tumor and surrogate tissue, resulted in partial response in 1.8% (1/57) and stable disease in 38.6% (22/57) of patients with advanced solid tumors (PMID: 21831953)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21831953	AVv-LNPHSS-TIFzzUJOijax	TP53	Selumetinib	"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-LNMFSS-TIFzzUJOdjax	TP53	Selumetinib	"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-LOaDSS-TIFzzUJQijax	TP53	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) inhibited tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-LOXuSS-TIFzzUJQejax	TP53	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) inhibited proliferation of human melanoma cells harboring TP53 D259Y in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-LOFCSS-TIFzzUJP-jax	TP53	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-LN9WSS-TIFzzUJPxjax	TP53	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-LN94SS-TIFzzUJPyjax	TP53	Seliciclib	"In a preclinical study, H1299 lung cancer cell lines expressing TP53 wild-type protein were sensitive to Roscovitine (seliciclib) (PMID: 22862161)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22862161	AVv-LNn2SS-TIFzzUJPLjax	TP53	Seliciclib	"In a preclinical study, H1299 lung cancer cell lines expressing TP53 Y220C showed weak sensitivity to Roscovitine (seliciclib) (PMID: 22862161)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22862161	AVv-LOpxSS-TIFzzUJQ9jax	TP53	Seliciclib	"In a preclinical study, H1299 lung cancer cell lines expressing TP53 P98A showed weak sensitivity to Roscovitine (seliciclib) (PMID: 22862161)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22862161	AVv-LNRESS-TIFzzUJOljax	TP53	SP600125	"In a preclinical study, SP600125 induced cell death in colon carcinoma cells deficient for p53 (PMID: 22438244)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22438244	AVv-LPO9SS-TIFzzUJR-jax	TP53	SAR405838	"In a preclinical study, SAR405838 inhibited growth of TP53 wild-type prostate cancer cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25145672	AVv-LNiGSS-TIFzzUJPBjax	TP53	SAR405838	"In a preclinical study, SAR405838 inhibited growth of TP53 wild-type colon cancer cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25145672	AVv-LNssSS-TIFzzUJPUjax	TP53	SAR405838	"In a preclinical study, SAR405838 inhibited growth of TP53 wild-type acute leukemia cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25145672	AVv-LNY4SS-TIFzzUJOyjax	TP53	ReACp53	"In a preclinical study, treatment with ReACp53 induced cell death in primary human uterine fibroblasts expressing TP53 R175H in culture (PMID: 26748848)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26748848	AVv-LPXtSS-TIFzzUJSOjax	TP53	ReACp53	"In a preclinical study, ReACp53 rescued p53 activity and decreased viability of ovarian cancer cells harboring TP53 R248Q in culture, and induced tumor regression in patient-derived ovarian cancer xenograft models harboring TP53 R248Q (PMID: 26748848)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26748848	AVv-LOfJSS-TIFzzUJQrjax	TP53	ReACp53	"In a preclinical study, ReACp53 induced cell death in human primary ovarian carcinoma cells harboring TP53 Y327L in culture (PMID: 26748848)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26748848	AVv-LOBLSS-TIFzzUJP4jax	TP53	ReACp53	"In a preclinical study, ReACp53 induced cell death in human primary ovarian carcinoma cells harboring TP53 Y234C in culture (PMID: 26748848)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26748848	AVv-LOGKSS-TIFzzUJQAjax	TP53	ReACp53	"In a preclinical study, ReACp53 induced cell death and decreased proliferation of ovarian carcinoma cells harboring TP53 mutations in culture, but did not effect viability of ovarian carcinoma cells with wild-type TP53 (PMID: 26748848)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26748848	AVv-LOhDSS-TIFzzUJQujax	TP53	ReACp53	"In a preclinical study, ReACp53 induced cell death and decreased proliferation of human primary ovarian carcinoma cells harboring both TP53 I195* and TP53 R248Q in culture (PMID: 26748848)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26748848	AVv-LOB6SS-TIFzzUJP5jax	TP53	ReACp53	"In a preclinical study, ReACp53 induced cell death and decreased proliferation of head and neck carcinoma cells harboring TP53 R175H in culture (PMID: 26748848)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26748848	AVv-LPUcSS-TIFzzUJSIjax	TP53	ReACp53	"In a preclincial study, ReACp53 did not induce cell death in ovarian cancer cells with loss of TP53 in culture (PMID: 26748848)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26748848	AVv-LPQiSS-TIFzzUJSBjax	TP53	R547	"In a preclinical study, R547 inhibited proliferation of prostate carcinoma cell lines harboring Tp53 and Rb1 mutations in culture and reduced tumor growth in xenograft models (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LPFpSS-TIFzzUJRtjax	TP53	R547	"In a preclinical study, R547 inhibited proliferation of osteosarcoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LOtzSS-TIFzzUJREjax	TP53	R547	"In a preclinical study, R547 inhibited proliferation of melanoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LN46SS-TIFzzUJPpjax	TP53	R547	"In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LN4TSS-TIFzzUJPojax	TP53	R547	"In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LOu8SS-TIFzzUJRGjax	TP53	R547	"In a preclinical study, R547 inhibited proliferation of lung carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LN6FSS-TIFzzUJPrjax	TP53	R547	"In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LN3sSS-TIFzzUJPnjax	TP53	R547	"In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LOvdSS-TIFzzUJRHjax	TP53	R547	"In a preclinical study, R547 inhibited proliferation of cervical carcinoma cell lines harboring Tp53 and Rb1 mutations (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LPGJSS-TIFzzUJRujax	TP53	R547	"In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LN5dSS-TIFzzUJPqjax	TP53	R547	"In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LOuXSS-TIFzzUJRFjax	TP53	R547	"In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring TP53 and RB1 mutations in culture (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LPGtSS-TIFzzUJRvjax	TP53	Prodigiosin	"In a preclinical study, Prodigiosin inhibited self-renewal of colorectal cancer cell lines harboring TP53 mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 26759239)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26759239	AVv-LOzFSS-TIFzzUJRNjax	TP53	Prodigiosin	"In a preclinical study, Prodigiosin inhibited self-renewal of colorectal cancer cell lines harboring TP53 loss in culture (PMID: 26759239)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26759239	AVv-LPOcSS-TIFzzUJR9jax	TP53	Prodigiosin	"In a preclinical study, Prodigiosin inhibited self-renewal of Tp53 wild-type colorectal cancer cell lines in culture (PMID: 26759239)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26759239	AVv-LNmMSS-TIFzzUJPIjax	TP53	Pimasertib + Gemcitabine	"In a preclinical study, the combination of pimasertib and Gemzar (gemcitabine) inhibited tumor growth in a syngeneic mouse model of pancreatic cancer expressing KRAS G12D and TP53 R175H (PMID: 26228206)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26228206	AVv-LPZcSS-TIFzzUJSRjax	TP53	Pazopanib	"In a retrospective study, advanced sarcoma patients with TP53 mutations displayed improved progression-free survival (208 days versus 136 days) relative to patients with wild-type TP53 when treated with Votrient (pazopanib) (PMID: 26646755)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26646755	AVv-LPCTSS-TIFzzUJRnjax	TP53	PT2399	"In a preclinical study, TP53 R248W was associated with resistance to PT2399 in VHL-defective clear cell renal cell carcinoma cell lines in culture (PMID: 27595393)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27595393	AVv-LObDSS-TIFzzUJQkjax	TP53	PI-3065	"In a preclinical study, PI-3065 treatment prolonged survival and decreased metastasis in allograft animal models of pancreatic ductal adenocarcinoma harboring KRAS G12D and TP53 R175H through upregulation of host anti-tumor immune response(PMID: 24919154)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/24919154	AVv-LPY2SS-TIFzzUJSQjax	TP53	PHA-680632 + Radiotherapy	"In a preclinical study, PHA-680632 synergized with radiotherapy to decrease tumor growth in Pdx models deficient in Tp53 (PMID: 18026198)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18026198	AVv-LPRDSS-TIFzzUJSCjax	TP53	PF-05212384	"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring TP53 R138G in culture (PMID: 21325073, PMID: 23980093)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-LOrgSS-TIFzzUJRAjax	TP53	PD0166285	"In a preclinical study, PD0166285 sensitizes colorectal cancer cells with TP53 mutation to radiation induced cell death (PMID: 11719452)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/11719452	AVv-LPALSS-TIFzzUJRjjax	TP53	Oxaliplatin + ABT-737	"In a preclinical study, Eloxatin (oxaliplatin), in combination with ABT-737, was only effective in tumor cell lines carrying KRAS mutants and wild-type TP53 (PMID: 21468686)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21468686	AVv-LNzzSS-TIFzzUJPhjax	TP53	Olaparib	"In a preclinical study, mouse breast cancer models harboring BRCA1 C61G with conditional loss of Tp53 had a decreased response to Lynparza (olaparib) compared to models with conditional loss of Brca1 and Tp53 (PMID: 22172724)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22172724	AVv-LPJkSS-TIFzzUJR0jax	TP53	Nutlin-3a	"In a preclinical study, treatment with Nutlin-3 had little effect on growth of ovarian cancer cells with deletion of TP53 in culture (PMID: 25964101)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/25964101	AVv-LONGSS-TIFzzUJQLjax	TP53	Nutlin-3a	"In a preclinical study, treatment with Nutlin-3 had little effect on growth of ovarian cancer cells with TP53 mutations in culture (PMID: 25964101)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/25964101	AVv-LPC8SS-TIFzzUJRojax	TP53	Nutlin-3a	"In a preclinical study, neuroblastoma cell lines harboring TP53 mutant were resistant to nutlin-3 mediated growth inhibition (PMID: 21725357)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21725357	AVv-LPB0SS-TIFzzUJRmjax	TP53	Nutlin-3a	"In a preclinical study, TP53 R280M resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21643018	AVv-LNG4SS-TIFzzUJOJjax	TP53	Nutlin-3a	"In a preclinical study, TP53 P177T resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21643018	AVv-LOCiSS-TIFzzUJP6jax	TP53	Nutlin-3a	"In a preclinical study, TP53 I232S resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21643018	AVv-LOokSS-TIFzzUJQ7jax	TP53	Nutlin-3a	"In a preclinical study, TP53 E258Q resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21643018	AVv-LOUfSS-TIFzzUJQYjax	TP53	Nutlin-3 + Etoposide	"In a preclinical study, Nutlin-3 and etoposide worked cooperatively to induce apoptosis in ovarian cancer cell lines with TP53 inactivating mutations in culture (PMID: 25964101)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25964101	AVv-LO3QSS-TIFzzUJRUjax	TP53	Nutlin-3 + Etoposide	"In a preclinical study, Nutlin-3 and etoposide worked cooperatively to induce apoptosis and decrease growth of ovarian cancer cells with TP53 deletion in culture (PMID: 25964101)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25964101	AVv-LOMjSS-TIFzzUJQKjax	TP53	Nutlin-3 + Cisplatin	"In a preclinical study, Nutlin-3 and cisplatin worked cooperatively to induce apoptosis in ovarian cancer cell lines with TP53 inactivating mutations in culture (PMID: 25964101)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25964101	AVv-LOhrSS-TIFzzUJQvjax	TP53	Nutlin-3 + Cisplatin	"In a preclinical study, Nutlin-3 and cisplatin worked cooperatively to induce apoptosis and decrease growth of ovarian cancer cells with TP53 deletion in culture (PMID: 25964101)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25964101	AVv-LOORSS-TIFzzUJQNjax	TP53	NSC59984	"In a preclinical study, treatment with NSC59984 resulted in increased degradation of mutant Tp53 and cell death in a colorectal cancer cell line harboring TP53 R175L in culture (PMID: 26294215)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26294215	AVv-LNFsSS-TIFzzUJOHjax	TP53	NSC59984	"In a preclinical study, treatment with NSC59984 resulted in increased degradation of mutant Tp53 and cell death in a colorectal cancer cell line harboring TP53 R175H in culture (PMID: 26294215)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26294215	AVv-LPU-SS-TIFzzUJSJjax	TP53	NSC59984	"In a preclinical study, treatment with NSC59984 induced Tp53 pathway signaling, degradation of mutant Tp53, and cell death in a colorectal cancer cell line harboring TP53 R273H and TP53 P309S in culture (PMID: 26294215)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26294215	AVv-LOHZSS-TIFzzUJQCjax	TP53	NSC319726	"In a preclinical study, ovarian cancer cells harboring TP53 R175H demonstrated increased sensitivity to NSC319726-induced growth inhibition in culture and in cell line xenograft models (PMID: 22624712)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22624712	AVv-LPWBSS-TIFzzUJSLjax	TP53	NSC319726	"In a preclinical study, lung large cell carcinoma cells harboring TP53 R175L demonstrated increased sensitivity to NSC319726 in culture (PMID: 22624712)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22624712	AVv-LNFESS-TIFzzUJOGjax	TP53	NSC319726	"In a preclinical study, breast cancer cells harboring TP53 R175H demonstrated increased sensitivity to NSC319726 in culture (PMID: 22624712)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22624712	AVv-LPXESS-TIFzzUJSNjax	TP53	NSC319726	"In a preclinical study, NSC319726 did not inhibit tumor growth in xenograft models of breast cancer harboring TP53 R273W (PMID: 22624712)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22624712	AVv-LOPeSS-TIFzzUJQPjax	TP53	NSC319726	"In a preclinical study, NSC319726 did not inhibit tumor growth in xenograft models of TP53 wild-type lung large cell carcinoma (PMID: 22624712)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22624712	AVv-LNlmSS-TIFzzUJPHjax	TP53	MPI-0479605	"In a preclinical study the TTK (MPS1) inhibitor, MPI-0479605, inhibited cell cycle progression of colon carcinoma cells deficient for Tp53 with equivalent efficacy to cells with wild-type Tp53 (PMID: 21980130)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21980130	AVv-LNkfSS-TIFzzUJPFjax	TP53	MLN0128 + PD-0325901	"In a preclinical study, TAK-228 (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PIK3CA H1047R in culture (PMID: 26272063)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-LNxjSS-TIFzzUJPdjax	TP53	MLN0128 + PD-0325901	"In a preclinical study, TAK-228 (MLN0128) and PD-0325901 combination treatment resulted in tumor growth stabilization in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D, PIK3CA E545K and H1047L (PMID: 26272063)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-LOAnSS-TIFzzUJP3jax	TP53	MLN0128 + PD-0325901	"In a preclinical study, TAK-228 (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R335fs (PMID: 26272063)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-LOVDSS-TIFzzUJQZjax	TP53	MLN0128 + PD-0325901	"In a preclinical study, TAK-228 (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PTEN loss, and TP53 V216M (PMID: 26272063)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-LNJCSS-TIFzzUJONjax	TP53	MLN0128 + PD-0325901	"In a preclinical study, TAK-228 (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12C, PIK3CA H1047R, and TP53 R248W (PMID: 26272063)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-LOblSS-TIFzzUJQljax	TP53	MLN0128	"In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to MLN0128 in culture (PMID: 25261369)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25261369	AVv-LPIcSS-TIFzzUJRyjax	TP53	MLN0128	"In a preclinical study, a skin cancer cell line harboring mutations in PTEN and TP53 demonstrated sensitivity to MLN0128 in culture (PMID: 25261369)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25261369	AVv-LPHPSS-TIFzzUJRwjax	TP53	MLN0128	"In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to MLN0128 resulting in inhibition of MTORC1 signaling (PMID: 25261369)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25261369	AVv-LOsoSS-TIFzzUJRCjax	TP53	MK-8745	"In a preclinical study, MK-8745 treatment resulted in apoptosis in Tp53 wild-type colorectal cancer cells in culture (PMID: 22293494)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22293494	AVv-LNUzSS-TIFzzUJOrjax	TP53	MK-1775 + Radiotherapy	"In a preclinical study, the combination of MK-1775 and radiation therapy synergized to inhibit tumor growth in a human glioblastoma multiforme cell line xenograft model harboring mutant TP53 (PMID: 21992793)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21992793	AVv-LO31SS-TIFzzUJRVjax	TP53	MK-1775 + Radiotherapy	"In a preclinical study, MK-1775 increased the efficacy of radiation in breast cancer cells with defective TP53 in culture (PMID: 21799033)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21799033	AVv-LOiQSS-TIFzzUJQwjax	TP53	MK-1775 + PF-00477736	"In a preclinical study, MK-1775, in combination with the Chk1 inhibitor, PF-00477736, showed efficacy in various human cancer cell lines (breast, ovarian, colon, prostate), independently of p53 status (PMID: 22713237)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22713237	AVv-LNj6SS-TIFzzUJPEjax	TP53	MK-1775 + Gemcitabine	"In a preclinical study, the combination of MK-1775 and Gemzar (gemcitabine) inhibited Wee1 expression, Cdc2 phosphorylation, and tumor growth in several patient-derived xenograft models of pancreatic cancer harboring TP53 mutations (PMID: 21389100)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21389100	AVv-LPRqSS-TIFzzUJSDjax	TP53	MK-1775	"In a preclinical study, tumor cell lines carrying deficient TP53 were sensitized to DNA-damaging agents upon MK-1775 administration (PMID: 19887545)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19887545	AVv-LPSLSS-TIFzzUJSEjax	TP53	MK-1775	"In a preclinical study, treatment with MK-1775 decreased CDK1 phosphorylation and reduced tumor growth in patient-derived xenograft models of glioblastoma multiforme that harbor TP53 mutations (PMID: 27196784)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27196784	AVv-LO5wSS-TIFzzUJRYjax	TP53	MI-63	"In a preclinical study, neuroblastoma cell lines harboring TP53 mutant were resistant to MI-63 mediated growth inhibition (PMID: 21725357)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21725357	AVv-LOwtSS-TIFzzUJRJjax	TP53	LY3009120	"In a preclinical study, LY3009120 modestly inhibited soft agar growth of human melanoma cancer cells harboring TP53 D259Y in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-LOFmSS-TIFzzUJP_jax	TP53	LY2835219	"In a Phase I trial, a colorectal cancer patient co-harboring a KRAS mutation and TP53 mutation demonstrated sensitivity when treated with Abemaciclib (LY2835219), which resulted in stable disease (PMID: 27217383)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27217383	AVv-LPD9SS-TIFzzUJRqjax	TP53	LB-100 + Cisplatin	"In a preclinical study, LB100 treatment decreased PP2A activity and increased sensitivity to Platinol (cisplatin) in cisplatin-resistant ovarian cancer cells with TP53 loss in culture and in xenograft models (PMID: 25376608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25376608	AVv-LPK1SS-TIFzzUJR2jax	TP53	LB-100 + Cisplatin	"In a preclinical study, LB100 treatment decreased PP2A activity and increased sensitivity to Platinol (cisplatin) in a cisplatin-resistant ovarian cancer cell line harboring a TP53 inactivating mutation in culture (PMID: 25376608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25376608	AVv-LOkESS-TIFzzUJQzjax	TP53	JQ1	"In a preclinical study, medulloblastoma cell lines with TP53 mutations had significantly less sensitivity to the BET inhibitor, JQ1, than cell lines carrying wild-type TP53 (PMID: 24231268)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24231268	AVv-LNdFSS-TIFzzUJO5jax	TP53	JQ1	"In a preclinical study, medulloblastoma cell lines with TP53 mutations had significantly less sensitivity to the BET inhibitor, JQ1, than cell lines carrying wild-type TP53 (PMID: 24231268)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24231268	AVv-LO-eSS-TIFzzUJRgjax	TP53	INC280	"In a clinical case study, Capmatinib (INC280) treatment resulted in decreased tumor volume by 53% in a patient with large cell lung carcinoma harboring MET del exon14 and TP53 N30fs*14 (PMID: 25971938)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-LNH_SS-TIFzzUJOLjax	TP53	Ganetespib	"In a preclinical study, Ganetespib inhibited growth of human prostate cancer cells harboring TP53 P223L and V274F in culture (PMID: 26009011)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26009011	AVv-LOXNSS-TIFzzUJQdjax	TP53	Ganetespib	"In a preclinical study, Ganetespib inhibited growth of human ovarian cancer cells harboring TP53 S241F in culture (PMID: 26009011)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26009011	AVv-LPdjSS-TIFzzUJSYjax	TP53	Ganetespib	"In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 R280K in culture (PMID: 26009011)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26009011	AVv-LOLRSS-TIFzzUJQIjax	TP53	Ganetespib	"In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 R175H in culture (PIMD: 26009011)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26009011	AVv-LPVeSS-TIFzzUJSKjax	TP53	Ganetespib	"In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 L194F in culture (PIMD: 26009011)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26009011	AVv-LNJjSS-TIFzzUJOOjax	TP53	Ganetespib	"In a preclinical study, Ganetespib extended survival by 48% in mice with tumors expressing TP53 R248Q (PMID: 26009011)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26009011	AVv-LOd6SS-TIFzzUJQpjax	TP53	GSK2830371	"In a preclinical study, neuroblastoma cell lines harboring TP53 mutations were resistant to GSK2830371 induced growth inhibition in culture (PMID: 25658463)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25658463	AVv-LPBQSS-TIFzzUJRljax	TP53	GSK2830371	"In a preclinical study, GSK2830371 inhibited proliferation of neuroblastoma cell lines carrying wild-type TP53 in culture (PMID: 25658463)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25658463	AVv-LNYYSS-TIFzzUJOxjax	TP53	Epirubicin + Cyclophosphamide	"In a Phase I clinical trial, a breast cancer patient carrying TP53 P72R and Y220C mutations demonstrated incomplete response to treatment with an Ellence (epirubicin)-Cytoxan (cyclophosphamide) combination regimen (PMID: 17388661)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/17388661	AVv-LOQASS-TIFzzUJQQjax	TP53	EMD 1214063 + Radiotherapy	"In a preclinical study, shRNA knock-down of Tp53 in Met over-expressing gastric carcinoma cells enhanced sensitivity to the combination of EMD 1214063 and radiation in culture (PMID: 26358474)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26358474	AVv-LOWrSS-TIFzzUJQcjax	TP53	Doxorubicin + Ifosfamide	"In a Phase I clinical trial, sarcoma patients harboring TP53 P72R mutations had longer progression-free survival after treatment with Cyfos (ifosfamide) and Adriamycin (doxorubicin) (PMID: 23165797)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23165797	AVv-LOSQSS-TIFzzUJQUjax	TP53	Doxorubicin + GSK2830371	"In a preclinical study, GSK283071 and Adriamycin (doxorubicin) worked synergistically to inhibit proliferation of neuroblastoma cell lines carrying wild-type TP53 (PMID: 25658463)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25658463	AVv-LNvZSS-TIFzzUJPZjax	TP53	Doxorubicin + Flourouracil + Cyclophosphamide	"In a Phase I clinical trial, breast cancer patients harboring TP53 P72R who were estrogen receptor negative had a more favorable response to Doxil (doxorubicin) in combination with Adrucil (fluorouracil) and Cytoxan (cyclophosphamide) (PMID: 16243804)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/16243804	AVv-LOTVSS-TIFzzUJQWjax	TP53	Doxil	"In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/16243804	AVv-LORKSS-TIFzzUJQSjax	TP53	Daunoxome	"In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/16243804	AVv-LOS0SS-TIFzzUJQVjax	TP53	Daunorubicin	"In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/16243804	AVv-LOQnSS-TIFzzUJQRjax	TP53	DS-7423	"In a preclinical study, ovarian clear cell adenocarcinoma cell lines harboring TP53 mutations demonstrated reduced sensitivity to DS-7423 induced apoptosis in culture compared to TP53 wild-type cells (PMID: 24504419)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24504419	AVv-LO4fSS-TIFzzUJRWjax	TP53	DS-7423	"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring TP53 S241F demonstrated reduced sensitivity to DS-7423 in culture (PMID: 24504419)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24504419	AVv-LPcaSS-TIFzzUJSWjax	TP53	DS-7423	"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA H1047R and TP53 S90fs*33 demonstrated reduced sensitivity to DS-7423 in culture (PMID: 24504419)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24504419	AVv-LNR3SS-TIFzzUJOmjax	TP53	Cyclophosphamide + Topotecan	"In a preclinical study, Topotecan and Cytoxan (cyclophosphamide) combination treatment resulted in mild  tumor growth suppression in neuroblastoma xenograft models harboring wild-type Alk and TP53 H168R (PMID: 26438783)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/26438783	AVv-LOVnSS-TIFzzUJQajax	TP53	Crizotinib + Cyclophosphamide + Topotecan	"In a preclinical study, Xalkori (crizotinib) did not improve the effect of Topotecan and Cytoxan (cyclophosphamide) on tumor growth suppression in xenograft models of a human neuroblastoma cell line harboring wild-type ALK and TP53 H168R (PMID: 26438783)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438783	AVv-LOWJSS-TIFzzUJQbjax	TP53	Crizotinib + Cyclophosphamide + Topotecan	"In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 P177T in culture (PMID: 26438783)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438783	AVv-LODGSS-TIFzzUJP7jax	TP53	Crizotinib + Cyclophosphamide + Topotecan	"In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 C176F in culture (PMID: 26438783)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438783	AVv-LODuSS-TIFzzUJP8jax	TP53	Crizotinib	"In a clinical case study, Xalkori (crizotinib) treatment resulted in a decrease in tumor volume by more than 60% in a patient with histiocytic sarcoma harboring MET del exon14 and TP53 R175H (PMID: 25971938)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-LPbSSS-TIFzzUJSUjax	TP53	Cisplatin + NSC59984	"In a preclinical study, the combination of Platinol (cisplatin) and NSC59984 worked synergistically to decrease viability of a colorectal cancer cell line harboring TP53 R273H and TP53 P309S in culture (PMID: 26294215)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26294215	AVv-LOIASS-TIFzzUJQDjax	TP53	Carboplatin + Nutlin-3	"In a preclinical study, Nutlin-3 and Paraplatin (carboplatin) synergistically inhibited growth in TP53 mutated triple-receptor negative breast cancer cell lines in culture and in cell line xenograft models (PMID: 26494859)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26494859	AVv-LO63SS-TIFzzUJRajax	TP53	Carboplatin + GSK2830371	"In a preclinical study, GSK283071 and Paraplatin (carboplatin) worked synergistically to inhibit proliferation of neuroblastoma cell lines carrying wild-type TP53 (PMID: 25658463)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25658463	AVv-LNeNSS-TIFzzUJO7jax	TP53	Camptosar + Cisplatin	"In phase I clinical studies, NSCLC patients with TP53 P72R mutations had a longer progression-free survival than wild-type TP53 patients, after combined treatment with Camptosar (irinotecan) and  Platinol (cisplatin) (PMID: 18618574)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18618574	AVv-LOT9SS-TIFzzUJQXjax	TP53	CTX-1 + Nutlin-3	"In a preclinical study, the combination of CTX-1 and Nutlin-3 resulting in improved survival time in mouse models of acute myeloid leukemia using TP53 wild-type primary human acute myeloid leukemia cells (PMID: 26883273)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26883273	AVv-LNtNSS-TIFzzUJPVjax	TP53	CTX-1 + Nutlin-3	"In a preclinical study, CTX-1 and Nutlin-3 worked cooperatively to induce cell death in several TP53 wild-type human tumor cell lines in culture (PMID: 26883273)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26883273	AVv-LNmuSS-TIFzzUJPJjax	TP53	CTX-1	"In a preclinical study, CTX-1 induced increased Tp53 protein levels and cell death in human tumor cell lines with mutant Tp53 in culture (PMID: 26883273)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26883273	AVv-LO2rSS-TIFzzUJRTjax	TP53	CTX-1	"In a preclinical study, CTX-1 induced cell death in several solid tumor cell lines with wild-type TP53 in culture (PMID: 26883273)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26883273	AVv-LNceSS-TIFzzUJO4jax	TP53	CTX-1	"In a preclinical study, CTX-1 induced cell death in TP53-deficient human tumor cell lines in culture, but had a greater effect on cell lines with wild-type TP53 compared to isogenic cell lines with TP53 loss (PMID: 26883273)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26883273	AVv-LPLUSS-TIFzzUJR3jax	TP53	CTX-1	"In a preclinical study, CTX-1 improved survival time in mouse models of acute myeloid leukemia using TP53 wild-type primary human acute myeloid leukemia cells (PMID: 26883273)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26883273	AVv-LNXDSS-TIFzzUJOvjax	TP53	CPUY201112	"In a preclinical study, colon cancer cells lacking TP53 had a decreased response to CPUY201112 in culture, when compared to colon cancer cells with wild-type TP53 (PMID: 26743233)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26743233	AVv-LPN8SS-TIFzzUJR8jax	TP53	CPUY201112	"In a preclinical study, an osteosarcoma cell line lacking TP53 demonstrated a decreased response to CPUY201112 in culture, when compared to osteosarcoma cells with wild-type TP53 (PMID: 26743233)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26743233	AVv-LPNaSS-TIFzzUJR7jax	TP53	CPUY201112	"In a preclinical study, CPUY201112 reduced viability and induced apoptosis in an osteosarcoma cell line with wild-type TP53 in culture, and had a limited effect on an osteosarcoma cell line lacking TP53 (PMID: 26743233)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26743233	AVv-LNTsSS-TIFzzUJOpjax	TP53	CPUY201112	"In a preclinical study, CPUY201112 reduced viability and induced apoptosis in a colon cancer cell line with wild-type TP53 in culture, and had a limited effect on a colon cancer cell line lacking TP53 (PMID: 26743233)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26743233	AVv-LNV7SS-TIFzzUJOtjax	TP53	CP-31398	"In a preclinical study, treatment with CP-31398 resulted in decreased proliferation, increased apoptosis, and cell-cycle arrest in a hepatocellular carcinoma cell line harboring TP53 Y220C in culture (PMID: 26250460)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26250460	AVv-LOqXSS-TIFzzUJQ-jax	TP53	CEP-8983 + Cisplatin	"In a preclinical study, the combination of CEP-8983 and Platinol (cisplatin) worked synergistically to induce cell death in non-small cell lung cancer cell lines in culture, irrespective of TP53 status (PMID: 23428903)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23428903	AVv-LNpiSS-TIFzzUJPOjax	TP53	CCT245737	"In a preclinical study, CCT245737 resulted in some decreased tumor volume in a pancreatic ductal adenocarcinoma transgenic mouse model harboring KRAS G12D and TP53 R175H when compared to control (PMID: 27167172)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27167172	AVv-LPajSS-TIFzzUJSTjax	TP53	Bevacizumab	"In a retrospective study, Avastin (bevacizumab) treatment was associated with increased progression-free survival in cancer patients carrying TP53 mutations (PMID: 23670029)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23670029	AVv-LOx4SS-TIFzzUJRLjax	TP53	Bevacizumab	"In a Phase III trial, Avastin (bevacizumab), in combination with chemotherapy, provided a significant survival benefit in patients with colorectal cancers regardless of mutational status in KRAS, BRAF, and TP53 (PMID: 17145525)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17145525	AVv-LO_GSS-TIFzzUJRhjax	TP53	BLZ945	"In a preclinical study, treatment with BLZ945 demonstrated some efficacy, specifically a 56% tumor reduction, in transgenic mouse models of glioblastoma with a loss of TP53 (PMID: 27199435)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27199435	AVv-LPMZSS-TIFzzUJR5jax	TP53	BEZ235	"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to BEZ235 treatment (PMID: 26272063)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-LNNOSS-TIFzzUJOfjax	TP53	BEZ235	"In a preclinical study, BEZ235 stabilized tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W (PMID: 26272063)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-LOZaSS-TIFzzUJQhjax	TP53	BEZ235	"In a preclinical study, BEZ235 inhibited tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-LN-YSS-TIFzzUJPzjax	TP53	BEZ235	"In a preclinical study, BEZ235 delayed tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-LOYQSS-TIFzzUJQfjax	TP53	BEZ235	"In a preclinical study, BEZ235 delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-LN8ySS-TIFzzUJPwjax	TP53	Alvespimycin + Vorinostat	"In a preclinical study, Alvespimycin (17-DMAG) and Zolinza (vorinostat) extended survival by 59% in mice with tumors expressing Tp53 R172H (which corresponds to R175H in the human Tp53 protein) (PMID: 26009011)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26009011	AVv-LPWjSS-TIFzzUJSMjax	TP53	Ad5CMV-p53 gene	"In a preclinical study, Ad5CMV-p53 gene therapy suppressed growth of allograft colorectal cancer in rat models (PMID: 15608394)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/15608394	AVv-LPQBSS-TIFzzUJSAjax	TP53	AZD7762 + Cisplatin	"In a preclinical study, the treatment of a head and neck squamous cell carcinoma cell line with mutant TP53 (C176F and A161S) with AZD7762, a pan Chk1/2 inhibitor, sensitizes the cells to Platinol (cisplatin) (PMID: 23839309)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23839309	AVv-LO2GSS-TIFzzUJRSjax	TP53	AZD6738 + Radiotherapy	"In a preclinical study, AZD6738 treatment increased sensitivity to radiotherapy in a lung carcinoma cell line harboring wild-type TP53 in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 28062704)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28062704	AVv-LNgKSS-TIFzzUJO-jax	TP53	AZD6738 + Ibrutinib	"In a preclinical study, AZD6738 sensitized TP53-deficient chronic lymphocytic leukemia cells to Imbruvica (Ibrutinib) treatment in culture (PMID: 26563132)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26563132	AVv-LOgUSS-TIFzzUJQtjax	TP53	AZD6482	"In a preclinical study, AZD6482 induced cell death in TP53-deficient chronic lymphocytic leukemia cells in culture and inhibited tumor growth in xenograft models (PMID: 26563132)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26563132	AVv-LOkpSS-TIFzzUJQ0jax	TP53	AZD2461	"In a preclinical study, a breast cancer model lacking BRCA1 and TP53 demonstrated sensitivity to treatment with AZD2461, which resulted in decreased tumor volume (PMID: 27550455)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27550455	AVv-LPTVSS-TIFzzUJSGjax	TP53	APR-246 + Cisplatin	"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of small lung cancer cells harboring TP53 Y163C in culture (PMID: 26086967)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26086967	AVv-LOm1SS-TIFzzUJQ4jax	TP53	APR-246 + Cisplatin	"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of non-small lung cancer cells harboring TP53 R248W in culture (PMID: 26086967)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26086967	AVv-LOIsSS-TIFzzUJQEjax	TP53	APR-246 + Cisplatin	"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically in culture, resulting in reduced cell viability in patient derived ovarian cancer cells harboring TP53 R280K (PMID: 27179933)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27179933	AVv-LOKtSS-TIFzzUJQHjax	TP53	APR-246 + Cisplatin	"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived peritoneum cancer cells harboring TP53 C135Y in culture (PMID: 27179933)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27179933	AVv-LNIeSS-TIFzzUJOMjax	TP53	APR-246 + Cisplatin	"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived ovarian cancer cells harboring TP53 Y163H in culture (PMID: 27179933)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27179933	AVv-LOnaSS-TIFzzUJQ5jax	TP53	APR-246 + Cisplatin	"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived ovarian cancer cells harboring TP53 P278R in culture (PMID: 27179933)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27179933	AVv-LOmTSS-TIFzzUJQ3jax	TP53	APR-246 + Cisplatin	"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived ovarian cancer cells harboring TP53 P151H in culture (PMID: 27179933)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27179933	AVv-LOdXSS-TIFzzUJQojax	TP53	APR-246 + Cisplatin	"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived ovarian cancer cells harboring TP53 L111Q in culture (PMID: 27179933)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27179933	AVv-LOKBSS-TIFzzUJQGjax	TP53	APR-246 + Cisplatin	"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived fallopian tube cancer cells harboring TP53 C238F in culture (PMID: 27179933)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27179933	AVv-LOGvSS-TIFzzUJQBjax	TP53	APR-246	"In a preclinical study, APR-246 inhibited growth of TP53 wild-type melanoma cells in 3D culture and in cell line xenograft models (PMID: 21239882)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21239882	AVv-LNrGSS-TIFzzUJPRjax	TP53	APR-246	"In a preclinical study, APR-246 induced apoptosis in small-cell lung cancer (SCLC) cell lines and decreased tumor growth in SCLC cell line xenograft models harboring Tp53 inactivating mutations (PMID: 21415220)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21415220	AVv-LOi9SS-TIFzzUJQxjax	TP53	APR-246	"In a preclinical study, APR-246 demonstrated efficacy in xenograft models of small cell lung cancer harboring TP53 S241F (PMID: 21415220)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21415220	AVv-LPc7SS-TIFzzUJSXjax	TP53	APR-246	"In a preclinical study, APR-246 demonstrated efficacy in cell line xenograft models of small cell lung cancer harboring TP53 R273L (PMID: 21415220)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21415220	AVv-LOczSS-TIFzzUJQnjax	TP53	AMG 900	"In a preclinical study, breast cancer cell lines with TP53 loss of function mutations had more pronounced apoptosis after treatment with AMG 900 in culture (PMID: 24091768)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24091768	AVv-LOlPSS-TIFzzUJQ1jax	TP53	AMG 337	"In a clinical case study, a patient with gastric adenocarcinoma containing amplification of ERBB2 (HER2) and a TP53 R158H mutation progressed and developed metastases while being treated with AMG 337 (PMID: 26432108)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/26432108	AVv-LPI-SS-TIFzzUJRzjax	TP53	AMG 232 + Radiotherapy	"In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type osteosarcoma cells in culture and in cell line xenograft models (PMID: 26162687)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26162687	AVv-LNqBSS-TIFzzUJPPjax	TP53	AMG 232 + Radiotherapy	"In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type melanoma cells in culture and in cell line xenograft models (PMID: 26162687)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26162687	AVv-LNwhSS-TIFzzUJPbjax	TP53	AMG 232 + Radiotherapy	"In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type lung cancer cell lines in culture and in cell line xenograft models (PMID: 26162687)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26162687	AVv-LNqiSS-TIFzzUJPQjax	TP53	AMG 232 + Radiotherapy	"In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type colon cancer cells in culture and in cell line xenograft models (PMID: 26162687)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26162687	AVv-LNlCSS-TIFzzUJPGjax	TP53	AMG 232 + Radiotherapy	"In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type breast cancer cells in culture (PMID: 26162687)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26162687	AVv-LNsLSS-TIFzzUJPTjax	TP53	AMG 232 + Radiotherapy	"In a preclinical study, AMG 232 did not enhance radiation-induced cytotoxicity in TP53-null lung cancer cells in culture and in cell line xenograft models (PMID: 26162687)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26162687	AVv-LPSxSS-TIFzzUJSFjax	TP53	AMG 232	"In a preclinical study, TP53-null lung cancer cells were resistant to AMG 232 induced growth inhibition in culture (PMID: 26162687)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26162687	AVv-LPL0SS-TIFzzUJR4jax	TP53	AMG 232	"In a preclinical study, AMG 232 inhibited growth of a melanoma cell line with wild-type TP53, that also harbored a BRAF mutation, in culture and inhibited tumor growth in a TP53 wild-type BRAF-mutant melanoma cell line xenograft model (PMID: 25567130)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25567130	AVv-LN1oSS-TIFzzUJPkjax	TP53	AMG 232	"In a preclinical study, AMG 232 induced activation of Tp53 target genes and inhibited growth of several human tumor cell lines with wild-type TP53 in culture and in cell line xenograft models (PMID: 25567130)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25567130	AVv-LNb2SS-TIFzzUJO3jax	TP53	AMG 232	"In a preclinical study, AMG 232 did not inhibit growth of human tumor cell lines harboring TP53 mutations in culture (PMID: 25567130)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25567130	AVv-LO_pSS-TIFzzUJRijax	TP53	AMG 232	"In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type osteosarcoma cells in culture (PMID: 26162687)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26162687	AVv-LNX0SS-TIFzzUJOwjax	TP53	AMG 232	"In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type melanoma cells in culture (PMID: 26162687)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26162687	AVv-LNuRSS-TIFzzUJPXjax	TP53	AMG 232	"In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type lung cancer cell lines in culture (PMID: 26162687)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26162687	AVv-LNVXSS-TIFzzUJOsjax	TP53	AMG 232	"In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type colon cancer cells in culture (PMID: 26162687)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26162687	AVv-LNttSS-TIFzzUJPWjax	TP53	AMG 232	"In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type breast cancer cells in culture (PMID: 26162687)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26162687	AVv-LNWfSS-TIFzzUJOujax	TP53	ABT-263 + ONC201	"In a preclinical study, the combination of ONC201 (TIC10) and Navitoclax (ABT-263) increased apoptosis and worked synergistically to inhibit proliferation of a glioblastoma cell line harboring mutations in PTEN and TP53 in culture (PMID: 26474387)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26474387	AVv-LPHxSS-TIFzzUJRxjax	TET2	N/A	"In multiple clinical studies, including a meta-analysis, TET2 mutations were associated with shorter overall survival in patients with acute myeloid leukemia (PMID: 24524305, PMID: 25412851, PMID: 24994606)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/24524305	AVv-LL8ESS-TIFzzUJODjax	TET2	N/A	"In clinical analyses, TET2 mutations correlated with favorable prognosis and increased response to treatment in patients with myelodysplastic syndrome (PMID: 25224413, PMID: 26769228, PMID: 19666869, PMID: 23099237, PMID: 24507812)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/24507812	AVv-LL9RSS-TIFzzUJOFjax	TET2	Decitabine	"In a clinical study, myelodysplastic syndrome patients carrying wild-type ASXL1 and TET2 mutations demonstrated increased response to the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) (PMID: 25224413)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25224413	AVv-LL7fSS-TIFzzUJOCjax	TET2	Azacitidine	"In a clinical study, myelodysplastic syndrome patients carrying wild-type ASXL1 and TET2 mutations demonstrated increased response to the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) (PMID: 25224413)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25224413	AVv-LL65SS-TIFzzUJOBjax	STK11	unspecified PD-1 antibody	"In a preclinical study, PD-1 antibodies were ineffective in treating Stk11 (also known as Lkb1) deficient lung tumors in mice (PMID: 26833127)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26833127	AVv-LLsPSS-TIFzzUJOAjax	STK11	XL147	"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a human non-small cell lung cancer cell line harboring KRAS G12S and an STK11(LKB) inactivating mutation (PMID: 25637314)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25637314	AVv-LLjWSS-TIFzzUJNxjax	STK11	Trametinib	"In a preclinical study, the presence of an STK11 loss expression signature, which correlated to STK11 inactivating mutations, was associated with increased sensitivity to Mekinist (trametinib) in human tumor cell lines in culture (PMID: 27821489)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27821489	AVv-LLn4SS-TIFzzUJN5jax	STK11	Trametinib	"In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 W332*, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27821489	AVv-LLfISS-TIFzzUJNqjax	STK11	Trametinib	"In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 Q37*, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27821489	AVv-LLiMSS-TIFzzUJNvjax	STK11	Trametinib	"In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 K48fs, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27821489	AVv-LLelSS-TIFzzUJNpjax	STK11	Trametinib	"In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 E57fs, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27821489	AVv-LLgZSS-TIFzzUJNsjax	STK11	Trametinib	"In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 E199*, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27821489	AVv-LLfwSS-TIFzzUJNrjax	STK11	Trametinib	"In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27821489	AVv-LLj5SS-TIFzzUJNyjax	STK11	Trametinib	"In a preclinical study, knockdown of STK11 increased sensitivity to Mekinist (trametinib) in non-small cell lung cancer cell lines in culture and in xenograft models (PMID: 27821489)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27821489	AVv-LLppSS-TIFzzUJN8jax	STK11	Sirolimus	"In a preclinical study, Rapamune (sirolimus) reduced S6K phosphorylation and inhibited tumor growth in mouse models of STK11 (LKB1)-deficient endometrial cancer, including models with advanced tumors (PMID: 20142330)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20142330	AVv-LLmrSS-TIFzzUJN3jax	STK11	Selumetinib	"In a preclinical study, the presence of an STK11 inactivating mutation and STK11 loss expression signature was associated with increased sensitivity to Selumetinib (AZD6244) in human tumor cell lines in culture (PMID: 27821489)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27821489	AVv-LLmISS-TIFzzUJN2jax	STK11	RDEA119	"In a preclinical study, the presence of an STK11 loss expression signature, which correlates with STK11 inactivating mutations, was associated with increased sensitivity to RDEA119 in human tumor cell lines in culture (PMID: 27821489)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27821489	AVv-LLlDSS-TIFzzUJN0jax	STK11	PKI-402	"In a preclinical study, PKI-402 inhibited growth of a non-small cell lung cancer cell line harboring both KRAS and STK11 mutations in culture and in cell line xenograft models (PMID: 20371716)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20371716	AVv-LLdQSS-TIFzzUJNnjax	STK11	PF-05212384	"In a preclinical study, Gedatolisib (PF-05212384) inhibited growth of human non-small cell lung carcinoma cells harboring an STK11 mutation in culture (PMID: 21325073)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-LLd-SS-TIFzzUJNojax	STK11	PD-0325901	"In a preclinical study, the presence of an STK11 loss expression signature, which correlates with STK11 inactivating mutations, was associated with increased sensitivity to PD-0325901 in human tumor cell lines in culture (PMID: 27821489)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27821489	AVv-LLkfSS-TIFzzUJNzjax	STK11	Metformin	"In a preclinical study, Glucophage (metformin) was unable to inhibit cancer cell growth in cancer cell lines with biallelic loss of STK11 (PMID: 17062558, 18006825)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/18006825	AVv-LLrnSS-TIFzzUJN_jax	STK11	Metformin	"In a preclinical studies, Glucophage (metformin) inhibited cancer cell growth by activating the AMP kinase pathway in a variety of cancer cell lines that retained one functional allele of STK11 (PMID: 17062558, 18006825)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18006825	AVv-LLhCSS-TIFzzUJNtjax	STK11	MLN0128	"In a preclinical study, MLN0128 inhibited lung tumor growth in mouse models with KRAS G12D and inactivation of STK11 (LKB1), and demonstrated limited efficacy in tumors with KRAS G12D and wild-type STK11 (PMID: 26574479)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26574479	AVv-LLixSS-TIFzzUJNwjax	STK11	GDC-0941	"In a preclinical study, the PI3K inhibitor GDC-0941 reduced tumor growth rate in immunodeficient mice engrafted with endometrial tumors from PTEN/STK11 (LKB1) deficient mice (PMID: 24322983)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24322983	AVv-LLrDSS-TIFzzUJN-jax	STK11	CI-1040	"In a preclinical study, the presence an STK11 loss expression signature, which correlates with STK11 inactivating mutations, was associated with increased sensitivity to CI-1040 (PD184352) in human tumor cell lines in culture (PMID: 27821489)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27821489	AVv-LLlkSS-TIFzzUJN1jax	STK11	AZD8055	"In a preclinical study, AZD8055 inhibited tumor growth in a mouse model of spontaneous breast cancer harboring an ERBB2 (HER2) activating mutation and loss of STK11 (LKB1), which was enhanced by the addition of 2-DG (2-deoxyglucose) (PMID: 25436981)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25436981	AVv-LLqUSS-TIFzzUJN9jax	STAG2	Vemurafenib	"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Zelboraf (vemurafenib) both in culture and in cell line xenograft models (PMID: 27500726)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27500726	AVv-LLAISS-TIFzzUJNejax	STAG2	Veliparib	"In a preclinical study, a glioblastoma cell line harboring STAG2 N357fs demonstrated increased sensitivity to treatment with Veliparib (ABT-888) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817, PMID: 21852505)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21852505	AVv-LLBWSS-TIFzzUJNgjax	STAG2	Trametinib + Dabrafenib	"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment in culture (PMID: 27500726)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27500726	AVv-LK9wSS-TIFzzUJNajax	STAG2	Trametinib	"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in NRAS mutated melanoma cell lines resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27500726	AVv-LLAwSS-TIFzzUJNfjax	STAG2	Trametinib	"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27500726	AVv-LK_fSS-TIFzzUJNdjax	STAG2	Rucaparib	"In a preclinical study, a glioblastoma cell line harboring STAG2 N357fs demonstrated increased sensitivity to treatment with Rubraca (rucaparib) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817, PMID: 21852505)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21852505	AVv-LLB7SS-TIFzzUJNhjax	STAG2	Olaparib	"In a preclinical study, colorectal cancer cells with knockdown of STAG2 expression demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture (PMID: 24356817)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24356817	AVv-LK89SS-TIFzzUJNZjax	STAG2	Olaparib	"In a preclinical study, a glioblastoma cell line harboring STAG2 S653* demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817, PMID: 21852505)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21852505	AVv-LLElSS-TIFzzUJNmjax	STAG2	Dabrafenib	"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Tafinlar (dabrafenib) in culture (PMID: 27500726)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27500726	AVv-LK-kSS-TIFzzUJNcjax	STAG2	Camptothecin + Olaparib	"In a preclinical study, glioblastoma cells harboring STAG2 N357fs demonstrated increased sensitivity to the combination of Lynparza (olaparib) and camptothecin compared to isogenic cells with wild-type STAG2 in culture (PMID: 24356817, PMID: 21852505)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21852505	AVv-LLCdSS-TIFzzUJNijax	STAG2	Camptothecin	"In a preclinical study, glioblastoma cells harboring STAG2 S653* demonstrated increased sensitivity to the combination of Lynparza (olaparib) and camptothecin compared to isogenic cells with wild-type STAG2 in culture (PMID: 24356817, PMID: 21852505)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24356817	AVv-LLD_SS-TIFzzUJNljax	SRSF2	N/A	"In multiple clinical studies, SRSF2 mutations were associated with shortened survival in patients with myelodysplastic syndrome (PMID: 26769228, PMID: 26508027)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/26508027	AVv-LKtdSS-TIFzzUJNYjax	SRC	UM-164	"In a preclinical study, UM-164 inhibited proliferation and induced apoptosis in human triple-receptor negative breast cancer cell lines with elevated Src activity in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27154914)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27154914	AVv-LKiCSS-TIFzzUJNJjax	SRC	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M in culture and in cell line xenograft models (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-LKXASS-TIFzzUJM2jax	SRC	Si306	"In a preclinical study, Si306 inhibited SRC phosphorylation and proliferation of SRC-expressing glioblastoma cell lines in culture, and inhibited tumor growth and increased survival in cell line xenograft models (PMID: 27196762)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27196762	AVv-LKfVSS-TIFzzUJNEjax	SRC	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-LKVzSS-TIFzzUJM0jax	SRC	Saracatinib + Ceritinib	"In a preclinical study, the combination of Saracatinib (AZD0530) and (Zykadia) ceritinib demonstrated efficacy in non-small cell lung cancer patient derived cells harboring an ALK fusion and upregulation of SRC in culture (PMID: 25394791)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25394791	AVv-LKaqSS-TIFzzUJM8jax	SRC	KX2-391	"In a preclinical study, KX2-392 inhibited Src signaling and proliferation in triple-receptor negative breast cancer cell lines in culture, and suppressed tumor growth in xenograft models (PMID: 22784709)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22784709	AVv-LKeOSS-TIFzzUJNCjax	SRC	Dasatinib + Selumetinib	"In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-LKY0SS-TIFzzUJM5jax	SRC	Dasatinib + SCH772984	"In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-LKYOSS-TIFzzUJM4jax	SRC	Dasatinib	"In a preclinical study, thyroid cancer cell lines harboring HRAS G13R and KRAS G12R with an acquired SRC T341M mutation demonstrated resistance to Sprycel (dasatinib) in culture and in cell line xenograft models (PMID: 27222538)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-LKWaSS-TIFzzUJM1jax	SRC	Dasatinib	"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S acquired resistance to Sprycel (dasatinib) after over expressing SRC T341I in culture (PMID: 27231123)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27231123	AVv-LKZbSS-TIFzzUJM6jax	SRC	Dasatinib	"In a preclinical study, Sprycel (dasatinib) exhibits a strong antitumoral effect in GBM cell lines with high levels of SRC phosphorylation (PMID: 19098899)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19098899	AVv-LKdpSS-TIFzzUJNBjax	SRC	Cediranib + Saracatinib	"In a Phase II clinical trial, baseline expression of SRC was not predictive for response to Saracatinib (AZD0530) and Recentin (cediranib) relative to Recentin (cediranib) in patients with metastatic clear-cell renal cell carcinoma (PMID: 26802156)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26802156	AVv-LKg-SS-TIFzzUJNHjax	SRC	Bosutinib	"In a preclinical study, Bosulif (bosutinib) inhibited Src signaling, resulted in cell cycle arrest and decreased invasion of billary tract cancer cell lines in culture, and delayed tumor growth in cell line xenograft models (PMID: 27196758)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27196758	AVv-LKbuSS-TIFzzUJM-jax	SMO	Vismodegib	"In a single patient study, the SMO D473H mutant conferred secondary resistance to the hedgehog pathway inhibitor Erivedge (vismodegib) in a medulloblastoma patient (PMID: 19726788)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19726788	AVv-LJvXSS-TIFzzUJMKjax	SMO	Vismodegib	"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO S391N (corresponding to human SMO S387N) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26823493	AVv-LKAiSS-TIFzzUJMnjax	SMO	Vismodegib	"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO E522K (corresponding to human SMO E518K) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26823493	AVv-LJfqSS-TIFzzUJLwjax	SMO	Vismodegib	"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO D477G (corresponding to human SMO D473G) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26823493	AVv-LJ3USS-TIFzzUJMXjax	SMO	Vismodegib	"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO D388N (corresponding to human SMO D384N) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26823493	AVv-LJr1SS-TIFzzUJMEjax	SMO	Vismodegib	"In a preclinical study, mouse sarcoma cell lines over expressing SMO S387N demonstrated reduced response to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 25759019)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25759019	AVv-LKABSS-TIFzzUJMmjax	SMO	Vismodegib	"In a preclinical study, mouse sarcoma cell lines over expressing SMO N219D demonstrated reduced response to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 25759019)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25759019	AVv-LJzJSS-TIFzzUJMQjax	SMO	Vismodegib	"In a preclinical study, mouse sarcoma cell lines over expressing SMO D384N demonstrated reduced response to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 25759019)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25759019	AVv-LJrMSS-TIFzzUJMDjax	SMO	Vismodegib	"In a preclinical study, a transformed cell line expressing SMO W535L demonstrated resistance to Erivedge (vismodegib) (PMID: 25759020)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25759020	AVv-LJoySS-TIFzzUJL_jax	SMO	Vismodegib	"In a preclinical study, a transformed cell line expressing SMO W281C was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25759020	AVv-LKFQSS-TIFzzUJMvjax	SMO	Vismodegib	"In a preclinical study, a transformed cell line expressing SMO V321M demonstrated resistance to Erivedge (vismodegib) (PMID: 25759020)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25759020	AVv-LJ9xSS-TIFzzUJMijax	SMO	Vismodegib	"In a preclinical study, a transformed cell line expressing SMO Q477E was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25759020	AVv-LJ4nSS-TIFzzUJMZjax	SMO	Vismodegib	"In a preclinical study, a transformed cell line expressing SMO L412F demonstrated resistance to Erivedge (vismodegib) (PMID: 25759020)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25759020	AVv-LJsWSS-TIFzzUJMFjax	SMO	Vismodegib	"In a preclinical study, a transformed cell line expressing SMO H231R was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25759020	AVv-LJ_eSS-TIFzzUJMljax	SMO	Vismodegib	"In a preclinical study, a transformed cell line expressing SMO F460L demonstrated resistance to Erivedge (vismodegib) as compared to wild-type (PMID: 25759020)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25759020	AVv-LJjMSS-TIFzzUJL2jax	SMO	Vismodegib	"In a preclinical study, a transformed cell line expressing SMO D473G was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25759020	AVv-LJ38SS-TIFzzUJMYjax	SMO	Vismodegib	"In a preclinical study, Vismodegib (GDC-0449) inhibited Hedgehog pathway signaling, increased apoptosis, and decreased proliferation of a gastric cancer cell line in culture (PMID: 26676867)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676867	AVv-LJiBSS-TIFzzUJL0jax	SMO	TAK-441	"In a preclinical study, TAK-441 inhibited Gli-reporter activation in cells transfected with SMO D473H in culture (PMID: 24291104)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24291104	AVv-LJwoSS-TIFzzUJMMjax	SMO	SANT1	"In a preclinical study, SANT1 inhibited survival of osteosarcoma cell lines with reduced SMO mRNA level in culture (PMID: 26781311)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26781311	AVv-LJmWSS-TIFzzUJL7jax	SMO	Posaconazole	"In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO S391N (corresponding to human SMO S387N) in culture (PMID: 26823493)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26823493	AVv-LKBGSS-TIFzzUJMojax	SMO	Posaconazole	"In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO N223D (corresponding to human SMO N219D) in culture (PMID: 26823493)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26823493	AVv-LJ0TSS-TIFzzUJMSjax	SMO	Posaconazole	"In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO E522K (corresponding to human SMO E518K) in culture (PMID: 26823493)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26823493	AVv-LJhcSS-TIFzzUJLzjax	SMO	Posaconazole	"In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO D477G (corresponding to human SMO D473G) in culture (PMID: 26823493)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26823493	AVv-LJ1eSS-TIFzzUJMUjax	SMO	Posaconazole	"In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO D388N (corresponding to human SMO D384N) in culture (PMID: 26823493)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26823493	AVv-LJqBSS-TIFzzUJMBjax	SMO	Posaconazole	"In a preclinical study, Posaconazole did not inhibit Hedghog signaling in mouse fibroblasts over expressing murine SMO W539L (corresponding to human SMO W535L) in culture (PMID: 26823493)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26823493	AVv-LJoMSS-TIFzzUJL-jax	SMO	MRT-92	"In a preclinical study, transformed human cells expressing SMO Y394A displayed reduced binding to MRT-92 (PMID: 25636740)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/25636740	AVv-LJbPSS-TIFzzUJLpjax	SMO	MRT-92	"In a preclinical study, transformed human cells expressing SMO V329F displayed reduced binding to MRT-92 (PMID: 25636740)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/25636740	AVv-LJx4SS-TIFzzUJMOjax	SMO	MRT-92	"In a preclinical study, transformed human cells expressing SMO T466F displayed reduced binding to MRT-92 (PMID: 25636740)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/25636740	AVv-LJ-ZSS-TIFzzUJMjjax	SMO	MRT-92	"In a preclinical study, transformed human cells expressing SMO M525G displayed reduced binding to MRT-92 (PMID: 25636740)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/25636740	AVv-LKHfSS-TIFzzUJMzjax	SMO	MRT-92	"In a preclinical study, transformed human cells expressing SMO L325F displayed reduced binding to MRT-92 (PMID: 25636740)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/25636740	AVv-LJ04SS-TIFzzUJMTjax	SMO	MRT-92	"In a preclinical study, transformed human cells expressing SMO E518K displayed reduced binding to MRT-92 (PMID: 25636740)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/25636740	AVv-LJe9SS-TIFzzUJLvjax	SMO	MRT-92	"In a preclinical study, transformed human cells expressing SMO D384A displayed reduced binding to MRT-92 (PMID: 25636740)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/25636740	AVv-LJeXSS-TIFzzUJLujax	SMO	MRT-92	"In a preclincal, transformed human cells expressing SMO R400A displayed reduced binding to MRT-92 (PMID: 25636740)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25636740	AVv-LJ--SS-TIFzzUJMkjax	SMO	LY2940680	"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25759019	AVv-LKG5SS-TIFzzUJMyjax	SMO	LY2940680	"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25759019	AVv-LJthSS-TIFzzUJMHjax	SMO	LY2940680	"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25759019	AVv-LJlpSS-TIFzzUJL6jax	SMO	LY2940680	"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25759019	AVv-LJ51SS-TIFzzUJMbjax	SMO	LY2940680	"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25759019	AVv-LJb1SS-TIFzzUJLqjax	SMO	LDE225	"In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in stable disease in a basal cell carcinoma patient harboring SMO W535L with resistance to Erivedge (vismodegib) (PMID: 26546616)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26546616	AVv-LJnCSS-TIFzzUJL8jax	SMO	LDE225	"In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient with resistance to Erivedge (vismodegib) harboring SMO D533N (PMID: 26546616)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26546616	AVv-LJakSS-TIFzzUJLojax	SMO	LDE225	"In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient harboring SMO Q477E with resistance to Erivedge (vismodegib) (PMID: 26546616)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26546616	AVv-LJ5NSS-TIFzzUJMajax	SMO	LDE225	"In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient harboring SMO D473H with resistance to Erivedge (vismodegib) (PMID: 26546616)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26546616	AVv-LJxRSS-TIFzzUJMNjax	SMO	LDE225	"In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient harboring SMO D473G with resistance to Erivedge (vismodegib) (PMID: 26546616)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26546616	AVv-LJ2CSS-TIFzzUJMVjax	SMO	LDE225	"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO S391N (corresponding to human SMO S387N) were resistant to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26823493	AVv-LKBoSS-TIFzzUJMpjax	SMO	LDE225	"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO N223D (corresponding to human SMO N219D) were resistant to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26823493	AVv-LJzvSS-TIFzzUJMRjax	SMO	LDE225	"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO E522K (corresponding to human SMO E518K) demonstrated decreased response to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26823493	AVv-LJg1SS-TIFzzUJLyjax	SMO	LDE225	"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO D388N (corresponding to human SMO D384N) were resistant to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26823493	AVv-LJpaSS-TIFzzUJMAjax	SMO	LDE225	"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25759019	AVv-LKF1SS-TIFzzUJMwjax	SMO	LDE225	"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25759019	AVv-LJs5SS-TIFzzUJMGjax	SMO	LDE225	"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25759019	AVv-LJjvSS-TIFzzUJL3jax	SMO	LDE225	"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25759019	AVv-LJ7BSS-TIFzzUJMdjax	SMO	LDE225	"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25759019	AVv-LJcfSS-TIFzzUJLrjax	SMO	LDE225	"In a preclinical study, Odomzo (sonidegib) did not decrease viability or migration of non-small cell lung cancer cells harboring EGFR E746_A750del and amplification of SMO in culture (PMID: 26124204)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26124204	AVv-LKC3SS-TIFzzUJMrjax	SMO	JQ1	"In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25759019	AVv-LKGXSS-TIFzzUJMxjax	SMO	JQ1	"In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO V321M on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25759019	AVv-LJ9QSS-TIFzzUJMhjax	SMO	JQ1	"In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25759019	AVv-LJuJSS-TIFzzUJMIjax	SMO	JQ1	"In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25759019	AVv-LJk9SS-TIFzzUJL5jax	SMO	JQ1	"In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25759019	AVv-LJ7lSS-TIFzzUJMejax	SMO	JQ1	"In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25759019	AVv-LJdDSS-TIFzzUJLsjax	SMO	Gefitinib	"In a preclinical study, amplification of SMO conferred acquired resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring EGFR E746_A750del in culture (PMID: 26124204)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26124204	AVv-LKD7SS-TIFzzUJMtjax	SMO	Arsenic trioxide + Posaconazole	"In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO S391N (corresponding to human SMO S387N) in culture (PMID: 26823493)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26823493	AVv-LKCQSS-TIFzzUJMqjax	SMO	Arsenic trioxide + Posaconazole	"In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO N223D (corresponding to human SMO N219D) in culture (PMID: 26823493)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26823493	AVv-LJyiSS-TIFzzUJMPjax	SMO	Arsenic trioxide + Posaconazole	"In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO E522K (corresponding to human SMO E518K) in culture (PMID: 26823493)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26823493	AVv-LJgQSS-TIFzzUJLxjax	SMO	Arsenic trioxide + Posaconazole	"In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO D477G (corresponding to human SMO D473G) in culture (PMID: 26823493)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26823493	AVv-LJ2sSS-TIFzzUJMWjax	SMO	Arsenic trioxide + Posaconazole	"In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO D388N (corresponding to human SMO D384N) in culture (PMID: 26823493)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26823493	AVv-LJqmSS-TIFzzUJMCjax	SMO	Arsenic trioxide	"In a preclinical study, treatment with arsenic trioxide resulted in improved survival in a transgenic mouse model of medulloblastoma expressing SMO W535L (PMID: 21183792)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21183792	AVv-LJnoSS-TIFzzUJL9jax	SMARCB1	Tazemetostat	"In a preclinical study, over expression of EZH2 Y111D in rhabdoid tumor cells harboring an SMARCB1 inactivating mutation resulted in resistance to Tazemetostat (EPZ-6438) treatment in culture (PMID: 26360609)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26360609	AVv-LI4xSS-TIFzzUJLejax	SMARCB1	Tazemetostat	"In a preclinical study, Tazemetostat (EPZ-6438) inhibited growth of SMARCB1-deficient malignant rhabdoid tumore cell lines in culture (PMID: 23620515)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23620515	AVv-LI9ISS-TIFzzUJLljax	SMARCB1	Tazemetostat	"In a preclinical study, Tazemetostat (EPZ-6438) inhibited H3K27 trimethylation and induced tumor regression in SMARCB1-deleted human cell line xenograft models of  malignant rhabdoid tumors (PMID: 23620515)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23620515	AVv-LI6CSS-TIFzzUJLgjax	SMARCB1	Palbociclib	"In a preclinical study, Ibrance (palbociclib) inhibited growth of  SMARCB1-negative malignant rhabdoid tumor cell lines in culture, and sensitivity was associated with low levels of p16 expression (PMID: 21871868)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21871868	AVv-LI9wSS-TIFzzUJLmjax	SMARCB1	Palbociclib	"In a preclinical study, CDKN2A (p16) over expression was associated with decreased sensitivity to Ibrance (palbociclib) in a SMARCB1-negative malignant rhabdoid tumor cell line in culture (PMID: 21871868)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/21871868	AVv-LI-WSS-TIFzzUJLnjax	SMARCB1	Fenretinide + Vorinostat	"In a preclinical study, the combination of Zolinza (vorinostat) and fenretinide induced apoptosis and inhibited growth of rhabdoid tumor cell lines in culture (PMID: 23764045)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23764045	AVv-LI8fSS-TIFzzUJLkjax	SMARCB1	DZNeP + radiotherapy	"In a preclinical study, DZNep increased radiosensitivity in SMARCB1-negative atypical teratoid rhabdoid tumor cell lines in culture (PMID: 23190500)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23190500	AVv-LI7LSS-TIFzzUJLijax	SMARCB1	DZNeP	"In a preclinical study, DZNep induced apoptosis and cell-cycle arrest and inhibited growth of SMARCB1-negative atypical teratoid rhabdoid tumor cell lines in culture (PMID: 23190500)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23190500	AVv-LI6pSS-TIFzzUJLhjax	SMARCB1	CFI-400945	"In a preclinical study, CFI-400945 inhibited proliferation and decreased survival and migration of SMARCB1-deficient atypical teratoid rhabdoid tumor cells in culture (PMID: 28398638)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28398638	AVv-LI5cSS-TIFzzUJLfjax	SMAD4	SD-093	"In a preclinical study, SD-093 reduced the migration and invasiveness of pancreatic carcinoma cell lines lacking Smad4 (PMID: 15289325)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/15289325	AVv-LImvSS-TIFzzUJLVjax	SMAD4	N/A	"In clinical and meta-analyses, loss of Smad4 expression and SMAD4 inactivating mutations were associated with decreased survival in patients with pancreatic cancer (PMID: 26947875, PMID: 25760429, PMID: 22504380, PMID: 19584151)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/22504380	AVv-LIn7SS-TIFzzUJLXjax	SMAD4	N/A	"In clinical and meta-analyses, decreased expression of Smad4 was correlated with poor prognosis in colorectal cancer (PMID: 25749173, PMID: 19478385, PMID: 25681512, PMID: 26861460)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/25749173	AVv-LInWSS-TIFzzUJLWjax	SMAD4	MLN0128	"In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to MLN0128 in culture (PMID: 25261369)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25261369	AVv-LIraSS-TIFzzUJLdjax	SMAD4	MLN0128	"In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to MLN0128 resulting in inhibition of MTORC1 signaling (PMID: 25261369)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25261369	AVv-LIq0SS-TIFzzUJLcjax	SMAD4	Irinotecan	"In a preclinical study, pancreatic cancer cell lines harboring inactivated SMAD4 (mutations or deletion) displayed 4.5-fold greater sensitivity to irinotecan in vitro than wild-type (PMID: 22753594)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22753594	AVv-LIogSS-TIFzzUJLYjax	SMAD4	Gemcitabine	"In a preclinical study, pancreatic cancer cell lines harboring SMAD4 homozygous deletions were half as sensitive to gemcitabine in vitro as wild-type cells (PMID: 22753594)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22753594	AVv-LIpESS-TIFzzUJLZjax	SMAD4	Cisplatin	"In a preclinical study, pancreatic cancer cell lines harboring SMAD4 homozygous deletions were twice as sensitive to cisplatin in vitro as wild-type cells (PMID: 22753594)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22753594	AVv-LIqQSS-TIFzzUJLbjax	SF3B1	Spliceostatin A	"In a preclinical study, Spliceostatin A inhibited survival of pancreatic cancer cells harboring SF3B1 K700E in culture (PMID: 25424858)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25424858	AVv-LIRGSS-TIFzzUJLQjax	SF3B1	Spliceostatin A	"In a preclinical study, Spliceostatin A inhibited survival of endometrial cancer cells harboring SF3B1 K666N in culture (PMID: 25424858)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25424858	AVv-LISkSS-TIFzzUJLSjax	SF3B1	N/A	"In multiple clinical studies, SF3B1 mutations were associated with better overall survival in patients with myelodysplastic syndrome (PMID: 21998214, PMID: 22096241, PMID: 24220272), but may not have independent prognostic significance (PMID: 22096241)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/22096241	AVv-LITQSS-TIFzzUJLTjax	SF3B1	E7107	"In a preclinical study, mouse cells expressing SF3B1 K700E demonstrated sensitivity to E7107 in culture, resulting in decreased viability of cells (PMID: 27622333)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27622333	AVv-LIR7SS-TIFzzUJLRjax	RUNX1	RN-1	"In a preclinical study, RN-1 inhibited growth of acute myeloid leukemia cell lines harboring RUNX1-RUNX1T1 in culture, and inhibited tumor growth in xenograft models (PMID: 26837761)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26837761	AVv-LHtsSS-TIFzzUJLBjax	RUNX1	N/A	"In clinical analyses, the t(8;21) cytogenetic abnormality, which leads to the RUNX1-RUNX1T1 fusion, is associated with core-binding factor acute myeloid leukemia and favorable prognosis (PMID: 22180162, PMID: 9746770, PMID: 25111512)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/9746770	AVv-LHsjSS-TIFzzUJK_jax	RUNX1	N/A	"In clinical analyses, coincident KIT mutations were associated with higher relapse rate and decreased overall survival in acute myeloid leukemia patients with RUNX1-RUNX1T1 fusions (PMID: 18648004, PMID: 16384925, PMID: 25111512)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/25111512	AVv-LHqFSS-TIFzzUJK7jax	RUNX1	N/A	"In clinical analyses, RUNX1 mutations were associated with poor overall survival in patients with myelodysplastic syndrome (PMID: 21714648, PMID: 22869879)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/22869879	AVv-LHuRSS-TIFzzUJLCjax	RUNX1	N/A	"In clinical analyses, RUNX1 mutations were associated with adverse clinical outcome in acute myeloid leukemia patients (PMID: 21343560, PMID: 22689681, PMID: 22753902, PMID: 25652455)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/21343560	AVv-LHu4SS-TIFzzUJLDjax	RUNX1	I-CBP112 + JQ1	"In a preclinical study, the combination of I-CBP112 and JQ1 worked synergistically to inhibit growth of leukemia cells harboring a RUNX1-RUNX1T1 (AML1-ETO) fusion in culture (PMID: 26552700)"	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26552700	AVv-LHrYSS-TIFzzUJK9jax	RUNX1	I-CBP112 + Doxorubicin	"In a preclinical study, the combination of I-CBP112 and Doxorubicin worked synergistically to inhibit growth of leukemia cells harboring a RUNX1-RUNX1T1 (AML1-ETO) fusion in culture (PMID: 26552700)"	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26552700	AVv-LHsASS-TIFzzUJK-jax	RUNX1	I-CBP112	"In a preclinical study, I-CBP112 inhibited clonogenic growth in a leukemia cell line harboring a RUNX1-RUNX1T1 (AML1-ETO) fusion in culture (PMID: 26552700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26552700	AVv-LHqvSS-TIFzzUJK8jax	RUNX1	GSK690	"In a preclinical study, GSK690 inhibited growth of acute myeloid leukemia cell lines harboring RUNX1-RUNX1T1 in culture (PMID: 26837761)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26837761	AVv-LHtISS-TIFzzUJLAjax	ROS1	NPS-1034	"In a preclinical study, NPS-1034 inhibited ROS1 activity and proliferation of a non-small cell lung cancer cell line harboring a ROS1 rearrangement in culture (PMID: 24165158)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24165158	AVv-LHQLSS-TIFzzUJK5jax	ROS1	Crizotinib	"In a retrospective analysis of Phase I clinical data, Xalkori (crizotinib) resulted in an objective response rate of 80% (24/30) and a median PFS of 9.1 months in patients with ROS1 fusion positive lung adenocarcinoma (PMID: 25667280)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25667280	AVv-LHMfSS-TIFzzUJKzjax	ROS1	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ROS1 fusion proteins in culture (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-LHL5SS-TIFzzUJKyjax	RET	cabozantinib	"In a preclinical study, Cometriq (cabozantinib) inhibited phosphorylation of RET C634W and decreased tumor growth in xenograft models of a human thyroid carcinoma cell line harboring RET C634W mutation (PMID: 23705946)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23705946	AVv-LGXmSS-TIFzzUJJ5jax	RET	cabozantinib	"In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (61 vs 17 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RET M918T (PMID: 27525386)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27525386	AVv-LGsQSS-TIFzzUJKbjax	RET	cabozantinib	"In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (60 vs 20 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RET mutations (PMID: 27525386)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27525386	AVv-LGPuSS-TIFzzUJJsjax	RET	cabozantinib	"In a Phase II clinical trial, treatment with Cometriq (cabozantinib) resulted in an overall response rate of 28% (7/25) in patients with RET-rearranged lung cancer (PMID: 27825636)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27825636	AVv-LG0KSS-TIFzzUJKojax	RET	Y078-DM4	"In a preclinical study, Y078-DM4 induced cytotoxicity in a RET-expressing medullary thyroid cell line in culture (PMID: 26240273)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26240273	AVv-LGk5SS-TIFzzUJKPjax	RET	Y078-DM4	"In a preclinical study, Y078-DM4 induced cytotoxicity in RET-expressing human breast cancer cell lines in culture and inhibited tumor growth in xenograft models (PMID: 26240273)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26240273	AVv-LGkUSS-TIFzzUJKOjax	RET	Y078-DM1	"In a preclinical study, Y078-DM1 induced cytotoxicity in a human breast cancer cell line with high levels of RET expression in culture and inhibited tumor growth in xenograft models (PMID: 26240273)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26240273	AVv-LGGhSS-TIFzzUJJdjax	RET	XMD15-44	"In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET M918T in culture (PMID: 26046350)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26046350	AVv-LGxKSS-TIFzzUJKjjax	RET	XMD15-44	"In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26046350	AVv-LGE8SS-TIFzzUJJajax	RET	XMD15-44	"In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET M918T in culture (PMID: 26046350)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26046350	AVv-LGqbSS-TIFzzUJKYjax	RET	XMD15-44	"In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET C634W in culture (PMID: 26046350)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26046350	AVv-LGYLSS-TIFzzUJJ6jax	RET	Vandetanib	"In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806F in culture demonstrated inhibition of Ret phosphorylation and activity in kinase assays when treated with Caprelsa (vandetanib) (PMID: 19029224)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19029224	AVv-LGB0SS-TIFzzUJJVjax	RET	Vandetanib	"In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806E were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19029224	AVv-LGVNSS-TIFzzUJJ1jax	RET	Vandetanib	"In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806C were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19029224	AVv-LGVxSS-TIFzzUJJ2jax	RET	Vandetanib	"In a preclinical study, transformed human cells co-expressing RET C634R and RET V804M were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19029224	AVv-LF-wSS-TIFzzUJJQjax	RET	Vandetanib	"In a preclinical study, transformed cells expressing RET V804M demonstrated resistance to growth inhibition by Caprelsa (vandetanib) in culture (PMID: 15184865)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/15184865	AVv-LF_cSS-TIFzzUJJRjax	RET	Vandetanib	"In a preclinical study, transformed cells expressing RET V804L demonstrated resistance to growth inhibition by Caprelsa (vandetanib) in culture (PMID: 15184865)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/15184865	AVv-LGfoSS-TIFzzUJKGjax	RET	Vandetanib	"In a preclinical study, transformed cell lines expressing Ret protein carrying both C634R and V804G mutations were more sensitive to Vandetanib induced inhibition of Ret activity than cells expressing Ret C634R alone in culture (PMID: 15184865)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/15184865	AVv-LGLASS-TIFzzUJJkjax	RET	Vandetanib	"In a preclinical study, Caprelsa (vandetanib) inhibited growth of small cell lung carcinoma lines expressing wild-type RET (PMID: 25122427)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25122427	AVv-LGMOSS-TIFzzUJJmjax	RET	Vandetanib	"In a preclinical study, Caprelsa (vandetanib) inhibited growth of small cell lung carcinoma lines expressing RET M918T (PMID: 25122427)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25122427	AVv-LGmJSS-TIFzzUJKRjax	RET	Vandetanib	"In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET Y791F in culture (PMID: 15184865)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/15184865	AVv-LGJxSS-TIFzzUJJijax	RET	Vandetanib	"In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET S891A in culture (PMID: 15184865)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/15184865	AVv-LGgtSS-TIFzzUJKIjax	RET	Vandetanib	"In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET L790F in culture (PMID: 15184865)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/15184865	AVv-LGRCSS-TIFzzUJJujax	RET	Vandetanib	"In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET E768D in culture (PMID: 15184865)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/15184865	AVv-LGJISS-TIFzzUJJhjax	RET	Vandetanib	"In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET A883F in culture (PMID: 15184865)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/15184865	AVv-LGjtSS-TIFzzUJKNjax	RET	Vandetanib	"In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation and transforming activity in cells expressing RET M918T in culture (PMID: 15184865)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/15184865	AVv-LGmsSS-TIFzzUJKSjax	RET	Vandetanib	"In a preclinical study, Caprelsa (vandetanib) inhibited RET phosphorylation and decreased growth of transformed cells expressing RET C634R in culture (PMID: 15184865)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/15184865	AVv-LGUkSS-TIFzzUJJ0jax	RET	Sorafenib	"In a preclinical study, Nexavar (sorafenib) inhibited wild-type RET and RET mutations to prevent cell proliferation in cell culture (PMID: 17664273)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17664273	AVv-LGNZSS-TIFzzUJJojax	RET	Sorafenib	"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation in cells expressing RET S891A in culture (PMID: 17664273)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17664273	AVv-LGhSSS-TIFzzUJKJjax	RET	Sorafenib	"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and inhibited tumor growth in cell line xenograft models of medullary thyroid carcinoma harboring RET C634W (PMID: 16507829)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/16507829	AVv-LGb7SS-TIFzzUJKAjax	RET	Sorafenib	"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased proliferation of cells expressing RET M918T in culture (PMID: 17664273)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17664273	AVv-LGwASS-TIFzzUJKhjax	RET	Sorafenib	"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of transformed cells expressing RET V804M in culture (PMID: 16507829)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/16507829	AVv-LGBMSS-TIFzzUJJUjax	RET	Sorafenib	"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of thyroid carcinoma cells harboring a RET C634W mutation in culture (PMID: 17664273)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17664273	AVv-LGbSSS-TIFzzUJJ_jax	RET	Sorafenib	"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of colorectal cancer cells harboring a RET M918T mutation in culture (PMID: 17664273)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17664273	AVv-LGoESS-TIFzzUJKUjax	RET	Sorafenib	"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of cells expressing RET C634R in culture (PMID: 17664273)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17664273	AVv-LGT9SS-TIFzzUJJzjax	RET	Sorafenib	"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and activation of downstream signaling, and decreased growth of papillary thyroid carcinoma cells harboring the RET/PTC1 oncogene in culture (PMID: 17664273)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17664273	AVv-LGzmSS-TIFzzUJKnjax	RET	Sorafenib	"In a preclinical study, Nexavar (sorafenib) inhibited RET kinase activity and proliferation in transformed cells expressing RET C634R in culture (PMID: 16507829)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/16507829	AVv-LGTbSS-TIFzzUJJyjax	RET	Sorafenib	"In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C634Y (PMID: 20368568)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20368568	AVv-LGDvSS-TIFzzUJJYjax	RET	Sorafenib	"In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C634F (PMID: 20368568)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20368568	AVv-LGFiSS-TIFzzUJJcjax	RET	Sorafenib	"In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C618R (PMID: 20368568)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20368568	AVv-LGHySS-TIFzzUJJfjax	RET	Sorafenib	"In a Phase II trial, Nexavar (sorafenib) treatment resulted in partial response in 50% (1/2) and stable disease in 50% (1/2) of patients with medullary thyroid carcinoma harboring RET C634R (PMID: 20368568)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20368568	AVv-LGSPSS-TIFzzUJJwjax	RET	Sorafenib	"In a Phase II trial, Nexavar (sorafenib) treatment resulted in partial response in 10% (1/10) and stable disease in 90% (9/10) of patients with medullary thyroid carcinoma harboring RET M918T (PMID: 20368568)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20368568	AVv-LGtfSS-TIFzzUJKdjax	RET	Regorafenib	"In a preclinical study, Stivarga (regorafenib) inhibited proliferation of thyroid cancer cells harboring RET C634W in culture (PMID: 21170960)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21170960	AVv-LGW-SS-TIFzzUJJ4jax	RET	Pz-1	"In a preclinical study, Pz-1 inhibited Ret signaling in transformed cells over expressing RET C634R and inhibited tumor growth in cell line xenografts models (PMID: 26126987)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26126987	AVv-LGS4SS-TIFzzUJJxjax	RET	Pz-1	"In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET V804M (PMID: 26126987)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26126987	AVv-LGAlSS-TIFzzUJJTjax	RET	Pz-1	"In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET V804L (PMID: 26126987)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26126987	AVv-LGgLSS-TIFzzUJKHjax	RET	Pz-1	"In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET M918T (PMID: 26126987)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26126987	AVv-LGvbSS-TIFzzUJKgjax	RET	Ponatinib	"In a preclinical study, transformed human cell lines expressing RET V804M demonstrated sensitivity to Iclusig (ponatinib) (PMID: 23811235)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23811235	AVv-LF_-SS-TIFzzUJJSjax	RET	Ponatinib	"In a preclinical study, transformed human cell lines expressing RET V804L demonstrated sensitivity to Iclusig (ponatinib) (PMID: 23811235)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23811235	AVv-LGfGSS-TIFzzUJKFjax	RET	Ponatinib	"In a preclinical study, transformed human cell lines expressing RET C634R demonstrated sensitivity to Iclusig (ponatinib) (PMID: 23811235)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23811235	AVv-LGRnSS-TIFzzUJJvjax	RET	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells harboring RET C634Y in culture (PMID: 23526464)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23526464	AVv-LGEUSS-TIFzzUJJZjax	RET	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of cancer cell lines harboring RET mutations in cultured and in cell line xenograft models (PMID: 23526464)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23526464	AVv-LGOnSS-TIFzzUJJqjax	RET	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET Y971F in culture (PMID: 23526464)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23526464	AVv-LGKWSS-TIFzzUJJjjax	RET	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET Y806C in culture (PMID: 23526464)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23526464	AVv-LGxwSS-TIFzzUJKkjax	RET	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET S891A in culture (PMID: 23526464)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23526464	AVv-LGh5SS-TIFzzUJKKjax	RET	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET M918T in culture (PMID: 23526464)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23526464	AVv-LGs5SS-TIFzzUJKcjax	RET	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET L790F in culture (PMID: 23526464)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23526464	AVv-LGQYSS-TIFzzUJJtjax	RET	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET E884K in culture (PMID: 23526464)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23526464	AVv-LGHLSS-TIFzzUJJejax	RET	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET E768D in culture (PMID: 23526464)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23526464	AVv-LGIeSS-TIFzzUJJgjax	RET	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET D898V in culture (PMID: 23526464)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23526464	AVv-LGy-SS-TIFzzUJKmjax	RET	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET A883F in culture (PMID: 23526464)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23526464	AVv-LGjISS-TIFzzUJKMjax	RET	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines expressing wild-type RET (PMID: 25122427)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25122427	AVv-LGMxSS-TIFzzUJJnjax	RET	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines expressing RET M918T (PMID: 25122427)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25122427	AVv-LGomSS-TIFzzUJKVjax	RET	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited RET signaling and decreased proliferation of thyroid carcinoma cells harboring a RET M918T mutation in culture (PMID: 23526464)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23526464	AVv-LGnXSS-TIFzzUJKTjax	RET	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited RET signaling and decreased growth of thyroid carcinoma cells harboring a RET C634W mutation in culture and in cell line xenograft models (PMID: 23526464)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23526464	AVv-LGYySS-TIFzzUJJ7jax	RET	Ponatinib	"In a preclinical study, Iclusig (ponatinib) demonstrated efficacy in RET mutant positive colorectal cancer cell lines (PMID: 23811235)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23811235	AVv-LGPJSS-TIFzzUJJrjax	RET	Ponatinib	"In a preclinical study, Iclusig (ponatinib) decreased proliferation of papillary thyroid carcinoma cells harboring the RET/PTC1 rearrangement in culture (PMID: 23526464)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23526464	AVv-LG1-SS-TIFzzUJKrjax	RET	Lenvatinib	"In a preclinical study, Lenvima (lenvatinib) inhibited RET phosphorylation and signaling in thyroid cancer cells expressing RET C634W (PMID: 25295214)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25295214	AVv-LGalSS-TIFzzUJJ-jax	RET	HG-6-63-01	"In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET M918T in culture (PMID: 26046350)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26046350	AVv-LGrASS-TIFzzUJKZjax	RET	HG-6-63-01	"In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26046350	AVv-LGCXSS-TIFzzUJJWjax	RET	HG-6-63-01	"In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET M918T in culture (PMID: 26046350)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26046350	AVv-LGpJSS-TIFzzUJKWjax	RET	HG-6-63-01	"In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET C634W in culture (PMID: 26046350)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26046350	AVv-LGaASS-TIFzzUJJ9jax	RET	Everolimus	"In a Phase II clinical trial, Afinitor (everolimus) treatment resulted in stable disease of 116 weeks in a MEN2A patient with medullary thyroid cancer carrying a RET C620R mutation (PMID: 26294908)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26294908	AVv-LGdPSS-TIFzzUJKCjax	RET	Everolimus	"In a Phase II clinical trial, Afinitor (everolimus) treatment resulted in stable disease in 71% (5/7) of medullary thyroid cancer patients, including patients harboring RET mutations, with median progression-free survival of 33 weeks (PMID: 26294908)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26294908	AVv-LGN_SS-TIFzzUJJpjax	RET	Everolimus	"In a Phase II clinical trial, Afinitor (everolimus) treatment resulted in stable disease in 71% (5/7)  of medullary thyroid cancer patients, and 4 of the 7 patients carried a RET M918T mutation (PMID: 26294908)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26294908	AVv-LGp0SS-TIFzzUJKXjax	RET	Dovitinib	"In a Phase I clinical trial, two patients with germline RET G691S mutations demonstrated sensitivity to Dovitinib (TKI258) treatment (PMID: 25103625)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25103625	AVv-LGLqSS-TIFzzUJJljax	RET	Alectinib	"In a clinical study, Alecensa (alectinib) treatment resulted in objective radiographic response in 50% (2/4) and stable disease in 25% (1/4) of non-small cell lung carcinoma patients harboring RET rearrangement (PMID: 27544060)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27544060	AVv-LG4GSS-TIFzzUJKujax	RET	AZD1480	"In a preclinical study, AZD1480 reduced phosphorylation of RET and downstream effectors, and inhibited growth and increased apoptosis of a thyroid cancer cell line harboring RET C634W in culture (PMID: 23056499)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23056499	AVv-LGZXSS-TIFzzUJJ8jax	RET	AZD1480	"In a preclinical study, AZD1480 reduced phosphorylation of RET and downstream effectors, and inhibited growth and increased apoptosis of a medullary thyroid cancer cell line harboring RET M918T in culture (PMID: 23056499)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23056499	AVv-LGuISS-TIFzzUJKejax	RET	ALW-II-41-27	"In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET M918T in culture (PMID: 26046350)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26046350	AVv-LGwoSS-TIFzzUJKijax	RET	ALW-II-41-27	"In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26046350	AVv-LGDISS-TIFzzUJJXjax	RET	ALW-II-41-27	"In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET C634W in culture (PMID: 26046350)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26046350	AVv-LGWaSS-TIFzzUJJ3jax	RET	ALW-II-41-27	"In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thryoid carcinoma cells harboring RET M918T in culture (PMID: 26046350)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26046350	AVv-LGuxSS-TIFzzUJKfjax	RB1	Vorinostat	"In a preclinical study, Zolinza (vorinostat) inhibited growth of retinoblastoma cell lines in culture (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23498719	AVv-LFFwSS-TIFzzUJIVjax	RB1	VCN-01	"In a preclinical study, VCN-01 decreased viability of a human RB1-mutant primary osteosarcoma cell line in culture, and inhibited tumor growth and decreased lung metastases in xenograft models (PMID: 26603261)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26603261	AVv-LFfmSS-TIFzzUJJAjax	RB1	Trichostatin A	"In a preclinical study, Trichostatin A (TSA) inhibited growth of retinoblastoma cell lines in culture (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23498719	AVv-LFFOSS-TIFzzUJIUjax	RB1	Trametinib	"In a preclinical study, a melanoma cell line harboring a BRAF mutation and RB1 loss demonstrated reduced sensitivity when treated with Mekinist (trametinib) in culture (PMID: 27488531)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27488531	AVv-LFJ2SS-TIFzzUJIbjax	RB1	Sirolimus	"In a preclinical study, Sirolimus (rapamycin) slowed pituitary tumors and decreased the occurrence of thyroid tumors in Rb1+/- mice (PMID: 23454836)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23454836	AVv-LFGZSS-TIFzzUJIWjax	RB1	Sirolimus	"In a preclinical study, Sirolimus (rapamycin) decreased tumor occurrence, tumor hypoxia and  tumor vascularization in a retinoblastoma mouse model with functionally inactivated Rb protein (PMID: 21468343, PMID: 1689463)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21468343	AVv-LFDZSS-TIFzzUJIRjax	RB1	Ribociclib + Prednisolone	"In a preclinical study, the combination of Ribociclib (LEE011) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-LFP_SS-TIFzzUJIljax	RB1	Ribociclib + Prednisolone	"In a preclinical study, the combination of Ribociclib (LEE011) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-LFVmSS-TIFzzUJIujax	RB1	Ribociclib + Methotrexate	"In a preclinical study, the addition of Ribociclib (LEE011) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-LFScSS-TIFzzUJIpjax	RB1	Ribociclib + Methotrexate	"In a preclinical study, the addition of Ribociclib (LEE011) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-LFYcSS-TIFzzUJIzjax	RB1	Ribociclib + Mercaptopurine	"In a preclinical study, the addition of Ribociclib (LEE011) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-LFVBSS-TIFzzUJItjax	RB1	Ribociclib + Mercaptopurine	"In a preclinical study, the addition of Ribociclib (LEE011) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-LFZiSS-TIFzzUJI1jax	RB1	Ribociclib + JQ1	"In a preclinical study, the combination of Ribociclib (LEE011) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-LFRySS-TIFzzUJIojax	RB1	Ribociclib + JQ1	"In a preclinical study, the combination of Ribociclib (LEE011) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-LFY8SS-TIFzzUJI0jax	RB1	Ribociclib + Bortezomib	"In a preclinical study, the combination of Ribociclib (LEE011) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-LFQmSS-TIFzzUJImjax	RB1	Ribociclib + Bortezomib	"In a preclinical study, the combination of Ribociclib (LEE011) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-LFWJSS-TIFzzUJIvjax	RB1	Ribociclib + Asparaginase	"In a preclinical study, the addition of Ribociclib (LEE011) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-LFTuSS-TIFzzUJIrjax	RB1	Ribociclib + Asparaginase	"In a preclinical study, the addition of Ribociclib (LEE011) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-LFaJSS-TIFzzUJI2jax	RB1	R547	"In a preclinical study, R547 inhibited proliferation of prostate carcinoma cell lines harboring Tp53 and Rb1 mutations in culture and reduced tumor growth in xenograft models (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LFgtSS-TIFzzUJJCjax	RB1	R547	"In a preclinical study, R547 inhibited proliferation of osteosarcoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LFbMSS-TIFzzUJI4jax	RB1	R547	"In a preclinical study, R547 inhibited proliferation of melanoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LFeVSS-TIFzzUJI-jax	RB1	R547	"In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LFcvSS-TIFzzUJI7jax	RB1	R547	"In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LFaoSS-TIFzzUJI3jax	RB1	R547	"In a preclinical study, R547 inhibited proliferation of lung carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LFd1SS-TIFzzUJI9jax	RB1	R547	"In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LFe7SS-TIFzzUJI_jax	RB1	R547	"In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LFbuSS-TIFzzUJI5jax	RB1	R547	"In a preclinical study, R547 inhibited proliferation of cervical carcinoma cell lines harboring Tp53 and Rb1 mutations (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LFgKSS-TIFzzUJJBjax	RB1	R547	"In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LFdRSS-TIFzzUJI8jax	RB1	R547	"In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LFcPSS-TIFzzUJI6jax	RB1	R547	"In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring TP53 and RB1 mutations in culture (PMID: 17121911)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17121911	AVv-LFhVSS-TIFzzUJJDjax	RB1	Palbociclib + Trametinib	"In a preclinical study, a melanoma cell line with a BRAF mutation and loss of RB1 demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27488531	AVv-LFKfSS-TIFzzUJIcjax	RB1	Palbociclib	"In preclinical studies, the CDK4/6 inhibitor, Ibrance (palbociclib), was not effective in a variety of solid tumors with Rb1-deficiency (PMID: 26649278)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26649278	AVv-LFEBSS-TIFzzUJISjax	RB1	Palbociclib	"In a preclinical study, patient-derived glioblastoma cells harboring RB1 truncation mutation and expressing Cdkn2a were resistant to Ibrance (palbociclib) in culture (PMID: 22711607)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22711607	AVv-LFPaSS-TIFzzUJIkjax	RB1	Palbociclib	"In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Ibrance (palbociclib) induced growth inhibition in culture (PMID: 27020857)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27020857	AVv-LFHvSS-TIFzzUJIYjax	RB1	Palbociclib	"In a preclinical study, a melanoma cell line harboring a BRAF mutation and loss of RB1 demonstrated a decreased response to Ibrance (palbociclib) treatment in culture when compared to treatment of melanoma cell lines wild-type for BRAF (PMID: 27488531)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27488531	AVv-LFJHSS-TIFzzUJIajax	RB1	Palbociclib	"In a preclinical study, Ibrance (palbociclib) inhibited proliferation of RB1-proficient glioblastoma cell lines in culture and inhibited tumor growth in intracranial cell line xenograft models (PMID: 20354191)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20354191	AVv-LFMWSS-TIFzzUJIfjax	RB1	Palbociclib	"In a preclinical study, Ibrance (palbociclib) inhibited Rb1 phosphorylation in tumor tissues and improved survival in patient-derived intracranial xenograft models of medulloblastoma (PMID: 27012813)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27012813	AVv-LFLOSS-TIFzzUJIdjax	RB1	Palbociclib	"In a preclinical study, Ibrance (palbociclib) failed to inhibit growth of RB1-deficient glioblastoma cell lines in culture and in intracranial cell line xenograft models (PMID: 20354191)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/20354191	AVv-LFM7SS-TIFzzUJIgjax	RB1	MLN0128	"In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to MLN0128 in culture (PMID: 25261369)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25261369	AVv-LFh5SS-TIFzzUJJEjax	RB1	LEE011	"In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 demonstrated sensitivity to treatment with Ribociclib (LEE011) in culture, resulting in inhibition of cell growth (PMID: 28151717)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-LFUVSS-TIFzzUJIsjax	RB1	LEE011	"In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation demonstrated sensitivity to treatment with Ribociclib (LEE011) in culture, resulting in inhibition of cell growth (PMID: 28151717)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-LFWwSS-TIFzzUJIwjax	RB1	LEE011	"In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type NOTCH1 and loss of RB1 demonstrated resistance to Ribociclib (LEE011) in culture, resulting in limited inhibition of cell growth (PMID: 28151717)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-LFBXSS-TIFzzUJIOjax	RB1	GDC-0941	"In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Pictilisib (GDC-0941) induced growth inhibition in culture (PMID: 27020857)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27020857	AVv-LFHESS-TIFzzUJIXjax	RB1	G1T28 + Topotecan	"In a preclinical study, the combination of G1T28 and Hycamtin (topotecan) inhibited tumor growth in RB1-deficient small cell lung cancer cell line xenograft models, with greater efficacy than Hycamtin (topotecan) alone (PMID: 26826116)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26826116	AVv-LFCzSS-TIFzzUJIQjax	RB1	G1T28	"In a preclinical study, RB1-deficient small cell lung cancer cell lines were resistant to G1T28 in culture and in xenograft models (PMID: 26826116)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26826116	AVv-LFCASS-TIFzzUJIPjax	RB1	Fostamatinib	"In a preclinical study, retinoblastoma cell lines demonstrated sensitivity to Fostamatinib resulting in cell death (PMID: 22237022)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22237022	AVv-LFNkSS-TIFzzUJIhjax	RB1	BAY 61-3606	"In a preclinical study, a retinoblastoma cell line was sensitive to BAY 61-3606 in cell culture and in xenograft models, demonstrating increased apoptosis (PMID: 22237022)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22237022	AVv-LFOKSS-TIFzzUJIijax	PTPN11	cryptotanshinone	"In a preclinical study, myeloid cells harboring PTPN11 E76K were sensitive to cryptotanshinone in culture, resulting in decreased cell growth (PMID: 23957426)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23957426	AVv-LEZoSS-TIFzzUJIIjax	PTPN11	U0126	"In a preclinical study, U0126 induced apoptotic activity of leukemia cells expressing PTPN11 E76K in culture (PMID: 17942397)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17942397	AVv-LEXmSS-TIFzzUJIFjax	PTPN11	PLX4720	"In a preclinical study, knocking down of Ptpn11 expression via shRNA sensitized BRAF mutant colorectal cancer cell lines to PLX4720 in culture (PMID: 26351322)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26351322	AVv-LEaRSS-TIFzzUJIJjax	PTPN11	PD98059	"In a preclinical study, PD98059 induced apoptotic activity of leukemia cells expressing PTPN11 E76K in culture (PMID: 17942397)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17942397	AVv-LEY9SS-TIFzzUJIHjax	PTPN11	II-B08	"In a preclinical study, hematopoietic progenitor cells expressing PTPN11 E76K were sensitive to II-B08, resulting in decreased cell proliferation (PMID: 20170098)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20170098	AVv-LEYTSS-TIFzzUJIGjax	PTEN	YU238259	"In a preclinical study, YU238259 demonstrated increased cytotoxicity in PTEN-deficient sarcoma cell lines in culture (PMID: 26116172)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26116172	AVv-LDTgSS-TIFzzUJGjjax	PTEN	XL147	"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a human glioblastoma cell line harboring PTEN V54fs (PMID: 25637314)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25637314	AVv-LCwRSS-TIFzzUJFpjax	PTEN	XL147	"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600E (PMID: 25637314)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25637314	AVv-LDC_SS-TIFzzUJGJjax	PTEN	XL147	"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600D (PMID: 25637314)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25637314	AVv-LC01SS-TIFzzUJFxjax	PTEN	Vemurafenib	"In a preclinical study, expression of AKT1 Q79K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265152	AVv-LEG5SS-TIFzzUJIDjax	PTEN	Vemurafenib	"In a preclinical study, expression of AKT1 E17K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265152	AVv-LEEDSS-TIFzzUJH-jax	PTEN	Vemurafenib	"In a clinical study, a melanoma patient harboring a BRAF V600 mutation and PTEN H93D treated with Zelboraf (vemurafenib) for 66 weeks demonstrated a partial response (PMID: 24265153)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-LCXQSS-TIFzzUJFCjax	PTEN	Vemurafenib	"In a clinical study, a melanoma patient harboring PTEN Y86fs and BRAF V600X developed the resistance mutation, PIK3CA H1047R, after treatment with Zelboraf (vemurafenib) (PMID: 24265153)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-LCGGSS-TIFzzUJEmjax	PTEN	VS-5584	"In a preclinical study, VS-5584 inhibited PI3K/mTOR signaling and cell proliferation in a human prostate cancer cell line harboring a PTEN deletion in culture, and inhibited PI3K/MTOR signaling and tumor growth in xenograft models (PMID: 23270925)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/23270925	AVv-LCRySS-TIFzzUJE5jax	PTEN	Temsirolimus	"In a retrospective study of a Phase II trial, mutation status of PTEN was not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with Torisel (temsirolimus) (PMID: 27016228)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27016228	AVv-LCdNSS-TIFzzUJFMjax	PTEN	TGX-221	"In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to TGX-221 induced growth inhibition in culture (PMID: 23674493)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23674493	AVv-LCg2SS-TIFzzUJFSjax	PTEN	TGX-221	"In a preclincal study, TGX-221 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LB52SS-TIFzzUJESjax	PTEN	Selumetinib	"In a preclinical study, treatment with Selumetinib (AZD6244) slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26232337	AVv-LCvGSS-TIFzzUJFnjax	PTEN	SF1126	"In a preclinical study, a glioblastoma cell line harboring a PTEN inactivating mutation (PMID: 24634413) was sensitive to SF1126, demonstrating inhibition of tumor growth in cell line xenograft models (PMID: 18172313)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18172313	AVv-LCBhSS-TIFzzUJEejax	PTEN	SF1126	"In a preclinical study, a glioblastoma cell line harboring PTEN loss (PMID: 24634413) was sensitive to SF1126, demonstrating a 76% decrease in tumor growth in cell line xenograft models (PMID: 18172313)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18172313	AVv-LDXOSS-TIFzzUJGpjax	PTEN	SAR260301 + Vemurafenib	"In a preclinical study, SAR260301 and Zelboraf (vemurafenib) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27196754	AVv-LC37SS-TIFzzUJF2jax	PTEN	SAR260301 + Selumetinib	"In a preclinical study, SAR260301 and Selumetinib (AZD6244) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27196754	AVv-LC2tSS-TIFzzUJF0jax	PTEN	SAR260301	"In a preclinical study, SAR260301 inhibited tumor growth in xenograft models of melanoma cell lines harboring PTEN deficiency (PMID: 24387221)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24387221	AVv-LD0nSS-TIFzzUJHjjax	PTEN	SAR260301	"In a preclinical study, SAR260301 inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27196754	AVv-LC3USS-TIFzzUJF1jax	PTEN	SAR260301	"In a precliinical study, PTEN deficient prostate carcinoma cells demonstrated reduced response to SAR260301 in cell culture and in cell line xenograft models (PMID: 27196754)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27196754	AVv-LDN9SS-TIFzzUJGajax	PTEN	SAR245409	"In a preclinical study, a breast adenocarcinoma cell line harboring PTEN loss was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture (PMID: 24634413)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24634413	AVv-LDqWSS-TIFzzUJHTjax	PTEN	Rucaparib	"In a preclinical study, Rubraca (rucaparib) induced senescence and increased radiosensitivity in PTEN null prostate cancer cells in culture (PMID: 23565244)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23565244	AVv-LCJfSS-TIFzzUJEsjax	PTEN	Refametinib	"In a Phase I clinical trial, Refametinib (BAY 86-9766) demonstrated preliminary clinical activity in patients with several tumor types, including prolonged stable disease in an ocular melanoma patient harboring GNAQ Q209L and PTEN R173S (PMID: 23434733)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23434733	AVv-LEDiSS-TIFzzUJH9jax	PTEN	Pemetrexed + Sorafenib	"In a Phase I clinical trial, low Pten expression or lack of Pten expression was associated with better response to treatment with the combination of Alimta (pemetrexed) and Nexavar (sorafenib) in patients with advanced solid tumors (PMID: 27213589)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27213589	AVv-LDzPSS-TIFzzUJHhjax	PTEN	Pembrolizumab	"In a preclinical study, Keytruda (pembrolizumab) resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26645196	AVv-LC2HSS-TIFzzUJFzjax	PTEN	Pembrolizumab	"In a clinical study, melanoma patients with PTEN positive tumors demonstrated a decrease in tumor size when treated with Keytruda (pembrolizumab) (PMID: 26645196)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26645196	AVv-LEFJSS-TIFzzUJIAjax	PTEN	Pembrolizumab	"In a clinical study, melanoma patients with PTEN loss demonstrated decreased response to Keytruda (pembrolizumab) compared to patients in which PTEN is present (PMID: 26645196)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26645196	AVv-LDgLSS-TIFzzUJHDjax	PTEN	Palbociclib	"In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Ibrance (palbociclib) induced growth inhibition in culture (PMID: 27020857)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27020857	AVv-LDEbSS-TIFzzUJGLjax	PTEN	PP242 + U0126	"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of PP242 and U0126 in culture (PMID: 21358673)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21358673	AVv-LC-oSS-TIFzzUJGCjax	PTEN	PP242 + Selumetinib	"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of PP242 and Selumetinib (AZD6244) in culture (PMID: 21358673)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21358673	AVv-LC_RSS-TIFzzUJGDjax	PTEN	PP242	"In a preclinical study, breast cancer cell lines with PTEN loss demonstrated resistance to Torkinib (PP242) in culture (PMID: 21358673)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21358673	AVv-LDgvSS-TIFzzUJHEjax	PTEN	PP242	"In a preclinical study, 9/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Torkinib (PP242) in culture, resulting in decreased cell viability (PMID: 21358673)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21358673	AVv-LD9JSS-TIFzzUJHxjax	PTEN	PKI-402	"In a preclinical study, PKI-402 inhibited tumor growth in PTEN-negative glioblastoma multiforme cell line xenograft models (PMID: 20371716)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20371716	AVv-LDVTSS-TIFzzUJGmjax	PTEN	PKI-179	"In a preclinical study, PKI-179 inhibited growth of prostate cancer cells harboring PIK3CA mutations and PTEN loss in culture (PMID: 20797855)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20797855	AVv-LDG0SS-TIFzzUJGPjax	PTEN	PF-4989216	"In a preclinical study, small cell lung carcinoma cells harboring PIK3CA D1029Y and PTEN inactivating mutation were resistant to PF-4989216 induced growth inhibition in culture (PMID: 24240111)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24240111	AVv-LB-_SS-TIFzzUJEajax	PTEN	PF-4989216	"In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN inactivating mutations were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24240111	AVv-LCEaSS-TIFzzUJEjjax	PTEN	PF-4989216	"In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN Y27fs*1 were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24240111	AVv-LBpYSS-TIFzzUJD3jax	PTEN	PF-4989216	"In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN R55fs*1 were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24240111	AVv-LCw1SS-TIFzzUJFqjax	PTEN	PF-4989216	"In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cells harboring PIK3CA H1047R, PIK3CA K111R, and wild-type PTEN in culture, and suppressed tumor growth in cell line xenograft models (PMID: 24240111)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24240111	AVv-LD-zSS-TIFzzUJH0jax	PTEN	PF-4989216	"In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cells harboring PIK3CA G106_R108del and wild-type PTEN in culture, and suppressed tumor growth in cell line xenograft models (PMID: 24240111)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24240111	AVv-LD-USS-TIFzzUJHzjax	PTEN	PF-05212384	"In a preclinical study, human renal carcinoma cells with PTEN loss had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-LDs5SS-TIFzzUJHXjax	PTEN	PF-05212384	"In a preclinical study, human renal carcinoma cells with PTEN loss and VHL loss had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-LCyeSS-TIFzzUJFtjax	PTEN	PF-05212384	"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human prostate cancer cells harboring PTEN deletion in culture (PMID: 21325073, PMID: 14737113)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/14737113	AVv-LCLwSS-TIFzzUJEwjax	PTEN	PF-05212384	"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human glioma cells with PTEN loss in culture (PMID: 21325073)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-LDKySS-TIFzzUJGVjax	PTEN	PF-05212384	"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring PTEN A72fs*5 in culture (PMID: 21325073, PMID: 17314276)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17314276	AVv-LCx5SS-TIFzzUJFsjax	PTEN	PF-04691502	"In a preclinical study, PF-04691502 inhibited tumor growth in PTEN-deleted non-small cell lung cancer cell line xenograft models (PMID: 21750219)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21750219	AVv-LCQCSS-TIFzzUJE2jax	PTEN	PF-04691502	"In a preclinical study, PF-04691502 inhibited Akt phosphorylation, resulted in growth inhibition of PTEN-null glioblastoma cells in culture and in cell line xenograft models (PMID: 21750219)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21750219	AVv-LDUDSS-TIFzzUJGkjax	PTEN	P7170	"In a preclinical study, Panulisib (P7170) inhibited tumor growth in PTEN null prostate cancer cell xenograft models (PMID: 25700704)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25700704	AVv-LDc1SS-TIFzzUJG9jax	PTEN	OSI-027	"In a preclinical study, OSI-027 inhibited tumor growth in PTEN-null ovarian cancer cell line xenograft models (PMID: 21673091)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21673091	AVv-LDV9SS-TIFzzUJGnjax	PTEN	OSI-027	"In a preclinical study, OSI-027 induced tumor regression in PTEN-null breast cancer cell line xenograft models (PMID: 21673091)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21673091	AVv-LDpSSS-TIFzzUJHSjax	PTEN	OP449	"In a preclinical study, prostate cancer mouse models deficient for Pten demonstrated inhibition of the PI3K/Akt signaling pathway and a decrease in both tumor size and cell proliferation when treated with OP449 (PMID: 26563471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26563471	AVv-LDkBSS-TIFzzUJHJjax	PTEN	Nivolumab	"In a clinical study, melanoma patients with PTEN positive tumors demonstrated a decrease in tumor size when treated with Opdivo (nivolumab) (PMID: 26645196)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26645196	AVv-LEFsSS-TIFzzUJIBjax	PTEN	Nivolumab	"In a clinical study, melanoma patients with PTEN loss demonstrated decreased response to Opdivo (nivolumab) as compared to patients in which PTEN is present (PMID: 26645196)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26645196	AVv-LDWoSS-TIFzzUJGojax	PTEN	Metformin	"In a preclinical study, bladder cancer cells with PTEN deletion were sensitive to Glucophage (metformin) in culture, resulting in inhibition of cell growth (PMID: 26921394)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26921394	AVv-LCRMSS-TIFzzUJE4jax	PTEN	Metformin	"In a preclinical study, Glucophage (metformin) inhibited cell proliferation and induced apoptosis in a PTEN-expressing human endometrial cancer cell line harboring KRAS G12D in culture and decreased tumor growth in xenograft models (PMID: 24077915)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24077915	AVv-LEEkSS-TIFzzUJH_jax	PTEN	MSC2363318A	"In a preclinical study, a triple-receptor negative breast cancer xenograft model harboring PTEN loss was sensitive to M2698 (MSC2363318A), demonstrating inhibition of tumor growth and tumor regression (PMID: 27186432)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27186432	AVv-LDOoSS-TIFzzUJGbjax	PTEN	MLN0128 + PD-0325901	"In a preclinical study, TAK-228 (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PTEN loss, and TP53 V216M (PMID: 26272063)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-LCzASS-TIFzzUJFujax	PTEN	MLN0128	"In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to MLN0128 in culture (PMID: 25261369)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25261369	AVv-LCbcSS-TIFzzUJFJjax	PTEN	MLN0128	"In a preclinical study, a skin cancer cell line harboring mutations in PTEN and TP53 demonstrated sensitivity to MLN0128 in culture (PMID: 25261369)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25261369	AVv-LCo1SS-TIFzzUJFdjax	PTEN	MLN0128	"In a preclinical study, MLN0128 induced apoptosis and inhibited MTORC1 signaling in breast cancer cells harboring a PTEN mutation (PMID: 25261369)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25261369	AVv-LCnOSS-TIFzzUJFbjax	PTEN	MK2206	"In a Phase I study, a patient with pancreatic adenocarcinoma harboring PTEN loss and KRAS G12D was treated with MK-2206 and demonstrated a 23% reduction in tumor size (PMID: 22025163)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22025163	AVv-LC9gSS-TIFzzUJGAjax	PTEN	MK2206	"In a Phase I clinical trial, 8 patients with metastatic, castration-resistant prostate cancer harboring a loss of PTEN did not respond to MK-2206 therapy, but prolonged stable disease was observed in 2 patients (PMID: 26187616)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26187616	AVv-LDomSS-TIFzzUJHQjax	PTEN	MEK162	"In a preclinical study, Binimetinib (MEK162) reduced proliferation in tumors acutely but did not improve survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26206338	AVv-LBtHSS-TIFzzUJD9jax	PTEN	MEK162	"In a preclinical study, Binimetinib (MEK162) increased both apoptosis and proliferation in tumors, resulted in no improvement in survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26206338	AVv-LBqDSS-TIFzzUJD4jax	PTEN	LY3023414	"In a preclinical study, LY3023414 inhibited proliferation of renal cancer cells harboring PTEN inactivating mutation in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27439478)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27439478	AVv-LCCqSS-TIFzzUJEgjax	PTEN	LY3023414	"In a preclinical study, LY3023414 inhibited Pi3k/mTor signaling and proliferation in PTEN deficient glioblastoma cells in culture, and resulted in tumor growth inhibition in cell line xenograft models (PMID: 27439478)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27439478	AVv-LDmtSS-TIFzzUJHNjax	PTEN	LGX818 + unspecified IGF-1R antibody	"In a preclinical study, combination treatment consists of Encorafenib (LGX818) and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LBvhSS-TIFzzUJEBjax	PTEN	KX2-391 + Oxaliplatin	"In a preclinical study, KX2-391 and Eloxatin (oxaliplatin) synergistically inhibited survival of PTEN wild-type mucinous ovarian carcinoma cell lines in culture, and reduced tumor growth in xenograft models (PMID: 24100628)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24100628	AVv-LEAWSS-TIFzzUJH3jax	PTEN	KX2-391 + Oxaliplatin	"In a preclinical study, KX2-391 and Eloxatin (oxaliplatin) combination treatment did not show improved tumor suppression in xenograft models of ovarian mucinous carcinoma harboring PTEN loss when compared to single agent treatment (PMID: 24100628)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/24100628	AVv-LDQiSS-TIFzzUJGejax	PTEN	KX2-391	"In a preclinical study, KX2-391 inhibited survival of PTEN wild-type mucinous ovarian carcinoma cell lines in culture, and reduced tumor growth in xenograft models (PMID: 24100628)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24100628	AVv-LEBYSS-TIFzzUJH5jax	PTEN	KX2-391	"In a preclincal study, mucinous ovarian carcinoma cell lines over-expressing PTEN G129R were less sensitive to KX2-391 induced growth inhibition in culture and tumor suppression in xenograft models (PMID: 24100628)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24100628	AVv-LEHlSS-TIFzzUJIEjax	PTEN	KX2-391	"In a preclincal study, mucinous ovarian carcinoma cell lines harboring PTEN loss were less sensitive to KX2-391 induced growth inhibition in culture and tumor suppression in xenograft models (PMID: 24100628)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24100628	AVv-LDlRSS-TIFzzUJHLjax	PTEN	KU-60019	"In a preclinical study, KU-60019 blocked tumor growth in PTEN-deficient human prostate cancer xenograft models (PMID: 25870146)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25870146	AVv-LDX0SS-TIFzzUJGqjax	PTEN	KU-55933	"In a preclinical study, KU-55933 induced cell cycle arrest and caspase activation in PTEN deficient human colon cancer cells in culture (PMID: 25870146)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25870146	AVv-LDS9SS-TIFzzUJGijax	PTEN	KTN3379	"In a preclinical study, knockdown of PTEN expression resulted in a decreased response to treatment with KTN3379 in ERBB2 (HER2)-amplified breast cancer cells in culture (PMID: 26880266)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26880266	AVv-LD2cSS-TIFzzUJHmjax	PTEN	Ipatasertib	"In a preclinical study, prostate cancer cell line xenograft models with PTEN deletion demonstrated sensitivity to treatment with Ipatasertib (GDC-0068), resulting in inhibition of tumor growth (PMID: 24141624)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24141624	AVv-LCKrSS-TIFzzUJEujax	PTEN	Ipatasertib	"In a Phase I trial, a patient with castration resistant prostate cancer harboring a loss of PTEN demonstrated an improved prostate specific antigen when treated with Ipatasertib (GDC-0068) (PMID: 27872130)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27872130	AVv-LDd7SS-TIFzzUJG_jax	PTEN	Gefitinib + Linsitinib	"In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring mutations in EGFR (EGFRvIII, A289T) and PTEN (I253N, N69D) in culture (PMID: 26561558)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26561558	AVv-LCWESS-TIFzzUJFAjax	PTEN	Gefitinib + Linsitinib	"In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26561558	AVv-LCHOSS-TIFzzUJEojax	PTEN	GSK2636771 + unspecified IGF-1R antibody	"In a preclinical study, combination treatment consisting of GSK2636771 and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LBu1SS-TIFzzUJEAjax	PTEN	GSK2636771 + NVP-AEW541	"In a preclinical study, GSK2636771 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LB6bSS-TIFzzUJETjax	PTEN	GSK2636771 + NVP-AEW541	"In a preclinical study, GSK2636771 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LD8jSS-TIFzzUJHwjax	PTEN	GSK2636771 + LGX818	"In a preclinical study, GSK2636771 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LBzuSS-TIFzzUJEIjax	PTEN	GSK2636771 + LGX818	"In a preclinical study, GSK2636771 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LD5lSS-TIFzzUJHrjax	PTEN	GSK2636771 + Binimetinib	"In a preclinical study, GSK2636771 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LB-TSS-TIFzzUJEZjax	PTEN	GSK2636771 + Binimetinib	"In a preclinical study, GSK2636771 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LD6OSS-TIFzzUJHsjax	PTEN	GSK2636771	"In a preclinical study, human melanoma cells with PTEN loss were sensitive to GSK2636771, resulting in decreased activation of Akt and some inhibition of tumor growth (PMID: 26645196)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26645196	AVv-LDLXSS-TIFzzUJGWjax	PTEN	GSK2636771	"In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to GSK2636771 induced growth inhibition in culture (PMID: 23674493)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23674493	AVv-LCjZSS-TIFzzUJFWjax	PTEN	GSK2636771	"In a preclinical study, GSK2636771 resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26645196	AVv-LC4gSS-TIFzzUJF3jax	PTEN	GSK2636771	"In a preclinical study, GSK2636771 inhibited viability of prostate cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23674493	AVv-LDq9SS-TIFzzUJHUjax	PTEN	GSK2636771	"In a preclinical study, GSK2636771 inhibited viability of breast cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23674493	AVv-LDh-SS-TIFzzUJHGjax	PTEN	GSK2636771	"In a Phase I trial, patients with advanced solid tumors deficient in PTEN lacked benefit from GSK2636771 (PMID: 26117819)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26117819	AVv-LCPYSS-TIFzzUJE1jax	PTEN	GSK2256098	"In a preclinical study, GSK2256098 treatment resulted in a decreased response in uterine cancer cells with PTEN wild-type versus uterine cancer cells harboring a PTEN mutation (PMID: 25833835)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25833835	AVv-LD_2SS-TIFzzUJH2jax	PTEN	GSK2141795	"In a preclinical study, lack of PTEN expression was associated with increased sensitivity to GSK2141795 in BRAF V600-mutant melanoma cell lines in culture (PMID: 24265152)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265152	AVv-LCUySS-TIFzzUJE-jax	PTEN	GDC0879 + GDC-0941	"In a preclinical study, GDC0879 and Pictilisib (GDC-0941) synergistically inhibited survival of melanoma cell lines harboring BFAF V600E and PTEN loss in cell culture (PMID: 19276360)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-LDDqSS-TIFzzUJGKjax	PTEN	GDC-0941 + vorinostat	"In a preclinical study, GDC-0941 and Zolinza (vorinostat) acted synergistically to inhibit growth of a human prostate cancer cell line harboring a PTEN deletion in culture (PMID: 9661880, PMID: 22693356)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22693356	AVv-LCMxSS-TIFzzUJExjax	PTEN	GDC-0941 + PLX4720	"In a preclinical study, a melanoma cell line harboring BRAF V600E and PTEN loss demonstrated sensitivity when treated with a combination of Pictilisib (GDC-0941) and PLX4720, resulting in decreased cell proliferation in culture (PMID: 24265153)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-LDBtSS-TIFzzUJGHjax	PTEN	GDC-0941 + NVP-AEW541	"In a preclinical study, Pictilisib (GDC-0941) and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LB1hSS-TIFzzUJELjax	PTEN	GDC-0941 + MS417	"In a preclinical study, Pictilisib (GDC-0941) and MS417 in combination resulted in improved growth inhibition and increased cell death compared to either agent alone in a PTEN-mutant breast cancer cell line in culture (PMID: 26058079)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26058079	AVv-LCgLSS-TIFzzUJFRjax	PTEN	GDC-0941 + LGX818	"In a preclinical study, Pictilisib (GDC-0941) and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LB8-SS-TIFzzUJEXjax	PTEN	GDC-0941 + Binimetinib	"In a preclinical study, Pictilisib (GDC-0941) and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LBycSS-TIFzzUJEGjax	PTEN	GDC-0941	"In preclinical studies, the PI3K inhibitor GDC-0941 demonstrated efficacy against NSCLC tumor cell lines in both culture and xenograft models harboring alterations in the PI3K pathway (PMID: 23136191)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23136191	AVv-LDimSS-TIFzzUJHHjax	PTEN	GDC-0941	"In a preclinical study, the PI3K inhibitor GDC-0941 reduced tumor growth rate in immunodeficient mice engrafted with endometrial tumors from PTEN/STK11 (LKB1) deficient mice (PMID: 24322983)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24322983	AVv-LC74SS-TIFzzUJF9jax	PTEN	GDC-0941	"In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Pictilisib (GDC-0941) induced growth inhibition in culture (PMID: 27020857)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27020857	AVv-LDFHSS-TIFzzUJGMjax	PTEN	GDC-0941	"In a preclincal study, Pictilisib (GDC-0941) inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LB7rSS-TIFzzUJEVjax	PTEN	GDC-0084	"In a preclinical study, two PTEN-deficient glioblastoma cell line xenograft models were sensitive to GDC-0084 treatment, resulting in decreased tumor volumes by 70% and 40%, and inhibition of PI3K pathway signaling (PMID: 27638506)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27638506	AVv-LDUnSS-TIFzzUJGljax	PTEN	GDC-0032	"In a preclinical study, head and neck squamous cell carcinoma cells homozygous for PTEN deletion were resistant to Taselisib (GDC-0032) in culture (PMID: 26589432)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26589432	AVv-LCI8SS-TIFzzUJErjax	PTEN	GDC-0032	"In a preclinical study, head and neck squamous cell carcinoma cell lines and cell line xenograft models with PTEN alterations were resistant to the apoptotic effects of Taselisib (GDC-0032) (PMID: 26589432)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26589432	AVv-LCe-SS-TIFzzUJFPjax	PTEN	Everolimus + U0126	"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss did not demonstrate any benefit when treated with a combination of Afinitor (everolimus) and U0126 (PMID: 21358673)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/21358673	AVv-LDAiSS-TIFzzUJGFjax	PTEN	Everolimus + Selumetinib	"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss did not demonstrate any benefit when treated with a combination of Afinitor (everolimus) and Selumetinib (AZD6244) (PMID: 21358673)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/21358673	AVv-LC_7SS-TIFzzUJGEjax	PTEN	Everolimus	"In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to Afinitor (everolimus) compared with cells without KRAS mutations in culture (PMID: 22662154)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-LCZnSS-TIFzzUJFGjax	PTEN	Everolimus	"In a preclinical study, Afinitor (everolimus) inhibited proliferation of endometrial cancer cells harboring PIK3CA R88Q and PTEN mutations in culture (PMID: 22662154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-LCtNSS-TIFzzUJFkjax	PTEN	Everolimus	"In a preclinical study, Afinitor (everolimus) inhibited growth of endometrial cancer cells harboring a PTEN nonsense mutation in culture and in xenograft models (PMID: 22662154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-LCd0SS-TIFzzUJFNjax	PTEN	Everolimus	"In a preclinical study, 8/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Afinitor (everolimus) in culture, resulting in decreased cell viability (PMID: 21358673)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21358673	AVv-LD9wSS-TIFzzUJHyjax	PTEN	Everolimus	"In a preclinical study, 10/12 breast cancer cell lines with PTEN loss demonstrated resistance to Afinitor (everolimus) in culture (PMID: 21358673)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21358673	AVv-LDSWSS-TIFzzUJGhjax	PTEN	Everolimus	"In a clinical study, a melanoma patient harboring PTEN loss and BRAF V600E demonstrated resistance to Afinitor (everolimus) treatment, resulting in progressive disease (PMID: 20664172)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/20664174	AVv-LDCUSS-TIFzzUJGIjax	PTEN	Everolimus	"In a Phase II trial, Afinitor (everolimus) treatment in patients with advanced solid tumors harboring PTEN loss did not reach its primary endpoint, resulting in only stable disease or progressive disease (PMID: 28330462)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/28330462	AVv-LDkpSS-TIFzzUJHKjax	PTEN	E6201	"In a preclinical study, E6201 resulted in a cytostatic response in melanoma cell lines harboring both BRAF and PTEN mutations in culture and only inhibited tumor growth at very high doses in cell line xenograft models (PMID: 23039341)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23039341	AVv-LCa1SS-TIFzzUJFIjax	PTEN	E6201	"In a preclinical study, E6201 resulted in a cytocidal response in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture and inhibited tumor growth in cell line xenograft models (PMID: 23039341)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23039341	AVv-LD7WSS-TIFzzUJHujax	PTEN	E6201	"In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and sensitivity was associated with wild-type PTEN (PMID: 23039341)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23039341	AVv-LEA3SS-TIFzzUJH4jax	PTEN	Dacomitinib	"In a preclinical study, patient-derived EGFR amplified glioblastoma cells harboring PTEN loss demonstrated reduced sensitivity to Dacomitinib induced growth inhibition in culture and in xenograft models (PMID: 25939761)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25939761	AVv-LC87SS-TIFzzUJF_jax	PTEN	DHM25	"In a preclinical study, DHM25 increased cell death in a triple-negative breast cancer cell line harboring PTEN A72fs*5 in culture (PMID: 26237138)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26237138	AVv-LCxWSS-TIFzzUJFrjax	PTEN	DHM25	"In a preclinical study, DHM25 increased cell death in a breast cancer cell line harboring PTEN L108R in culture (PMID: 26237138)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26237138	AVv-LD4WSS-TIFzzUJHpjax	PTEN	DHM25	"In a preclinical study, DHM25 increased cell death and decreased migration of a triple-negative breast cancer cell line harboring PTEN V275* in culture (PMID: 26237138)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26237138	AVv-LCWrSS-TIFzzUJFBjax	PTEN	DETD-35	"In a preclinical study, DETD-35 treatment resulted in reduced tumor size in cell line xenograft models of Zelboraf (vemurafenib)-resistant melanoma harboring PTEN loss (PMID: 27048951)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27048951	AVv-LDmESS-TIFzzUJHMjax	PTEN	CX-6258	"In a preclinical study, CX-6258 treatment resulted in decreased carcinoma in situ in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27486174	AVv-LDPRSS-TIFzzUJGcjax	PTEN	CX-5461 + CX-6258	"In a preclinical study, CX-6258 and CX-5461 combination treatment resulted in decreased tumor burden in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27486174	AVv-LDP5SS-TIFzzUJGdjax	PTEN	CX-5461	"In a preclinical study, CX-5461 treatment did not result in histological change in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27486174	AVv-LDRqSS-TIFzzUJGgjax	PTEN	CUDC-907	"In a preclinical study, CUDC-907 inhibited growth of breast cancer cells lines harboring Pten mutations and/or deletions (PMID: 22693356)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22693356	AVv-LCSXSS-TIFzzUJE6jax	PTEN	CH5132799	"In a preclinical study, CH5132799 inhibited tumor growth in xenograft models of a human prostate cancer cell line with deletion of PTEN (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-LCOBSS-TIFzzUJEzjax	PTEN	CH5132799	"In a preclinical study, CH5132799 inhibited proliferation of an endometrial cancer cell line harboring PIK3CA R38C and PTEN loss in culture (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-LC-CSS-TIFzzUJGBjax	PTEN	CH5132799	"In a preclinical study, CH5132799 induced tumor regression in xenograft models of a human stomach cancer cell line with deletion of PTEN (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-LCLMSS-TIFzzUJEvjax	PTEN	CCT128930	"In preclinical studies, CCT128930 prevented tumor growth in a PTEN-null human glioblastoma cell line xenograft model (PMID: 21191045)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21191045	AVv-LDurSS-TIFzzUJHajax	PTEN	CC-223	"In a Phase I trial, CC-223 demonstrated safety and preliminary efficacy in patients with solid tumors, including stable disease for greater than 110 days in 2 patients with PIK3CA mutation or PTEN deletion (PMID: 26177599)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26177599	AVv-LCKHSS-TIFzzUJEtjax	PTEN	BYL719 + NVP-AEW541	"In a preclinical study, BYL719 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LB3-SS-TIFzzUJEPjax	PTEN	BYL719 + MEK162	"In a preclinical study, BYL719 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LB2xSS-TIFzzUJENjax	PTEN	BYL719 + LGX818	"In a preclinical study, BYL719 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LB5SSS-TIFzzUJERjax	PTEN	BYL719 + GSK2636771 + LGX818	"In a preclinical study, the combination of GSK2636771, Encorafenib (LGX818), and BYL719 efficiently inhibited tumor growth in xenograft models of a human melanoma cell line harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LBx2SS-TIFzzUJEFjax	PTEN	BYL719	"In a preclinical study, breast cancer cells harboring PTEN C136Y demonstrated resistance to Alpelisib (BYL719) in culture (PMID: 27604488)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27604488	AVv-LCFjSS-TIFzzUJEljax	PTEN	BYL719	"In a preclinical study, Pbreast cancer cells harboring PTEN loss demonstrated resistance to Alpelisib (BYL719) in culture (PMID: 27604488)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27604488	AVv-LDn7SS-TIFzzUJHPjax	PTEN	BYL719	"In a preclinical study, BYL719 inhibited Akt signaling and cell migration in prostate cancer cell lines overexpressing PTEN A126G (PMID: 26504226)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26504226	AVv-LCYaSS-TIFzzUJFEjax	PTEN	BYL719	"In a preclincal study, melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations were less sensitive to BYL719 induced growth inhibition in culture (PMID: 26577700)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LB2LSS-TIFzzUJEMjax	PTEN	BMS-754807 + Dacomitinib	"In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26561558	AVv-LCH2SS-TIFzzUJEpjax	PTEN	BMS-754807 + Dacomitinib	"In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR (A289T, EGFRvIII) and PTEN (N69D, I253N) mutations in culture (PMID: 26561558)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26561558	AVv-LCVfSS-TIFzzUJE_jax	PTEN	BMN673	"In a preclinical study, PTEN deficient cancer cell lines with DNA repair deficiency demonstrated high sensitivity to the PARP inhibitor, BMN673 (PMID: 23881923)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23881923	AVv-LCS6SS-TIFzzUJE7jax	PTEN	BLZ945	"In a preclinical study, BLZ945 resulted in limited benefit in transgenic mouse models of glioblastoma harboring a loss of PTEN (PMID: 27199435)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27199435	AVv-LDfHSS-TIFzzUJHBjax	PTEN	BKM120	"In a Phase II trial, one patient with Pten negative squamous NSCLC had a partial response to Buparlisib (BKM120) however, stage 2 of the study was not initiated due to failure of meeting overall stage 1 response endpoints (PMID: 26098748)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26098748	AVv-LCUISS-TIFzzUJE9jax	PTEN	BI-69A11	"In a preclinical study, BI-69A11 resulted in antitumor activity in a melanoma cell line harboring a PTEN mutation, including induction of cell death in culture, and in xenograft models, tumor growth inhibition and tumor regression (PMID: 19175524)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19175524	AVv-LClDSS-TIFzzUJFYjax	PTEN	BGT226	"In a preclinical study, BGT226 treatment in PTEN-deficient acute lymphoblastic leukemia cells resulted in inhibition of PI3K/Akt signaling and apoptotic activity in culture (PMID: 23705826)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23705826	AVv-LDJcSS-TIFzzUJGTjax	PTEN	BEZ235 + WEHI-539	"In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to WEHI-539 in culture (PMID: 27974663)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-LC5rSS-TIFzzUJF5jax	PTEN	BEZ235 + WEHI-539	"In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA E542K and PTEN loss to WEHI-539 in culture (PMID: 27974663)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-LC7WSS-TIFzzUJF8jax	PTEN	BEZ235 + Venetoclax	"In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to Venclexta (venetoclax) in culture (PMID: 27974663)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-LC6USS-TIFzzUJF6jax	PTEN	BEZ235 + Binimetinib	"In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) increased survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206338	AVv-LBqqSS-TIFzzUJD5jax	PTEN	BEZ235 + Binimetinib	"In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) did not improve survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26206338	AVv-LBsdSS-TIFzzUJD8jax	PTEN	BEZ235	"In a preclinical study, treatment with BEZ235 slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26232337	AVv-LCvvSS-TIFzzUJFojax	PTEN	BEZ235	"In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to BEZ235 compared with cells without KRAS mutations in culture (PMID: 22662154)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-LCZBSS-TIFzzUJFFjax	PTEN	BEZ235	"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA R88Q and PTEN mutations in culture (PMID: 22662154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-LCsoSS-TIFzzUJFjjax	PTEN	BEZ235	"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA R108H and PTEN mutations in culture (PMID: 22662154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-LCoCSS-TIFzzUJFcjax	PTEN	BEZ235	"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA E365K and PTEN mutations in culture (PMID: 22662154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-LCsCSS-TIFzzUJFijax	PTEN	BEZ235	"In a preclinical study, BEZ235 inhibited mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation, and KRAS G12D (PMID: 26206338)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206338	AVv-LBrRSS-TIFzzUJD6jax	PTEN	BEZ235	"In a preclinical study, BEZ235 inhibited  PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206338	AVv-LBr4SS-TIFzzUJD7jax	PTEN	BEZ235	"In a preclinical study, BEZ235 decreased growth of endometrial cancer cells harboring a PTEN nonsense mutation in culture and in xenograft models (PMID: 22662154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-LCb_SS-TIFzzUJFKjax	PTEN	BEZ235	"In a preclinical study, BEZ235 decreased growth of endometrial cancer cells harboring PIK3CA R38C and PTEN mutations in culture and in xenograft models (PMID: 22662154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-LCqNSS-TIFzzUJFfjax	PTEN	BAY1125976	"In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring KRAS G12V and PTEN K6fs*4 in culture (PMID: 27699769)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27699769	AVv-LEDASS-TIFzzUJH8jax	PTEN	BAY1125976	"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PTEN T319fs*1 in culture (PMID: 27699769)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27699769	AVv-LCFBSS-TIFzzUJEkjax	PTEN	BAY1125976	"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PTEN L108R in culture (PMID: 27699769)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27699769	AVv-LD3qSS-TIFzzUJHojax	PTEN	BAY1125976	"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA H1047R and PTEN E307K in culture (PMID: 27699769)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27699769	AVv-LCGoSS-TIFzzUJEnjax	PTEN	AZD8835	"In a preclinical study, human breast cancer cells with wild-type PIK3CA and loss of PTEN were resistant to growth inhibition by AZD8835 in culture (PMID: 26839307)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26839307	AVv-LDBJSS-TIFzzUJGGjax	PTEN	AZD8186 + Enzalutamide	"In a preclinical study, AZD8186 and XTANDI (enzalutamide) combination treatment resulted in suppression of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25544636	AVv-LCNZSS-TIFzzUJEyjax	PTEN	AZD8186 + BYL719 + Enzalutamide	"In a preclinical study, AZD8186, BYL719 and XTANDI (enzalutamide) combination treatment resulted in near-complete suppression of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25544636	AVv-LCOwSS-TIFzzUJE0jax	PTEN	AZD8186 + BYL719	"In a preclinical study, AZD8186 and BYL719 combination treatment resulted in minor inhibition of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25544636	AVv-LCIXSS-TIFzzUJEqjax	PTEN	AZD8186	"In a preclinical study, AZD8186 inhibited tumor growth of PTEN deficient prostate xenografts models (PMID: 25514658)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25514658	AVv-LDhTSS-TIFzzUJHFjax	PTEN	AZD6482 + NVP-AEW541	"In a preclinical study, AZD6482 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LBwpSS-TIFzzUJEDjax	PTEN	AZD6482 + NVP-AEW541	"In a preclinical study, AZD6482 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LD5ASS-TIFzzUJHqjax	PTEN	AZD6482 + LGX818 + NVP-AEW541	"In a preclinical study, combination treatment consists of AZD6482, Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LBwISS-TIFzzUJECjax	PTEN	AZD6482 + LGX818 + BYL719	"In a preclinical study, combination treatment consists of AZD6482, Encorafenib (LGX818), and BYL719 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LB4mSS-TIFzzUJEQjax	PTEN	AZD6482 + LGX818	"In a preclinical study, AZD6482 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LB8aSS-TIFzzUJEWjax	PTEN	AZD6482 + LGX818	"In a preclinical study, AZD6482 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LD7-SS-TIFzzUJHvjax	PTEN	AZD6482 + Binimetinib + NVP-AEW541	"In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LBuRSS-TIFzzUJD_jax	PTEN	AZD6482 + Binimetinib + BYL719	"In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), and BYL719 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LB9pSS-TIFzzUJEYjax	PTEN	AZD6482 + Binimetinib	"In a preclinical study, AZD6482 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LBtsSS-TIFzzUJD-jax	PTEN	AZD6482 + Binimetinib	"In a preclinical study, AZD6482 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LD6xSS-TIFzzUJHtjax	PTEN	AZD6482 + BYL719	"In a preclinical study, AZD6482 and BYL719 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LB3YSS-TIFzzUJEOjax	PTEN	AZD6482	"In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to AZD6482 induced growth inhibition in culture (PMID: 23674493)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23674493	AVv-LCkTSS-TIFzzUJFXjax	PTEN	AZD6482	"In a preclinical study, AZD6482 inhibited viability of prostate cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23674493	AVv-LDKFSS-TIFzzUJGUjax	PTEN	AZD6482	"In a preclinical study, AZD6482 inhibited viability of breast cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23674493	AVv-LDcUSS-TIFzzUJG8jax	PTEN	AZD6482	"In a preclinical study, AZD6482 inhibited Akt signaling and cell migration in prostate cancer cell lines overexpressing PTEN A126G (PMID: 26504226)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26504226	AVv-LCX5SS-TIFzzUJFDjax	PTEN	AZD6482	"In a preclincal study, AZD6482 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-LBzGSS-TIFzzUJEHjax	PTEN	AZD5363	"In a preclinical study, AZD5363 inhibited growth of various solid tumor cell culture models with loss of Pten (PMID: 22294718)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22294718	AVv-LDteSS-TIFzzUJHYjax	PTEN	AZD5363	"In a preclinical study, AZD5363 inhibited growth of various solid tumor cell culture models with inactivating Pten mutations (PMID: 22294718)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22294718	AVv-LCAOSS-TIFzzUJEcjax	PTEN	AZD5363	"In a preclinical study, AZD5363 inhibited growth of renal cancer Pdx models with Pten loss (PMID: 22294718)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22294718	AVv-LDZfSS-TIFzzUJG3jax	PTEN	AT13148	"In a preclinical study, AT13148 inhibited tumor growth in a PTEN-deficient human uterine sarcoma cell line xenograft model (PMID: 22781553)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22781553	AVv-LDYnSS-TIFzzUJG2jax	PTEN	AT13148	"In a preclinical study, AT13148 inhibited tumor growth in a PTEN-deficient human prostate cancer cell line xenograft model (PMID: 22781553)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22781553	AVv-LDRESS-TIFzzUJGfjax	PTEN	ARQ092	"In a preclinical study, a patient-derived xenograft (PDX) model of endometrial cancer harboring PIK3CA D350G, PIK3CA R93W, and PTEN R130G was sensitive to ARQ092, demonstrating greater than 90% inhibition of tumor growth (PMID: 26469692)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26469692	AVv-LCt4SS-TIFzzUJFljax	PTEN	ABT-737 + MLN0128	"In a preclinical study, ABT-737 and TAK-228 (MLN0128) combination treatment resulted in inhibition of tumor growth in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-LC61SS-TIFzzUJF7jax	PTEN	ABT-737 + BEZ235	"In a preclinical study, ABT-737 and BEZ235 combination treatment resulted in tumor regression in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-LC5ISS-TIFzzUJF4jax	PTEN	ABT-263 + ONC201	"In a preclinical study, the combination of ONC201 (TIC10) and Navitoclax (ABT-263) increased apoptosis and worked synergistically to inhibit proliferation of a glioblastoma cell line harboring mutations in PTEN and TP53 in culture (PMID: 26474387)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26474387	AVv-LCpjSS-TIFzzUJFejax	PTEN	A66 + GSK2636771	"In a preclinical study, A66 and GSK2636771 combination treatment inhibited viability of endometrioid endometrial cancer cell lines harboring PTEN mutations in culture (PMID: 23674493)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23674493	AVv-LCfkSS-TIFzzUJFQjax	PTEN	A66 + AZD6482	"In a preclinical study, A66 and AZD6482 combination treatment inhibited viability of endometrioid endometrial cancer cell lines harboring PTEN mutations in culture (PMID: 23674493)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23674493	AVv-LCmhSS-TIFzzUJFajax	PTEN	A66	"In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to A66 induced growth inhibition in culture (PMID: 23674493)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23674493	AVv-LCivSS-TIFzzUJFVjax	PTEN	A66	"In a preclinical study, A66 did not inhibit tumor growth in a PTEN-null cell line xenograft model of glioblastoma (PMID: 21668414)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21668414	AVv-LDNQSS-TIFzzUJGZjax	PTEN	2-Methoxyestradiol	"In a preclinical study, 2-Methoxyestradiol (2ME2) inhibited tumor-induced angiogenesis and reduced tumor growth in PTEN reconstituted GBM cell lines and mouse models (PMID: 24162827)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24162827	AVv-LD_WSS-TIFzzUJH1jax	PIK3CA	trastuzumab emtansine	"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26920887	AVv-LAZCSS-TIFzzUJDhjax	PIK3CA	trastuzumab emtansine	"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture (PMID: 26920887)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26920887	AVv-K_07SS-TIFzzUJCnjax	PIK3CA	trastuzumab emtansine	"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA C420R in culture (PMID: 26920887)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26920887	AVv-K79VSS-TIFzzUI7-jax	PIK3CA	rigosertib	"In a preclinical study, head and neck squamous cell carcinoma patient-derived xenograft models harboring a PIK3CA E545K mutation demonstrated increased sensitivity to Estybon (rigosertib) (PMID: 23873848)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23873848	AVv-K8OZSS-TIFzzUI8ljax	PIK3CA	rigosertib	"In a preclinical study, Estybon (rigosertib) inhibited oncogenic transformation in fibroblast cells over-expressing PIK3CA H1047R in culture (PMID: 27104980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27104980	AVv-K9D0SS-TIFzzUI-Ajax	PIK3CA	rigosertib	"In a preclinical study, Estybon (rigosertib) inhibited oncogenic transformation in fibroblast cells over-expressing PIK3CA E545K in culture (PMID: 27104980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27104980	AVv-K8U8SS-TIFzzUI8xjax	PIK3CA	YM-024	"In a preclinical study, glioblastoma cell lines harboring PIK3CA H1047Y demonstrated increased sensitivity to YM-204 induced growth inhibition (PMID: 24718026)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24718026	AVv-K_znSS-TIFzzUJCljax	PIK3CA	YM-024	"In a preclinical study, YM-024 inhibited proliferation and anchorage-independent growth of glioblastoma cell lines with elevated Pik3ca protein level in culture (PMID: 24718026)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24718026	AVv-K76nSS-TIFzzUI75jax	PIK3CA	YM-024	"In a preclinical study, YM-024 did not inhibit proliferation of glioblastoma cell lines harboring PIK3CA V344G in culture (PMID: 24718026)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/24718026	AVv-K-_4SS-TIFzzUJBUjax	PIK3CA	XL147 + Carboplatin + Paclitaxel	"In a clinical study, the combination of XL147 plus Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in progressive disease in a patient with colorectal cancer harboring a PIK3CA H1047 mutation and KRAS G12 mutation (PMID: 21216929)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21216929	AVv-K9rnSS-TIFzzUI_Ajax	PIK3CA	XL147	"In a preclinical study, tumor cell lines with PIK3CA mutations demonstrated sensitivity to XL147 in culture (PMID: 25637314)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25637314	AVv-K-diSS-TIFzzUJARjax	PIK3CA	XL147	"In a preclinical study, XL147 inhibited PI3K signaling and proliferation of a human breast carcinoma cell line harboring PIK3CA E545K in culture and inhibited tumor growth in xenograft models (PMID: 25637314)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25637314	AVv-K8aZSS-TIFzzUI87jax	PIK3CA	XL147	"In a preclinical study, XL147 inhibited PI3K signaling and proliferation of a PIK3CA amplified human ovarian cancer cell line in culture, and inhibited tumor growth in xenograft models (PMID: 25637314)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25637314	AVv-K_SYSS-TIFzzUJBxjax	PIK3CA	XL147	"In a Phase I clinical trial, XL147 (SAR24508) was shown to be safe and potentially efficacious, with clinical activity seen irrespective of tumor PI3K pathway molecular alterations (PMID: 24166903)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24166903	AVv-K-c-SS-TIFzzUJAQjax	PIK3CA	WYE-125132	"In a preclinical study, WYE-125132 inhibited proliferation of breast cancer cells with a PIK3CA E545K mutation (PMID: 20068177)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20068177	AVv-K8cDSS-TIFzzUI8-jax	PIK3CA	Vemurafenib + ZSTK474	"In a preclinical study, ZSTK474 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26137449	AVv-LAKxSS-TIFzzUJDKjax	PIK3CA	Vemurafenib	"In a clinical study, a melanoma patient harboring PTEN Y86fs and BRAF V600X developed the resistance mutation, PIK3CA H1047R, after treatment with Zelboraf (vemurafenib) (PMID: 24265153)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-K9S8SS-TIFzzUI-Yjax	PIK3CA	VS-5584	"In preclinical studies, VS-5584 demonstrated efficacy in a variety of cancer cell lines, particularly those harboring PIK3CA mutations (PMID: 23270925)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23270925	AVv-K-RBSS-TIFzzUI_9jax	PIK3CA	VS-5584	"In a preclinical study, breast cancer cells with mutations in both ERBB2 (HER2) and PIK3CA were more sensitive to VS-5584 (PMID: 23270925)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23270925	AVv-K_XhSS-TIFzzUJB5jax	PIK3CA	VS-5584	"In a preclinical study, PIK3CA mutant breast cancer cells showed increased sensitivity to VS-5584 compared to PIK3CA wild-type cells in culture (PMID: 23270925)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23270925	AVv-K-WnSS-TIFzzUJAGjax	PIK3CA	Trastuzumab + Pertuzumab	"In a preclinical study, a mouse breast cancer model with ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Heceptin (trastuzumab) and Perjeta (pertuzumab) (PMID: 23940356)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23940356	AVv-K9pQSS-TIFzzUI-8jax	PIK3CA	Trastuzumab + Lapatinib	"In a preclinical study, a mouse breast cancer model with mammary ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23940356)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23940356	AVv-K9mpSS-TIFzzUI-4jax	PIK3CA	Trastuzumab	"In a preclinical study, mouse breast cancer models over expressing ERBB2 (HER2) and expressing PIK3CA H1047R were resistant to Herceptin (trastuzumab) (PMID: 23940356)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23940356	AVv-K9n6SS-TIFzzUI-6jax	PIK3CA	Trastuzumab	"In a clinical study, the PIK3CA R425L mutation was identified as a potential resistance mechanism in a non-small cell lung carcinoma patient harboring ERBB2 (HER2) A775_G776insYVMA, that progressed during Herceptin (trastuzumab) treatment (PMID: 28167203)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/28167203	AVv-K9u7SS-TIFzzUI_Fjax	PIK3CA	Trametinib + Dabrafenib	"In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to the combination therapy, Mekinist (trametinib) and Tafinlar (dabrafenib) (PMID: 27797976)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27797976	AVv-K9XLSS-TIFzzUI-fjax	PIK3CA	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_KySS-TIFzzUJBljax	PIK3CA	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K-87SS-TIFzzUJBPjax	PIK3CA	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K9IqSS-TIFzzUI-Ijax	PIK3CA	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_ERSS-TIFzzUJBbjax	PIK3CA	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K8VuSS-TIFzzUI8yjax	PIK3CA	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_KNSS-TIFzzUJBkjax	PIK3CA	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K-7ySS-TIFzzUJBNjax	PIK3CA	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K9NfSS-TIFzzUI-Qjax	PIK3CA	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_yaSS-TIFzzUJCjjax	PIK3CA	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_CQSS-TIFzzUJBYjax	PIK3CA	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K8XtSS-TIFzzUI82jax	PIK3CA	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K__MSS-TIFzzUJC4jax	PIK3CA	Torin 1 + WEHI-539	"In a preclinical study, the ATP–competitive mTORC1/2 inhibitor Torin1 sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-K_cQSS-TIFzzUJCAjax	PIK3CA	Temsirolimus + Bevacizumab	"In a clinical study, a colorectal cancer patient harboring a mutation at PIK3CA H1047 demonstrated progressive disease when treated with Torisel (temsirolimus) and Avastin (bevacizumab) (PMID: 21216929)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21216929	AVv-K9tcSS-TIFzzUI_Djax	PIK3CA	Temsirolimus + Bevacizumab	"In a clinical study, a colorectal cancer patient harboring a PIK3CA mutation and KRAS mutations at codons 12 and 13 demonstrated stable disease when treated with a combination of Torisel (temsirolimus) and Avastin (bevacizumab) (PMID: 21216929)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21216929	AVv-K9xFSS-TIFzzUI_Ijax	PIK3CA	Temsirolimus	"In a retrospective study of a Phase II trial, mutation status of PIK3CA was not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with Torisel (temsirolimus) (PMID: 27016228)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27016228	AVv-K-HWSS-TIFzzUI_tjax	PIK3CA	Temsirolimus	"In a clinical study, two colorectal cancer patients harboring both a PIK3CA E545 and KRAS G12 mutation demonstrated stable disease when treated with Torisel (temsirolimus) (PMID: 21216929)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21216929	AVv-LAcrSS-TIFzzUJDnjax	PIK3CA	Temsirolimus	"In a clinical study, a patient with endometrial adenocarcinoma harboring a PIK3CA H1047 mutation demonstrated a partial response when treated with Torisel (temsirolimus) (PMID: 21216929)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21216929	AVv-K9sNSS-TIFzzUI_Bjax	PIK3CA	Temsirolimus	"In a Phase II trial, treatment with Torisel (temsirolimus) resulted in disease stabilization in 57.6% (19/33) and tumor shrinkage in 39.4% (13/33) of patients with head and neck squamous cell carcinoma (PMID: 25527417)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25527417	AVv-K8PpSS-TIFzzUI8njax	PIK3CA	Temsirolimus	"In a Phase I trial, an ovarian cancer patient harboring a PIK3CA E542 mutation demonstrated stable disease when treated with Torisel (temsirolimus) (PMID: 21216929)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21216929	AVv-K_5xSS-TIFzzUJCvjax	PIK3CA	Temsirolimus	"In a Phase I clinical trial, Torisel (temsirolimus) demonstrated limited efficacy in ovarian cancer patients with PIK3CA mutations (PMID: 22271473)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22271473	AVv-K-bISS-TIFzzUJANjax	PIK3CA	TGX-221	"In a preclinical study, TGX-221 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26137449	AVv-LALXSS-TIFzzUJDLjax	PIK3CA	TAK-733	"In a preclinical study, colorectal cancer cell lines harboring mutations in KRAS or NRAS and with wild-type PIK3CA demonstrated a trend toward increased sensitivity to TAK-733 in culture (PMID: 26439693)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26439693	AVv-LAWsSS-TIFzzUJDdjax	PIK3CA	Sirolimus	"In a preclinical study, transformed cells expressing PIK3CA H1047R were sensitive to Rapamune (sirolimus), resulting in inhibition of transformation in culture (PMID: 15647370)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/15647370	AVv-K9J6SS-TIFzzUI-Kjax	PIK3CA	Sirolimus	"In a preclinical study, cells expressing PIK3CA C420R were sensitive to Rapamune (sirolimus) in culture (PMID: 17376864)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17376864	AVv-K79ySS-TIFzzUI7_jax	PIK3CA	Sirolimus	"In a preclinical study, Sirolimus (rapamycin) failed to inhibit tumor growth in a mouse lung adenocarcinoma model expressing the PIK3CA H1047R mutation (PMID: 19029981)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/19029981	AVv-K9DLSS-TIFzzUI9_jax	PIK3CA	Sirolimus	"In a preclinical study, Sirolimus (rapamycin) did not induce tumor shrinkage in mouse lung cancer models carrying PIK3CA H1047R (PMID: 19029981)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/19029981	AVv-K9AySS-TIFzzUI97jax	PIK3CA	Sirolimus	"In a preclinical study, Rapamune (sirolimus) inhibited proliferation in cultured cells expressing PIK3CA M1043V (PMID: 17376864)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17376864	AVv-LAehSS-TIFzzUJDqjax	PIK3CA	Sirolimus	"In a preclinical study, Rapamune (sirolimus) demonstrated efficacy in inhibiting transformation of cultured cells containing PIK3CA E545K mutations (PMID: 15647370)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/15647370	AVv-K8XJSS-TIFzzUI81jax	PIK3CA	Sirolimus	"In a preclinical study, Rapamune (sirolimus) demonstrated efficacy in inhibiting transformation of cultured cells containing PIK3CA E542K mutations (PMID: 15647370)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/15647370	AVv-K_3YSS-TIFzzUJCrjax	PIK3CA	Selumetinib + Vemurafenib	"In a preclinical study, Selumetinib (AZD6244) and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26137449	AVv-LAIbSS-TIFzzUJDGjax	PIK3CA	Selumetinib	"In a preclinical study, treatment with Selumetinib (AZD6244) slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26232337	AVv-K9cRSS-TIFzzUI-njax	PIK3CA	Selumetinib	"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-K8E0SS-TIFzzUI8Vjax	PIK3CA	Selumetinib	"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-K9UISS-TIFzzUI-ajax	PIK3CA	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) mildly inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with KRAS and PIK3CA mutations (PMID: 24939055)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24939055	AVv-K-ruSS-TIFzzUJAyjax	PIK3CA	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) inhibited tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-K_I4SS-TIFzzUJBijax	PIK3CA	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-K8oTSS-TIFzzUI9Sjax	PIK3CA	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-K9k4SS-TIFzzUI-1jax	PIK3CA	SAR245409	"In a preclinical study, an ovarian cancer cell line harboring PIK3CA E545K was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24634413	AVv-K_PPSS-TIFzzUJBsjax	PIK3CA	SAR245409	"In a preclinical study, a colorectal cancer cell line co-harboring a KRAS mutation and PIK3CA mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture (PMID: 24634413)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24634413	AVv-K-vvSS-TIFzzUJA5jax	PIK3CA	SAR245409	"In a Phase I clinical trial, SAR245409 (XL765) demonstrated equivalent safety and efficacy in patients with PIK3CA mutant or PIK3CA wild-type advanced solid tumors (PMID: 24583798)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24583798	AVv-K-EFSS-TIFzzUI_njax	PIK3CA	Regorafenib	"In a preclinical study, human colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R were resistant to Stivarga (regorafenib) in culture (PMID: 25838391)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-K9gjSS-TIFzzUI-ujax	PIK3CA	Regorafenib	"In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Stivarga (regorafenib) in culture (PMID: 25838391)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-K-5VSS-TIFzzUJBJjax	PIK3CA	Regorafenib	"In a preclinical study, human colorectal cancer cell lines harboring KRAS G13D, PIK3CA E545K and PIK3CA D549N were resistant to Stivarga (regorafenib) in culture (PMID: 25838391)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-K8mbSS-TIFzzUI9Pjax	PIK3CA	Regorafenib	"In a preclinical study, colorectal cancer cell lines with wild-type BRAF, KRAS, NRAS and PIK3CA were resistant to Stivarga (regorafenib) in culture (PMID: 25838391)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-LAWESS-TIFzzUJDcjax	PIK3CA	Pimasertib + Sorafenib	"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-K8lQSS-TIFzzUI9Njax	PIK3CA	Pimasertib + Sorafenib	"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-K-21SS-TIFzzUJBFjax	PIK3CA	Pimasertib + Regorafenib	"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-K8kmSS-TIFzzUI9Mjax	PIK3CA	Pimasertib + Regorafenib	"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-K8s9SS-TIFzzUI9ajax	PIK3CA	Pimasertib + Regorafenib	"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-K8ikSS-TIFzzUI9Jjax	PIK3CA	Pimasertib + Regorafenib	"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-K-2SSS-TIFzzUJBEjax	PIK3CA	Pimasertib + BEZ235	"In a preclinical study, Pimasertib (MSC1936369B) and BEZ235 combination treatment inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-K8saSS-TIFzzUI9Zjax	PIK3CA	Pimasertib + BEZ235	"In a preclinical study, Pimasertib (MSC1936369B) and BEZ235 combination treatment inhibited tumor growth in colorectal cancer cell line xenograft models harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-K8gwSS-TIFzzUI9Gjax	PIK3CA	Pimasertib	"In a preclinical study, non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-K8j4SS-TIFzzUI9Ljax	PIK3CA	Pimasertib	"In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, T790M, and PIK3CA G118D demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-K8uPSS-TIFzzUI9cjax	PIK3CA	Pimasertib	"In a preclinical study, colorectal cancer cells harboring KRAS G13D, PIK3CA D549N and PIK3CA E545K demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-K8iASS-TIFzzUI9Ijax	PIK3CA	Pimasertib	"In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-K-3aSS-TIFzzUJBGjax	PIK3CA	Palbociclib + Trametinib	"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of colorectal cancer cells harboring KRAS Q61H and PIK3CA E542K (PMID: 26369631)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26369631	AVv-K_1jSS-TIFzzUJCojax	PIK3CA	Palbociclib + Trametinib	"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of colorectal cancer cells harboring KRAS G12D and PIK3CA Q546L (PMID: 26369631)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26369631	AVv-K_G2SS-TIFzzUJBfjax	PIK3CA	Palbociclib + Trametinib	"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of PIK3CA wild-type colorectal cancer cells harboring KRAS G12V (PMID: 26369631)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26369631	AVv-LAOPSS-TIFzzUJDPjax	PIK3CA	Palbociclib + GDC-0941	"In a preclinical study, Ibrance (palbociclib) and Pictilisib (GDC-0941) worked synergistically to inhibit the survival of triple-receptor negative breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27020857	AVv-K-GRSS-TIFzzUI_rjax	PIK3CA	Palbociclib + GDC-0941	"In a preclinical study, Ibrance (palbociclib) and Pictilisib (GDC-0941) worked synergistically to inhibit survival of ERBB2 (HER2)-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27020857	AVv-K_a6SS-TIFzzUJB-jax	PIK3CA	PX-866	"In a Phase I trial, PX-866 demonstrated efficacy and was well tolerated in patients with advanced solid tumor with both PIK3CA wild-type and mutant status (PMID: 22693357)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22693357	AVv-K-UJSS-TIFzzUJACjax	PIK3CA	PX-866	"In a Phase I study, PX-866 demonstrated efficacy and was well tolerated in patients with advanced solid tumor with both PIK3CA wild-type and mutant status (PMID: 22693357)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22693357	AVv-LAFRSS-TIFzzUJDBjax	PIK3CA	PW12	"In a preclinical study, PW12 inhibited proliferation of cervical cancer cells with a PIK3CA E545K mutation (PMID: 22391131)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22391131	AVv-K8YsSS-TIFzzUI84jax	PIK3CA	PP242 + U0126	"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of PP242 and U0126 in culture (PMID: 21358673)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21358673	AVv-LAR_SS-TIFzzUJDVjax	PIK3CA	PP242 + Selumetinib	"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of PP242 and Selumetinib (AZD6244) in culture (PMID: 21358673)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21358673	AVv-LARZSS-TIFzzUJDUjax	PIK3CA	PP242	"In a preclinical study, 9/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Torkinib (PP242) in culture, resulting in decreased cell viability (PMID: 21358673)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21358673	AVv-K_VPSS-TIFzzUJB1jax	PIK3CA	PKI-402	"In a preclinical study, treatment with PKI-402 resulted in decreased Akt phosphorylation and tumor regression in ERBB2 (HER2)-positive breast cancer cell line xenograft models harboring PIK3CA E545K (PMID: 20371716)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20371716	AVv-K8LUSS-TIFzzUI8gjax	PIK3CA	PKI-179	"In a preclinical study, PKI-179 inhibited growth of prostate cancer cells harboring PIK3CA mutations and PTEN loss in culture (PMID: 20797855)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20797855	AVv-K90aSS-TIFzzUI_Njax	PIK3CA	PKI-179	"In a preclinical study, PKI-179 inhibited growth of breast cancer cells harboring PIK3CA mutations and ERBB2 (HER2) over expression in culture and cell line xenograft models (PMID: 20797855)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20797855	AVv-K-mXSS-TIFzzUJApjax	PIK3CA	PI-103 + 5-FU	"In a preclinical study, PI-103 enhanced sensitivity to 5-FU in gastric cancer cells with mutant PIK3CA (PMID: 22336586)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22336586	AVv-K-SQSS-TIFzzUI__jax	PIK3CA	PF-4989216	"In a preclinical study, small cell lung carcinoma cells harboring amplification of wild-type PIK3CA were resistant to PF-4989216 induced growth inhibition in culture (PMID: 24240111)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24240111	AVv-K_PzSS-TIFzzUJBtjax	PIK3CA	PF-4989216	"In a preclinical study, small cell lung carcinoma cells harboring PIK3CA D1029Y and PTEN inactivating mutation were resistant to PF-4989216 induced growth inhibition in culture (PMID: 24240111)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24240111	AVv-LAd7SS-TIFzzUJDpjax	PIK3CA	PF-4989216	"In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN inactivating mutations were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24240111	AVv-LAUTSS-TIFzzUJDZjax	PIK3CA	PF-4989216	"In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN Y27fs*1 were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24240111	AVv-LANeSS-TIFzzUJDOjax	PIK3CA	PF-4989216	"In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN R55fs*1 were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24240111	AVv-LAB5SS-TIFzzUJC8jax	PIK3CA	PF-4989216	"In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cells harboring PIK3CA T1025A in culture (PMID: 24240111)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24240111	AVv-K8xTSS-TIFzzUI9hjax	PIK3CA	PF-4989216	"In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cells harboring PIK3CA H1047R, PIK3CA K111R, and wild-type PTEN in culture, and suppressed tumor growth in cell line xenograft models (PMID: 24240111)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24240111	AVv-K78RSS-TIFzzUI78jax	PIK3CA	PF-4989216	"In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cells harboring PIK3CA G106_R108del and wild-type PTEN in culture, and suppressed tumor growth in cell line xenograft models (PMID: 24240111)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24240111	AVv-K780SS-TIFzzUI79jax	PIK3CA	PF-4989216	"In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cell lines harboring activating PIK3CA mutations in culture, and suppressed tumor growth in cell line xenograft models (PMID: 24240111)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24240111	AVv-K_kKSS-TIFzzUJCMjax	PIK3CA	PF-05212384	"In a preclinical study, some head and neck squamous cell carcinoma cell lines over expressing PIK3CA demonstrated sensitivity to treatment with Gedatolisib (PF-05212384) (PMID: 25977343)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25977343	AVv-K77JSS-TIFzzUI76jax	PIK3CA	PF-05212384	"In a preclinical study, human colon cancer cells harboring KRAS G13D, PIK3CA E545K, and PIK3CA D549N had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073, PMID: 24042735)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-K8npSS-TIFzzUI9Rjax	PIK3CA	PF-05212384	"In a preclinical study, head and neck squamous cell carcinoma cell lines harboring PIK3CA H1047R demonstrated sensitivity to treatment with Gedatolisib (PF-05212384) in culture (PMID: 25977343)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25977343	AVv-K9GLSS-TIFzzUI-Ejax	PIK3CA	PF-05212384	"In a preclinical study, PF-05212384 decreased viability of head and neck squamous carcinoma cells harboring a PIK3CA activating mutation in cell culture (PMID: 24823695)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24823695	AVv-K_qqSS-TIFzzUJCWjax	PIK3CA	PF-05212384	"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human colon cancer cells harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 21325073, PMID: 24042735)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-K9dmSS-TIFzzUI-pjax	PIK3CA	PF-05212384	"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring PIK3CA H1047R in culture (PMID: 21325073, PMID: 17314276)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17314276	AVv-K9LxSS-TIFzzUI-Njax	PIK3CA	PF-05212384	"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring PIK3CA E545K in culture (PMID: 21325073, PMID: 17314276)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17314276	AVv-K8PDSS-TIFzzUI8mjax	PIK3CA	PF-05212384	"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring ERBB2 (HER2) amplification and PIK3CA H1047R in culture (PMID: 21325073, PMID: 17314276)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17314276	AVv-K82ASS-TIFzzUI9ojax	PIK3CA	PF-04691502	"In a preclinical study, PF-04691502 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring both PIK3CA and KRAS mutations (PMID: 21750219)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21750219	AVv-K-vJSS-TIFzzUJA4jax	PIK3CA	PF-04691502	"In a preclinical study, PF-04691502 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring PIK3CA mutations (PMID: 21750219)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21750219	AVv-K-S2SS-TIFzzUJAAjax	PIK3CA	PF-04691502	"In a preclinical study, PF-04691502 inhibited Pi3k signaling, resulted in growth inhibition of ovarian cancer cells harboring PIK3CA H1047R in culture and in cell line xenograft models (PMID: 21750219)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21750219	AVv-K9JOSS-TIFzzUI-Jjax	PIK3CA	PF-04691502	"In a preclinical study, PF-04691502 inhibited Akt phosphorylation and proliferation of breast cancer cells harboring both PIK3CA P539R and H1047R in culture (PMID: 21750219)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21750219	AVv-K9RLSS-TIFzzUI-Wjax	PIK3CA	PD-0325901 + Gedatolisib	"In a preclinical study, the combination of Gedatolisib (PF-05212384) and PD-0325901 inhibited tumor growth in colon cancer cell line xenograft models harboring KRAS G13D and PIK3CA H1047R (PMID: 21325073)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-K9hISS-TIFzzUI-vjax	PIK3CA	PD-0325901 + GDC-0941	"In preclinical studies, the combination of GDC-0941 and PD-0325901 (PI3K and MEK inhibitors, respectively) inhibited tumor growth in colorectal cancer cell line xenograft models (PMID: 24339963)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24339963	AVv-K_6aSS-TIFzzUJCwjax	PIK3CA	P7170	"In a preclinical study, Panulisib (P7170) downregulated mTOR pathway signaling in ovarian cancer cells with amplified PIK3CA (PMID: 25700704)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25700704	AVv-K_OoSS-TIFzzUJBrjax	PIK3CA	OSI-027	"In a preclinical study, OSI-027 inhibited tumor growth in ovarian cancer cell line xenograft models harboring PIK3CA mutations (PMID: 21673091)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21673091	AVv-K-cXSS-TIFzzUJAPjax	PIK3CA	OSI-027	"In a preclinical study, OSI-027 induced tumor regression in breast cancer cell line xenograft models harboring PIK3CA mutations (PMID: 21673091)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21673091	AVv-K-V-SS-TIFzzUJAFjax	PIK3CA	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_JkSS-TIFzzUJBjjax	PIK3CA	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K--qSS-TIFzzUJBSjax	PIK3CA	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K9CCSS-TIFzzUI99jax	PIK3CA	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_xtSS-TIFzzUJCijax	PIK3CA	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_DkSS-TIFzzUJBajax	PIK3CA	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K8UKSS-TIFzzUI8vjax	PIK3CA	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_5LSS-TIFzzUJCujax	PIK3CA	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited growth of colorectal cancer cells harboring both BRAF G596R and PIK3CA E545K in culture (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-K8AZSS-TIFzzUI8Ejax	PIK3CA	Metformin	"In a preclinical study, Glucophage (metformin) inhibited cell proliferation of a dietary restriction-resistant PIK3CA H1047R-harboring human breast cancer cell line in culture, and inhibited tumor growth in xenograft models (PMID: 23986086)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23986086	AVv-K9OvSS-TIFzzUI-Sjax	PIK3CA	Metformin	"In a preclinical study, Glucophage (metformin) demonstrated efficacy in treating dietary restriction-resistant human xenograft tumors harboring a PIK3CA-activating mutation (PMID: 23986086)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23986086	AVv-K_ktSS-TIFzzUJCNjax	PIK3CA	Metformin	"In a preclinical study, Glucophage (metformin) demonstrated efficacy in treating dietary restriction-resistant human colorectal cancer cell line xenograft tumors harboring PIK3CA H1047R (PMID: 23986086)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23986086	AVv-K9CmSS-TIFzzUI9-jax	PIK3CA	MSC2363318A	"In a preclinical study, a breast cancer xenograft model harboring PIK3CA H1047R was sensitive to M2698 (MSC2363318A), demonstrating inhibition of tumor growth (PMID: 27186432)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27186432	AVv-K894SS-TIFzzUI92jax	PIK3CA	MLN0128 + WEHI-539	"In a preclinical study, the ATP–competitive mTORC1/2 inhibitor TAK-228 (MLN0128) sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-K_izSS-TIFzzUJCKjax	PIK3CA	MLN0128 + PD-0325901	"In a preclinical study, TAK-228 (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PIK3CA H1047R in culture (PMID: 26272063)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-K9ZqSS-TIFzzUI-jjax	PIK3CA	MLN0128 + PD-0325901	"In a preclinical study, TAK-228 (MLN0128) and PD-0325901 combination treatment resulted in tumor growth stabilization in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D, PIK3CA E545K and H1047L (PMID: 26272063)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-K8FZSS-TIFzzUI8Wjax	PIK3CA	MLN0128 + PD-0325901	"In a preclinical study, TAK-228 (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R335fs (PMID: 26272063)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-K8HkSS-TIFzzUI8ajax	PIK3CA	MLN0128 + PD-0325901	"In a preclinical study, TAK-228 (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12C, PIK3CA H1047R, and TP53 R248W (PMID: 26272063)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-K9TlSS-TIFzzUI-Zjax	PIK3CA	MLN0128	"In a preclinical study, human cancer cell lines harboring PIK3CA mutations were sensitive to MLN0128 as demonstrated by significant growth inhibition (PMID: 25261369)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25261369	AVv-K-j1SS-TIFzzUJAljax	PIK3CA	MLN0128	"In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to MLN0128 resulting in inhibition of MTORC1 signaling (PMID: 25261369)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25261369	AVv-K91CSS-TIFzzUI_Ojax	PIK3CA	MLN0128	"In a preclinical study, a breast cancer cell line harboring mutations in PIK3CA and CDKN2A demonstrated sensitivity to MLN0128 in culture (PMID: 25261369)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25261369	AVv-K-1ESS-TIFzzUJBCjax	PIK3CA	MLN0128	"In a preclinical study, MLN0128 demonstrated efficacy in PIK3CA mutant breast cancer xenograft models (PMID: 23085766)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23085766	AVv-K-OISS-TIFzzUI_4jax	PIK3CA	MK2206 + Temsirolimus	"In a preclinical study, MK2206 and Torisel (temsirolimus) demonstrated synergy in inhibiting growth of an anaplastic thyroid cancer cell line harboring PIK3CA H1047R in culture (PMID: 21289267)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21289267	AVv-K8-aSS-TIFzzUI93jax	PIK3CA	MK2206	"In a preclinical study, expression of PIK3CA E545K in a thyroid cancer cell line resulted in increased sensitivity to MK2206 in culture (PMID: 21289267)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21289267	AVv-K8N0SS-TIFzzUI8kjax	PIK3CA	MK2206	"In a preclinical study, breast cancer cell lines harboring activating mutations in PIK3CA had increased sensitivity to MK2206 in cell culture (PMID: 22932669)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22932669	AVv-K_g3SS-TIFzzUJCHjax	PIK3CA	MK2206	"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_L_SS-TIFzzUJBnjax	PIK3CA	MK2206	"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K--ESS-TIFzzUJBRjax	PIK3CA	MK2206	"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K9M-SS-TIFzzUI-Pjax	PIK3CA	MK2206	"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_vNSS-TIFzzUJCejax	PIK3CA	MK2206	"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_BrSS-TIFzzUJBXjax	PIK3CA	MK2206	"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K8a6SS-TIFzzUI88jax	PIK3CA	MK2206	"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_-mSS-TIFzzUJC3jax	PIK3CA	MK2206	"In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with  PI3K/AKT pathway alterations in culture, including an anaplastic thyroid cancer cell line harboring PIK3CA H1047R (PMID: 21289267)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21289267	AVv-K9AOSS-TIFzzUI96jax	PIK3CA	MK2206	"In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with  PI3K/AKT pathway alterations in culture, including a papillary thyroid cancer cell line harboring PIK3CA E542K (PMID: 21289267)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21289267	AVv-K_9TSS-TIFzzUJC1jax	PIK3CA	MK2206	"In a Phase II study, MK2206 increased stable disease to 12 months in a nasopharyngeal carcinoma patient with Pik3ca amplification (PMID: 26084990)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26084990	AVv-K_TCSS-TIFzzUJByjax	PIK3CA	Letrozole + BYL719	"In a Phase Ib trial, an estrogen-receptor positive breast cancer patient harboring PIK3CA mutations, E78K, D939G, and E726K, demonstrated progressive disease when treated with a combination of Femara (letrozole) and Alpelisib (BYL719) (PMID: 27126994)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27126994	AVv-K74fSS-TIFzzUI71jax	PIK3CA	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_MmSS-TIFzzUJBojax	PIK3CA	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K-9gSS-TIFzzUJBQjax	PIK3CA	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K9FmSS-TIFzzUI-Djax	PIK3CA	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_w_SS-TIFzzUJChjax	PIK3CA	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_FnSS-TIFzzUJBdjax	PIK3CA	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K8WMSS-TIFzzUI8zjax	PIK3CA	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-LAAhSS-TIFzzUJC6jax	PIK3CA	LY3023414	"In a preclinical study, LY3023414 inhibited tumor growth in a transgenic animal model of leukemia driven by PIK3CA E545K (PMID: 27439478)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27439478	AVv-K8QRSS-TIFzzUI8ojax	PIK3CA	LY3023414	"In a preclinical study, LY3023414 inhibited proliferation of non-small cell lung cancer cells harboring PIK3CA G118D in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27439478)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27439478	AVv-K8u8SS-TIFzzUI9djax	PIK3CA	LY294002	"In a preclinical study, LY294002 inhibited cell proliferation of esophagus squamous cell carcinoma cells expressing PIK3CA E545K (PMID: 18262558)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18262558	AVv-K8R-SS-TIFzzUI8rjax	PIK3CA	LY2780301	"In a Phase I trial, a colon cancer patient harboring PIK3CA E545K was sensitive to LY2780301, demonstrating stable disease for approximately 125 days (PMID: 25902900)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25902900	AVv-K8I2SS-TIFzzUI8cjax	PIK3CA	Irinotecan	"In a preclinical study, Camptostar (irinotecan) suppressed the growth of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in xenograft models (PMID: 21325073, PMID: 16707468)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-K9faSS-TIFzzUI-sjax	PIK3CA	Idelalisib	"In a preclinical study, Zydelig (idelalisib) did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26137449	AVv-LAI9SS-TIFzzUJDHjax	PIK3CA	Gedatolisib + Irinotecan	"In a preclinical study, Gedatolisib (PKI-587) and Camptostar (irinotecan) synergistically suppressed the growth of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R (PMID: 24042735) in xenograft models (PMID: 21325073)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-K9f_SS-TIFzzUI-tjax	PIK3CA	Gedatolisib + Camptothecin	"In a preclinical study, Gedatolisib (PKI-587) and Camptothecin in combination synergistictically enhanced Parp cleavage in a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 21325073, PMID: 24042735)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25688157	AVv-K9i_SS-TIFzzUI-yjax	PIK3CA	GDC-0980	"In a preclincal study, GDC-0980 delayed tumor growth in colon cancer cell line xenograft models harboring KRAS and PIKC3A mutations (PMID: 21998291)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21998291	AVv-K-npSS-TIFzzUJArjax	PIK3CA	GDC-0980	"In a Phase I trial, treatment with Apitolisib (GDC-0980) resulted in a partial response in a patient with malignant pleural mesothelioma harboring PIK3CA R88Q (PMID: 26787751)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26787751	AVv-K_tiSS-TIFzzUJCbjax	PIK3CA	GDC-0980	"In a Phase I trial, Apitolisib (GDC-0980) treatment resulted in partial response in 21% (3/14) and stable disease in 57% (8/14) of patients with advanced solid tumors harboring PIK3CA mutations (PMID: 26787751)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26787751	AVv-K-QbSS-TIFzzUI_8jax	PIK3CA	GDC-0980	"In a Phase I trial, Apitolisib (GDC-0980) treatment resulted in a partial response in a patient with head and neck squamous cell carcinoma harboring a PIK3CA E542K mutation (PMID: 26787751)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26787751	AVv-K_99SS-TIFzzUJC2jax	PIK3CA	GDC-0980	"In a Phase I trial, Apitolisib (GDC-0980) resulted in a partial response in two patients, one with head and neck squamous cell carcinoma and another with ovarian cancer, both harboring PIK3CA E545K (PMID: 26787751)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26787751	AVv-K8bhSS-TIFzzUI89jax	PIK3CA	GDC-0941 + NVP-AEW541	"In a preclinical study, NVP-AEW541 enhanced sensitivity of PIK3CA amplified triple-receptor negative breast cancer cells to Pictilisib (GDC-0941) in culture (PMID: 27196766)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27196766	AVv-K_RoSS-TIFzzUJBwjax	PIK3CA	GDC-0941 + MS417	"In a preclinical study, Pictilisib (GDC-0941) and MS417 in combination resulted in improved growth inhibition and increased cell death compared to either agent alone in colorectal cancer cell lines harboring PIK3CA mutations in culture (PMID: 26058079)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26058079	AVv-K-YqSS-TIFzzUJAJjax	PIK3CA	GDC-0941 + Linsitinib	"In a preclinical study, Linsitinib (OSI-906) enhanced sensitivity of PIK3CA amplified triple-receptor negative breast cancer cells to Pictilisib (GDC-0941) in culture (PMID: 27196766)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27196766	AVv-K_RCSS-TIFzzUJBvjax	PIK3CA	GDC-0941	"In preclinical studies, the PI3K inhibitor GDC-0941 demonstrated efficacy against NSCLC tumor cell lines in culture and in xenograft models harboring alterations in the PI3K pathway (PMID: 23136191)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23136191	AVv-K_lUSS-TIFzzUJCOjax	PIK3CA	GDC-0941	"In a preclinical study, triple-receptor negative breast cancer cell lines harboring PIK3CA mutations demonstrated increased sensitivity to Pictilisib (GDC-0941) in culture (PMID: 27196766)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27196766	AVv-K-VZSS-TIFzzUJAEjax	PIK3CA	GDC-0941	"In a preclinical study, endometrioid endometrial cancer cell lines harboring PIK3CA mutations demonstrated increased sensitivity to GDC-0941 (Pictilisib) induced growth inhibition comparing to PIK3CA wild-type cells in culture (PMID: 23674493)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23674493	AVv-K-ffSS-TIFzzUJAfjax	PIK3CA	GDC-0941	"In a preclinical study, GDC-0941 inhibited growth and induced apoptosis in breast cancer cells expressing PIK3CA mutations (PMID: 24601221)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24601221	AVv-K-PUSS-TIFzzUI_6jax	PIK3CA	GDC-0941	"In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA E545K resulted in resistance to Pictilisib (GDC-0941) in culture (PMID: 27604488)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27604488	AVv-K7_3SS-TIFzzUI8Djax	PIK3CA	GDC-0032 + Radiotherapy	"In a preclinical study, Taselisib (GDC-0032) enhanced the effects of radiation induced apoptosis of head and neck squamous carcinoma cells harboring PIK3CA H1047R (PMID: 26589432)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26589432	AVv-K88USS-TIFzzUI9zjax	PIK3CA	GDC-0032 + Radiotherapy	"In a preclinical study, Taselisib (GDC-0032) enhanced the effects of radiation induced apoptosis in HNSCC cell lines, cell line xenograft models, and a patient derived xenograft (PDX) model, all with PIK3CA mutations (PMID: 26589432)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26589432	AVv-K-GwSS-TIFzzUI_sjax	PIK3CA	GDC-0032 + Radiotherapy	"In a preclinical study, Taselisib (GDC-0032) enhanced the effects of radiation induced apoptosis in HNSCC cell lines and cell line xenograft models with PIK3CA amplification (PMID: 26589432)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26589432	AVv-K_QWSS-TIFzzUJBujax	PIK3CA	GDC-0032 + Neratinib	"In a preclinical study, the combination of Taselisib (GDC-0032) and Neratinib (HKI-272) delayed cell cycle activity in a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture (PMID: 26333383)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26333383	AVv-LAO9SS-TIFzzUJDQjax	PIK3CA	GDC-0032	"In preclinical studies, Taselisib (GDC-0032) effectively suppressed growth of multiple tumor types in a cell line xenograft models, with greater selectivity for PIK3CA activating mutants (PMID: 23662903)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23662903	AVv-K_jdSS-TIFzzUJCLjax	PIK3CA	GDC-0032	"In a preclinical study, Taselisib (GDC-0032) inhibited growth of HER2 positive uterine cancer cell lines with PIK3CA mutations (PMID: 25172762)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25172762	AVv-K_aOSS-TIFzzUJB9jax	PIK3CA	Fulvestrant + GDC-0941	"In a Phase II trial, Falsodex (fulvestrant) and Pictilisib (GDC-0941) combination treatment resulted in similar progression free survival in ER positive breast cancer patients harboring PIK3CA mutations and those who were PIK3CA wild-type (PMID: 27174596)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27174596	AVv-K-ZSSS-TIFzzUJAKjax	PIK3CA	Fulvestrant	"In a Phase II trial, Falsodex (fulvestrant) treatment resulted in similar progression free survival in ER positive breast cancer patients harboring PIK3CA mutations and those who were PIK3CA wild-type (PMID: 27174596)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27174596	AVv-K-e2SS-TIFzzUJATjax	PIK3CA	Everolimus + U0126	"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss did not demonstrate any benefit when treated with a combination of Afinitor (everolimus) and U0126 (PMID: 21358673)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/21358673	AVv-LATMSS-TIFzzUJDXjax	PIK3CA	Everolimus + Selumetinib	"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss did not demonstrate any benefit when treated with a combination of Afinitor (everolimus) and Selumetinib (AZD6244) (PMID: 21358673)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/21358673	AVv-LAQ0SS-TIFzzUJDTjax	PIK3CA	Everolimus + Pimasertib	"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-K8l0SS-TIFzzUI9Ojax	PIK3CA	Everolimus + Pimasertib	"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-K8tnSS-TIFzzUI9bjax	PIK3CA	Everolimus + Pimasertib	"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-K8hYSS-TIFzzUI9Hjax	PIK3CA	Everolimus + Pimasertib	"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-K-4nSS-TIFzzUJBIjax	PIK3CA	Everolimus	"In a preclinical study, human cancer cells with PIK3CA mutations demonstrated sensitivity to Afinitor (everolimus), but a coincident KRAS mutation led to Afinitor (everolimus) resistance  (PMID: 20664172)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/20664174	AVv-K-qhSS-TIFzzUJAwjax	PIK3CA	Everolimus	"In a preclinical study, expression of KRAS G13D in an endometrial cancer cell line harboring PIK3CA E545K conferred resistance to Afinitor (everolimus) in xenograft models (PMID: 20664172)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/20664172	AVv-K8F-SS-TIFzzUI8Xjax	PIK3CA	Everolimus	"In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to Afinitor (everolimus) compared with cells without KRAS mutations in culture (PMID: 22662154)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-K_uISS-TIFzzUJCcjax	PIK3CA	Everolimus	"In a preclinical study, breast cancer cell lines harboring a PIK3CA E545K mutation had increased sensitivity to Afinitor (everolimus) in culture (PMID: 20664172)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20664172	AVv-K8Q2SS-TIFzzUI8pjax	PIK3CA	Everolimus	"In a preclinical study, Afinitor (everolimus) inhibited proliferation of endometrial cancer cells harboring PIK3CA R88Q and PTEN mutations in culture (PMID: 22662154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-K_r4SS-TIFzzUJCYjax	PIK3CA	Everolimus	"In a preclinical study, Afinitor (everolimus) demonstrated efficacy in multiple cancer cell lines in culture and xenograft models with PIK3CA activating mutations (PMID: 20664172)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20664172	AVv-K_dpSS-TIFzzUJCCjax	PIK3CA	Everolimus	"In a preclinical study, 8/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Afinitor (everolimus) in culture, resulting in decreased cell viability (PMID: 21358673)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21358673	AVv-K_VxSS-TIFzzUJB2jax	PIK3CA	Everolimus	"In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to treatment with Afinitor (everolimus) (PMID: 27797976)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27797976	AVv-K9WlSS-TIFzzUI-ejax	PIK3CA	Deguelin	"In a preclinical study, Deguelin inhibited growth of the AGS gastric cancer cell line, which has been reported to harbor PIK3CA and KRAS mutations, in culture (PMID: 20811676, PMID: 24978597)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20811676	AVv-K-s7SS-TIFzzUJA0jax	PIK3CA	DS-7423	"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA H1047R and TP53 S90fs*33 demonstrated reduced sensitivity to DS-7423 in culture (PMID: 24504419)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24504419	AVv-K80oSS-TIFzzUI9mjax	PIK3CA	DS-7423	"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA E545V was sensitive to DS-7423 in culture, demonstrating inhibition of cell proliferation (PMID: 24504419)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24504419	AVv-K-6oSS-TIFzzUJBLjax	PIK3CA	DS-7423	"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA C420R was sensitive to DS-7423 in culture, demonstrating inhibition of cell proliferation (PMID: 24504419)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24504419	AVv-K7-OSS-TIFzzUI8Ajax	PIK3CA	DHM25	"In a preclinical study, DHM25 increased cell death in breast cancer cell lines harboring PIK3CA H1047R in culture (PMID: 26237138)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26237138	AVv-K9E_SS-TIFzzUI-Cjax	PIK3CA	DHM25	"In a preclinical study, DHM25 increased cell death in a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 26237138)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26237138	AVv-LAa2SS-TIFzzUJDkjax	PIK3CA	DHM25	"In a preclinical study, DHM25 increased cell death in a breast cancer cell line harboring PIK3CA E545K in culture (PMID: 26237138)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26237138	AVv-K8ZtSS-TIFzzUI86jax	PIK3CA	Copanlisib + Paclitaxel	"In a preclinical study, Copanlisib (BAY80-6946), in combination with Taxol (paclitaxel), induced tumor regression in PIK3CA E545K-mutant patient-derived non-small cell lung cancer xenografts (PMID: 24170767)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24170767	AVv-K8dLSS-TIFzzUI9Ajax	PIK3CA	Copanlisib	"In a preclinical study, treatment with Copanlisib inhibited tumor growth in xenograft models of a human colon cancer cell line harboring PIK3CA and KRAS mutations (PMID: 24170767)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24170767	AVv-K-z5SS-TIFzzUJBAjax	PIK3CA	Copanlisib	"In a preclinical study, Copanlisib (BAY80-6946) promoted tumor regression in xenograft models of a human ERBB2 (HER2)-amplified breast cancer cell line harboring a PIK3CA activating mutation (PMID: 24170767)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24170767	AVv-K93cSS-TIFzzUI_Sjax	PIK3CA	Cetuximab	"In a retrospective study, Erbitux (cetuximab) treatment, alone or in combination, resulted in disease regression or stable disease in 88% (7/8) KRAS/BRAF-wild type colorectal carcinoma patients harboring a PIK3CA mutation (PMID: 25714871)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25714871	AVv-K-0gSS-TIFzzUJBBjax	PIK3CA	Cetuximab	"In a retrospective study, Erbitux (cetuximab) treatment resulted in stable disease in a colorectal carcinoma patient harboring a PIK3CA E542V mutation (PMID: 25714871)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25714871	AVv-LAXUSS-TIFzzUJDejax	PIK3CA	Cetuximab	"In a retrospective study, Erbitux (cetuximab) combined with radiation therapy resulted in stable disease for 6 months in a colorectal carcinoma patient harboring a PIK3CA H1047R mutation (PMID: 25714871)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25714871	AVv-K9MXSS-TIFzzUI-Ojax	PIK3CA	Cetuximab	"In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Erbitux (cetuximab) in culture (PMID: 25838391)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-K-1sSS-TIFzzUJBDjax	PIK3CA	Cetuximab	"In a preclinical study, Erbitux (cetuximab) inhibited proliferation of a human colon cancer cell line harboring mutant KRAS and wild-type PIK3CA in culture and reduced tumor growth in xenograft models (PMID: 26715098)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26715098	AVv-LAHzSS-TIFzzUJDFjax	PIK3CA	Cetuximab	"In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells wild-type for BRAF, KRAS, NRAS and PIK3CA in culture (PMID: 25838391)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-LAU4SS-TIFzzUJDajax	PIK3CA	Cetuximab	"In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26715098	AVv-K8ymSS-TIFzzUI9jjax	PIK3CA	Cetuximab	"In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA E545K in culture (PMID: 26715098)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26715098	AVv-K8A-SS-TIFzzUI8Fjax	PIK3CA	CUDC-907	"In a preclinical study, CUDC-907 inhibited growth of human breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 22693356)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22693356	AVv-K-IqSS-TIFzzUI_vjax	PIK3CA	CUDC-907	"In a preclinical study, CUDC-907 inhibited growth and induced apoptosis in a human colon cancer cell line harboring PIK3CA and KRAS mutations (PMID: 22693356)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22693356	AVv-K-uDSS-TIFzzUJA2jax	PIK3CA	CUDC-907	"In a preclinical study, CUDC-907 inhibited downstream signaling and growth of PIK3CA-mutant breast cancer cells with ERBB2 amplification in culture (PMID: 22693356)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22693356	AVv-K91nSS-TIFzzUI_Pjax	PIK3CA	CUDC-907	"In a preclinical study, CUDC-907 induced caspase activation in a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 20570890, PMID: 22693356)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20570890	AVv-K9e3SS-TIFzzUI-rjax	PIK3CA	CH5132799	"In a preclinical study, human solid tumor cell lines harboring coincident PIK3CA and KRAS mutations demonstrated sensitivity to CH5132799 in culture (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-K-tiSS-TIFzzUJA1jax	PIK3CA	CH5132799	"In a preclinical study, breast cancer cells with PIK3CA mutations, both with and without ERBB2 (HER2) amplification, demonstrated sensitivity to CH5132799 in culture (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-K-BNSS-TIFzzUI_ijax	PIK3CA	CH5132799	"In a preclinical study, CH5132799 inhibited tumor growth in xenograft models of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R mutations (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-K9iXSS-TIFzzUI-xjax	PIK3CA	CH5132799	"In a preclinical study, CH5132799 inhibited proliferation of prostate cancer cells with PIK3CA mutations in culture (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-K-FxSS-TIFzzUI_qjax	PIK3CA	CH5132799	"In a preclinical study, CH5132799 inhibited proliferation of prostate cancer cells harboring PIK3CA Q546R in culture (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-LAX6SS-TIFzzUJDfjax	PIK3CA	CH5132799	"In a preclinical study, CH5132799 inhibited proliferation of ovarian cancer cells with PIK3CA mutations in culture (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-K-BvSS-TIFzzUI_jjax	PIK3CA	CH5132799	"In a preclinical study, CH5132799 inhibited proliferation of ovarian cancer cells harboring PIK3CA E545K in culture (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-K8RaSS-TIFzzUI8qjax	PIK3CA	CH5132799	"In a preclinical study, CH5132799 inhibited proliferation of endometrial cancer cells with PIK3CA mutations in culture (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-K-CXSS-TIFzzUI_kjax	PIK3CA	CH5132799	"In a preclinical study, CH5132799 inhibited proliferation of endometrial cancer cells harboring PIK3CA G1049R and KRAS G12D mutations in culture (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-K_BCSS-TIFzzUJBWjax	PIK3CA	CH5132799	"In a preclinical study, CH5132799 inhibited proliferation of breast cancer cells harboring PIK3CA H1047R in culture (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-K9GwSS-TIFzzUI-Fjax	PIK3CA	CH5132799	"In a preclinical study, CH5132799 inhibited proliferation of breast cancer cells expressing PIK3CA E545K (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-K8SiSS-TIFzzUI8sjax	PIK3CA	CH5132799	"In a preclinical study, CH5132799 inhibited proliferation of an endometrial cancer cell line harboring PIK3CA R38C and PTEN loss in culture (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-K_UeSS-TIFzzUJB0jax	PIK3CA	CH5132799	"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA N345K and ERBB2 (HER2) amplification in culture (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-K-7MSS-TIFzzUJBMjax	PIK3CA	CH5132799	"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K and ERBB2 (HER2) amplification in culture (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-K7_TSS-TIFzzUI8Cjax	PIK3CA	CH5132799	"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA E542K in culture (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-K_4pSS-TIFzzUJCtjax	PIK3CA	CH5132799	"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA C420R and ERBB2 (HER2) amplification (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-K7-tSS-TIFzzUI8Bjax	PIK3CA	CH5132799	"In a preclinical study, CH5132799 inhibited cell growth in a human ovarian cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-K82rSS-TIFzzUI9pjax	PIK3CA	CH5132799	"In a preclinical study, CH5132799 inhibited cell growth in a human endometrial cancer cell line harboring a PIK3CA H1047Y mutation, and inhibited tumor growth in xenograft models (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-K_0RSS-TIFzzUJCmjax	PIK3CA	CH5132799	"In a Phase I trial, CH5132799 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a partial response in a patient with ovarian cancer harboring PIK3CA H1047R (PMID: 25231405)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25231405	AVv-K9IASS-TIFzzUI-Hjax	PIK3CA	CCT128930	"In a preclinical study, CCT128930 induced growth arrest and inhibited tumor growth in a xenograft model of a ERBB2 (HER2)-positive human breast cancer cell line harboring a PIK3CA mutation (PMID: 21191045)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21191045	AVv-K-EqSS-TIFzzUI_ojax	PIK3CA	CC-223	"In a preclinical study, CC-223 inhibited proliferation of HCT-116 colon cancer cells, which have been reported to harbor KRAS G13D and PIK3CA H1047R mutations, in culture (PMID: 25855786, PMID: 24978597)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25855786	AVv-K9hySS-TIFzzUI-wjax	PIK3CA	CC-223	"In a Phase I trial, CC-223 demonstrated safety and preliminary efficacy in patients with solid tumors, including stable disease for greater than 110 days in 2 patients with PIK3CA mutation or PTEN deletion (PMID: 26177599)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26177599	AVv-K-hMSS-TIFzzUJAhjax	PIK3CA	Bortezomib + Temsirolimus + Topotecan	"In a clinical study, the combination of Torisel (temsirolimus) plus Velcade (bortezomib) and Hycamtin (topotecan) resulted in progressive disease in a patient with small intestine adenocarcinoma harboring a PIK3CA H1047 mutation (PMID: 21216929)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21216929	AVv-K9s2SS-TIFzzUI_Cjax	PIK3CA	Bevacizumab + Temsirolimus + Doxil	"In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in patients with advanced solid tumors harboring PIK3CA mutations (PMID: 21216929)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21216929	AVv-K-jNSS-TIFzzUJAkjax	PIK3CA	Bevacizumab + Temsirolimus + Doxil	"In a clinical study, the combination of Torisel (temisirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxirubicin) resulted in stable disease in patients with advanced solid tumors harboring PIK3CA mutations (PMID: 21216929)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21216929	AVv-K-ilSS-TIFzzUJAjjax	PIK3CA	BYL719	"In a preclinical study, BYL719 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_LXSS-TIFzzUJBmjax	PIK3CA	BYL719	"In a preclinical study, BYL719 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K-_PSS-TIFzzUJBTjax	PIK3CA	BYL719	"In a preclinical study, BYL719 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K8_jSS-TIFzzUI95jax	PIK3CA	BYL719	"In a preclinical study, BYL719 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_v6SS-TIFzzUJCfjax	PIK3CA	BYL719	"In a preclinical study, BYL719 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_E5SS-TIFzzUJBcjax	PIK3CA	BYL719	"In a preclinical study, BYL719 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K8KFSS-TIFzzUI8ejax	PIK3CA	BYL719	"In a preclinical study, BYL719 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_7kSS-TIFzzUJCyjax	PIK3CA	BYL719	"In a preclinical study, BYL719 inhibited growth in multiple tumor cell lines expressing PIK3CA mutations, and concurrent KRAS mutations was not associated with resistance (PMID: 24608574)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24608574	AVv-K-yASS-TIFzzUJA9jax	PIK3CA	BYL719	"In a preclinical study, BYL719 inhibited growth in multiple tumor cell lines expressing PIK3CA mutations (PMID: 24608574)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24608574	AVv-K-MUSS-TIFzzUI_1jax	PIK3CA	BYL719	"In a preclinical study, BYL719 inhibited PIK3CA E545K and showed anti-tumor activity in patient-derived xenograft models harboring a PIK3CA E545K mutation (PMID: 24608574)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24608574	AVv-K8ToSS-TIFzzUI8ujax	PIK3CA	BYL719	"In a preclinical study, Alpelisib (BYL719) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA H1047R in culture (PMID: 26013318)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26013318	AVv-K8-6SS-TIFzzUI94jax	PIK3CA	BYL719	"In a preclinical study, Alpelisib (BYL719) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA E545K in culture (PMID: 26013318)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26013318	AVv-K8KuSS-TIFzzUI8fjax	PIK3CA	BYL719	"In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27604488	AVv-K9p1SS-TIFzzUI-9jax	PIK3CA	BKM120 + WEHI-539	"In a preclinical study, Buparlisib (BKM120) did not sensitize breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-K_qBSS-TIFzzUJCVjax	PIK3CA	BKM120 + Cetuximab	"In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and wild-type PIK3CA in culture and tumor growth in xenograft models (PMID: 26715098)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26715098	AVv-LAGjSS-TIFzzUJDDjax	PIK3CA	BKM120 + Cetuximab	"In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26715098	AVv-K8z7SS-TIFzzUI9ljax	PIK3CA	BKM120 + Cetuximab	"In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA E545K in culture (PMID: 26715098)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26715098	AVv-K8COSS-TIFzzUI8Hjax	PIK3CA	BKM120 + Bevacizumab	"In a preclinical study, treatment with Buparlisib (BKM120) resulted in decreased tumor growth, but not tumor regression, in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R (PMID: 23940356)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23940356	AVv-K9oiSS-TIFzzUI-7jax	PIK3CA	BKM120	"In a preclinical study, colon cancer cell lines harboring mutant KRAS and PIK3CA E545K demonstrated reduced sensitivity to Buparlisib (BKM120) induced growth inhibition in culture (PMID: 26715098)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26715098	AVv-K8BmSS-TIFzzUI8Gjax	PIK3CA	BKM120	"In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and wild-type PIK3CA in culture and reduced tumor growth in xenograft models (PMID: 26715098)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26715098	AVv-LAF5SS-TIFzzUJDCjax	PIK3CA	BKM120	"In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26715098	AVv-K8zSSS-TIFzzUI9kjax	PIK3CA	BKM120	"In a preclinical study, Buparlisib (BKM120) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing wild-type Pik3ca in culture (PMID: 26013318)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26013318	AVv-K76ESS-TIFzzUI74jax	PIK3CA	BKM120	"In a preclinical study, Buparlisib (BKM120) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA E545K in culture (PMID: 26013318)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26013318	AVv-K8JaSS-TIFzzUI8djax	PIK3CA	BKM120	"In a preclinical study, BKM120 suppressed growth of a gastric cancer cell line harboring PIK3CA and KRAS mutations in culture (PMID: 22159814)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22159814	AVv-K-wXSS-TIFzzUJA6jax	PIK3CA	BKM120	"In a Phase II trial, one patient with Kras and Pikc3a mutant non-squamous NSCLC had a partial response to Buparlisib (BKM120) however, stage 2 of the study was not initiated due to failure of meeting overall stage 1 response endpoints (PMID: 26098748)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26098748	AVv-K-sUSS-TIFzzUJAzjax	PIK3CA	BEZ235 + WEHI-539	"In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-K_e7SS-TIFzzUJCEjax	PIK3CA	BEZ235 + WEHI-539	"In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to WEHI-539 in culture (PMID: 27974663)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-K84-SS-TIFzzUI9tjax	PIK3CA	BEZ235 + WEHI-539	"In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA E545K to WEHI-539 in culture (PMID: 27974663)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-K8drSS-TIFzzUI9Bjax	PIK3CA	BEZ235 + WEHI-539	"In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA E542K and PTEN loss to WEHI-539 in culture (PMID: 27974663)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-K_2ISS-TIFzzUJCpjax	PIK3CA	BEZ235 + WEHI-539	"In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize PIK3CA wild-type breast cancer cell lines to WEHI-539 in culture (PMID: 27974663)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-LADRSS-TIFzzUJC-jax	PIK3CA	BEZ235 + Venetoclax	"In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA activating mutations to Venclexta (venetoclax) in culture (PMID: 27974663)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-K_rRSS-TIFzzUJCXjax	PIK3CA	BEZ235 + Venetoclax	"In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to Venclexta (venetoclax) in culture (PMID: 27974663)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-K85jSS-TIFzzUI9ujax	PIK3CA	BEZ235 + Venetoclax	"In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA E545K to Venclexta (venetoclax) in culture (PMID: 27974663)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-K8L3SS-TIFzzUI8hjax	PIK3CA	BEZ235 + Vemurafenib	"In a preclinical study, BEZ235 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26137449	AVv-LAJkSS-TIFzzUJDIjax	PIK3CA	BEZ235 + PD98509	"In a preclinical study, the combination of BEZ235 and the MEK1 inhibitor PD98509 worked synergistically or additively to inhibit growth of endometrial cancer cells with amplification of PIK3CA and KRAS in culture (PMID: 22662154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-K_N-SS-TIFzzUJBqjax	PIK3CA	BEZ235 + PD98509	"In a preclinical study, the combination of BEZ235 and the MEK1 inhibitor PD98509 worked synergistically or additively to inhibit growth of endometrial cancer cells harboring PIK3CA G1049R, KRAS G12D, and amplification of PIK3CA in culture (PMID: 22662154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-K_AeSS-TIFzzUJBVjax	PIK3CA	BEZ235	"In a preclinical study, treatment with BEZ235 slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26232337	AVv-K9bCSS-TIFzzUI-ljax	PIK3CA	BEZ235	"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to BEZ235 treatment (PMID: 26272063)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-K8DCSS-TIFzzUI8Ijax	PIK3CA	BEZ235	"In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to BEZ235 compared with cells without KRAS mutations in culture (PMID: 22662154)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-K_upSS-TIFzzUJCdjax	PIK3CA	BEZ235	"In a preclinical study, colon cancer cells harboring KRAS and PIK3CA mutations demonstrated resistance to BEZ235 in culture and xenograft models (PMID: 23475782)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23475782	AVv-K-pbSS-TIFzzUJAujax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 stabilized tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W (PMID: 26272063)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-K9VTSS-TIFzzUI-cjax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 reduced tumor size in mouse models of lung cancer carrying PIK3CA H1047R (PMID: 19029981)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19029981	AVv-K87xSS-TIFzzUI9yjax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 promoted tumor regression in a mouse lung adenocarcinoma model expressing PIK3CA H1047R (PMID: 19029981)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19029981	AVv-K9HaSS-TIFzzUI-Gjax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 inhibited tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-K9jsSS-TIFzzUI-zjax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 inhibited tumor growth in a patient-derived xenograft (PDX) model of bladder cancer harboring PIK3CA H1047R (PMID: 26270481)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26270481	AVv-K89ZSS-TIFzzUI91jax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with KRAS and PIK3CA mutations (PMID: 24939055)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24939055	AVv-K-xMSS-TIFzzUJA8jax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_NYSS-TIFzzUJBpjax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K-8USS-TIFzzUJBOjax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K9KhSS-TIFzzUI-Ljax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_wcSS-TIFzzUJCgjax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_C4SS-TIFzzUJBZjax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K8WqSS-TIFzzUI80jax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627007	AVv-K_20SS-TIFzzUJCqjax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA R88Q and PTEN mutations in culture (PMID: 22662154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-K_saSS-TIFzzUJCZjax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA R108H and PTEN mutations in culture (PMID: 22662154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-K9rCSS-TIFzzUI-_jax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA E365K and PTEN mutations in culture (PMID: 22662154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-K8qqSS-TIFzzUI9Wjax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing wild-type Pik3ca in culture (PMID: 26013318)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26013318	AVv-K77wSS-TIFzzUI77jax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA H1047R in culture (PMID: 26013318)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26013318	AVv-K9LISS-TIFzzUI-Mjax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA E545K in culture (PMID: 26013318)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26013318	AVv-K8clSS-TIFzzUI8_jax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 demonstrated efficacy in promoting apoptosis of gastric cancer cells harboring a PIK3CA mutation in culture (PMID: 22543857)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22543857	AVv-K-FOSS-TIFzzUI_pjax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 demonstrated efficacy in promoting apoptosis of colon cancer cells harboring a PIK3CA mutation in culture  (PMID: 22543857)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22543857	AVv-K-AnSS-TIFzzUI_hjax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 demonstrated efficacy in mouse xenograft models of ovarian clear cell adenocarcinoma with PIK3CA mutations (PMID: 24927217)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24927217	AVv-K_c-SS-TIFzzUJCBjax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 delayed tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-K_HhSS-TIFzzUJBgjax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-K8o8SS-TIFzzUI9Tjax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 decreased growth of endometrial cancer cells harboring PIK3CA R38C and PTEN mutations in culture and in xenograft models (PMID: 22662154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-K_T3SS-TIFzzUJBzjax	PIK3CA	BEZ235	"In a preclinical study, BEZ235 decreased cell proliferation in colorectal cancer cells harboring a PIK3CA E545K mutation in cell culture (PMID: 21966435)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21966435	AVv-K8NMSS-TIFzzUI8jjax	PIK3CA	BAY1125976	"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA P539R in culture (PMID: 27699769)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27699769	AVv-LAdTSS-TIFzzUJDojax	PIK3CA	BAY1125976	"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 27699769)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27699769	AVv-LAZnSS-TIFzzUJDijax	PIK3CA	BAY1125976	"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA H1047R and PTEN E307K in culture (PMID: 27699769)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27699769	AVv-K8x_SS-TIFzzUI9ijax	PIK3CA	BAY1125976	"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K in culture, and inhibited AKT signaling and tumor growth in xenograft models (PMID: 27699769)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27699769	AVv-K8YNSS-TIFzzUI83jax	PIK3CA	BAY1125976	"In a preclinical study, BAY1125976 inhibited proliferation of  breast cancer cell lines harboring PIK3CA H1047R in culture, and inhibited AKT signaling and tumor growth in a PIK3CA H1047R-mutant cell line xenograft model (PMID: 27699769)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27699769	AVv-K86sSS-TIFzzUI9wjax	PIK3CA	Alpelisib + WEHI-539	"In a preclinical study, Alpelisib (BYL719) did not sensitize breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-K_fiSS-TIFzzUJCFjax	PIK3CA	Alpelisib + Lucitanib	"In a preclinical study, an estrogen-receptor positive breast cancer cell line over expressing FGFR1 and expressing a PIK3CA mutation demonstrated sensitivity to the combination of Apelisib (BYL719) and Lucitanib (E-3810) in culture (PMID: 27126994)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27126994	AVv-K-lFSS-TIFzzUJAnjax	PIK3CA	Alpelisib + GSK2334470	"In a preclinical study, GSK2334470 resensitized Alpelisib (BYL719)-resistant breast cancer cell lines harboring PIK3CA mutations to Alpelisib (BYL719) in culture and in cell line xenograft models (PMID: 27451907)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27451907	AVv-K-eJSS-TIFzzUJASjax	PIK3CA	Afuresertib	"In a preclinical study, various tumor cell lines harboring PI3KCA activating mutations demonstrated increased sensitivity to Afuresertib (GSK2110183) in cultured cells (PMID: 24978597)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24978597	AVv-K_mnSS-TIFzzUJCQjax	PIK3CA	AZD8835	"In a preclinical study, human breast cancer cells with wild-type PIK3CA and loss of PTEN were resistant to growth inhibition by AZD8835 in culture (PMID: 26839307)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26839307	AVv-LASkSS-TIFzzUJDWjax	PIK3CA	AZD8835	"In a preclinical study, AZD8835 inhibited proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA mutations in culture and suppressed tumor growth in xenograft models (PMID: 26839307)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26839307	AVv-K-KdSS-TIFzzUI_yjax	PIK3CA	AZD8835	"In a preclinical study, AZD8835 inhibited proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA K111N in culture and induced tumor regression in xenograft models (PMID: 26839307)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26839307	AVv-LAaQSS-TIFzzUJDjjax	PIK3CA	AZD8835	"In a preclinical study, AZD8835 inhibited proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA E545K in culture and suppressed tumor growth in xenograft models (PMID: 26839307)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26839307	AVv-K8gDSS-TIFzzUI9Fjax	PIK3CA	AZD8835	"In a preclinical study, AZD8835 inhibited growth of a variety of advanced solid tumor models with Pik3ca mutations in culture (PMID: 26839307)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26839307	AVv-K9-3SS-TIFzzUI_ejax	PIK3CA	AZD8055 + Selumetinib	"In a preclinical study, the combination of AZD8055 and Selumetinib (AZD6244) inhibited tumor growth in a colorectal cancer xenograft model harboring PIK3CA and KRAS mutations and had increased efficacy compared to either agent alone (PMID: 22271687)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22271687	AVv-K-ulSS-TIFzzUJA3jax	PIK3CA	AZD5363	"In a preclinical study, gastric cancer cells harboring PI3KCA E545K mutations were sensitive to the AKT inhibitor AZD5363 (PMID: 24088382)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24088382	AVv-K8ePSS-TIFzzUI9Cjax	PIK3CA	AZD5363	"In a preclinical study, gastric cancer cells harboring PI3KCA E542K mutations were sensitive to the AKT inhibitor AZD5363 (PMID: 24088382)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24088382	AVv-K__6SS-TIFzzUJC5jax	PIK3CA	AZD5363	"In a preclinical study, AZD5363 inhibited proliferation of the AGS gastric cancer cell line, which has been reported to harbor KRAS G12D and PIK3CA E453K mutations (PMID: 24088382, PMID: 19755509)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19755509	AVv-K9veSS-TIFzzUI_Gjax	PIK3CA	AZD5363	"In a preclinical study, AZD5363 inhibited growth in breast cancer cell lines and xenograft models expressing PIK3CA mutations (PMID: 22294718)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22294718	AVv-K-P1SS-TIFzzUI_7jax	PIK3CA	AZD5363	"In a preclinical study, AZD5363 inhibited growth in a patient-derived xenograft model of gastric cancer harboring a PIK3CA H1047R mutation (PMID: 24088382)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24088382	AVv-K9BZSS-TIFzzUI98jax	PIK3CA	AZD2014 + WEHI-539	"In a preclinical study, the ATP–competitive mTORC1/2 inhibitor AZD2014 sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-K_oCSS-TIFzzUJCSjax	PIK3CA	AT13148	"In a preclinical study, a colon cancer cell line harboring PIK3CA and KRAS mutations demonstrated sensitivity to AT13148 in culture (PMID: 22781553)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22781553	AVv-K-zQSS-TIFzzUJA_jax	PIK3CA	AT13148	"In a preclinical study, a ERBB3 (HER3) positive breast cancer cell line xenograft model harboring a PIK3CA mutation was demonstrated decreased tumor growth when treated with AT13148 (PMID: 22781553)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22781553	AVv-K-JRSS-TIFzzUI_wjax	PIK3CA	AT13148	"In a preclinical study, AT13148 inhibited tumor growth in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model harboring mutant PIK3CA (PMID: 22781553)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22781553	AVv-K96RSS-TIFzzUI_Xjax	PIK3CA	AT-7867	"In a preclinical study, AT-7867 inhibited proliferation of cultured HCT-116 colon cancer cells, which have been reported to harbor KRAS G13D and PIK3CA H1047R mutations (PMID: 20423992, PMID: 24978597)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24978597	AVv-K9c6SS-TIFzzUI-ojax	PIK3CA	AT-7867	"In a preclinical study, AT-7867 inhibited proliferation in several human tumor cell lines harboring PIK3CA mutations in culture (PMID: 20423992)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20423992	AVv-K9-QSS-TIFzzUI_djax	PIK3CA	ARQ092	"In a preclinical study, treatment with ARQ092 resulted in growth inhibition in hormone receptor positive breast cancer cells harboring PIK3CA E545K in culture (PMID: 26469692)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26469692	AVv-K8MhSS-TIFzzUI8ijax	PIK3CA	ARQ092	"In a preclinical study, hormone receptor positive breast cancer cells harboring PIK3CA K111N were sensitive to ARQ092 in culture, demonstrating inhibition of cell growth (PMID: 26469692)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26469692	AVv-LAbfSS-TIFzzUJDljax	PIK3CA	ARQ092	"In a preclinical study, breast cancer cells harboring PIK3CA P539R and H1047R were sensitive to ARQ092 in culture, demonstrating inhibition of cell growth (PMID: 26469692)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26469692	AVv-K9QkSS-TIFzzUI-Vjax	PIK3CA	ARQ092	"In a preclinical study, a patient-derived xenograft (PDX) model of endometrial cancer harboring PIK3CA D350G, PIK3CA R93W, and PTEN R130G was sensitive to ARQ092, demonstrating greater than 90% inhibition of tumor growth (PMID: 26469692)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26469692	AVv-K75BSS-TIFzzUI72jax	PIK3CA	ARQ092	"In a preclinical study, a hormone breast cancer cell line harboring PIK3CA E542K was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26469692	AVv-K_8sSS-TIFzzUJC0jax	PIK3CA	ARQ092	"In a preclinical study, a breast cancer cell line harboring PIK3CA H1047R demonstrated sensitivity to treatment with ARQ092 in culture, resulting in inhibition of cell proliferation (PMID: 26469692)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26469692	AVv-K9P8SS-TIFzzUI-Ujax	PIK3CA	ARQ 751	"In a preclinical study, a breast cancer cell line harboring PIK3CA P539R and PH1047R was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26469692	AVv-K9SLSS-TIFzzUI-Xjax	PIK3CA	ARQ 751	"In a preclinical study, a breast cancer cell line harboring PIK3CA K111N was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26469692	AVv-LAcCSS-TIFzzUJDmjax	PIK3CA	ARQ 751	"In a preclinical study, a breast cancer cell line harboring PIK3CA H1047R demonstrated sensitivity to treatment with ARQ 751 in culture, resulting in inhibition of cell proliferation (PMID: 26469692)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26469692	AVv-K9EYSS-TIFzzUI-Bjax	PIK3CA	ARQ 751	"In a preclinical study, a breast cancer cell line harboring PIK3CA E545K was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26469692	AVv-K8ZOSS-TIFzzUI85jax	PIK3CA	ABT-737 + MLN0128	"In a preclinical study, ABT-737 and TAK-228 (MLN0128) combination treatment resulted in inhibition of tumor growth in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-K830SS-TIFzzUI9rjax	PIK3CA	ABT-737 + BEZ235	"In a preclinical study, ABT-737 and BEZ235 combination treatment resulted in tumor regression in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-K84bSS-TIFzzUI9sjax	PIK3CA	A66	"In a preclinical study, cancer cell lines harboring PIK3CA E545K did not demonstrate sensitivity to A66 in culture, in contrast with cells harboring PIK3CA H1047R (PMID: 21668414)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21668414	AVv-K8fbSS-TIFzzUI9Ejax	PIK3CA	A66	"In a preclinical study, A66 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26137449	AVv-LAMxSS-TIFzzUJDNjax	PIK3CA	A66	"In a preclinical study, A66 delayed tumor growth in human tumor xenograft models harboring PIK3CA H1047R mutations (PMID: 21668414)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21668414	AVv-K9PXSS-TIFzzUI-Tjax	PIK3CA	A66	"In a preclinical study, A66 delayed tumor growth in an ovarian cancer cell line xenograft model harboring PIK3CA H1047R (PMID: 21668414)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21668414	AVv-K86GSS-TIFzzUI9vjax	PIK3CA	A-443654	"In a preclinical study, cells expressing mutant PIK3CA demonstrated increased sensitivity to A-443654 compared to cells expressing wild-type PIK3CA (PMID: 19208828)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19208828	AVv-K-bySS-TIFzzUJAOjax	PIK3CA	A-443654	"In a preclinical study, A-443654 inhibited proliferation of colon cancer cell lines that have been reported to harbor KRAS and PIK3CA mutations in culture (PMID: 24569089, PMID: 24978597)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24978597	AVv-K-oSSS-TIFzzUJAsjax	PIK3CA	A-1210477 + WEHI-539	"In a preclinical study, combination of WEHI-539 and A-1210477 resulted in enhanced apoptosis in PIK3CA wild-type breast cancer cell lines in culture (PMID: 27974663)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-LAD-SS-TIFzzUJC_jax	PDGFRA	Sunitinib	"In a preclinical study, cells expressing PDGFRA D842V demonstrated resistance to inhibition of PDGFRA phosphorylation by Sutent (sunitinib) in culture (PMID: 18955458)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18955458	AVv-K6ijSS-TIFzzUI7qjax	PDGFRA	Sunitinib	"In a preclinical study, Sutent (sunitinib) decreased cell proliferation and inhibited downstream signaling in a NSCLC cell line harboring a PDGFRA amplification (PMID: 19366796)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19366796	AVv-K6UbSS-TIFzzUI7Rjax	PDGFRA	Sunitinib	"In a preclinical study, PDGFRA D842V conferred resistance to inhibition of PDGFRA phosphorylation by Sutent (sunitinib) in cells expressing PDGFRA V561D in culture (PMID: 18955458)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18955458	AVv-K6RBSS-TIFzzUI7Ljax	PDGFRA	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited growth of lung squamous cell cancer cells with PDGFRA amplification in culture (PMID: 22328973)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22328973	AVv-K6T5SS-TIFzzUI7Qjax	PDGFRA	Nilotinib	"In a preclinical study, transformed cells expressing PDGFRA D842V demonstrated resistance to growth inhibition by Tasigna (nilotinib) in culture (PMID: 18794084)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18794084	AVv-K6hcSS-TIFzzUI7ojax	PDGFRA	N/A	"PDGFRA mutations are used in the diagnosis of gastrointestinal stromal tumors (PMID: 26276366, PMID: 25729899)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/25729899	AVv-K6kSSS-TIFzzUI7tjax	PDGFRA	Imatinib	"In a preclinical study, transformed mouse myeloid cells over expressing PDGFRA N659S demonstrated reduced sensitivity to Gleevec (imatinib) in culture (PMID: 21224473)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/21224473	AVv-K6P3SS-TIFzzUI7Jjax	PDGFRA	Imatinib	"In a preclinical study, transformed cells over expressing PDGFRA R841_D842delinsKI were resistant to inhibition of Pdgfra phosphorylation by Gleevec (imatinib) in culture (PMID: 21224473)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21224473	AVv-K6dcSS-TIFzzUI7hjax	PDGFRA	Imatinib	"In a preclinical study, transformed cells over expressing PDGFRA D842_I843delinsIM were resistant to inhibition of Pdgfra phosphorylation by Gleevec (imatinib) in culture (PMID: 21224473)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21224473	AVv-K6c1SS-TIFzzUI7gjax	PDGFRA	Imatinib	"In a preclinical study, mice injected with transformed cells harboring PDGFRA H650Q developed leukemia-like disease that is sensitive to Gleevec (imatinib) (PMID: 21224473)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21224473	AVv-K6kySS-TIFzzUI7ujax	PDGFRA	Imatinib	"In a preclinical study, expression of PDGFRA D842V conferred resistance to Gleevec (imatinib) in cell culture (PMID: 15928335)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/15928335	AVv-K6gOSS-TIFzzUI7mjax	PDGFRA	Imatinib	"In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA V658A in culture (PMID: 24132921)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24132921	AVv-K6XWSS-TIFzzUI7Wjax	PDGFRA	Imatinib	"In a preclinical study, cells expressing PDGFRA V561D demonstrated sensitivity to Gleevec (imatinib) in cell culture (PMID: 15928335)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/15928335	AVv-K6QZSS-TIFzzUI7Kjax	PDGFRA	Imatinib	"In a preclinical study, a malignant peripheral nerve sheath tumor cell line harboring a PDGFRA amplification demonstrated cell growth inhibition when treated with Gleevec (imatinib) (PMID: 16357008)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/16357008	AVv-K6WQSS-TIFzzUI7Ujax	PDGFRA	Imatinib	"In a preclinical study, Gleevec (imatinib) inhibited growth of transformed mouse myeloid cells over expressing PDGFRA Y849S in culture (PMID: 21224473)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21224473	AVv-K6OySS-TIFzzUI7Hjax	PDGFRA	Imatinib	"In a preclinical study, Gleevec (imatinib) inhibited growth of transformed mouse myeloid cells over expressing PDGFRA R748G in culture and prolonged survival in xenograft models (PMID: 21224473)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21224473	AVv-K6aDSS-TIFzzUI7bjax	PDGFRA	Imatinib	"In a preclinical study, Gleevec (imatinib) inhibited growth of lung squamous cell cancer cells with PDGFRA amplification in culture (PMID: 22328973)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22328973	AVv-K6VDSS-TIFzzUI7Sjax	PDGFRA	Imatinib	"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation in transformed cells over expressing PDGFRA V561_I562insER in culture (PMID: 21224473)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21224473	AVv-K6WySS-TIFzzUI7Vjax	PDGFRA	Imatinib	"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation in transformed cells over expressing PDGFRA S566_E571delinsR in culture (PMID: 21224473)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21224473	AVv-K6eFSS-TIFzzUI7ijax	PDGFRA	Imatinib	"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation in transformed cells over expressing PDGFRA H845_N848delinsP in culture (PMID: 21224473)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21224473	AVv-K6ZjSS-TIFzzUI7ajax	PDGFRA	Imatinib	"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation in cells expressing PDGFRA H845Y in culture (PMID: 24132921)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24132921	AVv-K6ZBSS-TIFzzUI7Zjax	PDGFRA	Imatinib	"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA G853D in culture (PMID: 24132921)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24132921	AVv-K6n2SS-TIFzzUI7zjax	PDGFRA	Imatinib	"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA D842Y in culture (PMID: 24132921)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24132921	AVv-K6brSS-TIFzzUI7ejax	PDGFRA	Imatinib	"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA R841K in culture (PMID: 24132921)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24132921	AVv-K6fHSS-TIFzzUI7kjax	PDGFRA	Imatinib	"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA P577S in culture (PMID: 24132921)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24132921	AVv-K6SGSS-TIFzzUI7Njax	PDGFRA	Imatinib	"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and cell proliferation in transformed cells over expressing PDGFRA Y849S in culture (PMID: 21224473)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21224473	AVv-K6OMSS-TIFzzUI7Gjax	PDGFRA	Imatinib	"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and cell proliferation in transformed cells over expressing PDGFRA D846Y in culture (PMID: 21224473)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21224473	AVv-K6PVSS-TIFzzUI7Ijax	PDGFRA	Imatinib	"In a preclinical study, Gleevec (imatinib) decreased phosphorylation of Pdgfra in cell lines expressing PDGFRA I843del mutation in culture (PMID: 14645423)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/14645423	AVv-K6mrSS-TIFzzUI7xjax	PDGFRA	Imatinib	"In a preclinical study, Gleevec (imatinib) decreased Pdgfra phosphorylation in cells expressing PDGFRA N659K in culture (PMID: 22745105)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22745105	AVv-K6jtSS-TIFzzUI7sjax	PDGFRA	Imatinib	"In a Phase I retrospective study, treatment with Gleevec (imatinib) demonstrated a prolonged response in a patient with a gastrointestinal stromal tumor harboring a PDGFRA L221F mutation (PMID: 22718859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22718859	AVv-K6cLSS-TIFzzUI7fjax	PDGFRA	Gefitinib + Imatinib	"In a preclinical study, Gleevec (imatinib) and Iressa (gefitinib) acted synergistically to decrease downstream signaling activity and inhibit cell growth of glioblastoma cell lines with EGFR and PDGFRA coamplification (PMID: 22323597)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22323597	AVv-K6SrSS-TIFzzUI7Ojax	PDGFRA	Dasatinib	"In a preclinical study, Sprycel (dasatinib) inhibited growth of a lung squamous cell cancer (SCC) cell line with amplification of PDGFRA in culture, and inhibited tumor growth in PDGFRA-amplified lung SCC xenograft models (PMID: 22328973)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22328973	AVv-K6VrSS-TIFzzUI7Tjax	PDGFRA	Crenolanib	"In a preclinical study, crenolanib inhibited Pdgfra phosphorylation in cells expressing PDGFRA H845Y in culture (PMID: 24132921)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24132921	AVv-K6YfSS-TIFzzUI7Yjax	PDGFRA	Crenolanib	"In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA G853D in culture (PMID: 24132921)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24132921	AVv-K6nSSS-TIFzzUI7yjax	PDGFRA	Crenolanib	"In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA V658A in culture (PMID: 24132921)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24132921	AVv-K6X9SS-TIFzzUI7Xjax	PDGFRA	Crenolanib	"In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA R841K in culture (PMID: 24132921)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24132921	AVv-K6elSS-TIFzzUI7jjax	PDGFRA	Crenolanib	"In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA P577S in culture (PMID: 24132921)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24132921	AVv-K6RnSS-TIFzzUI7Mjax	PDGFRA	Crenolanib	"In a preclinical study, crenolanib decreased Pdgfra phosphorylation in cells expressing PDGFRA N659K in culture (PMID: 22745105)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22745105	AVv-K6jKSS-TIFzzUI7rjax	PDGFRA	Crenolanib	"In a preclinical study, Crenolanib inhibited Pdgfra phosphorylation and proliferation of transformed cells expressing PDGFRA D842V in culture (PMID: 22745105)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22745105	AVv-K6iASS-TIFzzUI7pjax	PDGFRA	Crenolanib	"In a preclinical study, Crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA D842Y in culture (PMID: 24132921)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24132921	AVv-K6bJSS-TIFzzUI7djax	PDGFRA	AZD2014	"In a Phase I trial, AZD2014 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a patient with pancreatic cancer harboring a PDGFRA activating mutation (PMID: 25805799)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25805799	AVv-K6laSS-TIFzzUI7vjax	NRAS	XL888	"In a preclinical study, treatment with XL888 resulted in increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant melanoma cells harboring BRAF V600E along with NRAS Q61K in cell culture (PMID: 22351686)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22351686	AVv-K5eTSS-TIFzzUI6Fjax	NRAS	WZ4002	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to WZ4002 after the emergence of NRAS Q61K in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-K5mPSS-TIFzzUI6Sjax	NRAS	Vemurafenib	"In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-K5UeSS-TIFzzUI52jax	NRAS	Vemurafenib	"In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-K5y3SS-TIFzzUI6zjax	NRAS	Vemurafenib	"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5QLSS-TIFzzUI5ujax	NRAS	Vemurafenib	"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5L4SS-TIFzzUI5mjax	NRAS	Vemurafenib	"In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5HYSS-TIFzzUI5ejax	NRAS	Vemurafenib	"In a preclinical study, human melanoma cells harboring NRAS Q61L were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K5vsSS-TIFzzUI6tjax	NRAS	Vemurafenib	"In a preclinical study, human melanoma cells harboring NRAS G13D were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K5sYSS-TIFzzUI6njax	NRAS	Vemurafenib	"In a preclinical study, human melanoma cells harboring BRAF G469R and NRAS G61K were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K5phSS-TIFzzUI6ijax	NRAS	Vemurafenib	"In a preclinical study, human melanoma cell lines harboring a mutation in NRAS were resistant to Zelboraf (vemurafenib) mediated growth inhibition in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K4eySS-TIFzzUI4Zjax	NRAS	Vemurafenib	"In a preclinical study, human melanoma cell lines harboring NRAS Q61K were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K5clSS-TIFzzUI6Djax	NRAS	Vemurafenib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5SYSS-TIFzzUI5yjax	NRAS	Vemurafenib	"In a preclinical study, expression of NRAS G12V in melanoma cells harboring BRAF V600E conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 26267534)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-K4XpSS-TIFzzUI4Njax	NRAS	Vemurafenib	"In a preclinical study, a NRAS Q61K mutation conferred resistance to Zelboraf (vemurafenib) in melanoma cells harboring BRAF V600E in culture (PMID: 21107323)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21107323	AVv-K5gcSS-TIFzzUI6Ijax	NRAS	Vemurafenib	"In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to Zelboraf (vemurafenib) in culture (PMID: 27523909)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-K5AHSS-TIFzzUI5Rjax	NRAS	Vemurafenib	"In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, MAP2K1 V60E, NRAS T58I, and NRAS Q61R, after 18 weeks of treatment with Zelboraf (vemurafenib) (PMID: 24265153)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-K556SS-TIFzzUI6_jax	NRAS	Vemurafenib	"In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, BRAF amplification and NRAS Q61K, during treatment with Zelboraf (vemurafenib) (PMID: 24265153)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-K5khSS-TIFzzUI6Pjax	NRAS	Tubastatin A	"In a preclinical study, Tubastatin A inhibited proliferation of NRAS mutant melanoma cell lines in culture (PMID: 25957812)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25957812	AVv-K4y3SS-TIFzzUI47jax	NRAS	Trametinib + Dabrafenib	"In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5e9SS-TIFzzUI6Gjax	NRAS	Trametinib + Dabrafenib	"In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cells harboring BRAF V600E and NRAS A146T and NRAS Q61K in culture (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5NZSS-TIFzzUI5pjax	NRAS	Trametinib + Dabrafenib	"In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5H4SS-TIFzzUI5fjax	NRAS	Trametinib + Dabrafenib	"In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5ixSS-TIFzzUI6Mjax	NRAS	Trametinib	"In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were 3-7 fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600K in culture (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5hASS-TIFzzUI6Jjax	NRAS	Trametinib	"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5PpSS-TIFzzUI5tjax	NRAS	Trametinib	"In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were >10-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5FsSS-TIFzzUI5bjax	NRAS	Trametinib	"In a preclinical study, human urinary tract transitional cell carcinoma cells harboring mutant NRAS were moderately sensitive to Mekinist (trametinib) growth inhibition in culture (PMID: 26343583)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K4dZSS-TIFzzUI4Xjax	NRAS	Trametinib	"In a preclinical study, human sarcoma cells harboring mutant NRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K4npSS-TIFzzUI4ojax	NRAS	Trametinib	"In a preclinical study, human non-Hodgkin lymphoma cells harboring mutant NRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K4fcSS-TIFzzUI4ajax	NRAS	Trametinib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5RzSS-TIFzzUI5xjax	NRAS	Trametinib	"In a preclinical study, human lung adenocarcinoma cell lines harboring mutant NRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K4p6SS-TIFzzUI4sjax	NRAS	Trametinib	"In a preclinical study, human liver cancer cells harboring mutant NRAS and mutant CTNNB1 were insensitive to Mekinist (trametinib) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K4cxSS-TIFzzUI4Wjax	NRAS	Trametinib	"In a preclinical study, human acute lymphoblastic leukemia cells harboring NRAS and CDKN2A mutations were insensitive to Mekinist (trametinib) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K58QSS-TIFzzUI7Djax	NRAS	Trametinib	"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in NRAS mutated melanoma cell lines resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27500726	AVv-K43KSS-TIFzzUI5Cjax	NRAS	Trametinib	"In a preclinical study, an NRAS wild-type melanoma cell line demonstrated inhibition of cell growth when treated with Mekinist (trametinib) in culture (PMID: 27488531)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27488531	AVv-K5BPSS-TIFzzUI5Tjax	NRAS	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of ovarian cancer cells harboring mutant NRAS in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K4pVSS-TIFzzUI4rjax	NRAS	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of liver cancer cell lines harboring mutant NRAS in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K4vySS-TIFzzUI42jax	NRAS	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of human multiple myeloma cells harboring mutant NRAS in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K4uoSS-TIFzzUI40jax	NRAS	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of human lymphoma cells harboring mutant NRAS in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K4taSS-TIFzzUI4yjax	NRAS	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of human central nervous system cancer cells harboring mutant NRAS in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K4xhSS-TIFzzUI45jax	NRAS	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of human autonomic ganglia cancer cells harboring mutant NRAS in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K4vNSS-TIFzzUI41jax	NRAS	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of human acute myeloid leukemia cell lines harboring mutant NRAS in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K4mkSS-TIFzzUI4mjax	NRAS	TAK-733	"In a preclinical study, colorectal cancer cell lines harboring mutations in KRAS or NRAS and with wild-type PIK3CA demonstrated a trend toward increased sensitivity to TAK-733 in culture (PMID: 26439693)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26439693	AVv-K442SS-TIFzzUI5Fjax	NRAS	TAK-632	"In a preclinical study, TAK-632 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-K5T9SS-TIFzzUI51jax	NRAS	TAK-632	"In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-K5yVSS-TIFzzUI6yjax	NRAS	TAK-632	"In a preclinical study, TAK-632 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-K5ArSS-TIFzzUI5Sjax	NRAS	Selumetinib	"In a preclinical study, human melanoma cells harboring BRAF K601E, BRAF A665V, and NRAS R167L were insensitive to Selumetinib (AZD6244) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K54cSS-TIFzzUI69jax	NRAS	Selumetinib	"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS in culture (PMID: 25870145)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-K46oSS-TIFzzUI5Ijax	NRAS	Selumetinib	"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K in culture (PMID: 25870145)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-K5mwSS-TIFzzUI6Tjax	NRAS	Selumetinib	"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R in culture (PMID: 25870145)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-K4WdSS-TIFzzUI4Ljax	NRAS	Selumetinib	"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K in culture (PMID: 25870145)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-K56bSS-TIFzzUI7Ajax	NRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) modestly inhibited proliferation of human melanoma cells harboring NRAS Q61L in culture (PMID: 26343583)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K5w1SS-TIFzzUI6vjax	NRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) modestly inhibited proliferation of human melanoma cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K5o9SS-TIFzzUI6hjax	NRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) inhibited proliferation of human melanoma cells harboring NRAS G13D in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K5tfSS-TIFzzUI6pjax	NRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) inhibited proliferation of human melanoma cell lines harboring NRAS Q61K in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K5Z8SS-TIFzzUI5_jax	NRAS	Selumetinib	"In a Phase I study, selumetinib demonstrated an increase in iodine uptake and retention in a subgroup of patients with thyroid cancer that was refractory to radioiodine; including patients with BRAF and NRAS mutations disease (PMID: 23406027)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23406027	AVv-K4oySS-TIFzzUI4qjax	NRAS	SHP099	"In a preclinical study, hematopoietic cancer cell lines harboring NRAS mutations demonstrated resistance to SHP099 in cell culture (PMID: 27362227)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/27362227	AVv-K4hVSS-TIFzzUI4djax	NRAS	SBI-0640756	"In a preclinical study, SBI-0640756 inhibited proliferation and transformation of human melanoma cell lines harboring NRAS mutation in culture (PMID: 26603897)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26603897	AVv-K4qfSS-TIFzzUI4tjax	NRAS	SBI-0640756	"In a preclinical study, SBI-0640726 delayed tumor growth of melanomas in mice with a genetic background of NRAS Q61K and CDKN2A loss (PMID: 26603897)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26603897	AVv-K5lwSS-TIFzzUI6Rjax	NRAS	SBI-0640726	"In a preclinical study, SBI-0640726 inhibited proliferation and transformation of human melanoma cell lines harboring NRAS mutation in culture (PMID: 26603897)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26603897	AVv-K41XSS-TIFzzUI4_jax	NRAS	S63845 + Trametinib	"In a preclinical study, combination of S63845 and Mekinist (trametinib) resulted in potent cytotoxic effects in NRAS-mutated melanoma cells in culture compared to the cytostatic effect of Mekinist (trametinib) alone (PMID: 27760111)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27760111	AVv-K42jSS-TIFzzUI5Bjax	NRAS	Regorafenib	"In a preclinical study, colorectal cancer cell lines with wild-type BRAF, KRAS, NRAS and PIK3CA were resistant to Stivarga (regorafenib) in culture (PMID: 25838391)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-K48aSS-TIFzzUI5Ljax	NRAS	Pimasertib + Sorafenib	"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-K5YJSS-TIFzzUI59jax	NRAS	Pimasertib + Regorafenib	"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-K5XnSS-TIFzzUI58jax	NRAS	Pimasertib	"In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-K5a5SS-TIFzzUI6Ajax	NRAS	Panitumumab	"In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with RAS wild-type colorectal cancer compared to FOLFIRI treatment alone (PMID: 26341920)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26341920	AVv-K5DhSS-TIFzzUI5Xjax	NRAS	Palbociclib + Trametinib	"In a preclinical study, the combination of Ibrance (palbociclib) and Mekinist (trametinib) induced tumor regression in a mouse melanoma model expressing NRAS Q61K and harboring CDKN2A loss (PMID: 22983396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22983396	AVv-K5lLSS-TIFzzUI6Qjax	NRAS	Palbociclib + Trametinib	"In a preclinical study, an NRAS wild-type melanoma cell line demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27488531	AVv-K5C_SS-TIFzzUI5Wjax	NRAS	Palbociclib	"In a preclinical study, NRAS wild-type melanoma cells demonstrated decreased cell viability when treated with Ibrance (palbociclib) in culture (PMID: 27488531)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27488531	AVv-K5EESS-TIFzzUI5Yjax	NRAS	Palbociclib	"In a preclinical study, Ibrance (palbociclib) treatment resulted in stable tumor growth in melanoma cell line xenograft models harboring an NRAS mutation, however, growth later ensued and thus, demonstrated a lack of benefit (PMID: 27488531)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27488531	AVv-K4gISS-TIFzzUI4bjax	NRAS	PLX7904	"In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61L demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-K5WDSS-TIFzzUI55jax	NRAS	PLX7904	"In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-K5xzSS-TIFzzUI6xjax	NRAS	PLX7904	"In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to PLX7904 in culture (PMID: 27523909)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-K4-MSS-TIFzzUI5Ojax	NRAS	PLX4720	"In a preclinical study, PLX4720 did not inhibit growth of melanoma cells harboring NRAS Q61L in culture or in cell line xenograft models (PMID: 25500121, PMID: 23431193)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25500121	AVv-K5uASS-TIFzzUI6qjax	NRAS	PF-05212384	"In a preclinical study, human non-small cell lung cancer cells harboring NRAS Q61K had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073, PMID: 12068308)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-K5XGSS-TIFzzUI57jax	NRAS	PD-0325901 + Palbociclib	"In a preclinical study, the combination treatment of PD-0325901 and Ibrance (palbociclib) resulted in tumor regression in 33% (2/6) of melanoma xenograft models harboring an NRAS mutation (PMID: 27488531)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27488531	AVv-K4rpSS-TIFzzUI4vjax	NRAS	PD-0325901	"In a preclinical study, PD-0325901 treatment resulted in stable tumor growth in melanoma cell line xenograft models harboring an NRAS mutation, however, growth later ensued and thus, demonstrates a lack of benefit (PMID: 27488531)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27488531	AVv-K4oQSS-TIFzzUI4pjax	NRAS	Obatoclax	"In a preclinical study, obatoclax decreased proliferation in human tumor cell lines with NRAS mutation in culture (PMID: 22460902)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22460902	AVv-K4rESS-TIFzzUI4ujax	NRAS	NS1	"In a preclinical study, transformed cells expressing an NRAS mutation did not respond to treatment with NS1 in culture, resulting in sustained downstream signaling and cell transformation (PMID: 27820802)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27820802	AVv-K4w9SS-TIFzzUI44jax	NRAS	MK2206	"In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with  PI3K/AKT pathway alterations in culture, including an anaplastic thyroid cancer cell line harboring NRAS Q61R (PMID: 21289267)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21289267	AVv-K59VSS-TIFzzUI7Fjax	NRAS	MK-1775	"In a preclinical study, MK-1775 showed efficacy in NRAS mutant melanoma and in mutant KRAS colorectal, pancreatic, and lung cancers (PMID: 24791855)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24791855	AVv-K4eKSS-TIFzzUI4Yjax	NRAS	MEK162	"In a preclinical study, Binimetinib (MEK162) inhibited growth of acute myeloid leukemia cells that have been demonstrated to harbor NRAS G12D in culture and decreased disease burden in xenograft models with NRAS G12D (PMID: 24569456, PMID: 11238126)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24569456	AVv-K51JSS-TIFzzUI63jax	NRAS	MEK162	"In a Phase III trial, Binimetinib (MEK162) treatment resulted in improved median progression free survival (2.8 vs 1.5 months) compared to Deticene (dacarbazine) in melanoma patients harboring NRAS mutations (PMID: 28284557)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28284557	AVv-K40ESS-TIFzzUI49jax	NRAS	MEK162	"In a Phase II trial, 20% (6/30) of melanoma patients with NRAS mutations had a partial response to the MEK1/2 inhibitor binimetinib (MEK162) (PMID: 23414587)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23414587	AVv-K40sSS-TIFzzUI4-jax	NRAS	MEK162	"In a Phase I trial, Binimetinib (MEK162) treatment resulted in partial response in a biliary tract cancer patient harboring NRAS mutation (PMID: 28152546)"	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28152546	AVv-K4kYSS-TIFzzUI4ijax	NRAS	Lenvatinib	"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 83% (5/6) of melanoma patients harboring NRAS mutations and wild-type BRAF (PMID: 26169970)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26169970	AVv-K43tSS-TIFzzUI5Djax	NRAS	Lenvatinib	"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 50% (1/2) of melanoma patients harboring both BRAF and NRAS mutations (PMID: 26169970)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26169970	AVv-K4cNSS-TIFzzUI4Vjax	NRAS	Lenvatinib	"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 44% (4/9) and partial response in 22% (2/9) of melanoma patients carrying wild-type BRAF and NRAS (PMID: 26169970)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26169970	AVv-K49kSS-TIFzzUI5Njax	NRAS	Lenvatinib	"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 100% (5/5) of melanoma patients harboring BRAF mutations and wild-type NRAS (PMID: 26169970)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26169970	AVv-K47JSS-TIFzzUI5Jjax	NRAS	LY3009120	"In a preclinical study, LY3009120 modestly inhibited soft agar growth of human melanoma cancer cells harboring NRAS R167L, BRAF K601E, and BRAF A665V in culture (PMID: 26343583)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K55USS-TIFzzUI6-jax	NRAS	LY3009120	"In a preclinical study, LY3009120 modestly inhibited soft agar growth of human melanoma cancer cells harboring NRAS Q61L in culture (PMID: 26343583)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K5vISS-TIFzzUI6sjax	NRAS	LY3009120	"In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring NRAS Q61K in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K5bkSS-TIFzzUI6Cjax	NRAS	LY3009120	"In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring NRAS G13D in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K5rzSS-TIFzzUI6mjax	NRAS	LY3009120	"In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K5qHSS-TIFzzUI6jjax	NRAS	LY3009120	"In a preclinical study, LY3009120 inhibited proliferation of human NRAS mutant acute myeloid leukemia cell lines in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K4sxSS-TIFzzUI4xjax	NRAS	LY3009120	"In a preclinical study, LY3009120 inhibited growth of NRAS mutant human melanoma cell lines in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-K4nFSS-TIFzzUI4njax	NRAS	LY2835219	"In a Phase I study, Abemaciclib (LY2835219) resulted in a partial response in a melanoma patient with CDKN2A loss and NRAS mutation (PMID: 27217383)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27217383	AVv-K44RSS-TIFzzUI5Ejax	NRAS	Gefitinib	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of NRAS E63K in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-K57ESS-TIFzzUI7Bjax	NRAS	GSK2126458 + Trametinib	"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5jWSS-TIFzzUI6Njax	NRAS	GSK2126458 + Trametinib	"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5GMSS-TIFzzUI5cjax	NRAS	GSK2126458	"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5O8SS-TIFzzUI5sjax	NRAS	GSK2126458	"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5M6SS-TIFzzUI5ojax	NRAS	GSK2126458	"In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5FLSS-TIFzzUI5ajax	NRAS	GSK2126458	"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5ROSS-TIFzzUI5wjax	NRAS	GSK2126458	"In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600K in culture (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5j-SS-TIFzzUI6Ojax	NRAS	GDC0879	"In a preclinical study, colon cancer cells harboring NRAS mutations were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-K4j2SS-TIFzzUI4hjax	NRAS	GDC0879	"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type melanoma cells harboring NRAS Q61K in patient-derived xenograft models (PMID: 19276360)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-K5WlSS-TIFzzUI56jax	NRAS	Everolimus + Pimasertib	"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-K5Y4SS-TIFzzUI5-jax	NRAS	E6201	"In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with wild-type NRAS (PMID: 23039341)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23039341	AVv-K5CbSS-TIFzzUI5Vjax	NRAS	Dabrafenib + GSK2126458	"In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5IZSS-TIFzzUI5gjax	NRAS	Dabrafenib + GSK2126458	"In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) did not improve the response to human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture (PMID: 22389471)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5MZSS-TIFzzUI5njax	NRAS	Dabrafenib + GSK2126458	"In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5iISS-TIFzzUI6Ljax	NRAS	Dabrafenib	"In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-K5VgSS-TIFzzUI54jax	NRAS	Dabrafenib	"In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-K5xTSS-TIFzzUI6wjax	NRAS	Dabrafenib	"In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5hkSS-TIFzzUI6Kjax	NRAS	Dabrafenib	"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5N8SS-TIFzzUI5qjax	NRAS	Dabrafenib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5QrSS-TIFzzUI5vjax	NRAS	Dabrafenib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5KISS-TIFzzUI5jjax	NRAS	Dabrafenib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing NRAS Q61K were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5fuSS-TIFzzUI6Hjax	NRAS	Dabrafenib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-K5GySS-TIFzzUI5djax	NRAS	DEL-22379	"In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and over expressing NRAS G12V in culture (PMID: 26267534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-K4YMSS-TIFzzUI4Ojax	NRAS	Cetuximab + Trametinib	"In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring NRAS G12V in culture (PMID: 28179366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28179366	AVv-K4ZXSS-TIFzzUI4Qjax	NRAS	Cetuximab + FOLFIRI	"In a retrospective analysis of a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI did not demonstrate an improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with RAS mutations (PMID: 25605843)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/25605843	AVv-K4gqSS-TIFzzUI4cjax	NRAS	Cetuximab + FOLFIRI	"In a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI demonstrated a significant clinical benefit in OS, PFS, and objective response compared to FOLFIRI alone in colorectal cancer patients with RAS wild-type status (PMID: 25605843)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25605843	AVv-K5BzSS-TIFzzUI5Ujax	NRAS	Cetuximab	"In a preclinical study, colorectal cancer cells harboring NRAS G12V demonstrated resistance to Erbitux (cetuximab) in culture (PMID: 28179366)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28179366	AVv-K4YtSS-TIFzzUI4Pjax	NRAS	Cetuximab	"In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells wild-type for BRAF, KRAS, NRAS and PIK3CA in culture (PMID: 25838391)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-K48_SS-TIFzzUI5Mjax	NRAS	CCT241161	"In a preclinical study, CCT241161 inhibited growth of melanoma cells harboring NRAS mutations in culture (PMID: 25500121)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25500121	AVv-K4ipSS-TIFzzUI4fjax	NRAS	CCT241161	"In a preclinical study, CCT241161 inhibited MEK and ERK activation and growth of a melanoma cell line harboring NRAS Q61L in culture, and inhibited tumor growth in a NRAS Q61L-mutant melanoma cell line xenograft model (PMID: 25500121, PMID: 23431193)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25500121	AVv-K5ulSS-TIFzzUI6rjax	NRAS	CCT196969	"In a preclinical study, CCT196969 inhibited growth of melanoma cells harboring NRAS mutations in culture (PMID: 25500121)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25500121	AVv-K4mDSS-TIFzzUI4ljax	NRAS	CCT196969	"In a preclinical study, CCT196969 inhibited MEK and ERK activation and growth of a melanoma cell line harboring NRAS Q61L in culture, and inhibited tumor growth in a NRAS Q61L-mutant melanoma cell line xenograft model (PMID: 25500121, PMID: 23431193)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25500121	AVv-K5wPSS-TIFzzUI6ujax	NRAS	Binimetinib + BKM120	"In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring an NRAS mutation (PMID: 27307593)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27307593	AVv-K4lhSS-TIFzzUI4kjax	NRAS	BYL719 + MEK162	"In a preclinical study, the combination of Binimetinib (MEK162) and BYL719 inhibited proliferation in a human acute myeloid leukemia (AML) cell line harboring NRAS G12D in culture, and decreased disease burden in xenograft models (PMID: 24569456)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24569456	AVv-K51tSS-TIFzzUI64jax	NRAS	BKM120	"In a preclinical study, Buparlisib (BKM120) treatment in human melanoma cell line xenograft models with brain metastases and harboring an NRAS mutation resulted in inhibition of brain tumor growth and an improved survival benefit (PMID: 27307593)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27307593	AVv-K4yPSS-TIFzzUI46jax	NRAS	BI-847325	"In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to an NRAS mutation in culture (PMID: 25873592)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25873592	AVv-K4blSS-TIFzzUI4Ujax	NRAS	BI-69A11	"In a preclinical study, BI-69A11 inhibited proliferation and transformation of human melanoma cell lines harboring NRAS mutation in culture (PMID: 26603897)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26603897	AVv-K4uASS-TIFzzUI4zjax	NRAS	BAY1125976	"In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring AKT E17K and NRAS G12D in culture, and demonstrated antitumor activity in xenograft models (PMID: 27699769)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27699769	AVv-K50GSS-TIFzzUI61jax	NRAS	Afatinib	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified NRAS in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-K45bSS-TIFzzUI5Gjax	NRAS	AZD9291	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-K5dSSS-TIFzzUI6Ejax	NRAS	AZD9291	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-K46CSS-TIFzzUI5Hjax	NRAS	AZD9291	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-K5niSS-TIFzzUI6fjax	NRAS	AZD9291	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12V were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-K4Z5SS-TIFzzUI4Rjax	NRAS	AZD9291	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-K4XGSS-TIFzzUI4Mjax	NRAS	AZD9291	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K were resistant to Tagrisso (osimertinib) AZD9291 treatment in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-K57pSS-TIFzzUI7Cjax	NRAS	AZD9291	"In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-K5ocSS-TIFzzUI6gjax	NRAS	AZD5153	"In a preclinical study, AZD5153 inhibited proliferation of acute myeloid leukemia cells harboring NRAS mutation in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27573426)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27573426	AVv-K4k_SS-TIFzzUI4jjax	NRAS	AZ628	"In a preclinical study, AZ628 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-K5U9SS-TIFzzUI53jax	NRAS	AZ628	"In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-K5zbSS-TIFzzUI60jax	NRAS	AZ628	"In a preclinical study, AZ628 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-K4_bSS-TIFzzUI5Qjax	NRAS	3144	"In a preclinical study, 3144 inhibited growth of patient-derived T-cell acute lymphocytic leukemia cells harboring NRAS G13V in culture, and reduced tumor burden in xenograft models (PMID: 28235199)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28235199	AVv-K5ElSS-TIFzzUI5Zjax	NRAS	3144	"In a preclinical study, 3144 inhibited growth of patient-derived T-cell acute lymphocytic leukemia cells harboring NRAS G13D in culture (PMID: 28235199)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28235199	AVv-K5s7SS-TIFzzUI6ojax	NPM1	TAE684	"In a preclinical study, TAE684 inhibited proliferation of transformed cells expressing NPM1-ALK in culture (PMID: 20207848)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20207848	AVv-K27pSS-TIFzzUI2Tjax	NPM1	PF-06463922	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3kySS-TIFzzUI3jjax	NPM1	PF-06463922	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3fWSS-TIFzzUI3ajax	NPM1	PF-06463922	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3cESS-TIFzzUI3Vjax	NPM1	PF-06463922	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3yKSS-TIFzzUI35jax	NPM1	PF-06463922	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3N4SS-TIFzzUI28jax	NPM1	PF-06463922	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3vzSS-TIFzzUI31jax	NPM1	PF-06463922	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K2dnSS-TIFzzUI1gjax	NPM1	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3pqSS-TIFzzUI3rjax	NPM1	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K2_NSS-TIFzzUI2Zjax	NPM1	NSC348884	"In a preclinical study, acute myeloid leukemia cells harboring a NPM1 mutation were sensitive to NSC348884 as demonstrated by induced apoptosis (PMID: 21719597)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21719597	AVv-K36ZSS-TIFzzUI4Hjax	NPM1	N/A	"In clinical analyses, mutations in NPM1 were associated with favorable prognosis in acute myeloid leukemia patients with normal karyotype in the absence of a FLT3 ITD mutation (PMID: 26239249, PMID: 26586702, PMID: 26676635, PMID: 16109776)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/26239249	AVv-K35ySS-TIFzzUI4Gjax	NPM1	ENMD-2076	"In a Phase I trial, two acute myeloid leukemia patients co-harboring a FLT3-ITD mutation and NPM1 mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27406088	AVv-K35NSS-TIFzzUI4Fjax	NPM1	ENMD-2076	"In a Phase I trial, three acute myeloid leukemia patient harboring an NPM1 mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27406088	AVv-K37DSS-TIFzzUI4Ijax	NPM1	Deguelin	"In preclinical studies, deguelin treatment of an AML cell line harboring NPM1 exon12 mutation resulted in reduced levels of mutant Npm1 protein and induced differentiation of the cells (PMID: 25242579, PMID: 25348016)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25242579	AVv-K37qSS-TIFzzUI4Jjax	NPM1	Crizotinib	"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3HoSS-TIFzzUI2njax	NPM1	Crizotinib	"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1198F in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K2tVSS-TIFzzUI17jax	NPM1	Crizotinib	"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3FPSS-TIFzzUI2jjax	NPM1	Crizotinib	"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K2nFSS-TIFzzUI1wjax	NPM1	Crizotinib	"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3WXSS-TIFzzUI3Ljax	NPM1	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K3J5SS-TIFzzUI2rjax	NPM1	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Xalkori (Crizotinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2hoSS-TIFzzUI1njax	NPM1	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K32RSS-TIFzzUI4Ajax	NPM1	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K241SS-TIFzzUI2Ojax	NPM1	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Xalkori (critzotinb) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3jnSS-TIFzzUI3hjax	NPM1	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2qcSS-TIFzzUI12jax	NPM1	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Xalkori (critzotinb) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3ddSS-TIFzzUI3Xjax	NPM1	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K22SSS-TIFzzUI2Kjax	NPM1	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Xalkori (critzotinb) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3xlSS-TIFzzUI34jax	NPM1	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2yqSS-TIFzzUI2Ejax	NPM1	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Xalkori (critzotinb) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K2esSS-TIFzzUI1ijax	NPM1	Crizotinib	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK R1192P were resistant to Xalkori (crizotinib) in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2hHSS-TIFzzUI1mjax	NPM1	Crizotinib	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1161S were resistant to Xalkori (crizotinib) in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2p5SS-TIFzzUI11jax	NPM1	Crizotinib	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK G1269A were resistant to Xalkori (crizotinib) in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K21JSS-TIFzzUI2Ijax	NPM1	Crizotinib	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing ALK L1196Q were resistant to Xalkori (crizotinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K2kpSS-TIFzzUI1sjax	NPM1	Crizotinib	"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K2awSS-TIFzzUI1bjax	NPM1	Crizotinib	"In a preclinical study, an anaplastic large-cell lymphoma cell line expressing NPM-ALK I1171T demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 24509625)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24509625	AVv-K3ibSS-TIFzzUI3fjax	NPM1	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3nzSS-TIFzzUI3ojax	NPM1	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3pDSS-TIFzzUI3qjax	NPM1	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK E1210K in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3QpSS-TIFzzUI3Bjax	NPM1	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK C1156F in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3ugSS-TIFzzUI3zjax	NPM1	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K28OSS-TIFzzUI2Ujax	NPM1	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK ALK S1206C to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3YTSS-TIFzzUI3Ojax	NPM1	Ceritinib	"In a preclinical trial, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3ECSS-TIFzzUI2hjax	NPM1	Ceritinib	"In a preclinical trial, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K2oOSS-TIFzzUI1yjax	NPM1	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with E1210K were resistant to Zykadia (ceritinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3QFSS-TIFzzUI3Ajax	NPM1	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with C1156F and D1203N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K2f4SS-TIFzzUI1kjax	NPM1	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K3KcSS-TIFzzUI2sjax	NPM1	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2j-SS-TIFzzUI1rjax	NPM1	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Zykadia (ceritinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3lXSS-TIFzzUI3kjax	NPM1	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K2t_SS-TIFzzUI18jax	NPM1	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3RvSS-TIFzzUI3Djax	NPM1	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Zykadia (ceritinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3jBSS-TIFzzUI3gjax	NPM1	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2rASS-TIFzzUI13jax	NPM1	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3bUSS-TIFzzUI3Tjax	NPM1	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K227SS-TIFzzUI2Ljax	NPM1	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Zykadia (ceritinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3zVSS-TIFzzUI37jax	NPM1	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3UASS-TIFzzUI3Hjax	NPM1	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2vySS-TIFzzUI1_jax	NPM1	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Zykadia (ceritinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3wcSS-TIFzzUI32jax	NPM1	Ceritinib	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K3LxSS-TIFzzUI25jax	NPM1	Ceritinib	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174L were resistant to Zykadia (ceritinib) in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2xhSS-TIFzzUI2Cjax	NPM1	Ceritinib	"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K2bbSS-TIFzzUI1cjax	NPM1	Ceritinib	"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK S1206C to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3ZgSS-TIFzzUI3Qjax	NPM1	Ceritinib	"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3IOSS-TIFzzUI2ojax	NPM1	Ceritinib	"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K33_SS-TIFzzUI4Djax	NPM1	Ceritinib	"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3sESS-TIFzzUI3vjax	NPM1	Ceritinib	"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K29bSS-TIFzzUI2Wjax	NPM1	Ceritinib	"In a preclinical study, Zykadia (ceritinib) inhibited growth of an anaplastic large cell lymphoma cell line harboring NPM1-ALK in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3AWSS-TIFzzUI2bjax	NPM1	Alectinib	"In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3FxSS-TIFzzUI2kjax	NPM1	Alectinib	"In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3ErSS-TIFzzUI2ijax	NPM1	Alectinib	"In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K31rSS-TIFzzUI3_jax	NPM1	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K3MrSS-TIFzzUI26jax	NPM1	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206C were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3XuSS-TIFzzUI3Njax	NPM1	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2ivSS-TIFzzUI1pjax	NPM1	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K2sySS-TIFzzUI16jax	NPM1	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3RJSS-TIFzzUI3Cjax	NPM1	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K259SS-TIFzzUI2Qjax	NPM1	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Alecensa (alectinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3hMSS-TIFzzUI3djax	NPM1	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2o1SS-TIFzzUI1zjax	NPM1	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Alecensa (alectinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3auSS-TIFzzUI3Sjax	NPM1	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K23nSS-TIFzzUI2Mjax	NPM1	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Alecensa (alectinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3yySS-TIFzzUI36jax	NPM1	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3UlSS-TIFzzUI3Ijax	NPM1	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2zRSS-TIFzzUI2Fjax	NPM1	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Alecensa (alectinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3NOSS-TIFzzUI27jax	NPM1	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Alecensa (alectinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3t0SS-TIFzzUI3yjax	NPM1	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Alecensa (alectinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K2cfSS-TIFzzUI1ejax	NPM1	Alectinib	"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3nJSS-TIFzzUI3njax	NPM1	Alectinib	"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K2l1SS-TIFzzUI1ujax	NPM1	Alectinib	"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3ocSS-TIFzzUI3pjax	NPM1	Alectinib	"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K2_wSS-TIFzzUI2ajax	NPM1	Alectinib	"In a preclinical study, Alecensa (alectinib) inhibited growth of an anaplastic large cell lymphoma cell line harboring NPM1-ALK in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K2-ESS-TIFzzUI2Xjax	NPM1	AZD3463	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K3K9SS-TIFzzUI2tjax	NPM1	AZD3463	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P had a reduced response to AZD3463 mediated growth inhibition in culture relative to NPM1-ALK (PMID: 27009859)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2gdSS-TIFzzUI1ljax	NPM1	AZD3463	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2wXSS-TIFzzUI2Ajax	NPM1	AZD3463	"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing NPM1-ALK with ALK I1171S in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2roSS-TIFzzUI14jax	NPM1	AZD3463	"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K20jSS-TIFzzUI2Hjax	NPM1	ASP3026	"In a preclinical trial, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K2maSS-TIFzzUI1vjax	NPM1	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K3JUSS-TIFzzUI2qjax	NPM1	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2iMSS-TIFzzUI1ojax	NPM1	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to ASP3026 in culture (PMID: 25749034)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3kLSS-TIFzzUI3ijax	NPM1	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K2vJSS-TIFzzUI1-jax	NPM1	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to ASP3026 treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3S0SS-TIFzzUI3Fjax	NPM1	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K26hSS-TIFzzUI2Rjax	NPM1	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to ASP3026 in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3f8SS-TIFzzUI3bjax	NPM1	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2pXSS-TIFzzUI10jax	NPM1	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to ASP3026 in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3eySS-TIFzzUI3Zjax	NPM1	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to ASP3026 in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3w9SS-TIFzzUI33jax	NPM1	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3VJSS-TIFzzUI3Jjax	NPM1	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2w8SS-TIFzzUI2Bjax	NPM1	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174I were resistant to ASP3026 relative to wild type NPM1-ALK in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3qXSS-TIFzzUI3sjax	NPM1	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to ASP3026 in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3PASS-TIFzzUI2-jax	NPM1	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to ASP3026 in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3vPSS-TIFzzUI30jax	NPM1	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to ASP3026 in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K2dCSS-TIFzzUI1fjax	NPM1	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with  ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3DaSS-TIFzzUI2gjax	NPM1	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK and ALK S1206C were resistant to ASP3026 treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3XDSS-TIFzzUI3Mjax	NPM1	ASP3026	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK F1174I were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3rbSS-TIFzzUI3ujax	NPM1	ASP3026	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK E1210K were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3OaSS-TIFzzUI29jax	NPM1	ASP3026	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK C1156F and D1203N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K2fUSS-TIFzzUI1jjax	NPM1	ASP3026	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK N1178H were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3mmSS-TIFzzUI3mjax	NPM1	ASP3026	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1171T were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3gjSS-TIFzzUI3cjax	NPM1	ASP3026	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1171N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3eJSS-TIFzzUI3Yjax	NPM1	ASP3026	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK G1128S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K30bSS-TIFzzUI39jax	NPM1	ASP3026	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156Y were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K31ISS-TIFzzUI3-jax	NPM1	ASP3026	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156F were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3tQSS-TIFzzUI3xjax	NPM1	ASP3026	"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to ASP3026 treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K2aLSS-TIFzzUI1ajax	NPM1	ASP3026	"In a preclinical study, ASP3026 inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2z7SS-TIFzzUI2Gjax	NPM1	ASP3026	"In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3HDSS-TIFzzUI2mjax	NPM1	ASP3026	"In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K321SS-TIFzzUI4Bjax	NPM1	ASP3026	"In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3BfSS-TIFzzUI2djax	NPM1	ASP3026	"In a preclinical study, ASP3026 inhibited growth of human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing the crizotinib-resistant mutation ALK L1196Q in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K2lLSS-TIFzzUI1tjax	NPM1	ASP3026	"In a preclinical study, ASP3026 inhibited growth of an anaplastic large cell lymphoma cell line harboring NPM1-ALK in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3CFSS-TIFzzUI2ejax	NPM1	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Brigatinib (AP26113) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K3I1SS-TIFzzUI2pjax	NPM1	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206C were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3Y9SS-TIFzzUI3Pjax	NPM1	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Brigatinib (AP26113) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3l_SS-TIFzzUI3ljax	NPM1	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K2unSS-TIFzzUI19jax	NPM1	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K33YSS-TIFzzUI4Cjax	NPM1	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3SPSS-TIFzzUI3Ejax	NPM1	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K24NSS-TIFzzUI2Njax	NPM1	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Brigatinib (AP26113) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3h6SS-TIFzzUI3ejax	NPM1	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Brigatinib (AP26113) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3cxSS-TIFzzUI3Wjax	NPM1	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK1198F were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3TXSS-TIFzzUI3Gjax	NPM1	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Brigatinib (AP26113) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3PhSS-TIFzzUI2_jax	NPM1	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Brigatinib (AP26113) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3spSS-TIFzzUI3wjax	NPM1	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Brigatinib (AP26113) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K2eISS-TIFzzUI1hjax	NPM1	AP26113	"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Brigatinib (AP26113) in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K2b7SS-TIFzzUI1djax	NPM1	AP26113	"In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Brigatinib (AP26113) in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K25WSS-TIFzzUI2Pjax	NPM1	AP26113	"In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Brigatinib (AP26113) in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3VySS-TIFzzUI3Kjax	NPM1	AP26113	"In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK ALK S1206C were resistant to brigatinib (AP26113) in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3aDSS-TIFzzUI3Rjax	NPM1	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK R1192P in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2jYSS-TIFzzUI1qjax	NPM1	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK I1171S in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2sKSS-TIFzzUI15jax	NPM1	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K21sSS-TIFzzUI2Jjax	NPM1	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK F1174L in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-K2yFSS-TIFzzUI2Djax	NPM1	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3CySS-TIFzzUI2fjax	NPM1	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK G1128S in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3z4SS-TIFzzUI38jax	NPM1	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K2nqSS-TIFzzUI1xjax	NPM1	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-K3q6SS-TIFzzUI3tjax	NPM1	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K2-qSS-TIFzzUI2Yjax	NPM1	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK P1139S in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-K3GdSS-TIFzzUI2ljax	NPM1	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited Alk phosphorylation and growth in anaplastic large cell lymphoma cell lines harboring NPM1-ALK in culture, and induced near complete tumor regression in cell line xenograft models (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-K27HSS-TIFzzUI2Sjax	NOTCH1	Ribociclib + Prednisolone	"In a preclinical study, the combination of Ribociclib (LEE011) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-K1qNSS-TIFzzUI0ujax	NOTCH1	Ribociclib + Prednisolone	"In a preclinical study, the combination of Ribociclib (LEE011) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-K1vxSS-TIFzzUI04jax	NOTCH1	Ribociclib + Methotrexate	"In a preclinical study, the addition of Ribociclib (LEE011) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-K1sfSS-TIFzzUI0yjax	NOTCH1	Ribociclib + Methotrexate	"In a preclinical study, the addition of Ribociclib (LEE011) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-K1yRSS-TIFzzUI08jax	NOTCH1	Ribociclib + Mercaptopurine	"In a preclinical study, the addition of Ribociclib (LEE011) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-K1n8SS-TIFzzUI0qjax	NOTCH1	Ribociclib + Mercaptopurine	"In a preclinical study, the addition of Ribociclib (LEE011) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-K1wYSS-TIFzzUI05jax	NOTCH1	Ribociclib + JQ1	"In a preclinical study, the combination of Ribociclib (LEE011) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-K1olSS-TIFzzUI0rjax	NOTCH1	Ribociclib + JQ1	"In a preclinical study, the combination of Ribociclib (LEE011) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-K1w_SS-TIFzzUI06jax	NOTCH1	Ribociclib + Bortezomib	"In a preclinical study, the combination of Ribociclib (LEE011) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-K1quSS-TIFzzUI0vjax	NOTCH1	Ribociclib + Bortezomib	"In a preclinical study, the combination of Ribociclib (LEE011) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-K1y0SS-TIFzzUI09jax	NOTCH1	Ribociclib + Asparaginase	"In a preclinical study, the addition of Ribociclib (LEE011) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-K1prSS-TIFzzUI0tjax	NOTCH1	Ribociclib + Asparaginase	"In a preclinical study, the addition of Ribociclib (LEE011) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-K1z9SS-TIFzzUI0_jax	NOTCH1	PF-03084014	"In a preclinical study, the gamma secretase inhibitor PF-03084014 reduced Notch1 cleavage, decreased activation of Notch targets, and increased apoptosis in colorectal cancer cell lines exhibiting increased Notch activation (PMID: 23868008)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23868008	AVv-K17XSS-TIFzzUI1Ljax	NOTCH1	PF-03084014	"In a preclinical study, PF-03084014 treatment resulted in tumor regression in patient-derived xenograft models of triple receptor negative breast cancer harboring NOTCH1 mutations (PMID: 25564152)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25564152	AVv-K10jSS-TIFzzUI1Ajax	NOTCH1	PF-03084014	"In a preclinical study, PF-03084014 treatment resulted in tumor regression in patient derived xenograft animal models of triple receptor negative breast cancer harboring NOTCH1 S2449fs (PMID: 25564152)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25564152	AVv-K176SS-TIFzzUI1Mjax	NOTCH1	MRK-003 + SCH772984	"In a preclinical study, SCH772984 did not potentiate the growth inhibition effect of MRK-003 in triple receptor-negative breast cancer cells harboring NOTCH1 rearrangement in culture (PMID: 25104330)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/25104330	AVv-K2CzSS-TIFzzUI1Yjax	NOTCH1	MRK-003 + Paclitaxel	"In a preclinical study, the combination of MRK-003 and Taxol (paclitaxel) did not potentiate the anti-tumor effects compared to single agent therapy in triple receptor-negative breast cancer xenograft models harboring wild-type NOTCH1 (PMID: 25104330)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/25104330	AVv-K1muSS-TIFzzUI0ojax	NOTCH1	MRK-003 + Paclitaxel	"In a preclinical study, MRK-003 and Taxol (paclitaxel) worked synergistically to inhibit tumor growth in triple receptor-negative breast cancer xenograft models harboring NOTCH1 rearrangement, resulting in tumor regression (PMID: 25104330)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25104330	AVv-K2CPSS-TIFzzUI1Xjax	NOTCH1	MRK-003	"In a preclinical study, triple receptor-negative breast cancer xenograft models harboring wild-type NOTCH1 demonstrated reduced sensitivity to MRK-003 induced tumor growth inhibition (PMID: 25104330)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25104330	AVv-K1nVSS-TIFzzUI0pjax	NOTCH1	MRK-003	"In a preclinical study, transformed cells expressing NOTCH1 A1707T demonstrated sensitivity to MRK-003 in culture (PMID: 25104330)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25104330	AVv-K13kSS-TIFzzUI1Fjax	NOTCH1	MRK-003	"In a preclinical study, MRK-003 inhibited growth of triple receptor-negative breast cancer cells harboring NOTCH1 rearrangement in culture and reduced tumor growth in xenograft models (PMID: 25104330)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25104330	AVv-K2BtSS-TIFzzUI1Wjax	NOTCH1	MRK-003	"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 V1676I in culture (PMID: 25104330)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25104330	AVv-K15ASS-TIFzzUI1Hjax	NOTCH1	MRK-003	"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 V1599M in culture (PMID: 25104330)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25104330	AVv-K1tlSS-TIFzzUI00jax	NOTCH1	MRK-003	"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 V1575A in culture (PMID: 25104330)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25104330	AVv-K1lWSS-TIFzzUI0mjax	NOTCH1	MRK-003	"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 R1683W in culture (PMID: 25104330)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25104330	AVv-K12XSS-TIFzzUI1Djax	NOTCH1	MRK-003	"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 I1680S in culture (PMID: 25104330)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25104330	AVv-K2BFSS-TIFzzUI1Vjax	NOTCH1	MRK-003	"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 E1567K in culture (PMID: 25104330)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25104330	AVv-K128SS-TIFzzUI1Ejax	NOTCH1	MRK-003	"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1707T in culture (PMID: 25104330)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25104330	AVv-K14TSS-TIFzzUI1Gjax	NOTCH1	MRK-003	"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1570G in culture (PMID: 25104330)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25104330	AVv-K11OSS-TIFzzUI1Bjax	NOTCH1	MRK-003	"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1552V in culture (PMID: 25104330)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25104330	AVv-K1tBSS-TIFzzUI0zjax	NOTCH1	MRK-003	"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1552G in culture (PMID: 25104330)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25104330	AVv-K111SS-TIFzzUI1Cjax	NOTCH1	LGK974	"In a preclinical study, LGK974 inhibited growth of head and neck squamous cell carcinoma cells harboring NOTCH1 C478F in culture and xenograft models (PMID: 24277854)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24277854	AVv-K1uLSS-TIFzzUI01jax	NOTCH1	LEE011	"In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 demonstrated sensitivity to treatment with Ribociclib (LEE011) in culture, resulting in inhibition of cell growth (PMID: 28151717)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-K1pHSS-TIFzzUI0sjax	NOTCH1	LEE011	"In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation demonstrated sensitivity to treatment with Ribociclib (LEE011) in culture, resulting in inhibition of cell growth (PMID: 28151717)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-K1xnSS-TIFzzUI07jax	NOTCH1	LEE011	"In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type NOTCH1 and loss of RB1 demonstrated resistance to Ribociclib (LEE011) in culture, resulting in limited inhibition of cell growth (PMID: 28151717)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28151717	AVv-K1mHSS-TIFzzUI0njax	NOTCH1	Brontictuzumab	"In a preclinical study, xenograft models of patient-derived acute lymphocytic leukemia cells harboring NOTCH1 activating muatations demonstrated better response to Brontictuzumab (OMP-52M51) compared to NOTCH1 wild-type models (PMID: 23774673)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23774673	AVv-K160SS-TIFzzUI1Kjax	MYD88	Vorinostat	"In a preclinical study, a diffuse large B-cell lymphoma cell line harboring MYD88 L256P demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased apoptosis (PMID: 27733371)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27733371	AVv-K07RSS-TIFzzUI0ijax	MYD88	N/A	"MYD88 mutations are used in the diagnosis of lymphoplasmacytic lymphoma (Guidelines, PMID: 22944768)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/26230596	AVv-K05_SS-TIFzzUI0gjax	MYD88	N/A	"In multiple clinical studies, MYD88 L265P was associated with a worse overall survival in patients with diffuse large B-cell lymphoma when compared to MYD88 wild-type (PMID: 24903481, PMID: 25055137, PMID: 26792260)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/26792260	AVv-K074SS-TIFzzUI0jjax	MSH6	Temozolomide	"In a preclinical study, glioblastoma cells harboring a MSH6 T1219I mutation were resistant to Temodar (temozolomide) in cell culture (PMID: 19584161)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19584161	AVv-K0t6SS-TIFzzUI0Pjax	MSH6	N/A	"Germline mutations in MSH6 are associated with microsatellite instability in colorectal cancer (CRC), and are diagnostic for Lynch syndrome (hereditary nonpolyposis colorectal cancer) in colorectal cancer patients (PMID: 26582061; PMID: 19125127)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/26582061	AVv-K0vPSS-TIFzzUI0cjax	MPL	Ruxolitinib + ZSTK474	"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-K0Q_SS-TIFzzUI0Fjax	MPL	Ruxolitinib + ZSTK474	"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-K0OTSS-TIFzzUI0Ajax	MPL	Ruxolitinib + ZSTK474	"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-K0VMSS-TIFzzUI0Njax	MPL	Ruxolitinib + TGX-221	"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-K0ReSS-TIFzzUI0Gjax	MPL	Ruxolitinib + TGX-221	"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-K0O7SS-TIFzzUI0Bjax	MPL	Ruxolitinib + TGX-221	"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-K0TkSS-TIFzzUI0Kjax	MPL	MK2206	"In a preclinical study, MK2206 treatment reduced disease burden in MPL W515L transduced mouse models of myelofibrosis (PMID: 23748344)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23748344	AVv-K0VsSS-TIFzzUI0Ojax	MPL	GDC-0941 + Ruxolitinib	"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-K0QeSS-TIFzzUI0Ejax	MPL	GDC-0941 + Ruxolitinib	"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-K0NySS-TIFzzUIz_jax	MPL	GDC-0941 + Ruxolitinib	"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-K0SiSS-TIFzzUI0Ijax	MPL	Everolimus	"In a phase II study of patients with myelofibrosis, 2/2 patients with MPL W515L/K had tumor response to everolimus, with one patient displaying clinical benefit (PMID: 21725052)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21725052	AVv-K0UsSS-TIFzzUI0Mjax	MPL	CHZ868	"In a preclinical study, CHZ868 inhibited proliferation of bone marrow cell lines expressing MPL W515L in culture, including cells with decreased response to Type I JAK inhibitors due to chronic exposure (PMID: 26175413)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26175413	AVv-K0TDSS-TIFzzUI0Jjax	MPL	CHZ868	"In a preclinical study, CHZ868 demonstrated efficacy in a mouse model of MPL W515L induced myelofibrosis (PMID: 26175413)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26175413	AVv-K0R_SS-TIFzzUI0Hjax	MPL	BEZ235 + Ruxolitinib	"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-K0P8SS-TIFzzUI0Djax	MPL	BEZ235 + Ruxolitinib	"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-K0PbSS-TIFzzUI0Cjax	MPL	BEZ235 + Ruxolitinib	"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-K0UGSS-TIFzzUI0Ljax	MLH1	N/A	"In a preclinical study, MLH1 inactivation through hypermethylation was associated with high microsatellite instability (MSI-H) colorectal carcinoma by whole genome sequencing of tumor samples (PMID: 22810696), suggesting it may be a potential biomarker."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/22810696	AVv-Kz7TSS-TIFzzUIz8jax	MET	cabozantinib	"In a preclinical study, transformed human cells expressing MET D1228V were sensitive to Cometriq (Cabometyx, cabozantinib) in culture, resulting in suppression of Met phosphorylation (PMID: 27694386)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27694386	AVv-KzqySS-TIFzzUIz7jax	MET	cabozantinib	"In a preclinical study, Cometriq (cabozantinib) treatment had no effect on the cellular outgrowth or tumor volume of a TNBC cell line negative for MET expression in culture (PMID: 26432786)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26432786	AVv-KyKOSS-TIFzzUIxHjax	MET	cabozantinib	"In a preclinical study, Cometriq (cabozantinib) inhibited Met activity, cell growth, and invasive cellular characteristics in a human MET positive TNBC cell line in culture, and reduced tumor volume in xenograft models (PMID: 26432786)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26432786	AVv-Kzb_SS-TIFzzUIzijax	MET	cabozantinib	"In a clinical study, a patient with lung adenocarcinoma harboring MET del exon14 demonstrated a complete response via PERCIST criteria when treated with Cometriq (Cabometyx, cabozantinib) (PMID: 25971939)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25971939	AVv-KzGGSS-TIFzzUIy7jax	MET	cabozantinib	"In a Phase II trial, higher baseline soluble Met level correlated with longer overall survival in cholangiocarcinoma patients treated with Cometriq (cabozantinib) (PMID: 28192597)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28192597	AVv-Kzd7SS-TIFzzUIzljax	MET	cabozantinib	"In a Phase II trial, a cholangiocarcinoma patient with high Met expression in tumor stayed on Cometriq (cabozantinib) treatment for 278 days (PMID: 28192597)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28192597	AVv-KzMjSS-TIFzzUIzHjax	MET	XL147	"In a preclinical study, XL147 inhibited migration and growth of mouse melanoma cells with MET over expression in culture (PMID: 25637314)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25637314	AVv-KzO4SS-TIFzzUIzLjax	MET	Volitinib	"In a preclinical study, transformed human cells expressing MET D1228V demonstrated resistance to treatment with Savolitinib (AZD6094) in culture, resulting in sustained Met phosphorylation (PMID: 27694386)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27694386	AVv-KzoGSS-TIFzzUIz2jax	MET	Volitinib	"In a preclinical study, Savolitinib (AZD6094) demonstrated antitumor activity in patient-derived papillary renal cell carcinoma xenograft models harboring MET amplification (PMID: 25779944)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25779944	AVv-Ky0aSS-TIFzzUIycjax	MET	Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin	"In a clinical case study, a patient with ERBB2 (HER2) and MET amplified gastric adenocarcinoma was insensitive to treatment with Herceptin (trastuzumab) and FOLFOX (PMID: 26432108)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26432108	AVv-Kye4SS-TIFzzUIx2jax	MET	TAS-115	"In a preclinical study, MET amplified gastric cancer cell lines were sensitive to TAS-115, resulting in suppression of cell proliferation in culture (PMID: 24140932)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24140932	AVv-KywJSS-TIFzzUIyVjax	MET	TAE226	"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring MET amplification in culture (PMID: 26090892)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26090892	AVv-Ky4ISS-TIFzzUIyijax	MET	TAE226	"In a preclinical study, TAE226 treatment inhibited proliferation of gastric cancer cell lines harboring MET amplification in culture (PMID: 26090892)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26090892	AVv-KyjASS-TIFzzUIx_jax	MET	Selumetinib + BEZ235	"In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically inhibited proliferation of an Iressa (gefitinib)-resistant NSCLC cell line harboring MET amplification in culture and in cell line xenograft models (PMID: 24939055)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24939055	AVv-Ky1nSS-TIFzzUIyejax	MET	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with MET amplification (PMID: 24939055)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24939055	AVv-Ky25SS-TIFzzUIygjax	MET	SU11274	"In a preclinical study, cells expressing MET N375S had decreased sensitivity to SU11274 in culture compared to cells expressing wild-type MET (PMID: 19723643)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/19723643	AVv-Ky_KSS-TIFzzUIyujax	MET	SU11274	"In a preclinical study, a cell line expressing MET Y1248H showed resistance to SU11274 treatment (PMID: 15064724)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/15064724	AVv-KzYZSS-TIFzzUIzcjax	MET	SU11274	"In a preclinical study, a cell line expressing MET V1238I demonstrated sensitivity to SU11274 treatment (PMID: 19783361)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19783361	AVv-KyGdSS-TIFzzUIxBjax	MET	SU11274	"In a preclinical study, a cell line expressing MET V1206I demonstrated sensitivity to SU11274 treatment (PMID: 19783361)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19783361	AVv-KzY9SS-TIFzzUIzdjax	MET	SU11274	"In a preclinical study, a cell line expressing MET V1110I demonstrated sensitivity to SU11274 treatment (PMID: 19783361)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19783361	AVv-KzItSS-TIFzzUIzAjax	MET	SU11274	"In a preclinical study, a cell line expressing MET M1268T demonstrated sensitivity to SU11274 treatment (PMID: 15064724)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/15064724	AVv-KzGmSS-TIFzzUIy8jax	MET	SU11274	"In a preclinical study, a cell line expressing MET L1213V showed resistance to SU11274 treatment (PMID: 15064724)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/15064724	AVv-KyRESS-TIFzzUIxSjax	MET	SU11274	"In a preclinical study, a cell line expressing MET H1112Y demonstrated sensitivity to SU11274 treatment (PMID: 19783361)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/15064724	AVv-KzkqSS-TIFzzUIzwjax	MET	SU11274	"In a preclinical study, a cell line expressing MET H1112L demonstrated sensitivity to SU11274 treatment (PMID: 19783361)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19783361	AVv-KyF0SS-TIFzzUIxAjax	MET	SU11274	"In a preclinical study, SU11274 induced apoptosis of cells expressing MET E168D, which demonstrated increased sensitivity compared to cells expressing wild-type MET (PMID: 19723643)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19723643	AVv-Ky81SS-TIFzzUIyqjax	MET	SGX523	"In a preclinical study, SGX523 inhibited survival of MET-amplified non-small cell lung cancer cells in culture (PMID: 26483207)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26483207	AVv-KyylSS-TIFzzUIyZjax	MET	SGX523	"In a preclinical study, SGX523 inhibited Met signaling and proliferation of MET amplified gastric cancer cells in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 19934279)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19934279	AVv-KyueSS-TIFzzUIySjax	MET	SAR125844	"In a preclinical study, SAR125844 inhibited Met signaling, leading to growth inhibition of MET amplified lung cancer cells in culture (PMID: 25504634)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25504634	AVv-Ky6fSS-TIFzzUIymjax	MET	SAR125844	"In a preclinical study, SAR125844 inhibited Met signaling leading to growth inhibition of MET amplified gastric cancer cell lines  in culture and in xenograft models (PMID: 25504634)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25504634	AVv-Kyz1SS-TIFzzUIybjax	MET	SAR125844	"In a preclinical study, MET amplified lung cancer cells harboring KRAS G12A were insensitive to SAR125844-mediated growth inhibition in culture (PMID: 25504634)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25504634	AVv-KyaGSS-TIFzzUIxtjax	MET	S-49076	"In a preclinical study, S-49076 inhibited Met activation, resulting in growth inhibition of gastric carcinoma cells harboring MET activating mutations in culture and in cell line xenograft models (PMID: 23804704)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23804704	AVv-KyNRSS-TIFzzUIxMjax	MET	Rucaparib	"In a preclinical study, triple-receptor negative breast cancer cell lines over expressing Met demonstrated decreased sensitivity to Rubraca (rucaparib) induced growth and colony formation inhibition in culture (PMID: 26779812)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26779812	AVv-KzOQSS-TIFzzUIzKjax	MET	Rucaparib	"In a preclinical study, decreasing Brca2 expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells with low expression of Met to Rubraca (rucaparib) in culture (PMID: 26779812)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26779812	AVv-KzlQSS-TIFzzUIzxjax	MET	Rucaparib	"In a preclinical study, decreasing Brca2 expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells with Met over expression to Rubraca (rucaparib) in culture (PMID: 26779812)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26779812	AVv-KzMCSS-TIFzzUIzGjax	MET	Rucaparib	"In a preclinical study, decreasing Brca1 expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells with low expression of Met to Rubraca (rucaparib) in culture (PMID: 26779812)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26779812	AVv-KzlxSS-TIFzzUIzyjax	MET	Rucaparib	"In a preclinical study, decreasing Brca1 expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells with Met over expression to Rubraca (rucaparib) in culture (PMID: 26779812)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26779812	AVv-KzLdSS-TIFzzUIzFjax	MET	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines over-expressing MET (PMID: 25122427)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25122427	AVv-KzP5SS-TIFzzUIzNjax	MET	PP-121	"In a preclinical study, the multitarget kinase inhibitor PP-121 inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26483207	AVv-KytOSS-TIFzzUIyQjax	MET	PHA-665752	"In a preclinical study, MET Y1230H was associated with resistance to PHA-665752 in a gastric cancer cell line with MET over expression in culture (PMID: 21266357)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21266357	AVv-KzBNSS-TIFzzUIyyjax	MET	Onartuzumab	"In a preclinical study, Onartuzumab inhibited tumor growth and decreased MET expression in a non-small cell lung cancer xenograft model harboring MET exon 14 deletion (PMID: 23882082)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23882082	AVv-KzDcSS-TIFzzUIy2jax	MET	MSC2156119J	"In a preclinical study, Tepotinib (MSC2156119J) treatment resulted in tumor regression in patient-derived xenograft models of hepatocellular cancer with high Met expression level (PMID: 25256830)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25256830	AVv-KzSySS-TIFzzUIzSjax	MET	MGCD265	"In a preclinical study, transformed human cells expressing MET D1228V were sensitive to Glesatinib (MGCD265) in culture, resulting in suppression of Met phosphorylation (PMID: 27694386)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27694386	AVv-KzpuSS-TIFzzUIz5jax	MET	Lapatinib	"In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 and MET was resistant to Tykerb (lapatinib) in culture (PMID: 26432108)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26432108	AVv-KybkSS-TIFzzUIxwjax	MET	LY2875358 + erlotinib	"In a Phase I trial, Emibetuzumab (LY2875358) and Tarceva (erlotinib) combination treatment resulted in durable partial response in 14.3% (2/14) of patients with non-small cell lung carcinoma, with both responders being Met positive (PMID: 27803065)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27803065	AVv-KzfTSS-TIFzzUIznjax	MET	LY2875358	"In a preclinical study, Emibetuzumab (LY2875358) treatment inhibited MET activation and proliferation of tumor cells with constitutive MET activation in culture, and inhibited tumor growth in xenograft models (PMID: 25231402)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25231402	AVv-KyKwSS-TIFzzUIxIjax	MET	LY2875358	"In a preclinical study, Emibetuzumab (LY2875358) treatment inhibited MET activation and proliferation of tumor cells with MET amplification in culture, and inhibited growth in MET-amplified tumor xenograft models (PMID: 25231402)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25231402	AVv-KykuSS-TIFzzUIyBjax	MET	LY2801653	"In a preclinical study, transformed human cells expressing MET D1228V were sensitive to Merestinib (LY2801653) in culture, resulting in suppression of Met phosphorylation (PMID: 27694386)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27694386	AVv-KzpKSS-TIFzzUIz4jax	MET	LY2801653	"In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells over expressing MET Y1230C in culture (PMID: 23275061)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23275061	AVv-KyIQSS-TIFzzUIxEjax	MET	LY2801653	"In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells over expressing MET D1228N in culture (PMID: 23275061)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23275061	AVv-KzHrSS-TIFzzUIy-jax	MET	LY2801653	"In a preclinical study, Merestinib (LY2801653) demonstrated anti-tumor activity in cell line xenograft models of lung adenocarcinoma with Met over expression (PMID: 23275061)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23275061	AVv-KzRrSS-TIFzzUIzQjax	MET	LY2801653	"In a preclinical study, Merestinib (LY2801653) demonstrated anti-tumor activity in cell line xenograft models of glioma with autocrine activation of Met signaling (PMID: 23275061)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23275061	AVv-KyL-SS-TIFzzUIxKjax	MET	LY2801653	"In a preclinical study, LY2801653 inhibited phosphorylation of Met, resulting in inhibition of cholangiocarcinoma proliferation in cell culture and growth of tumors in Pdx models (PMID: 26757360)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26757360	AVv-Ky-oSS-TIFzzUIytjax	MET	LY2801653	"In a preclinical study, LY2801653 blocked tumor growth in a gastric cancer cell line xenograft model over expressing Met (PMID: 23275061)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23275061	AVv-KzX4SS-TIFzzUIzbjax	MET	KTN0073-IgG2	"In a preclinical study, KTN0073-IgG2 inhibited MET phosphorylation and induced MET degradation, and inhibited proliferation of a MET-amplified non-small cell lung cancer cell line in culture (PMID: 27550450)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27550450	AVv-Ky56SS-TIFzzUIyljax	MET	KTN0073-IgG2	"In a preclinical study, KTN0073-IgG2 inhibited MET phosphorylation and induced MET degradation, and inhibited growth of a MET-amplified gastric cancer cell line in culture and in xenograft models (PMID: 27550450)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27550450	AVv-KyqzSS-TIFzzUIyMjax	MET	KTN0073-IgG1	"In a preclinical study, KTN0073-IgG1 inhibited growth of a non-small cell lung cancer cell line harboring deletion of MET exon 14 in culture (PMID: 27550450)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27550450	AVv-KzFDSS-TIFzzUIy5jax	MET	KRC-00715	"In a preclinical study, KRC-00715 induced cell-cycle arrest and inhibited growth of Met-over expressing gastric cancer cell lines in culture and in xenograft models, and did not inhibit growth of cell lines with low Met expression (PMID: 26801760)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26801760	AVv-KzSPSS-TIFzzUIzRjax	MET	KRC-00509	"In a preclinical study, KRC-00509 induced cell-cycle arrest and inhibited growth of Met-over expressing gastric cancer cell lines in culture, and did not inhibit growth of cell lines with low Met expression (PMID: 26801760)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26801760	AVv-KzNKSS-TIFzzUIzIjax	MET	K252a	"In preclinical studies, cell lines transformed by MET M1268T were sensitive to K252a treatment in both culture and mouse model experiments (PMID: 12118367)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/12118367	AVv-KzHHSS-TIFzzUIy9jax	MET	K252a	"In preclinical studies, a MET amplified, gastric carcinoma cell over expressing Met was sensitive to K252a treatment in both culture and mouse model experiments (PMID: 12118367)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/12118367	AVv-KyRrSS-TIFzzUIxTjax	MET	JNJ-61186372	"In a preclinical study, JNJ-61186372 inhibited tumor growth in Tarceva (erlotinib)-resistant non-small cell lung cancer cell line xenograft models harboring an EGFR exon 19 deletion and MET amplification (PMID: 27216193)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27216193	AVv-KyYqSS-TIFzzUIxqjax	MET	INC280	"In a preclinical study, transformed human cells expressing MET D1228V demonstrated resistance to treatment with Capmatinib (INC280) in culture, resulting in sustained Met phosphorylation (PMID: 27694386)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27694386	AVv-KzqSSS-TIFzzUIz6jax	MET	INC280	"In a clinical case study, Capmatinib (INC280) treatment resulted in decreased tumor volume by 53% in a patient with large cell lung carcinoma harboring MET del exon14 and TP53 N30fs*14 (PMID: 25971938)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-KzB5SS-TIFzzUIyzjax	MET	INC280	"In a clinical case study, Capmatinib (INC280) treatment resulted in a decreased tumor volume of 61% in a patient with lung squamous cell carcinoma harboring MET del exon14 (PMID: 25971938)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-KzEcSS-TIFzzUIy4jax	MET	Golvatinib	"In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of lung cancer cells in culture and tumor regression in cell line xenograft models (PMID: 19832844)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19832844	AVv-KywtSS-TIFzzUIyWjax	MET	Golvatinib	"In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of gastric cancer cell lines in culture and in cell line xenograft models (PMID: 19832844)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19832844	AVv-KyidSS-TIFzzUIx9jax	MET	Gefitinib	"In a preclinical study, amplification of MET conferred resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring an EGFR exon 19 deletion mutation in culture (PMID: 17463250)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/17463250	AVv-KybESS-TIFzzUIxvjax	MET	Gefitinib	"In a preclinical study, acquired amplification of MET conferred resistance to Iressa (gefitinib) in a non-small cell lung cancer cell line harboring EGFR E746_A750del in culture (PMID: 27612490)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27612490	AVv-Kyf5SS-TIFzzUIx4jax	MET	Foretinib + Veliparib	"In a preclinical study, Foretinib (GSK1363089) and Veliparib (ABT-888) worked synergistically to inhibit growth of Met-over expressing triple-receptor negative breast cancer cells in culture, and reduced tumor growth in xenograft models (PMID: 26779812)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26779812	AVv-KzUfSS-TIFzzUIzVjax	MET	Foretinib + Rucaparib	"In a preclinical study, Foretinib (GSK1363089) and Rubraca (rucaparib) combination treatment resulted in enhanced growth inhibition in Met-over expressing triple-receptor negative breast cancer cells in culture (PMID: 26779812)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26779812	AVv-KzTYSS-TIFzzUIzTjax	MET	Ficlatuzumab	"In a Phase I trial, Ficlatuzumab treatment resulted in stable disease in 57% (12/21) of patients with advanced solid tumors and a decrease in phosphorylated Met in one patient with multiple myeloma (PMID: 24901237)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24901237	AVv-KzemSS-TIFzzUIzmjax	MET	FF-284	"In a preclinical study, Debio 1347 did not inhibit tumor growth in cell line xenograft models of MET amplified gastric cancer (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-Kyl3SS-TIFzzUIyDjax	MET	Erlotinib	"In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Tarceva (erlotinib) (PMID: 27694386)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27694386	AVv-KyYLSS-TIFzzUIxpjax	MET	EMD 1214063 + Radiotherapy	"In a preclinical study, shRNA knock-down of Tp53 in Met over-expressing gastric carcinoma cells enhanced sensitivity to the combination of EMD 1214063 and radiation in culture (PMID: 26358474)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26358474	AVv-KzJwSS-TIFzzUIzCjax	MET	EMD 1214063	"In a preclinical study, EMD 1214063 inhibited Met phosphorylation and cell viability of Met over-expressing lung squamous cell carcinoma cells in culture (PMID: 26358474)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26358474	AVv-KzXWSS-TIFzzUIzajax	MET	EMD 1214063	"In a preclinical study, EMD 1214063 inhibited Met phosphorylation and cell viability of Met over-expressing gasric carcinoma cell lines in culture, regardless of their TP53 status (PMID: 26358474)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26358474	AVv-KzVDSS-TIFzzUIzWjax	MET	EMD 1214063	"In a preclinical study, EMD 1214063 induced tumor regression in mouse cell line xenograft models of non-small cell lung carcinoma harboring MET amplification (PMID: 23553846)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23553846	AVv-KykFSS-TIFzzUIyAjax	MET	EMD 1214063	"In a preclinical study, EMD 1214063 induced tumor regression in mouse cell line xenograft models of gastric carcinoma harboring MET amplification (PMID: 23553846)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23553846	AVv-Ky7ESS-TIFzzUIynjax	MET	Crizotinib + Rucaparib	"In a preclinical study, the combination of Xalkori (crizotinib) and Rubraca (rucaparib) synergized to inhibit growth of a Met-over expressing human lung cancer cell line in culture, and reduced tumor growth in xenograft models (PMID: 26779812)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26779812	AVv-KzVtSS-TIFzzUIzXjax	MET	Crizotinib + Rucaparib	"In a preclinical study, the combination of Xalkori (crizotinib) and Rubraca (rucaparib) synergized to inhibit growth of a Met-over expressing human breast cancer cell line in culture, and reduced tumor growth in xenograft models (PMID: 26779812)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26779812	AVv-KzNwSS-TIFzzUIzJjax	MET	Crizotinib + Lapatinib	"In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 (HER2) and MET was sensitive to inhibition by Tykerb (lapatinib) and Xalkori (crizotinib) in culture (PMID: 26432108)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26432108	AVv-KycpSS-TIFzzUIxyjax	MET	Crizotinib	"In a preclinical study, transformed human cells expressing MET D1228V demonstrated resistance to treatment with Xalkori (crizotinib) in culture, resulting in sustained Met phosphorylation (PMID: 27694386)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27694386	AVv-KzonSS-TIFzzUIz3jax	MET	Crizotinib	"In a preclinical study, cultured cells with MET R998C mutations demonstrated sensitivity to Xalkori (crizotinib, PF-2341066) (PMID: 17483355)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17483355	AVv-Ky7oSS-TIFzzUIyojax	MET	Crizotinib	"In a preclinical study, a human gastric cancer cell line with high levels of MET expression and expressing KRAS G12D was resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26432108)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26432108	AVv-KzKTSS-TIFzzUIzDjax	MET	Crizotinib	"In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 and MET was resistant to Xalkori (crizotinib) in culture (PMID: 26432108)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26432108	AVv-KyeaSS-TIFzzUIx1jax	MET	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited tumor grow in patient-derived xenograft models of MET amplified non-small cell lung cancer (PMID: 26483207)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26483207	AVv-KyvjSS-TIFzzUIyUjax	MET	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited tumor grow in patient-derived xenograft models of MET amplified liver cancer (PMID: 26483207)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26483207	AVv-Ky3iSS-TIFzzUIyhjax	MET	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited growth of a human gastric cancer cell line with high levels of MET expression in culture (PMID: 26432108)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26432108	AVv-KzQhSS-TIFzzUIzOjax	MET	Crizotinib	"In a preclinical study, MET T1010I showed sensitivity to Xalkori (crizotinib) in cell culture (PMID: 17483355)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17483355	AVv-KzALSS-TIFzzUIywjax	MET	Crizotinib	"In a clinical study, three patients with lung adenocarcinoma harboring MET del exon14 demonstrated partial responses when treated with Xalkori (crizotinib) (PMID: 25971939)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25971939	AVv-KzFmSS-TIFzzUIy6jax	MET	Crizotinib	"In a clinical case study, a patient with squamous cell lung cancer harboring a MET exon 14 skipping mutation was determined to have acquired MET D1228N after progression on Xalkori (crizotinib) therapy (PMID: 27343442)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/27343442	AVv-KzC8SS-TIFzzUIy1jax	MET	Crizotinib	"In a clinical case study, a patient with a carcinoma of unknown primary harboring MET amplification and KRAS G12V demonstrated a durable response following treatment with Xalkori (crizotinib) (PMID: 25232318)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25232318	AVv-KyXnSS-TIFzzUIxojax	MET	Crizotinib	"In a clinical case study, Xalkori (crizotinib) treatment resulted in a decrease in tumor volume by more than 60% in a patient with histiocytic sarcoma harboring MET del exon14 and TP53 R175H (PMID: 25971938)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-KzCaSS-TIFzzUIy0jax	MET	CO1686 + Crizotinib	"In a preclinical study, the combination of Rociletinib (CO-1686) and Xalkori (crizotinib) overcame resistance to Rociletinib (CO-1686) in non-small cell lung cancer cell line harboring EGFR E746_A750del and MET amplification in culture (PMID: 27283993)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27283993	AVv-KyhVSS-TIFzzUIx7jax	MET	CO1686	"In a preclinical study, emergence of MET amplification was associated with resistance to Rociletinib (CO1686) in non-small cell lung cancer cell line xenograft models harboring EGFR E746_A750del (PMID: 27283993)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27283993	AVv-KygYSS-TIFzzUIx5jax	MET	Bevacizumab + Sorafenib	"In a clinical case study, a patient with ovarian cancer harboring MET N375S demonstrated sensitivity to the combination treatment, Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for greater than six months (PMID: 25363205)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25363205	AVv-Ky_sSS-TIFzzUIyvjax	MET	Bevacizumab + Sorafenib	"In a clinical case study, a GIST patient harboring KIT S476I and MET R988C demonstrated sensitivity to the combination treatment, Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for 6 months (PMID: 25363205)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25363205	AVv-Ky8OSS-TIFzzUIypjax	MET	BMS-777607	"In a preclinical study, BMS-777607 (ASLAN002) demonstrated efficacy in inhibiting migration and invasion of cultured prostate cancer cells expressing wild-type Met (PMID: 20515943)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20515943	AVv-Ky-ISS-TIFzzUIysjax	MET	BMS-777607	"In a preclinical study, BMS-777607 (ASLAN002) demonstrated efficacy in blocking Met phosphorylation and inhibiting cell proliferation and metastasis in cultured cells and murine models with activating Met mutations (PMID: 22286523)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22286523	AVv-KyPJSS-TIFzzUIxPjax	MET	BEZ235	"In a preclinical study, BEZ235 suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with MET amplification (PMID: 24939055)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24939055	AVv-KyorSS-TIFzzUIyIjax	MET	Amuvatinib	"In a preclinical study, Amuvatinib (MP470) demonstrated efficacy in reducing Met phosphorylation and inducing apoptosis in cultured myeloma cells (PMID: 24326130)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24326130	AVv-Ky9jSS-TIFzzUIyrjax	MET	Altiratinib	"In a preclinical study, Altiratinib (DCC-2701) inhibited viability of several MET-expressing glioblastoma cell lines in culture and inhibited tumor growth in cell line xenograft models (PMID: 26965451)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26965451	AVv-Kzg-SS-TIFzzUIzqjax	MET	Altiratinib	"In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET Y1230H in an in vitro kinase assay (PMID: 26285778)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26285778	AVv-KzAtSS-TIFzzUIyxjax	MET	Altiratinib	"In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET Y1230D in an in vitro kinase assay (PMID: 26285778)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26285778	AVv-KyQfSS-TIFzzUIxRjax	MET	Altiratinib	"In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET Y1230C in an in vitro kinase assay (PMID: 26285778)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26285778	AVv-KyI2SS-TIFzzUIxFjax	MET	Altiratinib	"In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET M1250T in an in vitro kinase assay (PMID: 26285778)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26285778	AVv-KyP3SS-TIFzzUIxQjax	MET	Altiratinib	"In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET D1228N in an in vitro kinase assay (PMID: 26285778)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26285778	AVv-KzILSS-TIFzzUIy_jax	MET	Altiratinib	"In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET D1228H in an in vitro kinase assay (PMID: 26285778)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26285778	AVv-KzJPSS-TIFzzUIzBjax	MET	Altiratinib	"In a preclinical study, Altiratinib (DCC-2701) inhibited Met phosphorylation and viability of several Met over expressing glioblastoma cell lines in culture and inhibited tumor growth in cell line xenograft models (PMID: 26965451)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26965451	AVv-KzWOSS-TIFzzUIzYjax	MET	Altiratinib	"In a preclinical study, Altiratinib (DCC-2701) inhibited Met phosphorylation and proliferation of a non-small cell lung cancer cell line with MET amplification and overexpression in culture (PMID: 26285778)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26285778	AVv-KySTSS-TIFzzUIxfjax	MET	Altiratinib	"In a preclinical study, Altiratinib (DCC-2701) inhibited MET activity, including MET activating mutations, and inhibited proliferation of MET-driven tumor cell lines in culture (PMID: 26285778)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26285778	AVv-KyLRSS-TIFzzUIxJjax	MET	Altiratinib	"In a preclinical study, Altiratinib (DCC-2701) inhibited MET activation, decreased viability and migration of c-MET positive ovarian cancer cells in culture, and reduced tumor growth in ovarian cancer cell line xenograft models (PMID: 24362531)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24362531	AVv-Kzi3SS-TIFzzUIztjax	MET	Afatinib	"In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Gilotrif (afatinib) (PMID: 27694386)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27694386	AVv-KyZmSS-TIFzzUIxsjax	MET	AZD9291	"In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M developed resistance to Tagrisso (osimertinib), and was found to have acquired high level amplification of MET (PMID: 27393507)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27393507	AVv-KyXISS-TIFzzUIxnjax	MET	AMG 337	"In clinical case studies, patients with MET amplified esophageal cancer responded to AMG 337 therapy (PMID: 26432108)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26432108	AVv-KypsSS-TIFzzUIyKjax	MET	AMG 337	"In a preclinical study, a MET-amplified lung cancer cell line harboring KRAS G12A was not sensitive to growth inhibition by AMG 337 in culture (PMID: 27196782)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27196782	AVv-KyakSS-TIFzzUIxujax	MET	AMG 337	"In a preclinical study, AMG 337 inhibited growth of gastric cancer cell lines in culture, and inhibited growth and induced regression of tumors in MET-amplified gastric cancer cell line xenograft models (PMID: 27196782)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27196782	AVv-KyrRSS-TIFzzUIyNjax	MET	AMG 337	"In a preclinical study, AMG 337 inhibited growth of MET-amplified lung cancer cell lines in culture (PMID: 27196782)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27196782	AVv-KyxVSS-TIFzzUIyXjax	MET	AMG 337	"In a preclinical study, AMG 337 inhibited Met phosphorylation and growth of hepatocellular carcinoma (HCC) cell lines with MET amplification in culture, and inhibited tumor growth in MET-amplified HCC patient-derived xenograft models (PMID: 27196749)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27196749	AVv-Ky5TSS-TIFzzUIykjax	MET	AMG 337	"In a clinical case study, a patient with a MET amplified esophageal carcinoma that initially responded to AMG 337, developed resistance upon emergence of KRAS G12D (PMID: 26432108)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26432108	AVv-KyUZSS-TIFzzUIxijax	MET	AMG 337	"In a clinical case study, a patient with MET amplified esophageal adenocarcinoma had a partial response to AMG 337 therapy after 2 months of treatment (PMID: 26432108)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26432108	AVv-KymaSS-TIFzzUIyEjax	MET	AMG 337	"In a clinical case study, a patient with ERBB2 (HER2) and MET amplified gastric adenocarcinoma was insensitive to AMG 337 therapy (PMID: 26432108)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26432108	AVv-KycISS-TIFzzUIxxjax	MET	ABBV-399	"In a preclinical study, treatment with ABBV-399 resulted in complete response in a MET-over expressing papillary lung adenocarcinoma cell line xenograft model (PMID: 27573171)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27573171	AVv-KzRHSS-TIFzzUIzPjax	MET	ABBV-399	"In a preclinical study, ABBV-399 inhibited growth of MET-amplified gastric cancer cell in culture, and induced tumor regression in a MET-amplified gastric cancer cell line xenograft model (PMID: 27573171)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27573171	AVv-KyngSS-TIFzzUIyGjax	MET	ABBV-399	"In a preclinical study, ABBV-399 inhibited growth of MET over expressing non-small cell lung cancer cell lines in culture (PMID: 27573171)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27573171	AVv-KzW0SS-TIFzzUIzZjax	MET	ABBV-399	"In a preclinical study, ABBV-399 demonstrated efficacy in MET-expressing lung adenocarcinoma patient-derived xenograft (PDX) models, with the PDX model with higher MET expression levels showing improved tumor growth delay (PMID: 27573171)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27573171	AVv-KzT6SS-TIFzzUIzUjax	MAP2K1	Vemurafenib	"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KxJMSS-TIFzzUIwajax	MAP2K1	Vemurafenib	"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KxLwSS-TIFzzUIwfjax	MAP2K1	Vemurafenib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KxG_SS-TIFzzUIwWjax	MAP2K1	Vemurafenib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-Kwc0SS-TIFzzUIvOjax	MAP2K1	Vemurafenib	"In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, MAP2K1 V60E, NRAS T58I, and NRAS Q61R, after 18 weeks of treatment with Zelboraf (vemurafenib) (PMID: 24265153)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-KxcnSS-TIFzzUIw9jax	MAP2K1	Vemurafenib	"In a clinical case study, a patient harboring BRAF V600E demonstrated an initial response to treatment with Zelboraf (vemurafenib), but progressed following emergence of a MAP2K1 C121S mutation (PMID: 21383288)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/21383288	AVv-KxWbSS-TIFzzUIwyjax	MAP2K1	VX-11e	"In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25370473	AVv-Kw2bSS-TIFzzUIv5jax	MAP2K1	VX-11e	"In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25370473	AVv-Kw1PSS-TIFzzUIv3jax	MAP2K1	VRT11E	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-KxdUSS-TIFzzUIw-jax	MAP2K1	VRT11E	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-KxavSS-TIFzzUIw6jax	MAP2K1	VRT11E	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-Kwh3SS-TIFzzUIvXjax	MAP2K1	VRT11E	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-KxXcSS-TIFzzUIw0jax	MAP2K1	Trametinib + Dabrafenib	"In a preclinical study, the combination of Talfinlar (dabrafenib)    and Mekinist (trametinib) resulted in improved growth inhibition in melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KwuHSS-TIFzzUIvsjax	MAP2K1	Trametinib + Dabrafenib	"In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E harboring MAP2K1 K59del in culture (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KwbCSS-TIFzzUIvLjax	MAP2K1	Trametinib + Dabrafenib	"In a preclinical study, MAP2K1 G128V conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265154	AVv-Kwi-SS-TIFzzUIvZjax	MAP2K1	Trametinib + Dabrafenib	"In a preclinical study, MAP2K1 C121S conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265154	AVv-KxVVSS-TIFzzUIwwjax	MAP2K1	Trametinib	"In a preclinical study, treatment with Mekinist (trametinib) had no effect on a lung adenocarcinoma cell line co-harboring MAP2K1 Y134C and KRAS Q61H in culture (PMID: 26582713)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26582713	AVv-KwrLSS-TIFzzUIvnjax	MAP2K1	Trametinib	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 24265153)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-KxZJSS-TIFzzUIw3jax	MAP2K1	Trametinib	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Mekinist (trametinib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-KwibSS-TIFzzUIvYjax	MAP2K1	Trametinib	"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KxLOSS-TIFzzUIwejax	MAP2K1	Trametinib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KxHkSS-TIFzzUIwXjax	MAP2K1	Trametinib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P displayed reduced sensitivity to Mekinist (trametinib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KwtjSS-TIFzzUIvrjax	MAP2K1	Trametinib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KwaRSS-TIFzzUIvKjax	MAP2K1	Trametinib	"In a preclinical study, a melanoma cell line expressing MAP2K1 V60E demonstrated resistance to Mekinist (trametinib) in culture (PMID: 24265153)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-Kxb8SS-TIFzzUIw8jax	MAP2K1	Trametinib	"In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Mekinist (trametinib), resulting in decreased cell viability (PMID: 26582713)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26582713	AVv-Kwx_SS-TIFzzUIvyjax	MAP2K1	Trametinib	"In a preclinical study, a gastric cancer cell line harboring MAP2K1 Q56P demonstrated sensitivity to Mekinist (trametinib), resulting in decreased cell viability (PMID: 26582713)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26582713	AVv-KwxaSS-TIFzzUIvxjax	MAP2K1	Trametinib	"In a preclinical study, a colorectal cancer cell line harboring MAP2K1 mutations Q56P, H119Y, and D351G and an EGFR G719S mutation demonstrated some sensitivity to Mekinist (trametinib) in culture, resulting in decreased cell viability (PMID: 26582713)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26582713	AVv-KwjlSS-TIFzzUIvajax	MAP2K1	Trametinib	"In a preclinical study, a colorectal cancer cell line harboring MAP2K1 F53L demonstrated sensitivity to Mekinist (trametinib) in culture, resulting in decreased cell viability (PMID: 26582713)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26582713	AVv-KwkMSS-TIFzzUIvbjax	MAP2K1	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25370473	AVv-Kw3CSS-TIFzzUIv6jax	MAP2K1	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25370473	AVv-Kw0qSS-TIFzzUIv2jax	MAP2K1	Trametinib	"In a clinical study, a patient with refractory Erdheim–Chester disease harboring a MAP2K1 K57N mutation had a sustained clinical response to Mekinist (trametinib) for over 6 months (PMID: 26566875)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26566875	AVv-KxQTSS-TIFzzUIwnjax	MAP2K1	Selumetinib + PLX4720	"In a preclinical study, combined treatment with selumetinib and PLX4720 strongly suppressed the emergence of resistant MAP2K1 mutations in BRAF V600E cells in culture (PMID: 19915144)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-KwrzSS-TIFzzUIvojax	MAP2K1	Selumetinib	"In a preclinical study, transformed human melanoma cells expressing MAP2K1 P124L demonstrated resistance to the MEK inhibitor, Selumetinib (AZD6244) (PMID: 19915144)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-Kw0CSS-TIFzzUIv1jax	MAP2K1	Selumetinib	"In a preclinical study, selumetinib (AZD6244) inhibited phosphorylation of ERK in cells expressing MAP2K1 K57N and inhibited MAP2K1 K57N-dependent growth in cell culture (PMID: 18632602)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18632602	AVv-KxRgSS-TIFzzUIwpjax	MAP2K1	Selumetinib	"In a preclinical study, selumetinib (AZD6244) inhibited growth of a gastric cancer cell line that requires MAP2K1 Q56P and inhibited phosphorylation of ERK in these cells (PMID: 22327936)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22327936	AVv-KwwvSS-TIFzzUIvwjax	MAP2K1	Selumetinib	"In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the MEK inhibitor selumetinib (AZD6244) cell culture."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-Kws6SS-TIFzzUIvqjax	MAP2K1	Selumetinib	"In a preclinical study, melanoma cells harboring BRAF V600E treated with Selumetinib (AZD6244) in culture demonstrated resistance, which was a result of the resistance mutation, MAP2K1 H119P (PMID: 19915144)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-KwgqSS-TIFzzUIvVjax	MAP2K1	Selumetinib	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by Selumetinib (AZD6244) in cell culture (PMID: 19915144)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-KxDWSS-TIFzzUIwPjax	MAP2K1	Selumetinib	"In a preclinical study, melanoma cells harboring BRAF V600E and MAP2K1 P124S demonstrated decreased sensitivity to Selumetinib (AZD6244) compared to cells harboring BRAF V600E alone in culture (PMID: 22197931)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22197931	AVv-KxaNSS-TIFzzUIw5jax	MAP2K1	Selumetinib	"In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Selumetinib (AZD6244), resulting in decreased cell viability (PMID: 26582713)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26582713	AVv-KwvaSS-TIFzzUIvujax	MAP2K1	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) did not inhibit proliferation of melanoma cells expressing Map2k1 L115P (PMID: 19915144)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-Kw41SS-TIFzzUIv9jax	MAP2K1	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) did not inhibit proliferation of melanoma cells expressing Map2k1 I103N (PMID: 19915144)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-KwpGSS-TIFzzUIvjjax	MAP2K1	Refametinib	"In a preclinical study, treatment with Refametanib (BAY86-9766) had no effect on a lung adenocarcinoma cell line co-harboring MAP2K1 Y134C and KRAS Q61H in culture (PMID: 26582713)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26582713	AVv-KwquSS-TIFzzUIvmjax	MAP2K1	Refametinib	"In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Refametinib (BAY86-9766), resulting in decreased cell viability (PMID: 26582713)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26582713	AVv-KwyxSS-TIFzzUIvzjax	MAP2K1	RO4927350	"In a preclinical study, a colorectal cancer cell line harboring MAP2K1 F129L demonstrated sensitivity to treatment with RO4927350 in culture and in cell line xenograft models, demonstrating inhibition of tumor growth (PMID: 21705440)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21705440	AVv-KwqNSS-TIFzzUIvljax	MAP2K1	Panitumumab + Trametinib	"In a preclinical study, Vectibix (panitumumab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57N in culture (PMID: 26644315)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26644315	AVv-KxSBSS-TIFzzUIwqjax	MAP2K1	Panitumumab	"In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Vectibix (panitumumab) in culture (PMID: 26644315)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26644315	AVv-KxQ3SS-TIFzzUIwojax	MAP2K1	Panitumumab	"In a preclinical study, a colorectal cancer cell line expressing MAP2K1 K57T was resistant to Vectibix (panitumumab) in culture (PMID: 26644315)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26644315	AVv-KweXSS-TIFzzUIvRjax	MAP2K1	PLX4720	"In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the B-RAF inhibitor PLX4720 in culture (PMID: 19915144)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-KwsXSS-TIFzzUIvpjax	MAP2K1	PLX4720	"In a preclinical study, expression of MAP2K1 C121S conferred resistance to PLX4720 in melanoma cells harboring BRAF V600E in culture (PMID: 21383288)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21383288	AVv-KxV5SS-TIFzzUIwxjax	MAP2K1	PD-0325901	"In a preclinical study, over expression of MAPK21 L115P in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-Kw7PSS-TIFzzUIwBjax	MAP2K1	PD-0325901	"In a preclinical study, over expression of MAPK21 I103N in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-KwnUSS-TIFzzUIvgjax	MAP2K1	PD-0325901	"In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to PD-0325901, resulting in decreased cell viability (PMID: 26582713)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26582713	AVv-KwwCSS-TIFzzUIvvjax	MAP2K1	GSK2126458	"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KxKuSS-TIFzzUIwdjax	MAP2K1	GSK2126458	"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KxM5SS-TIFzzUIwhjax	MAP2K1	GSK2126458	"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KxGgSS-TIFzzUIwVjax	MAP2K1	GSK2126458	"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-Kwd1SS-TIFzzUIvQjax	MAP2K1	E6201	"In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell line harboring BRAF V600E mutation and overexpressing MAP2K1 C121S in culture (PMID: 24448821)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24448821	AVv-KxYBSS-TIFzzUIw1jax	MAP2K1	Dabrafenib + GSK2126458	"In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) did not improve the response to human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture (PMID: 22389471)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KxMWSS-TIFzzUIwgjax	MAP2K1	Dabrafenib	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-Kxd2SS-TIFzzUIw_jax	MAP2K1	Dabrafenib	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture (PMID: 24265153)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-KxZtSS-TIFzzUIw4jax	MAP2K1	Dabrafenib	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-KwhQSS-TIFzzUIvWjax	MAP2K1	Dabrafenib	"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KxJsSS-TIFzzUIwbjax	MAP2K1	Dabrafenib	"In a preclinical study, melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KwuwSS-TIFzzUIvtjax	MAP2K1	Dabrafenib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KxIESS-TIFzzUIwYjax	MAP2K1	Dabrafenib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KxOESS-TIFzzUIwjjax	MAP2K1	Dabrafenib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KwcRSS-TIFzzUIvNjax	MAP2K1	Dabrafenib	"In a preclinical study, expression of MAP2K1 K57E in a melanoma cell line harboring BRAF V600E conferred resistance to Tafinlar (dabrafenib) in culture (PMID: 25370473)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25370473	AVv-KwmASS-TIFzzUIvejax	MAP2K1	Dabrafenib	"In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25370473	AVv-Kw3pSS-TIFzzUIv7jax	MAP2K1	Dabrafenib	"In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124L demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25370473	AVv-Kw10SS-TIFzzUIv4jax	MAP2K1	Dabrafenib	"In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in cell culture (PMID: 25370473)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25370473	AVv-Kw4NSS-TIFzzUIv8jax	MAP2K1	Dabrafenib	"In a preclinical study, a melanoma cell line expressing MAP2K1 V60E demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 24265153)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-KxbUSS-TIFzzUIw7jax	MAP2K1	Dabrafenib	"In a preclinical study, MAP2K1 (MEK1) K57E mutations restored extracellular signal–regulated kinase (ERK) activation in the presence of Tafinlar (dabrafenib) in cultured melanoma cell lines (PMID: 24463458)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24463458	AVv-KwmsSS-TIFzzUIvfjax	MAP2K1	DEL-22379	"In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 26267534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-Kw_-SS-TIFzzUIwJjax	MAP2K1	DEL-22379	"In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N in culture (PMID: 26267534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-Kwn7SS-TIFzzUIvhjax	MAP2K1	Cobimetinib	"In a clinical study, a patient with refractory Erdheim–Chester disease harboring a MAP2K1 Q56P mutation had a reduction of lymphatic infiltrates to background within a month of receiving Cotellic (cobimetinib) therapy (PMID: 26566875)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26566875	AVv-KwzWSS-TIFzzUIv0jax	MAP2K1	Cetuximab + Trametinib	"In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring MAP2K1 F53L in culture (PMID: 28179366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28179366	AVv-Kwk5SS-TIFzzUIvcjax	MAP2K1	Cetuximab + Trametinib	"In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring MAP2K1 C121S in culture (PMID: 28179366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28179366	AVv-KxUSSS-TIFzzUIwujax	MAP2K1	Cetuximab + Trametinib	"In a preclinical study, Erbitux (cetuximab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57T in culture (PMID: 26644315)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26644315	AVv-KwfASS-TIFzzUIvSjax	MAP2K1	Cetuximab + Trametinib	"In a preclinical study, Erbitux (cetuximab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57N in culture (PMID: 26644315)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26644315	AVv-KxPvSS-TIFzzUIwmjax	MAP2K1	Cetuximab	"In a preclinical study, expression of MAP2K1 F53L conferred resistance to Erbitux (cetuximab) in colorectal cancer cells in culture (PMID: 28179366)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28179366	AVv-KwldSS-TIFzzUIvdjax	MAP2K1	Cetuximab	"In a preclinical study, expression of MAP2K1 C121S conferred resistance to Erbitux (cetuximab) in colorectal cancer cells in culture (PMID: 28179366)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28179366	AVv-KxTxSS-TIFzzUIwtjax	MAP2K1	Cetuximab	"In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Erbitux (cetuximab) in culture (PMID: 26644315)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26644315	AVv-KxPLSS-TIFzzUIwljax	MAP2K1	CI-1040	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by CI-1040 in cell culture (PMID: 19915144)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-KxEfSS-TIFzzUIwRjax	MAP2K1	CI-1040	"In a preclinical study, CI-1040 (PD184352) partially inhibited kinase activity of Map2k1 L115A expressed in transformed human kidney cells (PMID: 12370306)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/12370306	AVv-KxBpSS-TIFzzUIwMjax	MAP2K1	CI-1040	"In a preclinical study, CI-1040 (PD184352) partially inhibited kinase activity of Map2k1 I103N expressed in transformed human kidney cells (PMID: 12370306)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/12370306	AVv-KwogSS-TIFzzUIvijax	MAP2K1	CI-1040	"In a preclinical study, CI-1040 (PD184352) inhibited kinase activity of Map2k1 F53S expressed in transformed human kidney cells (PMID: 12370306)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/12370306	AVv-KxYlSS-TIFzzUIw2jax	MAP2K1	CI-1040	"In a preclinical study, CI-1040 (PD184352) did not inhibit proliferation of melanoma cells expressing Map2k1 L115P (PMID: 19915144)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-Kw5XSS-TIFzzUIv-jax	MAP2K1	CI-1040	"In a preclinical study, CI-1040 (PD184352) did not inhibit proliferation of melanoma cells expressing Map2k1 I103N (PMID: 19915144)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-KwpuSS-TIFzzUIvkjax	MAP2K1	CI-1040	"In a preclinical study, CI-1040 (PD184352) did not inhibit kinase activity of Map2k1 L115P expressed in transformed human kidney cells (PMID: 12370306)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/12370306	AVv-Kw56SS-TIFzzUIv_jax	KRAS	rigosertib	"In a preclinical study, Estybon (rigosertib) inhibited tumorigenesis in transgenic animal model of pancreatic cancer driven by KRAS G12D (PMID: 27104980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27104980	AVv-Kq3uSS-TIFzzUIl7jax	KRAS	rigosertib	"In a preclinical study, Estybon (rigosertib) inhibited Mek/Erk signaling and tumor growth in cell line xenograft models of lung cancer harboring KRAS G12S (PMID: 27104980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27104980	AVv-KuoySS-TIFzzUIspjax	KRAS	rigosertib	"In a preclinical study, Estybon (rigosertib) inhibited Mek/Erk signaling and tumor growth in cell line xenograft models of colorectal cancer harboring KRAS G13D (PMID: 27104980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27104980	AVv-KvDFSS-TIFzzUItYjax	KRAS	poziotinib	"In a preclinical study, a human gastric cancer cell line harboring a KRAS mutation demonstrated resistance to Poziotinib (PMID: 21306821)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21306821	AVv-KsKfSS-TIFzzUIoTjax	KRAS	cabozantinib	"In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (47 vs 8 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RAS mutations (PMID: 27525386)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27525386	AVv-KsJ1SS-TIFzzUIoSjax	KRAS	bortezomib + fasudil	"In a preclinical study, the combination of bortezomib and fasudil blocked GATA2 downstream signals in KRAS activated NSCLC cells, resulting in reduced tumor burden, size and number in treated mice (PMID: 22541434)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22541434	AVv-KtbqSS-TIFzzUIqljax	KRAS	XL147 + Carboplatin + Paclitaxel	"In a clinical study, the combination of XL147 plus Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in progressive disease in a patient with colorectal cancer harboring a PIK3CA H1047 mutation and KRAS G12 mutation (PMID: 21216929)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21216929	AVv-KtvwSS-TIFzzUIrIjax	KRAS	XL147	"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a human non-small cell lung cancer cell line harboring KRAS G12S and an STK11(LKB) inactivating mutation (PMID: 25637314)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25637314	AVv-KugNSS-TIFzzUIsbjax	KRAS	XL147	"In a preclinical study, XL147 inhibited tumor growth and vascularization in xenograft models of a human non-small cell lung cancer cell line harboring KRAS Q61K (PMID: 25637314)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25637314	AVv-KuJLSS-TIFzzUIr0jax	KRAS	Volasertib	"In a preclinical study, non-small cell lung carcinoma cells harboring a KRAS mutation were more sensitive to volasertib than cells wild-type for KRAS (PMID: 26597303)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26597303	AVv-Kr6iSS-TIFzzUIn6jax	KRAS	Venetoclax + VX-11e	"In a preclinical study, inhibition of Erk signaling by VX-11e did not sensitize colorectal cancer cell lines harboring KRAS or BRAF activating mutations to Venclexta (venetoclax) in culture (PMID: 27974663)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-Kvt3SS-TIFzzUIuhjax	KRAS	VX-11e + WEHI-539	"In a preclinical study, inhibition of Erk signaling by VX-11e sensitized colorectal cancer cell lines harboring KRAS or BRAF activating mutations to WEHI-539 in culture (PMID: 27974663)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-KvugSS-TIFzzUIuijax	KRAS	UC-857993	"In a preclinical study, UC-857993 did not inhibit growth of pancreatic cancer cells harboring KRAS G12D in culture (PMID: 25825487)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25825487	AVv-KrDPSS-TIFzzUImbjax	KRAS	UC-773587	"In a preclinical study, UC-773587 did not inhibit growth of pancreatic cancer cells harboring KRAS G12D in culture (PMID: 25825487)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25825487	AVv-KrDzSS-TIFzzUImcjax	KRAS	Trametinib + TW-37	"In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 25665005)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25665005	AVv-Kug6SS-TIFzzUIscjax	KRAS	Trametinib + TW-37	"In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human lung cells harboring KRAS G12C in culture (PMID: 25665005)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25665005	AVv-KuPRSS-TIFzzUIr-jax	KRAS	Trametinib + Navitoclax	"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 25665005)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25665005	AVv-KupYSS-TIFzzUIsqjax	KRAS	Trametinib + Navitoclax	"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring KRAS G12C in culture (PMID: 25665005)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25665005	AVv-KuMFSS-TIFzzUIr5jax	KRAS	Trametinib	"In a preclinical study, treatment with Mekinist (trametinib) had no effect on a lung adenocarcinoma cell line co-harboring MAP2K1 Y134C and KRAS Q61H in culture (PMID: 26582713)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26582713	AVv-KvWmSS-TIFzzUIt5jax	KRAS	Trametinib	"In a preclinical study, the effect of Mekinist (trametinib) on human gastric adenocarcinoma cell lines harboring mutant KRAS is conflicting as cell lines were both sensitive and insensitive to Mekinist (trametinib) in culture (PMID: 26343583)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KtAASS-TIFzzUIprjax	KRAS	Trametinib	"In a preclinical study, knocking down of Fgfr3 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture  (PMID: 27338794)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-KtUHSS-TIFzzUIqOjax	KRAS	Trametinib	"In a preclinical study, knocking down of Fgfr2 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-KtkvSS-TIFzzUIq0jax	KRAS	Trametinib	"In a preclinical study, knocking down of Fgfr1 through shRNA did not sensitize KRAS wild-type lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture  (PMID: 27338794)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-Krj9SS-TIFzzUInTjax	KRAS	Trametinib	"In a preclinical study, knocking down of Fgfr1 through shRNA did not sensitize KRAS mutant colorectal cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-KrrCSS-TIFzzUInfjax	KRAS	Trametinib	"In a preclinical study, human triple negative breast cancer cells harboring mutant BRAF, KRAS, and CDKN2A were insensitive to Mekinist (trametinib) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-Ktf7SS-TIFzzUIqsjax	KRAS	Trametinib	"In a preclinical study, human pancreatic ductal carcinoma cell lines harboring mutant KRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KsWcSS-TIFzzUIoojax	KRAS	Trametinib	"In a preclinical study, human multiple myeloma cells harboring mutant KRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-Ks6RSS-TIFzzUIphjax	KRAS	Trametinib	"In a preclinical study, human endometrial cancer cells harboring mutant KRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KtCsSS-TIFzzUIpwjax	KRAS	Trametinib	"In a preclinical study, a lung adenocarcinoma cell line harboring KRAS G12S demonstrated a decreased response when treated with Mekinist (trametinib) in culture (PMID: 26582713)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26582713	AVv-KuiQSS-TIFzzUIsejax	KRAS	Trametinib	"In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition of KRAS mutant pancreatic cancer cells with decreased Fgfr1 expression through shRNA knockdown in culture (PMID: 27338794)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-KrqdSS-TIFzzUInejax	KRAS	Trametinib	"In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition in KRAS mutant lung cancer cells with decreased Fgfr1 expression through shRNA knockdown in culture, and tumor regression in xenograft models (PMID: 27338794)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-KrpsSS-TIFzzUIndjax	KRAS	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture and in cell line xenograft models (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-Kvi1SS-TIFzzUIuPjax	KRAS	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of squamous cell lung carcinoma cells harboring mutant KRAS in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KswHSS-TIFzzUIpRjax	KRAS	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of non-small cell cancer cell lines harboring mutant KRAS in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KswwSS-TIFzzUIpSjax	KRAS	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of a majority (4/5) of human pancreatic adenocarcinoma cell lines harboring mutant KRAS in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KsELSS-TIFzzUIoJjax	KRAS	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of a majority (12/17) lung adenocarcinoma cell lines harboring mutant KRAS in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-Ks4hSS-TIFzzUIpejax	KRAS	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M in culture and in cell line xenograft models (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-Kv6rSS-TIFzzUIvDjax	KRAS	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited Erk activation and growth of thyroid cancer cells harboring KRAS G12R in culture, and reduced tumor size in cell line xenograft models (PMID: 26324075)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26324075	AVv-Kv3jSS-TIFzzUIu9jax	KRAS	Trametinib	"In a Phase I trial, Mekinist (trametinib) reduced tumor formation in 36% (8/22) of solid tumor patients harboring KRAS mutations (PMID: 22805291)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22805291	AVv-KsbDSS-TIFzzUIowjax	KRAS	Temsirolimus + Bevacizumab	"In a clinical study, a colorectal cancer patient harboring a PIK3CA mutation and KRAS mutations at codons 12 and 13 demonstrated stable disease when treated with a combination of Torisel (temsirolimus) and Avastin (bevacizumab) (PMID: 21216929)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21216929	AVv-KtoXSS-TIFzzUIq6jax	KRAS	Temsirolimus	"In a retrospective study of a Phase II trial, mutation status of KRAS was not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with Torisel (temsirolimus) (PMID: 27016228)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27016228	AVv-KsnBSS-TIFzzUIpDjax	KRAS	Temsirolimus	"In a clinical study, two colorectal cancer patients harboring both a PIK3CA E545 and KRAS G12 mutation demonstrated stable disease when treated with Torisel (temsirolimus) (PMID: 21216929)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21216929	AVv-Kto-SS-TIFzzUIq7jax	KRAS	TAE226	"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring KRAS G12S mutation in culture (PMID: 26090892)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26090892	AVv-KuklSS-TIFzzUIsijax	KRAS	Sunitinib	"In a preclinical study, a colorectal cancer cell line harboring the KRAS G13D mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23455880	AVv-KvBkSS-TIFzzUItVjax	KRAS	Sunitinib	"In a preclinical study, a colorectal cancer cell line harboring the KRAS G12V mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23455880	AVv-KuDQSS-TIFzzUIrpjax	KRAS	Sunitinib	"In a preclinical study, a colorectal cancer cell line harboring the KRAS G12S mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23455880	AVv-KurQSS-TIFzzUIstjax	KRAS	Sunitinib	"In a preclinical study, a colorectal cancer cell line harboring the KRAS G12D mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23455880	AVv-Kq72SS-TIFzzUImDjax	KRAS	Sunitinib	"In a preclinical study, a colorectal cancer cell line harboring the KRAS G12C mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23455880	AVv-KuSESS-TIFzzUIsDjax	KRAS	Sunitinib	"In a preclinical study,  colorectal cancer cells harboring a KRAS G12R mutation demonstrated resistance to Sutent (sunitinib) treatment (PMID: 23455880)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23455880	AVv-Kv4jSS-TIFzzUIu_jax	KRAS	Sorafenib	"In a Phase II trial, treatment with Nexavar (sorafenib) resulted in partial response in 8.8% (5/57) and stable disease in 43.8% (25/57) of patients with KRAS-mutant non-small cell lung cancer (PMID: 23224737)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23224737	AVv-KsnnSS-TIFzzUIpEjax	KRAS	Sorafenib	"In a Phase II trial, Nexavar (sorafenib) treatment resulted in comparable 8-week disease control rate in KRAS wild-type (47%, 20/43) and KRAS mutated (44%, 8/18) patients with advanced non-small cell lung carcinoma (PMID: 27480147)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27480147	AVv-KsoVSS-TIFzzUIpFjax	KRAS	Selumetinib + Tazemetostat	"In a preclinical study, the addition of Tazemetostat (EPZ-6438) increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C in culture (PMID: 26676756)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KuYgSS-TIFzzUIsOjax	KRAS	Selumetinib + Tazemetostat	"In a preclinical study, the addition of Tazemetostat (EPZ-6438) did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KrKcSS-TIFzzUImnjax	KRAS	Selumetinib + Docetaxel	"In a Phase II trial, Selumetinib (AZD6244) in combination with Taxotere (docetaxel) improved progression-free survival in KRAS-mutant non-small cell lung cancer patients (PMID: 23200175)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/23200175	AVv-KsuFSS-TIFzzUIpOjax	KRAS	Selumetinib + BEZ235	"In a preclinical study, a mouse lung adenocarcinoma model harboring the KRAS G12D mutation treated with a combination of the MEK inhibitor selumetinib (AZD6244) and the PI3K inhibitor BEZ235 resulted in significant tumor regression (PMID: 19029981)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19029981	AVv-KrIySS-TIFzzUImkjax	KRAS	Selumetinib + BEZ235	"In a preclinical study, BEZ235 in combination with Selumetinib (AZD6244) induced tumor shrinkage in mouse lung cancer models carrying KRAS G12D (PMID: 19029981)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19029981	AVv-KrCESS-TIFzzUImZjax	KRAS	Selumetinib	"In a preclinical study, treatment with Selumetinib (AZD6244) slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26232337	AVv-KrRCSS-TIFzzUImzjax	KRAS	Selumetinib	"In a preclinical study, the treatment of a mouse model lung adenocarcinoma harboring the KRAS G12D mutant with selumetinib, a MEK inhibitor, resulted in modest tumor regression (PMID: 19029981)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/19029981	AVv-Kq63SS-TIFzzUImBjax	KRAS	Selumetinib	"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-KuGmSS-TIFzzUIrvjax	KRAS	Selumetinib	"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-Kqv8SS-TIFzzUIltjax	KRAS	Selumetinib	"In a preclinical study, gastric cancer cell lines with Kras mutations were sensitive to Selumetinib (AZD6244) (PMID: 24935174)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24935174	AVv-Kr9FSS-TIFzzUIn-jax	KRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS mutations due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27422710	AVv-KtBkSS-TIFzzUIpujax	KRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS Q61K mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27422710	AVv-KuIoSS-TIFzzUIrzjax	KRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS Q61H mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27422710	AVv-KvZZSS-TIFzzUIt-jax	KRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G13C mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27422710	AVv-KvrVSS-TIFzzUIudjax	KRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12V mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27422710	AVv-KuAPSS-TIFzzUIrkjax	KRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12S mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27422710	AVv-KumQSS-TIFzzUIsljax	KRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12R mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27422710	AVv-Kv5GSS-TIFzzUIvAjax	KRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12C mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27422710	AVv-KuRhSS-TIFzzUIsCjax	KRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) mildly inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with KRAS and PIK3CA mutations (PMID: 24939055)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24939055	AVv-KtSaSS-TIFzzUIqLjax	KRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) inhibited tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-KtyoSS-TIFzzUIrNjax	KRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) inhibited growth of thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-Kvh1SS-TIFzzUIuNjax	KRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-Kv7OSS-TIFzzUIvEjax	KRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-Kt2HSS-TIFzzUIrTjax	KRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-KqxCSS-TIFzzUIlvjax	KRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD-6244) inhibited proliferation of colorectal adenocarcinoma cells harboring KRAS G13D in culture (PMID: 26438159)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KvAmSS-TIFzzUItTjax	KRAS	Selumetinib	"In a clinical case study, treatment with Selumetinib (AZD6244)  resulted in lack of tumor progression for greater than 7 years in patient with low grade serous ovarian carcinoma harboring KRAS G12V (PMID: 27231576)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27231576	AVv-Kt9vSS-TIFzzUIrgjax	KRAS	Saracatinib + Selumetinib	"In a preclinical study, Saracatinib (AZD0530) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-KsA1SS-TIFzzUIoEjax	KRAS	Saracatinib + SCH772984	"In a preclinical study, Saracatinib (AZD0530) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-Ks1WSS-TIFzzUIpZjax	KRAS	Saracatinib	"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH2 R172K and KRAS G12D demonstrated increased sensitivity to Saracatinib (AZD0530) induced growth inhibition in culture (PMID: 27231123)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27231123	AVv-Kqp_SS-TIFzzUIljjax	KRAS	Salirasib	"In a Phase II clinical trial, salirasib showed no benefit in KRAS-mutant lung adenocarcinoma patients (PMID: 21847063)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/21847063	AVv-Kr-9SS-TIFzzUIoBjax	KRAS	SML-10-70-1	"In a preclinical study, SML-10-70-1 inhibited proliferation and Erk/Akt signaling in cells expressing KRAS G12C (PMID: 24259466)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24259466	AVv-KuOESS-TIFzzUIr8jax	KRAS	SHP099	"In a preclinical study, colorectal cancer cell lines harboring KRAS mutations demonstrated resistance to SHP099 in culture (PMID: 27362227)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/27362227	AVv-KsyISS-TIFzzUIpUjax	KRAS	SH-1242	"In a preclinical study, SH-1242 inhibited lung tumor growth in a KRAS G12D-expressing transgenic mouse model that forms spontaneous lung tumors (PMID: 26645561)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26645561	AVv-Kq_5SS-TIFzzUImVjax	KRAS	SH-1242	"In a preclinical study, SH-1242 inhibited growth of non-small cell lung cancer cells expressing mutant KRAS in culture (PMID: 26645561)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26645561	AVv-KsF-SS-TIFzzUIoMjax	KRAS	SCH772984 + Trametinib	"In a preclinical study, Mekinist (trametinib) and SCH772984 combination treatment demonstrated enhanced growth inhibition and sustained inhibition of Erk signaling in lung cancer cells harboring KRAS G12C in culture (PMID: 27338794)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-KuKcSS-TIFzzUIr2jax	KRAS	SCH772984 + Temsirolimus	"In a preclinical study, Torisel (temsirolimus) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-KsqUSS-TIFzzUIpIjax	KRAS	SCH772984	"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to SCH772984 in culture (PMID: 27312529)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-KvStSS-TIFzzUItyjax	KRAS	SCH772984	"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-Kvd8SS-TIFzzUIuGjax	KRAS	SCH772984	"In a preclinical study, SCH772984 inhibited tumor growth in both cell line and patient-derived xenograft models of KRAS mutant pancreatic ductal adenocarcinoma through down-regulation of Myc protein level (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-KrvhSS-TIFzzUInnjax	KRAS	SAR245409	"In a preclinical study, a colorectal cancer cell line co-harboring a KRAS mutation and PIK3CA mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture (PMID: 24634413)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24634413	AVv-KtRNSS-TIFzzUIqJjax	KRAS	SAR125844	"In a preclinical study, MET amplified lung cancer cells harboring KRAS G12A were insensitive to SAR125844-mediated growth inhibition in culture (PMID: 25504634)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25504634	AVv-KvvCSS-TIFzzUIujjax	KRAS	Rilotumumab + Panitumumab	"In a Phase Ib/II trial, the combination of HGF inhibitor, rilotumumab, with Vectibix (panitumumab) demonstrated efficacy in previously treated patients with wild-type KRAS metastatic colorectal cancer (PMID: 24919569)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24919569	AVv-KrcGSS-TIFzzUInFjax	KRAS	Rigosertib + Gemcitabine	"In a Phase II study, Estybon (rigosertib) in combination with, gemcitabine, did not demonstrate increased efficacy over gemcitabine alone and there was no correlation of reponse with Kras mutational status in pancreatic patients (PMID: 26091808)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26091808	AVv-KsGxSS-TIFzzUIoNjax	KRAS	Ridaforolimus + SCH772984	"In a preclinical study, Ridaforolimus (MK-8669) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-Ksq5SS-TIFzzUIpJjax	KRAS	Reolysin + Gemcitabine	"In a clinical case report, treatment with Reolysin (pelareorep) in combination with Gemzar (gemcitabine) resulted in stable disease in a patient with pancreatic cancer harboring KRAS G12D (PMID: 26156229)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26156229	AVv-Kq9eSS-TIFzzUImRjax	KRAS	Regorafenib + Cetuximab	"In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G12V in culture (PMID: 25838391)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-Kt-YSS-TIFzzUIrhjax	KRAS	Regorafenib + Cetuximab	"In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis in human colorectal cancer cell lines harboring KRAS G13D in culture (PMID: 25838391)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-Ku-5SS-TIFzzUItQjax	KRAS	Regorafenib	"In a preclinical study, human colorectal cancer cells harboring KRAS G13D were resistant to Stivarga (regorafenib) in culture (PMID: 25838391)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-Ku_hSS-TIFzzUItRjax	KRAS	Regorafenib	"In a preclinical study, human colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R were resistant to Stivarga (regorafenib) in culture (PMID: 25838391)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-Ku0BSS-TIFzzUIs9jax	KRAS	Regorafenib	"In a preclinical study, human colorectal cancer cells harboring KRAS G12V were resistant to Stivarga (regorafenib) in culture (PMID: 25838391)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-KuCqSS-TIFzzUIrojax	KRAS	Regorafenib	"In a preclinical study, human colorectal cancer cell lines harboring KRAS G13D, PIK3CA E545K and PIK3CA D549N were resistant to Stivarga (regorafenib) in culture (PMID: 25838391)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-Ku6tSS-TIFzzUItJjax	KRAS	Regorafenib	"In a preclinical study, colorectal cancer cells harboring KRAS G12A were resistant to Stivarga (regorafenib) in culture (PMID: 25838391)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-KvwPSS-TIFzzUIuljax	KRAS	Regorafenib	"In a preclinical study, colorectal cancer cell lines with wild-type BRAF, KRAS, NRAS and PIK3CA were resistant to Stivarga (regorafenib) in culture (PMID: 25838391)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-KrmOSS-TIFzzUInXjax	KRAS	Regorafenib	"In a preclinical study, Stivarga (regorafenib) inhibited proliferation of breast cancer cells harboring BRAF G464V and KRAS G13D in culture and inhibited angiogenesis and tumor growth in cell line xenograft models (PMID: 21170960)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21170960	AVv-Ku30SS-TIFzzUItEjax	KRAS	Regorafenib	"In a clinical case study, Stivarga (regorafenib) treatment resulted in durable partial response in a colorectal cancer patient harboring KDR R961W and mutations in APC and KRAS (PMID: 27004155)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27004155	AVv-KtgjSS-TIFzzUIqtjax	KRAS	Refametinib + Sorafenib	"In a Phase II trial, Refametinib (BAY86-9766), in combination with Nexavar (sorafenib), demonstrated more clinical benefit in hepatocellular carcinoma patients with mutant Kras than in patients with wild-type Kras (PMID: 25294897)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25294897	AVv-KrxUSS-TIFzzUInqjax	KRAS	Refametinib	"In a preclinical study, treatment with Refametanib (BAY86-9766) had no effect on a lung adenocarcinoma cell line co-harboring MAP2K1 Y134C and KRAS Q61H in culture (PMID: 26582713)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26582713	AVv-KvXLSS-TIFzzUIt6jax	KRAS	Refametinib	"In a preclinical study, a lung adenocarcinoma cell line harboring KRAS G12S demonstrated a decreased response when treated with Refametinib (BAY86-9766) in culture (PMID: 26582713)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26582713	AVv-KulHSS-TIFzzUIsjjax	KRAS	Ramucirumab + FOLFIRI	"In a Phase III trial, Cyramza (ramucirumab) followed by FOLFIRI was equally efficacious in metastatic colorectal carcinoma patients with Kras exon 2 mutations as patients with wild-type Kras (PMID: 25877855)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25877855	AVv-KrydSS-TIFzzUInsjax	KRAS	Ralimetinib + SCH772984	"In a preclinical study, Ralimetinib (LY2228820) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-Ks-4SS-TIFzzUIppjax	KRAS	RO5126766	"In a preclinical study, RO5126766 inhibited proliferation of colorectal adenocarcinoma cells harboring KRAS G13D in culture (PMID: 26438159)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KvADSS-TIFzzUItSjax	KRAS	RO4987655	"In a preclinical study, RO4987655 inhibited proliferation of colorectal adenocarcinoma cells harboring KRAS G13D in culture (PMID: 26438159)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KvCISS-TIFzzUItWjax	KRAS	RO4987655	"In a Phase I trial, none of 30 colorectal cancer patients with KRAS mutations achieved favorable response after treatment with RO4987655 (PMID: 24947927)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/24947927	AVv-KsXASS-TIFzzUIopjax	KRAS	RO4987655	"In a Phase I trial, 11% (2/11) of NSCLC patients with Kras mutations achieved partial response after treatment with RO4987655 (PMID: 24947927)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24947927	AVv-Kr2-SS-TIFzzUIn0jax	KRAS	Ponatinib + Trametinib	"In a preclinical study, the combination of Mekinist (trametinib) and Iclusig (ponatinib) induced cell death in tumors and prolonged survival in an animal model of pancreatic cancer harboring KRAS G12D (PMID: 27338794)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-KrHfSS-TIFzzUImijax	KRAS	Ponatinib + Trametinib	"In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) synergistically inhibited proliferation of KRAS mutant pancreatic cancer cells in culture (PMID: 27338794)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-Kr0QSS-TIFzzUInvjax	KRAS	Ponatinib + Trametinib	"In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture and induced tumor regression in xenograft models (PMID: 27338794)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-KsdjSS-TIFzzUIo0jax	KRAS	Ponatinib + Trametinib	"In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) combination treatment was less efficient at inhibiting proliferation of KRAS wild-type lung cancer cells in culture (PMID: 27338794)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-Kra7SS-TIFzzUInDjax	KRAS	Ponatinib + Trametinib	"In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) combination treatment was less efficient at inhibiting proliferation of KRAS mutant colon cancer cells in culture (PMID: 27338794)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-KtBFSS-TIFzzUIptjax	KRAS	Pimasertib + Sorafenib	"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-KvU_SS-TIFzzUIt2jax	KRAS	Pimasertib + Sorafenib	"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-Kuj_SS-TIFzzUIshjax	KRAS	Pimasertib + Sorafenib	"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-KvBESS-TIFzzUItUjax	KRAS	Pimasertib + Regorafenib	"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-KvVjSS-TIFzzUIt3jax	KRAS	Pimasertib + Regorafenib	"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-Kur1SS-TIFzzUIsujax	KRAS	Pimasertib + Regorafenib	"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-KvMjSS-TIFzzUItojax	KRAS	Pimasertib + Regorafenib	"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-Ku9tSS-TIFzzUItOjax	KRAS	Pimasertib + Gemcitabine	"In a preclinical study, the combination of pimasertib and Gemzar (gemcitabine) inhibited tumor growth in a syngeneic mouse model of pancreatic cancer expressing KRAS G12D and TP53 R175H (PMID: 26228206)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26228206	AVv-Kql-SS-TIFzzUIldjax	KRAS	Pimasertib + BEZ235	"In a preclinical study, Pimasertib (MSC1936369B) and BEZ235 combination treatment inhibited tumor growth in colorectal cancer cell line xenograft models harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-KvL8SS-TIFzzUItnjax	KRAS	Pimasertib	"In a preclinical study, non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-KvUbSS-TIFzzUIt1jax	KRAS	Pimasertib	"In a preclinical study, colorectal cancer cells harboring KRAS G13D, PIK3CA D549N and PIK3CA E545K demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-KvLQSS-TIFzzUItmjax	KRAS	Pimasertib	"In a preclinical study, colorectal cancer cells harboring KRAS G13D demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-Ku78SS-TIFzzUItLjax	KRAS	Pimasertib	"In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of non-small cell lung cancer cells harboring KRAS G12V in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-Kt8hSS-TIFzzUIrejax	KRAS	Pazopanib + Trametinib	"In a preclinical study, combination of Mekinist (trametinib) and Votrient (pazopanib) significantly delayed tumor progression in cell line xenograft models of thyroid cancer harboring KRAS G12R (PMID: 26324075)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26324075	AVv-Kv5oSS-TIFzzUIvBjax	KRAS	Pazopanib	"In a preclinical study, Votrient (pazopanib) inhibited Erk activation and growth of thyroid cancer cells harboring KRAS G12R in culture, and reduced tumor size in cell line xenograft models (PMID: 26324075)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26324075	AVv-Kv4GSS-TIFzzUIu-jax	KRAS	Panobinostat + SCH772984	"In a preclinical study, Farydak (panobinostat) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-KsNTSS-TIFzzUIoYjax	KRAS	Panobinostat	"In a preclinical study, Farydak (panobinostat) induced caspase activation and apoptosis in a human multiple myeloma cell line harboring KRAS G12A in culture (PMD: 19490892, PMID: 22693356)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19490892	AVv-KvwwSS-TIFzzUIumjax	KRAS	Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan	"In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with RAS wild-type colorectal cancer compared to FOLFIRI treatment alone (PMID: 26341920)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26341920	AVv-KrYjSS-TIFzzUIm_jax	KRAS	Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan	"In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in patients with KRAS exon 2 mutant colorectal cancer (PMID: 26341920)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26341920	AVv-KtrdSS-TIFzzUIrAjax	KRAS	Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan	"In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with KRAS mutations (PMID: 26341920)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26341920	AVv-Kr3sSS-TIFzzUIn1jax	KRAS	Panitumumab	Vectibix (panitumumab) is not indicated for use in patients with KRAS-mutant colorectal cancer (Guidelines).	resistant	http://www.ncbi.nlm.nih.gov/pubmed/detail...	AVv-KsIkSS-TIFzzUIoQjax	KRAS	Panitumumab	Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).	resistant	http://www.ncbi.nlm.nih.gov/pubmed/detail...	AVv-Kq5WSS-TIFzzUIl-jax	KRAS	Panitumumab	Vectibix (panitumumab) has demonstrated clinical efficacy only in colorectal cancer patients with wild-type KRAS (PMID: 19064407).	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19064407	AVv-KsJMSS-TIFzzUIoRjax	KRAS	Panitumumab	Vectibix (panitumumab) has demonstrated clinical efficacy only in colorectal cancer patients with wild-type KRAS (PMID: 18316791).	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-KrhzSS-TIFzzUInPjax	KRAS	Panitumumab	Patients with metastatic colorectal cancer harboring KRAS mutations in codons 12 or 13 showed resistance to Vectibix (panitumumab) (PMID: 18316791).	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-Kq54SS-TIFzzUIl_jax	KRAS	Panitumumab	Colorectal cancer patients with KRAS mutations in exon 2 or 3 are resistant to Vectibix (panitumumab) (PMID: 18316791).	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-KvI9SS-TIFzzUItijax	KRAS	Panitumumab	Colorectal cancer patients with KRAS mutations in exon 12 or 13 are resistant to Vectibix (panitumumab) (PMID: 18316791).	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/18316791	AVv-KrA8SS-TIFzzUImXjax	KRAS	Palbociclib + Trametinib	"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of colorectal cancer cells harboring KRAS Q61H and PIK3CA E542K (PMID: 26369631)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26369631	AVv-KvXySS-TIFzzUIt7jax	KRAS	Palbociclib + Trametinib	"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of colorectal cancer cells harboring KRAS G12D and PIK3CA Q546L (PMID: 26369631)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26369631	AVv-KrSUSS-TIFzzUIm1jax	KRAS	Palbociclib + Trametinib	"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of PIK3CA wild-type colorectal cancer cells harboring KRAS G12V (PMID: 26369631)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26369631	AVv-KtzPSS-TIFzzUIrOjax	KRAS	Palbociclib + Trametinib	"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in objective response in PDX models of colorectal cancer cells  harboring KRAS mutations (PMID: 26369631)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26369631	AVv-KrtOSS-TIFzzUInjjax	KRAS	PX-866	"In a preclinical study, the treatment of KRAS G12D mutant mouse lung cancer with PX-866, a PI3K inhibitor, resulted in inhibition of tumor growth (PMID: 18493606)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18493606	AVv-Kq7WSS-TIFzzUImCjax	KRAS	PKI-402	"In a preclinical study, PKI-402 inhibited growth of a non-small cell lung cancer cell line harboring both KRAS and STK11 mutations in culture and in cell line xenograft models (PMID: 20371716)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20371716	AVv-KthHSS-TIFzzUIqujax	KRAS	PI-3065	"In a preclinical study, PI-3065 treatment prolonged survival and decreased metastasis in allograft animal models of pancreatic ductal adenocarcinoma harboring KRAS G12D and TP53 R175H through upregulation of host anti-tumor immune response(PMID: 24919154)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/24919154	AVv-KqlRSS-TIFzzUIlcjax	KRAS	PHT-427	"In a preclinical study, a pancreatic cancer cell line harboring a KRAS codon 12 mutation demonstrated resistance to PHT-427, resulting in increased Akt activity (PMID: 20197390, PMID: 20418756)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/20197390	AVv-KtsASS-TIFzzUIrBjax	KRAS	PF3644022 + PF-477736	"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant pancreatic cancer (PMID: 26140595)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26140595	AVv-Kr58SS-TIFzzUIn5jax	KRAS	PF3644022 + PF-477736	"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant lung cancer (PMID: 26140595)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26140595	AVv-KsBgSS-TIFzzUIoFjax	KRAS	PF3644022 + PF-477736	"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant colon cancer (PMID: 26140595)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26140595	AVv-KsLFSS-TIFzzUIoUjax	KRAS	PF3644022 + PF-477736	"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant bladder cancer (PMID: 26140595)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26140595	AVv-KszXSS-TIFzzUIpWjax	KRAS	PF3644022 + PF-477736	"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of various cancer cell lines harboring KRAS mutations in culture and in cell line xenograft models (PMID: 26140595)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26140595	AVv-KsN1SS-TIFzzUIoZjax	KRAS	PF3644022 + PF-477736	"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of transformed cells over expressing KRAS G12V in culture, while single agent inhibition had no effect (PMID: 26140595)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26140595	AVv-KuA2SS-TIFzzUIrljax	KRAS	PF3644022 + PF-477736	"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 combination treatment resulted in significant apoptosis in primary tumor cells isolated from pancreas adenocarcinoma patients harboring KRAS mutations in culture (PMID: 26140595)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26140595	AVv-KsmcSS-TIFzzUIpCjax	KRAS	PF-05212384	"In a preclinical study, human colon cancer cells harboring KRAS G13D, PIK3CA E545K, and PIK3CA D549N had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073, PMID: 24042735)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-Ku6ESS-TIFzzUItIjax	KRAS	PF-05212384	"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human pancreatic cancer cell lines harboring KRAS G12C in culture (PMID: 21325073, PMID: 12068308)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-KuRASS-TIFzzUIsBjax	KRAS	PF-05212384	"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring KRAS G12S in culture (PMID: 21325073, PMID: 23012248)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-KuiySS-TIFzzUIsfjax	KRAS	PF-05212384	"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human colon cancer cells harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 21325073, PMID: 24042735)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-Kuy9SS-TIFzzUIs7jax	KRAS	PF-05212384	"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring BRAF G464V and KRAS G13D in culture (PMID: 21325073, PMID: 17314276)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17314276	AVv-Ku3TSS-TIFzzUItDjax	KRAS	PF-05212384	"In a preclinical study, Gedatolisib (PF-05212384) inhibited growth of several human solid tumor cell lines in culture, including cell lines harboring KRAS mutations (PMID: 21325073)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-KrwxSS-TIFzzUInpjax	KRAS	PF-04691502 + SCH772984	"In a preclinical study, PF-04691502 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-Ks3xSS-TIFzzUIpdjax	KRAS	PF-04691502	"In a preclinical study, PF-04691502 resulted in tumor regression in KRAS-mutant non-small cell lung cancer cell line xenograft models (PMID: 21750219)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21750219	AVv-Kr40SS-TIFzzUIn3jax	KRAS	PF-04691502	"In a preclinical study, PF-04691502 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring both PIK3CA and KRAS mutations (PMID: 21750219)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21750219	AVv-KtIQSS-TIFzzUIp6jax	KRAS	PD-0325901 + Gedatolisib	"In a preclinical study, the combination of Gedatolisib (PF-05212384) and PD-0325901 inhibited tumor growth in colon cancer cell line xenograft models harboring KRAS G13D and PIK3CA H1047R (PMID: 21325073)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-Ku2LSS-TIFzzUItBjax	KRAS	PD-0325901	"In a preclinical study, transformed cell lines with various KRAS codon 12 mutations displayed differential inhibition by PD-0325901 (PMID: 26037647)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23934108	AVv-KttASS-TIFzzUIrDjax	KRAS	PD-0325901	"In a preclinical study, over expression of BRAF V600E in KRAS-mutant colorectal cancer cells resulted in resistance to growth inhibition by PD-0325901 in cell culture (PMID: 26267534)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-KtjfSS-TIFzzUIqyjax	KRAS	PD-0325901	"In a preclinical study, a lung cancer cell line harboring KRAS G12S demonstrated a decreased response when treated with PD-0325901 in culture (PMID: 26582713)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26582713	AVv-KuhsSS-TIFzzUIsdjax	KRAS	PD-0325901	"In a preclinical study, PD-0325901 inhibited growth of lung adenocarcinomas in mouse models expressing Kras G12D (PMID: 22684718)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22684718	AVv-KrBjSS-TIFzzUImYjax	KRAS	PD-0325901	"In a preclinical study, PD-0325901 inhibited growth of colorectal cancer cell lines harboring KRAS A146T in culture and in cell line xenograft models (PMID: 20570890)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20570890	AVv-KvmTSS-TIFzzUIuVjax	KRAS	PD-0325901	"In a Phase I study, PD-325901 demonstrated efficacy but toxicity at current dose was unacceptable (PMID: 21516509)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21516509	AVv-KsXkSS-TIFzzUIoqjax	KRAS	Oxaliplatin + ABT-737	"In a preclinical study, Eloxatin (oxaliplatin), in combination with ABT-737, was only effective in tumor cell lines carrying KRAS mutants and wild-type TP53 (PMID: 21468686)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21468686	AVv-KtF4SS-TIFzzUIp2jax	KRAS	Oxaliplatin	"In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colorectal tumor cell lines carrying KRAS codon 12 or 13 mutations (PMID: 23209813)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23209813	AVv-KtlZSS-TIFzzUIq1jax	KRAS	Oxaliplatin	"In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colorectal tumor cell lines carrying KRAS G12V (PMID: 23209813)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23209813	AVv-KuB-SS-TIFzzUIrnjax	KRAS	Oxaliplatin	"In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colon tumor cell lines carrying KRAS G13D (PMID: 23209813)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23209813	AVv-KvHPSS-TIFzzUItfjax	KRAS	OSI-027 + SCH772984	"In a preclinical study, OSI-027 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-Kr_oSS-TIFzzUIoCjax	KRAS	OSI-027	"In a preclinical study, OSI-027 inhibited tumor growth in ovarian cancer cell line xenograft models harboring KRAS mutations (PMID: 21673091)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21673091	AVv-KsgHSS-TIFzzUIo4jax	KRAS	Nilotinib + SCH772984	"In a preclinical study, Tasigna (nilotinib) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-KsSYSS-TIFzzUIohjax	KRAS	Neratinib + Trastuzumab	"In a preclinical study, Herceptin (trastuzumab) and Neratinib (HKI-272) combination treatment resulted in continued tumor growth in xenograft models of patient derived colorectal cancer cells harboring KRAS G12D (PMID: 26243863)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-Kq8_SS-TIFzzUImFjax	KRAS	Neratinib + Selumetinib	"In a preclinical study, Neratinib (HKI-272) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-KsMOSS-TIFzzUIoWjax	KRAS	Neratinib	"In a preclinical study, colorectal cancer cells harboring KRAS G13D were less sensitive to Neratinib (HKI-272) induced growth inhibition in culture (PMID: 26243863)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-Ku8dSS-TIFzzUItMjax	KRAS	Neratinib	"In a preclinical study, colorectal cancer cells harboring KRAS G12V were less sensitive to Neratinib (HKI-272) induced growth inhibition in culture (PMID: 26243863)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KuEYSS-TIFzzUIrrjax	KRAS	Neratinib	"In a preclinical study, Neratinib (HKI-272) treatment resulted in continued tumor growth in xenograft models of patient derived colorectal cancer cells harboring KRAS G12D (PMID: 26243863)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KrAbSS-TIFzzUImWjax	KRAS	NS1	"In a preclinical study, transformed cells expressing a KRAS mutation demonstrated sensitivity to NS1 in culture, resulting in decreased Mapk and Akt signaling and inhibition of cell transformation (PMID: 27820802)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27820802	AVv-KsZSSS-TIFzzUIotjax	KRAS	Midostaurin + SCH772984	"In a preclinical study, Rydapt (midostaurin) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-Ks2nSS-TIFzzUIpbjax	KRAS	Metformin	"In a preclinical study, Glucophage (metformin) inhibited tumor growth in a variety of KRAS-mutant cancer cell line xenograft models (PMID: 23877793)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23877793	AVv-Kr7LSS-TIFzzUIn7jax	KRAS	Metformin	"In a preclinical study, Glucophage (metformin) inhibited cell proliferation and induced apoptosis in a PTEN-expressing human endometrial cancer cell line harboring KRAS G12D in culture and decreased tumor growth in xenograft models (PMID: 24077915)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24077915	AVv-KrRwSS-TIFzzUIm0jax	KRAS	Metformin	"In a preclinical study, Glucophage (metformin) did not induce growth inhibition or apoptosis in a KRAS wild-type squamous cell carcinoma cell line in culture and did not inhibit tumor growth in xenograft models (PMID: 23877793)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/23877793	AVv-KrZySS-TIFzzUInBjax	KRAS	MLN0128 + PD-0325901	"In a preclinical study, TAK-228 (MLN0128) and PD-0325901 combination treatment resulted in tumor growth stabilization in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D, PIK3CA E545K and H1047L (PMID: 26272063)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-KqpXSS-TIFzzUIlijax	KRAS	MLN0128 + PD-0325901	"In a preclinical study, TAK-228 (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R335fs (PMID: 26272063)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-Kt5mSS-TIFzzUIrZjax	KRAS	MLN0128 + PD-0325901	"In a preclinical study, TAK-228 (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PTEN loss, and TP53 V216M (PMID: 26272063)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-Kq1fSS-TIFzzUIl3jax	KRAS	MLN0128 + PD-0325901	"In a preclinical study, TAK-228 (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12C, PIK3CA H1047R, and TP53 R248W (PMID: 26272063)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-KucwSS-TIFzzUIsVjax	KRAS	MLN0128	"In a preclinical study, MLN0128 inhibited lung tumor growth in mouse models with KRAS G12D and inactivation of STK11 (LKB1), and demonstrated limited efficacy in tumors with KRAS G12D and wild-type STK11 (PMID: 26574479)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26574479	AVv-KqzwSS-TIFzzUIl0jax	KRAS	MK2206 + Tazemetostat	"In a preclinical study, the addition of Tazemetostat (EPZ-6438) increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture (PMID: 26676756)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KrMmSS-TIFzzUImrjax	KRAS	MK2206 + Tazemetostat	"In a preclinical study, the addition of Tazemetostat (EPZ-6438) did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C in culture (PMID: 26676756)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KucJSS-TIFzzUIsUjax	KRAS	MK2206 + SCH772984	"In a preclinical study, MK2206 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-Krx3SS-TIFzzUInrjax	KRAS	MK2206	"In a Phase I study, a patient with pancreatic adenocarcinoma harboring PTEN loss and KRAS G12D was treated with MK-2206 and demonstrated a 23% reduction in tumor size (PMID: 22025163)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22025163	AVv-Kqn_SS-TIFzzUIlgjax	KRAS	MEK162	"In a preclinical study, pancreatic cell lines with KRAS codon 12 mutations had increased sensitivity to Binimetinib (MEK162) (PMID: 25167228)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25167228	AVv-KtqoSS-TIFzzUIq_jax	KRAS	MEK162	"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS mutations due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27422710	AVv-KsjFSS-TIFzzUIo9jax	KRAS	MEK162	"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS Q61K mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27422710	AVv-KuIESS-TIFzzUIryjax	KRAS	MEK162	"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS Q61H mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27422710	AVv-KvY1SS-TIFzzUIt9jax	KRAS	MEK162	"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G13C mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27422710	AVv-Kvr5SS-TIFzzUIuejax	KRAS	MEK162	"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12V mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27422710	AVv-Kt_ASS-TIFzzUIrijax	KRAS	MEK162	"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12S mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27422710	AVv-KuluSS-TIFzzUIskjax	KRAS	MEK162	"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12R mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27422710	AVv-Kv6KSS-TIFzzUIvCjax	KRAS	MEK162	"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12C mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27422710	AVv-KuQcSS-TIFzzUIsAjax	KRAS	MEK162	"In a preclinical study, Binimetinib (MEK162) increased both apoptosis and proliferation in tumors, resulted in no improvement in survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26206338	AVv-KqsdSS-TIFzzUIlnjax	KRAS	MEK162	"In a preclinical study, Binimetinib (MEK162) increased apoptosis in tumors and improved survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206338	AVv-Kq2rSS-TIFzzUIl5jax	KRAS	Linsitinib + SCH772984	"In a preclinical study, Linsitinib (OSI-906) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-KruXSS-TIFzzUInljax	KRAS	LY3009120	"In a preclinical study, LY3009120 inhibited growth of, and blocked MAPK signaling in human colorectal cancer cells harboring KRAS G13D in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KvCmSS-TIFzzUItXjax	KRAS	LY294002	"In a preclinical study, LY294002 reduced phosphorylation of Akt in pancreatic epithelial cells expressing Kras G12D (PMID: 22871572)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22871572	AVv-KrFmSS-TIFzzUImfjax	KRAS	LY2835219	"In a Phase I trial, treatment with Abemaciclib (LY2835219) in non-small cell lung carcinoma patients harboring a KRAS mutation resulted in a disease control rate of 55% (16/29) and a median PFS of 2.8 months (LY2835219) (PMID: 27217383)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27217383	AVv-Ks1-SS-TIFzzUIpajax	KRAS	LY2835219	"In a Phase I trial, a squamous non-small cell lung carcinoma patient with KRAS wild-type and loss of CDKN2A demonstrated a partial response when treated with Abemaciclib (LY2835219) (PMID: 27217383)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27217383	AVv-Krm2SS-TIFzzUInYjax	KRAS	LY2835219	"In a Phase I trial, a colorectal cancer patient co-harboring a KRAS mutation and TP53 mutation demonstrated sensitivity when treated with Abemaciclib (LY2835219), which resulted in stable disease (PMID: 27217383)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27217383	AVv-KtezSS-TIFzzUIqqjax	KRAS	Irinotecan + Selumetinib	"In a Phase II study, Selumetinib (AZD6244), in combination with Camptosar (irinotecan), produced stable disease in 52% (16/32) of colorectal patients with KRAS exon 2 mutations (PMID: 25322874)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25322874	AVv-KtvLSS-TIFzzUIrHjax	KRAS	Irinotecan	"In a preclinical study, Camptostar (irinotecan) suppressed the growth of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in xenograft models (PMID: 21325073, PMID: 16707468)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-KuzcSS-TIFzzUIs8jax	KRAS	Ipatasertib + Selumetinib	"In a preclinical study, Ipatasertib (GDC-0068) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-KsV4SS-TIFzzUIonjax	KRAS	Gefitinib + Trametinib	"In a preclinical study, Mekinist (trametinib) and Iressa (gefitinib) did not demonstrate synergy at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-KrzqSS-TIFzzUInujax	KRAS	Gefitinib	Lung adenocarcinoma patients with KRAS codon 12 or 13 mutations lack sensitivity to Iressa (gefitinib) (PMID: 15696205).	resistant	http://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-KtsgSS-TIFzzUIrCjax	KRAS	Gefitinib	"In clinical studies, lung adenocarcinoma patients with KRAS codon 12 or 13 mutations lack sensitivity to Iressa (gefitinib) (PMID: 15696205)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-KtmjSS-TIFzzUIq3jax	KRAS	Gefitinib	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of EGFR T790M and amplified KRAS in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KvhPSS-TIFzzUIuMjax	KRAS	Gedatolisib + Irinotecan	"In a preclinical study, Gedatolisib (PKI-587) and Camptostar (irinotecan) synergistically suppressed the growth of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R (PMID: 24042735) in xenograft models (PMID: 21325073)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-Ku1ISS-TIFzzUIs_jax	KRAS	Gedatolisib + Camptothecin	"In a preclinical study, Gedatolisib (PKI-587) and Camptothecin in combination synergistictically enhanced Parp cleavage in a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 21325073, PMID: 24042735)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25688157	AVv-Ku1pSS-TIFzzUItAjax	KRAS	GSK343 + Selumetinib	"In a preclinical study, the addition of GSK343 increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C in culture (PMID: 26676756)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KuZkSS-TIFzzUIsQjax	KRAS	GSK343 + Selumetinib	"In a preclinical study, the addition of GSK343 did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KrNtSS-TIFzzUImtjax	KRAS	GSK343 + MK2206	"In a preclinical study, the addition of GSK343 increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture (PMID: 26676756)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KrLiSS-TIFzzUImpjax	KRAS	GSK343 + MK2206	"In a preclinical study, the addition of GSK343 did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C in culture (PMID: 26676756)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KuaLSS-TIFzzUIsRjax	KRAS	GI-4000	"In a Phase II clinical trial, GI-4000 was well-tolerated and resulted in some immune response to KRAS in lung adenocarcinoma patients carrying KRAS mutations (PMID: 25044103)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25044103	AVv-KsYISS-TIFzzUIorjax	KRAS	GI-4000	"In a Phase I clinical trial, GI-4000 was well-tolerated and led to some RAS-directed immune response in patients with RAS-mutant pancreatic cancer (PMID: 25585100)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24372276	AVv-Ks66SS-TIFzzUIpijax	KRAS	GDC0879	"In a preclinical study, non-small cell lung cancer cells harboring KRAS mutations were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-KssNSS-TIFzzUIpLjax	KRAS	GDC0879	"In a preclinical study, colon cancer cells harboring KRAS mutations were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-KsQESS-TIFzzUIodjax	KRAS	GDC0879	"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type pancreatic cancer cells harboring KRAS G12D in cell line xenograft models (PMID: 19276360)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-KqzNSS-TIFzzUIlzjax	KRAS	GDC0879	"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS Q61K in culture and in cell line xenograft models (PMID: 19276360)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-KuJ3SS-TIFzzUIr1jax	KRAS	GDC0879	"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS G12V in patient-derived xenograft models (PMID: 19276360)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-Ktz0SS-TIFzzUIrPjax	KRAS	GDC0879	"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS G12C in patient-derived xenograft models (PMID: 19276360)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-Kud4SS-TIFzzUIsXjax	KRAS	GDC0879	"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type colon cancer cells harboring KRAS G13D in culture ann in cell line xenograft models (PMID: 19276360)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-Ku5hSS-TIFzzUItHjax	KRAS	GDC-0980	"In a preclincal study, GDC-0980 delayed tumor growth in colon cancer cell line xenograft models harboring KRAS and PIKC3A mutations (PMID: 21998291)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21998291	AVv-KtNiSS-TIFzzUIqDjax	KRAS	GDC-0941 + Selumetinib	"In a preclinical study, the combination of Pictilisib (GDC-0941) and Selumetinib (AZD6244) worked synergistically to induce tumor regression in pancreatic cancer cell line xenograft models harboring KRAS mutations (PMID: 22952903)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22952903	AVv-KtCESS-TIFzzUIpvjax	KRAS	GDC-0941 + Selumetinib	"In a preclinical study, the combination of Pictilisib (GDC-0941) and Selumetinib (AZD6244) worked synergistically to induce tumor regression in a pancreatic cancer cell line xenograft model harboring KRAS G12D (PMID: 22952903)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22952903	AVv-Kq4zSS-TIFzzUIl9jax	KRAS	GDC-0941 + Selumetinib	"In a preclinical study, Pictilisib (GDC-0941) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-KsxZSS-TIFzzUIpTjax	KRAS	GDC-0941 + SCH772984	"In a preclinical study, Ipatasertib (GDC-0068) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-KsAOSS-TIFzzUIoDjax	KRAS	GDC-0941	"In a preclinical study, a human non-small cell lung cancer cell line harboring KRAS Q61H (PMID: 19165201) were insensitive to pictilisib (GDC-0941) growth inhibition in culture (PMID: 22693356)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22693356	AVv-KvaZSS-TIFzzUIuAjax	KRAS	GDC-0941	"In a preclinical study, Pictilisib (GDC-0941) demonstrated limited efficacy as a single agent in pancreatic cell line xenograft models harboring KRAS mutations (PMID: 22952903)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22952903	AVv-KtDNSS-TIFzzUIpxjax	KRAS	GDC-0941	"In a preclinical study, Pictilisib (GDC-0941) demonstrated limited efficacy as a single agent in a pancreatic cell line xenograft model harboring KRAS G12D (PMID: 22952903)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22952903	AVv-KrE7SS-TIFzzUImejax	KRAS	GDC-0623	"In a preclinical study, GDC-0623 induced tumor regression in pancreatic cancer cell line xenograft models harboring KRAS G12C (PMID: 23934108)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23934108	AVv-KuTPSS-TIFzzUIsFjax	KRAS	GDC-0623	"In a preclinical study, GDC-0623 demonstrated efficacy in several human tumor cell line xenograft models harboring KRAS mutations (PMID: 23934108)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23934108	AVv-Kss0SS-TIFzzUIpMjax	KRAS	GDC-0623	"In a preclinical study, GDC-0623 demonstrated efficacy against both KRAS-mutant and BRAF-mutant cancer models in cell based assays and cell line xenografts (PMID: 23934108)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23934108	AVv-KvHySS-TIFzzUItgjax	KRAS	GA201	"In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant non-small cell lung cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23209031	AVv-KtV1SS-TIFzzUIqRjax	KRAS	GA201	"In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23209031	AVv-KtWfSS-TIFzzUIqSjax	KRAS	GA201	"In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS wild-type colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23209031	AVv-KrooSS-TIFzzUInbjax	KRAS	GA201	"In a preclinical study, treatment with GA201 resulted in improved overall survival in EGFR-positive renal cell carcinoma cell line xenograft models harboring KRAS mutations, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23209031	AVv-KtiWSS-TIFzzUIqwjax	KRAS	GA201	"In a preclinical study, treatment with GA201 resulted in improved overall survival in EGFR-positive pancreatic cancer cell line xenograft models harboring KRAS mutations, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23209031	AVv-KthwSS-TIFzzUIqvjax	KRAS	GA201	"In a preclinical study, treatment with GA201 induced antibody-dependent cell-mediated cytotoxicity against KRAS wild-type gastric adenocarcinoma in culture, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23209031	AVv-Kri4SS-TIFzzUInRjax	KRAS	Everolimus + SCH772984	"In a preclinical study, AZD8186 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-KsCqSS-TIFzzUIoHjax	KRAS	Everolimus + Pimasertib	"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-KvWCSS-TIFzzUIt4jax	KRAS	Everolimus + Pimasertib	"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-Kum-SS-TIFzzUIsmjax	KRAS	Everolimus + Pimasertib	"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-KvKlSS-TIFzzUItljax	KRAS	Everolimus + Pimasertib	"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-KvJ-SS-TIFzzUItkjax	KRAS	Everolimus	"In a preclinical study, human cancer cells with PIK3CA mutations demonstrated sensitivity to Afinitor (everolimus), but a coincident KRAS mutation led to Afinitor (everolimus) resistance  (PMID: 20664172)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/20664174	AVv-KtTkSS-TIFzzUIqNjax	KRAS	Everolimus	"In a preclinical study, expression of KRAS G13D in an endometrial cancer cell line harboring PIK3CA E545K conferred resistance to Afinitor (everolimus) in xenograft models (PMID: 20664172)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/20664172	AVv-KvTQSS-TIFzzUItzjax	KRAS	Everolimus	"In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to Afinitor (everolimus) compared with cells without KRAS mutations in culture (PMID: 22662154)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-Kt61SS-TIFzzUIrbjax	KRAS	Everolimus	"In a clinical study, KRAS mutations were associated with resistance to Afinitor (everolimus) in patients with advanced solid tumors (PMID: 20664172)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/20664172	AVv-Kr2YSS-TIFzzUInzjax	KRAS	Erlotinib + MK2206	"In a Phase II trial, Tarceva (erlotinib) and MK2206 combination treatment resulted in comparable 8-week disease control rate in KRAS wild-type (57%, 16/28) and KRAS mutated (25%, 2/8) patients with advanced non-small cell lung carcinoma (PMID: 27480147)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27480147	AVv-Ks5HSS-TIFzzUIpfjax	KRAS	Erlotinib	"In a clinical study, KRAS mutations were associated with resistance to Tarceva (erlotinib) in patients with lung adenocarcinoma (PMID: 15696205)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-KsDoSS-TIFzzUIoIjax	KRAS	Erlotinib	"In a Phase II trial, Tarceva (erlotinib) treatment resulted in comparable 8-week disease control rate in KRAS wild-type (36%, 5/14) and KRAS mutated (20%, 1/5) patients with advanced non-small cell lung carcinoma (PMID: 27480147)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27480147	AVv-KsPhSS-TIFzzUIocjax	KRAS	Erlotinib	"In a Phase I trial, Tarceva (erlotinib) treatment resulted in a greater survival benefit in non-small cell lung cancer patients with wild-type KRAS compared to treatment in those patients harboring KRAS mutations (PMID: 18626007)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18626007	AVv-KrVgSS-TIFzzUIm6jax	KRAS	Dinaciclib	"In a preclinical study, lung cancer cell lines harboring activating KRAS mutations demonstrated increased sensitivity to Dinaciclib (SCH 727965) in culture (PMID: 27550941)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27550941	AVv-KvsnSS-TIFzzUIufjax	KRAS	Deguelin	"In a preclinical study, Deguelin inhibited growth of the AGS gastric cancer cell line, which has been reported to harbor PIK3CA and KRAS mutations, in culture (PMID: 20811676, PMID: 24978597)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20811676	AVv-KtI1SS-TIFzzUIp7jax	KRAS	Dasatinib + Trametinib	"In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-KvjWSS-TIFzzUIuQjax	KRAS	Dasatinib + Selumetinib	"In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-Kv9BSS-TIFzzUIvHjax	KRAS	Dasatinib + Selumetinib	"In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-Kvj3SS-TIFzzUIuRjax	KRAS	Dasatinib + SCH772984	"In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-Kv9oSS-TIFzzUIvIjax	KRAS	Dasatinib + SCH772984	"In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-KviTSS-TIFzzUIuOjax	KRAS	Dasatinib + SCH772984	"In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-KskaSS-TIFzzUIo_jax	KRAS	Dasatinib	"In a preclinical study, thyroid cancer cell lines harboring HRAS G13R and KRAS G12R with an acquired SRC T341M mutation demonstrated resistance to Sprycel (dasatinib) in culture and in cell line xenograft models (PMID: 27222538)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-Kv8fSS-TIFzzUIvGjax	KRAS	Dasatinib	"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH2 R172K and KRAS G12D demonstrated increased sensitivity to Sprycel (dasatinib) induced growth inhibition in culture and in xenograft models (PMID: 27231123)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27231123	AVv-KqqsSS-TIFzzUIlkjax	KRAS	Danusertib + SCH772984	"In a preclinical study, Danusertib (PHA-739358) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-KsR1SS-TIFzzUIogjax	KRAS	DZNep + Selumetinib	"In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12C in culture (PMID: 26676756)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KubiSS-TIFzzUIsTjax	KRAS	DZNep + Selumetinib	"In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12S in culture (PMID: 26676756)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KufDSS-TIFzzUIsZjax	KRAS	DZNep + Selumetinib	"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 26676756)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KrMESS-TIFzzUImqjax	KRAS	DZNep + Selumetinib	"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12V (PMID: 26676756)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-Kt0YSS-TIFzzUIrQjax	KRAS	DZNep + Selumetinib	"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KrNOSS-TIFzzUImsjax	KRAS	DZNep + Selumetinib	"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KrJYSS-TIFzzUImljax	KRAS	DZNep + MK2206	"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 26676756)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KrLDSS-TIFzzUImojax	KRAS	DZNep + MK2206	"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12C in culture (PMID: 26676756)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-Kua8SS-TIFzzUIsSjax	KRAS	DZNep + MK2206	"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12S in culture (PMID: 26676756)"	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KufnSS-TIFzzUIsajax	KRAS	DZNep + MK2206	"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KrJ4SS-TIFzzUImmjax	KRAS	DZNep + MK2206	"In a preclinical study, the addition of DZNep did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12V (PMID: 26676756)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-Kt0-SS-TIFzzUIrRjax	KRAS	DZNep + MK2206	"In a preclinical study, the addition of DZNep did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C (PMID: 26676756)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KuX8SS-TIFzzUIsNjax	KRAS	DHM25	"In a preclinical study, DHM25 increased cell death and decreased migration of a triple-negative breast cancer cell line harboring KRAS G13D and BRAF G464V in culture, and reduced tumor growth and lung metastasis in xenograft models (PMID: 26237138)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26237138	AVv-Ku4-SS-TIFzzUItGjax	KRAS	DEL-22379	"In a preclinical study, DEL-22379 inhibited growth of KRAS-mutant melanoma cells over expressing BRAF V600E in culture (PMID: 26267534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-KtkHSS-TIFzzUIqzjax	KRAS	DEL-22379	"In a preclinical study, DEL-22379 induced tumor regression in colorectal cancer xenograft models harboring mutant KRAS (PMID: 26267534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-KrtwSS-TIFzzUInkjax	KRAS	Crizotinib + Trametinib	"In a preclinical study, Mekinist (trametinib) and Xalkori (crizotinib) did not demonstrate synergy at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-KsppSS-TIFzzUIpHjax	KRAS	Crizotinib	"In a preclinical study, a human gastric cancer cell line with high levels of MET expression and expressing KRAS G12D was resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26432108)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26432108	AVv-KrPYSS-TIFzzUImwjax	KRAS	Crizotinib	"In a clinical case study, a patient with a carcinoma of unknown primary harboring MET amplification and KRAS G12V demonstrated a durable response following treatment with Xalkori (crizotinib) (PMID: 25232318)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25232318	AVv-Kt4-SS-TIFzzUIrYjax	KRAS	Copanlisib	"In a preclinical study, treatment with Copanlisib inhibited tumor growth in xenograft models of a human colon cancer cell line harboring PIK3CA and KRAS mutations (PMID: 24170767)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24170767	AVv-KtRwSS-TIFzzUIqKjax	KRAS	Cobimetinib	"In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of human colorectal cancer cell lines harboring KRAS G13D (PMID: 23934108)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23934108	AVv-KvJeSS-TIFzzUItjjax	KRAS	Cobimetinib	"In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of a human pancreatic cancer cell line harboring a KRAS codon 12 mutation (PMID: 23934108)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23934108	AVv-KttjSS-TIFzzUIrEjax	KRAS	Cobimetinib	"In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of a human pancreatic cancer cell line harboring KRAS G12C (PMID: 23934108)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23934108	AVv-KuVsSS-TIFzzUIsJjax	KRAS	Cobimetinib	"In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of a human non-small cell lung cancer cell line harboring a KRAS codon 12 mutation (PMID: 23934108)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23934108	AVv-KtplSS-TIFzzUIq8jax	KRAS	Cobimetinib	"In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of a human non-small cell lung cancer cell line harboring KRAS G12C (PMID: 23934108)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23934108	AVv-KuWzSS-TIFzzUIsLjax	KRAS	Cetuximab + Trametinib	"In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring KRAS G12C in culture (PMID: 28179366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28179366	AVv-KuMxSS-TIFzzUIr6jax	KRAS	Cetuximab + Irinotecan	"In a retrospective study, 100% (2/2) colorectal carcinoma patients harboring an AKT1 E17K mutation and wild-type KRAS/BRAF demonstrated resistance to Erbitux (cetuximab) in combination with Camptosar (irinotecan) (PMID: 25714871)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25714871	AVv-KrneSS-TIFzzUInZjax	KRAS	Cetuximab + FOLFIRI	"In a retrospective analysis of a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI did not demonstrate an improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with RAS mutations (PMID: 25605843)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/25605843	AVv-Kr9sSS-TIFzzUIn_jax	KRAS	Cetuximab + FOLFIRI	"In a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI demonstrated a significant clinical benefit in OS, PFS, and objective response compared to FOLFIRI alone in colorectal cancer patients with RAS wild-type status (PMID: 25605843)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25605843	AVv-KraWSS-TIFzzUInCjax	KRAS	Cetuximab	"In a retrospective study, Erbitux (cetuximab) treatment, alone or in combination, resulted in disease regression or stable disease in 88% (7/8) KRAS/BRAF-wild type colorectal carcinoma patients harboring a PIK3CA mutation (PMID: 25714871)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25714871	AVv-KrTrSS-TIFzzUIm3jax	KRAS	Cetuximab	"In a preclinical study, human colorectal cancer cells harboring KRAS G12V were resistant to Erbitux (cetuximab) in culture (PMID: 25838391)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-KuE-SS-TIFzzUIrsjax	KRAS	Cetuximab	"In a preclinical study, Erbitux (cetuximab) inhibited proliferation of a human colon cancer cell line harboring mutant KRAS and wild-type PIK3CA in culture and reduced tumor growth in xenograft models (PMID: 26715098)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26715098	AVv-KtXpSS-TIFzzUIqUjax	KRAS	Cetuximab	"In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells wild-type for BRAF, KRAS, NRAS and PIK3CA in culture (PMID: 25838391)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-KrlGSS-TIFzzUInVjax	KRAS	Cetuximab	"In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells harboring KRAS G12A in culture (PMID: 25838391)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-Kvx3SS-TIFzzUIuojax	KRAS	Cetuximab	"In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26715098	AVv-KtZgSS-TIFzzUIqXjax	KRAS	Cetuximab	"In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA E545K in culture (PMID: 26715098)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26715098	AVv-KtdcSS-TIFzzUIqojax	KRAS	Cetuximab	"In a clinical study, KRAS mutations were associated with resistance to Erbitux (cetuximab) in patients with colorectal cancer (PMID: 18202412)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18202412	AVv-KsUFSS-TIFzzUIokjax	KRAS	Cetuximab	"In a clinical study, KRAS mutations in codon 12 or 13 were associated with resistance to Erbitux (cetuximab) in colorectal cancer patients (PMID: 18202412)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18202412	AVv-Kq_QSS-TIFzzUImUjax	KRAS	Cetuximab	"In a clinical case report, an acquired KRAS mutation was associated with resistance to Erbitux (cetuximab) in a patient with metastatic colorectal cancer (PMID: 24304820)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24304820	AVv-KsTfSS-TIFzzUIojjax	KRAS	Cetuximab	Ertibux (cetuximab) is not indicated for use in patients with KRAS-mutant colorectal cancer (Guidelines).	resistant	http://www.ncbi.nlm.nih.gov/pubmed/detail...	AVv-KsUoSS-TIFzzUIoljax	KRAS	Cetuximab	Clinical efficacy of Erbitux (cetuximab) has only been demonstrated in patients with wild-type KRAS (PMID: 19064407).	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19064407	AVv-KrbeSS-TIFzzUInEjax	KRAS	CUDC-907	"In a preclinical study, CUDC-907 inhibited growth and induced apoptosis in a human colon cancer cell line harboring PIK3CA and KRAS mutations (PMID: 22693356)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22693356	AVv-KtKCSS-TIFzzUIp9jax	KRAS	CUDC-907	"In a preclinical study, CUDC-907 induced caspase activation in a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 20570890, PMID: 22693356)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20570890	AVv-KuydSS-TIFzzUIs6jax	KRAS	CUDC-907	"In a preclinical study, CUDC-907 induced caspase activation and apoptosis in a human multiple myeloma cell line harboring KRAS G12A in culture (PMID: 19490892, PMID: 22693356)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19490892	AVv-KvxWSS-TIFzzUIunjax	KRAS	CID1067700	"In a preclinical study, CID1067700 inhibited growth and increased apoptosis of non-small cell lung cancer cells that harbor KRAS G12C in culture (PMID: 26247207, PMID: 19477428)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26247207	AVv-KuLeSS-TIFzzUIr4jax	KRAS	CI-1040	"In a preclinical study, colorectal cancer cells harboring KRAS mutations demonstrated sensitivity to CI-1040 in culture (PMID: 19372556)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19372556	AVv-Ksl1SS-TIFzzUIpBjax	KRAS	CI-1040	"In a preclinical study, CI-1040 inhibited growth of a human ovarian cancer cell line harboring a KRAS mutation in culture, and inhibited tumor growth in xenograft models (PMID: 19018267)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19018267	AVv-KsH_SS-TIFzzUIoPjax	KRAS	CH5132799	"In a preclinical study, human tumor cell lines harboring KRAS mutations did not demonstrate sensitivity to CH5132799 in culture (PMID: 22159814)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/22159814	AVv-KsS7SS-TIFzzUIoijax	KRAS	CH5132799	"In a preclinical study, human solid tumor cell lines harboring coincident PIK3CA and KRAS mutations demonstrated sensitivity to CH5132799 in culture (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-KtL0SS-TIFzzUIqAjax	KRAS	CH5132799	"In a preclinical study, CH5132799 inhibited tumor growth in xenograft models of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R mutations (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-Ku2rSS-TIFzzUItCjax	KRAS	CH5132799	"In a preclinical study, CH5132799 inhibited proliferation of endometrial cancer cells harboring PIK3CA G1049R and KRAS G12D mutations in culture (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-KqmrSS-TIFzzUIlejax	KRAS	CH5132799	"In a preclinical study, CH5132799 demonstrated decreased response to tumor growth inhibition in xenograft models of human breast cancer cell lines harboring KRAS G13D and BRAF G464V (PMID: 21558396)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-Ku4bSS-TIFzzUItFjax	KRAS	CCT245737	"In a preclinical study, CCT245737 resulted in some decreased tumor volume in a pancreatic ductal adenocarcinoma transgenic mouse model harboring KRAS G12D and TP53 R175H when compared to control (PMID: 27167172)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27167172	AVv-KqjSSS-TIFzzUIlZjax	KRAS	CC-223	"In a preclinical study, CC-223 inhibited proliferation of HCT-116 colon cancer cells, which have been reported to harbor KRAS G13D and PIK3CA H1047R mutations, in culture (PMID: 25855786, PMID: 24978597)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25855786	AVv-KuxbSS-TIFzzUIs4jax	KRAS	Bevacizumab + Sorafenib	"In a clinical case study, a patient with ovarian carcinoma harboring KRAS Q61H demonstrated sensitivity to treatment with the combination of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in 62% tumor regression (PMID: 25363205)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25363205	AVv-KvZ5SS-TIFzzUIt_jax	KRAS	Bevacizumab	"In a systematic review of 2,266 colorectal cancer patients, treatment with Avastin (bevacizumab) increased progression-free survival in patients harboring wild-type KRAS but not in patients with mutant KRAS (PMID: 23828442)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23828442	AVv-KriVSS-TIFzzUInQjax	KRAS	Bevacizumab	"In a systematic review of 2,266 colorectal cancer patients, treatment with Avastin (bevacizumab) increased progression-free survival in patients harboring wild-type KRAS but not in patients with mutant KRAS (PMID: 23828442)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23828442	AVv-KscQSS-TIFzzUIoyjax	KRAS	BYL719	"In a preclinical study, BYL719 inhibited growth in multiple tumor cell lines expressing PIK3CA mutations, and concurrent KRAS mutations was not associated with resistance (PMID: 24608574)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24608574	AVv-KtHiSS-TIFzzUIp5jax	KRAS	BMS-754807 + SCH772984	"In a preclinical study, BMS-754807 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-Kse0SS-TIFzzUIo2jax	KRAS	BKM120 + Cetuximab	"In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and wild-type PIK3CA in culture and tumor growth in xenograft models (PMID: 26715098)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26715098	AVv-KtY5SS-TIFzzUIqWjax	KRAS	BKM120 + Cetuximab	"In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26715098	AVv-KtaDSS-TIFzzUIqjjax	KRAS	BKM120 + Cetuximab	"In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA E545K in culture (PMID: 26715098)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26715098	AVv-KteFSS-TIFzzUIqpjax	KRAS	BKM120 + AG490	"In a preclinical study, the combination of Buparlisib (BKM120) and Tyrphostin B42 (AG-490) worked synergistically to inhibit proliferation and induce apoptosis in gastric cancer cell lines harboring KRAS mutations in culture (PMID: 22159814)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22159814	AVv-Ks5tSS-TIFzzUIpgjax	KRAS	BKM120 + AG490	"In a preclinical study, the combination of Buparlisib (BKM120) and Tyrphostin B42 (AG-490) worked synergistically to inhibit proliferation and induce apoptosis in gastric cancer cell lines harboring KRAS G12D in culture (PMID: 22159814)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22159814	AVv-Kq4QSS-TIFzzUIl8jax	KRAS	BKM120	"In a preclinical study, colon cancer cell lines harboring mutant KRAS and PIK3CA E545K demonstrated reduced sensitivity to Buparlisib (BKM120) induced growth inhibition in culture (PMID: 26715098)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26715098	AVv-Ktc2SS-TIFzzUIqnjax	KRAS	BKM120	"In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and wild-type PIK3CA in culture and reduced tumor growth in xenograft models (PMID: 26715098)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26715098	AVv-KtXDSS-TIFzzUIqTjax	KRAS	BKM120	"In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26715098	AVv-KtbHSS-TIFzzUIqkjax	KRAS	BKM120	"In a preclinical study, BKM120 suppressed growth of a gastric cancer cell line harboring PIK3CA and KRAS mutations in culture (PMID: 22159814)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22159814	AVv-KtM_SS-TIFzzUIqCjax	KRAS	BKM120	"In a preclinical studu, BKM120 alone failed to induce tumor regression in mouse xenograft models of Kras G13D mutant colorectal cancer (PMID: 24576621)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/24576621	AVv-Ku9ESS-TIFzzUItNjax	KRAS	BKM120	"In a Phase II trial, one patient with Kras and Pikc3a mutant non-squamous NSCLC had a partial response to Buparlisib (BKM120) however, stage 2 of the study was not initiated due to failure of meeting overall stage 1 response endpoints (PMID: 26098748)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26098748	AVv-KtMYSS-TIFzzUIqBjax	KRAS	BI2536	"In a preclinical study, non-small cell lung carcinoma cells harboring a KRAS mutation were more sensitive to BI2536 than cells wild-type for KRAS (PMID: 26597303)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26597303	AVv-Kr13SS-TIFzzUInyjax	KRAS	BI-847325	"In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to a KRAS mutation in culture (PMID: 25873592)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25873592	AVv-KtcUSS-TIFzzUIqmjax	KRAS	BI-847325	"In a preclinical study, BI-847325 induced sustained tumor regression in pancreatic adenocarcinoma cell line xenograft models harboring KRAS G12C (PMID: 27496137)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27496137	AVv-KuP2SS-TIFzzUIr_jax	KRAS	BGJ398 + Trametinib	"In a preclinical study, the combination of Mekinist (trametinib) and BGJ398 synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-KsHdSS-TIFzzUIoOjax	KRAS	BEZ235 + PD98509	"In a preclinical study, the combination of BEZ235 and the MEK1 inhibitor PD98509 worked synergistically or additively to inhibit growth of endometrial cancer cells with amplification of PIK3CA and KRAS in culture (PMID: 22662154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-Kvc2SS-TIFzzUIuEjax	KRAS	BEZ235 + PD98509	"In a preclinical study, the combination of BEZ235 and the MEK1 inhibitor PD98509 worked synergistically or additively to inhibit growth of endometrial cancer cells harboring PIK3CA G1049R, KRAS G12D, and amplification of PIK3CA in culture (PMID: 22662154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-Kq0aSS-TIFzzUIl1jax	KRAS	BEZ235 + Binimetinib	"In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) increased survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206338	AVv-Kqr3SS-TIFzzUIlmjax	KRAS	BEZ235	"In a preclinical study, treatment with BEZ235 slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26232337	AVv-KrP9SS-TIFzzUImxjax	KRAS	BEZ235	"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to BEZ235 treatment (PMID: 26272063)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-KuFjSS-TIFzzUIrtjax	KRAS	BEZ235	"In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to BEZ235 compared with cells without KRAS mutations in culture (PMID: 22662154)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22662154	AVv-Kt6KSS-TIFzzUIrajax	KRAS	BEZ235	"In a preclinical study, colon cancer cells harboring KRAS and PIK3CA mutations demonstrated resistance to BEZ235 in culture and xenograft models (PMID: 23475782)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23475782	AVv-KtLNSS-TIFzzUIp_jax	KRAS	BEZ235	"In a preclinical study, BEZ235 stabilized tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W (PMID: 26272063)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-KqvYSS-TIFzzUIlsjax	KRAS	BEZ235	"In a preclinical study, BEZ235 inhibited tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-KqyISS-TIFzzUIlxjax	KRAS	BEZ235	"In a preclinical study, BEZ235 inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with KRAS and PIK3CA mutations (PMID: 24939055)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24939055	AVv-KtQoSS-TIFzzUIqIjax	KRAS	BEZ235	"In a preclinical study, BEZ235 inhibited mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation, and KRAS G12D (PMID: 26206338)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206338	AVv-KqrSSS-TIFzzUIlljax	KRAS	BEZ235	"In a preclinical study, BEZ235 inhibited growth of colorectal cancer cells harboring KRAS mutations in culture and in xenograft models (PMID: 23475782)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23475782	AVv-Kru-SS-TIFzzUInmjax	KRAS	BEZ235	"In a preclinical study, BEZ235 inhibited  PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206338	AVv-Kq2HSS-TIFzzUIl4jax	KRAS	BEZ235	"In a preclinical study, BEZ235 did not induce tumor shrinkage in mouse lung cancer models carrying KRAS G12D (PMID: 19029981)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/19029981	AVv-KrIHSS-TIFzzUImjjax	KRAS	BEZ235	"In a preclinical study, BEZ235 delayed tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-KtxgSS-TIFzzUIrLjax	KRAS	BEZ235	"In a preclinical study, BEZ235 delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-Kt2pSS-TIFzzUIrUjax	KRAS	BAY1125976	"In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring KRAS G12V and PTEN K6fs*4 in culture (PMID: 27699769)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27699769	AVv-Kt3PSS-TIFzzUIrVjax	KRAS	Aurora Kinase Inhibitor II	"In a preclinical study, Aurora Kinase Inhibitor II (AI II) induced apoptosis and inhibited growth of KRAS-mutant non-small cell lung cancer cell lines in culture (PMID: 26842935)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26842935	AVv-Ks-VSS-TIFzzUIpojax	KRAS	Aurora Kinase Inhibitor II	"In a preclinical study, Aurora Kinase Inhibitor II (AI II) decreased viability of transformed lung cells expressing KRAS G12V  in culture (PMID: 26842935)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26842935	AVv-KuD2SS-TIFzzUIrqjax	KRAS	Aphanin	"In a preclinical study, KRAS wild-type pancreatic cancer cells were less sensitive to Aphanin induced growth inhibition and apoptosis in culture (PMID: 27333990)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27333990	AVv-KrXUSS-TIFzzUIm9jax	KRAS	Aphanin	"In a preclinical study, Aphanin inhibited proliferation and induced apoptosis in pancreatic cancer cells harboring KRAS G12D in culture (PMID: 27333990)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27333990	AVv-KrCrSS-TIFzzUImajax	KRAS	Afatinib + Trametinib	"In a preclinical study, Mekinist (trametinib) and Gilotrif (afatinib) did not demonstrate synergy at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-KsO-SS-TIFzzUIobjax	KRAS	Afatinib + Cetuximab	"In a preclinical study, KRAS G12V was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Kt3xSS-TIFzzUIrWjax	KRAS	Afatinib + Cetuximab	"In a preclinical study, KRAS G12R was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-Kv3DSS-TIFzzUIu8jax	KRAS	Afatinib + Cetuximab	"In a preclinical study, KRAS G12D was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-KqovSS-TIFzzUIlhjax	KRAS	Afatinib	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified KRAS in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KvbGSS-TIFzzUIuBjax	KRAS	AZD9291	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M and amplified KRAS were resistant to Tagrisso (osimertinib) treatment in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KvgGSS-TIFzzUIuKjax	KRAS	AZD9291	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified KRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KvbuSS-TIFzzUIuCjax	KRAS	AZD8835	"In a preclinical study, tumor cell lines harboring KRAS mutations were resistant to AZD8835 induced growth inhibition in culture (PMID: 26839307)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26839307	AVv-Ks9xSS-TIFzzUIpnjax	KRAS	AZD8186 + SCH772984	"In a preclinical study, AZD8186 and SCH772984 synergistically inhibited growth of both established and patient-derived, SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-KsFdSS-TIFzzUIoLjax	KRAS	AZD8055 + Selumetinib	"In a preclinical study, the combination of AZD8055 and Selumetinib (AZD6244) inhibited tumor growth in a colorectal cancer xenograft model harboring PIK3CA and KRAS mutations and had increased efficacy compared to either agent alone (PMID: 22271687)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22271687	AVv-KtPUSS-TIFzzUIqGjax	KRAS	AZD8055 + SCH772984	"In a preclinical study, AZD8055 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-KshTSS-TIFzzUIo6jax	KRAS	AZD8055 + MK-1775	"In a preclinical study, AZD8055 worked synergistically with MK-1775 to inhibit proliferation and promote apoptosis in transformed cells expressing KRAS G12D in culture (PMID: 24791855)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24791855	AVv-KrGPSS-TIFzzUImgjax	KRAS	AZD5363	"In a preclinical study, AZD5363 inhibited proliferation of the AGS gastric cancer cell line, which has been reported to harbor KRAS G12D and PIK3CA E453K mutations (PMID: 24088382, PMID: 19755509)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19755509	AVv-KqypSS-TIFzzUIlyjax	KRAS	AZD4547 + Trametinib	"In a preclinical study, the combination of Mekinist (trametinib) and AZD4547 synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-Ks8GSS-TIFzzUIpkjax	KRAS	AZD2014 + SCH772984	"In a preclinical study, AZD2014 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-KstcSS-TIFzzUIpNjax	KRAS	AZ628 + Selumetinib	"In a preclinical study, Selumetinib (AZD6244) and AZ628 synergistically inhibited Mapk signaling and cell proliferation in colorectal cancer cell lines harboring KRAS activating mutations in culture (PMID: 26351322)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26351322	AVv-KvtRSS-TIFzzUIugjax	KRAS	AZ628 + Selumetinib	"In a preclinical study, BRAF mutant melanoma cells over-expressing KRAS G12V were resistant to Selumetinib (AZD6244) and AZ628 combination treatment in culture (PMID: 26351322)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26351322	AVv-Kt4WSS-TIFzzUIrXjax	KRAS	AZ-TAK1 + Selumetinib	"In a preclinical study, the combination of AZ-TAK1 and Selumetinib (AZD6244) resulted in an additive effect in colon cancer cells harboring KRAS mutant in culture, demonstrating a 90% growth reduction (PMID: 27655129)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27655129	AVv-KrwKSS-TIFzzUInojax	KRAS	AZ-TAK1	"In a preclinical study, a colon cancer cell line harboring a KRAS mutation demonstrated sensitivity to AZ-TAK1 in culture, resulting in a 50% cell growth reduction (PMID: 27655129)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27655129	AVv-Ks9LSS-TIFzzUIpmjax	KRAS	AZ-TAK1	"In a preclinical study, a colon cancer cell line harboring KRAS G12V demonstrated sensitivity to AZ-TAK1 in culture, resulting in inhibition of cell growth (PMID: 27655129)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27655129	AVv-Kt_nSS-TIFzzUIrjjax	KRAS	AUY922	"In a preclinical study, colon cancer cell lines with KRAS codon 12 or 13 mutations demonstrated increased sensitivity to treatment with AUY922 in culture and in xenograft models (PMID: 26832792)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26832792	AVv-Kr1TSS-TIFzzUInxjax	KRAS	AUY922	"In a preclinical study, AUY922 inhibited growth of colon cancer cell lines harboring KRAS G12V in culture (PMID: 26832792)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26832792	AVv-Kt74SS-TIFzzUIrdjax	KRAS	AUY922	"In a preclinical study, AUY922 inhibited growth of a colon cancer cell line harboring KRAS G12D in culture (PMID: 26832792)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26832792	AVv-KrEWSS-TIFzzUImdjax	KRAS	AT13148	"In a preclinical study, a colon cancer cell line harboring PIK3CA and KRAS mutations demonstrated sensitivity to AT13148 in culture (PMID: 22781553)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22781553	AVv-KtOFSS-TIFzzUIqEjax	KRAS	AT13148	"In a preclinical study, AT13148 inhibited tumor growth in a human lung adenocarcinoma cell line xenograft model harboring mutant KRAS (PMID: 22781553)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22781553	AVv-KsrlSS-TIFzzUIpKjax	KRAS	AT-7867	"In a preclinical study, AT-7867 inhibited proliferation of cultured HCT-116 colon cancer cells, which have been reported to harbor KRAS G13D and PIK3CA H1047R mutations (PMID: 20423992, PMID: 24978597)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24978597	AVv-Kux9SS-TIFzzUIs5jax	KRAS	ARS-853	"In a preclinical study, ARS-853 treatment in culture resulted in decreased cell proliferation and apoptotic induction in non-small cell lung carcinoma cells harboring KRAS G12C (PMID: 26841430)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26841430	AVv-KuK7SS-TIFzzUIr3jax	KRAS	ARS-853	"In a preclinical study, ARS-853 inhibited growth of several human tumor cell lines harboring KRAS G12C in 3-dimensional culture conditions (PMID: 26739882)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26739882	AVv-KuT3SS-TIFzzUIsGjax	KRAS	APS-2-79 + Trametinib	"In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of several KRAS mutant cancer cell lines in culture (PMID: 27556948)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27556948	AVv-KsjtSS-TIFzzUIo-jax	KRAS	APS-2-79 + Trametinib	"In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27556948	AVv-KunlSS-TIFzzUIsnjax	KRAS	APS-2-79 + Trametinib	"In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of a colon cancer cell line harboring KRAS G13D in culture (PMID: 27556948)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27556948	AVv-KvIVSS-TIFzzUIthjax	KRAS	APS-2-79 + Selumetinib	"In a preclinical study, the combination of APS-2-49 and Selumetinib (AZD6244) worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27556948	AVv-Kup6SS-TIFzzUIsrjax	KRAS	APS-2-79 + PD-0325901	"In a preclinical study, the combination of APS-2-49 and PD-0325901 worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27556948	AVv-KuoLSS-TIFzzUIsojax	KRAS	APS-2-79 + Binimetinib	"In a preclinical study, the combination of APS-2-49 and Binimetinib (MEK162) worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27556948	AVv-KujaSS-TIFzzUIsgjax	KRAS	AMG 337	"In a preclinical study, a MET-amplified lung cancer cell line harboring KRAS G12A was not sensitive to growth inhibition by AMG 337 in culture (PMID: 27196782)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27196782	AVv-KvvrSS-TIFzzUIukjax	KRAS	AMG 337	"In a clinical case study, a patient with a MET amplified esophageal carcinoma that initially responded to AMG 337, developed resistance upon emergence of KRAS G12D (PMID: 26432108)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26432108	AVv-KqnSSS-TIFzzUIlfjax	KRAS	ABT-263 + SCH772984	"In a preclinical study, Navitoclax (ABT-263)  and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26725216	AVv-Ks8oSS-TIFzzUIpljax	KRAS	A-443654	"In a preclinical study, A-443654 inhibited proliferation of colon cancer cell lines that have been reported to harbor KRAS and PIK3CA mutations in culture (PMID: 24569089, PMID: 24978597)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24978597	AVv-KtTBSS-TIFzzUIqMjax	KRAS	3144	"In a preclinical study, 3144 inhibited growth of a colorectal cancer cell line harboring KRAS G12V in culture (PMID: 28235199)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28235199	AVv-KuBYSS-TIFzzUIrmjax	KRAS	3144	"In a preclinical study, 3144 inhibited growth of a breast cancer cell line harboring KRAS G13D in culture and reduced tumor growth in xenograft models (PMID: 28235199)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28235199	AVv-Ku-RSS-TIFzzUItPjax	KMT2A	N/A	"In multiple clinical studies, KMT2A rearrangements, specifically partial tandem duplications, were associated with a poor overall survival in acute myeloid leukemia patients (PMID: 24487413, PMID: 22915647, PMID: 22417203, PMID: 21881046)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/21881046	AVv-KpTZSS-TIFzzUIlIjax	KMT2A	IRAK1/4	"In a preclinical study, leukemia cells harboring KMT2A-AFF1 demonstrated sensitivity to IRAK1/4 in culture, resulting in decreased cell proliferation (PMID: 28065413)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28065413	AVv-KpYqSS-TIFzzUIlRjax	KMT2A	IRAK1/4	"In a preclinical study, a transgenic leukemic mouse model harboring KMT2A-MLLT3 demonstrated sensitivity to IRAK1/4, resulting in delayed progression and improved survival (PMID: 28065413)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28065413	AVv-KpcQSS-TIFzzUIlXjax	KMT2A	I-CBP112 + JQ1	"In a preclinical study, I-CBP112 sensitized leukemia cells harboring KMT2A fusions to JQ1, resulting in decreased cell growth in culture (PMID: 26552700)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26552700	AVv-KpT7SS-TIFzzUIlJjax	KMT2A	I-CBP112 + Doxorubicin	"In a preclinical study, I-CBP112 sensitized leukemia cells harboring KMT2A fusions to Doxorubicin, leading to decreased cell growth in culture (PMID: 26552700)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26552700	AVv-KpXgSS-TIFzzUIlPjax	KMT2A	Dinaciclib	"In a preclinical study, treatment with Dinaciclib resulted in induced cell death of acute myeloid leukemia cells harboring KMT2A-MLLT3 in culture (PMID: 26627013)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627013	AVv-Kpc6SS-TIFzzUIlYjax	KMT2A	Dinaciclib	"In a preclinical study, treatment with Dinaciclib resulted in induced cell death of acute myeloid leukemia cells harboring KMT2A-AFF1 in culture (PMID: 26627013)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26627013	AVv-KpYFSS-TIFzzUIlQjax	KMT2A	Cytarabine + Panobinostat	"In a preclinical study, Farydak (panobinostat) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cells harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27443263	AVv-KpVESS-TIFzzUIlLjax	KMT2A	Cytarabine + Mocetinostat	"In a preclinical study, Mocetinostat (MGCD0103) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cell lines harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27443263	AVv-KpSvSS-TIFzzUIlHjax	KMT2A	Cytarabine + Dacinostat	"In a preclinical study, Dacinostat (LAQ824) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cell lines harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27443263	AVv-KpVrSS-TIFzzUIlMjax	KMT2A	Cytarabine	"In a preclinical study, Cytosar-U (cytarabine) decreased leukemic cells by 66% in acute lymphocytic leukemia cell line xenograft models harboring a KMT2A rearrangement (PMID: 27443263)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27443263	AVv-KpUeSS-TIFzzUIlKjax	KMT2A	AZD5153	"In a preclinical study, AZD5153 inhibited proliferation of acute myeloid leukemia cells harboring KMT2A-AFF1 (MLL-AF4) in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27573426)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27573426	AVv-KpZ1SS-TIFzzUIlTjax	KMT2A	AZD5153	"In a preclinical study, AZD5153 inhibited proliferation of acute lymphocytic leukemia cells harboring KMT2A-AFF1 (MLL-AF4) in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27573426)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27573426	AVv-KpZQSS-TIFzzUIlSjax	KMT2A	AMI-408	"In a preclinical study, treatment with AMI-408 decreased growth of leukemia cells expressing KMT2A-GAS7 (MLL-GAS7) in culture, and increased survival in xenograft models (PMID: 26766589)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26766589	AVv-KpaeSS-TIFzzUIlUjax	KIT	cabozantinib	"In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Cometriq (cabozantinib) in culture (PMID: 24205792)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24205792	AVv-Koz0SS-TIFzzUIktjax	KIT	cabozantinib	"In a preclinical study, Cometriq (Cabometyx, cabozantinib) slowed tumor growth and decreased mitotic activity in a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT mutations, P577del, W557Lfs*5, and D820G (PMID: 27777285)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27777285	AVv-KoHtSS-TIFzzUIjXjax	KIT	cabozantinib	"In a preclinical study, Cometriq (Cabometyx, cabozantinib) resulted in decreased tumor volume and reduced mitotic activity in a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT A502_Y503dup (PMID: 27777285)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27777285	AVv-KopFSS-TIFzzUIkajax	KIT	Sunitinib	"In a preclinical study, transformed cells expressing a KIT exon 9 mutation demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoGkSS-TIFzzUIjVjax	KIT	Sunitinib	"In a preclinical study, transformed cells expressing W557_K558del demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoWFSS-TIFzzUIjxjax	KIT	Sunitinib	"In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-Kn2eSS-TIFzzUIi6jax	KIT	Sunitinib	"In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KolqSS-TIFzzUIkVjax	KIT	Sunitinib	"In a preclinical study, transformed cells expressing K558delinsNP demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KnonSS-TIFzzUIihjax	KIT	Sunitinib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were resistant to Sutent (sunitinb) in an in vitro kinase assay (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoZ7SS-TIFzzUIj4jax	KIT	Sunitinib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were resistant to Sutent (sunitinib) in an in vitro kinase assay (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoSkSS-TIFzzUIjrjax	KIT	Sunitinib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820A were resistant to Sutent (sunitinib) in an in vitro kinase assay (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KnuiSS-TIFzzUIisjax	KIT	Sunitinib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were resistant to Sutent (sunitinib) in an in vitro kinase assay (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoBsSS-TIFzzUIjMjax	KIT	Sunitinib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Sutent (sunitinb) in an in vitro kinase assay (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoPWSS-TIFzzUIjljax	KIT	Sunitinib	"In a preclinical study, melanoma cells expressing KIT A829P demonstrated resistance to treatment with Sutent (sunitinib) (PMID: 23582185, PMID: 25594040)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23582185	AVv-KpAFSS-TIFzzUIlDjax	KIT	Sunitinib	"In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT T670I demonstrated sensitivity to treatment with Sutent (sunitinib) (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-Knj0SS-TIFzzUIiYjax	KIT	Sunitinib	"In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT D816E demonstrated a decreased response to treatment with Sutent (sunitinib) (PMID: 25239608)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KnvHSS-TIFzzUIitjax	KIT	Sunitinib	"In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT A829P demonstrated a decreased response to treatment with Sutent (sunitinib) (PMID: 25239608)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KovYSS-TIFzzUIkljax	KIT	Sunitinib	"In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_L576del and KIT V654A demonstrated sensitivity to treatment with Sutent (sunitinib) (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KnzdSS-TIFzzUIi1jax	KIT	Sunitinib	"In a preclinical study, a gastrointestinal stromal tumor cell line harboring KIT V560D and KIT D820A demonstrated resistance to Sutent (sunitinib) in culture (PMID: 18955458)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18955458	AVv-KnsdSS-TIFzzUIiojax	KIT	Sunitinib	"In a preclinical study, Sutent (sunitinib) inhibited growth of transformed cell lines overexpressing KIT H697Y in culture (PMID: 19861435)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19861435	AVv-KobESS-TIFzzUIj6jax	KIT	Sunitinib	"In a preclinical study, Sutent (sunitinib) inhibited growth of transformed cell lines over expressing KIT V560del in culture (PMID: 19861435)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19861435	AVv-KoNHSS-TIFzzUIjhjax	KIT	Sunitinib	"In a preclinical study, Sutent (sunitinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT T670I (PMID: 23582185, PMID: 25594040)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23582185	AVv-KngWSS-TIFzzUIiSjax	KIT	Sunitinib	"In a preclinical study, KIT D816V mutations demonstrated resistance to Sutent (sunitinib) in a biochemical assay (PMID: 19164557)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19164557	AVv-KozSSS-TIFzzUIksjax	KIT	Sorafenib	"In a preclinical study, transformed hematopoietic cells expressing KIT D816V demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 17229632)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/17229632	AVv-Ko3CSS-TIFzzUIkzjax	KIT	Sorafenib	"In a preclinical study, transformed cells expressing KIT V560D were sensitive to Nexavar (sorafenib) in culture (PMID: 22665524)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22665524	AVv-Knz-SS-TIFzzUIi2jax	KIT	Sorafenib	"In a preclinical study, Nexavar (sorafenib) inhibited Erk signaling, induced apoptosis, resulted in tumor growth inhibition in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT P551_V555delinsTL (PMID: 19139124)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19139124	AVv-KoprSS-TIFzzUIkbjax	KIT	Sorafenib	"In a preclinical study, Nexavar (sorafenib) inhibited Erk signaling, induced apoptosis, resulted in tumor growth inhibition in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT P551_V555del (PMID: 19139124)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19139124	AVv-KojNSS-TIFzzUIkRjax	KIT	Sorafenib	"In a preclinical study, KIT N505I induced phosphorylation of KIT, ERK, and AKT, and was inhibited by Nexavar (sorafenib) in cell culture of melanocytes, demonstrating sensitivity of N505I to sorafenib (PMID: 24317392)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24317392	AVv-Koq_SS-TIFzzUIkdjax	KIT	Sorafenib	"In a clinical case report, a patient with metastatic thymic carcinoma harboring KIT D820E demonstrated a partial response to treatment with Nexavar (sorafenib) (PMID: 19461405)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19461405	AVv-Kn32SS-TIFzzUIi8jax	KIT	Sorafenib	"In a clinical case report, a patient with advanced thymic carcinoma harboring KIT P577_D579del demonstrated response to treatment with Nexavar (sorafenib), with a decrease in tumor size (PMID: 20970876)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20970876	AVv-KorjSS-TIFzzUIkejax	KIT	Sorafenib	"In a clinical case report, Nexavar (sorafenib) treatment resulted in stable disease in a patient with anal melanoma and pulmonary metastases harboring KIT D820Y (PMID: 20372153)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20372153	AVv-KoK8SS-TIFzzUIjdjax	KIT	Regorafenib	"In a preclinical study, transformed cells expressing KIT W557_K558del demonstrated sensitivity to treatment with Stivarga (regorafineb) in culture, resulting in reduced cell viability (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoVfSS-TIFzzUIjwjax	KIT	Regorafenib	"In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Stivarga (regorafineb) in culture, resulting in reduced cell viability (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-Kn3JSS-TIFzzUIi7jax	KIT	Regorafenib	"In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Stivarga (regorafenib) in culture, resulting in reduced cell viability (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KonASS-TIFzzUIkXjax	KIT	Regorafenib	"In a preclinical study, transformed cells expressing K558delinsNP demonstrated sensitivity to treatment with Stivarga (regorafenib) in culture, resulting in reduced cell viability (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KnnmSS-TIFzzUIifjax	KIT	Regorafenib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT V654A demonstrated resistance to treatment with Stivarga (regorafenib) in culture (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KnybSS-TIFzzUIizjax	KIT	Regorafenib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT T670I demonstrated resistance to treatment with Stivarga (regorafenib) in culture (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KniISS-TIFzzUIiVjax	KIT	Regorafenib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoZbSS-TIFzzUIj3jax	KIT	Regorafenib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoQ8SS-TIFzzUIjojax	KIT	Regorafenib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820A were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KntgSS-TIFzzUIiqjax	KIT	Regorafenib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816H demonstrated a decreased response to treatment with Stivarga (regorafenib) in culture (PMID: 25239608)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoTwSS-TIFzzUIjtjax	KIT	Regorafenib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoCMSS-TIFzzUIjNjax	KIT	Regorafenib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoNpSS-TIFzzUIjijax	KIT	Regorafenib	"In a preclinical study, Stivarga (regorafineb) had no effect on transformed cells expressing a KIT exon 9 mutation in culture (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoEzSS-TIFzzUIjSjax	KIT	Regorafenib	"In a preclinical study, Stivarga (regorafenib) inhibited proliferation of gastrointestinal stromal tumor cells harboring KIT K642E in culture (PMID: 21170960)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21170960	AVv-KnlYSS-TIFzzUIibjax	KIT	Regorafenib	"In a preclinical study, KIT D816H demonstrated resistance to Stivarga (regorafenib) in an in vitro assay, and conferred secondary resistance to Stivarga (regorafenib) in transformed cells expressing other KIT mutations (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-Ko4nSS-TIFzzUIk2jax	KIT	Quizartinib	"In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Quizartinib in culture (PMID: 23497317)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23497317	AVv-Ko11SS-TIFzzUIkxjax	KIT	Quizartinib	"In a preclinical study, KIT D816V conferred resistance to Quizartinib in a mast cell line harboring both KIT V560G and KIT D816V in culture (PMID: 23497317)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23497317	AVv-KoeYSS-TIFzzUIj_jax	KIT	Ponatinib	"In a preclinical study, transformed cells expressing a KIT exon 9 mutation demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoHFSS-TIFzzUIjWjax	KIT	Ponatinib	"In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-Kn11SS-TIFzzUIi5jax	KIT	Ponatinib	"In a preclinical study, transformed cells expressing KIT K558delinsNP demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KnoGSS-TIFzzUIigjax	KIT	Ponatinib	"In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KonvSS-TIFzzUIkYjax	KIT	Ponatinib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoYaSS-TIFzzUIj1jax	KIT	Ponatinib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoReSS-TIFzzUIjpjax	KIT	Ponatinib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820A were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-Kns9SS-TIFzzUIipjax	KIT	Ponatinib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoDLSS-TIFzzUIjPjax	KIT	Ponatinib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoO0SS-TIFzzUIjkjax	KIT	Ponatinib	"In a preclinical study, cells expressing KIT V654A demonstrated some sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-Knw2SS-TIFzzUIiwjax	KIT	Ponatinib	"In a preclinical study, cells expressing KIT V560G demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KocZSS-TIFzzUIj8jax	KIT	Ponatinib	"In a preclinical study, cells expressing KIT V559D demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoJ7SS-TIFzzUIjbjax	KIT	Ponatinib	"In a preclinical study, cells expressing KIT T670I demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KneESS-TIFzzUIiOjax	KIT	Ponatinib	"In a preclinical study, cells expressing KIT D820E demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-Kn4kSS-TIFzzUIi9jax	KIT	Ponatinib	"In a preclinical study, cells expressing KIT D816H demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-Ko4FSS-TIFzzUIk1jax	KIT	Ponatinib	"In a preclinical study, cells expressing KIT A829P demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-Ko_jSS-TIFzzUIlCjax	KIT	Ponatinib	"In a preclinical study, a patient-derived gastrointestinal stromal tumor (GIST) cell line harboring KIT V560_Y578del demonstrated sensitivity to Iclusig (ponatinib) in culture (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-Kow_SS-TIFzzUIkojax	KIT	Ponatinib	"In a preclinical study, a patient derived GIST cell line harboring KIT V560_L576del demonstrated sensitivity to Iclusig (ponatinib) in both culture and PDX models, resulting in phosphorylation inhibition of Akt, Kit, and Erk (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoDuSS-TIFzzUIjQjax	KIT	Ponatinib	"In a preclinical study, a patient derived GIST cell line harboring KIT K642E demonstrated sensitivity to Iclusig (ponatinib) in culture (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KnkzSS-TIFzzUIiajax	KIT	Ponatinib	"In a preclinical study, a patient derived GIST cell line co-harboring KIT W557_K558del and KIT Y823D demonstrated sensitivity to Iclusig (ponatinib) in a PDX model, resulting in complete tumor regression (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoP2SS-TIFzzUIjmjax	KIT	Ponatinib	"In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT T670I demonstrated sensitivity to treatment with Iclusig (ponatinib) (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KnjRSS-TIFzzUIiXjax	KIT	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited growth of a human mast cell line harboring both KIT V560G and KIT D816V in culture (PMID: 24552773)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24552773	AVv-KodwSS-TIFzzUIj-jax	KIT	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited Kit signaling and viability in leukemia cells harboring KIT N822K in culture (PMID: 21482694)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21482694	AVv-Ko7dSS-TIFzzUIk7jax	KIT	Ponatinib	"In a preclinical study, Iclusig (ponatinib) did not inhibit growth of transformed cells expressing KIT D816V in culture (PMID: 22301675)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22301675	AVv-Ko0WSS-TIFzzUIkujax	KIT	Ponatinib	"In a clinical study, a GIST patient harboring KIT M552_K558del, resistant to multiple tyrosine kinase inhibitors, demonstrated resistance to Iclusig (ponatinib) treatment as indicated by disease progression after 4 weeks of treatment (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KokcSS-TIFzzUIkTjax	KIT	PLX3397	"In a preclinical study, PLX3397 inhibited growth of gastrointestinal stromal tumor cell lines harboring KIT activating mutations in culture and in cell line xenograft models (PMID: 24583793)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24583793	AVv-Ko93SS-TIFzzUIk_jax	KIT	PD-0325901	"In a preclinical study, PD-0325901 treatment inhibited Erk phosphorylation and decreased expression of ETV1 and CXCR4 in gastrointestinal stromal tumor cells harboring KIT W557_K558del (PMID: 26936919)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26936919	AVv-KoXYSS-TIFzzUIjzjax	KIT	Nilotinib	"In a preclinical study, transformed cells expressing KIT V560G demonstrated inhibition of cell proliferation and tumor regression both in culture and in vivo when treated with Tasigna (nilotinib) (PMID: 20442311)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20442311	AVv-KobxSS-TIFzzUIj7jax	KIT	Nilotinib	"In a preclinical study, melanoma cells expressing KIT T670I demonstrated resistance to treatment with Tasigna (nilotinib) (PMID: 23582185, PMID: 25594040)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23582185	AVv-KnfuSS-TIFzzUIiRjax	KIT	Nilotinib	"In a preclinical study, Tasigna (nilotinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT A829P (PMID: 23582185, PMID: 25594040)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23582185	AVv-Ko_ASS-TIFzzUIlBjax	KIT	Nilotinib	"In a preclinical study, Tasigna (nilotinib) decreased viability of cells expressing KIT D816V in culture, but did not inhibit KIT phosphorylation or growth of KIT D816V-expressing tumors in mouse models (PMID: 20442311)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/20442311	AVv-Ko1XSS-TIFzzUIkwjax	KIT	N/A	"KIT mutations are used in the diagnosis of gastrointestinal stromal tumors (PMID: 25193432, PMID: 26276366, PMID: 25729899)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/25193432	AVv-KotSSS-TIFzzUIkhjax	KIT	N/A	"In clinical analyses, coincident KIT mutations were associated with higher relapse rate and decreased overall survival in acute myeloid leukemia patients with RUNX1-RUNX1T1 fusions (PMID: 18648004, PMID: 16384925, PMID: 25111512)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/25111512	AVv-KosHSS-TIFzzUIkfjax	KIT	Imatinib + MK2206	"In a preclinical study, the combination of Gleevec (imatinib) and MK2206 demonstrated synergy in inhibiting growth of a gastrointestinal stromal tumor cell line harboring a KIT exon 13 mutation in culture (PMID: 27370604)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27370604	AVv-KoI2SS-TIFzzUIjZjax	KIT	Imatinib	"In a small Phase II study, 18 patients with KIT-positive refractory germ cell tumors treated with Gleevec (imatinib) experienced no significant antitumor activity (PMID: 16462496)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/16462496	AVv-KnqTSS-TIFzzUIikjax	KIT	Imatinib	"In a preclinical study, transformed cells expressing KIT W557_K558del demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoWxSS-TIFzzUIjyjax	KIT	Imatinib	"In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-Kn1KSS-TIFzzUIi4jax	KIT	Imatinib	"In a preclinical study, transformed cells expressing KIT K558delinsNP demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KnnGSS-TIFzzUIiejax	KIT	Imatinib	"In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KomXSS-TIFzzUIkWjax	KIT	Imatinib	"In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Gleevec (imatinib mesylate) in culture (PMID: 15790786)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/15790786	AVv-Ko04SS-TIFzzUIkvjax	KIT	Imatinib	"In a preclinical study, transformed cells co-expressing W557_K558del and KIT D820A were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KnuCSS-TIFzzUIirjax	KIT	Imatinib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT V654A demonstrated no response to treatment with Gleevec (imatinib) in both culture and xenograft models (PMID: 25239608)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-Kny7SS-TIFzzUIi0jax	KIT	Imatinib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT T670I demonstrated no response to treatment with Gleevec (imatinib) in both culture and xenograft models (PMID: 25239608)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-Kng8SS-TIFzzUIiTjax	KIT	Imatinib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoY7SS-TIFzzUIj2jax	KIT	Imatinib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoSDSS-TIFzzUIjqjax	KIT	Imatinib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoCsSS-TIFzzUIjOjax	KIT	Imatinib	"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoOPSS-TIFzzUIjjjax	KIT	Imatinib	"In a preclinical study, transformed cell lines overexpressing KIT H697Y demonstrated reduced sensitivity to Gleevec (imatinib mesylate)-induced growth inhibition in culture (PMID: 19861435)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/19861435	AVv-KoagSS-TIFzzUIj5jax	KIT	Imatinib	"In a preclinical study, melanoma cells expressing KIT T670I demonstrated resistance to treatment with Gleevec (imatinib mesylate) (PMID: 23582185, PMID: 25594040)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23582185	AVv-KndaSS-TIFzzUIiNjax	KIT	Imatinib	"In a preclinical study, melanoma cells expressing KIT A829P demonstrated resistance to treatment with Gleevec (imatinib mesylate) (PMID: 23582185, PMID: 25594040)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23582185	AVv-KpBRSS-TIFzzUIlFjax	KIT	Imatinib	"In a preclinical study, melanocytes expressing KIT N505I were inhibited by Gleevec (imatinib) in culture (PMID: 24317392)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24317392	AVv-KoqXSS-TIFzzUIkcjax	KIT	Imatinib	"In a preclinical study, cells expressing KIT V654A demonstrated resistance to Gleevec (imatinib) in culture (PMID: 16751810)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/16751810	AVv-KnwUSS-TIFzzUIivjax	KIT	Imatinib	"In a preclinical study, a prostate neuroendocrine tumor mouse model expressing Kit did not respond to Gleevec (imatinib), a result of impaired signaling of the Kit pathway (PMID: 27980106)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27980106	AVv-Knq1SS-TIFzzUIiljax	KIT	Imatinib	"In a preclinical study, a patient derived GIST cell line harboring KIT V560_Y578del demonstrated sensitivity to Gleevec (imatinib) in culture (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-Kov6SS-TIFzzUIkmjax	KIT	Imatinib	"In a preclinical study, a patient derived GIST cell line harboring KIT V560_L576del demonstrated sensitivity to Gleevec (imatinib) in both culture and PDX models, resulting in phosphorylation inhibition of Akt, Kit, and Erk (PMID: 25239608)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoEQSS-TIFzzUIjRjax	KIT	Imatinib	"In a preclinical study, a mouse myeloid cell line expressing KIT D816V demonstrated resistance to Gleevec (imatinib) in culture (PMID: 12481435)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/12481435	AVv-KoyYSS-TIFzzUIkrjax	KIT	Imatinib	"In a preclinical study, a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT mutations, P577del, W557Lfs*5, and D820G, demonstrated resistance to treatment with Gleevec (imatinib) (PMID: 27777285)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27777285	AVv-KoIRSS-TIFzzUIjYjax	KIT	Imatinib	"In a preclinical study, a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT A502_Y503dup demonstrated resistance to treatment with Gleevec (imatinib), resulting in increased tumor volume (PMID: 27777285)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27777285	AVv-KooeSS-TIFzzUIkZjax	KIT	Imatinib	"In a preclinical study, a gastrointestinal stromal tumor cell line harboring KIT V560D and KIT D820A demonstrated resistance to Gleevec (imatinib) in culture (PMID: 16954519)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/16954519	AVv-Knr7SS-TIFzzUIinjax	KIT	Imatinib	"In a preclinical study, Gleevec (imatinib) treatment resulted in tumor regression and decreased mitotic activity in gastrointestinal stromal tumor patient derived xenograft (PDX) models harboring KIT K558_G565delinsR (PMID: 27777285)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27777285	AVv-KohZSS-TIFzzUIkPjax	KIT	Imatinib	"In a preclinical study, Gleevec (imatinib) inhibited growth of transformed cell lines over expressing KIT V560del in culture (PMID: 19861435)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19861435	AVv-KoMkSS-TIFzzUIjgjax	KIT	Imatinib	"In a preclinical study, Gleevec (imatinib) had no effect on transformed cells expressing a KIT exon 9 mutation in culture (PMID: 25239608)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25239608	AVv-KoGASS-TIFzzUIjUjax	KIT	Imatinib	"In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation in transformed cells over expressing KIT T417_D419delinsI in culture (PMID: 16015387)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/16015387	AVv-KoJXSS-TIFzzUIjajax	KIT	Imatinib	"In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation efficiently in transformed human cells over expressing both KIT W557C and KIT Y578C in culture (PMID: 23567324)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23567324	AVv-KogTSS-TIFzzUIkCjax	KIT	Imatinib	"In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation efficiently in transformed human cells over expressing KIT Y578C in culture (PMID: 23567324)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23567324	AVv-KoifSS-TIFzzUIkQjax	KIT	Imatinib	"In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation efficiently in transformed human cells over expressing KIT W557G in culture (PMID: 23567324)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23567324	AVv-Kou3SS-TIFzzUIkkjax	KIT	Imatinib	"In a clinical case study, KIT N822K was identified in the tumor of a gastrointestinal stromal tumor patient that was resistant to Gleevec (imatinib mesylate) treatment. (PMID: 26316776)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26316776	AVv-Ko60SS-TIFzzUIk6jax	KIT	Imatinib	"In a clinical case report, a patient with thymic carcinoma harboring KIT D579del achieved disease stabilization following treatment with Gleevec (imatinib) (PMID: 24419427)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24419427	AVv-KpB4SS-TIFzzUIlGjax	KIT	Imatinib	"In a clinical case report, a patient with metastatic thymic carcinoma harboring KIT Y553N demonstrated improved clinical performance and reduction in metastatic lesions following treatment with Gleevec (imatinib) (PMID: 21969494)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21969494	AVv-Koj1SS-TIFzzUIkSjax	KIT	Imatinib	"In a clinical case report, a patient with a gastrointestinal stromal tumor developed disease progression while being treated with Gleevec (imatinib), demonstrating a KIT T670I mutation in the progressive lesion (PMID: 15236194)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/15236194	AVv-KnelSS-TIFzzUIiPjax	KIT	Imatinib	"In a clinical case report, Gleevec (imatinib) in conjunction with third-line chemotherapy resulted in a complete response in a patient with stage IV chemoresistant pure seminoma with KIT over expression (PMID: 18751412)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18751412	AVv-Ko-aSS-TIFzzUIlAjax	KIT	Imatinib	"In a clinical case report, Gleevec (imatinib mesylate) treatment resulted in partial response in a patient with recurrent vulval melanoma harboring KIT K642E, reduced tumor mass by 35% (PMID: 20372153)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20372153	AVv-Knl6SS-TIFzzUIicjax	KIT	Imatinib	"In a clinical case report, Gleevec (imatinib mesylate) treatment resulted in partial response in a patient with metastasized anal melanoma harboring a 21 base-pair duplication in exon 11 of KIT, reduced pulmonary metastasis by 60% (PMID: 20372153)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20372153	AVv-Kn85SS-TIFzzUIjEjax	KIT	Imatinib	"In a clinical case report, Gleevec (imatinib mesylate) treatment resulted in initial tumor reduction followed by disease progression in a patient with metastasized labial melanoma harboring KIT L576P (PMID: 20372153)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/20372153	AVv-KoABSS-TIFzzUIjJjax	KIT	Imatinib	"In a case report study, a patient with mucosal melanoma harboring KIT C443S demonstrated a substantial response to Gleevec (imatinib) in the first two weeks and then developed progression at 15 weeks (PMID: 25003536)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25003536	AVv-KoLcSS-TIFzzUIjejax	KIT	Imatinib	"In a Phase II trial that supported FDA approval, treatment with Gleevec (imatinib) resulted in a 38% overall response rate in patients with c-KIT positive GIST (PMID: 12374669)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/12374669	AVv-KnpySS-TIFzzUIijjax	KIT	Imatinib	"In Phase I trials, KIT M541L has been associated with response to Gleevec (imatinib) in chronic eosinophilic leukemia, NOS (PMID: 25015329) and mastocytosis (PMID: 18795925)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25015329	AVv-KoflSS-TIFzzUIkBjax	KIT	Dasatinib + Cytarabine	"In a clinical case study, a patient with acute myeloid leukemia harboring KIT D816V achieved long-term remission and loss of KIT D816V following treatment with the combination of Sprycel (dasatinib) and Cytosar-U (cytarabine) (PMID: 18986703)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18986703	AVv-KoxkSS-TIFzzUIkpjax	KIT	Dasatinib	"In two clinical case studies, patients with Gleevec (imatinib)-melanoma that harboring KIT L576P demonstrated initial clinical benefit following treatment with Sprycel (dasatinib), however progressed after 3-4 months of treatment (PMID: 19671763)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19671763	AVv-KoAjSS-TIFzzUIjKjax	KIT	Dasatinib	"In a preclinical study, transformed cells expressing KIT V560D were sensitive to Sprycel (dasatinib) in culture (PMID: 16397263)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/16397263	AVv-Kn0lSS-TIFzzUIi3jax	KIT	Dasatinib	"In a preclinical study, melanoma cells expressing KIT T670I demonstrated resistance to treatment with Sprycel (dasatinib) (PMID: 23582185, PMID: 25594040)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23582185	AVv-KnfLSS-TIFzzUIiQjax	KIT	Dasatinib	"In a preclinical study, Sprycel (dasatinib) inhibited growth and induced apoptosis in a mast-cell leukemia cell line harboring both KIT V560G and KIT D816V in culture (PMID: 18024392)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18024392	AVv-KodGSS-TIFzzUIj9jax	KIT	Dasatinib	"In a preclinical study, Sprycel (dasatinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT A829P (PMID: 23582185, PMID: 25594040)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23582185	AVv-KpApSS-TIFzzUIlEjax	KIT	Bevacizumab + Sorafenib	"In a clinical case study, a melanoma patient harboring KIT L576P demonstrated sensitivity to the combination treatment of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in a partial response for 8 months (PMID: 25363205)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25363205	AVv-KoBISS-TIFzzUIjLjax	KIT	Bevacizumab + Sorafenib	"In a clinical case study, a GIST patient harboring KIT S476I and MET R988C demonstrated sensitivity to the combination treatment, Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for 6 months (PMID: 25363205)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25363205	AVv-KolESS-TIFzzUIkUjax	KIT	BPR1J373	"In a preclinical study, transformed cells expressing KIT D816V were sensitive to BPR1J373, demonstrating inhibition of Kit phosphorylation (PMID: 27512117)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27512117	AVv-Ko3mSS-TIFzzUIk0jax	KIT	BPR1J373	"In a preclinical study, an acute myeloid leukemia cell line harboring KIT wild-type was sensitive to BPR1J373 in culture, demonstrating apoptotic induction and inhibition of cell proliferation (PMID: 27512117)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27512117	AVv-KnpNSS-TIFzzUIiijax	KIT	BPR1J373	"In a preclinical study, a mast-cell leukemia cell line simultaneously harboring KIT D816V and KIT V560G was sensitive to BPR1J373 in culture, demonstrating inhibition of Kit phosphorylation and apoptotic activity (PMID: 27512117)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27512117	AVv-Koe-SS-TIFzzUIkAjax	KIT	BGJ398 + Imatinib	"In a preclinical study, BGJ398 and Gleevec (imatinib mesylate) combination treatment demonstrated enhanced antitumor activity in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT mutations (PMID: 25673643)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25673643	AVv-Kot0SS-TIFzzUIkijax	KIT	BGJ398 + Imatinib	"In a preclinical study, BGJ398 and Gleevec (imatinib mesylate) combination treatment demonstrated enhanced antiproliferative activity in gastrointestinal stromal tumor cells harboring KIT V560_Y578del in culture (PMID: 25673643)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25673643	AVv-KowcSS-TIFzzUIknjax	KIT	BGJ398 + Imatinib	"In a preclinical study, BGJ398 and Gleevec (imatinib mesylate) combination treatment demonstrated enhanced antiproliferative activity in gastrointestinal stromal tumor cells harboring KIT K642E in culture (PMID: 25673643)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25673643	AVv-KnkTSS-TIFzzUIiZjax	KDR	TAS-115	"In a preclinical study, pancreatic islet endothelial cells were sensitive to TAS-115, resulting in decreased phosphorylation of Vegfr2, and inhibition of cell growth and angiogenesis in culture and mouse models (PMID: 24140932)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24140932	AVv-KmroSS-TIFzzUIh_jax	KDR	Sunitinib	"In a preclinical study, upregulation of Kdr (Vegfr2) was identified in tumors acquired resistance to Sutent (sunitinib) in allograft models of breast cancer (PMID: 28011623)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/28011623	AVv-KmtkSS-TIFzzUIiCjax	KDR	Sunitinib	"In a preclinical study, cells expressing KDR activating mutations were sensitive to Sutent (sunitinib) in cell culture (PMID: 19723655)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19723655	AVv-Kmq6SS-TIFzzUIh-jax	KDR	Sunitinib	"In a preclinical study, cells expressing KDR D717V were sensitive to Sutent (sunitinib) in culture (PMID: 19723655)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19723655	AVv-Kms6SS-TIFzzUIiBjax	KDR	Sunitinib	"In a preclinical study, cells expressing KDR A1065T were sensitive to Sutent (sunitinib) in culture (PMID: 19723655)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19723655	AVv-KmuLSS-TIFzzUIiDjax	KDR	Sunitinib	"In a Phase II clinical trial of patients with metastatic urothelial cancer, Sutent (sunitinib) demonstrated limited antitumor activity, warranting further investigation of VEGF pathways as a therapeutic target (PMID: 20142593)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20142593	AVv-KmqXSS-TIFzzUIh9jax	KDR	Sorafenib	"In a preclinical study, Nexavar (sorafenib) demonstrated efficacy in cells expressing KDR activating mutations (PMID: 19723655)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19723655	AVv-KmpASS-TIFzzUIh7jax	KDR	Regorafenib	"In a clinical case study, Stivarga (regorafenib) treatment resulted in durable partial response in a colorectal cancer patient harboring KDR R961W and mutations in APC and KRAS (PMID: 27004155)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27004155	AVv-KmvXSS-TIFzzUIiFjax	KDR	Ramucirumab	"In a Phase I trial, Cyramza (ramucirumab), an inhibitor of KDR (VEGFR2), demonstrated safety and efficacy (partial response or stable disease) in patients with advanced solid tumors (PMID: 20048182)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20048182	AVv-KmxiSS-TIFzzUIiJjax	KDR	Pz-1	"In a preclinical study, Pz-1 inhibited Kdr2 phosphorylation in transformed cells expressing KDR wild-type (PMID: 26126987)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26126987	AVv-KmyISS-TIFzzUIiKjax	KDR	Lucitanib	"In a Phase I trial, Lucitanib (E-3810) demonstrated safety and efficacy in patients with FGF-aberrant or angiogenesis-sensitive advanced solid tumors (PMID: 25193991)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25193991	AVv-KmprSS-TIFzzUIh8jax	KDR	Anti-VEGFR2 CAR CD8 lymphocytes	"In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes, displayed efficacy in inhibiting cell and tumor growth in a variety of solid tumor cell lines and mouse tumor models (PMID: 20978347)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20978347	AVv-KmyrSS-TIFzzUIiLjax	KDR	Anti-VEGFR2 CAR CD8 lymphocytes	"In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes increased survival of melanoma mouse models (PMID: 23633494)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23633494	AVv-KmzPSS-TIFzzUIiMjax	KDM6A	GSK343	"In a preclinical study, GSK343 inhibited proliferation of KDM6A null urothelial bladder carcinoma cell lines in culture and delayed tumor onset, improved survival in cell line xenograft models (PMID: 28228601)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28228601	AVv-KmaSSS-TIFzzUIh6jax	JAK3	Tofacitinib	"In a preclinical study, Xeljanz (tofacitinib), a pan-JAK inhibitor, reduced cell viability and increased apoptosis in a JAK3 A572V mutant natural killer/T-cell lymphoma cell line (PMID: 22705984)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22705984	AVv-KmH5SS-TIFzzUIhxjax	JAK3	Tofacitinib	"In a preclinical study, Xeljanz (tofacitinib) treatment converted cells expressing JAK3 V221I from factor-independent to factor-dependent growth in cell culture (PMID: 25146434)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25146434	AVv-KmIhSS-TIFzzUIhyjax	JAK3	Tofacitinib	"In a preclinical study, Xeljanz (tofacitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing both JAK3 L857P and Y100A in culture (PMID: 26446793)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26446793	AVv-KmHCSS-TIFzzUIhwjax	JAK3	Tofacitinib	"In a preclinical study, Xeljanz (tofacitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 V674A in culture (PMID: 26446793)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26446793	AVv-KmMFSS-TIFzzUIh4jax	JAK3	Tofacitinib	"In a preclinical study, Xeljanz (tofacitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 L857P in culture (PMID: 26446793)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26446793	AVv-KmJvSS-TIFzzUIh0jax	JAK3	Ruxolitinib	"In a preclinical study, transformed cells over expressing both JAK3 L857P and JAK3 Y100A demonstrated reduced sensitivity to Jakafi (ruxolitinib) in culture (PMID: 26446793)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26446793	AVv-KmGRSS-TIFzzUIhvjax	JAK3	Ruxolitinib	"In a preclinical study, transformed cells over expressing JAK3 L857P demonstrated reduced sensitivity to Jakafi (ruxolitinib) in culture (PMID: 26446793)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26446793	AVv-KmJKSS-TIFzzUIhzjax	JAK3	Ruxolitinib	"In a preclinical study, Jakafi (ruxolitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 V674A in culture (PMID: 26446793)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26446793	AVv-KmK8SS-TIFzzUIh2jax	JAK3	NIBR3049	"In a preclinical study, transformed cells over expressing JAK3 V674A demonstrated reduced sensitivity to NIBR3049 in culture (PMID: 26446793)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26446793	AVv-KmLgSS-TIFzzUIh3jax	JAK3	NIBR3049	"In a preclinical study, NIBR3049 inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing both JAK3 L857P and Y100A in culture (PMID: 26446793)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26446793	AVv-KmFHSS-TIFzzUIhujax	JAK3	NIBR3049	"In a preclinical study, NIBR3049 inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 L857P in culture (PMID: 26446793)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26446793	AVv-KmKUSS-TIFzzUIh1jax	JAK2	SHP099	"In a preclinical study, SHP099 inhibited proliferation of a hematopoietic cancer cell line harboring JAK2 V617F in culture (PMID: 27362227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27362227	AVv-KlmZSS-TIFzzUIhIjax	JAK2	SGI-1776	"In a preclinical study, myeloproliferative cancer cell lines harboring JAK2 V617F demonstrated reduced sensitivity to SGI-1776 induced growth inhibition in culture (PMID: 26472029)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26472029	AVv-KlncSS-TIFzzUIhKjax	JAK2	SAR302503	"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to fedratinib (SAR302503) in culture (PMID: 21926964)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21926964	AVv-KleLSS-TIFzzUIg5jax	JAK2	SAR302503	"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Fedratinib (SAR302503) in culture (PMID: 21926964)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21926964	AVv-KlUQSS-TIFzzUIgnjax	JAK2	SAR302503	"In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Fedratinib (SAR302503) in culture (PMID: 24398328)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24398328	AVv-KlY5SS-TIFzzUIgvjax	JAK2	Ruxolitinib + ZSTK474	"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-KluvSS-TIFzzUIhXjax	JAK2	Ruxolitinib + ZSTK474	"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-Kln9SS-TIFzzUIhLjax	JAK2	Ruxolitinib + ZSTK474	"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-KlqrSS-TIFzzUIhQjax	JAK2	Ruxolitinib + ZSTK474	"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-KllPSS-TIFzzUIhGjax	JAK2	Ruxolitinib + TGX-221	"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-KlthSS-TIFzzUIhVjax	JAK2	Ruxolitinib + TGX-221	"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-KlpASS-TIFzzUIhNjax	JAK2	Ruxolitinib + TGX-221	"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-KlrMSS-TIFzzUIhRjax	JAK2	Ruxolitinib + TGX-221	"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-KlhkSS-TIFzzUIg_jax	JAK2	Ruxolitinib + SGI-1776	"In a preclinical study, Jakafi (ruxolitinib) worked synergistically with SGI-1776 to inhibit proliferation of myeloproliferative cancer cell lines harboring JAK2 V617F in culture (PMID: 26472029)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26472029	AVv-KlioSS-TIFzzUIhBjax	JAK2	Ruxolitinib	"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21926964	AVv-KlchSS-TIFzzUIg2jax	JAK2	Ruxolitinib	"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 M929I double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21926964	AVv-KlWGSS-TIFzzUIgqjax	JAK2	Ruxolitinib	"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21926964	AVv-KlTMSS-TIFzzUIgljax	JAK2	Ruxolitinib	"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 22271575)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22271575	AVv-KlbdSS-TIFzzUIg0jax	JAK2	Ruxolitinib	"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 E985K double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21926964	AVv-KlVeSS-TIFzzUIgpjax	JAK2	Ruxolitinib	"In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Jakafi (ruxolitinib) in culture (PMID: 24398328)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24398328	AVv-KlYXSS-TIFzzUIgujax	JAK2	Ruxolitinib	"In a preclinical study, cells harboring the JAK2 V617F/Y931C double mutation displayed resistance to ATP-competetive JAK inhibitors, such as  Jakafi (Ruxolitinib) (PMID: 21393331)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21393331	AVv-KlQUSS-TIFzzUIggjax	JAK2	Ruxolitinib	"In a preclinical study, cells harboring JAK2 Y931C displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21393331	AVv-KlPuSS-TIFzzUIgfjax	JAK2	Ruxolitinib	"In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 22271575)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22271575	AVv-KlxMSS-TIFzzUIhbjax	JAK2	Pyridone 6	"In a preclinical study, immune cells expressing ETV6-JAK2 with the Y918H mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22916261	AVv-KlXPSS-TIFzzUIgsjax	JAK2	Pyridone 6	"In a preclinical study, immune cells expressing ETV6-JAK2 with the V881A mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22916261	AVv-KlzbSS-TIFzzUIhfjax	JAK2	Pyridone 6	"In a preclinical study, immune cells expressing ETV6-JAK2 with the R975G mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22916261	AVv-KlRdSS-TIFzzUIgijax	JAK2	Pyridone 6	"In a preclinical study, immune cells expressing ETV6-JAK2 with the R1127K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22916261	AVv-KlafSS-TIFzzUIgyjax	JAK2	Pyridone 6	"In a preclinical study, immune cells expressing ETV6-JAK2 with the P1057S mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22916261	AVv-KlQ0SS-TIFzzUIghjax	JAK2	Pyridone 6	"In a preclinical study, immune cells expressing ETV6-JAK2 with the N909K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22916261	AVv-KlSDSS-TIFzzUIgjjax	JAK2	Pyridone 6	"In a preclinical study, immune cells expressing ETV6-JAK2 with the M929I mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22916261	AVv-KlWoSS-TIFzzUIgrjax	JAK2	Pyridone 6	"In a preclinical study, immune cells expressing ETV6-JAK2 with the G935R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22916261	AVv-KlwDSS-TIFzzUIhZjax	JAK2	Pyridone 6	"In a preclinical study, immune cells expressing ETV6-JAK2 with the G831R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22916261	AVv-KlqISS-TIFzzUIhPjax	JAK2	Pyridone 6	"In a preclinical study, immune cells expressing ETV6-JAK2 with the E864K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22916261	AVv-Kl1LSS-TIFzzUIhijax	JAK2	NVP-BVB808	"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22271575	AVv-Kla_SS-TIFzzUIgzjax	JAK2	NVP-BVB808	"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 E864K double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22271575	AVv-KlfzSS-TIFzzUIg8jax	JAK2	NVP-BVB808	"In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22271575	AVv-KlwqSS-TIFzzUIhajax	JAK2	NVP-BVB808	"In a preclinical study, cells expressing the JAK2 R683G/E864K double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22271575	AVv-Kl0jSS-TIFzzUIhhjax	JAK2	NVP-BSK805 + paclitaxel	"In a preclinical study, NVP-BSK805 with Abraxane (paclitaxel) inhibited tumor growth in triple-negative breast cancer patient-derived xenograft models with JAK2 amplification (PMID: 27075627)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27075627	AVv-Kly7SS-TIFzzUIhejax	JAK2	NVP-BSK805 + paclitaxel	"In a preclinical study, NVP-BSK805 with Abraxane (paclitaxel) inhibited tumor growth in patient-derived xenograft models of triple-negative breast cancer with JAK2 overexpression (PMID: 27075627)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27075627	AVv-KlruSS-TIFzzUIhSjax	JAK2	NVP-BSK805	"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22271575	AVv-KlcASS-TIFzzUIg1jax	JAK2	NVP-BSK805	"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 E864K double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22271575	AVv-KlfPSS-TIFzzUIg7jax	JAK2	NVP-BSK805	"In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22271575	AVv-Klx0SS-TIFzzUIhcjax	JAK2	NVP-BSK805	"In a preclinical study, cells expressing the JAK2 R683G/E864K double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22271575	AVv-Klz_SS-TIFzzUIhgjax	JAK2	NVP-BSK805	"In a preclinical study, NVP-BSK805 inhibited tumor growth in triple-negative breast cancer patient-derived xenograft models harboring JAK2 amplification (PMID: 27075627)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27075627	AVv-KlyWSS-TIFzzUIhdjax	JAK2	Momelotinib	"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to Momelotinib (CYT387) in culture (PMID: 21926964)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21926964	AVv-KldCSS-TIFzzUIg3jax	JAK2	Momelotinib	"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Momelotinib in culture (PMID: 21926964)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21926964	AVv-KlU0SS-TIFzzUIgojax	JAK2	Momelotinib	"In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Momelotinib (CYT387) in culture (PMID: 24398328)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24398328	AVv-KlZbSS-TIFzzUIgwjax	JAK2	Lestaurtinib	"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to lestauranib in culture (PMID: 21926964)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21926964	AVv-KldmSS-TIFzzUIg4jax	JAK2	Lestaurtinib	"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Lestauranib in culture (PMID: 21926964)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21926964	AVv-KlSpSS-TIFzzUIgkjax	JAK2	Imatinib	"In a preclinical study, transformed mouse myeloid cells over expressing JAK2 V617F were resistant to Gleevec (imatinib) in culture (PMID: 21224473)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21224473	AVv-KlhCSS-TIFzzUIg-jax	JAK2	Go 6976	"In a preclinical study, Go 6976 inhibited proliferation of cultured acute myeloid leukemia cells expressing the JAK2 V617F mutation (PMID: 16956345)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/16956345	AVv-KljqSS-TIFzzUIhDjax	JAK2	GDC-0941 + Ruxolitinib	"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-KluESS-TIFzzUIhWjax	JAK2	GDC-0941 + Ruxolitinib	"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-KlplSS-TIFzzUIhOjax	JAK2	GDC-0941 + Ruxolitinib	"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-KlsWSS-TIFzzUIhTjax	JAK2	GDC-0941 + Ruxolitinib	"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-KljKSS-TIFzzUIhCjax	JAK2	BEZ235 + Ruxolitinib	"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-KlveSS-TIFzzUIhYjax	JAK2	BEZ235 + Ruxolitinib	"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-KlofSS-TIFzzUIhMjax	JAK2	BEZ235 + Ruxolitinib	"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-Kls9SS-TIFzzUIhUjax	JAK2	BEZ235 + Ruxolitinib	"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24251790	AVv-KlgYSS-TIFzzUIg9jax	JAK2	AZD1480	"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to AZD1480 in culture (PMID: 21926964)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21926964	AVv-KletSS-TIFzzUIg6jax	JAK2	AZD1480	"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to AZD1480 in culture (PMID: 21926964)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21926964	AVv-KlTsSS-TIFzzUIgmjax	JAK2	AZD1208 + Ruxolitinib	"In a preclinical study, Jakafi (ruxolitinib) worked synergistically with AZD1208 to inhibit proliferation of myeloproliferative cancer cell lines harboring JAK2 V617F  in culture (PMID: 26472029)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26472029	AVv-Klm9SS-TIFzzUIhJjax	JAK2	AZD1208	"In a preclinical study, myeloproliferative cancer cell lines harboring JAK2 V617F demonstrated reduced sensitivity to AZD1208 induced growth inhibition in culture (PMID: 26472029)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26472029	AVv-KlkKSS-TIFzzUIhEjax	JAK2	AZ960	"In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to AZ960 in culture (PMID: 24398328)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24398328	AVv-KlZ_SS-TIFzzUIgxjax	JAK2	AUY922	"In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to AUY922 in culture (PMID: 24398328)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24398328	AVv-KlXySS-TIFzzUIgtjax	JAK2	A-1155463	"In a preclinical study, acute myeloid leukemia cells harboring JAK2 V617F demonstrated sensitivity to A-1155463 in culture (PMID: 25787766)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25787766	AVv-KllxSS-TIFzzUIhHjax	IKZF1	lenalidomide	"In a preclinical study, Revlimid (lenalidomide) treatment resulted in IKZF1 degradation and decreased proliferation of multiple myeloma cells in culture (PMID: 24292625)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24292625	AVv-Kk2bSS-TIFzzUIgcjax	IKZF1	N/A	"In multiple clinical studies, including a meta-analysis, IKZF1 deletion was associated with a worse event-free survival and overall survival in patients with acute lymphocytic leukemia (PMID: 25335741, PMID: 26194343, PMID: 27067989)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/25335741	AVv-Kk3CSS-TIFzzUIgdjax	IDH2	Venetoclax	"In a Phase II trial, an acute myeloid leukemia patient harboring IDH2 D76fs demonstrated sensitivity to treatment with Venclexta (venetoclax), achieving a complete response with incomplete blood count recovery after 24 weeks (PMID: 27520294)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27520294	AVv-KkiMSS-TIFzzUIgOjax	IDH2	Saracatinib	"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH2 R172K and KRAS G12D demonstrated increased sensitivity to Saracatinib (AZD0530) induced growth inhibition in culture (PMID: 27231123)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27231123	AVv-KkqVSS-TIFzzUIgbjax	IDH2	Dasatinib	"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH2 R172K and KRAS G12D demonstrated increased sensitivity to Sprycel (dasatinib) induced growth inhibition in culture and in xenograft models (PMID: 27231123)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27231123	AVv-KkpySS-TIFzzUIgajax	IDH2	AGI-6780	"In a preclinical study, treatment with AGI-6780 resulted in the differentiation of erythroleukemia and AML cell lines expressing IDH2 R140Q (PMID: 23558173)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23558173	AVv-KkmCSS-TIFzzUIgUjax	IDH2	AG-221	"In a preclinical study, AG-221 decreased 2-hydroxyglutarate (2HG) levels in a glioblastoma cell line expressing IDH2 R172K in culture (PMID: 28193778)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28193778	AVv-KkomSS-TIFzzUIgYjax	IDH2	AG-221	"In a preclinical study, AG-221 decreased 2-hydroxyglutarate (2HG) levels in a glioblastoma cell line expressing IDH2 R140Q in culture and in xenograft models (PMID: 28193778)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28193778	AVv-KknZSS-TIFzzUIgWjax	IDH2	AG-221	"In a preclinical study, AG-221 decreased 2-hydroxyglutarate (2HG) levels in a colorectal carcinoma cell line expressing IDH2 R172K in culture (PMID: 28193778)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28193778	AVv-KkpMSS-TIFzzUIgZjax	IDH2	AG-221	"In a preclinical study, AG-211 decreased 2-hydroxyglutarate (2HG) levels and induced differentiation of leukemic blasts from acute myeloid leukemia (AML) patients harboring IDH2 R172K in culture (PMID: 28193778)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28193778	AVv-KkoASS-TIFzzUIgXjax	IDH1	VX-970	"In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to VX-970-induced growth inhibition in culture (PMID: 28148839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28148839	AVv-KkB7SS-TIFzzUIfujax	IDH1	Saracatinib	"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S demonstrated increased sensitivity to Saracatinib (AZD0530) induced growth inhibition compared to IDH1 wild-type cells in culture (PMID: 27231123)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27231123	AVv-KkTFSS-TIFzzUIgNjax	IDH1	Saracatinib	"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132C demonstrated increased sensitivity to Saracatinib (AZD0530) induced growth inhibition compared to IDH1 wild-type cells in culture (PMID: 27231123)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27231123	AVv-KkHJSS-TIFzzUIf3jax	IDH1	Rucaparib	"In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Rubraca (rucaparib)-induced growth inhibition in culture (PMID: 28148839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28148839	AVv-Kj5xSS-TIFzzUIfhjax	IDH1	Olaparib	"In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Lynparza (olaparib)-induced growth inhibition in culture (PMID: 28148839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28148839	AVv-KkBZSS-TIFzzUIftjax	IDH1	Olaparib	"In a preclinical study, colon carcinoma cells over expressing IDH1 R132H demonstrated increased sensitivity to Lynparza (olaparib)-induced growth inhibition in culture (PMID: 28148839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28148839	AVv-Kj5CSS-TIFzzUIffjax	IDH1	Olaparib	"In a preclinical study, Lynparza (olaparib) treatment delayed tumor growth in cell line xenograft models of sarcoma harboring IDH1 R132C (PMID: 28148839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28148839	AVv-KkJ6SS-TIFzzUIf8jax	IDH1	Niraparib	"In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Niraparib (MK8427)-induced growth inhibition in culture (PMID: 28148839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28148839	AVv-KkAxSS-TIFzzUIfsjax	IDH1	N/A	"In two meta-analyses, IDH1 mutations were associated with a worse overall survival in patients with acute myeloid leukemia (PMID: 22616558, PMID: 23226625)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/22616558	AVv-KkLZSS-TIFzzUIf_jax	IDH1	N/A	"In multiple clinical studies, including two meta-analyses, IDH1 mutations were associated with improved overall survival and progression free survival in patients with gliomas (PMID: 23817809, PMID: 26220714, PMID: 23894344)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/23894344	AVv-KkMZSS-TIFzzUIgBjax	IDH1	N/A	"In multiple clinical studies, including two meta-analyses, IDH1 mutations were associated with a greater overall survival and progression free survival in patients with glioblastoma (PMID: 23904262, PMID: 26945349, PMID: 20560678)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/20560678	AVv-KkQrSS-TIFzzUIgJjax	IDH1	N/A	"IDH1 mutations are used in the diagnosis of various subtypes of gliomas (PMID: 23041832, PMID: 19755387, PMID: 19915484)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/23041832	AVv-KkM9SS-TIFzzUIgCjax	IDH1	Metformin + AGI-5198	"In a preclinical study, colorectal cancer cells harboring IDH1 R132H demonstrated increased cell proliferation when treated with a combination of Glucophage (metformin) and AGI-5198 (PMID: 26363012)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26363012	AVv-Kj-8SS-TIFzzUIfpjax	IDH1	Metformin	"In a preclinical study, colorectal carcinoma cells expressing IDH1 R132H were sensitive to Glucophage (metformin), resulting in decreased cell proliferation in culture (PMID: 26363012)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26363012	AVv-Kj_fSS-TIFzzUIfqjax	IDH1	Gemcitabine + Radiotherapy	"In a Phase I trial, Gemzar (gemcitabine) plus radiation therapy resulted in median overall survival of 73.5 months in 7 high-grade glioma patients with IDH mutated, non-codeleted tumors with ATRX loss (PMID: 26853339)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26853339	AVv-KkK6SS-TIFzzUIf-jax	IDH1	Decitabine	"In a preclinical study, Dacogen (decitabine) decreased colony formation and tumor growth in patient derived xenograft (PDX) models of patient derived oligodendroglioma cells with IDH1 R132H mutations and co-deletion of 1p and 19q (PMID: 24077826)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24077826	AVv-Kj-VSS-TIFzzUIfojax	IDH1	Dasatinib	"In a preclinical study, lung adenocarcinoma cells harboring IDH1 mutations were resistant to Sprycel (dasatinib) in culture (PMID: 27231123)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27231123	AVv-KkOgSS-TIFzzUIgFjax	IDH1	Dasatinib	"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S demonstrated increased sensitivity to Sprycel (dasatinib) induced growth inhibition compared to IDH1 wild-type cells in culture (PMID: 27231123)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27231123	AVv-KkSeSS-TIFzzUIgMjax	IDH1	Dasatinib	"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S acquired resistance to Sprycel (dasatinib) after over expressing SRC T341I in culture (PMID: 27231123)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27231123	AVv-KkGhSS-TIFzzUIf2jax	IDH1	Dasatinib	"In a preclinical study, chondrosarcoma cells harboring IDH1 mutations were resistant to Sprycel (dasatinib) in culture (PMID: 27231123)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27231123	AVv-KkPnSS-TIFzzUIgHjax	IDH1	Dasatinib	"In a preclinical study, Sprycel (dasatinib)  inhibited growth of intrahepatic cholangiocarcinoma cells harboring IDH1 R132C in culture, and suppressed tumor growth in PDX models (PMID: 27231123)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27231123	AVv-KkHsSS-TIFzzUIf4jax	IDH1	Bevacizumab + Lomustine	"In a retrospective analysis of a Phase II trial, IDH1 mutation correlated with favorable overall survival in recurrent glioblastoma patients treated with a combination of  Avastin (bevacizumab) and Lomustine (PMID: 26762204)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26762204	AVv-KkRQSS-TIFzzUIgKjax	IDH1	BPTES	"In a preclinical study, a glioma cell line expressing IDH1 R132H demonstrated increased sensitivity to growth inhibition by BPTES compared to a cell line expressing wild-type IDH1 in culture (PMID: 21045145)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21045145	AVv-Kj7xSS-TIFzzUIfkjax	IDH1	BMN673 + Cisplatin	"In a preclinical study, Talazoparib (BMN-673) and Cisplatin synergistically inhibited growth of transformed cells over expressing IDH1 R132H in culture (PMID: 28148839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28148839	AVv-Kj9rSS-TIFzzUIfnjax	IDH1	BMN673	"In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28148839	AVv-Kj7QSS-TIFzzUIfjjax	IDH1	BMN673	"In a preclinical study, patient-derived glioma cells harboring IDH1 R132H demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28148839	AVv-Kj9ESS-TIFzzUIfmjax	IDH1	BMN673	"In a preclinical study, patient-derived glioma cells harboring IDH1 R132C demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28148839	AVv-KkJZSS-TIFzzUIf7jax	IDH1	BMN673	"In a preclinical study, colon carcinoma cells over expressing IDH1 R132H demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28148839	AVv-Kj8gSS-TIFzzUIfljax	IDH1	AGI-5198 + Radiotherapy	"In a preclinical study, colorectal cancer cells expressing IDH1 R132H were resistant to radiotherapy when treated with AGI-5198 (PMID: 26363012)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26363012	AVv-Kj6lSS-TIFzzUIfijax	IDH1	AGI-5198 + Olaparib	"In a preclinical study, AGI-5198 reverted the sensitivity of sarcoma cells harboring IDH1 R132C to Lynparza (olaparib)-induced growth inhibition in culture (PMID: 28148839)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28148839	AVv-KkIzSS-TIFzzUIf6jax	IDH1	AGI-5198 + BMN673	"In a preclinical study, AGI-5198 reverted the sensitivity of transformed cells over expressing IDH1 R132H to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28148839	AVv-KkAKSS-TIFzzUIfrjax	IDH1	AGI-5198 + BMN673	"In a preclinical study, AGI-5198 reverted the sensitivity of sarcoma cells harboring IDH1 R132C to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28148839	AVv-KkKZSS-TIFzzUIf9jax	IDH1	AGI-5198	"In a preclinical study, AGI-5198 inhibited growth of a glioma cell line harboring IDH1 R132H in culture and in xenograft models (PMID: 23558169)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23558169	AVv-KkDGSS-TIFzzUIfwjax	IDH1	AGI-5198	"In a preclinical study, AGI-5198 inhibited growth and promoted differentiation in glioma cells expressing IDH1 R132C (PMID: 23558169)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23558169	AVv-KkIOSS-TIFzzUIf5jax	HRAS	rigosertib	"In a preclinical study, Estybon (rigosertib) inhibited oncogenic transformation in fibroblast cells over-expressing HRAS G12V in culture (PMID: 27104980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27104980	AVv-Kja3SS-TIFzzUIe9jax	HRAS	cabozantinib	"In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (47 vs 8 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RAS mutations (PMID: 27525386)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27525386	AVv-KjjoSS-TIFzzUIfMjax	HRAS	Trametinib	"In a preclinical study, human urinary transitional cell carcinoma cells harboring mutant HRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KjlgSS-TIFzzUIfPjax	HRAS	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture and in cell line xenograft models (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-KjQXSS-TIFzzUIesjax	HRAS	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of human endometrial cancer cells harboring mutant HRAS in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KjifSS-TIFzzUIfKjax	HRAS	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M in culture and in cell line xenograft models (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-KjTTSS-TIFzzUIexjax	HRAS	Selumetinib	"In a preclinical study, human solid tumor cell lines harboring HRAS mutations demonstrated increased sensitivity to growth inhibition by  Selumetinib (AZD6244) in culture compared to cell lines with wild-type HRAS (PMID: 26544513)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26544513	AVv-KjmFSS-TIFzzUIfQjax	HRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) inhibited growth of thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-KjRjSS-TIFzzUIeujax	HRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) inhibited growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture, and inhibited tumor growth in xenograft models (PMID: 26544513)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26544513	AVv-KjJ6SS-TIFzzUIehjax	HRAS	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-KjV2SS-TIFzzUIe1jax	HRAS	SF1126	"In a preclinical study, SF1126 inhibited Akt activation, proliferation, and migration of transgenic mouse glioma cells expressing HRAS G12V in culture, and suppressed tumor growth in xenograft models (PMID: 25425962)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25425962	AVv-Kjd2SS-TIFzzUIfCjax	HRAS	Pz-1	"In a preclinical study, Pz-1 reduced tumor growth in xenograft models of transformed cells over expressing HRAS G12V in a dose-dependent manner (PMID: 26126987)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26126987	AVv-KjebSS-TIFzzUIfDjax	HRAS	Panitumumab	"In a preclinical study, tumor cells expressing HRAS G12V demonstrated resistance to treatment with Vectibix (panitumumab) (PMID: 22797062)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22797062	AVv-KjZISS-TIFzzUIe6jax	HRAS	PLX7904	"In a preclinical study, PLX7904 did not stimulate growth of Zelboraf (vemurafenib)-induced cutaneous squamous cell carcinoma cells harboring HRAS Q61L in culture or in cell line xenograft models (PMID: 26466569)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26466569	AVv-KjOmSS-TIFzzUIepjax	HRAS	PD173074	"In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to PD173074 in culture (PMID: 22869148)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-Kje9SS-TIFzzUIfEjax	HRAS	PD173074	"In a preclinical study, PD173074 inhibited Fgfr3 signaling, induced cell-cycle arrest, and decreased proliferation of multiple myeloma cells harboring HRAS H117E and over expression of FGFR3 K650E in culture (PMID: 22869148)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-KjhUSS-TIFzzUIfIjax	HRAS	NS1	"In a preclinical study, bladder carcinoma cells expressing HRAS Q61L demonstrated sensitivity to NS1, resulting in inhibition of Mapk signaling and cell proliferation in culture (PMID: 27820802)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27820802	AVv-KjPKSS-TIFzzUIeqjax	HRAS	Metformin	"In a preclinical study, mouse models of bladder cancer harboring an HRAS mutation were sensitive to Glucophage (metformin), resulting in tumor growth reduction and prevention of hyperplasia regression (PMID: 26921394)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26921394	AVv-Kjk3SS-TIFzzUIfOjax	HRAS	MK2206	"In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with  PI3K/AKT pathway alterations in culture, including an anaplastic thyroid cancer cell line harboring HRAS G13R (PMID: 21289267)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21289267	AVv-KjSrSS-TIFzzUIewjax	HRAS	MEK162	"In a preclinical study, transformed cells expressing HRAS Q61R demonstrated sensitivity to growth inhibition by Binimetinib (MEK162) in culture (PMID: 26544513)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26544513	AVv-KjXMSS-TIFzzUIe3jax	HRAS	MEK162	"In a preclinical study, transformed cells expressing HRAS Q61L demonstrated sensitivity to growth inhibition by Binimetinib (MEK162) in culture (PMID: 26544513)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26544513	AVv-KjODSS-TIFzzUIeojax	HRAS	MEK162	"In a preclinical study, transformed cells expressing HRAS G12V demonstrated sensitivity to growth inhibition by Binimetinib (MEK162) in culture (PMID: 26544513)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26544513	AVv-KjdVSS-TIFzzUIfBjax	HRAS	MEK162	"In a preclinical study, Binimetinib (MEK162) inhibited growth and induced apoptosis in human solid tumor cell lines harboring HRAS mutations in culture (PMID: 26544513)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26544513	AVv-KjkNSS-TIFzzUIfNjax	HRAS	FTI-277	"In a preclinical study, the farnesyltransferase inhibitor FTI-277 sensitized Hras transformed rat fibroblasts to radiation therapy (PMID: 8620483)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/8620483	AVv-Kjn-SS-TIFzzUIfTjax	HRAS	Everolimus + Selumetinib	"In a preclinical study, the combination of Selumetinib (AZD6244) and Afinitor (everolimus) reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a bladder cancer cell line harboring HRAS G12V in culture (PMID: 26544513)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26544513	AVv-KjZtSS-TIFzzUIe7jax	HRAS	Everolimus	"In a preclinical study, transformed cells expressing HRAS Q61R demonstrated sensitivity to growth inhibition by Afinitor (everolimus) in culture (PMID: 26544513)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26544513	AVv-KjX4SS-TIFzzUIe4jax	HRAS	Everolimus	"In a preclinical study, transformed cells expressing HRAS Q61L demonstrated sensitivity to growth inhibition by Afinitor (everolimus) in culture (PMID: 26544513)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26544513	AVv-KjLrSS-TIFzzUIekjax	HRAS	Everolimus	"In a preclinical study, transformed cells expressing HRAS G12V demonstrated sensitivity to growth inhibition by Afinitor (everolimus) in culture (PMID: 26544513)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26544513	AVv-KjcwSS-TIFzzUIfAjax	HRAS	Everolimus	"In a preclinical study, human solid tumor cell lines harboring HRAS mutations demonstrated increased sensitivity to growth inhibition by Afinitor (everolimus) in culture compared to cell lines with wild-type HRAS (PMID: 26544513)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26544513	AVv-KjjFSS-TIFzzUIfLjax	HRAS	E6201	"In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with wild-type HRAS (PMID: 23039341)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23039341	AVv-KjnaSS-TIFzzUIfSjax	HRAS	Dasatinib + Trametinib	"In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-KjPtSS-TIFzzUIerjax	HRAS	Dasatinib + Selumetinib	"In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-KjUqSS-TIFzzUIezjax	HRAS	Dasatinib + Selumetinib	"In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-KjSISS-TIFzzUIevjax	HRAS	Dasatinib + SCH772984	"In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-KjT7SS-TIFzzUIeyjax	HRAS	Dasatinib + SCH772984	"In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-KjRASS-TIFzzUIetjax	HRAS	Dasatinib	"In a preclinical study, thyroid cancer cell lines harboring HRAS G13R and KRAS G12R with an acquired SRC T341M mutation demonstrated resistance to Sprycel (dasatinib) in culture and in cell line xenograft models (PMID: 27222538)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-KjVRSS-TIFzzUIe0jax	HRAS	Cetuximab	"In a preclinical study, tumor cells expressing HRAS G12V demonstrated resistance to treatment with Erbitux (cetuximab) (PMID: 22797062)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22797062	AVv-KjYgSS-TIFzzUIe5jax	HRAS	CI-1040	In a preclinical study CI-1040 (PD-184352) inhibited melanoma progression in a transgenic zebrafish model of melanoma expressing HRAS G12V (PMID: 26267534).	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-KjcOSS-TIFzzUIe_jax	HRAS	Binimetinib + Everolimus	"In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) worked synergistically to inhibit growth of transformed cells expressing HRAS Q61L in culture (PMID: 26544513)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26544513	AVv-KjJOSS-TIFzzUIegjax	HRAS	Binimetinib + Everolimus	"In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) worked synergistically to inhibit growth of transformed cells expressing HRAS G12V in culture (PMID: 26544513)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26544513	AVv-KjbiSS-TIFzzUIe-jax	HRAS	Binimetinib + Everolimus	"In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a bladder cell line harboring HRAS G12V in culture (PMID: 26544513)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26544513	AVv-KjaTSS-TIFzzUIe8jax	HRAS	BKM120	"In a preclinical study, BKM120 did not inhibit growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture (PMID: 26544513)"	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26544513	AVv-KjLCSS-TIFzzUIejjax	HRAS	BEZ235	"In a preclinical study, BEZ235 inhibited growth of thyroid cancer cells harboring an HRAS pathway activating mutation in cell culture (PMID: 21831957)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21831957	AVv-KjgsSS-TIFzzUIfHjax	HRAS	AZD8055 + Binimetinib	"In a preclinical study, the combination of Binimetinib (MEK162) and AZD8055 reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture (PMID: 26544513)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26544513	AVv-KjNbSS-TIFzzUIenjax	HRAS	AZD4547	"In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZD4547 in culture (PMID: 22869148)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-KjffSS-TIFzzUIfFjax	HRAS	AZ8010	"In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZ8010 in culture (PMID: 22869148)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-KjgGSS-TIFzzUIfGjax	HRAS	AZ8010	"In a preclinical study, AZ8010 inhibited Fgfr3 signaling and decreased proliferation of myeloma cells with HRAS K117E and overexpression of FGFR3 K650E in culture (PMID: 22869148)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-Kjh2SS-TIFzzUIfJjax	HNF1A	N/A	"Inactivating mutations in HNF1A (TCF1) are used in the diagnosis of the HCA-H subtype of hepatocellular adenoma (PMID: 25076298, PMID: 26961851, PMID: 25434466)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/25076298	AVv-Ki10SS-TIFzzUIefjax	GNAQ	Verteporfin	"In a preclinical study, Visudyne (verteporfin) inhibited tumor formation in a uveal melanoma cell line xenograft model harboring GNAQ Q209L (PMID: 27308390)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27308390	AVv-KiYoSS-TIFzzUIeVjax	GNAQ	U0126	"In a preclinical study, treatment with U0126 resulted in reduced cell numbers in uveal melanoma cell lines harboring GNAQ Q209L in culture (PMID: 19078957)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19078957	AVv-KiYCSS-TIFzzUIeUjax	GNAQ	Trametinib	"In a preclinical study, uveal melanoma cell lines harboring GNAQ Q209L demonstrated increased sensitivity to growth inhibition by Mekinist (trametinib) in culture, compared to cells with wild-type GNAQ (PMID: 22733540)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22733540	AVv-KiXeSS-TIFzzUIeTjax	GNAQ	TAK-733	"In a preclinical study, TAK-733 inhibited growth of uveal melanoma cell lines harboring GNAQ Q209P in culture (PMID: 22515704)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22515704	AVv-Kib5SS-TIFzzUIebjax	GNAQ	TAK-733	"In a preclinical study, TAK-733 inhibited growth of a uveal melanoma cell line harboring GNAQ Q209L in culture (PMID: 22515704)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22515704	AVv-KiU6SS-TIFzzUIePjax	GNAQ	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) induced cell-cycle arrest and decreased viability of uveal melanoma cells harboring GNAQ Q209P in culture (PMID: 22550165)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22550165	AVv-KidgSS-TIFzzUIeejax	GNAQ	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) induced cell-cycle arrest and decreased viability of uveal melanoma cells harboring GNAQ Q209L in culture (PMID: 22550165)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22550165	AVv-KiWySS-TIFzzUIeSjax	GNAQ	Refametinib	"In a Phase I clinical trial, Refametinib (BAY 86-9766) demonstrated preliminary clinical activity in patients with several tumor types, including prolonged stable disease in an ocular melanoma patient harboring GNAQ Q209L and PTEN R173S (PMID: 23434733)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23434733	AVv-KiZvSS-TIFzzUIeXjax	GNAQ	NAV-2729	"In a preclinical study, NAV-2729 inhibited signaling downstream of GNAQ Q209L in melanoma cells in culture, and inhibited initiation and growth of tumors in a uveal melanoma cell line xenograft model harboring GNAQ Q209L (PMID: 27265506)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27265506	AVv-KiZJSS-TIFzzUIeWjax	GNAQ	GSK2126458 + Trametinib	"In a preclinical study, treatment with the combination of Mekinist (trametinib) and GSK2126458 induced apoptosis in uveal melanoma cell lines harboring GNAQ Q209L in culture (PMID: 22733540)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22733540	AVv-KiUPSS-TIFzzUIeOjax	GNAQ	Enzastaurin	"In a preclinical study, Enzastaurin (LY317615) increased cell-cycle arrest and apoptosis and decreased viability of uveal melanoma cell lines harboring GNAQ Q209L in culture (PMID: 22253748)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22253748	AVv-KiWMSS-TIFzzUIeRjax	GNAQ	Enzastaurin	"In a preclinical study, Enzastaurin (LY317615) increased cell-cycle arrest and apoptosis and decreased viability of a uveal melanoma cell line harboring GNAQ Q209P in culture (PMID: 22253748)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22253748	AVv-Kic_SS-TIFzzUIedjax	GNAQ	AEB071 + PD-0325901	"In a preclinical study, Sotrastaurin (AEB071), in combination with PD-0325901, worked synergisitically to inhibit MAPK pathway activation and proliferation of a uveal melanoma cell line harboring GNAQ Q209L (PMID: 24141786)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24141786	AVv-KiTjSS-TIFzzUIeNjax	GNAQ	AEB071	"In a preclinical study, Sotrastaurin (AEB071) induced cell-cycle arrest and apoptosis, and decreased viability of a uveal melanoma cell line harboring GNAQ Q209P in culture (PMID: 22653968)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22653968	AVv-KicfSS-TIFzzUIecjax	GNA11	Trametinib	"In a preclinical study, uveal melanoma cell lines harboring GNA11 Q209L demonstrated increased sensitivity to growth inhibition by Mekinist (trametinib) in culture, compared to cells with wild-type GNA11 (PMID: 22733540)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22733540	AVv-KiBlSS-TIFzzUIeHjax	GNA11	TAK-733	"In a preclinical study, TAK-733 inhibited growth of uveal melanoma cell lines harboring GNA11 Q209L in culture (PMID: 22515704)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22515704	AVv-KiCRSS-TIFzzUIeIjax	GATA2	bortezomib + fasudil	"In a preclinical study, the combination of bortezomib and fasudil blocked GATA2 downstream signals in KRAS activated NSCLC cells, resulting in reduced tumor burden, size and number in treated mice (PMID: 22541434)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22541434	AVv-Khy9SS-TIFzzUIeEjax	GATA2	N/A	"In multiple clinical studies, GATA2 germline mutations were shown to be a risk factor for the development of acute myeloid leukemia following myelodysplastic syndrome (PMID: 21892162, PMID: 22271902, PMID: 22147895, PMID: 22533337)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/22533337	AVv-KhzqSS-TIFzzUIeFjax	GATA2	N/A	"In clinical analyses, mutations in GATA2 were associated with better overall survival in patients with cytogenetically normal acute myeloid leukemia (CN-AML) harboring biallelic CEBPA gene mutations (PMID: 22814295, PMID: 23521373, PMID: 25241285)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/25241285	AVv-Kh0SSS-TIFzzUIeGjax	GATA1	N/A	"GATA1 mutations are used in the diagnosis of Down Syndrome related acute megakaryoblastic leukemia (PMID: 25266042, PMID: 14636651, PMID: 12586620)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/14636651	AVv-KhijSS-TIFzzUIeBjax	GATA1	Daunorubicin	"In a preclinical study, overexpression of GATA1 confers resistance to chemotherapy drugs, Cytosar-U (cytarabine) and Acetyladriamycin (daunorubicin), in a non-Down Syndrom acute megakaryocytic leukemia cell line (PMID: 23874683)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23874683	AVv-KhjNSS-TIFzzUIeCjax	GATA1	Cytarabine	"In a preclinical study, overexpression of GATA1 confers resistance to chemotherapy drugs, Cytosar-U (cytarabine) and Acetyladriamycin (daunorubicin), in a non-Down Syndrom acute megakaryocytic leukemia cell line (PMID: 23874683)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23874683	AVv-KhjxSS-TIFzzUIeDjax	FOXL2	N/A	"FOXL2 C134W mutations are used in the diagnosis of adult granulosa cell tumors of the ovary (PMID: 26791928, PMID: 22240241)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/26791928	AVv-KhUASS-TIFzzUId_jax	FLT3	rebastinib	"In a Phase I trial, acute myeloid leukemia patients harboring a FLT3 internal tandem duplication did not benefit from treatment with Rebastinib (DCC-2036) (PMID: 27927766)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27927766	AVv-KgKTSS-TIFzzUIcHjax	FLT3	cabozantinib	"In a preclinical study, transformed cells expressing a FLT3-ITD mutation were sensitive to Cometriq (cabozantinib) (PMID: 21926191)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21926191	AVv-Kg-mSS-TIFzzUIdfjax	FLT3	VS-5584	"In a preclinical study, VS-5584 inhibited PI3K/mTOR signaling and cell proliferation in a FLT3-ITD positive human acute myeloid leukemia cell line in culture, and inhibited tumor growth in xenograft models (PMID: 23270925)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23270925	AVv-KhDXSS-TIFzzUIdojax	FLT3	UNC2025	"In a preclinical study, UNC2025 inhibited FLT3 activation and growth of acute myeloid leukemia cells harboring a FLT3-ITD mutation in culture (PMID: 25068800)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25068800	AVv-Kgv_SS-TIFzzUIdHjax	FLT3	Tandutinib	"In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 Y599_D600insGLYVDFREYEY in culture (PMID: 12124172)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/12124172	AVv-Kf62SS-TIFzzUIbtjax	FLT3	Tandutinib	"In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 L611_E612insCSSDNEYFYVDFREYEYDLKWEFPRENL in culture (PMID: 12124172)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/12124172	AVv-KhKHSS-TIFzzUIdzjax	FLT3	Tandutinib	"In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 E612_F613insGYVDFREYEYDLKWEFRPRENLEF in culture (PMID: 12124172)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/12124172	AVv-Kg1RSS-TIFzzUIdQjax	FLT3	Tandutinib	"In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE in culture (PMID: 12124172)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/12124172	AVv-KhJlSS-TIFzzUIdyjax	FLT3	Tandutinib	"In a preclinical study, tandutinib (CT53518) inhibited cell proliferation in cell culture and in mouse models carrying FLT3 L601_K602insREYEYDL (PMID: 12124172)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/12124172	AVv-KhCzSS-TIFzzUIdnjax	FLT3	TCS 359	"In a preclinical study, TCS-359 inhibited growth of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27099147	AVv-KhIWSS-TIFzzUIdwjax	FLT3	TCS 359	"In a preclinical study, TCS-359 inhibited growth of FLT3 wild-type acute myeloid leukemia cell lines in culture (PMID: 27099147)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27099147	AVv-Kg4zSS-TIFzzUIdWjax	FLT3	Sunitinib + Cytarabine + Daunorubicin	"In a Phase Ib/II trial, 59% (13/22) of acute myeloid leukemia patients harboring FLT3 activating mutations achieved complete remission following treatment with Sutent (sunitinib) in combination with Cytarabine and Daunorubicin (PMID: 25818407)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25818407	AVv-KhEiSS-TIFzzUIdqjax	FLT3	Sunitinib	"In a preclinical study, transformed cells over expressing FLT3 ITD and F691I demonstrated reduced response to Sutent (sunitinib) in culture (PMID: 23392356)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23392356	AVv-KgszSS-TIFzzUIdCjax	FLT3	Sunitinib	"In a preclinical study, transformed cells over expressing FLT3 ITD and A848P were resistant to Sutent (sunitinib) in culture (PMID: 23392356)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23392356	AVv-KgE0SS-TIFzzUIb-jax	FLT3	Sorafenib	"In a preclinical study, transformed cells over expressing FLT3 ITD and Y842H demonstrated reduced sensitivity to Nexavar (sorafenib) in culture (PMID: 23392356)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23392356	AVv-KgG6SS-TIFzzUIcBjax	FLT3	Sorafenib	"In a preclinical study, transformed cells over expressing FLT3 ITD and F691L were resistant to Nexavar (sorafenib) in culture (PMID: 23392356)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23392356	AVv-KgTSSS-TIFzzUIcWjax	FLT3	Sorafenib	"In a preclinical study, transformed cells over expressing FLT3 ITD and F691I were resistant to Nexavar (sorafenib) in culture (PMID: 23392356)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23392356	AVv-KguKSS-TIFzzUIdEjax	FLT3	Sorafenib	"In a preclinical study, transformed cells over expressing FLT3 ITD and A848P demonstrated reduced sensitivity to Nexavar (sorafenib) in culture (PMID: 23392356)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23392356	AVv-KgENSS-TIFzzUIb9jax	FLT3	Sorafenib	"In a clinical case report, Nexavar (sorafenib) treatment targeting FLT3 amplification in a rectal adenocarcinoma patient who had progressed on all standard therapies resulted in rapid clinical improvement (PMID: 25848357)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25848357	AVv-KhCOSS-TIFzzUIdmjax	FLT3	SHP099	"In a preclinical study, treatment with SHP099 resulted in reduction of CD45-positive leukemic cells and decreased splenomegaly in a human primary tumor-derived xenograft model of acute myeloid leukemia harboring a FLT3-ITD mutation (PMID: 27362227)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27362227	AVv-KgQlSS-TIFzzUIcSjax	FLT3	Quizartinib	"In a preclinical study, transformed cells over expressing FLT3 ITD and Y842H demonstrated reduced sensitivity to Quizartinib (AC220) in culture (PMID: 23392356)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23392356	AVv-KgIISS-TIFzzUIcDjax	FLT3	Quizartinib	"In a preclinical study, transformed cells over expressing FLT3 ITD and N676D demonstrated reduced sensitivity to Quizartinib (AC220) in culture (PMID: 23392356)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23392356	AVv-Kf3BSS-TIFzzUIbmjax	FLT3	Quizartinib	"In a preclinical study, transformed cells over expressing FLT3 ITD and F691L were resistant to Quizartinib (AC220) in culture (PMID: 23392356)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23392356	AVv-KgVGSS-TIFzzUIcZjax	FLT3	Quizartinib	"In a preclinical study, transformed cells over expressing FLT3 ITD and F691I were resistant to Quizartinib (AC220) in culture (PMID: 23392356)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23392356	AVv-KgtfSS-TIFzzUIdDjax	FLT3	Quizartinib	"In a preclinical study, transformed cells over expressing FLT3 ITD and A848P demonstrated reduced sensitivity to Quizartinib (AC220) in culture (PMID: 23392356)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23392356	AVv-KgFcSS-TIFzzUIb_jax	FLT3	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited viability of patient derived acute myeloid leukemia cells harboring FLT3 ITD mutations in culture, and inhibited growth of tumors in cell line xenograft models (PMID: 21482694)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21482694	AVv-KgMXSS-TIFzzUIcLjax	FLT3	Ponatinib	"In a Phase I trial, Iclusig (ponatinib) resulted in a 25% (3/12) overall response rate, indicated as partial remission or better, in acute myeloid leukemia patients harboring FLT3-ITD (PMID: 23691988)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23691988	AVv-KhAQSS-TIFzzUIdijax	FLT3	Palbociclib + Tandutinib	"In a preclinical study, Ibrance (palbociclib) and tandutinib (MLN518) were synergistic towards growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27099147	AVv-KhHGSS-TIFzzUIdujax	FLT3	Palbociclib + TCS 359	"In a preclinical study, Ibrance (palbociclib) following TCS-359 treatment enhanced growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27099147	AVv-KhF6SS-TIFzzUIdsjax	FLT3	Palbociclib + TCS 359	"In a preclinical study, Ibrance (palbociclib) following TCS-359 treatment enhanced growth inhibition of FLT3 wild-type acute myeloid leukemia cell lines in culture (PMID: 27099147)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27099147	AVv-Kg4OSS-TIFzzUIdVjax	FLT3	Palbociclib + SGI-1776	"In a preclinical study, Ibrance (palbociclib) and SGI-1776 were synergistic towards growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27099147	AVv-KhI8SS-TIFzzUIdxjax	FLT3	Palbociclib + Quizartinib	"In a preclinical study, Ibrance (palbociclib) and Quizartinib (AC220) were synergistic towards growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27099147	AVv-KhGjSS-TIFzzUIdtjax	FLT3	Palbociclib	"In a preclinical study, Ibrance (palbociclib) inhibited growth of human FLT3 wild-type human leukemia cells in culture (PMID: 27099147)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27099147	AVv-Kg6HSS-TIFzzUIdYjax	FLT3	Palbociclib	"In a preclinical study, Ibrance (palbociclib) blocked growth, induced apoptosis, and inhibited STAT activation in human FLT3-ITD positive human acute myeloid leukemia cells in culture (PMID: 27099147)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27099147	AVv-KhFTSS-TIFzzUIdrjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691Q/R834Q mutation were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-Kgj6SS-TIFzzUIczjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691Q/G846R mutation were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgX_SS-TIFzzUIcejax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/Y842S mutation were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgpESS-TIFzzUIc8jax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/Y842H mutation were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgIqSS-TIFzzUIcEjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/Y842C mutation were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgC_SS-TIFzzUIb7jax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/R845G mutation were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgZxSS-TIFzzUIchjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/N841K mutation were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KghUSS-TIFzzUIcvjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/N676S mutation were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgfvSS-TIFzzUIcsjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/M664I mutation were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgenSS-TIFzzUIcqjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D839N were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-Kgq4SS-TIFzzUIc_jax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835Y mutation were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-Kf-eSS-TIFzzUIbzjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835N mutation were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgieSS-TIFzzUIcxjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835H mutation were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-Kgl4SS-TIFzzUIc2jax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835G mutation were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-Kf3lSS-TIFzzUIbnjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835A mutation were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgRKSS-TIFzzUIcTjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D698N mutation were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgSbSS-TIFzzUIcVjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing a compound FLT3-ITD /F691L/D839G mutation were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KggSSS-TIFzzUIctjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 Y842S were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KggxSS-TIFzzUIcujax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 Y842H were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgGQSS-TIFzzUIcAjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 R845G were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KglMSS-TIFzzUIc1jax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 R834Q were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgeGSS-TIFzzUIcpjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 N676S were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgkkSS-TIFzzUIc0jax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 M664I displayed reduced sensitivity to PLX3397 relative to cells expressing FLT3-ITD in culture (PMID: 25847190)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgYiSS-TIFzzUIcfjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 G846R were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgjGSS-TIFzzUIcyjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 N841K were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgZMSS-TIFzzUIcgjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D839H were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgRySS-TIFzzUIcUjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D839A were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgnhSS-TIFzzUIc5jax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835V were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgcaSS-TIFzzUIcmjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835G were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-Kf4FSS-TIFzzUIbojax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835F were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-Kf5sSS-TIFzzUIbrjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835E were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgfNSS-TIFzzUIcrjax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D698N were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-Kgm4SS-TIFzzUIc4jax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing FLT3-ITD  along with FLT3 D839N were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgDlSS-TIFzzUIb8jax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing FLT3-ITD  along with FLT3 D835N were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-Kgb5SS-TIFzzUIcljax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing FLT3 ITD with R834Q and F691L were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgoiSS-TIFzzUIc7jax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing FLT3 D835Y were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-Kf--SS-TIFzzUIb0jax	FLT3	PLX3397	"In a preclinical study, transformed cells expressing FLT3 D835V were resistant to PLX3397 in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KguuSS-TIFzzUIdFjax	FLT3	PLX3397	"In a preclinical study, PLX3397 inhibited proliferation of transformed cells expressing FLT3-ITD in culture (PMID: 25847190)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgL5SS-TIFzzUIcKjax	FLT3	PLX3397	"In a preclinical study, PLX3397 inhibited proliferation of human leukemia cells harboring both FLT3-ITD and FLT3 F691L in culture (PMID: 25847190)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgT7SS-TIFzzUIcXjax	FLT3	PLX3397	"In a preclinical study, PLX3397 inhibited proliferation of human leukemia cells harboring FLT3-ITD in culture and in cell line xenograft models (PMID: 25847190)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgJwSS-TIFzzUIcGjax	FLT3	PLX3397	"In a preclinical study, PLX3397 inhibited growth of transformed cells expressing a compound FLT3 F691L/FLT3-ITD mutation in culture (PMID: 25847190)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgXeSS-TIFzzUIcdjax	FLT3	PLX3397	"In a preclinical study, FLT3 Y842C conferred resistance to PLX3397 when expressed in a compound mutation with FLT3-ITD in cell culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgaVSS-TIFzzUIcijax	FLT3	PLX3397	"In a preclinical study, FLT3 D835Y conferred resistance to PLX3397 when expressed in a compound mutation with FLT3-ITD in cell culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-Kf7kSS-TIFzzUIbujax	FLT3	PLX3397	"In a preclinical study, FLT3 D835H conferred resistance to PLX3397 in transformed cells when expressed as a compound mutation with FLT3-ITD in culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgppSS-TIFzzUIc9jax	FLT3	PLX3397	"In a preclinical study, FLT3 D835G conferred resistance to PLX3397 when expressed in a compound mutation with FLT3-ITD in cell culture (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-Kgh2SS-TIFzzUIcwjax	FLT3	PLX3397	"In a clinical study, a patient with FLT3-ITD positive leukemia initially responded to PLX3397, but experienced relapse after emergence of a FLT3 S652G mutation on the same allele as FLT3-ITD (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgdhSS-TIFzzUIcojax	FLT3	PLX3397	"In a clinical study, a patient with FLT3-ITD positive leukemia initially responded to PLX3397, but experienced relapse after emergence of a FLT3 D835H mutation on the same allele as the FLT3-ITD mutation (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgqRSS-TIFzzUIc-jax	FLT3	PLX3397	"In a clinical study, a patient with FLT3-ITD positive leukemia initially responded to PLX3397 therapy, but experienced relapse after emergence of FLT3 D835Y on the same allele as the FLT3-ITD mutation (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-Kf8JSS-TIFzzUIbvjax	FLT3	PLX3397	"In a clinical study, a leukemia patient with FLT3-ITD positive leukemia initially responded to PLX3397, but experienced relapse after emergence of a compound FLT3 M837G/S838R/D839H mutation on the FLT3-ITD allele (PMID: 25847190)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25847190	AVv-KgoCSS-TIFzzUIc6jax	FLT3	PD98059	"In a preclinical study, PD98059 inhibited ERK1/2 phosphorylation and reduced cell growth in transformed cells expressing FLT3 R834Q (PMID: 18068628)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18068628	AVv-Kg0qSS-TIFzzUIdPjax	FLT3	Midostaurin	"In a preclinical study, treatment with Rydapt (midostaurin) inhibited FLT3 phosphorylation and resulted in decreased proliferation and viability of transformed cells expressing FLT3 D835Y in culture (PMID: 12124173)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/12124173	AVv-KgBLSS-TIFzzUIb4jax	FLT3	Midostaurin	"In a preclinical study, transformed cells over expressing FLT3 ITD and N676D were resistant to Rydapt (midostaurin) in culture (PMID: 23392356)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23392356	AVv-Kf2XSS-TIFzzUIbljax	FLT3	Midostaurin	"In a preclinical study, transformed cells over expressing FLT3 ITD and F691I were resistant to Rydapt (midostaurin) in culture (PMID: 23392356)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23392356	AVv-KgsJSS-TIFzzUIdBjax	FLT3	Midostaurin	"In a preclinical study, Rydapt (midostaurin) inhibited FLT3-induced phosphorylation of ERK1/2 and reduced growth of transformed cells expressing FLT3 V592G in culture (PMID: 18068628)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18068628	AVv-Kg76SS-TIFzzUIdbjax	FLT3	Midostaurin	"In a preclinical study, Rydapt (midostaurin) inhibited FLT3-induced phosphorylation of ERK1/2 and reduced growth of transformed cells expressing FLT3 R834Q in culture (PMID: 18068628)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18068628	AVv-Kg0FSS-TIFzzUIdOjax	FLT3	Midostaurin	"In a preclinical study, Rydapt (midostaurin) inhibited FLT3 phosphorylation of ERK1/2 and reduced cell growth in transformed cells expressing FLT3 Y572C in culture (PMID: 18068628)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18068628	AVv-KgB0SS-TIFzzUIb5jax	FLT3	Midostaurin	"In a preclinical study, Rydapt (midostaurin) inhibited FLT3 phosphorylation in transformed cells expressing wild-type FLT3 in culture (PMID: 12124173)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/12124173	AVv-Kg5aSS-TIFzzUIdXjax	FLT3	Midostaurin	"In a preclinical study, Rydapt (midostaurin) induced cell death and inhibited FLT3 activation and downstream STAT5 activation in primary acute myeloid leukemic blasts harboring FLT3 Y842C in culture (PMID: 15345593)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/15345593	AVv-Kg12SS-TIFzzUIdRjax	FLT3	Midostaurin	"In a preclinical study, Rydapt (midostaurin) demonstrated efficacy in inhibiting proliferation and viability of transformed cells expressing a FLT3-ITD mutation in culture (PMID: 12124173)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/12124173	AVv-KgPaSS-TIFzzUIcQjax	FLT3	MRX-2843	"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and Y842H in culture (PMID: 27158668)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27158668	AVv-KgHkSS-TIFzzUIcCjax	FLT3	MRX-2843	"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and Y842C in culture (PMID: 27158668)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27158668	AVv-KgbXSS-TIFzzUIckjax	FLT3	MRX-2843	"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and F691L in culture (PMID: 27158668)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27158668	AVv-KgW3SS-TIFzzUIccjax	FLT3	MRX-2843	"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and D835Y in culture (PMID: 27158668)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27158668	AVv-Kf97SS-TIFzzUIbyjax	FLT3	MRX-2843	"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and D835V in culture (PMID: 27158668)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27158668	AVv-Kgc5SS-TIFzzUIcnjax	FLT3	MRX-2843	"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and D835F in culture (PMID: 27158668)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27158668	AVv-Kf6WSS-TIFzzUIbsjax	FLT3	MRX-2843	"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing FLT3 D835Y in culture (PMID: 27158668)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27158668	AVv-KgAoSS-TIFzzUIb3jax	FLT3	MRX-2843	"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing FLT3 D835V in culture (PMID: 27158668)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27158668	AVv-KgvYSS-TIFzzUIdGjax	FLT3	Imatinib	"In a preclinical study, primary AML blasts expressing FLT3 Y842C were resistant to Gleevec (imatinib) as demonstrated by constitutively phosphorylated FLT3 and STAT-5 (PMID: 15345593)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/15345593	AVv-Kg2eSS-TIFzzUIdSjax	FLT3	ENMD-2076	"In a Phase I trial, two acute myeloid leukemia patients co-harboring a FLT3-ITD mutation and NPM1 mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27406088	AVv-KgmXSS-TIFzzUIc3jax	FLT3	ENMD-2076	"In a Phase I trial, an acute myeloid leukemia patient with a FLT3-ITD mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27406088	AVv-KgNeSS-TIFzzUIcNjax	FLT3	E6201	"In a preclinical study, acute myeloid leukemia cell lines harboring FLT3 mutations demonstrated increased sensitivity to E6201 induced growth inhibition and apoptosis in culture compared to FLT3 wild-type cells (PMID: 26822154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26822154	AVv-KgxwSS-TIFzzUIdKjax	FLT3	E6201	"In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines over expressing FLT3 D835Y in culture (PMID: 26822154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26822154	AVv-Kf_hSS-TIFzzUIb1jax	FLT3	E6201	"In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines over expressing FLT3 D835G in culture (PMID: 26822154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26822154	AVv-Kf4lSS-TIFzzUIbpjax	FLT3	E6201	"In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines harboring FLT3 Y842C in addition to FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26822154	AVv-Kga2SS-TIFzzUIcjjax	FLT3	E6201	"In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines harboring FLT3 N676D and Y842C in addition to FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26822154	AVv-Kf1uSS-TIFzzUIbkjax	FLT3	E6201	"In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines harboring FLT3 F691L in addition to FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26822154	AVv-KgUiSS-TIFzzUIcYjax	FLT3	E6201	"In a preclinical study, E6201 induced growth inhibition and apoptosis in leukemia cell lines harboring FLT3 internal tandem duplications (ITD) and reduced tumor burden in xenograft models (PMID: 26822154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26822154	AVv-KgLXSS-TIFzzUIcJjax	FLT3	E6201	"In a preclinical study, E6201 induced apoptosis in blast samples derived from acute myeloid leukemia patients harboring FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26822154	AVv-KgK1SS-TIFzzUIcIjax	FLT3	E6201	"In a preclinical study, E6201 induced apoptosis in blast samples derived from acute myeloid leukemia patients harboring FLT3 D835Y in culture (PMID: 26822154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26822154	AVv-KgAESS-TIFzzUIb2jax	FLT3	E6201	"In a preclinical study, E6201 induced apoptosis in blast samples derived from acute myeloid leukemia patients harboring FLT3 D835G in culture (PMID: 26822154)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26822154	AVv-Kf5HSS-TIFzzUIbqjax	FLT3	Cytarabine + Daunorubicin + Midostaurin	"In a Phase Ib clinical trial, Rydapt (midostaurin) treatment after Daunorubicin and Cytosar-U (cytarabine) induction resulted in  complete remission in 74% (20 of 27) of acute myeloid leukemia patients carrying wild-type FLT3 (PMID: 22627678)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22627678	AVv-Kg3pSS-TIFzzUIdUjax	FLT3	Crenolanib	"In a preclinical study, Crenolanib (CP-868596) inhibited Flt3 phosphorylation and induced apoptosis in leukemia cells expressing FLT3 D835H (PMID: 24623852)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24623852	AVv-Kg7SSS-TIFzzUIdajax	FLT3	Azacitidine + Midostaurin	"In a Phase Ib/II trial, acute myeloid leukemia patients harboring a FLT3 mutation demonstrated an improved remission duration when treated with the combination therapy, Rydapt (midostaurin) and Vidaza (azacitidine) (PMID: 25530214)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25530214	AVv-KgziSS-TIFzzUIdNjax	FLT3	Altiratinib	"In a preclinical study, Altiratinib (DCC-0701) inhibited proliferation of an acute myeloid leukemia cell harboring a FLT3-ITD mutation in culture (PMID: 26285778)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26285778	AVv-KgOOSS-TIFzzUIcOjax	FLT3	AP26113	"In a preclinical study, transformed cells expressing FLT3 ITD and F691I demonstrated reduced sensitivity to Brigatinib (AP26113) in culture (PMID: 27780853)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KgrhSS-TIFzzUIdAjax	FLT3	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing FLT3 ITD in culture (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KgM7SS-TIFzzUIcMjax	FLT3	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing FLT3 ITD and F691L in culture (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KgVqSS-TIFzzUIcajax	FLT3	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing FLT3 ITD and D835Y in culture (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-Kf9SSS-TIFzzUIbxjax	FGFR3	U0126	"In a preclinical study, U0126 inhibited downstream signaling and growth of glioblastoma cells over-expressing Fgfr3 in culture (PMID: 23298836)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23298836	AVv-KfDuSS-TIFzzUIbPjax	FGFR3	U0126	"In a preclinical study, U0126 inhibited downstream signaling and growth of glioblastoma cells expressing the FGFR3-TACC3 fusion in culture (PMID: 23298836)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23298836	AVv-KePKSS-TIFzzUIZsjax	FGFR3	Trametinib	"In a preclinical study, knocking down of Fgfr3 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture  (PMID: 27338794)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-Ke1ASS-TIFzzUIa3jax	FGFR3	Selumetinib	"In a preclinical study, renal pelvis transitional cell carcinoma cells harboring FGFR3 S249C were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-Kee7SS-TIFzzUIaHjax	FGFR3	Selumetinib	"In a preclinical study, myeloma cells harboring FGFR3 Y373C were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KdylSS-TIFzzUIY8jax	FGFR3	Selumetinib	"In a preclinical study, bladder cancer cells harboring FGFR3-TACC were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KeJ5SS-TIFzzUIZkjax	FGFR3	SU5402	"In a preclinical study, SU5402 inhibited proliferation of myeloma cells expressing wild-type FGFR3 in culture (PMID: 23597562)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23597562	AVv-KepZSS-TIFzzUIaZjax	FGFR3	SU5402	"In a preclinical study, SU5402 inhibited proliferation of myeloma cells expressing FGFR3 K650E in culture (PMID: 23597562)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23597562	AVv-Ke7cSS-TIFzzUIbBjax	FGFR3	SU5402	"In a preclinical study, SU5402 inhibited growth of bladder cancer cells over expressing wild-type FGFR3 in culture (PMID: 21119661)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21119661	AVv-KfHYSS-TIFzzUIbVjax	FGFR3	SU5402	"In a preclinical study, SU5402 induced cell-cycle arrest and inhibited proliferation of bladder cancer cells that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 21119661, PMID: 23175443)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21119661	AVv-KeQZSS-TIFzzUIZujax	FGFR3	SSR128129E	"In a preclinical study, SSR128129E inhibited proliferation of myeloma cells expressing wild-type FGFR3 in culture (PMID: 23597562)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23597562	AVv-KerCSS-TIFzzUIacjax	FGFR3	SSR128129E	"In a preclinical study, SSR128129E did not inhibit proliferation of myeloma cells expressing FGFR3 K650E in culture (PMID: 23597562)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/23597562	AVv-Ke93SS-TIFzzUIbFjax	FGFR3	S-49076	"In a preclinical study, S-49076 inhibited autophosphorylation of FGFR3 and downstream signaling in bladder cancer cells that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 23804704, PMID: 23175443)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23175443	AVv-Kd-WSS-TIFzzUIZRjax	FGFR3	S-49076	"In a preclinical study, S-49076 inhibited autophosphorylation of FGFR3 and downstream signaling in bladder cancer cells over expressing constitutively active FGFR3 in culture (PMID: 23804704)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23804704	AVv-KeurSS-TIFzzUIaijax	FGFR3	RO5126766	"In a preclinical study, renal pelvis transitional cell carcinoma cells harboring FGFR3 S249C were not sensitive to RO5126766 in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KejnSS-TIFzzUIaPjax	FGFR3	RO5126766	"In a preclinical study, myeloma cells harboring FGFR3 Y373C were not sensitive to RO5126766 in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KdyASS-TIFzzUIY7jax	FGFR3	RO5126766	"In a preclinical study, bladder transitional cell papilloma cells harboring FGFR3-TACC3 were not sensitive to RO5126766 in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KeDPSS-TIFzzUIZZjax	FGFR3	RO4987655	"In a preclinical study, renal pelvis transitional cell carcinoma cells harboring FGFR3 S249C were not sensitive to RO4987655 in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KeiWSS-TIFzzUIaNjax	FGFR3	RO4987655	"In a preclinical study, myeloma cells harboring FGFR3 Y373C were not sensitive to RO4987655 in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KdzSSS-TIFzzUIY9jax	FGFR3	RO4987655	"In a preclinical study, bladder transitional cell papilloma cells harboring FGFR3-TACC3 were not sensitive to RO4987655 in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KeGqSS-TIFzzUIZfjax	FGFR3	R3Mab	"In a preclinical study, R3Mab prevented ligand-dependent cell proliferation induced by FGFR3 Y375C in cultured cells (PMID: 19381019)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19381019	AVv-KeljSS-TIFzzUIaSjax	FGFR3	R3Mab	"In a preclinical study, R3Mab prevented ligand-dependent cell proliferation induced by FGFR3 K652E in cultured cells (PMID: 19381019)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19381019	AVv-KeW2SS-TIFzzUIZ4jax	FGFR3	R3Mab	"In a preclinical study, R3Mab prevented ligand-dependent cell proliferation induced by FGFR3 G372C in cultured cells (PMID: 19381019)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19381019	AVv-Kd1gSS-TIFzzUIZBjax	FGFR3	R3Mab	"In a preclinical study, R3Mab prevented constitutive cell proliferation induced by FGFR3 R248C in cultured cells (PMID: 19381019)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19381019	AVv-Ke0USS-TIFzzUIa2jax	FGFR3	R3Mab	"In a preclinical study, R3Mab inhibited proliferation of transformed cells over expressing FGFR3 S249C in culture (PMID: 19381019)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19381019	AVv-KehQSS-TIFzzUIaLjax	FGFR3	R3Mab	"In a preclinical study, R3Mab inhibited FGFR3 signaling and tumor growth in bladder cancer cell line xenograft models harboring FGFR3-TACC3 (PMID: 25326231)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25326231	AVv-KePwSS-TIFzzUIZtjax	FGFR3	R3Mab	"In a preclinical study, R3Mab decreased wild-type FGFR3 activation, thereby inhibited cell proliferation of FGFR3 wild-type human bladder cancer cells in culture and in cell line xenograft models (PMID: 19381019)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19381019	AVv-KeqASS-TIFzzUIaajax	FGFR3	R3Mab	"In a preclinical study, R3Mab decreased activation of FGFR3 S249C, thereby inhibited cell proliferation of human bladder cancer cells in culture and in cell line xenograft models (PMID: 19381019)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19381019	AVv-KecxSS-TIFzzUIaDjax	FGFR3	Ponatinib	"In a preclinical study, bladder cancer cells with wild-type FGFR3 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KeqhSS-TIFzzUIabjax	FGFR3	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited receptor phosphorylation and cell growth in transformed cells expressing constitutively active FGFR3 in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KexWSS-TIFzzUIaxjax	FGFR3	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-Kd8tSS-TIFzzUIZOjax	FGFR3	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 N540K in culture (PMID: 28034880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-KeU0SS-TIFzzUIZ1jax	FGFR3	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-KfLxSS-TIFzzUIbdjax	FGFR3	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-Ke63SS-TIFzzUIbAjax	FGFR3	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited growth of bladder cancer cells harboring FGFR3 S249C in culture and in cell line xenograft models (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KecQSS-TIFzzUIaCjax	FGFR3	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in bladder cancer cells harboring FGFR3 Y375C in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KemLSS-TIFzzUIaTjax	FGFR3	Ponatinib	"In a preclinical study, Iclusig (ponatanib) inhibited growth and FGFR3 phosphorylation in cells expressing FGFR3-TACC3 fusion in culture (PMID: 25294908)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25294908	AVv-KeFBSS-TIFzzUIZcjax	FGFR3	Pazopanib	"In a preclinical study, bladder cancer cells harboring FGFR3-TACC3 demonstrated sensitivity to Votrient (pazopanib) in culture (PMID: 23558953)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23558953	AVv-Kd--SS-TIFzzUIZSjax	FGFR3	PD98059	"In a preclinical study, PD98059 inhibited FGFR3 K650E-induced transformation of cells in culture (PMID: 14534538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/14534538	AVv-Ke5lSS-TIFzzUIa-jax	FGFR3	PD173074	"In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to PD173074 in culture (PMID: 22869148)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-KesuSS-TIFzzUIafjax	FGFR3	PD173074	"In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to PD173074 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-KezHSS-TIFzzUIa0jax	FGFR3	PD173074	"In a preclinical study, PD173074 inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25589496	AVv-KeYnSS-TIFzzUIZ7jax	FGFR3	PD173074	"In a preclinical study, PD173074 inhibited growth of urothelial carcinoma (UC) cells expressing high levels of FGFR3 S249C, but had reduced efficacy against UC cells with low levels of FGFR3 S249C expression (PMID: 22869148)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-KebrSS-TIFzzUIaBjax	FGFR3	PD173074	"In a preclinical study, PD173074 inhibited Fgfr3 signaling, induced cell-cycle arrest, and decreased proliferation of multiple myeloma cells harboring HRAS H117E and over expression of FGFR3 K650E in culture (PMID: 22869148)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-KfAcSS-TIFzzUIbJjax	FGFR3	PD173074	"In a preclinical study, PD173074 inhibited Fgfr3 signaling and decreased proliferation and survival of multiple myeloma cells over expressing FGFR3 Y373C in culture (PMID: 22869148)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-Kd0-SS-TIFzzUIZAjax	FGFR3	PD173074	"In a preclinical study, PD173074 inhibited Fgfr3 kinase activity and growth in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture and in cell line xenograft models (PMID: 22837387)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22837387	AVv-KeJJSS-TIFzzUIZjjax	FGFR3	Nintedanib	"In a preclinical study, transformed cells expressing constitutively active FGFR3 demonstrated reduced sensitivity to Ofev (Nintedanib) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KevUSS-TIFzzUIajjax	FGFR3	Nintedanib	"In a preclinical study, bladder cancer cells harboring FGFR3 Y375C were resistant to growth inhibition by Ofev (Nintedanib) in culture (PMID: 22238366)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KenPSS-TIFzzUIaVjax	FGFR3	Nintedanib	"In a preclinical study, bladder cancer cells harboring FGFR3 S249C were resistant to Ofev (Nintedanib) induced inhibition of cell proliferation in culture (PMID: 22238366)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KeeUSS-TIFzzUIaGjax	FGFR3	LY2874455	"In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to LY2874455 in culture (PMID: 28034880)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-KeULSS-TIFzzUIZ0jax	FGFR3	LY2874455	"In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-Kd9OSS-TIFzzUIZPjax	FGFR3	LY2874455	"In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-KfPLSS-TIFzzUIbjjax	FGFR3	LY2874455	"In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-Ke6PSS-TIFzzUIa_jax	FGFR3	LY2874455	"In a preclinical study, LY2874455 induced tumor regression in bladder cancer xenograft models that have been demonstrated to harbor an FGFR3-TACC3 fusion (PMID: 21900693, PMID: 23175443)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21900693	AVv-KeN0SS-TIFzzUIZqjax	FGFR3	LY2874455	"In a preclinical study, LY2874455 induced tumor regression in FGFR3-over expressing bladder and multiple myeloma xenograft models (PMID: 21900693)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21900693	AVv-KfDKSS-TIFzzUIbOjax	FGFR3	JNJ-42756493	"In a preclinicl study, JNJ-42756493 inhibited proliferation of transformed cells over expressing FGFR3-TACC3 in culture (PMID: 26992226)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26992226	AVv-KeKcSS-TIFzzUIZljax	FGFR3	JNJ-42756493	"In a preclinicl study, JNJ-42756493 inhibited proliferation of transformed cells over expressing FGFR3 K560E in culture (PMID: 26992226)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26992226	AVv-KeRpSS-TIFzzUIZwjax	FGFR3	JNJ-42756493	"In a preclinical study, JNJ-42756493 inhibited proliferation of glioma cells harboring FGFR3 - TACC3 fusion in culture and xenograft tumor growth in animal models (PMID: 25609060)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25609060	AVv-KeLKSS-TIFzzUIZmjax	FGFR3	JNJ-42756493	"In a Phase I trial, JNJ-42756493 treatment resulted tumor shrinkage and no disease progression for 10 months in an adrenal carcinoma patient harboring FGFR3 - TACC3 and FGFR2 - CCDC6 fusions (PMID: 26324363)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26324363	AVv-KeRDSS-TIFzzUIZvjax	FGFR3	JNJ-42756493	"In a Phase I trial, JNJ-42756493 treatment resulted in tumor reduction and stable disease in 2 glioblastoma multiforme patients harboring FGFR3 - TACC3 fusion (PMID: 25609060)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25609060	AVv-KeFlSS-TIFzzUIZdjax	FGFR3	JNJ-42756493	"In a Phase I trial, JNJ-42756493 treatment resulted in partial response in a glioblastoma patient harboring FGFR3 - TACC3 fusion (PMID: 26324363)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26324363	AVv-KeGGSS-TIFzzUIZejax	FGFR3	JNJ-42756493	"In a Phase I trial, JNJ-42756493 treatment resulted in 25% tumor shrinkage at week 8 in an urothelial cancer patient harboring FGFR3 mutations (PMID: 26324363)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26324363	AVv-KfKqSS-TIFzzUIbbjax	FGFR3	JNJ-42756493	"In a Phase I clinical trial, JNJ-42756493 treatment resulted in partial response in 2 urothelial cancer patients harboring FGFR3-TACC3 (PMID: 26324363)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26324363	AVv-KeAPSS-TIFzzUIZUjax	FGFR3	FIIN-2	"In a preclinical study, transformed cells over expressing FGFR3 V555M demonstrated reduced sensitivity to FIIN-2 in culture (PMID: 28034880)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-Kd6ZSS-TIFzzUIZKjax	FGFR3	FIIN-2	"In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to FIIN-2 in culture (PMID: 28034880)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-KeVgSS-TIFzzUIZ2jax	FGFR3	FIIN-2	"In a preclinical study, FIIN-2 inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-KfMUSS-TIFzzUIbejax	FGFR3	FIIN-2	"In a preclinical study, FIIN-2 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-Ke8CSS-TIFzzUIbCjax	FGFR3	FIIN-01	"In a preclinical study, FIIN-1 inhibited growth of the RT4 bladder cancer cell line, which has been demonstrated to harbor an FGFR3-TACC3 fusion, in culture (PMID: 20338520, PMID: 23175443)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23175443	AVv-KeHSSS-TIFzzUIZgjax	FGFR3	FF-284	"In a preclinical study, transformed cells over expressing FGFR3 V555M demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-Kd5uSS-TIFzzUIZJjax	FGFR3	FF-284	"In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-KeTmSS-TIFzzUIZzjax	FGFR3	FF-284	"In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-KfM3SS-TIFzzUIbfjax	FGFR3	FF-284	"In a preclinical study, Debio 1347 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-Ke-cSS-TIFzzUIbGjax	FGFR3	FF-284	"In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 Y373C in culture (PMID: 25169980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25169980	AVv-KdxiSS-TIFzzUIY6jax	FGFR3	FF-284	"In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 K650E in culture (PMID: 25169980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25169980	AVv-Ke_GSS-TIFzzUIbHjax	FGFR3	FF-284	"In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 F386L in culture (PMID: 25169980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25169980	AVv-Ke1rSS-TIFzzUIa4jax	FGFR3	FF-284	"In a preclinical study, Debio 1347 inhibited proliferation of bladder cancer cells harboring FGFR3 S249C in culture and inhibited tumor growth in FGFR3 S249C-positive bladder cancer cell line xenograft models (PMID: 25169980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25169980	AVv-KedwSS-TIFzzUIaFjax	FGFR3	FF-284	"In a preclinical study, Debio 1347 inhibited proliferation of bladder cancer cell lines harboring an FGFR3-TACC3 fusion in culture and inhibited tumor growth in FGFR3-TACC3-positive bladder cancer cell line xenograft models (PMID: 25169980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25169980	AVv-KeOgSS-TIFzzUIZrjax	FGFR3	FF-284	"In a preclinical study, Debio 1347 inhibited proliferation of a bladder cancer cell line harboring an FGFR3-BAIAP2L1 fusion in culture (PMID: 25169980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25169980	AVv-KeZISS-TIFzzUIZ8jax	FGFR3	E7090	"In a preclinical study, urinary bladder cancer cells harboring FGFR3-TACC3 demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability, and antitumor activity in xenograft models (PMID: 27535969)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23175443	AVv-KeEfSS-TIFzzUIZbjax	FGFR3	E7090	"In a preclinical study, a multiple myeloma cell line harboring FGFR3 Y373C (PMID: 19901323) demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability (PMID: 27535969)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19901323	AVv-Kdz6SS-TIFzzUIY-jax	FGFR3	E7090	"In a preclinical study, a mouse breast carcinoma cell line xenograft model demonstrated inhibition of tumor growth when treated with E7090, a result of decreased FGFR2 and FGFR3 activity (PMID: 27535969)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27535969	AVv-KdweSS-TIFzzUIY4jax	FGFR3	Dovitinib	"In a preclinical study, Dovitinib (TKI258) inhibited receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR3 in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KewgSS-TIFzzUIawjax	FGFR3	Dovitinib	"In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-Kd8GSS-TIFzzUIZNjax	FGFR3	Dovitinib	"In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 N540K in culture (PMID: 28034880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-KeSRSS-TIFzzUIZxjax	FGFR3	Dovitinib	"In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-KfN-SS-TIFzzUIbhjax	FGFR3	Dovitinib	"In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-Ke9SSS-TIFzzUIbEjax	FGFR3	Dovitinib	"In a preclinical study, Dovitinib (TKI258) inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25589496	AVv-KeYESS-TIFzzUIZ6jax	FGFR3	Dovitinib	"In a preclinical study, Dovitinib (TKI258) inhibited growth of bladder cancer cell lines that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 24325461, PMID: 23175443)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23175443	AVv-KeD5SS-TIFzzUIZajax	FGFR3	Dovitinib	"In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in bladder cancer cells harboring FGFR3 Y375C in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KekNSS-TIFzzUIaQjax	FGFR3	Dovitinib	"In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in bladder cancer cells harboring FGFR3 S249C mutation in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KejDSS-TIFzzUIaOjax	FGFR3	Cediranib	"In a preclinical study, bladder cancer cells harboring an FGFR3 Y375C mutation were resistant to growth inhibition by Cediranib (AZD-2171) in culture (PMID: 22238366)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-Kek6SS-TIFzzUIaRjax	FGFR3	Cediranib	"In a preclinical study, Cediranib (AZD-2171) inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25589496	AVv-KebKSS-TIFzzUIaAjax	FGFR3	Cediranib	"In a preclinical study, Cediranib (AZD-2171) inhibited growth of bladder cancer cells harboring FGFR3 S249C mutation in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KedRSS-TIFzzUIaEjax	FGFR3	Brivanib	"In a preclinical study, Brivanib (BMS-540215) did not inhibit receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR3 in culture (PMID: 22238366)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-Ket-SS-TIFzzUIahjax	FGFR3	Brivanib	"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of bladder cancer cells harboring FGFR3 Y375C in culture (PMID: 22238366)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KemtSS-TIFzzUIaUjax	FGFR3	Brivanib	"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of bladder cancer cells harboring FGFR3 S249C in culture (PMID: 22238366)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KegmSS-TIFzzUIaKjax	FGFR3	BGJ398	"In a preclinical study, tumor cell lines with FGFR3 mutations demonstrated sensitivity to BGJ398 in culture (PMID: 23002168)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23002168	AVv-KfIiSS-TIFzzUIbXjax	FGFR3	BGJ398	"In a preclinical study, treatment with BGJ398 led to improved progression-free survival in a patient-derived xenograft (PDX) model of  bladder cancer with FGFR3 over expression (PMID: 26270481)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26270481	AVv-KfBPSS-TIFzzUIbLjax	FGFR3	BGJ398	"In a preclinical study, transformed cells over expressing FGFR3 V555M were resistant to BGJ398 in culture (PMID: 28034880)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-Kd68SS-TIFzzUIZLjax	FGFR3	BGJ398	"In a preclinical study, transformed cells over expressing FGFR3 V555L demonstrated reduced sensitivity to BGJ398 in culture (PMID: 28034880)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-KdvRSS-TIFzzUIY2jax	FGFR3	BGJ398	"In a preclinical study, transformed cells over expressing FGFR3 N540K were resistant to BGJ398 in culture (PMID: 28034880)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-KeS5SS-TIFzzUIZyjax	FGFR3	BGJ398	"In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to BGJ398 in culture (PMID: 28034880)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-KfNZSS-TIFzzUIbgjax	FGFR3	BGJ398	"In a preclinical study, transformed cells over expressing FGFR3 K650E demonstrated reduced sensitivity to BGJ398 in culture (PMID: 28034880)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-Ke4ZSS-TIFzzUIa8jax	FGFR3	BGJ398	"In a preclinical study, a head and neck squamous cell carcinoma cell line expressing FGFR3 S131L demonstrated decreased sensitivity to BGJ398 compared to cells expressing wild-type FGFR3 in culture (PMID: 27053219)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27053219	AVv-Kd5KSS-TIFzzUIZIjax	FGFR3	BGJ398	"In a preclinical study, BJG398 inhibited Fgfr3 kinase activity in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture (PMID: 22837387)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22837387	AVv-KeLySS-TIFzzUIZnjax	FGFR3	BGJ398	"In a preclinical study, BGJ398 inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25589496	AVv-KeXdSS-TIFzzUIZ5jax	FGFR3	BGJ398	"In a preclinical study, BGJ398 inhibited growth and FGFR3 phosphorylation in cells expressing FGFR3-TACC3 fusion in culture (PMID: 25294908)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25294908	AVv-KeMbSS-TIFzzUIZojax	FGFR3	BGJ398	"In a preclinical study, BGJ398 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 amplification in culture (PMID: 27401245)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27401245	AVv-Kd3fSS-TIFzzUIZFjax	FGFR3	BGJ398	"In a preclinical study, BGJ398 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 S249C in culture (PMID: 27401245)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27401245	AVv-KefbSS-TIFzzUIaIjax	FGFR3	BGJ398	"In a Phase I trial, patients with urinary bladder urothelial carcinoma demonstrated a disease control rate of 75% (6/8) when treated with BGJ398, resulting in 3 patients with a partial response and 3 with stable disease (PMID: 27870574)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27870574	AVv-KfKMSS-TIFzzUIbajax	FGFR3	AZD5363 + AZD4547	"In a preclinical study, the combined therapy of AZD5363 and AZD4547 resulted in tumor regression in urinary bladder cancer xenograft models simultaneously harboring the mutations, AKT1 E17K and FGFR3 Y373C (PMID: 26351323)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26351323	AVv-Kdw-SS-TIFzzUIY5jax	FGFR3	AZD4547	"In a preclinicl study, AZD4547 inhibited proliferation of transformed cells over expressing FGFR3-TACC3 in culture (PMID: 26992226)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26992226	AVv-Kd_pSS-TIFzzUIZTjax	FGFR3	AZD4547	"In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZD4547 in culture (PMID: 22869148)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-KerlSS-TIFzzUIadjax	FGFR3	AZD4547	"In a preclinical study, transformed cells over expressing FGFR3 V555M were resistant to AZD4547 in culture (PMID: 28034880)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-Kd7gSS-TIFzzUIZMjax	FGFR3	AZD4547	"In a preclinical study, transformed cells over expressing FGFR3 N540K were reistant to growth inhibition by AZD4547 in culture (PMID: 26992226)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26992226	AVv-KeWKSS-TIFzzUIZ3jax	FGFR3	AZD4547	"In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to AZD4547 in culture (PMID: 28034880)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-KfOlSS-TIFzzUIbijax	FGFR3	AZD4547	"In a preclinical study, transformed cells over expressing FGFR3 K650E demonstrated reduced sensitivity to growth inhibition by AZD4547 in culture (PMID: 26992226)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26992226	AVv-Ke8pSS-TIFzzUIbDjax	FGFR3	AZD4547	"In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to AZD4547 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-KeyfSS-TIFzzUIazjax	FGFR3	AZD4547	"In a preclinical study, AZD4547 inhibited survival of myeloma cells harboring FGFR3 translocation in culture and in cell line xenograft models (PMID: 27550940)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27550940	AVv-KeoTSS-TIFzzUIaXjax	FGFR3	AZD4547	"In a preclinical study, AZD4547 inhibited survival of bladder cancer cells harboring FGFR3 mutation in culture (PMID: 27550940)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27550940	AVv-KfJnSS-TIFzzUIbZjax	FGFR3	AZD4547	"In a preclinical study, AZD4547 inhibited survival of bladder cancer cells harboring FGFR3 fusion in culture (PMID: 27550940)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27550940	AVv-Ke2dSS-TIFzzUIa5jax	FGFR3	AZD4547	"In a preclinical study, AZD4547 inhibited proliferation of urothelial cancer cells with over expression of FGFR3 in culture (PMID: 22869148)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-KfG2SS-TIFzzUIbUjax	FGFR3	AZD4547	"In a preclinical study, AZD4547 inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25589496	AVv-KeaqSS-TIFzzUIZ_jax	FGFR3	AZD4547	"In a preclinical study, AZD4547 inhibited Fgfr3 kinase activity in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture (PMID: 22837387)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22837387	AVv-KeA3SS-TIFzzUIZVjax	FGFR3	AZD4547	"In a preclinical study, AZD4547 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 amplification in culture (PMID: 27401245)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27401245	AVv-Kd1-SS-TIFzzUIZCjax	FGFR3	AZD4547	"In a preclinical study, AZD4547 decreased Myc expression and inhibited growth of a urinary tract cancer cell line harboring FGFR3 S249C in culture and in xenograft models (PMID: 27401245)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27401245	AVv-Kef9SS-TIFzzUIaJjax	FGFR3	AZ8010	"In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZ8010 in culture (PMID: 22869148)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-KesMSS-TIFzzUIaejax	FGFR3	AZ8010	"In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to AZ8010 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-KezuSS-TIFzzUIa1jax	FGFR3	AZ8010	"In a preclinical study, AZ8010 inhibited proliferation of urothelial cancer cells with over expression of FGFR3 in culture (PMID: 22869148)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-KfGSSS-TIFzzUIbTjax	FGFR3	AZ8010	"In a preclinical study, AZ8010 inhibited Fgfr3 signaling, induced cell-cycle arrest, and decreased proliferation of multiple myeloma cells over expressing FGFR3 Y373C in culture (PMID: 22869148)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-Kd0bSS-TIFzzUIY_jax	FGFR3	AZ8010	"In a preclinical study, AZ8010 inhibited Fgfr3 signaling and decreased proliferation of myeloma cells with HRAS K117E and overexpression of FGFR3 K650E in culture (PMID: 22869148)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-Ke_xSS-TIFzzUIbIjax	FGFR3	AZ8010	"In a preclinical study, AZ12908010 (AZ8010) induced cell cycle arrest and inhibited proliferation of urothelial cancer cell lines that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 22869148, PMID: 23175443)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-KeNHSS-TIFzzUIZpjax	FGFR2	Trametinib	"In a preclinical study, knocking down of Fgfr2 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-KcGdSS-TIFzzUIWqjax	FGFR2	Selumetinib	"In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-Kb1mSS-TIFzzUIWOjax	FGFR2	Selumetinib	"In a preclinical study, endometrial carcinoma cells harboring FGFR2 S252W demonstrated decreased sensitivity to Selumetinib (AZD-6244) in culture (PMID: 26438159)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KcRgSS-TIFzzUIW7jax	FGFR2	Selumetinib	"In a preclinical study, endometrial carcinoma cells harboring FGFR2 N549K were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-Kb4CSS-TIFzzUIWSjax	FGFR2	Selumetinib	"In a preclinical study, Selumetinib (AZD-6244) did not inhibit growth of gastric cancer cells with FGFR2 amplification in culture (PMID: 19755509)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19755509	AVv-KdJ1SS-TIFzzUIYnjax	FGFR2	Selumetinib	"In a preclinical study, FGFR2 amplified colorectal adenocarcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-Kc6TSS-TIFzzUIYNjax	FGFR2	S-49076	"In a preclinical study, S-49076 inhibited Met activation, resulting in growth inhibition of gastric carcinoma cells harboring FGFR2 activating mutations in culture and in cell line xenograft models (PMID: 23804704)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23804704	AVv-KbrCSS-TIFzzUIV7jax	FGFR2	RO5126766	"In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to RO5126766 in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-Kb2wSS-TIFzzUIWQjax	FGFR2	RO5126766	"In a preclinical study, endometrial carcinoma cells harboring FGFR2 N549K were not sensitive to RO5126766 in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-Kb9QSS-TIFzzUIWbjax	FGFR2	RO5126766	"In a preclinical study, RO5126766 inhibited proliferation of endometrial carcinoma cells harboring FGFR2 S252W in culture (PMID: 26438159)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KcT0SS-TIFzzUIXKjax	FGFR2	RO5126766	"In a preclinical study, RO5126766 inhibited proliferation of FGFR2 amplified colorectal adenocarcinoma cells in culture (PMID: 26438159)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KdHBSS-TIFzzUIYijax	FGFR2	RO5126766	"In a preclinical study, FGFR2 amplified gastric carcinoma cell lines were not sensitive to RO5126766 in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-Kc9eSS-TIFzzUIYSjax	FGFR2	RO4987655	"In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to RO4987655 in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-Kb3YSS-TIFzzUIWRjax	FGFR2	RO4987655	"In a preclinical study, endometrial carcinoma cells harboring FGFR2 S252W demonstrated decreased response to RO4987655 in culture (PMID: 26438159)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KcUuSS-TIFzzUIXLjax	FGFR2	RO4987655	"In a preclinical study, endometrial carcinoma cells harboring FGFR2 N549K were not sensitive to RO4987655 in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-Kb8tSS-TIFzzUIWajax	FGFR2	RO4987655	"In a preclinical study, FGFR2 amplified gastric carcinoma cell lines were not sensitive to RO4987655 in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KcxrSS-TIFzzUIX_jax	FGFR2	RO4987655	"In a preclinical study, FGFR2 amplified colorectal adenocarcinoma cells demonstrated decreased response to RO4987655 in culture (PMID: 26438159)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KdJPSS-TIFzzUIYmjax	FGFR2	Ponatinib	"In a preclinical study, transformed cells expressing FGFR2 V565I were resistant to treatment with Iclusig (ponatinib) (PMID: 23908597)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KcgLSS-TIFzzUIXgjax	FGFR2	Ponatinib	"In a preclinical study, transformed cells expressing FGFR2 M538I demonstrated a decreased response to treatment with Iclusig (ponatinib) (PMID: 23908597)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KcEDSS-TIFzzUIWmjax	FGFR2	Ponatinib	"In a preclinical study, transformed cells expressing FGFR2 L618M were sensitive to treatment with Iclusig (ponatinib) ( (PMID: 23908597)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KbzaSS-TIFzzUIWKjax	FGFR2	Ponatinib	"In a preclinical study, transformed cells expressing FGFR2 K660E demonstrated a decreased response to treatment with Iclusig (ponatinib) (PMID: 23908597)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-Kby5SS-TIFzzUIWJjax	FGFR2	Ponatinib	"In a preclinical study, gastric cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KcYESS-TIFzzUIXRjax	FGFR2	Ponatinib	"In a preclinical study, endometrial cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KcZ0SS-TIFzzUIXUjax	FGFR2	Ponatinib	"In a preclinical study, colon cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KcW4SS-TIFzzUIXPjax	FGFR2	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited receptor phosphorylation and cell growth in transformed cells expressing constitutively active FGFR2 in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KbsvSS-TIFzzUIV-jax	FGFR2	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of FGFR2-amplified gastric cancer cells in culture, and inhibited tumor growth in FGFR2-amplified gastric cancer cell line xenograft models (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-Kc_bSS-TIFzzUIYVjax	FGFR2	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited growth of endometrial cancer cells harboring FGFR2 N549K in culture and in cell line xenograft models (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-Kb4qSS-TIFzzUIWTjax	FGFR2	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited downstream phosphorylation of Akt and Erk1/2 in cells expressing the fusion, FGFR2 - TACC3 (PMID: 26048680)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26048680	AVv-KcfoSS-TIFzzUIXfjax	FGFR2	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited downstream phosphorylation of Akt and Erk1/2 in cells expressing Fgfr2 W290_I291delinsC (PMID: 26048680)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26048680	AVv-KborSS-TIFzzUIV3jax	FGFR2	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited downstream phosphorylation of Akt and Erk1/2 in cells expressing Fgfr2 S267_D273dup (PMID: 26048680)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26048680	AVv-KcBASS-TIFzzUIWhjax	FGFR2	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 N550S (PMID: 23908597)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KcCxSS-TIFzzUIWkjax	FGFR2	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 N550K (PMID: 23908597)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KcnGSS-TIFzzUIXsjax	FGFR2	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 N550H (PMID: 23908597)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KbwDSS-TIFzzUIWEjax	FGFR2	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 M536I (PMID: 23908597)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KcsuSS-TIFzzUIX2jax	FGFR2	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 I548V (PMID: 23908597)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KdQqSS-TIFzzUIYyjax	FGFR2	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 E566G (PMID: 23908597)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KdRQSS-TIFzzUIYzjax	FGFR2	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and cell proliferation in endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KcQ4SS-TIFzzUIW6jax	FGFR2	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KdGiSS-TIFzzUIYhjax	FGFR2	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in ER-negative breast cancer cells harboring FGFR2 amplification in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-Kc1NSS-TIFzzUIYFjax	FGFR2	Ponatinib	"In a preclinical study, ER-negative breast cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KcaWSS-TIFzzUIXVjax	FGFR2	PHA-665752	"In a preclinical study, PHA-665752 treatment did not result in decreased colony formation or reduced phosphorylation levels of FGFR1 and FGFR2 in hepatocellular carcinoma cells in culture (PMID: 26351320)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26351320	AVv-KcITSS-TIFzzUIWtjax	FGFR2	PD173074 + Trabectedin	"In a preclinical study, PD173034 and Yondelis (trabectedin) worked synergistically to increase apoptosis, inhibit cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification in culture (PMID: 26036639)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26036639	AVv-Kc5ASS-TIFzzUIYLjax	FGFR2	PD173074	"In a preclinical study, treatment with PD173074 prevented transformation of cells expressing FGFR2-BICC1 in culture (PMID: 24122810)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24122810	AVv-KcdgSS-TIFzzUIXbjax	FGFR2	PD173074	"In a preclinical study, treatment with PD173074 prevented transformation of cells expressing FGFR2-AHCYL1 in culture (PMID: 24122810)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24122810	AVv-KcelSS-TIFzzUIXdjax	FGFR2	PD173074	"In a preclinical study, transformed cells expressing FGFR2 V565I were resistant to treatment with PD173074 (PMID: 23908597)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KchOSS-TIFzzUIXijax	FGFR2	PD173074	"In a preclinical study, transformed cells expressing FGFR2 N550S demonstrated a decreased response to treatment with PD173074 (PMID: 23908597)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KcDXSS-TIFzzUIWljax	FGFR2	PD173074	"In a preclinical study, transformed cells expressing FGFR2 N550K were resistant to PD173074 (PMID: 23908597)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KclBSS-TIFzzUIXpjax	FGFR2	PD173074	"In a preclinical study, transformed cells expressing FGFR2 N550H were resistant to treatment with PD173074 (PMID: 23908597)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KbvjSS-TIFzzUIWDjax	FGFR2	PD173074	"In a preclinical study, transformed cells expressing FGFR2 M538I demonstrated a decreased response to treatment with PD173074 (PMID: 23908597)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KcFNSS-TIFzzUIWojax	FGFR2	PD173074	"In a preclinical study, transformed cells expressing FGFR2 M536I demonstrated a decreased response to treatment with PD173074 (PMID: 23908597)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KctNSS-TIFzzUIX3jax	FGFR2	PD173074	"In a preclinical study, transformed cells expressing FGFR2 L618M demonstrated a decreased response to treatment with PD173074 (PMID: 23908597)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-Kbz9SS-TIFzzUIWLjax	FGFR2	PD173074	"In a preclinical study, transformed cells expressing FGFR2 K660E demonstrated a decreased response when treated with PD173074 (PMID: 23908597)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KbxySS-TIFzzUIWHjax	FGFR2	PD173074	"In a preclinical study, transformed cells expressing FGFR2 I548V demonstrated a decreased response to treatment with PD173074 (PMID: 23908597)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KdPWSS-TIFzzUIYwjax	FGFR2	PD173074	"In a preclinical study, transformed cells expressing FGFR2 E566G were resistant to treatment with PD173074 (PMID: 23908597)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KdR6SS-TIFzzUIY0jax	FGFR2	PD173074	"In a preclinical study, an endometrial cancer cell line harboring FGFR2 C383R and expressing FGFR2 N550K demonstrated resistance when treated with PD173074 (PMID: 23908597)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KckOSS-TIFzzUIXnjax	FGFR2	PD173074	"In a preclinical study, PD173074 inhibited proliferation of breast cancer cells over expressing FGFR2 in culture (PMID: 22869148)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-KcLASS-TIFzzUIWxjax	FGFR2	PD173074	"In a preclinical study, PD173074 inhibited proliferation of a gastric cancer cell line harboring FGFR2 amplification in culture (PMID: 26036639)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26036639	AVv-Kc7mSS-TIFzzUIYPjax	FGFR2	PD173074	"In a preclinical study, PD173074 increased apoptosis, inhibited cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification  in culture (PMID: 26036639)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26036639	AVv-KdCkSS-TIFzzUIYajax	FGFR2	Nintedanib	"In a preclinical study, transformed cells expressing constitutively active FGFR2 demonstrated reduced sensitivity to Ofev (Nintedanib) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KbtvSS-TIFzzUIWAjax	FGFR2	Nintedanib	"In a preclinical study, Ofev (nintedanib) inhibited growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KdDvSS-TIFzzUIYcjax	FGFR2	Nintedanib	"In a preclinical study, Ofev (Nintedanib) inhibited cell proliferation in endometrial cancer cells harboring FGFR2 S252W mutation in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KcWXSS-TIFzzUIXOjax	FGFR2	Nintedanib	"In a preclinical study, Ofev (Nintedanib) did not inhibit growth of endometrial cancer cells harboring FGFR2 N549K in cell culture (PMID: 22238366)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-Kb69SS-TIFzzUIWXjax	FGFR2	M-COPA	"In a preclinical study, treatment with M-COPA resulted in decreased Fgfr2 cell surface expression and phosphorylation and reduced growth of an FGFR2-amplified signet cell gastric cancer cell line in culture (PMID: 27197184)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27197184	AVv-Kc82SS-TIFzzUIYRjax	FGFR2	JNJ-42756493	"In a Phase I trial, JNJ-42756493 treatment resulted tumor shrinkage and no disease progression for 10 months in an adrenal carcinoma patient harboring FGFR3 - TACC3 and FGFR2 - CCDC6 fusions (PMID: 26324363)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26324363	AVv-KdOHSS-TIFzzUIYujax	FGFR2	JNJ-42756493	"In a Phase I trial, JNJ-42756493 treatment resulted in partial response in an endometrial cancer patient harboring FGFR2 - BICC1 and FGFR2 - OFD1 fusions (PMID: 26324363)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26324363	AVv-KdNfSS-TIFzzUIYtjax	FGFR2	JNJ-42756493	"In a Phase I trial, JNJ-42756493 treatment resulted in partial response for more than 12 months in a urothelial cancer patient harboring FGFR2 - BICC1 and FGFR2 - CASP7 fusions (PMID: 26324363)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26324363	AVv-KdM3SS-TIFzzUIYsjax	FGFR2	FIIN-01	"In a preclinical study, an endometrial carcinoma cell line harboring wild-type FGFR2 was resistant to FIIN-01-induced growth inhibition in culture (PMID: 20338520)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/20338520	AVv-KcYtSS-TIFzzUIXSjax	FGFR2	FIIN-01	"In a preclinical study, FIIN-01 inhibited proliferation of endometrial carcinoma cell lines harboring FGFR2 N549K mutation in culture (PMID: 20338520)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20338520	AVv-Kb6aSS-TIFzzUIWWjax	FGFR2	FIIN-01	"In a preclinical study, FIIN-01 inhibited proliferation of endometrial carcinoma cell lines harboring FGFR2 N549K and FGFR2 K310R mutations in culture (PMID: 20338520)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20338520	AVv-Kb2ISS-TIFzzUIWPjax	FGFR2	FIIN-01	"In a preclinical study, FIIN-01 inhibited Fgfr2-dependent cell proliferation of gastric cancer cell lines harboring FGFR2 amplification (PMID: 20338520)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20338520	AVv-KczhSS-TIFzzUIYCjax	FGFR2	FF-284	"In a preclinical study, Debio 1347 inhibited tumor growth in cell line xenograft models of FGFR2 amplified gastric carcinoma (PMID: 26438159)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-Kc2dSS-TIFzzUIYHjax	FGFR2	FF-284	"In a preclinical study, Debio 1347 inhibited proliferation of transformed cells over expressing FGFR2 V564F in culture and inhibited tumor growth in cell line xenograft models (PMID: 25169980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25169980	AVv-KcjJSS-TIFzzUIXljax	FGFR2	FF-284	"In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring an FGFR2 S252W mutation in culture and inhibited tumor growth in FGFR2 S252W-positive endometrial cancer cell line xenograft models (PMID: 25169980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25169980	AVv-KcTPSS-TIFzzUIW-jax	FGFR2	FF-284	"In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring FGFR2 N549K mutation in culture (PMID: 25169980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25169980	AVv-Kb7iSS-TIFzzUIWYjax	FGFR2	FF-284	"In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring FGFR2 K310R and FGFR2 N549K mutations in culture (PMID: 25169980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25169980	AVv-Kb1GSS-TIFzzUIWNjax	FGFR2	FF-284	"In a preclinical study, Debio 1347 inhibited proliferation of colorectal cancer cell lines harboring FGFR2 amplification in culture (PMID: 25169980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25169980	AVv-Kc3GSS-TIFzzUIYIjax	FGFR2	FF-284	"In a preclinical study, Debio 1347 inhibited proliferation of breast cancer cell lines harboring FGFR2 amplification in culture (PMID: 25169980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25169980	AVv-KdHjSS-TIFzzUIYjjax	FGFR2	FF-284	"In a preclinical study, Debio 1347 inhibited proliferation of FGFR-amplified gastric cancer cells in culture and inhibited tumor growth in cell line xenograft models of gastric cancer harboring FGFR2 amplification (PMID: 25169980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25169980	AVv-Kc-MSS-TIFzzUIYTjax	FGFR2	FF-284	"In a preclinical study, Debio 1347 did not inhibit Fgfr2 phosphorylation in transformed cells over expressing FGFR2 V564L in culture (PMID: 25169980)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25169980	AVv-Kb_kSS-TIFzzUIWfjax	FGFR2	FF-284	"In a preclinical study, Debio 1347 did not inhibit Fgfr2 phosphorylation in transformed cells over expressing FGFR2 V564I in culture (PMID: 25169980)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25169980	AVv-KbwoSS-TIFzzUIWFjax	FGFR2	E7090	"In a preclinical study, an endometrial cancer cell line harboring FGFR2 S252W (PMID: 18552176) demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability (PMID: 27535969)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18552176	AVv-KcSHSS-TIFzzUIW8jax	FGFR2	E7090	"In a preclinical study, a mouse breast carcinoma cell line xenograft model demonstrated inhibition of tumor growth when treated with E7090, a result of decreased FGFR2 and FGFR3 activity (PMID: 27535969)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27535969	AVv-KcHASS-TIFzzUIWrjax	FGFR2	E7090	"In a preclinical study, a gastric cancer cell line harboring FGFR2 amplification demonstrated decreased cell viability in culture and antitumor activity in xenograft models when treated with E7090 (PMID: 27535969)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27535969	AVv-KcwpSS-TIFzzUIX9jax	FGFR2	E7090	"In a preclinical study, a breast cancer cell line, harboring FGFR1 amplification and FGFR2 amplification, treated with E7090 demonstrated decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27535969	AVv-KcvZSS-TIFzzUIX7jax	FGFR2	Dovitinib + Trabectedin	"In a preclinical study, Dovitinib (TKI258) and Yondelis (trabectedin) worked synergistically to increase apoptosis, inhibit cell proliferation and migration of myxoid liposarcoma cell lines harbors FGFR2 amplification in culture (PMID: 26036639)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26036639	AVv-KdIGSS-TIFzzUIYkjax	FGFR2	Dovitinib	"In a preclinical study, transformed cells expressing FGFR2 V565I were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KcgvSS-TIFzzUIXhjax	FGFR2	Dovitinib	"In a preclinical study, transformed cells expressing FGFR2 S252W were sensitive to Dovitinib (TKI258) (PMID: 23908597)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KcPoSS-TIFzzUIW4jax	FGFR2	Dovitinib	"In a preclinical study, transformed cells expressing FGFR2 N550S demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KcCMSS-TIFzzUIWjjax	FGFR2	Dovitinib	"In a preclinical study, transformed cells expressing FGFR2 N550K were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KcnvSS-TIFzzUIXtjax	FGFR2	Dovitinib	"In a preclinical study, transformed cells expressing FGFR2 N550H demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-Kbu7SS-TIFzzUIWCjax	FGFR2	Dovitinib	"In a preclinical study, transformed cells expressing FGFR2 M538I demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KcEpSS-TIFzzUIWnjax	FGFR2	Dovitinib	"In a preclinical study, transformed cells expressing FGFR2 M536I demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KcsKSS-TIFzzUIX1jax	FGFR2	Dovitinib	"In a preclinical study, transformed cells expressing FGFR2 L618M demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-Kb0hSS-TIFzzUIWMjax	FGFR2	Dovitinib	"In a preclinical study, transformed cells expressing FGFR2 K660E were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KbyWSS-TIFzzUIWIjax	FGFR2	Dovitinib	"In a preclinical study, transformed cells expressing FGFR2 I548V demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KdP9SS-TIFzzUIYxjax	FGFR2	Dovitinib	"In a preclinical study, transformed cells expressing FGFR2 E566G were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23908597	AVv-KdSeSS-TIFzzUIY1jax	FGFR2	Dovitinib	"In a preclinical study, both cell lines and cell line xenograft models of endometrial cancer with FGFR2 activating mutations showed greater sensitivity to Dovitinib (TKI258) as compared to FGFR2 wild-type (PMID: 23443805)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23443805	AVv-Kbp2SS-TIFzzUIV5jax	FGFR2	Dovitinib	"In a preclinical study, Dovitinib (TKI258) inhibited receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR2 in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KbsJSS-TIFzzUIV9jax	FGFR2	Dovitinib	"In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in gastric cancer cell lines harboring FGFR2 amplification in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KdE9SS-TIFzzUIYejax	FGFR2	Dovitinib	"In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KcySSS-TIFzzUIYAjax	FGFR2	Dovitinib	"In a preclinical study, Dovitinib (TKI258) increased apoptosis, inhibited cell proliferation and migration of myxoid liposarcoma cell lines harbors FGFR2 amplification in culture (PMID: 26036639)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26036639	AVv-Kc8MSS-TIFzzUIYQjax	FGFR2	Dovitinib	"In a preclinical study, Dovitinib (TKI258) did not potently inhibit proliferation of endometrial cancer cell lines harboring FGFR2 N549K in cell culture (PMID: 22238366)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-Kb8ISS-TIFzzUIWZjax	FGFR2	Dovitinib	"In a preclinical study, Dovitinib (TKI258) did not potently inhibit cell proliferation in endometrial cancer cells harboring FGFR2 S252W mutation in culture (PMID: 22238366)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KcSvSS-TIFzzUIW9jax	FGFR2	Dovitinib	"In a Phase I trial, Dovitinib (TKI258) displayed safety and preliminary efficacy resulting in tumor regression of 28.2% and 18.5% in two patients with FGFR2 amplified Erbb2 (Her2)-receptor positive breast cancer (PMID: 23658459)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23658459	AVv-Kc0mSS-TIFzzUIYEjax	FGFR2	Cediranib	"In a preclinical study, Cediranib (AZD-2171) inhibited growth of gastric cancer cells harboring FGFR2 amplification in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KcwBSS-TIFzzUIX8jax	FGFR2	Cediranib	"In a preclinical study, Cediranib (AZD-2171) inhibited growth of endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KcQQSS-TIFzzUIW5jax	FGFR2	Cediranib	"In a preclinical study, Cediranib (AZD-2171) inhibited growth of endometrial cancer cells harboring FGFR2 N549K in cell culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-Kb5zSS-TIFzzUIWVjax	FGFR2	Cediranib	"In a preclinical study, Cediranib (AZD-2171) inhibited growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KdB2SS-TIFzzUIYZjax	FGFR2	Brivanib	"In a preclinical study, Brivanib (BMS-540215) inhibited growth of endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KcVzSS-TIFzzUIXNjax	FGFR2	Brivanib	"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of gastric cancer cells harboring FGFR2 amplification in culture (PMID: 22238366)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-Kcy6SS-TIFzzUIYBjax	FGFR2	Brivanib	"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of estrogen receptor (ER)-negative breast cancer cells with FGFR2 amplification in culture (PMID: 22238366)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KdBJSS-TIFzzUIYYjax	FGFR2	Brivanib	"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of endometrial cancer cells harboring FGFR2 N549K in cell culture (PMID: 22238366)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-Kb5NSS-TIFzzUIWUjax	FGFR2	Brivanib	"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KdKbSS-TIFzzUIYojax	FGFR2	BGJ398 + Trabectedin	"In a preclinical study, BGJ398 and Yondelis (trabectedin) worked synergistically to increase apoptosis, inhibit cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification in culture (PMID: 26036639)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26036639	AVv-KcxLSS-TIFzzUIX-jax	FGFR2	BGJ398	"In a preclinical study, treatment with BGJ398 prevented transformation of cells expressing FGFR2-BICC1 in culture (PMID: 24122810)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24122810	AVv-Kcc-SS-TIFzzUIXajax	FGFR2	BGJ398	"In a preclinical study, treatment with BGJ398 prevented transformation of cells expressing FGFR2-AHCYL1 in culture (PMID: 24122810)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24122810	AVv-KceBSS-TIFzzUIXcjax	FGFR2	BGJ398	"In a preclinical study, transformed cells over expressing FGFR2 V564F were resistant to BGJ398 in culture (PMID: 28034880)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-KciiSS-TIFzzUIXkjax	FGFR2	BGJ398	"In a preclinical study, BGJ398 reduced Myc expression, induced cell-cycle arrest, and inhibited growth of a colon cancer cell line with FGFR2 amplification in culture (PMID: 27401245)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27401245	AVv-Kc4bSS-TIFzzUIYKjax	FGFR2	BGJ398	"In a preclinical study, BGJ398 prevented oncogenic transformation of cells expressing FGFR2 W290_I291delinsC (PMID: 26048680)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26048680	AVv-KbpSSS-TIFzzUIV4jax	FGFR2	BGJ398	"In a preclinical study, BGJ398 prevented oncogenic transformation of cells expressing FGFR2 S267_D273dup (PMID: 26048680)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26048680	AVv-KcAbSS-TIFzzUIWgjax	FGFR2	BGJ398	"In a preclinical study, BGJ398 prevented oncogenic transformation of cells expressing FGFR2 - TACC3 (PMID: 26048680)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26048680	AVv-KcfFSS-TIFzzUIXejax	FGFR2	BGJ398	"In a preclinical study, BGJ398 inhibited the growth of FGFR2-mutated endometrial cancer cells in vitro and in xenograft models (PMID: 23443805)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23443805	AVv-KcrKSS-TIFzzUIXzjax	FGFR2	BGJ398	"In a preclinical study, BGJ398 inhibited proliferation of gastric cancer cell lines harboring FGFR2 amplification in culture (PMID: 26036639)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26036639	AVv-Kc-0SS-TIFzzUIYUjax	FGFR2	BGJ398	"In a preclinical study, BGJ398 increased apoptosis, and inhibited cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification  in culture (PMID: 26036639)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26036639	AVv-KdEYSS-TIFzzUIYdjax	FGFR2	BGJ398	"In a preclinical study, BGJ398 decreased Myc expression and inhibited tumor growth in patient-derived xenograft (PDX) models of gastric cancer with FGFR2 amplification and over expression (PMID: 27401245)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27401245	AVv-KcO4SS-TIFzzUIW3jax	FGFR2	BGJ398	"In a preclincal study, BGJ398 demonstrated enhanced inhibition of the survival in patient-derived ovarian cancer cells harboring FGFR2 - FAM76A in culture (PMID: 24563622)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24563622	AVv-KcBmSS-TIFzzUIWijax	FGFR2	BGJ398	"In a clinical study, FGFR2 mutations E565A, K659M, N549H, N549K and V564F were identified in the cell-free DNA of a cholangiocarcinoma patient harboring FGFR2-ZMYM4 fusion after the patient progressed while on BGJ398 treatment (PMID: 28034880)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-Kb93SS-TIFzzUIWcjax	FGFR2	BGJ398	"In a clinical study, FGFR2 mutations E565A, K641R, L617V, N549H and V564F were identified in the cell-free DNA of a cholangiocarcinoma patient harboring FGFR2-OPTN fusion after the patient progressed while on BGJ398 treatment (PMID: 28034880)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-Kbn5SS-TIFzzUIV2jax	FGFR2	BGJ398	"In a clinical study, FGFR2 V564F was identified in the cell-free DNA of a cholangiocarcinoma patient harboring FGFR2-BICC1 fusion after the patient progressed while on BGJ398 treatment (PMID: 28034880)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-KcccSS-TIFzzUIXZjax	FGFR2	BGJ398	"In a clinical study, FGFR2 V564F was identified in the cell-free DNA of 3 cholangiocarcinoma patients harboring FGFR2 fusion after the patients progressed while on BGJ398 treatment (PMID: 28034880)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/28034880	AVv-Kch1SS-TIFzzUIXjjax	FGFR2	BGJ398	"In a Phase I trial, two patients with cholangiocarcinoma harboring FGFR2 fusions demonstrated a decreased tumor burden when treated with BGJ398 (PMID: 27870574)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27870574	AVv-KdMQSS-TIFzzUIYrjax	FGFR2	BGJ398	"In a Phase I trial, a patient with cholangiocarcinoma harboring an FGFR2 mutation demonstrated a decreased tumor burden when treated with BGJ398 (PMID: 27870574)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27870574	AVv-KcrpSS-TIFzzUIX0jax	FGFR2	BGJ398	"In a Phase I trial, a breast cancer patient harboring an FGFR2 amplification demonstrated stable disease when treated with BGJ398 (PMID: 27870574)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27870574	AVv-KdGASS-TIFzzUIYgjax	FGFR2	BAY1187982	"In a preclinical study, sensitivity to BAY1187982 positively correlated with Fgfr2 expression level in a variety of cancer cell lines in culture, and in cell line or patient-derived xenograft models (PMID: 27543601)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27543601	AVv-KcJnSS-TIFzzUIWvjax	FGFR2	BAY1187982	"In a preclinical study, BAY1187982 inhibited tumor growth in patient-derived xenograft models of FGFR2 amplified ovarian cancer (PMID: 27543601)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27543601	AVv-Kc0DSS-TIFzzUIYDjax	FGFR2	BAY1187982	"In a preclinical study, BAY1187982 inhibited survival of gastric cancer cell lines with elevated Fgfr2 expression level in culture, and suppressed tumor growth in cell line or patient-derived xenograft models (PMID: 27543601)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27543601	AVv-KcKPSS-TIFzzUIWwjax	FGFR2	BAY1187982	"In a preclinical study, BAY1187982 inhibited survival of colorectal cancer cells with over expressing Fgfr2 in culture, and suppressed tumor growth in cell line xenograft models (PMID: 27543601)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27543601	AVv-KcNeSS-TIFzzUIW1jax	FGFR2	BAY1187982	"In a preclinical study, BAY1187982 inhibited survival of Fgfr2 positive breast cancer cell lines in culture, and suppressed tumor growth in both cell line and patient-derived xenograft models (PMID: 27543601)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27543601	AVv-KcI4SS-TIFzzUIWujax	FGFR2	BAY1187982	"In a preclinical study, BAY1187982 did not inhibit growth of breast cancer cells with very low Fgfr2 expression level in culture (PMID: 27543601)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27543601	AVv-KcFvSS-TIFzzUIWpjax	FGFR2	AZD4547	"In a preclinical study, transformed cells over expressing FGFR2 V564F were resistant to AZD4547 in culture and in cell line xenograft models (PMID: 25169980)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25169980	AVv-KcjoSS-TIFzzUIXmjax	FGFR2	AZD4547	"In a preclinical study, hepatocellular carcinoma cell lines treated with AZD4547 demonstrated decreased phosphorylation of FGFR1 and FGFR2, reduced colony formation, and evidence of apoptotic activity in culture (PMID: 26351320)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26351320	AVv-KcHpSS-TIFzzUIWsjax	FGFR2	AZD4547	"In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26936917	AVv-KcuYSS-TIFzzUIX5jax	FGFR2	AZD4547	"In a preclinical study, gastric cancer cells with wild-type FGFR2  and ERBB2 (HER2) amplification were resistant to treatment with AZD4547 in culture (PMID: 22869148)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-KcbZSS-TIFzzUIXXjax	FGFR2	AZD4547	"In a preclinical study, endometrial cells with Fgfr2 wild-type were resistant to the anti-proliferative effects of AZD4547 (PMID: 26294741)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26294741	AVv-KcXiSS-TIFzzUIXQjax	FGFR2	AZD4547	"In a preclinical study, endometrial cells with Fgfr2 overexpression were resistant to the anti-proliferative effects of AZD4547 (PMID: 26294741)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26294741	AVv-KcLrSS-TIFzzUIWyjax	FGFR2	AZD4547	"In a preclinical study, endometrial cells harboring Fgfr2 S252W were less sensitive to the anti-proliferative effects of AZD4547 than the Fgfr2 double mutant, K310R, N550K (PMID: 26294741)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26294741	AVv-KcVTSS-TIFzzUIXMjax	FGFR2	AZD4547	"In a preclinical study, endometrial cells harboring Fgfr2 N550K were less sensitive to the anti-proliferative effects of AZD4547 than the Fgfr2 double mutant, K310R, N550K (PMID: 26294741)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26294741	AVv-KcmjSS-TIFzzUIXrjax	FGFR2	AZD4547	"In a preclinical study, AZD4547 inhibited survival of FGFR2 amplified endometrial cancer cells in cell line xenograft models (PMID: 27550940)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27550940	AVv-Kc3vSS-TIFzzUIYJjax	FGFR2	AZD4547	"In a preclinical study, AZD4547 inhibited survival of FGFR2 amplified colon cancer cells in culture (PMID: 27550940)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27550940	AVv-KdFfSS-TIFzzUIYfjax	FGFR2	AZD4547	"In a preclinical study, AZD4547 inhibited survival of FGFR2 amplified breast cancer cells in culture (PMID: 27550940)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27550940	AVv-KdDLSS-TIFzzUIYbjax	FGFR2	AZD4547	"In a preclinical study, AZD4547 inhibited proliferation of endometrial cells and delayed tumor growth in cell-line derived xenografts harboring the Fgfr2 double mutant, K310R, N550K (PMID: 26294741)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26294741	AVv-Kb-dSS-TIFzzUIWdjax	FGFR2	AZD4547	"In a preclinical study, AZD4547 inhibited downstream Erk phosphorylation and proliferation of breast cancer cells over expressing FGFR2 in culture (PMID: 22869148)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-KcMPSS-TIFzzUIWzjax	FGFR2	AZD4547	"In a preclinical study, AZD4547 inhibited FGFR signaling, and decreased proliferation and induced cell-cycle arrest in gastric cancer cells with amplification and over expression of FGFR2 in culture (PMID: 22869148)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-Kc_-SS-TIFzzUIYWjax	FGFR2	AZD4547	"In a preclinical study, AZD4547 decreased Myc expression and inhibited tumor growth in patient-derived xenograft (PDX) models of gastric cancer with FGFR2 amplification and over expression (PMID: 27401245)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27401245	AVv-KcONSS-TIFzzUIW2jax	FGFR2	AZD4547	"In a Phase II clinical trial, treatment with AZD4547 resulted in a 33% (3/9) response rate in patients with FGFR2-amplified gastroesophageal cancer, and high-level amplification was associated with clinical response (PMID: 27179038)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27179038	AVv-KdAhSS-TIFzzUIYXjax	FGFR2	AZ8010	"In a preclinical study, AZ8010 inhibited downstream Erk phosphorylation and proliferation of breast cancer cells over expressing FGFR2 in culture (PMID: 22869148)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-KcM1SS-TIFzzUIW0jax	FGFR2	AZ6089	"In a preclinical study, AZ12576089 (AZ6089) inhibited FGF2-induced ERK1/2 phosphorylation and cell proliferation in transformed fibroblasts in culture (PMID: 22869148)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-Kca1SS-TIFzzUIXWjax	FGFR1	Trametinib	"In a preclinical study, knocking down of Fgfr1 through shRNA did not sensitize KRAS wild-type lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture  (PMID: 27338794)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-KaJSSS-TIFzzUIUbjax	FGFR1	Trametinib	"In a preclinical study, knocking down of Fgfr1 through shRNA did not sensitize KRAS mutant colorectal cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-KaKOSS-TIFzzUIUcjax	FGFR1	Trametinib	"In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition of KRAS mutant pancreatic cancer cells with decreased Fgfr1 expression through shRNA knockdown in culture (PMID: 27338794)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-KaKySS-TIFzzUIUdjax	FGFR1	Trametinib	"In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition in KRAS mutant lung cancer cells with decreased Fgfr1 expression through shRNA knockdown in culture, and tumor regression in xenograft models (PMID: 27338794)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27338794	AVv-KaLaSS-TIFzzUIUejax	FGFR1	Sorafenib	"In a clinical analysis of a Phase II trial, high Fgfr1 expression level was associated with decreased progression free survival in renal cell carcinoma patients treated with Nexavar (sorafenib) (PMID: 25900027)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/25900027	AVv-Ka7dSS-TIFzzUIVvjax	FGFR1	Selumetinib	"In a preclinical study, FGFR1 amplified non-small cell lung carcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KamYSS-TIFzzUIVLjax	FGFR1	Selumetinib	"In a preclinical study, FGFR1 amplified lung squamous cell carcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KajrSS-TIFzzUIVGjax	FGFR1	Selumetinib	"In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KaemSS-TIFzzUIU9jax	FGFR1	RO5126766	"In a preclinical study, FGFR1 amplified non-small cell lung carcinoma cells were not sensitive to RO5126766 in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KapsSS-TIFzzUIVRjax	FGFR1	RO5126766	"In a preclinical study, FGFR1 amplified lung squamous cell carcinoma cells were not sensitive to RO5126766 in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KaboSS-TIFzzUIU4jax	FGFR1	RO5126766	"In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to RO5126766 in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KanhSS-TIFzzUIVNjax	FGFR1	RO4987655	"In a preclinical study, FGFR1 amplified non-small cell lung carcinoma cells were not sensitive to RO4987655 in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KaV6SS-TIFzzUIUujax	FGFR1	RO4987655	"In a preclinical study, FGFR1 amplified lung squamous cell carcinoma cells were not sensitive to RO4987655 in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KabISS-TIFzzUIU3jax	FGFR1	RO4987655	"In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to RO4987655 in culture (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KaoESS-TIFzzUIVOjax	FGFR1	Ponatinib	"In a preclinical study, non-small cell lung cancer cells harboring mutant EGFR and wild-type FGFR1 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-Kaq2SS-TIFzzUIVTjax	FGFR1	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited receptor phosphorylation and cell growth in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KaPdSS-TIFzzUIUkjax	FGFR1	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited growth of squamous cell lung cancer cell lines harboring FGFR1 amplification (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KakRSS-TIFzzUIVHjax	FGFR1	Ponatinib	"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in ER-positive breast cancer cells harboring FGFR1 amplification in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KaipSS-TIFzzUIVEjax	FGFR1	Ponatinib	"In a preclinical study, Iclusig (ponatinib) blocked proliferation of Ewing’s sarcoma cells over expressing Fgfr1 (PMID: 26179511)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26179511	AVv-Ka9zSS-TIFzzUIVzjax	FGFR1	Ponatinib	"In a preclinical study, ER-positive breast cancer cells with wild-type FGFR1 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KasDSS-TIFzzUIVVjax	FGFR1	PHA-665752	"In a preclinical study, PHA-665752 treatment did not result in decreased colony formation or reduced phosphorylation levels of FGFR1 and FGFR2 in hepatocellular carcinoma cells in culture (PMID: 26351320)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26351320	AVv-Ka5bSS-TIFzzUIVsjax	FGFR1	PD173074	"In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27535980	AVv-Ka2bSS-TIFzzUIVnjax	FGFR1	PD173074	"In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27535980	AVv-Ka3oSS-TIFzzUIVpjax	FGFR1	PD173074	"In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27535980	AVv-Ka11SS-TIFzzUIVmjax	FGFR1	PD173074	"In a preclinical study, PD173074 inhibited survival of FGFR1 over expressing uterus leiomyosarcoma cells in culture (PMID: 27535980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27535980	AVv-Ka-aSS-TIFzzUIV0jax	FGFR1	PD173074	"In a preclinical study, PD173074 inhibited survival of FGFR1 amplified synovial sarcoma cells in culture (PMID: 27535980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27535980	AVv-KaaDSS-TIFzzUIU1jax	FGFR1	PD173074	"In a preclinical study, PD173074 inhibited Fgfr1 kinase activity and cell growth in transformed cells expressing the FGFR1-TACC1 fusion in culture (PMID: 22837387)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22837387	AVv-KaMFSS-TIFzzUIUfjax	FGFR1	Nintedanib	"In a preclinical study, transformed cells expressing constitutively active FGFR1 demonstrated reduced sensitivity to Ofev (Nintedanib) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KaSHSS-TIFzzUIUojax	FGFR1	Nintedanib	"In a preclinical study, Ofev (nintedanib) inhibited the growth of ER-positive breast cancer cells harboring FGFR1 amplification in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KaZeSS-TIFzzUIU0jax	FGFR1	Lucitanib	"In a preclinical study, an estrogen-receptor positive breast cancer cell line harboring FGFR1 amplification demonstrated sensitivity to treatment with Lucitanib (E-3810) in culture (PMID: 27126994)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27126994	AVv-KaiFSS-TIFzzUIVDjax	FGFR1	Lenvatinib	"In a preclinical study, Lenvima (lenvatinib) inhibited FGFR1 phosphorylation and signaling in thyroid cancer cells overexpressing FGFR1 (PMID: 25295214)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25295214	AVv-Ka8sSS-TIFzzUIVxjax	FGFR1	FIIN-01	"In a preclinical study, FIIN-01 inhibited Fgfr1 autophosphorylation in a human transformed embryonic kidney cell line harboring FGFR1 V561M mutation in culture (PMID: 20338520)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20338520	AVv-Kau0SS-TIFzzUIVajax	FGFR1	FIIN-01	"In a preclinical study, FIIN-01 inhibited Fgfr1 activation-induced proliferation and transformation of human breast epithelial cell lines in culture (PMID: 20338520)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20338520	AVv-KaRXSS-TIFzzUIUnjax	FGFR1	FF-284	"In a preclinical study, Debio 1347 inhibited proliferation of small cell lung cancer cell lines harboring FGFR1 amplification in culture (PMID: 25169980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25169980	AVv-KacxSS-TIFzzUIU6jax	FGFR1	FF-284	"In a preclinical study, Debio 1347 inhibited proliferation of non-small cell lung cancer cell lines harboring FGFR1 amplification in culture (PMID: 25169980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25169980	AVv-KaalSS-TIFzzUIU2jax	FGFR1	E7090	"In a preclinical study, an estrogen-receptor positive breast cancer cell line harboring FGFR1 amplification (PMID: 7506125) demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability (PMID: 27535969)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/7506125	AVv-KafwSS-TIFzzUIU_jax	FGFR1	E7090	"In a preclinical study, a small cell lung cancer cell line harboring FGFR1 amplification demonstrated sensitivity to E7090, resulting in decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27535969	AVv-KapGSS-TIFzzUIVQjax	FGFR1	E7090	"In a preclinical study, a non-small cell lung cancer cell line, harboring FGFR1 amplification, treated with E7090 demonstrated decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27535969	AVv-KadZSS-TIFzzUIU7jax	FGFR1	E7090	"In a preclinical study, a breast cancer cell line, harboring FGFR1 amplification and FGFR2 amplification, treated with E7090 demonstrated decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27535969	AVv-KaqVSS-TIFzzUIVSjax	FGFR1	Dovitinib	"In a preclinical study, primary cells from 8p11 myeloproliferative syndrome patients harboring FGFR1 rearrangement were sensitive to Dovitinib (TKI258)-induced growth inhibition in culture (PMID: 17698633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17698633	AVv-KatISS-TIFzzUIVXjax	FGFR1	Dovitinib	"In a preclinical study, Dovitinib (TKI258) inhibited receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KaOzSS-TIFzzUIUjjax	FGFR1	Dovitinib	"In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in estrogen receptor (ER)-positive breast cancer cells harboring FGFR1 amplification in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KaXDSS-TIFzzUIUwjax	FGFR1	Dovitinib	"In a preclinical study, Dovitinib (TKI258) inhibited Erk, Stat5 signaling and survival of transformed cell lines overexpressing FGFR1 fusion proteins (ZMYM2-FGFR1 or BCR-FGFR1) in culture (PMID: 17698633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17698633	AVv-KaIHSS-TIFzzUIUZjax	FGFR1	Dovitinib	"In a preclinical study, Dovitinib (TKI258) increased apoptosis and inhibited survival of acute myelogenous leukemia cell lines harboring FGFR1OP2-FGFR1 fusion in culture (PMID: 17698633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17698633	AVv-KaHfSS-TIFzzUIUYjax	FGFR1	Dovitinib	"In a Phase I trial, Dovitinib (TKI258) promoted 6-month stable disease in Erbb2 (Her2)-positive breast cancer patients with FGFR1 amplification (PMID: 23658459)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23658459	AVv-KaVVSS-TIFzzUIUtjax	FGFR1	Cediranib	"In a preclinical study, Cediranib (AZD-2171) inhibited growth of estrogen receptor (ER)-positive breast cancer cells with FGFR1 amplification in culture (PMID: 22238366)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KalzSS-TIFzzUIVKjax	FGFR1	Brivanib	"In a preclinical study, Brivanib (BMS-540215) did not inhibit receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KaStSS-TIFzzUIUpjax	FGFR1	Brivanib	"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of lung cancer cells with FGFR1 amplification in culture (PMID: 22238366)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KaWaSS-TIFzzUIUvjax	FGFR1	Brivanib	"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of estrogen receptor (ER)-positive breast cancer cells with FGFR2 amplification in culture (PMID: 22238366)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KacPSS-TIFzzUIU5jax	FGFR1	BYL719	"In a preclinical study, an estrogen-receptor positive breast cancer cell line harboring an FGFR1 amplification demonstrated resistance to Alpelisib (BYL719) in culture (PMID: 27126994)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27126994	AVv-KaXrSS-TIFzzUIUxjax	FGFR1	BGJ398	"In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to BGJ398 in culture (PMID: 27535980)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27535980	AVv-KayVSS-TIFzzUIVgjax	FGFR1	BGJ398	"In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to BGJ398 in culture (PMID: 27535980)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27535980	AVv-KawASS-TIFzzUIVcjax	FGFR1	BGJ398	"In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to BGJ398 in culture (PMID: 27535980)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27535980	AVv-Ka1OSS-TIFzzUIVljax	FGFR1	BGJ398	"In a preclinical study, PD173074 inhibited survival of FGFR1 over expressing uterus leiomyosarcoma cells in culture (PMID: 27535980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27535980	AVv-Ka8ISS-TIFzzUIVwjax	FGFR1	BGJ398	"In a preclinical study, BJG398 inhibited Fgfr1 kinase activity and cell growth in transformed cells expressing the FGFR1-TACC1 fusion in culture (PMID: 22837387)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22837387	AVv-KaMvSS-TIFzzUIUgjax	FGFR1	BGJ398	"In a preclinical study, BGJ398 inhibited survival of FGFR1 amplified synovial sarcoma cells in culture (PMID: 27535980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27535980	AVv-KahgSS-TIFzzUIVCjax	FGFR1	BGJ398	"In a preclinical study, BGJ398 inhibited cell growth and induced apoptosis in HNSCC cells over expressing Fgfr1 in culture and in xenograft models (PMID: 26015511)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26015511	AVv-Ka_FSS-TIFzzUIV1jax	FGFR1	BGJ398	"In a Phase I trial, 28% (9/32) of breast cancer patients harboring FGFR1 amplification demonstrated stable disease when treated with BGJ398 (PMID: 27870574)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27870574	AVv-KagSSS-TIFzzUIVAjax	FGFR1	Alpelisib + Lucitanib	"In a preclinical study, an estrogen-receptor positive breast cancer cell line over expressing FGFR1 and expressing a PIK3CA mutation demonstrated sensitivity to the combination of Apelisib (BYL719) and Lucitanib (E-3810) in culture (PMID: 27126994)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27126994	AVv-Ka6SSS-TIFzzUIVtjax	FGFR1	AZD4547 + Sirolimus	"In a preclinical study, AZD4547 and Rapamune (sirolimus) synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture (PMID: 26359452)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26359452	AVv-Ka4NSS-TIFzzUIVqjax	FGFR1	AZD4547 + Sirolimus	"In a preclinical study, AZD4547 and Rapamune (sirolimus) synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture (PMID: 26359452)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26359452	AVv-Ka0FSS-TIFzzUIVjjax	FGFR1	AZD4547 + AZD8055	"In a preclinical study, AZD4547 and AZD8055 synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture (PMID: 26359452)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26359452	AVv-KaxPSS-TIFzzUIVejax	FGFR1	AZD4547 + AZD8055	"In a preclinical study, AZD4547 and AZD8055 synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture (PMID: 26359452)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26359452	AVv-KaxwSS-TIFzzUIVfjax	FGFR1	AZD4547	"In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27535980	AVv-Ka3ASS-TIFzzUIVojax	FGFR1	AZD4547	"In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27535980	AVv-Ka0nSS-TIFzzUIVkjax	FGFR1	AZD4547	"In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27535980	AVv-KavaSS-TIFzzUIVbjax	FGFR1	AZD4547	"In a preclinical study, hepatocellular carcinoma cell lines treated with AZD4547 demonstrated decreased phosphorylation of FGFR1 and FGFR2, reduced colony formation, and evidence of apoptotic activity in culture (PMID: 26351320)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26351320	AVv-Ka41SS-TIFzzUIVrjax	FGFR1	AZD4547	"In a preclinical study, head and neck squamous cell carcinoma cells with EGFR over expression and FGFR1 amplification demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26936917	AVv-KaUGSS-TIFzzUIUrjax	FGFR1	AZD4547	"In a preclinical study, FGFR1 non-amplified lung cancer cell lines demonstrated reduced sensitivity to AZD4547 induced growth inhibition in culture and in xenograft models (PMID: 23082000)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23082000	AVv-KarbSS-TIFzzUIVUjax	FGFR1	AZD4547	"In a preclinical study, AZD4547 treatment of head and neck squamous cell carcinoma cells over expressing FGFR1 and negative for EGFR resulted in decreased cell growth and reduced downstream signaling of Erk1/2 (PMID: 26936917)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26936917	AVv-Ka62SS-TIFzzUIVujax	FGFR1	AZD4547	"In a preclinical study, AZD4547 inhibited survival of small cell lung cancer cells harboring FGFR1 translocation in culture (PMID: 27550940)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27550940	AVv-KattSS-TIFzzUIVYjax	FGFR1	AZD4547	"In a preclinical study, AZD4547 inhibited survival of leukemia cells harboring FGFR1 translocation in culture and in cell line xenograft models (PMID: 27550940)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27550940	AVv-KaskSS-TIFzzUIVWjax	FGFR1	AZD4547	"In a preclinical study, AZD4547 inhibited survival of FGFR1 over expressing uterus leiomyosarcoma cells in culture (PMID: 27535980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27535980	AVv-Ka9PSS-TIFzzUIVyjax	FGFR1	AZD4547	"In a preclinical study, AZD4547 inhibited survival of FGFR1 amplified synovial sarcoma cells in culture (PMID: 27535980)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27535980	AVv-KajLSS-TIFzzUIVFjax	FGFR1	AZD4547	"In a preclinical study, AZD4547 inhibited proliferation of lung cancer cell lines harboring FGFR1 amplification in culture and induced tumor regression in xenograft models (PMID: 23082000)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23082000	AVv-Kag7SS-TIFzzUIVBjax	FGFR1	AZD4547	"In a preclinical study, AZD4547 inhibited proliferation of a small cell lung cancer cell line harboring FGFR1 amplification in culture (PMID: 23082000)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23082000	AVv-KaY7SS-TIFzzUIUzjax	FGFR1	AZD4547	"In a preclinical study, AZD4547 inhibited proliferation of a large cell lung cancer cell line harboring FGFR1 amplification in culture and induced tumor regression in xenograft models (PMID: 23082000)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23082000	AVv-Kad-SS-TIFzzUIU8jax	FGFR1	AZD4547	"In a preclinical study, AZD4547 inhibited Fgfr1 kinase activity and cell growth in transformed cells expressing the FGFR1-TACC1 fusion in culture (PMID: 22837387)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22837387	AVv-KaNeSS-TIFzzUIUhjax	FGFR1	AZD4547	"In a Phase II clinical trial, treatment with AZD4547 resulted in a response rate of 12.5% (1/8) in patients with FGFR1-amplified breast cancer, and did not meet the predetermined criteria for efficacy (PMID: 27179038)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27179038	AVv-KakySS-TIFzzUIVIjax	FGFR1	AZD2014 + AZD4547	"In a preclinical study, AZD4547 and AZD2014 synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture and in cell line xenograft models (PMID: 26359452)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26359452	AVv-KazdSS-TIFzzUIVijax	FGFR1	AZD2014 + AZD4547	"In a preclinical study, AZD4547 and AZD2014 synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture and in cell line xenograft models (PMID: 26359452)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26359452	AVv-Kay6SS-TIFzzUIVhjax	FGFR1	AZD2014 + AZD4547	"In a preclinical study, AZD4547 and AZD2014 synergistically inhibited survival of FGFR1-dependent head and neck squamous cell carcinoma cells in culture (PMID: 26359452)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26359452	AVv-KawmSS-TIFzzUIVdjax	FBXW7	Vorinostat	"In a preclinical study, Zolinza (vorinostat) inhibited growth of a head and neck squamous cell carcinoma cell line harboring FBXW7 R505C in culture (PMID: 23274910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23274910	AVv-KZsBSS-TIFzzUIT-jax	FBXW7	Temsirolimus	"In a clinical case report, a patient with lung adenocarcinoma harboring FBXW7 R465H demonstrated tumor shrinkage when treated with Torisel (temsirolimus) (PMID: 24360397)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24360397	AVv-KZyvSS-TIFzzUIUKjax	FBXW7	Sirolimus	"In a preclinical study, breast cancer cells harboring a FBXW7 mutation demonstrated sensitivity to Rapamune (sirolimus) in culture and in cell line xenograft models (PMID: 18787170)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18787170	AVv-KZtHSS-TIFzzUIUAjax	FBXW7	Sirolimus	"In a preclinical study, Rapamune (sirolimus) inhibited epithelial-mesenchymal transition, motility, and invasiveness in colon cancer cells lacking FBXW7 in culture (PMID: 23558291)"	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23558291	AVv-KZqFSS-TIFzzUIT7jax	FBXW7	Sirolimus	"In a Phase I study, Rapamune (sirolimus) resulted in prolonged stable disease in a patient with hepatocellular fibrolamellar carcinoma harboring a FBXW7 mutation (PMID: 24586741)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24586741	AVv-KZvPSS-TIFzzUIUEjax	FBXW7	MRK-003	"In a preclinical study, FBXW7 R505L may conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/17646409	AVv-KZyESS-TIFzzUIUJjax	FBXW7	MRK-003	"In a preclinical study, FBXW7 R505C conferred resistance to gamma secretase inhibitor, MRK-300, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/17646409	AVv-KZsjSS-TIFzzUIT_jax	FBXW7	MRK-003	"In a preclinical study, FBXW7 R479Q conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/17646409	AVv-KZz_SS-TIFzzUIUMjax	FBXW7	MRK-003	"In a preclinical study, FBXW7 R465H conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/17646409	AVv-KZzYSS-TIFzzUIULjax	FBXW7	MRK-003	"In a preclinical study, FBXW7 R465C conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/17646409	AVv-KZrZSS-TIFzzUIT9jax	FBXW7	Entinostat	"In a preclinical study, entinostat (MS-275) inhibited cancer cells from advanced solid tumors and hematological cells harboring FBXW7 inactivating mutations in culture (PMID: 23274910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23274910	AVv-KZvxSS-TIFzzUIUFjax	FBXW7	Docetaxel	"In a preclinical study, human cancer cell lines harboring FBXW7 inactivating mutations were resistant to docetaxel in culture (PMID: 23274910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23274910	AVv-KZuvSS-TIFzzUIUDjax	FBXW7	Belinostat	"In a preclinical study, Beleodaq (belinostat) inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23274910	AVv-KZwbSS-TIFzzUIUGjax	FBXW7	Belinostat	"In a preclinical study, Beleodaq (belinostat) inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23274910	AVv-KZtoSS-TIFzzUIUBjax	FBXW7	AR-42	"In a preclinical study, AR-42 inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23274910	AVv-KZuJSS-TIFzzUIUCjax	FBXW7	AR-42	"In a preclinical study, AR-42 inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23274910	AVv-KZxiSS-TIFzzUIUIjax	EZH2	Vorinostat	"In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25605023	AVv-KZO9SS-TIFzzUIT0jax	EZH2	Vorinostat	"In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25605023	AVv-KZL8SS-TIFzzUITvjax	EZH2	UNC1999	"In a preclinical study, UNC1999 treatment reduced H3K27me3 levels, decreased proliferation, and increased cell death in diffuse large B-cell lymphoma cells harboring an EZH2 Y641N mutation in cell culture (PMID: 23614352)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23614352	AVv-KZJASS-TIFzzUITqjax	EZH2	Tazemetostat	"In a preclinical study, treatment with EPZ-6438 inhibited proliferation and promoted cell death in lymphoma cells expressing EZH2 Y646F (PMID: 24563539)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24563539	AVv-KZSJSS-TIFzzUIT5jax	EZH2	Tazemetostat	"In a preclinical study, transformed cells over expressing EZH2 carrying simultaneous Y641F and Y111D mutations demonstrated reduced sensitivity to Tazemetostat (EPZ-6438) in culture (PMID: 26360609)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26360609	AVv-KZDhSS-TIFzzUITgjax	EZH2	Tazemetostat	"In a preclinical study, transformed cells over expressing EZH2 carrying simultaneous A677G and Y111D mutations were resistant to Tazemetostat (EPZ-6438) in culture (PMID: 26360609)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26360609	AVv-KZH5SS-TIFzzUITojax	EZH2	Tazemetostat	"In a preclinical study, over expression of EZH2 Y111D in transformed cells harboring wild-type Ezh2 resulted in resistance to Tazemetostat (EPZ-6438) treatment in culture (PMID: 26360609)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26360609	AVv-KZFLSS-TIFzzUITjjax	EZH2	Tazemetostat	"In a preclinical study, over expression of EZH2 Y111D in rhabdoid tumor cells harboring an SMARCB1 inactivating mutation resulted in resistance to Tazemetostat (EPZ-6438) treatment in culture (PMID: 26360609)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26360609	AVv-KZFtSS-TIFzzUITkjax	EZH2	Tazemetostat	"In a preclinical study, EZH2 Y111D conferred resistance to Tazemetostat (EPZ-6438) when occurred in the same allele as EZH2 A677G in B-cell lymphoma cells in culture (PMID: 26360609)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26360609	AVv-KZHTSS-TIFzzUITnjax	EZH2	Selumetinib + Tazemetostat	"In a preclinical study, the addition of Tazemetostat (EPZ-6438) increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C in culture (PMID: 26676756)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KY4VSS-TIFzzUITNjax	EZH2	Selumetinib + Tazemetostat	"In a preclinical study, the addition of Tazemetostat (EPZ-6438) did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KY9zSS-TIFzzUITWjax	EZH2	MK2206 + Tazemetostat	"In a preclinical study, the addition of Tazemetostat (EPZ-6438) increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture (PMID: 26676756)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KY_nSS-TIFzzUITZjax	EZH2	MK2206 + Tazemetostat	"In a preclinical study, the addition of Tazemetostat (EPZ-6438) did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C in culture (PMID: 26676756)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KY3nSS-TIFzzUITMjax	EZH2	JQEZ5	"In a preclinical study, JQEZ5 inhibited proliferation of human EZH2 over expressing non-small cell lung cancer cells in culture and induced tumor regression in mouse models of EZH2-over expressing lung adenocarcinoma (PMID: 27312177)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27312177	AVv-KYxkSS-TIFzzUITCjax	EZH2	GSK343 + Selumetinib	"In a preclinical study, the addition of GSK343 increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C in culture (PMID: 26676756)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KY4_SS-TIFzzUITOjax	EZH2	GSK343 + Selumetinib	"In a preclinical study, the addition of GSK343 did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KY-aSS-TIFzzUITXjax	EZH2	GSK343 + MK2206	"In a preclinical study, the addition of GSK343 increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture (PMID: 26676756)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KZAJSS-TIFzzUITajax	EZH2	GSK343 + MK2206	"In a preclinical study, the addition of GSK343 did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C in culture (PMID: 26676756)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KY3ASS-TIFzzUITLjax	EZH2	GSK126	"In a preclinical study, transformed cells over expressing EZH2 carrying simultaneous A677G and Y111D mutations were resistant to GSK126 in culture (PMID: 26360609)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26360609	AVv-KZGzSS-TIFzzUITmjax	EZH2	GSK126	"In a preclinical study, transformed cells over expressing EZH2 carrying simultaneous A677G and Y111D mutations demonstrated reduced sensitivity to GSK126 in culture (PMID: 26360609)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26360609	AVv-KZDASS-TIFzzUITfjax	EZH2	GSK126	"In a preclinical study, over expression of EZH2 Y111D in transformed cells harboring wild-type Ezh2 resulted in resistance to GSK126 treatment in culture (PMID: 26360609)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26360609	AVv-KZEoSS-TIFzzUITijax	EZH2	GSK126	"In a preclinical study, GSK126 treatment inhibited cell growth via suppression of downstream tumor suppressor gene targets and induced apoptosis in melanoma cells harboring EZH2 Y646N in culture (PMID: 26304929)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26304929	AVv-KYySSS-TIFzzUITDjax	EZH2	GSK126	"In a preclinical study, GSK126 reversed transcriptional silencing in human melanoma cells harboring wild-type EZH2 Y641S in culture (PMID: 26936398)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26936398	AVv-KZQ6SS-TIFzzUIT3jax	EZH2	GSK126	"In a preclinical study, GSK126 inhibited H3K27 trimethylation in human melanoma cells harboring wild-type EZH2 in culture (PMID: 26936398)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26936398	AVv-KZEISS-TIFzzUIThjax	EZH2	GSK126	"In a preclinical study, GSK126 inhibited H3K27 trimethylation and reversed transcriptional silencing in human melanoma cells harboring EZH2 Y641N in culture (PMID: 26936398)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26936398	AVv-KZJjSS-TIFzzUITrjax	EZH2	GSK126	"In a preclinical study, GSK126 inhibited H3K27 trimethylation and reversed transcriptional silencing in human melanoma cells harboring EZH2 Y641H in culture (PMID: 26936398)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26936398	AVv-KZStSS-TIFzzUIT6jax	EZH2	GSK126	"In a preclinical study, EZH2 Y111D conferred resistance to GSK126 when occurred in the same allele as EZH2 A677G in B-cell lymphoma cells in culture (PMID: 26360609)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26360609	AVv-KZGSSS-TIFzzUITljax	EZH2	GSK126	"In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated a decreased response to GSK126 in culture (PMID: 25605023)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25605023	AVv-KZNmSS-TIFzzUITyjax	EZH2	GSK126	"In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated a decreased response to GSK126 in culture (PMID: 25605023)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25605023	AVv-KZLZSS-TIFzzUITujax	EZH2	EPZ005687	"In a preclinical study, EPZ005687 promoted apoptosis in non-Hodgkin lymphoma cell lines expressing EZH2 Y641C (PMID: 23023262)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23023262	AVv-KZCeSS-TIFzzUITejax	EZH2	DZNep + Selumetinib	"In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12C in culture (PMID: 26676756)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KY2YSS-TIFzzUITKjax	EZH2	DZNep + Selumetinib	"In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12S in culture (PMID: 26676756)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KYzeSS-TIFzzUITFjax	EZH2	DZNep + Selumetinib	"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 26676756)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KY8rSS-TIFzzUITUjax	EZH2	DZNep + Selumetinib	"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12V (PMID: 26676756)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KY0pSS-TIFzzUITHjax	EZH2	DZNep + Selumetinib	"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KY9QSS-TIFzzUITVjax	EZH2	DZNep + Selumetinib	"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KZArSS-TIFzzUITbjax	EZH2	DZNep + MK2206	"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 26676756)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KZB5SS-TIFzzUITdjax	EZH2	DZNep + MK2206	"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12C in culture (PMID: 26676756)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KY6PSS-TIFzzUITQjax	EZH2	DZNep + MK2206	"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12S in culture (PMID: 26676756)"	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KY0ESS-TIFzzUITGjax	EZH2	DZNep + MK2206	"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KZBSSS-TIFzzUITcjax	EZH2	DZNep + MK2206	"In a preclinical study, the addition of DZNep did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12V (PMID: 26676756)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KY1MSS-TIFzzUITIjax	EZH2	DZNep + MK2206	"In a preclinical study, the addition of DZNep did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C (PMID: 26676756)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26676756	AVv-KY1wSS-TIFzzUITJjax	EZH2	DZNeP	"In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated a decreased response to DZNeP in culture (PMID: 25605023)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25605023	AVv-KZPjSS-TIFzzUIT1jax	EZH2	DZNeP	"In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated a decreased response to DZNeP in culture (PMID: 25605023)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25605023	AVv-KZIfSS-TIFzzUITpjax	EZH2	ACY-957 + GSK126	"In a preclinical study, GSK126 enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641S in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25605023	AVv-KZONSS-TIFzzUITzjax	EZH2	ACY-957 + GSK126	"In a preclinical study, GSK126 enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641N in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25605023	AVv-KZKISS-TIFzzUITsjax	EZH2	ACY-957 + Doxorubicin	"In a preclinical study, DLBCL cells harboring EZH2 Y641N treated with the combination of ACY-957 and Adriamycin (doxorubicin) resulted in a greater sensitivity to cell death compared to treatment with either agent alone (PMID: 25605023)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25605023	AVv-KZNDSS-TIFzzUITxjax	EZH2	ACY-957 + DZNeP	"In a preclinical study, DZNeP enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641S in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25605023	AVv-KZRiSS-TIFzzUIT4jax	EZH2	ACY-957 + DZNeP	"In a preclinical study, DZNeP enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641N in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25605023	AVv-KZKwSS-TIFzzUITtjax	EZH2	ACY-957	"In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated sensitivity to ACY-957 in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25605023	AVv-KZQPSS-TIFzzUIT2jax	EZH2	ACY-957	"In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated sensitivity to ACY-957 in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25605023	AVv-KZMeSS-TIFzzUITwjax	ETV6	RXDX-101	"In a preclinical study, transformed cells expressing ETV6-ROS1 were sensitive to Entrectinib (RXDX-101), resulting in inhibition of cell proliferation in culture and decreased tumor growth in xenograft models (PMID: 26939704)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26939704	AVv-KYdNSS-TIFzzUITBjax	ETV6	RXDX-101	"In a preclinical study, transformed cells expressing ETV6-NTRK3 were sensitive to Entrectinib (RXDX-101), resulting in inhibition of cell proliferation (PMID: 26939704)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26939704	AVv-KYVkSS-TIFzzUIS0jax	ETV6	RXDX-101	"In a preclinical study, transformed cells expressing ETV6-NTRK2 were sensitive to Entrectinib (RXDX-101), resulting in inhibition of cell proliferation (PMID: 26939704)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26939704	AVv-KYLaSS-TIFzzUISjjax	ETV6	RXDX-101	"In a preclinical study, transformed cells expressing ETV6-ALK demonstrated sensitivity  to Entrectinib (RXDX-101) in culture (PMID: 26939704)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26939704	AVv-KYb7SS-TIFzzUIS_jax	ETV6	RXDX-101	"In a Phase I clinical trial, treatment with Entrectinib (RXDX-101) resulted in a durable partial response in a patient with mammary analogue secretory carcinoma harboring ETV6-NTRK3 (PMID: 26884591)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26884591	AVv-KYVDSS-TIFzzUISzjax	ETV6	Pyridone 6	"In a preclinical study, immune cells expressing ETV6-JAK2 with the Y918H mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22916261	AVv-KYYhSS-TIFzzUIS5jax	ETV6	Pyridone 6	"In a preclinical study, immune cells expressing ETV6-JAK2 with the V881A mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22916261	AVv-KYZvSS-TIFzzUIS7jax	ETV6	Pyridone 6	"In a preclinical study, immune cells expressing ETV6-JAK2 with the R975G mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22916261	AVv-KYazSS-TIFzzUIS9jax	ETV6	Pyridone 6	"In a preclinical study, immune cells expressing ETV6-JAK2 with the R1127K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22916261	AVv-KYaSSS-TIFzzUIS8jax	ETV6	Pyridone 6	"In a preclinical study, immune cells expressing ETV6-JAK2 with the P1057S mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22916261	AVv-KYZLSS-TIFzzUIS6jax	ETV6	Pyridone 6	"In a preclinical study, immune cells expressing ETV6-JAK2 with the N909K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22916261	AVv-KYX9SS-TIFzzUIS4jax	ETV6	Pyridone 6	"In a preclinical study, immune cells expressing ETV6-JAK2 with the M929I mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22916261	AVv-KYbVSS-TIFzzUIS-jax	ETV6	Pyridone 6	"In a preclinical study, immune cells expressing ETV6-JAK2 with the G935R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22916261	AVv-KYXYSS-TIFzzUIS3jax	ETV6	Pyridone 6	"In a preclinical study, immune cells expressing ETV6-JAK2 with the G831R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22916261	AVv-KYWvSS-TIFzzUIS2jax	ETV6	Pyridone 6	"In a preclinical study, immune cells expressing ETV6-JAK2 with the E864K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22916261	AVv-KYWHSS-TIFzzUIS1jax	ETV6	N/A	"In multiple clinical studies, the ETV6-RUNX1 fusion was associated with a favorable prognosis in acute lymphocytic leukemia patients (PMID: 8609706, PMID: 10086740, PMID: 11432885, Guidelines)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/11432885	AVv-KYN4SS-TIFzzUISnjax	ETV6	N/A	"In multiple clinical studies, ETV6 mutations were associated with a shorter overall survival in patients with myelodysplastic syndrome (Guidelines, PMID: 21714648, PMID: 21877899, PMID: 26769228)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/21877899	AVv-KYOcSS-TIFzzUISojax	ETV6	N/A	"In multiple clinical studies, ETV6 inactivating germline mutations were shown to be a risk factor for the development of acute lymphocytic leukemia (PMID: 26522332, PMID: 26102509, PMID: 25807284)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/25807284	AVv-KYKKSS-TIFzzUIShjax	ETV6	N/A	"ETV6-RUNX1 is used in the diagnosis of acute lymphocytic leukemia (PMID: 26711002, PMID: 15704129, PMID: 8609706, Guidelines)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/15704129	AVv-KYNLSS-TIFzzUISmjax	ETV6	N/A	"ETV6-NTRK3 fusions are used in the diagnosis of congenital fibrosarcoma (Guidelines, PMID: 24517889, PMID: 9462753)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/24517889	AVv-KYUfSS-TIFzzUISyjax	ETV6	Midostaurin	"In a preclinical study, the broad spectrum kinase inhibitor midostaurin inhibited growth of cells dependent on the fusion protein ETV6–NTRK3, reducing ETV6–NTRK3 kinase activity and downstream signaling and inducing apoptosis (PMID: 23131561)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23131561	AVv-KYQSSS-TIFzzUISrjax	ETV6	Lestaurtinib	"In a preclinical study, transformed cells expressing the fusion, ETV6-NTRK3, were treated with Lestaurtinib (CEP-701), which resulted in inhibition of ETV6-NTRK3 autophosphorylation and restoration of Tgf-b1 signaling (PMID: 16258068)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/16258068	AVv-KYQ3SS-TIFzzUISsjax	ETV6	LOXO-101	"In a preclinical study, LOXO-101 inhibited cell growth and downstream signaling in acute myeloid leukemia cells harboring ETV6-NTRK3 in culture and xenografts (PMID: 26216294)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26216294	AVv-KYTVSS-TIFzzUISwjax	ETV6	LOXO-101	"In a Phase I clinical trial, treatment with LOXO-101 resulted in a partial response in a pediatric patient with infantile fibrosarcoma harboring ETV6-NTRK3 (PMID: 27093299)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27093299	AVv-KYSvSS-TIFzzUISvjax	ETV6	Imatinib	"In a clinical case report, a patient with ETV6-PDGFRA positive chronic eosinophilic leukemia experienced complete cytogenic remission after treatment with Gleevec (imatinib) (PMID: 17555450)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17555450	AVv-KYKwSS-TIFzzUISijax	ETV6	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited ETV6-NTRK3 activity, reduced cell growth in a human acute myeloid leukemia cell line harboring ETV6-NTRK3, and had anti-tumor activity in xenograft models (PMID: 23811600)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23811600	AVv-KYT8SS-TIFzzUISxjax	ETV6	BMS-754807	"In a preclinical study, BMS-754807 inhibited growth of a breast cancer xenograft models expressing ETV6-NTRK3 (PMID: 21148487)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21148487	AVv-KYSKSS-TIFzzUISujax	ETV6	BMS-536924	"In a preclinical study, transformed human cells expressing ETV6-NTRK3 were sensitive to BMS-536924, demonstrating a reduction in both cell survival and transformation activity in culture (PMID: 21804605)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21804605	AVv-KYPqSS-TIFzzUISqjax	ETV6	AZD4547	"In a preclinical study, treatment with AZD4547 decreased Myc expression and inhibited growth of transformed cells expressing ETV6-FGFR4 (TEL-FGFR4) in culture (PMID: 27401245)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27401245	AVv-KYPESS-TIFzzUISpjax	ETV6	AZD4547	"In a preclinical study, treatment with AZD4547 decreased Myc expression and inhibited growth of transformed cells expressing ETV6-FGFR3 (TEL-FGFR3) in culture (PMID: 27401245)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27401245	AVv-KYMmSS-TIFzzUISljax	ETV6	AZD4547	"In a preclinical study, treatment with AZD4547 decreased Myc expression and inhibited growth of transformed cells expressing ETV6-FGFR1 (TEL-FGFR1) in culture (PMID: 27401245)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27401245	AVv-KYL_SS-TIFzzUISkjax	ERBB4	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited survival of melanoma cells harboring ERBB4 R393W in culture (PMID: 19718025)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19718025	AVv-KX1JSS-TIFzzUISfjax	ERBB4	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited survival and induced apoptosis in melanoma cells harboring ERBB4 E563K in culture (PMID: 19718025)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19718025	AVv-KX1vSS-TIFzzUISgjax	ERBB4	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited survival and induced apoptosis in melanoma cells harboring ERBB4 E452K in culture (PMID: 19718025)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19718025	AVv-KXzeSS-TIFzzUIScjax	ERBB4	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited survival and induced apoptosis in melanoma cells harboring ERBB4 E317K in culture (PMID: 19718025)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19718025	AVv-KX0ASS-TIFzzUISdjax	ERBB4	Lapatinib	"In a preclinical study, Tykerb (lapatinib) induced apoptosis in melanoma cells harboring ERBB4 R544W in culture (PMID: 19718025)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19718025	AVv-KX0mSS-TIFzzUISejax	ERBB4	Erlotinib	"In a preclinical study, head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C demonstrated resistance to treatment with Tarceva (erlotinib) in a cell viability assay (PMID: 27207775)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27207775	AVv-KXyRSS-TIFzzUISajax	ERBB4	Cetuximab	"In a preclinical study, head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C demonstrated resistance to treatment with Erbitux (cetuximab) in a cell viability assay (PMID: 27207775)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27207775	AVv-KXxnSS-TIFzzUISZjax	ERBB4	Afatinib	"In a preclinical study, Gilotrif (afatinib) treatment resulted in apoptotic induction in head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C in culture and inhibited tumor growth in cell line xenograft models (PMID: 27207775)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27207775	AVv-KXy5SS-TIFzzUISbjax	ERBB2	trastuzumab emtansine	"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification and over expression (PMID: 21458915)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21458915	AVv-KXM7SS-TIFzzUIRxjax	ERBB2	trastuzumab emtansine	"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26920887	AVv-KV47SS-TIFzzUIPljax	ERBB2	trastuzumab emtansine	"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture (PMID: 26920887)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26920887	AVv-KWduSS-TIFzzUIQgjax	ERBB2	trastuzumab emtansine	"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA C420R in culture (PMID: 26920887)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26920887	AVv-KV1mSS-TIFzzUIPfjax	ERBB2	trastuzumab emtansine	"In a Phase III trial that supported FDA approval, treatment with Kadclya (trastuzumab emtansine) improved median progression free survival in patients with metastatic ERBB2 (HER2) positive breast cancer (PMID: 24879797)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24879797	AVv-KWW4SS-TIFzzUIQVjax	ERBB2	poziotinib	"In a preclinical study, Poziotinib suppressed cell growth, decreased phosphorylation of downstream signaling molecules, and induced apoptosis of human gastric cancer cells harboring ERBB2 (HER2) amplification (PMID: 21306821)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21306821	AVv-KUG2SS-TIFzzUIMWjax	ERBB2	XL647	"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) Y803N in culture (PMID: 18413839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KT7NSS-TIFzzUIMDjax	ERBB2	XL647	"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) V839G in culture (PMID: 18413839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KU7wSS-TIFzzUINwjax	ERBB2	XL647	"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) T798I in culture (PMID: 18413839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KT1rSS-TIFzzUIL5jax	ERBB2	XL647	"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) T733I in culture (PMID: 18413839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KT0fSS-TIFzzUIL3jax	ERBB2	XL647	"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) S783P in culture (PMID: 18413839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KT8YSS-TIFzzUIMFjax	ERBB2	XL647	"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) P780L in culture (PMID: 18413839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KUuuSS-TIFzzUINajax	ERBB2	XL647	"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L915M in culture (PMID: 19718025)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19718025	AVv-KU7NSS-TIFzzUINvjax	ERBB2	XL647	"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L785F in culture (PMID: 18413839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KVXZSS-TIFzzUIOrjax	ERBB2	XL647	"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L755S in culture (PMID: 18413839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KUzoSS-TIFzzUINijax	ERBB2	XL647	"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L726F in culture (PMID: 19718025)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19718025	AVv-KWrESS-TIFzzUIQ2jax	ERBB2	XL647	"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E812K in culture (PMID: 18413839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KWqgSS-TIFzzUIQ1jax	ERBB2	XL647	"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E719G in culture (PMID: 18413839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KU45SS-TIFzzUINrjax	ERBB2	XL647	"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E717K in culture (PMID: 18413839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KVqaSS-TIFzzUIPMjax	ERBB2	XL647	"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) D821N in culture (PMID: 18413839)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KVjGSS-TIFzzUIO_jax	ERBB2	XL147	"In a preclinical study, breast cancer cell lines expressing ERBB2 (HER2) T798M demonstrated sensitivity to XL147 (SAR245408) in cell culture (PMID: 23948973)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23948973	AVv-KW5ySS-TIFzzUIRQjax	ERBB2	Withacnistin	"In a preclinical study, withacnistin induced tumor regression in transgenic mouse models of Erbb2 (Her2)-driven breast cancer (PMID: 24983364)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24983364	AVv-KWZfSS-TIFzzUIQZjax	ERBB2	WZ4002	"In a preclinical study, WZ4002 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T798M in culture (PMID: 22046346)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KW6XSS-TIFzzUIRRjax	ERBB2	WZ4002	"In a preclinical study, WZ4002 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755S in culture (PMID: 22046346)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KUydSS-TIFzzUINgjax	ERBB2	WZ4002	"In a preclinical study, WZ4002 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755P in culture (PMID: 22046346)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KXEmSS-TIFzzUIRjjax	ERBB2	VS-5584	"In a preclinical study, breast cancer cells with mutations in both ERBB2 (HER2) and PIK3CA were more sensitive to VS-5584 (PMID: 23270925)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23270925	AVv-KWkySS-TIFzzUIQrjax	ERBB2	VS-5584	"In a preclinical study, VS-5584 inhibited tumor growth in human gastric cancer cell line xenograft models overexpressing ERBB2 (HER2) (PMID: 23270925)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23270925	AVv-KXQnSS-TIFzzUIR3jax	ERBB2	Trodusquemine	"In a preclinical study, Trodusquemine (MSI-1436) inhibited tumor growth and metastasis in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model (PMID: 24845231)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24845231	AVv-KWMvSS-TIFzzUIQFjax	ERBB2	Trastuzumab + XL147	"In a preclinical study, breast cancer cells expressing ERBB2 T798M were sensitive to the combination of Herceptin (trastuzumab) and XL147 (PMID: 23948973)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23948973	AVv-KW8ISS-TIFzzUIRUjax	ERBB2	Trastuzumab + Pertuzumab	"In a preclinical study, a mouse breast cancer model with ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Heceptin (trastuzumab) and Perjeta (pertuzumab) (PMID: 23940356)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23940356	AVv-KXXjSS-TIFzzUISDjax	ERBB2	Trastuzumab + Oxaliplatin	"In a preclinical study, the combination of Herceptin (trastuzumab) and Eloxatin (oxaliplatin) resulted in growth inhibition of ERBB2 (HER2)-positive gastric cancer cells in culture (PMID: 24300914)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24300914	AVv-KWQaSS-TIFzzUIQLjax	ERBB2	Trastuzumab + Oxaliplatin	"In a preclinical study, the combination of Herceptin (trastuzumab) and Eloxatin (oxaliplatin) resulted in growth inhibition of ERBB2 (HER2)-positive breast cancer cells in culture (PMID: 24300914)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24300914	AVv-KV7eSS-TIFzzUIPpjax	ERBB2	Trastuzumab + Lapatinib	"In a preclinical study, the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) treatment induced tumor regression in patient-derived colorectal cancer tumorgraft models harboring ERBB2 (HER2) amplification (PMID: 26296355)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26296355	AVv-KUNOSS-TIFzzUIMgjax	ERBB2	Trastuzumab + Lapatinib	"In a preclinical study, the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) treatment induced tumor regression in ERBB2 (HER2)-amplified cell line xenograft models of gastric cancer (PMID: 26296355)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26296355	AVv-KUCBSS-TIFzzUIMOjax	ERBB2	Trastuzumab + Lapatinib	"In a preclinical study, human breast cancer cell lines and cell line xenografts expressing ERBB2 T798M demonstrated sensitivity to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23948973)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23948973	AVv-KW_eSS-TIFzzUIRajax	ERBB2	Trastuzumab + Lapatinib	"In a preclinical study, a mouse breast cancer model with mammary ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23940356)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23940356	AVv-KXYKSS-TIFzzUISEjax	ERBB2	Trastuzumab + Lapatinib	"In a preclinical study, Herceptin (trastuzumab) and Tykerb (lapatinib) combination treatment resulted in tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KT6DSS-TIFzzUIMBjax	ERBB2	Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin	"In a clinical case study, a patient with ERBB2 (HER2) and MET amplified gastric adenocarcinoma was insensitive to treatment with Herceptin (trastuzumab) and FOLFOX (PMID: 26432108)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26432108	AVv-KUl1SS-TIFzzUINLjax	ERBB2	Trastuzumab	"In a preclinical study, transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V842I were resistant to Herceptin (trastuzumab) in culture (PMID: 26243863)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KVX8SS-TIFzzUIOsjax	ERBB2	Trastuzumab	"In a preclinical study, transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V777L were resistant to Herceptin (trastuzumab) in culture (PMID: 26243863)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KW3DSS-TIFzzUIRLjax	ERBB2	Trastuzumab	"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Herceptin (trastuzumab) in culture, resulting in decreased colony formation (PMID: 27697991)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27697991	AVv-KWufSS-TIFzzUIQ8jax	ERBB2	Trastuzumab	"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) L768S were sensitive to Herceptin (trastuzumab) in culture, resulting in decreased colony formation (PMID: 27697991)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27697991	AVv-KVepSS-TIFzzUIO3jax	ERBB2	Trastuzumab	"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) K753E were resistant to Herceptin (trastuzumab) in culture (PMID: 27697991)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27697991	AVv-KVVOSS-TIFzzUIOnjax	ERBB2	Trastuzumab	"In a preclinical study, transformed human breast cell lines expressing ERBB2 V842I reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KVYlSS-TIFzzUIOtjax	ERBB2	Trastuzumab	"In a preclinical study, transformed human breast cell lines expressing ERBB2 V777L reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KW1YSS-TIFzzUIRIjax	ERBB2	Trastuzumab	"In a preclinical study, transformed human breast cell lines expressing ERBB2 R896C reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KVjrSS-TIFzzUIPAjax	ERBB2	Trastuzumab	"In a preclinical study, transformed human breast cell lines expressing ERBB2 P780_Y781insGSP demonstrated resistance when treated with Herceptin (trastuzumab) (PMID: 23220880)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KTvuSS-TIFzzUILvjax	ERBB2	Trastuzumab	"In a preclinical study, transformed human breast cell lines expressing ERBB2 G309A reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KWjKSS-TIFzzUIQojax	ERBB2	Trastuzumab	"In a preclinical study, transformed human breast cell lines expressing ERBB2 D769Y reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KVmDSS-TIFzzUIPEjax	ERBB2	Trastuzumab	"In a preclinical study, transformed human breast cell lines expressing ERBB2 D769H reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KT_BSS-TIFzzUIMJjax	ERBB2	Trastuzumab	"In a preclinical study, mouse breast cancer models over expressing ERBB2 (HER2) and expressing PIK3CA H1047R were resistant to Herceptin (trastuzumab) (PMID: 23940356)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23940356	AVv-KXauSS-TIFzzUISIjax	ERBB2	Trastuzumab	"In a preclinical study, colorectal cancer tumorgrafts with ERBB2 (HER2) amplification demonstrated resistance to Herceptin (trastuzumab) treatment in animal models (PMID: 26296355)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26296355	AVv-KUSLSS-TIFzzUIMojax	ERBB2	Trastuzumab	"In a preclinical study, a human ERBB2-amplified breast cancer cell line expressing ERBB2 (HER2) T798M was resistant to Herceptin (trastuzumab) in culture and in xenograft models (PMID: 23948973)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23948973	AVv-KUrpSS-TIFzzUINVjax	ERBB2	Trastuzumab	"In a preclinical study, Herceptin (trastuzumab) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification (PMID: 26296355)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26296355	AVv-KUS0SS-TIFzzUIMpjax	ERBB2	Trastuzumab	"In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KVOrSS-TIFzzUIObjax	ERBB2	Trastuzumab	"In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KVsBSS-TIFzzUIPPjax	ERBB2	Trastuzumab	"In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KUwsSS-TIFzzUINdjax	ERBB2	Trastuzumab	"In a preclinical study, Herceptin (trastuzumab) had no effect on tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KUjLSS-TIFzzUINGjax	ERBB2	Trastuzumab	"In a preclinical study, Herceptin (trastuzumab) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KT4-SS-TIFzzUIL_jax	ERBB2	Trastuzumab	"In a meta-analysis, breast cancer patients with >12 copies of ERBB2 (HER2) had a better response to Herceptin (trastuzumab) than patients with 6-12 copies of ERBB2 (HER2) (PMID: 24691421)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24691421	AVv-KUPuSS-TIFzzUIMkjax	ERBB2	Trastuzumab	"In a clinical study, the PIK3CA R425L mutation was identified as a potential resistance mechanism in a non-small cell lung carcinoma patient harboring ERBB2 (HER2) A775_G776insYVMA, that progressed during Herceptin (trastuzumab) treatment (PMID: 28167203)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/28167203	AVv-KVdeSS-TIFzzUIO1jax	ERBB2	Trastuzumab	"In a Phase III trial that supported FDA approval, gastric cancer patients with ERBB2 (HER2) amplification had increased overall survival when treated with Herceptin (trastuzumab), in combination with chemotherapy (PMID: 20728210)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20728210	AVv-KUIySS-TIFzzUIMZjax	ERBB2	Temsirolimus + Neratinib	"In a Phase I clinical trial, Neratinib (HKI-272) administered with Torisel (temsirolimus) was tolerable and demonstrated antitumor activity in ERBB2 (HER2)-amplified breast cancer resistant to (Herceptin) trastuzumab (PMID: 24323026)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24323026	AVv-KUVISS-TIFzzUIMtjax	ERBB2	TAK-285	"In a preclinical study, TAK-285 inhibited tumor growth in gastric cancer cell line xenograft models over expressing ERBB2 (HER2)  (PMID: 23983820)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23983820	AVv-KXKSSS-TIFzzUIRtjax	ERBB2	TAK-285	"In a preclinical study, TAK-285 inhibited growth of breast cancer cell line harboring ERBB2 (HER2) over expression in culture and in cell line xenograft models (PMID: 23983820)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23983820	AVv-KXUISS-TIFzzUIR9jax	ERBB2	Sunitinib + Trastuzumab	"In a Phase II trial, Sutent (sunitinib), in combination with Herceptin (trastuzumab), demonstrated safety and efficacy in ERBB2 (HER2) positive advanced breast cancer patients (PMID: 24606768)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24606768	AVv-KWFVSS-TIFzzUIP5jax	ERBB2	Selumetinib	"In a preclinical study, bladder cancer cells over expressing both ERBB2 (HER2) D277H and S310F demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture (PMID: 24971884)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24971884	AVv-KVSbSS-TIFzzUIOijax	ERBB2	Selumetinib	"In a preclinical study, bladder cancer cells over expressing ERBB2 (HER2) S653C demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture (PMID: 24971884)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24971884	AVv-KU9mSS-TIFzzUINzjax	ERBB2	Selumetinib	"In a preclinical study, bladder cancer cells over expressing ERBB2 (HER2) S310F demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture (PMID: 24971884)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24971884	AVv-KVM_SS-TIFzzUIOYjax	ERBB2	Sapitinib	"In a preclinical study, Sapitinib (AZD8931) demonstrated antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erb2 (Her2) protein in culture and in xenograft models (PMID: 24886365)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24886365	AVv-KVigSS-TIFzzUIO-jax	ERBB2	SYD985	"In a preclinical study, SYD985 decreased survival of a ERBB2 (HER2)-positive ovarian carcinoma cell line in culture (PMID: 25589493)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25589493	AVv-KWS8SS-TIFzzUIQPjax	ERBB2	SYD985	"In a preclinical study, SYD985 decreased survival of a ERBB2 (HER2)-positive gastric carcinoma cell line in culture (PMID: 25589493)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25589493	AVv-KWUUSS-TIFzzUIQRjax	ERBB2	S-222611	"In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human lung cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24837299	AVv-KVyCSS-TIFzzUIPZjax	ERBB2	S-222611	"In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human colon cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24837299	AVv-KVxgSS-TIFzzUIPYjax	ERBB2	S-222611	"In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human breast cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24837299	AVv-KVylSS-TIFzzUIPajax	ERBB2	S-222611	"In a Phase I clinical trial, S-222611 demonstrated safety and some efficacy in patients with advanced solid tumors expressing EGFR or ERBB2 (HER2), with an overall clinical benefit rate of 27% (7/33) (PMID: 25434923)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25434923	AVv-KWGhSS-TIFzzUIP7jax	ERBB2	Ramucirumab + Docetaxel	"In a Phase III trial, Cyramze (ramucirumab) in combination with Taxotere (docetaxel) did not improve clinical outcomes in ERBB2 (HER2)-negative breast cancer patients (PMID: 25185099)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/25185099	AVv-KTo2SS-TIFzzUILjjax	ERBB2	Panitumumab	"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) V777L were resistant to Vectibix (panitumumab) in culture (PMID: 26243863)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KWxVSS-TIFzzUIRBjax	ERBB2	Panitumumab	"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) S310F were resistant to Vectibix (panitumumab) in culture (PMID: 26243863)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KVPUSS-TIFzzUIOcjax	ERBB2	Panitumumab	"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L866M were resistant to Vectibix (panitumumab) in culture (PMID: 26243863)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KVsmSS-TIFzzUIPQjax	ERBB2	Panitumumab	"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L755S were resistant to Vectibix (panitumumab) in culture (PMID: 26243863)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KU2iSS-TIFzzUINnjax	ERBB2	Panitumumab	"In a preclinical study, colorectal cancer cell lines over expressing ERBB2 (HER2) V842I were resistant to Vectibix (panitumumab) in culture (PMID: 26243863)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KVc1SS-TIFzzUIO0jax	ERBB2	Palbociclib + Trastuzumab	"In a preclinical study, the combination of Ibrance (palbociclib) and Herceptin (trastuzumab) worked synergistically to inhibit growth of ERBB2 (HER2)-amplified breast cancer cells in culture (PMID: 19874578)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19874578	AVv-KUYZSS-TIFzzUIMzjax	ERBB2	Palbociclib + GDC-0941	"In a preclinical study, Ibrance (palbociclib) and Pictilisib (GDC-0941) worked synergistically to inhibit survival of ERBB2 (HER2)-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27020857	AVv-KVvMSS-TIFzzUIPUjax	ERBB2	PP242	"In a preclinical study, ERBB2 (HER2) amplified breast cancer cells treated with PP242 demonstrated some efficacy in culture including reduced phosphorylation of S6 and Akt, apoptosis, and decreased cell growth (PMID: 27197158)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27197158	AVv-KUWMSS-TIFzzUIMvjax	ERBB2	PKI-179	"In a preclinical study, PKI-179 inhibited growth of breast cancer cells harboring PIK3CA mutations and ERBB2 (HER2) over expression in culture and cell line xenograft models (PMID: 20797855)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20797855	AVv-KXFKSS-TIFzzUIRkjax	ERBB2	PF-05280014	"In a preclinical study, PF-05280014 inhibited growth of ERBB2 (HER2)-over expressing breast cancer cells with activity comparable to Herceptin (trastuzumab) in culture (PMID: 25001079)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25001079	AVv-KXQDSS-TIFzzUIR2jax	ERBB2	PF-05212384	"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring ERBB2 (HER2) amplification and PIK3CA H1047R in culture (PMID: 21325073, PMID: 17314276)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17314276	AVv-KUsQSS-TIFzzUINWjax	ERBB2	Neratinib + Trastuzumab	"In a preclinical study, Herceptin (trastuzumab) and Neratinib (HKI-272) combination treatment resulted in tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KT3aSS-TIFzzUIL8jax	ERBB2	Neratinib	"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Neratinib (HKI-272) in culture, resulting in decreased colony formation (PMID: 27697991)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27697991	AVv-KWt5SS-TIFzzUIQ7jax	ERBB2	Neratinib	"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) L768S were sensitive to Neratinib (HKI-272) in culture, resulting in decreased colony formation (PMID: 27697991)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27697991	AVv-KVeFSS-TIFzzUIO2jax	ERBB2	Neratinib	"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) K753 were sensitive to Neratinib (HKI-272) in culture, resulting in decreased colony formation (PMID: 27697991)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27697991	AVv-KVUFSS-TIFzzUIOljax	ERBB2	Neratinib	"In a preclinical study, transformed human breast cell lines expressing ERBB2 V842I demonstrated growth inhibition when treated with Neratinib (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KVcOSS-TIFzzUIOzjax	ERBB2	Neratinib	"In a preclinical study, transformed human breast cell lines expressing ERBB2 V777L demonstrated growth inhibition when treated with Neratinib (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KWzGSS-TIFzzUIREjax	ERBB2	Neratinib	"In a preclinical study, transformed human breast cell lines expressing ERBB2 R896C reverted to normal morphology in culture upon Neratinib treatment (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KVkRSS-TIFzzUIPBjax	ERBB2	Neratinib	"In a preclinical study, transformed human breast cell lines expressing ERBB2 R678Q demonstrated growth inhibition when treated with Neratinib (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KU6sSS-TIFzzUINujax	ERBB2	Neratinib	"In a preclinical study, transformed human breast cell lines expressing ERBB2 P780_Y781insGSP reverted to normal morphology in culture upon Neratinib treatment (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KTwwSS-TIFzzUILxjax	ERBB2	Neratinib	"In a preclinical study, transformed human breast cell lines expressing ERBB2 L755S demonstrated growth inhibition when treated with Neratinib (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KUxTSS-TIFzzUINejax	ERBB2	Neratinib	"In a preclinical study, transformed human breast cell lines expressing ERBB2 G309A demonstrated growth inhibition when treated with Neratinib (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KWjtSS-TIFzzUIQpjax	ERBB2	Neratinib	"In a preclinical study, transformed human breast cell lines expressing ERBB2 D769Y reverted to normal morphology in culture upon Neratinib treatment (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KVlgSS-TIFzzUIPDjax	ERBB2	Neratinib	"In a preclinical study, transformed human breast cell lines expressing ERBB2 D769H demonstrated growth inhibition when treated with Neratinib (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KT-VSS-TIFzzUIMIjax	ERBB2	Neratinib	"In a preclinical study, transformed cells co-expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) and ERBB2 (HER2) C805S demonstrated resistance to Neratinib (HKI-272) in culture (PMID: 28363995)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KVClSS-TIFzzUIOGjax	ERBB2	Neratinib	"In a preclinical study, transformed cells co-expressing ERBB2 (HER2) M774delinsWLV and ERBB2 (HER2) C805S demonstrated resistance to Neratinib (HKI-272) in culture (PMID: 28363995)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KWoOSS-TIFzzUIQxjax	ERBB2	Neratinib	"In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L755_T759del were sensitive to treatment with Neratinib (HKI-272)(PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KVpRSS-TIFzzUIPKjax	ERBB2	Neratinib	"In a preclinical study, a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification demonstrated sensitivity to treatment with Neratinib (HKI-272) in culture, resulting in inhibition of cell growth (PMID: 26333383)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26333383	AVv-KUcUSS-TIFzzUIM6jax	ERBB2	Neratinib	"In a preclinical study, Neratinib (HKI-272) treatment resulted in stable tumor size in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KUiISS-TIFzzUINEjax	ERBB2	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as ERBB2 A775_G776insYVMA) in culture (PMID: 28363995)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KVAPSS-TIFzzUIOCjax	ERBB2	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited growth of transformed cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) in culture (PMID: 28363995)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KTyBSS-TIFzzUILzjax	ERBB2	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture and suppressed tumor growth in cell line xenograft models (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KWzpSS-TIFzzUIRFjax	ERBB2	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KVLuSS-TIFzzUIOWjax	ERBB2	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KVt3SS-TIFzzUIPSjax	ERBB2	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KUx4SS-TIFzzUINfjax	ERBB2	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited growth of colorectal cancer cell lines over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KVaSSS-TIFzzUIOwjax	ERBB2	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KVbgSS-TIFzzUIOyjax	ERBB2	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V777L in culture (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KW2iSS-TIFzzUIRKjax	ERBB2	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KVQ5SS-TIFzzUIOfjax	ERBB2	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KVtRSS-TIFzzUIPRjax	ERBB2	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KU1-SS-TIFzzUINmjax	ERBB2	Neratinib	"In a preclinical study, Neratinib (HKI-272) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KT4dSS-TIFzzUIL-jax	ERBB2	Neratinib	"In a preclinical study, Neratinib (HKI-272) decreased cell survival of transformed human cells expressing ERBB2 S310F (PMID: 22908275)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22908275	AVv-KVKeSS-TIFzzUIOUjax	ERBB2	Neratinib	"In a Phase II clinical trial, Neratinib (HKI-272) demonstrated safety and efficacy as a monotherapy in patients with ERBB2 (HER2)-positive breast cancer (PMID: 23953056)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23953056	AVv-KV9aSS-TIFzzUIPsjax	ERBB2	Neratinib	"In a Phase I study, Neratinib administered with temsirolimus was tolerable and demonstrated antitumor activity in ERBB2-mutant non-small-cell lung cancer (PMID: 24323026)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24323026	AVv-KVF5SS-TIFzzUIOMjax	ERBB2	Neratinib	"In a Phase I clinical trial, Neratinib (HKI-272) administered with Torisel (temsirolimus) was tolerable and demonstrated antitumor activity in ERBB2 (HER2)-mutant non-small-cell lung cancer (PMID: 24323026)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24323026	AVv-KVFXSS-TIFzzUIOLjax	ERBB2	NAX014	"In a preclinical study, NAX014 induced cellular senescence, prevented tumor growth, and decreased tumor volume in a Her2 positive breast cancer mouse model (PMID: 26168818)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26168818	AVv-KXUsSS-TIFzzUIR-jax	ERBB2	MGAH22	"In a Phase I trial, Margetuximab (MGAH22) treatment resulted in tumor reduction in 78% (18/23) of patients with ERBB2 (HER2)-positive breast cancer (PMID: 28119295)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28119295	AVv-KWKWSS-TIFzzUIQBjax	ERBB2	Lapatinib + S63845	"In a preclinical study, combination of S63845 and Tykerb (lapatinib) resulted in potent cytotoxic effects in ERBB2 (HER2)-amplified breast cancer cells in culture compared to the cytostatic effect of Tykerb (lapatinib) alone (PMID: 27760111)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27760111	AVv-KUOdSS-TIFzzUIMijax	ERBB2	Lapatinib + Palbociclib	"In a preclinical study, the combination of Tykerb (lapatinib) and Ibrance (palbociclib) worked additively to suppress growth of ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 25221644)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25221644	AVv-KWVmSS-TIFzzUIQTjax	ERBB2	Lapatinib + Paclitaxel	"In a Phase III trial, second-line treatment using Tykerb (lapatinib) with paclitaxel demonstrated some efficacy in patients with HER2-positive advanced gastric cancer (PMID: 24868024)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24868024	AVv-KWHISS-TIFzzUIP8jax	ERBB2	Lapatinib + MK2206	"In a Phase I trial, Tykerb (lapatinib) and MK2206 combination treatment resulted in stable disease for more than 6 months in 40% (2/5) of patients with ERBB2 (HER2)-positive breast cancer (PMID: 27026198)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27026198	AVv-KWNTSS-TIFzzUIQGjax	ERBB2	Lapatinib	"In preclinical studies, Tykerb (lapatinib) demonstrated antiproliferative activity in HER2-amplified gastric cancer in cell assays and in xenograft models (PMID: 20179222)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20179222	AVv-KUFpSS-TIFzzUIMUjax	ERBB2	Lapatinib	"In a preclinical study, treatment with Tykerb (lapatinib) resulted in initial disease stabilization with subsequent progression, in patient-derived colorectal cancer tumorgraft models with ERBB2 (HER2) amplification (PMID: 26296355)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26296355	AVv-KUTWSS-TIFzzUIMqjax	ERBB2	Lapatinib	"In a preclinical study, transformed lung cancer cells over expressing ERBB2 (HER2) T798I were resistant to Tykerb (lapatinib) in culture (PMID: 25238247)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25238247	AVv-KT2RSS-TIFzzUIL6jax	ERBB2	Lapatinib	"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Tykerb (lapatinib) in culture, resulting in decreased colony formation (PMID: 27697991)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27697991	AVv-KWtWSS-TIFzzUIQ6jax	ERBB2	Lapatinib	"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) L768S were sensitive to Tykerb (lapatinib) in culture, resulting in decreased colony formation (PMID: 27697991)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27697991	AVv-KVfMSS-TIFzzUIO4jax	ERBB2	Lapatinib	"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) K753E were resistant to Tykerb (lapatinib) in culture (PMID: 27697991)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27697991	AVv-KVUpSS-TIFzzUIOmjax	ERBB2	Lapatinib	"In a preclinical study, transformed human breast cell lines expressing ERBB2 V842I demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KVa6SS-TIFzzUIOxjax	ERBB2	Lapatinib	"In a preclinical study, transformed human breast cell lines expressing ERBB2 V777L demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KWwwSS-TIFzzUIRAjax	ERBB2	Lapatinib	"In a preclinical study, transformed human breast cell lines expressing ERBB2 R896C reverted to normal morphology in culture upon Tykerb (lapatinib) treatment (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KVk2SS-TIFzzUIPCjax	ERBB2	Lapatinib	"In a preclinical study, transformed human breast cell lines expressing ERBB2 R678Q demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KU6FSS-TIFzzUINtjax	ERBB2	Lapatinib	"In a preclinical study, transformed human breast cell lines expressing ERBB2 P780_Y781insGSP demonstrated resistance when treated with Tykerb (lapatinib) (PMID: 23220880)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KTuCSS-TIFzzUILsjax	ERBB2	Lapatinib	"In a preclinical study, transformed human breast cell lines expressing ERBB2 G309A demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KWigSS-TIFzzUIQnjax	ERBB2	Lapatinib	"In a preclinical study, transformed human breast cell lines expressing ERBB2 D769Y reverted to normal morphology in culture upon Tykerb (lapatinib) treatment (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KVmlSS-TIFzzUIPFjax	ERBB2	Lapatinib	"In a preclinical study, transformed human breast cell lines expressing ERBB2 D769H demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KT9pSS-TIFzzUIMHjax	ERBB2	Lapatinib	"In a preclinical study, transformed cells over expressing ERBB2 (HER2) Y803N demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KT6nSS-TIFzzUIMCjax	ERBB2	Lapatinib	"In a preclinical study, transformed cells over expressing ERBB2 (HER2) T798I were resistant to Tykerb (lapatinib) in culture (PMID: 25238247)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25238247	AVv-KT1ASS-TIFzzUIL4jax	ERBB2	Lapatinib	"In a preclinical study, transformed cells over expressing ERBB2 (HER2) S783P were resistant to Tykerb (lapatinib) in culture (PMID: 18413839)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KT7ySS-TIFzzUIMEjax	ERBB2	Lapatinib	"In a preclinical study, transformed cells over expressing ERBB2 (HER2) L785F demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KVW1SS-TIFzzUIOqjax	ERBB2	Lapatinib	"In a preclinical study, transformed cells over expressing ERBB2 (HER2) L726F demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KWsLSS-TIFzzUIQ4jax	ERBB2	Lapatinib	"In a preclinical study, transformed cells over expressing ERBB2 (HER2) E812K demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KWp5SS-TIFzzUIQ0jax	ERBB2	Lapatinib	"In a preclinical study, transformed cells over expressing ERBB2 (HER2) E719G demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KU5fSS-TIFzzUINsjax	ERBB2	Lapatinib	"In a preclinical study, transformed cells over expressing ERBB2 (HER2) E717K demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KVpzSS-TIFzzUIPLjax	ERBB2	Lapatinib	"In a preclinical study, transformed cells expressing ERBB2 L755S demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KUwFSS-TIFzzUINcjax	ERBB2	Lapatinib	"In a preclinical study, transformed cells expressing ERBB2 (HER2) T733I demonstrated resistance to treatment with Tykerb (lapatinib) (PMID: 18413839)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KTz1SS-TIFzzUIL2jax	ERBB2	Lapatinib	"In a preclinical study, transformed cells expressing ERBB2 (HER2) P780L demonstrated resistance to treatment with Tykerb (lapatinib) (PMID: 18413839)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18413839	AVv-KUvYSS-TIFzzUINbjax	ERBB2	Lapatinib	"In a preclinical study, transformed cell lines expressing ERBB2 (HER2) L755P demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KXEBSS-TIFzzUIRijax	ERBB2	Lapatinib	"In a preclinical study, transformed cell lines expressing ERBB2  (HER2) T798M demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KW9ySS-TIFzzUIRXjax	ERBB2	Lapatinib	"In a preclinical study, transformed breast cancer cells over expressing ERBB2 (HER2) L869R were resistant to Tykerb (lapatinib) in culture, formed tumors and metastasized readily in xenograft animal models (PMID: 27900369)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27900369	AVv-KVJ3SS-TIFzzUIOTjax	ERBB2	Lapatinib	"In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V773A in culture (PMID: 22046346)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KVWRSS-TIFzzUIOpjax	ERBB2	Lapatinib	"In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) N862A in culture (PMID: 22046346)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KVnFSS-TIFzzUIPGjax	ERBB2	Lapatinib	"In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) N857S in culture (PMID: 22046346)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KW3mSS-TIFzzUIRMjax	ERBB2	Lapatinib	"In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L755_T759del were resistant to treatment with Tykerb (lapatinib), resulting in decreased growth inhibition (PMID: 23220880)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KVovSS-TIFzzUIPJjax	ERBB2	Lapatinib	"In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L726F demonstrated resistance to Tykerb (lapatinib) in both culture and xenograft models (PMID: 25435280)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25435280	AVv-KWrpSS-TIFzzUIQ3jax	ERBB2	Lapatinib	"In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 and MET was resistant to Tykerb (lapatinib) in culture (PMID: 26432108)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26432108	AVv-KUlUSS-TIFzzUINKjax	ERBB2	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cells expressing ERBB2 S310F in culture (PMID: 22908275)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22908275	AVv-KVP_SS-TIFzzUIOejax	ERBB2	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing wild-type ERBB2 (HER2) in culture (PMID: 22046346)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KU3oSS-TIFzzUINpjax	ERBB2	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V777L in culture (PMID: 22046346)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KWynSS-TIFzzUIRDjax	ERBB2	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited proliferation of  transformed cell lines expressing ERBB2 (HER2) H878Y in culture (PMID: 22046346)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KTzPSS-TIFzzUIL1jax	ERBB2	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited growth of HER2-over expressing breast carcinoma cell lines in culture (PMID: 27450453)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27450453	AVv-KXSZSS-TIFzzUIR6jax	ERBB2	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited growth of HER2-amplified and HER2-over expressing gastric cancer cell lines in culture (PMID: 18774637)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18774637	AVv-KXTBSS-TIFzzUIR7jax	ERBB2	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing both ERBB2 (HER2) D277H and S310F in culture (PMID: 24971884)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24971884	AVv-KVRZSS-TIFzzUIOgjax	ERBB2	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S653C in culture (PMID: 24971884)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24971884	AVv-KU8WSS-TIFzzUINxjax	ERBB2	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 24971884)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24971884	AVv-KVLMSS-TIFzzUIOVjax	ERBB2	Lapatinib	"In a preclinical study, Tykerb (lapatinib) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KT39SS-TIFzzUIL9jax	ERBB2	Lapatinib	"In a preclinical study, ERBB2 (HER2)-receptor positive breast cancer cells expressing ERBB2 (HER2) T798M were resistant to Tykerb (lapatinib) in both culture and xenograft models (PMID: 23948973)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23948973	AVv-KW5OSS-TIFzzUIRPjax	ERBB2	Lapatinib	"In a clinical study, ERBB2 (HER2) L869R conferred resistant to ERBB2 (HER2)-directed therapy including Tarceva (erlotinib) and Tykerb (lapatinib) in a patient with lung adenocarcinoma (PMID: 27900369)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27900369	AVv-KVIDSS-TIFzzUIOQjax	ERBB2	KU004	"In a preclinical study, KU004 inhibited growth and induced apoptosis in gastric cancer cell lines over expressing ERBB2 in culture and suppressed growth in a dose dependent manner in xenograft models (PMID: 26437915)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26437915	AVv-KXH7SS-TIFzzUIRpjax	ERBB2	KU004	"In a preclinical study, KU004 inhibited growth and induced apoptosis in breast cancer cell lines over expressing ERBB2 in culture (PMID: 26437915)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26437915	AVv-KXGxSS-TIFzzUIRnjax	ERBB2	KTN3379 + Trastuzumab	"In a preclinical study, the combination of Herceptin (trastuzumab) and KTN3379 inhibited tumor growth in xenograft models of ERBB2 (HER2)-amplified breast cancer, with increased efficacy compared to KTN3379 alone (PMID: 26880266)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26880266	AVv-KUXUSS-TIFzzUIMxjax	ERBB2	KTN3379	"In a preclinical study, knockdown of PTEN expression resulted in a decreased response to treatment with KTN3379 in ERBB2 (HER2)-amplified breast cancer cells in culture (PMID: 26880266)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26880266	AVv-KUfwSS-TIFzzUINAjax	ERBB2	KTN3379	"In a preclinical study, KTN3379 inhibited tumor growth in xenograft models of ERBB2 (HER2)-positive breast cancer (PMID: 26880266)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26880266	AVv-KV64SS-TIFzzUIPojax	ERBB2	KTN3379	"In a preclinical study, KTN3379 inhibited tumor growth in xenograft models of ERBB2 (HER2)-amplified breast cancer (PMID: 26880266)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26880266	AVv-KUQYSS-TIFzzUIMljax	ERBB2	KTN3379	"In a preclinical study, KTN3379 inhibited tumor growth by 43% in N87 gastric cancer xenograft model, which has been demonstrated to have ERBB2 (HER2) amplification and overexpression (AACR; 2015. Abstract nr 1558, PMID: 18441328)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18441328	AVv-KXPaSS-TIFzzUIR1jax	ERBB2	Ibrutinib	"In a preclinical study, Imbruvica (ibrutinib) inhibited Her family receptor signaling, resulted in apoptosis and growth inhibition in ERBB2 (HER2)-positive breast cancer cell lines in culture and in cell line xenograft models (PMID: 27256378)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27256378	AVv-KWbTSS-TIFzzUIQcjax	ERBB2	Hertuzumab-vc-MMAE	"In a preclinical study, treatment with Hertuzumab-vc-MMAE decreased viability of ERBB2 (HER2)-positive ovarian cancer cell lines in culture and inhibited tumor growth in ERBB2 (HER2)-positive ovarian cancer cell line xenograft models (PMID: 27509865)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27509865	AVv-KWb5SS-TIFzzUIQdjax	ERBB2	Hertuzumab-vc-MMAE	"In a preclinical study, Hertuzumab-vc-MMAE decreased viability of ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 27509865)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27509865	AVv-KWEoSS-TIFzzUIP4jax	ERBB2	HER2 Vaccine	"In a preclinical study, ERBB2 (HER2)-specific cytotoxic T-cell lines generated from gastric cancer patients demonstrated activity against autologous ERBB2 (HER2)-expressing gastric cancer cells in culture (PMID: 9754653)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/9754653	AVv-KV6VSS-TIFzzUIPnjax	ERBB2	HER2 Vaccine	"In Phase II clinical trials, ERBB2 (HER2) vaccines demonstrated safety and some efficacy in the adjuvant setting in ERBB2 (HER2)-positive breast cancer patients (PMID: 23585514)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23585514	AVv-KWEFSS-TIFzzUIP3jax	ERBB2	Gefitinib	"In a preclinical study, non-small cell lung cancer cells harboring ERBB2 (HER2) G776delinsVC demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 26545934)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26545934	AVv-KVfwSS-TIFzzUIO5jax	ERBB2	Gefitinib	"In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26545934	AVv-KVBeSS-TIFzzUIOEjax	ERBB2	Gefitinib	"In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) V659E did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26545934	AVv-KWvHSS-TIFzzUIQ9jax	ERBB2	Gefitinib	"In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26545934	AVv-KTtgSS-TIFzzUILrjax	ERBB2	Gefitinib	"In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G776delinsVC did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26545934	AVv-KVhfSS-TIFzzUIO8jax	ERBB2	Gefitinib	"In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G776delinsLC did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26545934	AVv-KVS_SS-TIFzzUIOjjax	ERBB2	Gefitinib	"In a preclinical study, bronchial epithelial cells cells expressing ERBB2 (HER2) G660D did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26545934	AVv-KU-uSS-TIFzzUIN1jax	ERBB2	Gefitinib	"In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L755_T759del were sensitive to treatment with Iressa (gefitinib) (PMID: 23220880)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-KVoLSS-TIFzzUIPIjax	ERBB2	Gefitinib	"In a preclinical study, an ERBB2 (HER2) L726I mutation was detected in a murine breast cancer cell line that acquired resistance to Iressa (gefitinib) in culture (PMID: 17638894)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/17638894	AVv-KT8_SS-TIFzzUIMGjax	ERBB2	Gefitinib	"In a preclinical study, a lung squamous cell carcinoma cell line with ERBB2 (HER2) amplification demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 26545934)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26545934	AVv-KULTSS-TIFzzUIMdjax	ERBB2	GDC-0032 + Neratinib	"In a preclinical study, the combination of Taselisib (GDC-0032) and Neratinib (HKI-272) delayed cell cycle activity in a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture (PMID: 26333383)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26333383	AVv-KUA5SS-TIFzzUIMMjax	ERBB2	GDC-0032	"In a preclinical study, a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification demonstrated sensitivity to treatment with Taselisib (GDC-0032) in culture, resulting in inhibition of cell growth (PMID: 26333383)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26333383	AVv-KUapSS-TIFzzUIM3jax	ERBB2	GDC-0032	"In a preclinical study, Taselisib (GDC-0032) inhibited growth of HER2 positive uterine cancer cell lines with PIK3CA mutations (PMID: 25172762)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25172762	AVv-KVvxSS-TIFzzUIPVjax	ERBB2	Fluorouracil + Leucovorin + Trastuzumab	"In a clinical case study, a rectal adenocarcinoma patient harboring APC Q1429fs, BRAF N581S, and ERBB2 L755S did not respond to Herceptin (trastuzumab) treatment in combination with Fluorouracil and Wellcovorin (leucovorin) (PMID: 27626067)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27626067	AVv-KU3GSS-TIFzzUINojax	ERBB2	FF-284	"In a preclinical study, Debio 1347 did not inhibit tumor growth in cell line xenograft models of ERBB2 (HER2) amplified gastric carcinoma (PMID: 26438159)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-KUT8SS-TIFzzUIMrjax	ERBB2	Erlotinib	"In a preclinical study, transformed breast cancer cells over expressing ERBB2 (HER2) L869R were resistant to Tarceva (erlotinib) in culture (PMID: 27900369)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27900369	AVv-KVIrSS-TIFzzUIORjax	ERBB2	Erlotinib	"In a clinical study, ERBB2 (HER2) L869R conferred resistant to ERBB2 (HER2)-directed therapy including Tarceva (erlotinib) and Tykerb (lapatinib) in a patient with lung adenocarcinoma (PMID: 27900369)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27900369	AVv-KVJRSS-TIFzzUIOSjax	ERBB2	EKI-285	"In a preclinical study, EKI-285 (CL-387785) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T798M in culture (PMID: 22046346)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KW8sSS-TIFzzUIRVjax	ERBB2	EKI-285	"In a preclinical study, EKI-285 (CL-387785) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755S in culture (PMID: 22046346)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KUy9SS-TIFzzUINhjax	ERBB2	EKI-285	"In a preclinical study, EKI-285 (CL-387785) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755P in culture (PMID: 22046346)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KXDcSS-TIFzzUIRhjax	ERBB2	Dacomitinib	"In a preclinical study, transformed cells co-expressing ERBB2 (HER2) C805S and ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) demonstrated resistance to dacomitinib in culture (PMID: 28363995)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KVDKSS-TIFzzUIOHjax	ERBB2	Dacomitinib	"In a preclinical study, dacomitinib was more effective in preventing proliferation in ERBB2 (HER2) amplified breast cancer cells than in wild-type ERBB2 (HER2) breast cancer cells (PMID: 22761403)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22761403	AVv-KUJeSS-TIFzzUIMajax	ERBB2	Dacomitinib	"In a preclinical study, dacomitinib inhibited growth of transformed cells expressing ERBB2 (HER2) M774delinsWLV in culture (PMID: 28363995)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KWoxSS-TIFzzUIQyjax	ERBB2	Dacomitinib	"In a preclinical study, dacomitinib inhibited growth of transformed cells expressing ERBB2 (HER2) G778_S779insCPG in culture (PMID: 28363995)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KT23SS-TIFzzUIL7jax	ERBB2	Dacomitinib	"In a preclinical study, dacomitinib inhibited growth of transformed cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) in culture (PMID: 28363995)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KTtASS-TIFzzUILqjax	ERBB2	Dacomitinib	"In a preclinical study, dacomitinib demonstrated significant growth-inhibitory effects in HER2- amplified gastric cancer cells (PMID: 18606718)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18606718	AVv-KUWuSS-TIFzzUIMwjax	ERBB2	Dacomitinib	"In a preclinical study, acquisition of ERBB2 (HER2) C805S in transformed cells expressing ERBB2 (HER2) M774delinsWLV conferred resistance to dacomitinib in culture (PMID: 28363995)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KWnuSS-TIFzzUIQwjax	ERBB2	Dacomitinib	"In a preclinical study, ERBB2 (HER2) over expressing gastric cancer cells were sensitive to Dacomitinib, resulting in inhibition of ERBB2 (HER2)/ERBB3 (HER3) heterodimers (PMID: 22135232)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22135232	AVv-KXJKSS-TIFzzUIRrjax	ERBB2	Dacomitinib	"In a Phase II trial, two lung adenocarcinoma patients harboring ERBB2 (HER2) P780_Y781insGSP (also referred to as G778_780dup) demonstrated partial response to treatment with dacomitinib (PMID: 25899785)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25899785	AVv-KTxbSS-TIFzzUILyjax	ERBB2	Dacomitinib	"In a Phase II trial, a lung adenocarcinoma patient harboring ERBB2 (HER2) M774delinsWLV demonstrated a partial response to treatment with dacomitinib (PMID: 25899785)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25899785	AVv-KWpVSS-TIFzzUIQzjax	ERBB2	DS-8201a	"In a preclinical study, DS-8201a inhibited tumor growth in a pancreatic cancer cell line xenograft model with low ERBB2 (HER2) expression (PMID: 27026201)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27026201	AVv-KWRESS-TIFzzUIQMjax	ERBB2	DS-8201a	"In a preclinical study, DS-8201 inhibited growth of an ERBB2 (HER2)-positive breast adenocarcinoma cell line in culture (PMID: 27026201)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27026201	AVv-KV8rSS-TIFzzUIPrjax	ERBB2	Crizotinib + Lapatinib	"In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 (HER2) and MET was sensitive to inhibition by Tykerb (lapatinib) and Xalkori (crizotinib) in culture (PMID: 26432108)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26432108	AVv-KUm7SS-TIFzzUINNjax	ERBB2	Crizotinib	"In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 and MET was resistant to Xalkori (crizotinib) in culture (PMID: 26432108)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26432108	AVv-KUmXSS-TIFzzUINMjax	ERBB2	Copanlisib	"In a preclinical study, Copanlisib (BAY80-6946) promoted tumor regression in xenograft models of a human ERBB2 (HER2)-amplified breast cancer cell line harboring a PIK3CA activating mutation (PMID: 24170767)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24170767	AVv-KUeqSS-TIFzzUIM-jax	ERBB2	Cetuximab + Lapatinib	"In preclinical studies, the combination of Erbitux (cetuximab) and Tykerb (lapatinib) inhibited cell growth of a human breast cancer cell line harboring ERBB2 T798M and synergized to inhibit tumor growth in xenograft models (PMID: 23948973)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23948973	AVv-KW9PSS-TIFzzUIRWjax	ERBB2	Cetuximab	"In a preclinical study, xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y were resistant to Erbitux (cetuximab) (PMID: 26243863)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KT5jSS-TIFzzUIMAjax	ERBB2	Cetuximab	"In a preclinical study, xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification were resistant to Erbitux (cetuximab) (PMID: 26243863)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KUjtSS-TIFzzUINHjax	ERBB2	Cetuximab	"In a preclinical study, human colorectal cancer cells over expressing ERBB2 (HER2) V777L were resistant to Erbitux (cetuximab) in culture and in patient-derived xenograft models (PMID: 26243863)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KWx-SS-TIFzzUIRCjax	ERBB2	Cetuximab	"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) S310F were resistant to Erbitux (cetuximab) in culture (PMID: 26243863)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KVMYSS-TIFzzUIOXjax	ERBB2	Cetuximab	"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L866M were resistant to Erbitux (cetuximab) in culture (PMID: 26243863)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KVrfSS-TIFzzUIPOjax	ERBB2	Cetuximab	"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L755S were resistant to Erbitux (cetuximab) in culture (PMID: 26243863)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KU0OSS-TIFzzUINjjax	ERBB2	Cetuximab	"In a preclinical study, colorectal cancer cell lines over expressing ERBB2 (HER2) V842I were resistant to Erbitux (cetuximab) in culture (PMID: 26243863)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KVZISS-TIFzzUIOujax	ERBB2	Cetuximab	"In a preclinical study, breast cancer cells expressing the ERBB2 (HER2) T798M mutant were resistant to Erbitux (cetuximab)(PMID: 23948973)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23948973	AVv-KW-XSS-TIFzzUIRYjax	ERBB2	Cetuximab	"In a preclinical study, ERBB2 (HER2) over expression was associated with resistance to Erbitux (cetuximab) treatment in a human cell line xenograft models of colorectal cancer (PMID: 26296355)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26296355	AVv-KUIKSS-TIFzzUIMYjax	ERBB2	Canertinib	"In a preclinical study, Canertinib inhibited Erbb2 (Her2) phosphorylation and cell growth in transformed human cell lines expressing ERBB2 (HER2) G776_V777insYVMA (PMID: 16843263)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/16843263	AVv-KWsrSS-TIFzzUIQ5jax	ERBB2	CUDC-907	"In a preclinical study, CUDC-907 inhibited downstream signaling and growth of PIK3CA-mutant breast cancer cells with ERBB2 amplification in culture (PMID: 22693356)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22693356	AVv-KUc4SS-TIFzzUIM7jax	ERBB2	CUDC-101	"In a Phase I clinical trial, a breast cancer patient with ERBB2 (HER2) over expression that had progressed on Herceptin (trastuzumab) demonstrated stable disease for more than 12 weeks following treatment with CUDC-101 (PMID: 25107918)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25107918	AVv-KXROSS-TIFzzUIR4jax	ERBB2	CI-1040	"In a preclinical study, breast cancer cells expressing ERBB2 T798M demonstrated resistance to CI-1040 (PMID: 23948973)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/23948973	AVv-KW66SS-TIFzzUIRSjax	ERBB2	CH5132799	"In a preclinical study, CH5132799 inhibited proliferation of breast cancer cells with ERBB2 (HER2) amplification in culture (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-KUX3SS-TIFzzUIMyjax	ERBB2	CH5132799	"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA N345K and ERBB2 (HER2) amplification in culture (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-KUovSS-TIFzzUINQjax	ERBB2	CH5132799	"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K and ERBB2 (HER2) amplification in culture (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-KUqgSS-TIFzzUINTjax	ERBB2	CH5132799	"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA C420R and ERBB2 (HER2) amplification (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-KUrDSS-TIFzzUINUjax	ERBB2	CH5132799	"In a preclinical study, CH5132799 inhibited cell growth in a human ovarian cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-KUuKSS-TIFzzUINZjax	ERBB2	BMS-690514	"In a preclinical study, BMS-690514 inhibited tumor growth in a gastric cancer xenograft model with ERBB2 (HER2) amplification and overexpression (PMID: 21531814)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21531814	AVv-KURnSS-TIFzzUIMnjax	ERBB2	BKM120 + Trastuzumab	"In a Phase I clinical trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated in patients with ERBB2 (HER2)-positive advanced or metastatic breast cancer that had progressed on Herceptin (trastuzumab) (PMID: 24470511)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24470511	AVv-KWcgSS-TIFzzUIQejax	ERBB2	BKM120 + Bevacizumab	"In a preclinical study, treatment with Buparlisib (BKM120) resulted in decreased tumor growth, but not tumor regression, in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R (PMID: 23940356)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23940356	AVv-KXW_SS-TIFzzUISCjax	ERBB2	BKM120	"In a preclinical study, human breast cancer cells expressing the ERBB2 (HER2) T798M mutation demonstrated sensitivity to BKM120 (PMID: 23948973)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23948973	AVv-KW4tSS-TIFzzUIROjax	ERBB2	BGB-283	"In a preclinical study, BGB-283 inhibited proliferation of ERBB2 (HER2) amplified breast cancer cells in culture (PMID: 26208524)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26208524	AVv-KUVsSS-TIFzzUIMujax	ERBB2	Afatinib	"In a preclinical study, transformed cells co-expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) and ERBB2 (HER2) C805S demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KVB9SS-TIFzzUIOFjax	ERBB2	Afatinib	"In a preclinical study, transformed cells co-expressing ERBB2 (HER2) M774delinsWLV and ERBB2 (HER2) C805S demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KWnHSS-TIFzzUIQvjax	ERBB2	Afatinib	"In a preclinical study, colorectal cancer cells positive for EGFR and ERBB2 (HER2) had decreased growth upon Gilotrif (afatinib) treatment (PMID: 21617858)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21617858	AVv-KV0XSS-TIFzzUIPdjax	ERBB2	Afatinib	"In a preclinical study, breast cancer cells expressing ERBB2(HER2) T798M were sensitive to Gilotrif (afatinib) (PMID: 23948973)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23948973	AVv-KW-8SS-TIFzzUIRZjax	ERBB2	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited proliferation of breast cancer cell lines with ERBB2 (HER2) amplification in culture (PMID: 26545934)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26545934	AVv-KUDRSS-TIFzzUIMQjax	ERBB2	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KW0uSS-TIFzzUIRHjax	ERBB2	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KVOGSS-TIFzzUIOajax	ERBB2	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KVq9SS-TIFzzUIPNjax	ERBB2	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KU1VSS-TIFzzUINljax	ERBB2	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cell lines over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KVZpSS-TIFzzUIOvjax	ERBB2	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited foci formation of bladder cancer cells over expressing both ERBB2 (HER2) D277H and S310F in culture (PMID: 24971884)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24971884	AVv-KVR4SS-TIFzzUIOhjax	ERBB2	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S653C in culture (PMID: 24971884)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24971884	AVv-KU9DSS-TIFzzUINyjax	ERBB2	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 24971884)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24971884	AVv-KVNhSS-TIFzzUIOZjax	ERBB2	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) in culture (PMID: 26545934)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26545934	AVv-KVA5SS-TIFzzUIODjax	ERBB2	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) V659E in culture (PMID: 26545934)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26545934	AVv-KWwPSS-TIFzzUIQ_jax	ERBB2	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) in culture (PMID: 26545934)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26545934	AVv-KTwQSS-TIFzzUILwjax	ERBB2	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 26545934)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26545934	AVv-KVg4SS-TIFzzUIO7jax	ERBB2	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G776delinsLC in culture (PMID: 26545934)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26545934	AVv-KVTfSS-TIFzzUIOkjax	ERBB2	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G660D in culture (PMID: 26545934)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26545934	AVv-KU-KSS-TIFzzUIN0jax	ERBB2	Afatinib	"In a preclinical study, Gilotrif (afatinib) induced tumor regression in a gastric cancer cell line xenograft model with HER2 (ERBB2) amplification and over expression (PMID: 23578997)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23578997	AVv-KUhjSS-TIFzzUINDjax	ERBB2	Afatinib	"In a clinical study, treatment with pulse Gilotrif (afatinib) resulted in an objective response rate of 33.3% (1/3) in lung adenocarcinoma patients with ERBB2 (HER2) exon 20 insertion mutations (PMID: 26964772)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26964772	AVv-KXBsSS-TIFzzUIRejax	ERBB2	Afatinib	"In a clinical study, treatment with Gilotrif (afatinib) resulted in an objective response rate of 33% (2/6) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies (PMID: 28167203)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28167203	AVv-KVEySS-TIFzzUIOKjax	ERBB2	Afatinib	"In a Phase II trial, treatment with Gilotrif (afatinib) resulted in objective response in 3 lung adenocarcinoma patients harboring ERBB2 (HER2) mutations (PMID: 22325357)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22325357	AVv-KVHhSS-TIFzzUIOPjax	ERBB2	Afatinib	"In a Phase II trial, Gilotrif (afatinib), demonstrated safety and efficacy in various advanced solid tumor patients with ERBB2 (HER2) amplification (PMID: 23775486)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23775486	AVv-KUUiSS-TIFzzUIMsjax	ERBB2	AZD8055	"In a preclinical study, AZD8055 inhibited tumor growth in a mouse model of spontaneous breast cancer harboring an ERBB2 (HER2) activating mutation and loss of STK11 (LKB1), which was enhanced by the addition of 2-DG (2-deoxyglucose) (PMID: 25436981)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25436981	AVv-KWkOSS-TIFzzUIQqjax	ERBB2	AZD4547	"In a preclinical study, gastric cancer cells with wild-type FGFR2  and ERBB2 (HER2) amplification were resistant to treatment with AZD4547 in culture (PMID: 22869148)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22869148	AVv-KUqASS-TIFzzUINSjax	ERBB2	AZD2014	"In a Phase I trial, AZD2014 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a patient with ER-positive breast cancer harboring an ERBB2 activating mutation (PMID: 25805799)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25805799	AVv-KWmjSS-TIFzzUIQujax	ERBB2	AV-412	"In a preclinical study, non-small cell lung cancer cells harboring an ERBB2 (HER2) mutation demonstrated sensitivity to AV-412, resulting in decreased phosphorylation of Erbb2, Akt, and Erk (PMID: 19459856)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19459856	AVv-KVG9SS-TIFzzUIOOjax	ERBB2	AV-412	"In a preclinical study, AV-412 inhibited growth of ERBB2 (HER2)-over expressing breast cancer cell lines in culture, and inhibited tumor growth in a ERBB2 (HER2)-over expressing breast cancer cell line xenograft model (PMID: 17888033)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17888033	AVv-KXLqSS-TIFzzUIRvjax	ERBB2	AT13148	"In a preclinical study, AT13148 inhibited tumor growth in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model harboring mutant PIK3CA (PMID: 22781553)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22781553	AVv-KV2ISS-TIFzzUIPgjax	ERBB2	ARRY-380	"In a Phase I trial, ARRY-380 treatment resulted in partial response (PR) in 14% (3/22) and a clinical benefit rate (PR and stable disease ? 24 weeks) of 27% (6/22) in Erbb2 (Her2)-positive breast cancer patients (PMID: 28053022)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28053022	AVv-KV8DSS-TIFzzUIPqjax	ERBB2	AMG 337	"In a clinical case study, a patient with gastric adenocarcinoma containing amplification of ERBB2 (HER2) and a TP53 R158H mutation progressed and developed metastases while being treated with AMG 337 (PMID: 26432108)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/26432108	AVv-KUkOSS-TIFzzUINIjax	ERBB2	AMG 337	"In a clinical case study, a patient with ERBB2 (HER2) and MET amplified gastric adenocarcinoma was insensitive to AMG 337 therapy (PMID: 26432108)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26432108	AVv-KUkySS-TIFzzUINJjax	ERBB2	AEE788	"In a preclinical study, transformed cells expressing ERBB2 (HER2) activation loop mutations demonstrated sensitivity to AEE788 in culture (PMID: 22046346)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KWl9SS-TIFzzUIQtjax	ERBB2	AEE788	"In a preclinical study, transformed cell lines expressing ERBB2 (HER2) V777L demonstrated growth inhibition when treated with AEE788 in culture (PMID: 22046346)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KW18SS-TIFzzUIRJjax	ERBB2	AEE788	"In a preclinical study, transformed cell lines expressing ERBB2 (HER2) T798M demonstrated resistance when treated with AEE788 in culture (PMID: 22046346)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KW7hSS-TIFzzUIRTjax	ERBB2	AEE788	"In a preclinical study, transformed cell lines expressing ERBB2 (HER2) L755S demonstrated resistance to AEE788 in culture, except at very high doses (PMID: 22046346)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KU00SS-TIFzzUINkjax	ERBB2	AEE788	"In a preclinical study, transformed cell lines expressing ERBB2 (HER2) L755P demonstrated resistance when treated with AEE788 in culture (PMID: 22046346)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KXC1SS-TIFzzUIRgjax	ERBB2	AEE788	"In a preclinical study, transformed cell lines expressing ERBB2 (HER2) H878Y demonstrated growth inhibition when treated with AEE788 in culture (PMID: 22046346)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KTyiSS-TIFzzUIL0jax	ERBB2	AEE788	"In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing wild-type ERBB2 (HER2) in culture (PMID: 22046346)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KU4PSS-TIFzzUINqjax	ERBB2	AEE788	"In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing ERBB2(HER2) N857S in culture (PMID: 22046346)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KW4KSS-TIFzzUIRNjax	ERBB2	AEE788	"In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V773A in culture (PMID: 22046346)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KVVvSS-TIFzzUIOojax	ERBB2	AEE788	"In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T862A in culture (PMID: 22046346)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22046346	AVv-KVnrSS-TIFzzUIPHjax	ERBB2	ADXS31-164	"In a preclinical study, ADXS31-164 prevented development of spontaneous mammary tumors in Erbb2 (Her2)-over expressing transgenic animal models (PMID: 20725099)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20725099	AVv-KXNiSS-TIFzzUIRyjax	ERBB2	ABT-414	"In a preclinical study, ABT-414 demonstrated cytoxicity against a EGFR-amplified vulvar epidermoid carcinoma cell line in culture and induced tumor regression in EGFR-amplified vulvar epidermoid carcinoma cell line xenograft models (PMID: 26846818)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26846818	AVv-KUMkSS-TIFzzUIMfjax	ERBB2	23814 + Tivozanib	"In a preclinical study, the combination of 23814 and Tivozanib (AV-951) inhibited tumor growth in several transgenic mouse models of breast cancer expressing ERBB2 (HER2) V659E, including those with resistance to VEGFR inhibitors (PMID: 25995436)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25995436	AVv-KWvsSS-TIFzzUIQ-jax	EML4	X-396	"In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK C1156Y (PMID: 21613408)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-KSYxSS-TIFzzUIK2jax	EML4	X-396	"In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK ALK L1196M (PMID: 21613408)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-KRXFSS-TIFzzUIJEjax	EML4	X-376	"In a preclinical study, X-376 inhibited Alk signaling, resulted in growth inhibition in lung cancer cells harboring EML4-ALK fusion in culture and in cell line xenograft models (PMID: 21613408)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-KQ4ESS-TIFzzUIIQjax	EML4	TAE684	"In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing EML4-ALK ALK V1180L in culture (PMID: 25228534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-KSQKSS-TIFzzUIKnjax	EML4	TAE684	"In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing EML4-ALK ALK I1171T in culture (PMID: 25228534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-KRR4SS-TIFzzUII7jax	EML4	TAE226	"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring EML4-ALK fusion in culture (PMID: 26090892)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26090892	AVv-KQ-uSS-TIFzzUIIbjax	EML4	Sirolimus + X-396	"In a preclinical study, transformed non-small cell lung cancer cells harboring EML4-ALK demonstrated enhanced growth inhibition to a combination treatment with Afinitor (sirolimus) and Ensartinib (X-396) (PMID: 21613408)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-KQ_2SS-TIFzzUIIdjax	EML4	RXDX-101	"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were sensitive to Entrectinib (RXDX-101), resulting in anti-proliferative activity (PMID: 26939704)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26939704	AVv-KRbRSS-TIFzzUIJLjax	EML4	RXDX-101	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated a decreased response when treated with Entrectinib (RXDX-101) (PMID: 26939704)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26939704	AVv-KSHMSS-TIFzzUIKXjax	EML4	RXDX-101	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to RXDX-101 (PMID: 26939704)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26939704	AVv-KR9GSS-TIFzzUIKFjax	EML4	RXDX-101	"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were sensitive to Entrectinib (RXDX-101), resulting in anti-proliferative activity (PMID: 26939704)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26939704	AVv-KSXdSS-TIFzzUIK0jax	EML4	RXDX-101	"In a preclinical study, non-small cell lung carcinoma cells harboring EML4-ALK were sensitive to Entrectinib (RXDX-101), resulting in inhibition of cell proliferation and complete tumor regression (PMID: 26939704)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26939704	AVv-KQ25SS-TIFzzUIIOjax	EML4	PF-06463922	"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KRndSS-TIFzzUIJhjax	EML4	PF-06463922	"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KRORSS-TIFzzUII1jax	EML4	PF-06463922	"In a preclinical study, transformed cells expressing EML4-ALK with L1198F had reduced sensitivity to growth inhibition mediated by Lorlatinib (PF-06463922) in comparison to EML4-ALK wild type in culture (PMID: 26698910)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSAISS-TIFzzUIKKjax	EML4	PF-06463922	"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSm8SS-TIFzzUILYjax	EML4	PF-06463922	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KRKhSS-TIFzzUIIvjax	EML4	PF-06463922	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KR3DSS-TIFzzUIJ8jax	EML4	PF-06463922	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KRFpSS-TIFzzUIInjax	EML4	PF-06463922	"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSTGSS-TIFzzUIKsjax	EML4	PF-06463922	"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KRCESS-TIFzzUIIhjax	EML4	PF-06463922	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KRQuSS-TIFzzUII5jax	EML4	PF-06463922	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171S demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KRh4SS-TIFzzUIJXjax	EML4	PF-06463922	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KSiVSS-TIFzzUILGjax	EML4	PF-06463922	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KSgeSS-TIFzzUILDjax	EML4	PF-06463922	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202R demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KR6iSS-TIFzzUIKBjax	EML4	PF-06463922	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KSEhSS-TIFzzUIKSjax	EML4	PF-06463922	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KR12SS-TIFzzUIJ6jax	EML4	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSMrSS-TIFzzUIKhjax	EML4	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KRvXSS-TIFzzUIJvjax	EML4	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KQ-ISS-TIFzzUIIajax	EML4	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of neuroblastoma cells harboring EML4-ALK in culture (PMID: 26554404)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26554404	AVv-KQ8aSS-TIFzzUIIXjax	EML4	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth and ALK phosphorylation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSdgSS-TIFzzUIK-jax	EML4	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis of non-small cell lung carcinoma cells harboring ALK V1180L in the context of EML4-ALK in culture (PMID: 26144315)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-KSOdSS-TIFzzUIKkjax	EML4	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and proliferation of non-small cell lung carcinoma cells harboring EML4-ALK fusion, and reduced tumor size in intracranial cell line xenograft models (PMID: 26144315)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-KRA6SS-TIFzzUIIfjax	EML4	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK S1206Y in the context of EML4-ALK in culture  (PMID: 26144315)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-KSBvSS-TIFzzUIKNjax	EML4	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK L1152R in the context of EML4-ALK in culture  (PMID: 26144315)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-KRyTSS-TIFzzUIJ0jax	EML4	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK F1174L in the context of EML4-ALK in culture  (PMID: 26144315)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-KRrXSS-TIFzzUIJojax	EML4	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell growth in patient derived non-small cell lung cancer cells harboring ALK I1171T in the context of EML4-ALK in culture (PMID: 26144315)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-KRThSS-TIFzzUII-jax	EML4	Crizotinib	"In preclinical studies, transformed cells expressing EML4-ALK with ALK G1269A were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859, PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSJvSS-TIFzzUIKcjax	EML4	Crizotinib	"In preclinical studies, transformed cells expressing EML4-ALK ALK L1196M were insensitive to Xalkori (crizotinib) as demonstrated by lack of growth inhibition and Alk phosphorylation in culture (PMID: 21613408, PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-KRWZSS-TIFzzUIJDjax	EML4	Crizotinib	"In preclinical studies, transformed cell lines expressing EML4-ALK L1152R demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 21791641)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21791641	AVv-KRxxSS-TIFzzUIJzjax	EML4	Crizotinib	"In preclinical studies, human lung cancer cell lines expressing EML4-ALK G1269A demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 22235099, PMID: 23344087, PMID: 24675041)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-KSGESS-TIFzzUIKVjax	EML4	Crizotinib	"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated resistance to treatment with Xalkori (crizotinib) in culture (PMID: 27432227)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KRn_SS-TIFzzUIJijax	EML4	Crizotinib	"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KRL1SS-TIFzzUIIxjax	EML4	Crizotinib	"In a preclinical study, transformed cells expressing EML4-ALK with G1269A were re-sensitized and modestly sensitive to Xalkori (crizotinib) with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KRJPSS-TIFzzUIItjax	EML4	Crizotinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KRfMSS-TIFzzUIJSjax	EML4	Crizotinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KR3wSS-TIFzzUIJ9jax	EML4	Crizotinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KRH9SS-TIFzzUIIrjax	EML4	Crizotinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KRwkSS-TIFzzUIJxjax	EML4	Crizotinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSUySS-TIFzzUIKvjax	EML4	Crizotinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSZ5SS-TIFzzUIK4jax	EML4	Crizotinib	"In a preclinical study, transformed cells expressing EML4-ALK ALK C1156Y were insensitive to Xalkori (crizotinib) as demonstrated by lack of growth inhibition and lack of kinase inhibition in culture (PMID: 21613408)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-KSZWSS-TIFzzUIK3jax	EML4	Crizotinib	"In a preclinical study, transformed cells expressing ALK T1151dup in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KQ1nSS-TIFzzUIIMjax	EML4	Crizotinib	"In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KRcaSS-TIFzzUIJNjax	EML4	Crizotinib	"In a preclinical study, transformed cells expressing ALK F1174V in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KRpGSS-TIFzzUIJkjax	EML4	Crizotinib	"In a preclinical study, transformed cells expressing ALK F1174L in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KRtoSS-TIFzzUIJsjax	EML4	Crizotinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KRS9SS-TIFzzUII9jax	EML4	Crizotinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KSj5SS-TIFzzUILTjax	EML4	Crizotinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KSfRSS-TIFzzUILBjax	EML4	Crizotinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KRzZSS-TIFzzUIJ2jax	EML4	Crizotinib	"In a preclinical study, a human non-small cell lung cancer cell line harboring EML4-ALK ALK V1180L was resistant to Xalkori (crizotinib) treatment in culture (PMID: 25228534)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-KSRZSS-TIFzzUIKpjax	EML4	Crizotinib	"In a preclinical study, Xalkori (crizotinib) resistance was reduced in transformed cells expressing EML4-ALK with ALK L1196M with the addition of ALK L1198F in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSnlSS-TIFzzUILZjax	EML4	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KRjlSS-TIFzzUIJajax	EML4	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KSoJSS-TIFzzUILajax	EML4	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KRtCSS-TIFzzUIJrjax	EML4	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KRDySS-TIFzzUIIkjax	EML4	Crizotinib	"In a preclinical study, Xalkori (crizotinib) enhanced growth inhibition of transformed cells expressing EML4-ALK with L1198F in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KR-6SS-TIFzzUIKIjax	EML4	Crizotinib	"In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing EML4-ALK in culture (PMID: 26554404)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26554404	AVv-KRAYSS-TIFzzUIIejax	EML4	Crizotinib	"In a clinical study, an ALK S1206Y secondary mutation in the context of EML4-ALK was associated with resistance to Xalkori (crizotinib) in a patient with non-small cell lung cancer, and resistance was replicated in cell culture studies (PMID: 22277784)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22277784	AVv-KSBJSS-TIFzzUIKMjax	EML4	Crizotinib	"In a clinical study, an ALK G1202R secondary mutation in the context of EML4-ALK was associated with resistance to Xalkori (crizotinib) in a patient with non-small cell lung cancer, and resistance was replicated in cell culture studies (PMID: 22277784)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22277784	AVv-KR8jSS-TIFzzUIKEjax	EML4	Crizotinib	"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer developed resistance to Xalkori (crizotinib) with the emergence of ALK C1156Y, a secondary resistance mutation (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSWYSS-TIFzzUIKyjax	EML4	Crizotinib	"In a clinical case study, a non-small cell lung cancer patient harboring EML4-ALK variant 3 demonstrated an initial response to treatment with Xalkori (crizotinib), but progressed after 27 months and was found to have acquired ALK F1245C (PMID: 26775591)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26775591	AVv-KSNRSS-TIFzzUIKijax	EML4	Crizotinib	"In a Phase I clinical trial, Xalkori (crizotinib) inhibited tumor growth by at least 30% from baseline in 90% (18/20) of patients with EML4-ALK positive non-small cell lung carcinoma (PMID: 20979469)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20979469	AVv-KQ6kSS-TIFzzUIIUjax	EML4	Ceritinib	"In preclinical studies, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 26698910, PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSLkSS-TIFzzUIKfjax	EML4	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated resistance to treatment with Zykadia (ceritinib) in culture (PMID: 27432227)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KRmaSS-TIFzzUIJfjax	EML4	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Zykadia (ceritinib) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KRNLSS-TIFzzUIIzjax	EML4	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KR-VSS-TIFzzUIKHjax	EML4	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK S1206Y demonstrated growth inhibition with Zykadia (ceritinib) treatment in culture (PMID: 24675041)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-KSCVSS-TIFzzUIKOjax	EML4	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KSp3SS-TIFzzUILdjax	EML4	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSmVSS-TIFzzUILXjax	EML4	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KRIlSS-TIFzzUIIsjax	EML4	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KR4gSS-TIFzzUIJ-jax	EML4	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were insensitive to Zykadia (ceritinib) in culture (PMID: 24675041)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-KR7RSS-TIFzzUIKCjax	EML4	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KRGwSS-TIFzzUIIpjax	EML4	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KRscSS-TIFzzUIJqjax	EML4	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSToSS-TIFzzUIKtjax	EML4	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KRBdSS-TIFzzUIIgjax	EML4	Ceritinib	"In a preclinical study, transformed cells expressing ALK L1152R in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) in culture (PMID: 27780853)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KRy4SS-TIFzzUIJ1jax	EML4	Ceritinib	"In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) in culture (PMID: 27780853)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KRc9SS-TIFzzUIJOjax	EML4	Ceritinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK L1196M demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KRZiSS-TIFzzUIJIjax	EML4	Ceritinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KSkcSS-TIFzzUILUjax	EML4	Ceritinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Zykadia (ceritinib) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KSf5SS-TIFzzUILCjax	EML4	Ceritinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KSC4SS-TIFzzUIKPjax	EML4	Ceritinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KR1OSS-TIFzzUIJ5jax	EML4	Ceritinib	"In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KRjDSS-TIFzzUIJZjax	EML4	Ceritinib	"In a preclinical study, human lung cancer cell lines harboring EML4-ALK with ALK G1269A demonstrated sensitivity to Zykadia (ceritinib) in culture (PMID: 24675041)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-KSJOSS-TIFzzUIKbjax	EML4	Ceritinib	"In a preclinical study, Zykadia (ceritinib) inhibited phosphorylation of Alk and inhibited growth of human non-small cell lung cancer cell lines harboring EML4-ALK in culture (PMID: 25173427)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25173427	AVv-KQ89SS-TIFzzUIIYjax	EML4	Ceritinib	"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 26698910)"	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KRY6SS-TIFzzUIJHjax	EML4	Ceritinib	"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSV2SS-TIFzzUIKxjax	EML4	Ceritinib	"In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-KSPlSS-TIFzzUIKmjax	EML4	Ceritinib	"In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK I1171T in culture (PMID: 25228534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-KRUsSS-TIFzzUIJAjax	EML4	Ceritinib	"In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK in culture (PMID: 25228534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-KQ7MSS-TIFzzUIIVjax	EML4	Ceritinib	"In a preclinical study, Zykadia (ceritinib) demonstrated tumor growth inhibition in xenograft models of a human non-small cell lung cancer cell line harboring EML4-ALK with ALK C1156Y when compared to Xalkori (crizotinib) (PMID: 24675041)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-KSbGSS-TIFzzUIK6jax	EML4	Ceritinib	"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer with a secondary Xalkori (crizotinib) resistance mutation C1156Y, did not respond to Zykadia (ceritinib) therapy (PMID: 26698910)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSamSS-TIFzzUIK5jax	EML4	Alectinib	"In a preclinical study, transformed human cells expressing EML4-ALK with ALK C1156Y were sensitive to Alecensa (alectinib) in culture (PMID: 21575866)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21575866	AVv-KScXSS-TIFzzUIK8jax	EML4	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Alecensa (alectinib) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KRl1SS-TIFzzUIJejax	EML4	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Alecensa (alectinib) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KRNuSS-TIFzzUII0jax	EML4	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M demonstrated decreased sensitivity to Alecensa (alectinib) compared to cells expressing EML4-ALK with wild-type ALK, in culture (PMID: 26698910)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KRapSS-TIFzzUIJKjax	EML4	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSlnSS-TIFzzUILWjax	EML4	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KRhSSS-TIFzzUIJWjax	EML4	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KSIMSS-TIFzzUIKZjax	EML4	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KRLNSS-TIFzzUIIwjax	EML4	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KR7-SS-TIFzzUIKDjax	EML4	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KRGNSS-TIFzzUIIojax	EML4	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition by Alecensa (alectinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSVTSS-TIFzzUIKwjax	EML4	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KRDJSS-TIFzzUIIjjax	EML4	Alectinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated resistance to treatment with Alecensa (alectinib) in culture (PMID: 27432227)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KSi4SS-TIFzzUILSjax	EML4	Alectinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Alecensa (alectinib) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KShKSS-TIFzzUILEjax	EML4	Alectinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KSFESS-TIFzzUIKTjax	EML4	Alectinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KR0jSS-TIFzzUIJ4jax	EML4	Alectinib	"In a preclinical study, a transformed cell line expressing EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-KSShSS-TIFzzUIKrjax	EML4	Alectinib	"In a preclinical study, a human non-small cell lung cancer cell line harboring EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-KSPCSS-TIFzzUIKljax	EML4	Alectinib	"In a preclinical study, Alecensa (alectinib) modestly inhibited growth of transformed cells expression EML4-ALK with ALK G1269A in culture (PMID: 26698910)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSHsSS-TIFzzUIKYjax	EML4	Alectinib	"In a preclinical study, Alecensa (alectinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KRkESS-TIFzzUIJbjax	EML4	Alectinib	"In a preclinical study, Alecensa (alectinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KSrJSS-TIFzzUILfjax	EML4	Alectinib	"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing an EML4-ALK fusion and ALK L1196M in culture and in xenograft models (PMID: 21575866)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/21575866	AVv-KRaHSS-TIFzzUIJJjax	EML4	Alectinib	"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KRqySS-TIFzzUIJnjax	EML4	Alectinib	"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSc8SS-TIFzzUIK9jax	EML4	Alectinib	"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KQ9gSS-TIFzzUIIZjax	EML4	Alectinib	"In a preclinical study, Alecensa (alectinib) inhibited Alk phosphorylation and growth of a human non-small cell lung cancer cell line harboring EML4-ALK in culture and in cell line xenografts (PMID: 21575866)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21575866	AVv-KQ7zSS-TIFzzUIIWjax	EML4	Alectinib	"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer initially responded to Alecensa (alectinib) but progressed with the emergence of a secondary ALK I1171S mutation (PMID: 25393796)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25393796	AVv-KRgxSS-TIFzzUIJVjax	EML4	Alectinib	"In a clinical case study, a patient with EML4-ALK fusion positive non-small cell lung cancer with ALK G1269A had a partial response to Alecensa (alectinib) treatment (PMID: 26849637)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26849637	AVv-KSK9SS-TIFzzUIKejax	EML4	AZD3463	"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KRgQSS-TIFzzUIJUjax	EML4	AZD3463	"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KRlGSS-TIFzzUIJdjax	EML4	AZD3463	"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KSqlSS-TIFzzUILejax	EML4	AZD3463	"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KSItSS-TIFzzUIKajax	EML4	AZD3463	"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KRr4SS-TIFzzUIJpjax	EML4	AUY922	"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer with an ALK C1156Y secondary Xalkori (crizotinib) resistance mutation did not respond to Luminespib (AUY922) therapy (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSW8SS-TIFzzUIKzjax	EML4	ASP3026	"In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KSpQSS-TIFzzUILcjax	EML4	ASP3026	"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KRftSS-TIFzzUIJTjax	EML4	ASP3026	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KSMFSS-TIFzzUIKgjax	EML4	ASP3026	"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KRqNSS-TIFzzUIJmjax	EML4	ASP3026	"In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to ASP3026 in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KRkjSS-TIFzzUIJcjax	EML4	ASP3026	"In a preclinical study, a transformed cell line expressing EML4-ALK with ALK I1171T was resistant to ASP3026 treatment in culture (PMID: 25228534)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-KRRRSS-TIFzzUII6jax	EML4	ASP3026	"In a preclinical study, ASP3026 inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-KSR-SS-TIFzzUIKqjax	EML4	ASP3026	"In a preclinical study, ASP3026 inhibited growth of a transformed cell line expressing EML4-ALK in culture (PMID: 25228534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-KQ_SSS-TIFzzUIIcjax	EML4	AP26113	"In preclinical studies, Brigatinib (AP26113) inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859, PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSFlSS-TIFzzUIKUjax	EML4	AP26113	"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Brigatinib (AP26113) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KRm8SS-TIFzzUIJgjax	EML4	AP26113	"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Brigatinib (AP26113) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KRMcSS-TIFzzUIIyjax	EML4	AP26113	"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F were resistant to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSlDSS-TIFzzUILVjax	EML4	AP26113	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KRHYSS-TIFzzUIIqjax	EML4	AP26113	"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to Brigatinib (AP26113) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KRpuSS-TIFzzUIJljax	EML4	AP26113	"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSUSSS-TIFzzUIKujax	EML4	AP26113	"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KREfSS-TIFzzUIIljax	EML4	AP26113	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Brigatinib (AP26113) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KShvSS-TIFzzUILFjax	EML4	AP26113	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Brigatinib (AP26113) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KSepSS-TIFzzUILAjax	EML4	AP26113	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Brigatinib (AP26113) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KSDcSS-TIFzzUIKQjax	EML4	AP26113	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Brigatinib (AP26113) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-KRz_SS-TIFzzUIJ3jax	EML4	AP26113	"In a preclinical study, Brigatinib (AP26113) modestly inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KRuQSS-TIFzzUIJtjax	EML4	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KRibSS-TIFzzUIJYjax	EML4	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-KSosSS-TIFzzUILbjax	EML4	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing S1206Y in the context of EML4-ALK in culture (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KSAnSS-TIFzzUIKLjax	EML4	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EML4-ALK with L1198F in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KR_lSS-TIFzzUIKJjax	EML4	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A and L1198F in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KRJ0SS-TIFzzUIIujax	EML4	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-KSYFSS-TIFzzUIK1jax	EML4	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK T1151dup in the context of EML4-ALK in culture (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KQ2RSS-TIFzzUIINjax	EML4	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK S1206F in the context of EML4-ALK in culture (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KSeGSS-TIFzzUIK_jax	EML4	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK L196M in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KRXySS-TIFzzUIJFjax	EML4	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK L1152R in the context of EML4-ALK in culture (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KRxJSS-TIFzzUIJyjax	EML4	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK L1152P in the context of EML4-ALK in culture (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KRdkSS-TIFzzUIJPjax	EML4	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK G1202R in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KR59SS-TIFzzUIKAjax	EML4	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK F1174V in the context of EML4-ALK in culture (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KRofSS-TIFzzUIJjjax	EML4	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of a transformed cell line expressing EML4-ALK in culture (PMID: 25228534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-KQ3bSS-TIFzzUIIPjax	EML4	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of a transformed cell line expressing EML4-ALK I1171T but to a lesser degree than EML4-ALK in culture (PMID: 25228534)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-KRUKSS-TIFzzUII_jax	EML4	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of a transformed cell line expressing EML4-ALK ALK V1180L in culture (PMID: 25228534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-KSQySS-TIFzzUIKojax	EML4	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited Alk phosphorylation and growth in non-small cell lung cancer cell lines harboring EML4-ALK in culture, and induced near complete tumor regression in cell line xenograft models (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KQ4pSS-TIFzzUIIRjax	EGFR	unspecified EGFR antibody + unspecified IGF-1R antibody	"In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Igf-1r antibody resulted in growth inhibition in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27196767	AVv-KK4mSS-TIFzzUH-Tjax	EGFR	XL647	"In a Phase II study, XL647 demonstrated antitumor activity and increased progression-free survival in non-small cell lung cancer patients harboring EGFR activating mutations (PMID: 22722787)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22722787	AVv-KOLrSS-TIFzzUIEJjax	EGFR	WZ4002	"In a preclinical study, transformed human cells harboring EGFR exon 19 deletion and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling in culture (PMID: 25964297)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25964297	AVv-KMqESS-TIFzzUIBYjax	EGFR	WZ4002	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to WZ4002 after the emergence of NRAS Q61K in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KNDcSS-TIFzzUICDjax	EGFR	WZ4002	"In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25964297	AVv-KMmhSS-TIFzzUIBSjax	EGFR	WZ4002	"In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25964297	AVv-KMpcSS-TIFzzUIBXjax	EGFR	WZ4002	"In a preclinical study, a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S demonstrated resistance to growth inhibition by WZ4002 in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL34SS-TIFzzUIAFjax	EGFR	WZ4002	"In a preclinical study, WZ4002 inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25964297	AVv-KNX4SS-TIFzzUICljax	EGFR	WZ4002	"In a preclinical study, WZ4002 inhibited EGFR signaling and cell growth in 1st generation TKI-resistant non-small cell lung carcinoma cells harboring EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25964297	AVv-KNXVSS-TIFzzUICkjax	EGFR	Vemurafenib	"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-KPz8SS-TIFzzUIG5jax	EGFR	Trametinib	"In a preclinical study, a colorectal cancer cell line harboring MAP2K1 mutations Q56P, H119Y, and D351G and an EGFR G719S mutation demonstrated some sensitivity to Mekinist (trametinib) in culture, resulting in decreased cell viability (PMID: 26582713)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26582713	AVv-KQISSS-TIFzzUIHljax	EGFR	TAK-285	"In a preclinical study, TAK-285 inhibited growth of squamous cell carcinoma cells harboring EGFR over expression in culture and in cell line xenograft models (PMID: 23983820)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23983820	AVv-KNuRSS-TIFzzUIDWjax	EGFR	TAE226	"In a preclinical study, TAE226 treatment inhibited proliferation of transformed human cell lines harboring EGFR L858R mutation in culture (PMID: 26090892)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26090892	AVv-KOtzSS-TIFzzUIFCjax	EGFR	TAE226	"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring both EGFR L858R and EGFR T790M mutations in culture (PMID: 26090892)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26090892	AVv-KOWYSS-TIFzzUIEbjax	EGFR	TAE226	"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring EGFR L858R mutation in culture (PMID: 26090892)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26090892	AVv-KOy8SS-TIFzzUIFLjax	EGFR	TAE226	"In a preclinical study, TAE226 treatment inhibited cell proliferation and decreased xenograft tumor size of non-small cell lung carcinoma cell lines harboring both EGFR T790M and EGFR Exon 19 deletion mutations (PMID: 26090892)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26090892	AVv-KNWvSS-TIFzzUICjjax	EGFR	TAE226	"In a preclinical study, TAE226 treatment inhibited cell proliferation and decreased xenograft tumor size of non-small cell lung carcinoma cell lines harboring EGFR Exon 19 deletion mutation (PMID: 26090892)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26090892	AVv-KNGvSS-TIFzzUICJjax	EGFR	TAE226	"In a preclinical study, TAE226 treatment demonstrated reduced potency inhibiting proliferation of non-small cell lung carcinoma cell lines harboring wild-type EGFR in culture (PMID: 26090892)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26090892	AVv-KPd4SS-TIFzzUIGUjax	EGFR	Sorafenib	"In a Phase III trial, treatment with Nexavar (sorafenib) in non-small cell lung cancer patients harboring an EGFR mutation resulted in a greater overall survival and progression free survival when compared to placebo (PMID: 26743856)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26743856	AVv-KLUBSS-TIFzzUH_Ljax	EGFR	Sorafenib	"In a Phase II clinical trial, Nexavar (sorafenib) demonstrated efficacy in NSCLC patients with wild-type EGFR (PMID: 24166906)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24166906	AVv-KPbrSS-TIFzzUIGQjax	EGFR	Selumetinib + BEZ235	"In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically inhibited proliferation of Iressa (gefitinib)-resistant NSCLC cells harboring EGFR T790M in culture and in cell line xenograft models (PMID: 24939055)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24939055	AVv-KQPzSS-TIFzzUIHxjax	EGFR	Selumetinib	"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS in culture (PMID: 25870145)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KNliSS-TIFzzUIC9jax	EGFR	Selumetinib	"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K in culture (PMID: 25870145)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KNC7SS-TIFzzUICCjax	EGFR	Selumetinib	"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R in culture (PMID: 25870145)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KNgGSS-TIFzzUIC0jax	EGFR	Selumetinib	"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K in culture (PMID: 25870145)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KNfCSS-TIFzzUICyjax	EGFR	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) mildly inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with an EGFR T790M mutation (PMID: 24939055)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24939055	AVv-KQbKSS-TIFzzUIIFjax	EGFR	Sapitinib	"In a preclinical study, Sapitinib (AZD8931) inhibited EGFR, ERBB2, and ERBB3 kinase activity, and inhibited growth in several non-small cell lung cancer cell lines and xenograft models, including those with EGFR activating mutations (PMID: 20145185)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20145185	AVv-KODiSS-TIFzzUID7jax	EGFR	Sapitinib	"In a preclinical study, Sapitinib (AZD8931) demonstrated antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erb2 (Her2) protein in culture and in xenograft models (PMID: 24886365)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24886365	AVv-KNxHSS-TIFzzUIDbjax	EGFR	SYM004 + Radiotherapy	"In a preclinical study, SYM004 enhanced sensitivity to radiation therapy in non-small cell lung cancer cells in culture and in cell line xenografts (PMID: 24130052)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24130052	AVv-KMMkSS-TIFzzUIAojax	EGFR	SYM004	"In a preclinical study, SYM004 inhibited phosphorylation of EGFR in cells expressing EGFR R451C in culture (PMID: 26888827)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26888827	AVv-KN0kSS-TIFzzUIDhjax	EGFR	SYM004	"In a preclinical study, SYM004 inhibited phosphorylation of EGFR in cells expressing EGFR K467T in culture (PMID: 26888827)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26888827	AVv-KP1sSS-TIFzzUIG8jax	EGFR	SYM004	"In a preclinical study, SYM004 inhibited EGFR downstream signaling and proliferation of a colorectal cancer cell line harboring EGFR G465R in culture, and induced tumor regression in xenograft models (PMID: 26888827)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26888827	AVv-KPt8SS-TIFzzUIGvjax	EGFR	SYM004	"In a preclinical study, SYM004 demonstrated efficacy in cell line xenograft models of Erbitux (cetuximab)-resistant non-small cell lung cancer (PMID: 24204198)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24204198	AVv-KMLVSS-TIFzzUIAmjax	EGFR	SYM004	"In a clinical study, a patient with Erbitux (cetuximab)-resistant metastatic colorectal cancer harboring EGFR G465R demonstrated stable disease for 15 weeks following treatment with SYM004 (PMID: 26888827)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26888827	AVv-KPulSS-TIFzzUIGwjax	EGFR	SYM004	"In a Phase I study, a colorectal cancer patient harboring EGFR S492R demonstrated a partial response when treated with SYM004 (PMID: 25962717)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25962717	AVv-KQBySS-TIFzzUIHQjax	EGFR	SYM004	"In a Phase I study, 13% (5/39) of patients with metastatic colorectal cancer resistant to EGFR therapy had a partial response to SYM004 while 44% (17/39) demonstrated tumor regression (PMID: 25962717)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25962717	AVv-KMSdSS-TIFzzUIAxjax	EGFR	SHP099	"In a preclinical study, SHP099 inhibited ERK activation and reduced proliferation of an EGFR-amplified triple-negative breast cancer cell line in culture (PMID: 27362227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27362227	AVv-KLF9SS-TIFzzUH-ojax	EGFR	S-222611	"In a preclinical study, S-222611 inhibited tumor growth of human kidney cancer cells expressing EGFR in cell line xenograft models (PMID: 24837299)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24837299	AVv-KMRzSS-TIFzzUIAwjax	EGFR	S-222611	"In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human lung cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24837299	AVv-KMWbSS-TIFzzUIA3jax	EGFR	S-222611	"In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human colon cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24837299	AVv-KMTwSS-TIFzzUIAzjax	EGFR	S-222611	"In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human breast cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24837299	AVv-KMVuSS-TIFzzUIA2jax	EGFR	S-222611	"In a Phase I clinical trial, S-222611 demonstrated safety and some efficacy in patients with advanced solid tumors expressing EGFR or ERBB2 (HER2), with an overall clinical benefit rate of 27% (7/33) (PMID: 25434923)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25434923	AVv-KMQmSS-TIFzzUIAujax	EGFR	Ponatinib	"In a preclinical study, non-small cell lung cancer cells harboring mutant EGFR and wild-type FGFR1 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-KLaISS-TIFzzUH_Vjax	EGFR	Pimasertib + Regorafenib	"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-KO7tSS-TIFzzUIFajax	EGFR	Pimasertib + BEZ235	"In a preclinical study, Pimasertib (MSC1936369B) and BEZ235 combination treatment inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-KO81SS-TIFzzUIFcjax	EGFR	Pimasertib	"In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, T790M, and PIK3CA G118D demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-KO8SSS-TIFzzUIFbjax	EGFR	Pelitinib	"In a Phase I study, patients with advanced solid tumors that were positive for EGFR expression demonstrated no complete or partial responses when treated with Pelitinib (EKB-569) (PMID: 16710023)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/16710023	AVv-KMOVSS-TIFzzUIArjax	EGFR	Pelitinib	"In a Phase I study, Pelitinib (EKB-569) demonstrated efficacy in 2 patients with non-small cell lung cancer with EGFR mutations and acquired resistance to gefitinib (PMID: 16364494)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/16364494	AVv-KLRKSS-TIFzzUH_Gjax	EGFR	Panitumumab	"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) in culture (PMID: 27312529)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-KPwdSS-TIFzzUIGzjax	EGFR	Panitumumab	"In a preclinical study, colorectal cancer cell lines over expressing EGFR S464L were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KPsQSS-TIFzzUIGsjax	EGFR	Panitumumab	"In a preclinical study, colorectal cancer cell lines over expressing EGFR I491M were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KMv4SS-TIFzzUIBijax	EGFR	Panitumumab	"In a preclinical study, colorectal cancer cell lines over expressing EGFR G465R were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KPvJSS-TIFzzUIGxjax	EGFR	Panitumumab	"In a preclinical study, colorectal cancer cell lines over expressing EGFR G465E were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KPHdSS-TIFzzUIFvjax	EGFR	Panitumumab	"In a preclinical study, Vectibix (panitumumab) inhibited survival of colorectal cancer cell lines over expressing EGFR S492R in culture (PMID: 26843189)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KQApSS-TIFzzUIHOjax	EGFR	Panitumumab	"In a preclinical study, Vectibix (panitumumab) inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KN0CSS-TIFzzUIDgjax	EGFR	Panitumumab	"In a preclinical study, Vectibix (panitumumab) inhibited survival of colorectal cancer cell lines over expressing EGFR K467T in culture (PMID: 26843189)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KP3cSS-TIFzzUIG_jax	EGFR	Panitumumab	"In a clinical study, a colorectal cancer patient harboring both EGFR amplification and EGFR S492R demonstrated a 50% tumor reduction when treated with Vectibix (panitumumab) (PMID: 22270724)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22270724	AVv-KKyjSS-TIFzzUH-Kjax	EGFR	Panitumumab	"In a Phase III study, response to Vectibix (pantitumumab) was associated with EGFR amplification in colorectal cancer patients (PMID: 17664472)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17664472	AVv-KK0hSS-TIFzzUH-Njax	EGFR	PF3644022 + PF-477736	"In a preclinical study, neither single agent or combination of Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 inhibited growth of transformed cells over expressing EGFR L858R in culture (PMID: 26140595)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26140595	AVv-KO6ASS-TIFzzUIFXjax	EGFR	PF-05212384	"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring EGFR L858R EGFR T790M in culture (PMID: 21325073, PMID: 19238632)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-KOiRSS-TIFzzUIEvjax	EGFR	PF-05212384	"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring  EGFR E746_A750del in culture (PMID: 21325073, PMID: 16731747)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-KLs3SS-TIFzzUH_yjax	EGFR	Neratinib	"In a preclinical study, transformed cells expressing EGFR L858R and T790M demonstrated decreased sensitivity to Neratinib (HKI-272) in culture (PMID: 17085664)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/17085664	AVv-KOb1SS-TIFzzUIEkjax	EGFR	Neratinib	"In a preclinical study, transformed cells expressing EGFR L858R and D761Y demonstrated decreased sensitivity to Neratinib (HKI-272) in culture (PMID: 17085664)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/17085664	AVv-KPDQSS-TIFzzUIFnjax	EGFR	Neratinib	"In a preclinical study, transformed cells expressing EGFR G719A demonstrated increased sensitivity to second-generation EGFR inhibitors including Neratinib in culture, when compared to first and third-generation inhibitors (PMID: 26206867)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206867	AVv-KN9RSS-TIFzzUIDwjax	EGFR	Neratinib	"In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated increased sensitivity to second-generation EGFR inhibitors including Neratinib in culture, when compared to first and third-generation inhibitors (PMID: 26206867)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206867	AVv-KM0tSS-TIFzzUIBqjax	EGFR	Neratinib	"In a preclinical study, transformed cells expressing EGFR E709K demonstrated increased sensitivity to second-generation EGFR inhibitors including Neratinib in culture, when compared to first and third-generation inhibitors (PMID: 26206867)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206867	AVv-KM-fSS-TIFzzUIB6jax	EGFR	Neratinib	"In a preclinical study, Neratinib inhibited growth of sinonasal squamous cell carcinoma cells harboring EGFR N771_H773dup in culture (PMID: 25931286)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25931286	AVv-KMZ8SS-TIFzzUIA9jax	EGFR	Neratinib	"In a preclinical study, Neratinib inhibited EGFR signaling and reduced growth of sinonasal squamous cell carcinoma cells harboring EGFR S768_D770dup in culture (PMID: 25931286)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25931286	AVv-KM5KSS-TIFzzUIBxjax	EGFR	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited growth of transformed cells expressing EGFR L858R in culture (PMID: 17085664)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17085664	AVv-KO4LSS-TIFzzUIFUjax	EGFR	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited EGFR phosphorylation and growth of cells expressing EGFR L844V in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KQNWSS-TIFzzUIHtjax	EGFR	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited EGFR phosphorylation and growth of cells expressing EGFR L718Q in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KP50SS-TIFzzUIHDjax	EGFR	Neratinib	"In a Phase II clinical trial, treatment with Neratinib resulted in partial response in 75% (3/4) and stable disease in 25% (1/4) of non-small cell lung cancer patients harboring EGFR G719 mutations (PMID: 20479403)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20479403	AVv-KLK8SS-TIFzzUH-xjax	EGFR	NGI-1	"In a preclinical study, NGI-1 inhibited EGFR phosphorylation and proliferation and induced cell cycle arrest in non-small cell lung cancer cell lines harboring kinase domain mutations in EGFR in culture (PMID: 27694802)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27694802	AVv-KLUoSS-TIFzzUH_Mjax	EGFR	MM-151	"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR S492R in culture (PMID: 26843189)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KQAASS-TIFzzUIHNjax	EGFR	MM-151	"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR S464L in culture (PMID: 26843189)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KPrrSS-TIFzzUIGrjax	EGFR	MM-151	"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KNy1SS-TIFzzUIDejax	EGFR	MM-151	"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR K467T in culture (PMID: 26843189)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KP2SSS-TIFzzUIG9jax	EGFR	MM-151	"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR I491M in culture (PMID: 26843189)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KMvQSS-TIFzzUIBhjax	EGFR	MM-151	"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR G465R in culture (PMID: 26843189)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KPvwSS-TIFzzUIGyjax	EGFR	MM-151	"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR G465E in culture (PMID: 26843189)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KPILSS-TIFzzUIFwjax	EGFR	MM-151	"In a preclinical study, MM-151 antagonized EGFR activity and inhibited proliferation in several tumor cell lines in culture (PMID: 25911688)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25911688	AVv-KK5OSS-TIFzzUH-Ujax	EGFR	MM-151	"In a Phase I trial, MM-151 treatment resulted in marked reduction of EGFR G465E in circulating cell-free tumor DNA and reduced tumor size in a colorectal cancer patient harboring both EGFR G465E and EGFR G465R (PMID: 26843189)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KPGYSS-TIFzzUIFtjax	EGFR	Lapatinib	"In a preclinical study, non-small cell lung carcinoma cells harboring EGFR E746_A750del demonstrated resistance to growth inhibition by Tykerb (lapatinib) in cell culture (PMID: 18199554)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18199554	AVv-KLv2SS-TIFzzUH_3jax	EGFR	Lapatinib	"In a preclinical study, non-small cell carcinoma cancer cell lines harboring EGFR L858R and T790M mutations demonstrated resistance to growth inhibition by Tykerb (lapatinib) in culture (PMID: 18199554)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18199554	AVv-KOaBSS-TIFzzUIEhjax	EGFR	Lapatinib	"In a preclinical study, Tykerb (lapatinib) inhibited cell survival of a human glioblastoma multiforme cell line harboring an EGFR-SEPT14 fusion, and inhibited tumor growth in xenograft models (PMID: 23917401)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23917401	AVv-KQC9SS-TIFzzUIHSjax	EGFR	Lapatinib	"In a Phase II trial, Tykerb (lapatinib) demonstrated safety in patients with non-small cell lung cancer, but demonstrated minimal antitumor activity with no responses in patients harboring EGFR mutations (PMID: 20215545)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/20215545	AVv-KLS5SS-TIFzzUH_Jjax	EGFR	LDE225	"In a preclinical study, Odomzo (sonidegib) did not decrease viability or migration of non-small cell lung cancer cells harboring EGFR E746_A750del and amplification of SMO in culture (PMID: 26124204)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26124204	AVv-KMAfSS-TIFzzUIAUjax	EGFR	K-756 + Gefitinib	"In a preclinical study, the combination of K-756 and Iressa (gefitinib) worked synergistically to inhibit growth of non-small cell lung cancer cells with wild-type EGFR or EGFR exon 19 deletion in culture (PMID: 27196752)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27196752	AVv-KPjeSS-TIFzzUIGdjax	EGFR	JNJ-61186372	"In a preclinical study, JNJ-61186372 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring an EGFR exon 19 deletion, with increased efficacy following treatment cessation compared to Tarceva (erlotinib) (PMID: 27216193)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27216193	AVv-KNFnSS-TIFzzUICHjax	EGFR	JNJ-61186372	"In a preclinical study, JNJ-61186372 inhibited tumor growth in Tarceva (erlotinib)-resistant non-small cell lung cancer cell line xenograft models harboring an EGFR exon 19 deletion and MET amplification (PMID: 27216193)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27216193	AVv-KNjpSS-TIFzzUIC6jax	EGFR	JNJ-61186372	"In a preclinical study, JNJ-61186372 induced tumor regression in lung adenocaricnoma patient-derived xenograft (PDX) models harboring an EGFR exon 19 deletion, with continued response following treatment cessation (PMID: 27216193)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27216193	AVv-KNJLSS-TIFzzUICNjax	EGFR	JNJ-61186372	"In a preclinical study, JNJ-61186372 induced tumor regression in lung adenocaricnoma patient-derived xenograft (PDX) models harboring EGFR L858R and EGFR T790M, with response continuing up to 2 months post-treatment cessation (PMID: 27216193)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27216193	AVv-KOizSS-TIFzzUIEwjax	EGFR	Gefitinib + Linsitinib	"In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring mutations in EGFR (EGFRvIII, A289T) and PTEN (I253N, N69D) in culture (PMID: 26561558)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26561558	AVv-KNoLSS-TIFzzUIDBjax	EGFR	Gefitinib + Linsitinib	"In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFRvIII in culture (PMID: 26561558)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26561558	AVv-KOKaSS-TIFzzUIEHjax	EGFR	Gefitinib + Linsitinib	"In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26561558	AVv-KKoNSS-TIFzzUH95jax	EGFR	Gefitinib + Linsitinib	"In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification and EGFR G719A in culture (PMID: 26561558)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26561558	AVv-KLHqSS-TIFzzUH-rjax	EGFR	Gefitinib + Imatinib	"In a preclinical study, Gleevec (imatinib) and Iressa (gefitinib) acted synergistically to decrease downstream signaling activity and inhibit cell growth of glioblastoma cell lines with EGFR and PDGFRA coamplification (PMID: 22323597)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22323597	AVv-KLHGSS-TIFzzUH-qjax	EGFR	Gefitinib + Golvatinib	"In a preclinical study, addition of Golvatinib (E7050) overcame Hgf-induced Iressa (gefitinib)-resistance in lung adenocarcinoma cell lines harboring EGFR exon 19 deletions in culture and in cell line xenograft models (PMID: 22789825)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22789825	AVv-KNMPSS-TIFzzUICSjax	EGFR	Gefitinib	Iressa (gefitinib) has been recommended as a first-line treatment in patients with EGFR activating mutations (PMID: 22997455).	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22997455	AVv-KOHTSS-TIFzzUIECjax	EGFR	Gefitinib	"In preclinical in vitro assays, EGFR G719S was demonstrated to stabilize the active conformation of Egfr and sensitize the protein to Iressa (gefitinib) (PMID: 17349580)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17349580	AVv-KQGISS-TIFzzUIHXjax	EGFR	Gefitinib	"In an analysis of published clinical data, 7/11 non-small cell lung cancer patients harboring EGFR G719A were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Iressa (gefitinib) (PMID: 23344264)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23344264	AVv-KN4FSS-TIFzzUIDnjax	EGFR	Gefitinib	"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR H773_V774insH, displayed progressive disease following treatment with Iressa (gefitinib) (PMID: 24353160)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24353160	AVv-KLNeSS-TIFzzUH-1jax	EGFR	Gefitinib	"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L858R that had developed Iressa (gefitinib) resistance was demonstrated to have acquired an EGFR L747S mutation (PMID: 18981003)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18981003	AVv-KOm6SS-TIFzzUIE3jax	EGFR	Gefitinib	"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_T751delinsP that had developed Iressa (gefitinib) resistance was demonstrated to have acquired an EGFR T790M mutation (PMID: 18981003)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18981003	AVv-KOPQSS-TIFzzUIEPjax	EGFR	Gefitinib	"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_S752del that developed Iressa (gefitinib) resistance was demonstrated to have acquired an EGFR T790M mutation (PMID: 18981003)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18981003	AVv-KNqWSS-TIFzzUIDFjax	EGFR	Gefitinib	"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_S752del had a partial response to Iressa (gefitinib) therapy (PMID: 18981003)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18981003	AVv-KNpTSS-TIFzzUIDDjax	EGFR	Gefitinib	"In a retrospective analysis, a patient with EGFR L858R-mutant non-small lung cancer that developed resistance to Iressa (gefitinib) was demonstrated to have acquired a secondary EGFR D761Y mutation (PMID: 17085664)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/17085664	AVv-KPDzSS-TIFzzUIFojax	EGFR	Gefitinib	"In a retrospective analysis, 5 patients with lung adenocarcinoma harboring EGFR E746_A750del were found to respond to Iressa (gefitinib) therapy, with 4 achieving partial response and 1 stable disease (PMID: 18981003)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18981003	AVv-KLrhSS-TIFzzUH_wjax	EGFR	Gefitinib	"In a retrospective analysis, 4 patients with lung adenocarcinoma harboring EGFR E746_A750del that had developed Iressa (gefitinib) resistance were found to have acquired EGFR T790M mutations (PMID: 18981003)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18981003	AVv-KMDbSS-TIFzzUIAZjax	EGFR	Gefitinib	"In a retrospective analysis, 3 patients with lung adenocarcinoma harboring EGFR L747_T751delinsP were found to respond to Iressa (gefitinib) therapy (PMID: 18981003)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18981003	AVv-KOP3SS-TIFzzUIEQjax	EGFR	Gefitinib	"In a preclinical study, transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M were resistant to Iressa (gefitinib) induced suppression of EGFR signaling in culture (PMID: 25964297)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25964297	AVv-KNZmSS-TIFzzUICojax	EGFR	Gefitinib	"In a preclinical study, transformed cells expressing EGFR N826S demonstrated resistance to Iressa (gefitinib) in cell culture (PMID: 19147750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19147750	AVv-KPnBSS-TIFzzUIGjjax	EGFR	Gefitinib	"In a preclinical study, transformed cells expressing EGFR L858R and EGFR D761Y demonstrated decreased sensitivity to Iressa (gefitinib) in culture (PMID: 17085664)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/17085664	AVv-KPCHSS-TIFzzUIFljax	EGFR	Gefitinib	"In a preclinical study, transformed cells expressing EGFR G719A demonstrated decreased sensitivity to first-generation EGFR inhibitors including Iressa (gefitinib) in culture, when compared to second-generation inhibitors (PMID: 26206867)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26206867	AVv-KN6aSS-TIFzzUIDrjax	EGFR	Gefitinib	"In a preclinical study, transformed cells expressing EGFR E709K demonstrated decreased sensitivity to first-generation EGFR inhibitors including Iressa (gefitinib) in culture, when compared to second-generation inhibitors (PMID: 26206867)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26206867	AVv-KM9WSS-TIFzzUIB4jax	EGFR	Gefitinib	"In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR S768_D770dup demonstrated resistance to Iressa (gefinitib) in culture (PMID: 25931286)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25931286	AVv-KM6PSS-TIFzzUIBzjax	EGFR	Gefitinib	"In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR N771_H773dup demonstrated resistance to Iressa (gefinitib) in culture (PMID: 25931286)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25931286	AVv-KMZYSS-TIFzzUIA8jax	EGFR	Gefitinib	"In a preclinical study, non-small cell lung cancercarcinoma cells harboring EGFR exon 19 deletion and EGFR T790M were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25964297	AVv-KNVXSS-TIFzzUIChjax	EGFR	Gefitinib	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of NRAS E63K in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KNd3SS-TIFzzUICwjax	EGFR	Gefitinib	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of EGFR T790M and amplified KRAS in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KNczSS-TIFzzUICujax	EGFR	Gefitinib	"In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25964297	AVv-KMgXSS-TIFzzUIBIjax	EGFR	Gefitinib	"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Iressa (gefitinib) in culture (PMID: 27312529)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-KP1GSS-TIFzzUIG7jax	EGFR	Gefitinib	"In a preclinical study, cells expressing the double EGFR L858R/E884K mutation demonstrated increased sensitivity to inhibition by Iressa (gefitinib) compared to cells expressing EGFR L858R alone (PMID: 20942962)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20942962	AVv-KPBiSS-TIFzzUIFkjax	EGFR	Gefitinib	"In a preclinical study, amplification of SMO conferred acquired resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring EGFR E746_A750del in culture (PMID: 26124204)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26124204	AVv-KMBJSS-TIFzzUIAVjax	EGFR	Gefitinib	"In a preclinical study, amplification of MET conferred resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring an EGFR exon 19 deletion mutation in culture (PMID: 17463250)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/17463250	AVv-KNCUSS-TIFzzUICBjax	EGFR	Gefitinib	"In a preclinical study, acquired amplification of MET conferred resistance to Iressa (gefitinib) in a non-small cell lung cancer cell line harboring EGFR E746_A750del in culture (PMID: 27612490)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27612490	AVv-KMG8SS-TIFzzUIAfjax	EGFR	Gefitinib	"In a preclinical study, Iressa (gefitinib) inhibited the growth of cultured cells expressing the EGFR exon 19 variant, L747_P753delinsS (PMID: 19147750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19147750	AVv-KP8PSS-TIFzzUIHHjax	EGFR	Gefitinib	"In a preclinical study, Iressa (gefitinib) inhibited growth of a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL2MSS-TIFzzUIACjax	EGFR	Gefitinib	"In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25964297	AVv-KMnuSS-TIFzzUIBUjax	EGFR	Gefitinib	"In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling and cell growth in lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25964297	AVv-KMnHSS-TIFzzUIBTjax	EGFR	Gefitinib	"In a clinical study, EGFR T790M mutations were associated with resistance to Iressa (gefitinib) in lung adenocarcinoma patients (PMID: 15737014)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24410791	AVv-KQSESS-TIFzzUIH1jax	EGFR	Gefitinib	"In a clinical study, EGFR T790M mutations were associated with acquired resistance to Iressa (gefitinib) in non-small cell lung cancer patients harboring EGFR L858R (PMID: 22263058)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22263058	AVv-KOlKSS-TIFzzUIE0jax	EGFR	Gefitinib	"In a clinical case study, a lung adenocarcinoma patient harboring a compound EGFR L833V/H835L mutation responded to treatment with Iressa (gefitinib), with disease progression after 34 weeks of treatment (PMID: 21422421)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21422421	AVv-KMuHSS-TIFzzUIBfjax	EGFR	Gefitinib	"In a clinical case report, a non-small cell lung cancer patient that progressed on Iressa (gefitinib) was demonstrated to harbor EGFR L858R and a secondary EGFR T790M mutation (PMID: 15737014)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/15737014	AVv-KOklSS-TIFzzUIEzjax	EGFR	Gefitinib	"In a Phase III trial, postoperative adjuvant Iressa (gefitinib) did not provide prolonged disease-free survival nor increased overall survival in NSCLC patients with wild-type EGFR (PMID: 23980091)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/23980091	AVv-KPbESS-TIFzzUIGPjax	EGFR	Gefitinib	"In a Phase III clinical trial, Iressa (gefitinib) treatment resulted in an objective response rate of 71.2% (94/132) and increased progression-free survival in non-small cell lung cancer patients harboring EGFR activating mutations (PMID: 19692680)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19692680	AVv-KOGoSS-TIFzzUIEBjax	EGFR	Gedatolisib + Neratinib	"In a preclinical study, Gedatolisib (PKI-587) and Neratinib (HKI-272) in combination worked syngerstically to inhibit Akt phosphorylation in a human non-small cell lung cancer cell line harboring EGFR L858R and T790M in culture (PMID: 21325073)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21325073	AVv-KOgcSS-TIFzzUIEsjax	EGFR	Ganetespib	"In a preclinical study, Ganetespib inhibited growth of a non-small cell lung cancer cell line with EGFR amplification and overexpression in culture (PMID: 25077897)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25077897	AVv-KK_1SS-TIFzzUH-ejax	EGFR	GA201	"In a preclinical study, treatment with GA201 resulted in inhibition of EGFR signaling and induced antibody-dependent cell-mediated cytotoxicity towards EGFR-over expressing squamous cell carcinoma cells in culture (PMID: 23209031)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23209031	AVv-KNvWSS-TIFzzUIDYjax	EGFR	GA201	"In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant non-small cell lung cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23209031	AVv-KPJ3SS-TIFzzUIFzjax	EGFR	GA201	"In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23209031	AVv-KPLlSS-TIFzzUIF2jax	EGFR	GA201	"In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS wild-type colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23209031	AVv-KPJVSS-TIFzzUIFyjax	EGFR	GA201	"In a preclinical study, treatment with GA201 resulted in improved overall survival in EGFR-positive renal cell carcinoma cell line xenograft models harboring KRAS mutations, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23209031	AVv-KMKBSS-TIFzzUIAkjax	EGFR	GA201	"In a preclinical study, treatment with GA201 resulted in improved overall survival in EGFR-positive pancreatic cancer cell line xenograft models harboring KRAS mutations, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23209031	AVv-KMKnSS-TIFzzUIAljax	EGFR	Everolimus + Pimasertib	"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-KO9cSS-TIFzzUIFdjax	EGFR	Etoposide	"In a preclinical study, neuroblastoma cells over expressing EGFR T34_A289del were resistant to Eposin (etoposide) in culture (PMID: 27216155)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27216155	AVv-KLnCSS-TIFzzUH_pjax	EGFR	Erlotinib + S63845	"In a preclinical study, combination of S63845 and Tarceva (erlotinib) resulted in potent cytotoxic effects in EGFR mutated non-small cell lung cancer cells in culture compared to the cytostatic effect of Tarceva (erlotinib) alone (PMID: 27760111)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27760111	AVv-KLQpSS-TIFzzUH_Fjax	EGFR	Erlotinib + Ganetespib	"In a preclinical study, the combination of Tarceva (erlotinib) and Ganetespib led to tumor regression in cell line xenograft models of EGFR wild-type non-small cell lung cancer, and demonstrated improved efficacy over either agent alone (PMID: 25077897)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25077897	AVv-KPgWSS-TIFzzUIGYjax	EGFR	Erlotinib + Ganetespib	"In a preclinical study, the combination of Ganetespib and Tarceva (erlotinib) demonstrated improved antitumor activity compared to either agent alone in cell line xenograft models of non-small cell lung cancer harboring EGFR E746_A750del (PMID: 25077897)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25077897	AVv-KLqNSS-TIFzzUH_ujax	EGFR	Erlotinib + Ganetespib	"In a preclinical study, the addition of Ganetespib overcame resistance to Tarceva (erlotinib) in cell line xenograft models of non-small cell lung cancer harboring EGFR L858R and EGFR T790M (PMID: 25077897)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25077897	AVv-KOW_SS-TIFzzUIEcjax	EGFR	Erlotinib	"In preclinical in vitro assays, EGFR G719S was demonstrated to stabilize the active conformation of Egfr and sensitize the protein to Gilotrif (afatinib) (PMID: 17349580)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17349580	AVv-KQE1SS-TIFzzUIHVjax	EGFR	Erlotinib	"In contrast to other known exon 20 insertions, EGFR A763_Y764insFQEA is sensitive to tyrosine kinase inhibitors, such as Tarceva (erlotinib), in cells, in animal models and in NSCLC patients (PMID: 24353160)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24353160	AVv-KOQZSS-TIFzzUIERjax	EGFR	Erlotinib	"In an analysis of published clinical data, 7/11 non-small cell lung cancer patients harboring EGFR G719A were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Tarceva (erlotinib) (PMID: 23344264)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23344264	AVv-KN7OSS-TIFzzUIDtjax	EGFR	Erlotinib	"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR L747S had an initial partial response to Tarceva (erlotinib), but was found to progress after 6 months (PMID: 18981003)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/18981003	AVv-KOmUSS-TIFzzUIE2jax	EGFR	Erlotinib	"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_T751delinsP and EGFR T790M was found to rapidly progress on Tarceva (erlotinib) therapy (PMID: 18981003)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18981003	AVv-KOOqSS-TIFzzUIEOjax	EGFR	Erlotinib	"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_S752del and EGFR T790M was found to rapidly progress on Tarceva (erlotinib) therapy (PMID: 18981003)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18981003	AVv-KNp2SS-TIFzzUIDEjax	EGFR	Erlotinib	"In a retrospective analysis, 3 of 4 patients with lung adenocarcinoma harboring EGFR E746_A750del and EGFR T790M were found to rapidly progress on Tarceva (erlotinib) therapy (PMID: 18981003)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18981003	AVv-KMD_SS-TIFzzUIAajax	EGFR	Erlotinib	"In a preclinical study, transformed cells expressing EGFR N826S demonstrated resistance to Tarceva (erlotinib) in cell culture (PMID: 19147750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19147750	AVv-KPmgSS-TIFzzUIGijax	EGFR	Erlotinib	"In a preclinical study, transformed cells expressing EGFR L858R and EGFR C797S demonstrated sensitivity to Tarceva (erlotinib) in culture (PMID: 27913578)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27913578	AVv-KMc4SS-TIFzzUIBCjax	EGFR	Erlotinib	"In a preclinical study, transformed cells expressing EGFR G719A demonstrated decreased sensitivity to first-generation EGFR inhibitors including Tarceva (erlotinib) in culture, when compared to second-generation inhibitors (PMID: 26206867)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26206867	AVv-KN-ZSS-TIFzzUIDyjax	EGFR	Erlotinib	"In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated decreased sensitivity to first-generation EGFR inhibitors including Tarceva (erlotinib) in culture, when compared to second-generation inhibitors (PMID: 26206867)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26206867	AVv-KM1ZSS-TIFzzUIBrjax	EGFR	Erlotinib	"In a preclinical study, transformed cells expressing EGFR E709K demonstrated decreased sensitivity to first-generation EGFR inhibitors including Tarceva (erlotinib) in culture, when compared to second-generation inhibitors (PMID: 26206867)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26206867	AVv-KM8GSS-TIFzzUIB2jax	EGFR	Erlotinib	"In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR S768_D770dup demonstrated resistance to Tarceva (erlotinib) in culture (PMID: 25931286)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25931286	AVv-KM4hSS-TIFzzUIBwjax	EGFR	Erlotinib	"In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR N771_H773dup demonstrated resistance to Tarceva (erlotinib) in culture (PMID: 25931286)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25931286	AVv-KMYwSS-TIFzzUIA7jax	EGFR	Erlotinib	"In a preclinical study, non-small cell lung carcinoma cells expressing EGFR S768I had decreased sensitivity to Tarceva (erltonib) in cell culture (PMID: 19147750)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/19147750	AVv-KPOiSS-TIFzzUIF7jax	EGFR	Erlotinib	"In a preclinical study, head and neck squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to  Tarceva (erlotinib) in a cell viability assay (PMID: 27207775)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27207775	AVv-KK8ESS-TIFzzUH-Yjax	EGFR	Erlotinib	"In a preclinical study, expression of EGFR T854A decreased sensitivity of transformed cells expressing EGFR L858R to Tarceva (erlotinib) in culture (PMID: 19010870)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/19010870	AVv-KNmxSS-TIFzzUIC_jax	EGFR	Erlotinib	"In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Tarceva (erlotinib) in a cell viability assay (PMID: 27207775)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27207775	AVv-KK13SS-TIFzzUH-Pjax	EGFR	Erlotinib	"In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR L861Q demonstrated resistance to treatment with Tarceva (erlotinib) in a cell viability assay (PMID: 27207775)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27207775	AVv-KPXMSS-TIFzzUIGJjax	EGFR	Erlotinib	"In a preclinical study, cells expressing the double EGFR L858R/E844K mutation demonstrated decreased sensitivity to Tarceva (erlotinib) in culture compared to cells expressing EGFR L858R alone (PMID: 19015641)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/19015641	AVv-KPAZSS-TIFzzUIFijax	EGFR	Erlotinib	"In a preclinical study, cells expressing EGFR E734Q demonstrated sensitivity to Tarceva (erlotinib) in culture (PMID: 20942962)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20942962	AVv-KNyUSS-TIFzzUIDdjax	EGFR	Erlotinib	"In a preclinical study, Tarceva (erlotinib) inhibited cell survival of a human glioblastoma multiforme cell line harboring an EGFR-SEPT14 fusion, and inhibited tumor growth in xenograft models (PMID: 23917401)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23917401	AVv-KQCYSS-TIFzzUIHRjax	EGFR	Erlotinib	"In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation in cells expressing EGFR R831H in culture (PMID: 20942962)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20942962	AVv-KNngSS-TIFzzUIDAjax	EGFR	Erlotinib	"In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation in cells expressing EGFR E868G in culture (PMID: 20942962)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20942962	AVv-KMI2SS-TIFzzUIAijax	EGFR	Erlotinib	"In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation and cell proliferation in transformed cells over expressing EGFR T34_A289del in culture (PMID: 27216155)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27216155	AVv-KLoVSS-TIFzzUH_rjax	EGFR	Erlotinib	"In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation and cell proliferation in neuroblastoma cells over expressing EGFR T34_A289del in culture (PMID: 27216155)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27216155	AVv-KLmYSS-TIFzzUH_ojax	EGFR	Erlotinib	"In a preclinical study, Tarceva (erlotinib) inhibited EGFR phosphorylation and cell proliferation in transformed cells expressing the kinase domain duplication mutant EGFR L698_S1037dup in culture (PMID: 26286086)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26286086	AVv-KPovSS-TIFzzUIGmjax	EGFR	Erlotinib	"In a preclinical study, Tarceva (erlotinib) decreased viability of transformed cells expressing EGFR T263P in culture (PMID: 17177598)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17177598	AVv-KMafSS-TIFzzUIA-jax	EGFR	Erlotinib	"In a preclinical study, Tarceva (erlotinib) decreased viability of transformed cells expressing EGFR R108K in culture (PMID: 17177598)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17177598	AVv-KP5OSS-TIFzzUIHCjax	EGFR	Erlotinib	"In a preclinical study, Tarceva (erlotinib) decreased viability of transformed cells expressing EGFR A289V in culture (PMID: 17177598)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17177598	AVv-KN1qSS-TIFzzUIDjjax	EGFR	Erlotinib	"In a preclinical study, EGFR T790M was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which occurred after repeated treatments with Tarceva (erlotinib) and resulted in drug resistance (PMID: 26341921)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-KOj-SS-TIFzzUIEyjax	EGFR	Erlotinib	"In a clinical study, three patients with lung adenocarcinoma harboring EGFR-RAD51 demonstrated partial responses as indicated by tumor regression, when treated with Tarceva (erlotinib) (PMID: 27102076)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27102076	AVv-KPUGSS-TIFzzUIGEjax	EGFR	Erlotinib	"In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Tarceva (erlotinib) (PMID: 27694386)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27694386	AVv-KNh2SS-TIFzzUIC3jax	EGFR	Erlotinib	"In a clinical case study, Tarceva (erlotinib) treatment resulted in partial response lasting for 18 months in a patient with lung adenocarcinoma harboring EGFR G719A and L861Q (PMID: 28343545)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28343545	AVv-KOBOSS-TIFzzUID3jax	EGFR	Erlotinib	"In a clinical case study, EGFR T790M was detected at the time of progression in a patient with lung adenocarcinoma harboring EGFR G719A and L861Q that was treated with Tarceva (erlotinib) (PMID: 28343545)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/28343545	AVv-KOAGSS-TIFzzUID1jax	EGFR	Erlotinib	"In a Phase III trial, no difference in disease free survival was observed in non-small cell lung cancer patients positive for Egfr treated with Tarceva (erlotinib) vs placebo in the adjuvant setting (PMID: 26324372)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26324372	AVv-KMQESS-TIFzzUIAtjax	EGFR	Erlotinib	"In a Phase III trial that supported FDA approval, Tarceva (erlotinib) improved progression-free survival in non-small cell lung cancer patients harboring EGFR exon 21 (L858R) substitution mutations (HR= 0.52) (PMID: 24868098)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24868098	AVv-KOr4SS-TIFzzUIE_jax	EGFR	Erlotinib	"In a Phase III trial that supported FDA approval, Tarceva (erlotinib) improved progression-free survival in non-small cell lung cancer patients harboring EGFR exon 19 deletions (HR= 0.27), such as EGFR E746_A750del (PMID: 24868098)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24868098	AVv-KLuBSS-TIFzzUH_0jax	EGFR	Erlotinib	"In a Phase III trial that supported FDA approval, Tarceva (erlotinib) improved progression-free survival in non-small cell lung cancer patients harboring EGFR exon 19 deletions (HR= 0.27) (PMID: 24868098)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24868098	AVv-KNJsSS-TIFzzUICOjax	EGFR	ER2 + Cisplatin	"In a preclinical study, the combination of ER2 and Platinol (cisplatin) demonstrated synergy in inhibiting tumor growth in non-small cell lung cancer cell line xenograft models with wild-type EGFR (PMID: 27040853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27040853	AVv-KPfPSS-TIFzzUIGWjax	EGFR	ER2 + Cisplatin	"In a preclinical study, the combination of ER2 and Platinol (cisplatin) demonstrated synergy in inhibiting tumor growth in a non-small cell lung cancer cell line xenograft model harboring EGFR E746_A750del (PMID: 27040853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27040853	AVv-KLvOSS-TIFzzUH_2jax	EGFR	EKI-285	"In a preclinical study, transformed cells expressing EGFR L858R and T790M demonstrated decreased sensitivity to EKI-285 (CL-387,785) in culture (PMID: 17085664)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/17085664	AVv-KOdDSS-TIFzzUIEmjax	EGFR	EKI-285	"In a preclinical study, cells expressing the double EGFR L858R/E884K mutation demonstrated increased sensitivity to inhibition of Egfr phosphorylation by EKI-285 compared to cells expressing EGFR L858R alone (PMID: 20942962)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20942962	AVv-KPA9SS-TIFzzUIFjjax	EGFR	EKI-285	"In a preclinical study, EKI-285 inhibited EGFR phosphorylation and growth of cells expressing EGFR L844V in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KQMDSS-TIFzzUIHrjax	EGFR	EKI-285	"In a preclinical study, EKI-285 inhibited EGFR phosphorylation and growth of cells expressing EGFR L718Q in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KP6bSS-TIFzzUIHEjax	EGFR	EKI-285	"In a preclinical study, EKI-285 (CL-387,785) inhibited growth of transformed cells expressing EGFR L858R in culture (PMID: 17085664)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17085664	AVv-KOqGSS-TIFzzUIE8jax	EGFR	EKI-285	"In a preclinical study, EKI-285 (CL-387,785) inhibited growth of transformed cells expressing EGFR L858R and EGFR D716Y in culture (PMID: 17085664)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17085664	AVv-KPCsSS-TIFzzUIFmjax	EGFR	EGFRBi-armed autologous activated T cells	"In a preclinical study, EGFRBi-armed autologous activated T cells demonstrated efficacy in cultured cells of a variety of EGFR positive tumor types (PMID: 16397041)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/16397041	AVv-KML3SS-TIFzzUIAnjax	EGFR	EGFRBi-armed autologous activated T cells	"In a preclinical study, EGFRBi-armed autologous activated T cells demonstrated efficacy in cultured cells and cell line mouse xenograft models of a variety of EGFR positive tumor types including pancreatic adenocarcinoma (PMID: 16397041)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/16397041	AVv-KMNHSS-TIFzzUIApjax	EGFR	EGF816	"In a preclinical study, EGF816 inhibited tumor growth in patient-derived xenograft models of non-small cell lung cancer harboring EGFR H773_V774insNPH (PMID: 26825170)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26825170	AVv-KQOlSS-TIFzzUIHvjax	EGFR	EGF816	"In a preclinical study, EGF816 inhibited growth of transformed cells expressing EGFR V769_D770insASV in culture (PMID: 26825170)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26825170	AVv-KPMwSS-TIFzzUIF4jax	EGFR	EGF816	"In a preclinical study, EGF816 inhibited growth of transformed cells expressing EGFR H773_V774insNPH in culture (PMID: 26825170)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26825170	AVv-KQN9SS-TIFzzUIHujax	EGFR	EGF816	"In a preclinical study, EGF816 inhibited growth of transformed cells expressing EGFR D770_N771insSVD in culture (PMID: 26825170)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26825170	AVv-KP86SS-TIFzzUIHIjax	EGFR	EGF816	"In a preclinical study, EGF816 inhibited growth of transformed cell lines expressing three different EGFR exon 20 insertions in culture (PMID: 26825170)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26825170	AVv-KLhiSS-TIFzzUH_hjax	EGFR	EAI045	"In a preclinical study, transformed cells over expressing EGFR that harbors concomitant L858R, T790M and I941R mutations demonstrated increased sensitivity to EAI045 induced growth inhibition in culture (PMID: 27251290)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27251290	AVv-KM7bSS-TIFzzUIB1jax	EGFR	EAI045	"In a preclinical study, EAI045 inhibited proliferation of transformed cells over expressing EGFR that harbors both L858R and T790M in culture, although at a concentration much higher than the biochemical IC50 of the compound (PMID: 27251290)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27251290	AVv-KOf1SS-TIFzzUIErjax	EGFR	EAI045	"In a preclinical study, EAI045 inhibited proliferation of transformed cells over expressing EGFR L858R in culture, although at a concentration much higher than the biochemical IC50 of the compound (PMID: 27251290)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27251290	AVv-KO2gSS-TIFzzUIFRjax	EGFR	EAI045	"In a preclinical study, EAI045 inhibited Egfr activation but not proliferation of non-small cell lung cancer cells harboring EGFR with both L858R and T790M mutations in culture (PMID: 27251290)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27251290	AVv-KOakSS-TIFzzUIEijax	EGFR	EAI045	"In a preclinical study, EAI045 inhibited Egfr activation but not proliferation of non-small cell lung cancer cells harboring EGFR L858R in culture (PMID: 27251290)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27251290	AVv-KOwrSS-TIFzzUIFHjax	EGFR	EAI045	"In a preclinical study, EAI045 did not inhibit proliferation of transformed cells over expressing EGFR that harbors both exon 19 deletion and T790M in culture (PMID: 27251290)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27251290	AVv-KNbqSS-TIFzzUICsjax	EGFR	EAI045	"In a preclinical study, EAI045 did not inhibit proliferation of transformed cells harboring wild type EGFR in culture (PMID: 27251290)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27251290	AVv-KPcMSS-TIFzzUIGRjax	EGFR	Decitabine + Gefitinib	"In a preclinical study, the combined treatment of DNA methyltransferase inhibitor decitabine and EGFR inhibitor gefitinib on EGFR wild-type colon cancer cell lines resulted in synergistic effects in inhibiting cell growth and migration (PMID: 24874286)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24874286	AVv-KPehSS-TIFzzUIGVjax	EGFR	Dacomitinib	"In a preclinical study, transformed cells expressing an EGFR D770delinsGY/EGFR C797S double mutation demonstrated resistance to dacomitinib in culture (PMID: 28363995)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KMbDSS-TIFzzUIA_jax	EGFR	Dacomitinib	"In a preclinical study, transformed cells expressing EGFR Y764_V765insHH demonstrated resistance to dacomitinib in culture (PMID: 28363995)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KPl9SS-TIFzzUIGhjax	EGFR	Dacomitinib	"In a preclinical study, transformed cells expressing EGFR S768_D770dup (also referred to as D770_N771insSVD) demonstrated resistance to dacomitinib in culture (PMID: 28363995)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KM5sSS-TIFzzUIByjax	EGFR	Dacomitinib	"In a preclinical study, transformed cells expressing EGFR G719A demonstrated increased sensitivity to second-generation EGFR inhibitors including Dacomitinib in culture, when compared to first and third-generation inhibitors (PMID: 26206867)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206867	AVv-KN-9SS-TIFzzUIDzjax	EGFR	Dacomitinib	"In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated increased sensitivity to second-generation EGFR inhibitors including Dacomitinib in culture, when compared to first and third-generation inhibitors (PMID: 26206867)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206867	AVv-KMyRSS-TIFzzUIBmjax	EGFR	Dacomitinib	"In a preclinical study, transformed cells expressing EGFR E709K demonstrated increased sensitivity to second-generation EGFR inhibitors including Dacomitinib in culture, when compared to first and third-generation inhibitors (PMID: 26206867)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206867	AVv-KM_hSS-TIFzzUIB8jax	EGFR	Dacomitinib	"In a preclinical study, transformed cells expressing EGFR A767_V769dup (also referred to as V769_D770insASV) demonstrated resistance to dacomitinib in culture (PMID: 28363995)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KPZWSS-TIFzzUIGMjax	EGFR	Dacomitinib	"In a preclinical study, patient-derived EGFR amplified glioblastoma cells harboring PTEN loss demonstrated reduced sensitivity to Dacomitinib induced growth inhibition in culture and in xenograft models (PMID: 25939761)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25939761	AVv-KKx9SS-TIFzzUH-Jjax	EGFR	Dacomitinib	"In a preclinical study, dacomitinib inhibited growth of transformed cells expressing EGFR E709_T710delinsD and EGFR L792F in culture (PMID: 27913578)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27913578	AVv-KM39SS-TIFzzUIBvjax	EGFR	Dacomitinib	"In a preclinical study, dacomitinib inhibited EGFR phosphorylation and growth of transformed cells expressing EGFR D770delinsGY in culture (PMID: 28363995)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KMxoSS-TIFzzUIBljax	EGFR	Dacomitinib	"In a preclinical study, dacomitinib inhibited EGFR phosphorylation and growth of a patient-derived lung adenocarcinoma cell line harboring EGFR P772_H773insPNP in culture (PMID: 28363995)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KP_WSS-TIFzzUIHMjax	EGFR	Dacomitinib	"In a preclinical study, dacomitinib inhibited EGFR phosphorylation and growth of a patient-derived lung adenocarcinoma cell line harboring EGFR N771_H773dup (also referred to as H773_V774insNPH) in culture (PMID: 28363995)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KMYHSS-TIFzzUIA6jax	EGFR	Dacomitinib	"In a preclinical study, acquisition of EGFR T790M was associated with resistance to dacomitinib in transformed cells expressing EGFR D770delinsGY (PMID: 28363995)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KMxDSS-TIFzzUIBkjax	EGFR	Dacomitinib	"In a preclinical study, Dacomitinib inhibited Egfr signaling and survival of patient-derived EGFR amplified glioblastoma cells in culture and in intracranial xenograft models (PMID: 25939761)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25939761	AVv-KKz4SS-TIFzzUH-Mjax	EGFR	Dacomitinib	"In a preclinical study, Dacomitinib did not inhibit Egfr signaling or survival of patient-derived EGFR wild-type glioblastoma cells in culture and in intracranial xenograft models (PMID: 25939761)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/25939761	AVv-KPi7SS-TIFzzUIGcjax	EGFR	Dacomitinib	"In a Phase II clinical trial, progression-free survival at 4 months was 95.5% in patients with EGFR-mutant non-small cell lung cancer following treatment with dacomitinib, compared to 76.8% in the overall treatment population (PMID: 25456362)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25456362	AVv-KONaSS-TIFzzUIEMjax	EGFR	Dacomitinib	"In Phase III clinical trials, patients with NSCLC tumors harboring an EGFR G719X (X=A, C, or S) mutation responded to EGFR tyrosine kinase inhibitors including dacomitinib (PMID: 24857124)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24857124	AVv-KQDoSS-TIFzzUIHTjax	EGFR	Cetuximab + EAI045	"In a preclinical study, combination of EAI045 and Erbitux (cetuximab) did not inhibit proliferation of transformed cells over expressing EGFR that harbors both exon 19 deletion and T790M in culture (PMID: 27251290)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27251290	AVv-KNbMSS-TIFzzUICrjax	EGFR	Cetuximab + EAI045	"In a preclinical study, EAI045 and Erbitux (cetuximab) synergistically inhibited proliferation of transformed cells over expressing EGFR that harbors concomitant C797S, L858R and T790M mutations in culture (PMID: 27251290)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27251290	AVv-KMs5SS-TIFzzUIBdjax	EGFR	Cetuximab + EAI045	"In a preclinical study, EAI045 and Erbitux (cetuximab) synergistically inhibited proliferation of transformed cells over expressing EGFR that harbors both L858R and T790M in culture (PMID: 27251290)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27251290	AVv-KOT_SS-TIFzzUIEXjax	EGFR	Cetuximab + EAI045	"In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment induced tumor regression in an EGFR L858R/T790M/C797S-mutant-driven lung cancer mouse model (PMID: 27251290)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27251290	AVv-KMqmSS-TIFzzUIBZjax	EGFR	Cetuximab + EAI045	"In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment induced tumor regression in an EGFR L858R/T790M-mutant-driven lung cancer mouse model (PMID: 27251290)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27251290	AVv-KObNSS-TIFzzUIEjjax	EGFR	Cetuximab + EAI045	"In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment did not induced response in an EGFR exon 19 deletion/T790M-driven lung cancer mouse model (PMID: 27251290)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27251290	AVv-KNaHSS-TIFzzUICpjax	EGFR	Cetuximab	"In preclinical studies, Erbitux (cetuximab) promoted tumor growth inhibition in several patient-derived xenograft models of gastric cancers with EGFR amplification (PMID: 24141978)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24141978	AVv-KK2nSS-TIFzzUH-Qjax	EGFR	Cetuximab	"In a preclinical study, transformed cells expressing EGFR-RAD51 demonstrated sensitivity to treatment with Erbitux (cetuximab) in culture, resulting in decreased cell viability (PMID: 27102076)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27102076	AVv-KPS3SS-TIFzzUIGCjax	EGFR	Cetuximab	"In a preclinical study, head and neck squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Erbitux (cetuximab) in a cell viability assay (PMID: 27207775)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27207775	AVv-KK35SS-TIFzzUH-Sjax	EGFR	Cetuximab	"In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Erbitux (cetuximab) in a cell viability assay (PMID: 27207775)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27207775	AVv-KK98SS-TIFzzUH-bjax	EGFR	Cetuximab	"In a preclinical study, esophageal squamous cell carcinoma cells harboring EGFR L861Q demonstrated resistance to treatment with Erbitux (cetuximab) in a cell viability assay (PMID: 27207775)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27207775	AVv-KPUoSS-TIFzzUIGFjax	EGFR	Cetuximab	"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Erbitux (cetuximab) in culture (PMID: 27312529)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-KPzXSS-TIFzzUIG4jax	EGFR	Cetuximab	"In a preclinical study, colorectal cancer cell lines over expressing EGFR S492R were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KQBNSS-TIFzzUIHPjax	EGFR	Cetuximab	"In a preclinical study, colorectal cancer cell lines over expressing EGFR S464L were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KPsxSS-TIFzzUIGtjax	EGFR	Cetuximab	"In a preclinical study, colorectal cancer cell lines over expressing EGFR K467T were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KP21SS-TIFzzUIG-jax	EGFR	Cetuximab	"In a preclinical study, colorectal cancer cell lines over expressing EGFR I491M were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KMurSS-TIFzzUIBgjax	EGFR	Cetuximab	"In a preclinical study, colorectal cancer cell lines over expressing EGFR G465R were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KPtXSS-TIFzzUIGujax	EGFR	Cetuximab	"In a preclinical study, colorectal cancer cell lines over expressing EGFR G465E were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KPG8SS-TIFzzUIFujax	EGFR	Cetuximab	"In a preclinical study, Erbitux (cetuximab) inhibited tumor growth in mouse lung adenocarcinoma models expressing EGFR L858R (PMID: 24063894)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24063894	AVv-KO0KSS-TIFzzUIFNjax	EGFR	Cetuximab	"In a preclinical study, Erbitux (cetuximab) inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26843189	AVv-KNzcSS-TIFzzUIDfjax	EGFR	Cetuximab	"In a preclinical study, Erbitux (cetuximab) inhibited growth of transformed cells expressing a EGFR L858R/T790M/C797S triple mutation in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KMrxSS-TIFzzUIBbjax	EGFR	Cetuximab	"In a preclinical study, Erbitux (cetuximab) did not inhibit growth of transformed cells expressing a EGFR E746_A750del/T790M/C797S triple mutation in culture (PMID: 25948633)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL7zSS-TIFzzUIAMjax	EGFR	Cetuximab	"In a preclinical study, Erbitux (cetuximab) did not efficiently inhibit Egfr phosphorylation in transformed cells over expressing T34_A289del in culture (PMID: 27216155)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27216155	AVv-KLntSS-TIFzzUH_qjax	EGFR	Cetuximab	"In a clinical study, a colorectal cancer patient harboring EGFR amplification, BRAF V600E, and EGFR S492R demonstrated resistance to Erbitux (cetuximab) (PMID: 22270724)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22270724	AVv-KKmfSS-TIFzzUH93jax	EGFR	Cetuximab	"In a clinical study, a colorectal cancer patient harboring EGFR amplification and EGFR S492R demonstrated resistance to Erbitux (cetuximab) (PMID: 22270724)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22270724	AVv-KKzRSS-TIFzzUH-Ljax	EGFR	CUDC-101	"In a preclinical study, CUDC-101 inhibited the growth of lung cancer cells expressing EGFR T790M (PMID: 20388807)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20388807	AVv-KQPJSS-TIFzzUIHwjax	EGFR	CO1686 + Crizotinib	"In a preclinical study, the combination of Rociletinib (CO-1686) and Xalkori (crizotinib) overcame resistance to Rociletinib (CO-1686) in non-small cell lung cancer cell line harboring EGFR E746_A750del and MET amplification in culture (PMID: 27283993)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27283993	AVv-KMGbSS-TIFzzUIAejax	EGFR	CO1686	"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR Q791R triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KN21SS-TIFzzUIDljax	EGFR	CO1686	"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L844V triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KOSwSS-TIFzzUIEVjax	EGFR	CO1686	"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KO-lSS-TIFzzUIFfjax	EGFR	CO1686	"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR L844V double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KOo3SS-TIFzzUIE6jax	EGFR	CO1686	"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR L718Q double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KPEYSS-TIFzzUIFpjax	EGFR	CO1686	"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR C797S double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KMeDSS-TIFzzUIBEjax	EGFR	CO1686	"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR Q791R triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL7QSS-TIFzzUIALjax	EGFR	CO1686	"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL-wSS-TIFzzUIARjax	EGFR	CO1686	"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL5ASS-TIFzzUIAHjax	EGFR	CO1686	"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR L844V double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KLy0SS-TIFzzUH_8jax	EGFR	CO1686	"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR L718Q double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL88SS-TIFzzUIAOjax	EGFR	CO1686	"In a preclinical study, transformed cells expressing EGFR G719A demonstrated decreased sensitivity to third-generation EGFR inhibitors including Rociletinib (CO-1686) in culture, when compared to second-generation inhibitors (PMID: 26206867)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26206867	AVv-KN5PSS-TIFzzUIDpjax	EGFR	CO1686	"In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated decreased sensitivity to third-generation EGFR inhibitors including Rociletinib (CO-1686) in culture, when compared to second-generation inhibitors (PMID: 26206867)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26206867	AVv-KM2qSS-TIFzzUIBtjax	EGFR	CO1686	"In a preclinical study, transformed cells expressing EGFR E709K demonstrated decreased sensitivity to third-generation EGFR inhibitors including Rociletinib (CO-1686) in culture, when compared to second-generation inhibitors (PMID: 26206867)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26206867	AVv-KM8tSS-TIFzzUIB3jax	EGFR	CO1686	"In a preclinical study, expression of an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation conferred resistance to Rociletinib (CO-1686) in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL_4SS-TIFzzUIATjax	EGFR	CO1686	"In a preclinical study, expression of an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation conferred resistance to Rociletinib (CO-1686) in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL5mSS-TIFzzUIAIjax	EGFR	CO1686	"In a preclinical study, emergence of MET amplification was associated with resistance to Rociletinib (CO1686) in non-small cell lung cancer cell line xenograft models harboring EGFR E746_A750del (PMID: 27283993)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27283993	AVv-KMF2SS-TIFzzUIAdjax	EGFR	CO1686	"In a preclinical study, cells expressing an EGFR exon 20 insertion demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 24065731)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24065731	AVv-KLiMSS-TIFzzUH_ijax	EGFR	CO1686	"In a preclinical study, cells expressing an EGFR E746_A750del/EGFR C797S double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KLz1SS-TIFzzUH_-jax	EGFR	CO1686	"In a preclinical study, a non-small cell lung cancer cell line harboring EGFR DelE746_A750 and expressing EGFR DelE746_A750/C797S demonstrated resistance to growth inhibition by Rociletinib (CO1686) in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL05SS-TIFzzUIAAjax	EGFR	CO1686	"In a preclinical study, Rociletinib (CO-1686) inhibited tumor growth in xenograft models of human non-small cell lung cancer cell lines harboring EGFR activating mutations (PMID: 24065731)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24065731	AVv-KOIgSS-TIFzzUIEEjax	EGFR	CO1686	"In a preclinical study, Rociletinib (CO-1686) inhibited tumor growth in human non-small cell lung cancer cell line and patient-derived xenograft models of non-small cell lung cancer harboring both EGFR L858R and EGFR T790M (PMID: 24065731)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24065731	AVv-KOhESS-TIFzzUIEtjax	EGFR	CO1686	"In a preclinical study, Rociletinib (CO-1686) did not result in tumor regression or a survival benefit when treating a NSCLC cell line xenograft model harboring an EGFR exon 19 deletion (PMID: 27435396)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27435396	AVv-KNMySS-TIFzzUICTjax	EGFR	CO1686	"In a preclinical study, EGFR C797S conferred resistance to growth inhibition by Rociletinib (CO-1686) when expressed on the same allele as an EGFR exon 19 deletion mutation and T790M in transformed cells in culture (PMID: 25939061)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25939061	AVv-KMemSS-TIFzzUIBFjax	EGFR	CO1686	"In a preclinical study, EGFR C797S conferred resistance to growth inhibition by Rociletinib (CO-1686) when expressed on the same allele as EGFR L858R and T790M in transformed cells in culture (PMID: 25939061)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25939061	AVv-KMsWSS-TIFzzUIBcjax	EGFR	CO1686	"In a preclinical study, CO-1686 demonstrated efficacy in treating transgenic mouse models of lung adenocarcinoma expressing EGFR L858R (PMID: 24065731)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24065731	AVv-KOqvSS-TIFzzUIE9jax	EGFR	CO1686	"In a Phase Ib/II trial, treatment with Rociletinib (CO-1686) resulted in an objective response rate of 64.3% (18/28) in non-small cell lung cancer patients harboring both EGFR exon 19 deletions and EGFR T790M (PMID: 25923550)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25923550	AVv-KNV-SS-TIFzzUICijax	EGFR	CO1686	"In a Phase Ib/II trial, treatment with Rociletinib (CO-1686) resulted in an objective response rate of 53.3% (8/15) in non-small cell lung cancer patients harboring both EGFR L858R and EGFR T790M (PMID: 25923550)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25923550	AVv-KOhpSS-TIFzzUIEujax	EGFR	CO1686	"In a Phase Ib/II trial, treatment with Rociletinib (CO-1686) resulted in a response rate of 59% (27/46) and a disease control rate of 93% (43/46) in non-small cell lung cancer patients harboring EGFR T790M (PMID: 25923550)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25923550	AVv-KQYVSS-TIFzzUIIAjax	EGFR	BMS-754807 + Dacomitinib	"In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFRvIII in culture (PMID: 26561558)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26561558	AVv-KOECSS-TIFzzUID8jax	EGFR	BMS-754807 + Dacomitinib	"In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26561558	AVv-KKotSS-TIFzzUH96jax	EGFR	BMS-754807 + Dacomitinib	"In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification and EGFR G719A in culture (PMID: 26561558)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26561558	AVv-KLINSS-TIFzzUH-sjax	EGFR	BMS-754807 + Dacomitinib	"In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR (A289T, EGFRvIII) and PTEN (N69D, I253N) mutations in culture (PMID: 26561558)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26561558	AVv-KNoySS-TIFzzUIDCjax	EGFR	BGB-283	"In a preclinical study, BGB-283 inhibited proliferation of transformed cells over expressing both EGFR exon 19 deletion mutation and T790M in culture (PMID: 26208524)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26208524	AVv-KNZGSS-TIFzzUICnjax	EGFR	BGB-283	"In a preclinical study, BGB-283 inhibited proliferation of transformed cells over expressing EGFR exon 19 deletion mutation in culture (PMID: 26208524)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26208524	AVv-KNQbSS-TIFzzUICZjax	EGFR	BGB-283	"In a preclinical study, BGB-283 inhibited proliferation of transformed cells over expressing EGFR L858R in culture (PMID: 26208524)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26208524	AVv-KO14SS-TIFzzUIFQjax	EGFR	BGB-283	"In a preclinical study, BGB-283 inhibited proliferation of Egfr over expressing lung cancer cells in culture (PMID: 26208524)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26208524	AVv-KNtESS-TIFzzUIDUjax	EGFR	BGB-283	"In a preclinical study, BGB-283 inhibited Egfr phosphorylation in Egfr over expressing squamous cell carcinoma cells in culture, and inhibited tumor growth in cell line xenograft models (PMID: 26208524)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26208524	AVv-KNuzSS-TIFzzUIDXjax	EGFR	BGB-283	"In a preclinical study, BGB-283 inhibited Egfr phosphorylation and cell proliferation in lung carcinoma cells harboring EGFR E746_A750del in culture, and resulted in tumor regression in cell line xenograft models (PMID: 26208524)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26208524	AVv-KLtdSS-TIFzzUH_zjax	EGFR	BEZ235	"In a preclinical study, BEZ235 suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with an EGFR T790M mutation (PMID: 24939055)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24939055	AVv-KQb-SS-TIFzzUIIGjax	EGFR	Afatinib + Cetuximab	"In a preclinical study, KRAS G12V was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-KO_ySS-TIFzzUIFhjax	EGFR	Afatinib + Cetuximab	"In a preclinical study, KRAS G12R was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-KO6pSS-TIFzzUIFYjax	EGFR	Afatinib + Cetuximab	"In a preclinical study, KRAS G12D was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-KO7LSS-TIFzzUIFZjax	EGFR	Afatinib + Cetuximab	"In a preclinical study, EGFR T790M was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed  after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26341921	AVv-KOYLSS-TIFzzUIEejax	EGFR	Afatinib	"In preclinical in vitro assays, EGFR G719S was demonstrated to stabilize the active conformation of Egfr and sensitize the protein to Gilotrif (afatinib) (PMID: 17349580)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17349580	AVv-KQHrSS-TIFzzUIHkjax	EGFR	Afatinib	"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in stable disease in a non-small cell lung carcinoma patient harboring EGFR V769L (PMID: 26354527)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26354527	AVv-KPoJSS-TIFzzUIGljax	EGFR	Afatinib	"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in stable disease in a non-small cell lung carcinoma patient harboring EGFR S768I (PMID: 26354527)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26354527	AVv-KPQeSS-TIFzzUIF-jax	EGFR	Afatinib	"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in progressive disease in a non-small cell lung carcinoma patient carrying an EGFR R776H mutation (PMID: 26354527)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26354527	AVv-KP38SS-TIFzzUIHAjax	EGFR	Afatinib	"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in progressive disease in a non-small cell lung carcinoma patient carrying an EGFR A702S mutation (PMID: 26354527)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26354527	AVv-KMtgSS-TIFzzUIBejax	EGFR	Afatinib	"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in progressive disease in 50% (1/2) of non-small cell lung carcinoma patients carrying an EGFR A750V mutation (PMID: 26354527)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26354527	AVv-KLJzSS-TIFzzUH-vjax	EGFR	Afatinib	"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 50% (2/4) and stable disease in 50% (2/4) of non-small cell lung carcinoma patients carrying an EGFR E709 mutation (PMID: 26354527)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26354527	AVv-KM63SS-TIFzzUIB0jax	EGFR	Afatinib	"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 50% (1/2) and stable disease in 50% (1/2) of non-small cell lung carcinoma patients carrying an EGFR exon 19 deletion and insertion (PMID: 26354527)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26354527	AVv-KNhRSS-TIFzzUIC2jax	EGFR	Afatinib	"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 33% (2/6), stable disease in 50% (3/6), and progressive disease in 17% (1/6) of non-small cell lung carcinoma patients harboring EGFR L861Q (PMID: 26354527)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26354527	AVv-KPX1SS-TIFzzUIGKjax	EGFR	Afatinib	"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 100% (2 of 2) of non-small cell lung carcinoma patients carrying EGFR L858M mutation (PMID: 26354527)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26354527	AVv-KQI2SS-TIFzzUIHmjax	EGFR	Afatinib	"In a preclinical study, transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling in culture (PMID: 25964297)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25964297	AVv-KMiQSS-TIFzzUIBLjax	EGFR	Afatinib	"In a preclinical study, transformed cells expressing an EGFR D770delinsGY/EGFR T790M double mutation demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KMwcSS-TIFzzUIBjjax	EGFR	Afatinib	"In a preclinical study, transformed cells expressing an EGFR D770delinsGY/EGFR C797S double mutation demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KMbsSS-TIFzzUIBAjax	EGFR	Afatinib	"In a preclinical study, transformed cells expressing EGFR-RAD51 demonstrated sensitivity to treatment with Gilotrif (afatinib) in culture, resulting in decreased cell viability and inhibition of downstream MAPK and PI3K signaling (PMID: 27102076)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27102076	AVv-KPSQSS-TIFzzUIGBjax	EGFR	Afatinib	"In a preclinical study, transformed cells expressing EGFR exon 20 insertions, including EGFR V769_D770insASV (also known as A767_V769dupASV), demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24353160	AVv-KPNRSS-TIFzzUIF5jax	EGFR	Afatinib	"In a preclinical study, transformed cells expressing EGFR L858R and EGFR L792F demonstrated decreased sensitivity to Gilotrif (afatinib) in culture compared to cells expressing EGFR L858R alone (PMID: 27913578)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27913578	AVv-KN1JSS-TIFzzUIDijax	EGFR	Afatinib	"In a preclinical study, transformed cells expressing EGFR G719A demonstrated increased sensitivity to second-generation EGFR inhibitors including Gilotrif (afatinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206867	AVv-KN8FSS-TIFzzUIDujax	EGFR	Afatinib	"In a preclinical study, transformed cells expressing EGFR E746_A750del and EGFR L792F demonstrated decreased sensitivity to Gilotrif (afatinib) in culture compared to cells expressing E746_A750del alone (PMID: 27913578)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27913578	AVv-KMFKSS-TIFzzUIAcjax	EGFR	Afatinib	"In a preclinical study, transformed cells expressing EGFR E709K demonstrated increased sensitivity to second-generation EGFR inhibitors including Gilotrif (afatinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206867	AVv-KM-_SS-TIFzzUIB7jax	EGFR	Afatinib	"In a preclinical study, transformed cells expressing EGFR D770_N771insSVD, demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24353160	AVv-KP9iSS-TIFzzUIHJjax	EGFR	Afatinib	"In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25964297	AVv-KMj9SS-TIFzzUIBOjax	EGFR	Afatinib	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified NRAS in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KNk7SS-TIFzzUIC8jax	EGFR	Afatinib	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified KRAS in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KNRtSS-TIFzzUICbjax	EGFR	Afatinib	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of EGFR T790M in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KNaoSS-TIFzzUICqjax	EGFR	Afatinib	"In a preclinical study, non-small cell lung cancer cells harboring EGFR A763_Y764insFQEA mutations demonstrated sensitivity to Gilotrif (afatinib) in cell culture, in contrast to other EGFR exon 20 insertion mutations (PMID: 24353160)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24353160	AVv-KOQ8SS-TIFzzUIESjax	EGFR	Afatinib	"In a preclinical study, non-small cell carcinoma cell lines harboring EGFR exon 20 insertions, including EGFR H773_V774insH, demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24353160	AVv-KLOISS-TIFzzUH_Bjax	EGFR	Afatinib	"In a preclinical study, non-small cell carcinoma cell lines harboring EGFR exon 20 insertions demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24353160	AVv-KLgSSS-TIFzzUH_fjax	EGFR	Afatinib	"In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25964297	AVv-KMjXSS-TIFzzUIBNjax	EGFR	Afatinib	"In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Gilotrif (afatinib) in a cell viability assay (PMID: 27207775)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27207775	AVv-KLGhSS-TIFzzUH-pjax	EGFR	Afatinib	"In a preclinical study, colorectal cancer cells positive for EGFR and ERBB2 (HER2) had decreased growth upon Gilotrif (afatinib) treatment (PMID: 21617858)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21617858	AVv-KMVCSS-TIFzzUIA1jax	EGFR	Afatinib	"In a preclinical study, acquisition of EGFR T790M was associated with resistance to Gilotrif (afatinib) in transformed cells expressing EGFR G719A in culture (PMID: 27913578)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27913578	AVv-KN_hSS-TIFzzUID0jax	EGFR	Afatinib	"In a preclinical study, acquisition of EGFR L792F was associated with resistance to Gilotrif in transformed cells expressing EGFR E709_T710delinsD in culture (PMID: 27913578)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27913578	AVv-KM3TSS-TIFzzUIBujax	EGFR	Afatinib	"In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling and cell growth in lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25964297	AVv-KMo2SS-TIFzzUIBWjax	EGFR	Afatinib	"In a preclinical study, Gilotrif (afatinib) treatment resulted in apoptotic induction in esophagus squamous carcinoma cells harboring EGFR L861Q in culture and inhibited tumor growth in cell line xenograft models (PMID: 27207775)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27207775	AVv-KPVPSS-TIFzzUIGGjax	EGFR	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR L858R/EGFR L844V double mutation in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KOneSS-TIFzzUIE4jax	EGFR	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR L858R/EGFR L718Q double mutation in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KPE3SS-TIFzzUIFqjax	EGFR	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR L858R/EGFR C797S double mutation in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KMdgSS-TIFzzUIBDjax	EGFR	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR L844V double mutation in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KLzVSS-TIFzzUH_9jax	EGFR	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR L718Q double mutation in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL9lSS-TIFzzUIAPjax	EGFR	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR C797S double mutation in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL1dSS-TIFzzUIABjax	EGFR	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited growth of a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL2wSS-TIFzzUIADjax	EGFR	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25964297	AVv-KNYjSS-TIFzzUICmjax	EGFR	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25964297	AVv-KMoRSS-TIFzzUIBVjax	EGFR	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and growth of cells expressing EGFR L844V in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KQMsSS-TIFzzUIHsjax	EGFR	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and growth of cells expressing EGFR L718Q in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KP7CSS-TIFzzUIHFjax	EGFR	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and growth of a patient-derived lung adenocarcinoma cell line harboring EGFR P772_H773insPNP in culture (PMID: 28363995)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KP-wSS-TIFzzUIHLjax	EGFR	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and growth of a patient-derived lung adenocarcinoma cell line harboring EGFR N771_H773dup (also referred to as H773_V774insNPH) in culture (PMID: 28363995)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28363995	AVv-KMXkSS-TIFzzUIA5jax	EGFR	Afatinib	"In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and cell proliferation in transformed cells expressing kinase domain duplication mutant EGFR L698_S1037dup in culture (PMID: 26286086)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26286086	AVv-KPp5SS-TIFzzUIGojax	EGFR	Afatinib	"In a clinical study, second-site EGFR T790M mutations were detected in 47.6% (20/42) of lung adenocarcinoma patients with acquired resistance to Gilotrif (afatinib) (PMID: 26862733)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26862733	AVv-KQRfSS-TIFzzUIH0jax	EGFR	Afatinib	"In a clinical study, a patient with EGFR L698_S1037dup expressing lung adenocarcinoma had a partial response after two cycles of Gilotrif (afatinib) after failing first line chemotherapy (PMID: 26286086)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26286086	AVv-KPqcSS-TIFzzUIGpjax	EGFR	Afatinib	"In a clinical case study, treatment with Gilotrif (afatinib) in a lung adenocarcinoma patient harboring EGFR E709_T710delinsD resulted in tumor shrinkage, while prior treatment with Tarceva (erlotinib) had achieved stable disease (PMID: 26206867)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206867	AVv-KM1_SS-TIFzzUIBsjax	EGFR	Afatinib	"In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Gilotrif (afatinib) (PMID: 27694386)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27694386	AVv-KNiYSS-TIFzzUIC4jax	EGFR	Afatinib	"In a clinical case study, a patient with EGFR L698_S1037dup expressing lung adenocarcinoma had a partial response after two cycles of Gilotrif (afatinib), but subsequently developed resistance to the therapy after amplification of EGFR (PMID: 26286086)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26286086	AVv-KKwtSS-TIFzzUH-Hjax	EGFR	Afatinib	"In a Phase III study that supported FDA approval, Gilotrif (afatinib) treatment resulted in increased progression-free survival in NSCLC patients with EGFR exon 19 deletions (PMID: 23816960, PMID: 23991291)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23991291	AVv-KNHZSS-TIFzzUICKjax	EGFR	Afatinib	"In a Phase III study that supported FDA approval, Gilotrif (afatinib) treatment resulted in increased progression-free survival in NSCLC patients with EGFR L858R mutations (PMID: 23816960, PMID: 23991291)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23816960	AVv-KOu7SS-TIFzzUIFEjax	EGFR	Afatinib	"In a Phase II clinical trial, three urothelial carcinoma  patients with EGFR amplification in the absence of other ERBB family member alterations, received no benefit from Gilotrif (afatinib) therapy (PMID: 27044931)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27044931	AVv-KLCRSS-TIFzzUH-ijax	EGFR	Afatinib	"In Phase III trials, non-small cell lung carcinoma patients harboring EGFR G719X mutations (G719A, C, or S) demonstrated a response rate of 78% (14/18) following treatment with Gilotrif (afatinib) (PMID: 24790411)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24790411	AVv-KQJdSS-TIFzzUIHnjax	EGFR	Afatinib	"In Phase III trials, non-small cell lung carcinoma patients harboring EGFR G719X mutations (G719A, C, or S) demonstrated a response rate of 78% (14/18) following treatment with Gilotrif (afatinib) (PMID: 24790411)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23344264	AVv-KQG4SS-TIFzzUIHjjax	EGFR	AZD9291 + Selumetinib	"In a preclinical study, the combination of Tagrisso (osimertinib) and Selumetinib inhibited growth of lung adenocarcinoma tumors driven by EGFR L858R that had developed resistance through continued exposure to Tagrisso (osimertinib) (PMID: 25870145)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KOxQSS-TIFzzUIFIjax	EGFR	AZD9291	"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KO_MSS-TIFzzUIFgjax	EGFR	AZD9291	"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR L718Q double mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KPFWSS-TIFzzUIFrjax	EGFR	AZD9291	"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR C797S double mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KMcUSS-TIFzzUIBBjax	EGFR	AZD9291	"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL6ISS-TIFzzUIAJjax	EGFR	AZD9291	"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR C797S double mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL3QSS-TIFzzUIAEjax	EGFR	AZD9291	"In a preclinical study, transformed cells expressing EGFR-RAD51 demonstrated some sensitivity to treatment with Tagrisso (osimertinib) in culture, resulting in decreased cell viability (PMID: 27102076)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27102076	AVv-KPTeSS-TIFzzUIGDjax	EGFR	AZD9291	"In a preclinical study, transformed cells expressing EGFR G719A demonstrated decreased sensitivity to third-generation EGFR inhibitors including Tagrisso (AZD9291) in culture, when compared to second-generation inhibitors (PMID: 26206867)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26206867	AVv-KN8oSS-TIFzzUIDvjax	EGFR	AZD9291	"In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated decreased sensitivity to third-generation EGFR inhibitors including Tagrisso (AZD9291) in culture, when compared to second-generation inhibitors (PMID: 26206867)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26206867	AVv-KMzhSS-TIFzzUIBojax	EGFR	AZD9291	"In a preclinical study, transformed cells expressing EGFR E709K demonstrated decreased sensitivity to third-generation EGFR inhibitors including Tagrisso (AZD9291) in culture, when compared to second-generation inhibitors (PMID: 26206867)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26206867	AVv-KM9-SS-TIFzzUIB5jax	EGFR	AZD9291	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KNflSS-TIFzzUICzjax	EGFR	AZD9291	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M and amplified KRAS were resistant to Tagrisso (osimertinib) treatment in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KNdVSS-TIFzzUICvjax	EGFR	AZD9291	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KNmGSS-TIFzzUIC-jax	EGFR	AZD9291	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified KRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KNSYSS-TIFzzUICcjax	EGFR	AZD9291	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KND8SS-TIFzzUICEjax	EGFR	AZD9291	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12V were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KNRFSS-TIFzzUICajax	EGFR	AZD9291	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KNgtSS-TIFzzUIC1jax	EGFR	AZD9291	"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K were resistant to Tagrisso (osimertinib) AZD9291 treatment in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KNebSS-TIFzzUICxjax	EGFR	AZD9291	"In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25870145	AVv-KPF3SS-TIFzzUIFsjax	EGFR	AZD9291	"In a preclinical study, expression of EGFR C797S on the same allele as both EGFR L858R and T790M in transformed cell lines resulted in resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25939061)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25939061	AVv-KMrNSS-TIFzzUIBajax	EGFR	AZD9291	"In a preclinical study, expression of EGFR C797S on the same allele as an EGFR exon 19 deletion and EGFR T790M in transformed cell lines resulted in resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25939061)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25939061	AVv-KMlHSS-TIFzzUIBQjax	EGFR	AZD9291	"In a preclinical study, cells expressing an EGFR exon 20 insertion mutation were resistant to AZD9291 in culture (PMID: 24893891)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24893891	AVv-KLi4SS-TIFzzUH_jjax	EGFR	AZD9291	"In a preclinical study, a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S demonstrated resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25948633)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL0ZSS-TIFzzUH__jax	EGFR	AZD9291	"In a preclinical study, a human NSCLC cell line xenograft model with brain metastases harboring an EGFR exon 19 deletion demonstrated tumor regression and improved survival benefit when treated with Tagrisso (osimertinib) (PMID: 27435396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27435396	AVv-KNFESS-TIFzzUICGjax	EGFR	AZD9291	"In a preclinical study, Tagrisso (osimertinib) inhibited EGFR phosphorylation and cell proliferation in transformed cells expressing kinase domain duplication mutant EGFR L698_S1037dup in culture (PMID: 26286086)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26286086	AVv-KPpWSS-TIFzzUIGnjax	EGFR	AZD9291	"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR L858R/EGFR T790M/EGFR Q791R triple mutation in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KN3jSS-TIFzzUIDmjax	EGFR	AZD9291	"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L844V triple-mutation in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KOTWSS-TIFzzUIEWjax	EGFR	AZD9291	"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR L858R/EGFR L844V double mutation in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KOoNSS-TIFzzUIE5jax	EGFR	AZD9291	"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR Q791R triple mutation in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL6qSS-TIFzzUIAKjax	EGFR	AZD9291	"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL-KSS-TIFzzUIAQjax	EGFR	AZD9291	"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR L844V double mutation in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KLyPSS-TIFzzUH_7jax	EGFR	AZD9291	"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR L718Q double mutation in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL8ZSS-TIFzzUIANjax	EGFR	AZD9291	"In a preclinical study, AZD9291 inhibited growth of non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M and ectopically expressing an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL_VSS-TIFzzUIASjax	EGFR	AZD9291	"In a preclinical study, AZD9291 inhibited growth of non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M and ectopically expressing an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation in culture (PMID: 25948633)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25948633	AVv-KL4dSS-TIFzzUIAGjax	EGFR	AZD9291	"In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M developed resistance to Tagrisso (osimertinib), and was found to have acquired high level amplification of MET (PMID: 27393507)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27393507	AVv-KNBPSS-TIFzzUIB_jax	EGFR	AZD9291	"In a Phase I trial, treatment with AZD9291 resulted in a response rate of 11% (2/19) in NSCLC patients harboring EGFR L858R without EGFR T790M (PMID: 25923549)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-KOzgSS-TIFzzUIFMjax	EGFR	AZD9291	"In a Phase I trial, non-small cell lung cancer patients harboring EGFR exon 19 deletions demonstrated a response rate of 30% (8/27) following treatment with Tagrisso (osimertinib) (PMID: 25923549)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-KNEcSS-TIFzzUICFjax	EGFR	AZD9291	"In a Phase I trial, AZD9291 treatment resulted in an objective response rate of 61% (78/127) and a disease control rate of 95% (121/127) in NSCLC patients harboring EGFR T790M mutations (PMID: 25923549)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-KQWTSS-TIFzzUIH8jax	EGFR	AZD9291	"In a Phase I trial, AZD9291 treatment resulted in a response rate of 64% (49/77) in NSCLC patients that harbored both EGFR exon 19 deletions and T790M mutations (PMID: 25923549)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-KNTpSS-TIFzzUICejax	EGFR	AZD9291	"In a Phase I trial, AZD9291 treatment resulted in a response rate of 57% (24/24) in patients harboring both EGFR L858R and T790M mutations (PMID: 25923549)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25923549	AVv-KOevSS-TIFzzUIEpjax	EGFR	AZD9291	"In a Phase I trial, AZD9291 demonstrated efficacy in 50% (9/18) of NSCLC patients carrying EGFR T790M mutations (PMID: 24410791)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24410791	AVv-KQVmSS-TIFzzUIH7jax	EGFR	AZD9291	"In a Phase I clinical trial, 40% (6/15) of non-small cell lung cancer patients harboring an EGFR exon 19 deletion and EGFR T790M  developed resistance to Tagrisso (osimertinib) due to acquired EGFR C797S mutations (PMID: 25939061)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25939061	AVv-KMhmSS-TIFzzUIBKjax	EGFR	AZD4547	"In a preclinical study, head and neck squamous cell carcinoma cells with EGFR over expression and FGFR1 amplification demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26936917	AVv-KNv8SS-TIFzzUIDZjax	EGFR	AZD4547	"In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26936917	AVv-KNr5SS-TIFzzUIDSjax	EGFR	AZD4547	"In a preclinical study, AZD4547 treatment of head and neck squamous cell carcinoma cells over expressing FGFR1 and negative for EGFR resulted in decreased cell growth and reduced downstream signaling of Erk1/2 (PMID: 26936917)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26936917	AVv-KLbxSS-TIFzzUH_Yjax	EGFR	AZD3759	"In a preclinical study, a lung cancer cell line harboring EGFR L858R and T790M did not demonstrate sensitivity to AZD3759 in culture (PMID: 27928026)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27928026	AVv-KOeNSS-TIFzzUIEojax	EGFR	AZD3759	"In a preclinical study, AZD3759 inhibited EGFR activation and growth of a lung cancer cell line harboring EGFR L858R in culture, and inhibited tumor growth in xenograft models (PMID: 27928026)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27928026	AVv-KO5eSS-TIFzzUIFWjax	EGFR	AV-412	"In a preclinical study, AV-412 inhibited the kinase activity of EGFR T790M (PMID: 17888033)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17888033	AVv-KQQWSS-TIFzzUIHyjax	EGFR	AV-412	"In a preclinical study, AV-412 inhibited the kinase activity of EGFR L858R (PMID: 17888033)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17888033	AVv-KOuZSS-TIFzzUIFDjax	EGFR	AV-412	"In a preclinical study, AV-412 inhibited EGFR signaling in a NSCLC cell line carrying the double EGFR mutant, L858R and T790M (PMID: 17888033)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17888033	AVv-KOlzSS-TIFzzUIE1jax	EGFR	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EGFR L858R in culture (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KOsfSS-TIFzzUIFAjax	EGFR	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EGFR L858R and T790M in culture (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KOY6SS-TIFzzUIEfjax	EGFR	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EGFR E746_A750del in culture (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KLw_SS-TIFzzUH_5jax	EGFR	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EGFR E746_A750del and T790M in culture (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KMC1SS-TIFzzUIAYjax	EGFR	AP26113	"In a preclinical study, Brigatinib (AP26113) did not inhibit growth of lung carcinoma cells with activated wild-type EGFR signaling via EGF stimulation in culture (PMID: 27780853)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-KPkuSS-TIFzzUIGfjax	EGFR	AP26113	"In a Phase I/II trial, Brigatinib (AP26113) treatment did not result in objective response in EGFRT790M-positive non-small cell lung cancer patients resistant to one previous EGFR tyrosine kinase inhibitor (PMID: 27836716)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27836716	AVv-KQZ-SS-TIFzzUIIDjax	EGFR	AMG 337	"In a clinical case study, a patient with esophageal adenocarcinoma progressed on AMG 337 therapy upon outgrowth of EGFR amplified tumor cells (PMID: 26432108)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26432108	AVv-KLAgSS-TIFzzUH-fjax	EGFR	AEE788	"In a preclinical study, transformed cells expressing EGFR N826S demonstrated resistance to AEE788 in cell culture (PMID: 19147750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19147750	AVv-KPnkSS-TIFzzUIGkjax	EGFR	AEE788	"In a preclinical study, AEE788 inhibited the growth of cultured cells expressing the EGFR exon 19 variant, L747_P753delinsS (PMID: 19147750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19147750	AVv-KP7pSS-TIFzzUIHGjax	EGFR	AC0010MA	"In a preclinical study, AC0010MA resulted in no antitumor activity when treating a squamous cell carcinoma cell line xenograft model harboring wild-type EGFR (PMID: 27573423)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27573423	AVv-KPg8SS-TIFzzUIGZjax	EGFR	AC0010MA	"In a clinical study, two patients with non-small cell lung cancer harboring EGFR T790M demonstrated tumor reductions of 31% and 36% when treated with AC0010MA (PMID: 27573423)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27573423	AVv-KQQ8SS-TIFzzUIHzjax	EGFR	ABT-806	"In a Phase I trial, ABT-806 treatment resulted in stable disease for more than 2.5 years in a penile cancer patient harboring EGFR amplification (PMID: 25895099)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25895099	AVv-KK-gSS-TIFzzUH-cjax	EGFR	ABT-806	"In a Phase I trial, ABT-806 treatment in patients with advanced solid tumors that often express EGFR amplification or EGFR vIII was well-tolerated, demonstrated safety, and resulted in stable disease in two patients (PMID: 25895099)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25895099	AVv-KOJHSS-TIFzzUIEFjax	EGFR	ABT-414	"In a preclinical study, ABT-414 induced tumor regression in a patient-derived xenograft model of glioblastoma multiforme harboring amplified wild-type EGFR and EGFR vIII (exon 2-7 deletion) (PMID: 26846818)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26846818	AVv-KKnlSS-TIFzzUH94jax	EGFR	ABT-414	"In a preclinical study, ABT-414 demonstrated cytoxicity against an EGFR-amplified head and neck squamous cell carcinoma (HNSCC) cell line in culture and induced tumor regression in EGFR-amplified HNSCC cell line xenograft models (PMID: 26846818)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26846818	AVv-KLEzSS-TIFzzUH-mjax	EGFR	ABT-414	"In a preclinical study, ABT-414 demonstrated cytotoxicity against a lung adenocarcinoma cell line that harbored EGFR amplification and EGFR E746_A750del in culture and induced tumor regression in cell line xenograft models (PMID: 26846818)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26846818	AVv-KKxVSS-TIFzzUH-Ijax	EGFR	ABT-414	"In a preclinical study, ABT-414 demonstrated cytotoxicity against a EGFR-amplified triple-negative breast cancer cell line in culture (PMID: 26846818)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26846818	AVv-KK55SS-TIFzzUH-Vjax	DNMT3A	N/A	"In clinical analyses, mutations in DNMT3A were associated with poor prognosis and shorter overall survival in patients with acute myeloid leukemia (PMID: 22490330, PMID: 21881046, PMID: 21670448)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/22490330	AVv-KJLiSS-TIFzzUH92jax	CTNNB1	Vantictumab	"In a preclinical study, Vantictumab (OMP-18R5) inhibited tumor growth in patient-derived xenograft models of colon cancer with wild-type CTNNB1 (beta-catenin) and APC (PMID: 22753465)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22753465	AVv-KI45SS-TIFzzUH9tjax	CTNNB1	Trametinib	"In a preclinical study, human liver cancer cells harboring mutant NRAS and mutant CTNNB1 were insensitive to Mekinist (trametinib) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KI7zSS-TIFzzUH9yjax	CTNNB1	PMED-1	"In a preclinical study, PMED-1 decreased Wnt expression and decreased proliferation of hepatocellular carcinoma cells with Ctnnb1 mutations (PMID: 2481996)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24819961	AVv-KI7SSS-TIFzzUH9xjax	CTNNB1	NVP-TNKS656 + Triciribine	"In a preclinical study, the combination of NVP-TNKS656 and Triciribine (API-2) inhibited tumor growth in Triciribine (API-2)-resistant patient-derived xenograft (PDX) models of colon cancer with high nuclear CTNNB1 (Beta-catenin) levels (PMID: 26224873)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26224873	AVv-KI3GSS-TIFzzUH9qjax	CTNNB1	Imatinib	"In a retrospective analysis, patients with desmoid fibromatosis harboring CTNNB1 T41A demonstrated a greater progression arrest rate at 6 months (70%) compared to patients with CTNNB1 wild-type (45%) when treated with Gleevec (imatinib) (PMID: 26861905)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26861905	AVv-KI3wSS-TIFzzUH9rjax	CTNNB1	Imatinib	"In a retrospective analysis, patients with desmoid fibromatosis harboring CTNNB1 S45F demonstrated a greater progression arrest rate at 6 months (85%) compared to patients with CTNNB1 wild-type (45%) when treated with Gleevec (imatinib) (PMID: 26861905)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26861905	AVv-KI2cSS-TIFzzUH9pjax	CTNNB1	BC21	"In a preclinical study, BC21 inhibited growth and viability of a colorectal cancer cell line with a CTNNB1 mutation and increased beta-catenin expression in culture (PMID: 22224445)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22224445	AVv-KI6vSS-TIFzzUH9wjax	CSF3R	Ruxolitinib	"In a preclinical study, Jakafi (ruxolitinib) reduces colony formation of cells expressing CSF3R T640N in culture (PMID: 26475333)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26475333	AVv-KIauSS-TIFzzUH9cjax	CSF3R	Ruxolitinib	"In a preclinical study, Jakafi (ruxolitinib) reduces colony formation of cells expressing CSF3R T618I in culture (PMID: 26475333)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26475333	AVv-KIaGSS-TIFzzUH9bjax	CSF3R	N/A	"In clinical studies, high frequency of CSF3R mutations was identified in patients with chronic neutrophilic leukemia (PMID: 23656643, PMID: 24081659), suggesting that this may serve as a future diagnostic biomarker (PMID: 24441292)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/24081659	AVv-KIbSSS-TIFzzUH9djax	CSF1R	Sorafenib	"In a preclinical study, Nexavar (sorafenib) inhibited CSF1R phosphorylation and induced apoptosis in Hodgkin's lymphoma cells in culture (PMID: 21517818)"	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21517818	AVv-KIFxSS-TIFzzUH9Zjax	CSF1R	PLX3397	"In a Phase I trial, PLX3397 reduced tenosynovial giant cell tumor volume in patients with overexpression of Csf1r (PMID: 26222558)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26222558	AVv-KIEcSS-TIFzzUH9Xjax	CSF1R	N/A	"In multiple clinical studies, elevated levels of CSF1R expression were associated with a worse survival in patients with Hodgkin's lymphoma (PMID: 24619759, PMID: 26066800, PMID: 22955918)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/24619759	AVv-KIFFSS-TIFzzUH9Yjax	CSF1R	Imatinib	"In a preclinical study, CSFR1 Y571D conferred sensitivity to Gleevec (imatinib) in myeloid cell lines in culture (PMID: 18971950)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18971950	AVv-KIDxSS-TIFzzUH9Wjax	CEBPA	N/A	"In clinical analyses, mutations in GATA2 were associated with better overall survival in patients with cytogenetically normal acute myeloid leukemia (CN-AML) harboring biallelic CEBPA gene mutations (PMID: 22814295, PMID: 23521373, PMID: 25241285)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/25241285	AVv-KH0ASS-TIFzzUH9Ujax	CEBPA	N/A	"In clinical analyses, biallelic CEBPA mutations were associated with favorable clinical outcome in patients with cytogenetically normal acute myeloid leukemia (PMID: 26601784, PMID: 19171880, PMID: 20038735, PMID: 22915647)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/26601784	AVv-KH0oSS-TIFzzUH9Vjax	CDKN2A	ZK304709	"In a preclinical study, an orthotopic mouse model treated with ZK 304709 demonstrated an 80% tumor growth reduction in neuroendocrine tumor cells with CDKN2A loss (PMID: 18829975)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18829975	AVv-KHe6SS-TIFzzUH9Ejax	CDKN2A	Trametinib	"In a preclinical study, human triple negative breast cancer cells harboring mutant BRAF, KRAS, and CDKN2A were insensitive to Mekinist (trametinib) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KHoESS-TIFzzUH9Sjax	CDKN2A	Trametinib	"In a preclinical study, human acute lymphoblastic leukemia cells harboring NRAS and CDKN2A mutations were insensitive to Mekinist (trametinib) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KHm0SS-TIFzzUH9Qjax	CDKN2A	Trametinib	"In a preclinical study, a melanoma cell line with CDKN2A loss demonstrated sensitivity to Mekinist (trametinib) in culture, resulting in inhibition of cell growth (PMID: 27488531)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27488531	AVv-KHgXSS-TIFzzUH9Gjax	CDKN2A	SBI-0640756	"In a preclinical study, SBI-0640726 delayed tumor growth of melanomas in mice with a genetic background of NRAS Q61K and CDKN2A loss (PMID: 26603897)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26603897	AVv-KHa5SS-TIFzzUH8-jax	CDKN2A	Palbociclib + Trametinib	"In a preclinical study, the combination of Ibrance (palbociclib) and Mekinist (trametinib) induced tumor regression in a mouse melanoma model expressing NRAS Q61K and harboring CDKN2A loss (PMID: 22983396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22983396	AVv-KHaSSS-TIFzzUH89jax	CDKN2A	Palbociclib	"In a preclinical study, renal cell carcinoma cell lines with CDKN2A loss were sensitive to Palbociclib (PD-0332991) (PMID: 23898052)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23898052	AVv-KHiVSS-TIFzzUH9Jjax	CDKN2A	Palbociclib	"In a preclinical study, patient-derived glioblastoma cells harboring RB1 truncation mutation and expressing Cdkn2a were resistant to Ibrance (palbociclib) in culture (PMID: 22711607)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22711607	AVv-KHYOSS-TIFzzUH86jax	CDKN2A	Palbociclib	"In a preclinical study, a melanoma cell line deficient for CDKN2A demonstrated resistance to treatment with Ibrance (palbociclib) in culture (PMID: 27488531)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27488531	AVv-KHi8SS-TIFzzUH9Kjax	CDKN2A	Palbociclib	"In a preclinical study, a gastric carcinoma cell line harboring CDKN2A R80* was sensitive to Ibrance (palbociclib) both in culture and in cell line xenograft models (PMID: 26380006, PMID: 20952405)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26380006	AVv-KHmJSS-TIFzzUH9Pjax	CDKN2A	Palbociclib	"In a preclinical study, Ibrance (palbociclib) inhibited proliferation of patient-derived glioblastoma cells harboring homozygous deletion of CDKN2A in culture and prolonged survival in patient-derived xenograft models (PMID: 22711607)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22711607	AVv-KHZpSS-TIFzzUH88jax	CDKN2A	Palbociclib	"In a preclinical study, Ibrance (palbociclib) inhibited expression of phosphorylated Rb and growth of chordoma cell lines with CDKN2A loss and loss of p16 protein expression in culture (PMID: 26183925)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26183925	AVv-KHkRSS-TIFzzUH9Mjax	CDKN2A	Palbociclib	"In a preclinical study, CDKN2A (p16) over expression was associated with decreased sensitivity to Ibrance (palbociclib) in a SMARCB1-negative malignant rhabdoid tumor cell line in culture (PMID: 21871868)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/21871868	AVv-KHooSS-TIFzzUH9Tjax	CDKN2A	PHA-848125AC	"In a preclinical study, Milciclib (PHA-848125AC) resulted in tumor regression in glioma cell line xenograft models with CDKN2A loss (PMID: 23347136)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23347136	AVv-KHdlSS-TIFzzUH9Cjax	CDKN2A	PF3644022 + PF-477736	"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of CDKN2A-deleted lung cancer (PMID: 26140595)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26140595	AVv-KHZCSS-TIFzzUH87jax	CDKN2A	PF3644022 + PF-477736	"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of multiple cancer cell lines harboring CDKN2A loss and in Cdkn2a-depleted transformed cells in culture (PMID: 26140595)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26140595	AVv-KHhESS-TIFzzUH9Hjax	CDKN2A	PD0332991 + Gemcitabine	"In a preclinical study, Ibrance (palbociclib) antagonized the efficacy of Gemzar (gemcitabine) in pancreatic cancer cells with CDKN2A loss in culture (PMID: 25156567)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25156567	AVv-KHk4SS-TIFzzUH9Njax	CDKN2A	ON-01910 + PD0332991	"In a preclinical study, Ibrance (palbociclib) antagonized the efficacy of ON-01910 in pancreatic cancer cell lines with CDKN2A loss in culture (PMID: 25156567)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25156567	AVv-KHlZSS-TIFzzUH9Ojax	CDKN2A	MLN0128	"In a preclinical study, a breast cancer cell line harboring mutations in PIK3CA and CDKN2A demonstrated sensitivity to MLN0128 in culture (PMID: 25261369)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25261369	AVv-KHngSS-TIFzzUH9Rjax	CDKN2A	LY2835219	"In a preclinical study, Abemaciclib (LY2835219) inhibited growth of chordoma cell lines with CDKN2A loss and loss of p16 protein expression in culture (PMID: 26183925)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26183925	AVv-KHfqSS-TIFzzUH9Fjax	CDKN2A	LY2835219	"In a Phase I trial, a squamous non-small cell lung carcinoma patient with KRAS wild-type and loss of CDKN2A demonstrated a partial response when treated with Abemaciclib (LY2835219) (PMID: 27217383)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27217383	AVv-KHcQSS-TIFzzUH9Ajax	CDKN2A	LY2835219	"In a Phase I study, Abemaciclib (LY2835219) resulted in a partial response in a melanoma patient with CDKN2A loss and NRAS mutation (PMID: 27217383)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27217383	AVv-KHblSS-TIFzzUH8_jax	CDKN2A	HMN-214 + PD0332991	"In a preclinical study, Ibrance (palbociclib) antagonized the activity of HMN-214 in pancreatic cancer cell lines with CDKN2A loss in culture (PMID: 25156567)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25156567	AVv-KHjpSS-TIFzzUH9Ljax	CDKN2A	GSK461364 + PD0332991	"In a preclinical study, Ibrance (palbociclib) antagonized the efficacy of GSK461364 in pancreatic cancer cells with CDKN2A loss in culture (PMID: 25156567)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25156567	AVv-KHc6SS-TIFzzUH9Bjax	CDKN2A	Alvocidib	"In a preclinical study, melanoma cell lines with CDKN2A loss demonstrated a greater sensitivity to Alvocidib (flavopiridol) as compared to melanoma cell lines positive for CDKN2A (PMID: 12777976)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/12777976	AVv-KHhtSS-TIFzzUH9Ijax	CDH1	Volasertib	"In a preclinical study, non-small cell lung carcinoma cells over expressing CDH1 were resistant to volasertib in culture (PMID: 26597303)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26597303	AVv-KG_3SS-TIFzzUH84jax	CDH1	N/A	"Pathogenic germline CDH1 mutations are used in the diagnosis of hereditary diffuse gastric cancer (PMID: 26380059, PMID: 26182300)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/26380059	AVv-KG92SS-TIFzzUH81jax	CDH1	Erlotinib + Selumetinib	"In a Phase II clinical trial, patients with pancreatic ductal adenocarcinoma tumors expressing high levels of Cdh1 were more likely to respond to a combination therapy of Tarceva (erlotinib) and Selumetinib (AZD6244) (PMID: 26251290)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26251290	AVv-KHAfSS-TIFzzUH85jax	CDH1	BI2536	"In a preclinical study, non-small cell lung carcinoma cells over expressing CDH1 were resistant to BI2536 in culture (PMID: 26597303)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26597303	AVv-KG_LSS-TIFzzUH83jax	CBLC	Olaparib	"In a preclinical study, decreased Cblc expression through siRNA knockdown enhanced sensitivity to Lynparza (olaparib) in cultured osterosarcoma cell lines (PMID: 25883215)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25883215	AVv-KGhaSS-TIFzzUH8yjax	CBLC	Olaparib	"In a preclinical study, decreased Cblc expression through siRNA knockdown enhanced sensitivity to Lynparza (olaparib) in cultured breast cancer cell lines (PMID: 25883215)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25883215	AVv-KGgpSS-TIFzzUH8xjax	CBLC	N/A	"In a clinical study, over expression of Cblc was identified as a promising diagnostic biomarker for non-small cell lung cancer (PMID: 17671213)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/17671213	AVv-KGiESS-TIFzzUH8zjax	CBLB	Fluorouracil	"In a preclinical study, gastric cancer cell lines with decreased Cblb expression level via shRNA knockdown demonstrated reduced sensitivity to Adrucil (fluorouracil) in cell culture (PMID: 24351824)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/24351824	AVv-KGS7SS-TIFzzUH8kjax	CBLB	Fasudil	"In a preclinical study, Fasudil (HA-1077) selectively inhibited proliferation of CBL and CBLB double knockout hematopoietic stem/progenitor cells in mouse model of myeloproliferative disorder (PMID: 26177294)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26177294	AVv-KGTkSS-TIFzzUH8ljax	CBL	Quizartinib	"In a preclinical study, Quizartinib (AC220) reduced white blood cell counts and decreased myeloid cell invasion in a CBL mutant mouse model with myeloproliferative disorder (PMID: 22990016)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22990016	AVv-KGFoSS-TIFzzUH8hjax	CBL	N/A	"In clinical analyses, mutations in CBL were associated with adverse prognosis in patients with chronic myelomonocytic leukemia (PMID: 26230957, PMID: 23690417, PMID: 19901108)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/26230957	AVv-KGE_SS-TIFzzUH8gjax	CBL	Fasudil	"In a preclinical study, Fasudil (HA-1077) selectively inhibited proliferation of CBL and CBLB double knockout hematopoietic stem/progenitor cells in mouse model of myeloproliferative disorder (PMID: 26177294)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26177294	AVv-KGGwSS-TIFzzUH8jjax	CALR	N/A	"CALR mutations are used in the diagnosis of myeloproliferative neoplasms, especially of essential thrombocythemia and primary myelofibrosis (PMID: 26697989, PMID: 26449662, PMID: 26071474, PMID: 25873496)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/26697989	AVv-KFwCSS-TIFzzUH8fjax	CALR	Alpha 2 Interferon	"In a clinical study, Roferon-A (Alpha 2 Interferon) treatment resulted in hematologic response in 100% (31/31) and complete molecular response in 6% (2/31) of essential thrombocythemia (ET) patients harboring CALR mutations (PMID: 26486786)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26486786	AVv-KFvWSS-TIFzzUH8ejax	BRCA2	YU238259	"In a preclinical study, YU238259 induced cytotoxicity in a human BRCA2-deficient colorectal cancer cell line in culture and slowed tumor growth in xenograft models (PMID: 26116172)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26116172	AVv-KFi0SS-TIFzzUH8ajax	BRCA2	YU238259	"In a preclinical study, YU238259 demonstrated increased cytotoxicity in BRCA2-deficient ovarian adenocarcinoma cell lines in culture (PMID: 26116172)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26116172	AVv-KFhvSS-TIFzzUH8Yjax	BRCA2	TH-302	"In a preclinical study, colorectal adenocarcinoma cells with BRCA2 deletion demonstrated increased sensitivity to TH-302 compared to cells with intact BRCA2 in culture and human cell line xenograft models (PMID: 25193512)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25193512	AVv-KFgkSS-TIFzzUH8Wjax	BRCA2	Rucaparib	"In a preclinical study, decreasing Brca2 expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells with low expression of Met to Rubraca (rucaparib) in culture (PMID: 26779812)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26779812	AVv-KFdlSS-TIFzzUH8Rjax	BRCA2	Rucaparib	"In a preclinical study, decreasing Brca2 expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells with Met over expression to Rubraca (rucaparib) in culture (PMID: 26779812)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26779812	AVv-KFeGSS-TIFzzUH8Sjax	BRCA2	Rucaparib	"In a Phase II clinical trial, treatment with Rubraca (rucaparib) was tolerated and demonstrated activity in ovarian cancer patients with germline BRCA1/2 mutations (PMID: 27002934)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27002934	AVv-KFXXSS-TIFzzUH8Fjax	BRCA2	Radiotherapy + YU238259	"In a preclinical study, YU238259 and radiotherapy synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26116172	AVv-KFiUSS-TIFzzUH8Zjax	BRCA2	PR-104	"In a preclinical study, colorectal adenocarcinoma cells with BRCA2 deletion demonstrated increased sensitivity to PR-104 compared to cells with intact BRCA2 in culture and in cell line xenograft models (PMID: 25193512)"	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25193512	AVv-KFemSS-TIFzzUH8Tjax	BRCA2	Olaparib + YU238259	"In a preclinical study, YU238259 and Lynparza (olaparib) synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26116172	AVv-KFhJSS-TIFzzUH8Xjax	BRCA2	Olaparib	"In a preclinical study, Lynparza (olaparib) decreased tumor growth in patient-derived xenografts carrying BRCA2 mutation (PMID: 21097693)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21097693	AVv-KFaHSS-TIFzzUH8Kjax	BRCA2	Olaparib	"In a Phase II clinical trial, Lynparza (olaparib) demonstrated safety and efficacy in breast cancer patients with BRCA2 mutations (PMID: 20609467)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20609467	AVv-KFbjSS-TIFzzUH8Njax	BRCA2	Olaparib	"In a Phase II clinical trial, Lynparza (olaparib) demonstrated safety and efficacy in breast cancer patients with BRCA2 inactivating mutations (PMID: 20609467)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20609467	AVv-KFPpSS-TIFzzUH75jax	BRCA2	Olaparib	"In a Phase II clinical trial, 100% (7/7) of metastatic castration-resistant prostate cancer patients with BRCA2 loss demonstrated response to Lynparza (olaparib) treatment (PMID: 26510020)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26510020	AVv-KFjXSS-TIFzzUH8bjax	BRCA2	NU1025	"In a preclinical study, knockdown of Brca2 with siRNA sensitized breast cancer cell lines to NU1025 in culture (PMID: 15829966)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/15829966	AVv-KFdFSS-TIFzzUH8Qjax	BRCA2	Irinotecan + Veliparib	"In a Phase I trial, Veliparib (ABT-888) and Camptosar (irinotecan) combination therapy resulted in partial response in 11% (1/9) and stable disease in 67% (6/9) of ovarian cancer patients harboring germline mutations in BRCA1 or BRCA2 (PMID: 26842236)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26842236	AVv-KFbESS-TIFzzUH8Mjax	BRCA2	Etoposide + YU238259	"In a preclinical study, YU238259 and Eposin (etoposide) synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26116172	AVv-KFj8SS-TIFzzUH8cjax	BRCA2	E7449	"In a preclinical study, E7449 inhibited proliferation of a BRCA2-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair mutations (PMID: 26513298)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26513298	AVv-KFR6SS-TIFzzUH78jax	BRCA2	Cisplatin	"In a preclinical study, Platinol (cisplatin) inhibited growth of a human colorectal adenocarcinoma cell line harboring BRCA2 deletion in culture, and inhibited tumor growth in xenograft models (PMID: 25193512)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25193512	AVv-KFgASS-TIFzzUH8Vjax	BRCA2	Chlorambucil	"In a preclinical study, colorectal adenocarcinoma cells with BRCA2 deletion demonstrated increased sensitivity to Ambochlorin (chlorambucil) compared to cells with intact BRCA2 in culture  (PMID: 25193512)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25193512	AVv-KFffSS-TIFzzUH8Ujax	BRCA2	BMN673	"In a preclinical study, BRCA2 deficient cancer cell lines with DNA repair deficiency demonstrated high sensitivity to the PARP inhibitor, BMN673 (PMID: 23881923)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23881923	AVv-KFNeSS-TIFzzUH72jax	BRCA2	AZD6738 + Radiotherapy	"In a preclinical study, AZD6738 increased sensitivity to radiotherapy in a colorectal adenocarcinoma cell line harboring wild-type BRCA2 in culture, resulting in a greater decrease in cell survival compared to radiotherapy alone (PMID: 28062704)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28062704	AVv-KFTFSS-TIFzzUH7-jax	BRCA2	AZD6738 + Radiotherapy	"In a preclinical study, AZD6738 increased sensitivity to radiotherapy in a colorectal adenocarcinoma cell line deficient for BRCA2 in culture, resulting in a greater decrease in cell survival compared to radiotherapy alone (PMID: 28062704)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28062704	AVv-KFkcSS-TIFzzUH8djax	BRCA2	AZD2461	"In a preclinical study, a BRCA2 deficient breast cancer cell line resistant to Lynparza (olaparib) demonstrated sensitivity to treatment with AZD2461 in culture, resulting in reduced cell viability (PMID: 27550455)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27550455	AVv-KFQ_SS-TIFzzUH77jax	BRCA1	Veliparib + Carboplatin	"In a preclinical study, the combination of Veliparib (ABT-888) and Paraplatin (carboplatin) provided no survival benefit in an intracranial human BRCA wild-type triple-negative breast cancer cell line xenograft model (PMID: 25824335)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/25824335	AVv-KEf8SS-TIFzzUH71jax	BRCA1	Rucaparib	"In a preclinical study, decreasing Brca1 expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells with low expression of Met to Rubraca (rucaparib) in culture (PMID: 26779812)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26779812	AVv-KEGmSS-TIFzzUH7Ljax	BRCA1	Rucaparib	"In a preclinical study, decreasing Brca1 expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells with Met over expression to Rubraca (rucaparib) in culture (PMID: 26779812)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26779812	AVv-KEE3SS-TIFzzUH7Ijax	BRCA1	Rucaparib	"In a Phase II clinical trial, treatment with Rubraca (rucaparib) was tolerated and demonstrated activity in ovarian cancer patients with germline BRCA1/2 mutations (PMID: 27002934)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27002934	AVv-KEOMSS-TIFzzUH7Yjax	BRCA1	Olaparib	"In a preclinical study, mouse breast cancer models harboring BRCA1 C61G with conditional loss of Tp53 had a decreased response to Lynparza (olaparib) compared to models with conditional loss of Brca1 and Tp53 (PMID: 22172724)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22172724	AVv-KEYYSS-TIFzzUH7pjax	BRCA1	Olaparib	"In a preclinical study, Lynparza (olaparib) treatment resulted in prolonged overall survival in BRCA1 deficient transgenic mouse models of breast cancer (PMID: 27454287)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27454287	AVv-KEHySS-TIFzzUH7Njax	BRCA1	Olaparib	"In a preclinical study, Lynparza (olaparib) inhibited the growth of triple-receptor negative BRCA1-mutant breast cancer cell lines under hypoxic conditions (PMID: 25193512)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25193512	AVv-KERNSS-TIFzzUH7djax	BRCA1	Olaparib	"In a preclinical study, BRCA1 proficient transgenic mouse models of breast cancer did not respond to Lynparza (olaparib) treatment (PMID: 27454287)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27454287	AVv-KEexSS-TIFzzUH7zjax	BRCA1	Olaparib	"In a preclinical study,  Lynparza (olaparib) inhibited the growth of triple-receptor negative breast cancer cell lines expressing wild-type BRCA1 under hypoxic conditions (PMID: 25193512)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25193512	AVv-KEeHSS-TIFzzUH7yjax	BRCA1	Niraparib	"In a Phase I clinical trial, Niraparib (MK8427) demonstrated safety and efficacy in ovarian cancer patients with BRCA1 inactivating mutations (PMID: 23810788)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23810788	AVv-KEUwSS-TIFzzUH7jjax	BRCA1	Irinotecan + Veliparib	"In a Phase I trial, Veliparib (ABT-888) and Camptosar (irinotecan) combination therapy resulted in partial response in 11% (1/9) and stable disease in 67% (6/9) of ovarian cancer patients harboring germline mutations in BRCA1 or BRCA2 (PMID: 26842236)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26842236	AVv-KES9SS-TIFzzUH7gjax	BRCA1	E7449	"In a preclinical study, E7449 inhibited tumor growth in a triple-negative breast cancer cell line xenograft model harboring a BRCA1 splice donor site mutation (PMID: 26513298)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26513298	AVv-KEXLSS-TIFzzUH7njax	BRCA1	E7449	"In a preclinical study, E7449 inhibited proliferation of a BRCA1-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair pathway mutations (PMID: 26513298)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26513298	AVv-KEXySS-TIFzzUH7ojax	BRCA1	Denosumab	"In a clinical study, Xgeva (denosumab) inhibited cell proliferation in normal breast tissues of BRCA1 mutation carriers, provided a potential strategy to prevent breast cancer in this population (PMID: 27322743)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/27322743	AVv-KEP-SS-TIFzzUH7bjax	BRCA1	Cisplatin	"In a preclinical study, knockdown of BRCA1 increased sensitivity of triple-negative breast cancer cells to Platinol (cisplatin) under hypoxic conditions (PMID: 25193512)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25193512	AVv-KEFZSS-TIFzzUH7Jjax	BRCA1	Chlorambucil	"In a preclinical study, BRCA1 knockdown enhanced growth inhibition by Ambochlorin (chlorambucil) in triple-receptor negative breast cancer cell lines in culture (PMID: 25193512)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25193512	AVv-KEF_SS-TIFzzUH7Kjax	BRCA1	Carboplatin	"In a Phase II trial, high dose Paraplatin (carboplatin) chemotherapy was more beneficial for breast cancer patients with BRCA1 loss than was conventional anthracycline-based chemotherapy (PMID: 21135055)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21135055	AVv-KEIYSS-TIFzzUH7Ojax	BRCA1	BMN673	"In a preclinical study, BRCA1 deficient cancer cell lines with DNA repair deficiency demonstrated high sensitivity to the PARP inhibitor, BMN673 (PMID: 23881923)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23881923	AVv-KEEMSS-TIFzzUH7Hjax	BRCA1	AZD2461	"In a preclinical study, a breast cancer model lacking BRCA1 and TP53 demonstrated sensitivity to treatment with AZD2461, which resulted in decreased tumor volume (PMID: 27550455)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27550455	AVv-KEI8SS-TIFzzUH7Pjax	BRCA1	AZD2461	"In a preclinical study, AZD2461 inhibited cell growth of BRCA1 mutant breast cancer cells in culture (PMID: 27550455)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27550455	AVv-KELvSS-TIFzzUH7Ujax	BRAF	XL888	"In a preclinical study, treatment with XL888 resulted in increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant melanoma cells harboring BRAF V600E along with NRAS Q61K in cell culture (PMID: 22351686)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22351686	AVv-J-LVSS-TIFzzUHyXjax	BRAF	XL147	"In a preclinical study, tumor cell lines harboring BRAF mutations demonstrated limited sensitivity to XL147 treatment in culture (PMID: 25637314)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25637314	AVv-KA8tSS-TIFzzUH3Ejax	BRAF	XL147	"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600E (PMID: 25637314)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25637314	AVv-J93wSS-TIFzzUHx0jax	BRAF	XL147	"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600D (PMID: 25637314)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25637314	AVv-J9WJSS-TIFzzUHw_jax	BRAF	Venetoclax + VX-11e	"In a preclinical study, inhibition of Erk signaling by VX-11e did not sensitize colorectal cancer cell lines harboring KRAS or BRAF activating mutations to Venclexta (venetoclax) in culture (PMID: 27974663)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-KCR5SS-TIFzzUH5bjax	BRAF	Vemurafenib + ZSTK474	"In a preclinical study, ZSTK474 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26137449	AVv-KCemSS-TIFzzUH5vjax	BRAF	Vemurafenib + TW-37	"In a preclinical study, TW-37 enhanced the inhibitory effect of Zelboraf (vemurafenib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25665005	AVv-J_EySS-TIFzzUH0Cjax	BRAF	Vemurafenib + TW-37	"In a preclinical study, TW-37 enhanced the inhibitory effect of Zelboraf (vemurafenib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25665005	AVv-J_W_SS-TIFzzUH0gjax	BRAF	Vemurafenib + Panitumumab	"In a Phase I trial, 83% (10/12) of patients with colorectal cancer carrying a BRAF V600E mutation demonstrated tumor regression when treated with a combination of Zelboraf (vemurafenib) and Vectibix (panitumumab) (PMID: 25589621)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25589621	AVv-J_WdSS-TIFzzUH0fjax	BRAF	Vemurafenib + Gefitinib	"In a preclinical study, the combination of Zelboraf (vemurafenib) and Iressa (gefitinib) decreased the number of viable colorectal cancer cells harboring a BRAF V600E mutation in cell culture (PMID: 22448344)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22448344	AVv-J_O4SS-TIFzzUH0Tjax	BRAF	Vemurafenib + Cetuximab	"In a preclinical study, Zelboraf (vemurafenib) and Erbitux (cetuximab) combination treatment inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-KAR5SS-TIFzzUH2Ejax	BRAF	Vemurafenib + Cetuximab	"In a clinical case study, the combination of Zelboraf (vemurafenib) and Erbitux (cetuximab) was tolerated and showed clinical benefit in a patient with BRAF V600E mutant colorectal cancer (PMID: 24523613)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24523613	AVv-KARPSS-TIFzzUH2Djax	BRAF	Vemurafenib	Zelboraf (vemurafenib) is an active regimen for melanoma patients with BRAF V600E (Guidelines).	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/detail...	AVv-KAIxSS-TIFzzUH10jax	BRAF	Vemurafenib	"In a preclinical study, treatment of cells expressing BRAF L597S with the BRAF inhibitor, Zelboraf (vemurafenib), decreased activation of MEK and ERK (PMID: 22798288)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22798288	AVv-KCM8SS-TIFzzUH5Tjax	BRAF	Vemurafenib	"In a preclinical study, treatment of cells expressing BRAF L597R with the BRAF inhibitor, Zelboraf (vemurafenib), decreased activation of MEK and ERK (PMID: 22798288)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22798288	AVv-KDOJSS-TIFzzUH67jax	BRAF	Vemurafenib	"In a preclinical study, treatment of cells expressing BRAF K601E with the BRAF inhibitor, Zelboraf (vemurafenib), decreased activation of MEK and ERK (PMID: 22798288)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/22798288	AVv-KCi_SS-TIFzzUH52jax	BRAF	Vemurafenib	"In a preclinical study, thyroid cancer cells harboring BRAF V600E demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KAFFSS-TIFzzUH1ujax	BRAF	Vemurafenib	"In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KBvSSS-TIFzzUH4ijax	BRAF	Vemurafenib	"In a preclinical study, non-small cell lung cancer cells harboring BRAF G466V demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KBzLSS-TIFzzUH4pjax	BRAF	Vemurafenib	"In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KCtKSS-TIFzzUH6Hjax	BRAF	Vemurafenib	"In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KBlkSS-TIFzzUH4Sjax	BRAF	Vemurafenib	"In a preclinical study, melanoma cells expressing BRAF L505H were resistant to Zelboraf (vemurafenib) (PMID: 24283590)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24283590	AVv-KBsTSS-TIFzzUH4djax	BRAF	Vemurafenib	"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-TbSS-TIFzzUHyljax	BRAF	Vemurafenib	"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-6jSS-TIFzzUHznjax	BRAF	Vemurafenib	"In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-zVSS-TIFzzUHzajax	BRAF	Vemurafenib	"In a preclinical study, human melanoma cells harboring BRAF G469R and NRAS G61K were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KC7CSS-TIFzzUH6djax	BRAF	Vemurafenib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J9_VSS-TIFzzUHyBjax	BRAF	Vemurafenib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-YISS-TIFzzUHytjax	BRAF	Vemurafenib	"In a preclinical study, expression of NRAS G12V in melanoma cells harboring BRAF V600E conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 26267534)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-J-2LSS-TIFzzUHzfjax	BRAF	Vemurafenib	"In a preclinical study, expression of AKT1 Q79K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265152	AVv-KC_oSS-TIFzzUH6kjax	BRAF	Vemurafenib	"In a preclinical study, expression of AKT1 E17K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265152	AVv-KC9qSS-TIFzzUH6hjax	BRAF	Vemurafenib	"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Zelboraf (vemurafenib) both in culture and in cell line xenograft models (PMID: 27500726)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27500726	AVv-KBWbSS-TIFzzUH3vjax	BRAF	Vemurafenib	"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-KAqKSS-TIFzzUH2ljax	BRAF	Vemurafenib	"In a preclinical study, colorectal cancer cell lines harboring BRAF V600E demonstrated decreased response to Zelboraf (vemurafenib) in culture (PMID: 27312529)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-J_rXSS-TIFzzUH1Ejax	BRAF	Vemurafenib	"In a preclinical study, an ovarian cancer cell line harboring BRAF N486_P490del was resistant to Zelboraf (vemurafenib), resulting in minimal inhibition of both cell growth and phosphorylation of MEK and ERK in culture (PMID: 26732095)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26732095	AVv-KCVsSS-TIFzzUH5hjax	BRAF	Vemurafenib	"In a preclinical study, a non-small cell lung carcinoma cell line harboring BRAF L485_P490delinsY was resistant to Tafinlar (dabrafenib) (PMID: 26732095)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26732095	AVv-KB1kSS-TIFzzUH4tjax	BRAF	Vemurafenib	"In a preclinical study, a human pancreatic cancer cell line harboring BRAF V487_P492delinsA was resistant to treatment with Zelboraf (vemurafenib) in both culture and xenograft models (PMID: 26732095)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26732095	AVv-KCnLSS-TIFzzUH59jax	BRAF	Vemurafenib	"In a preclinical study, a NRAS Q61K mutation conferred resistance to Zelboraf (vemurafenib) in melanoma cells harboring BRAF V600E in culture (PMID: 21107323)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21107323	AVv-J-KsSS-TIFzzUHyWjax	BRAF	Vemurafenib	"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KB2JSS-TIFzzUH4ujax	BRAF	Vemurafenib	"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600D in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-J9YjSS-TIFzzUHxDjax	BRAF	Vemurafenib	"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF L597V (PMID: 26343582)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343582	AVv-KBwgSS-TIFzzUH4kjax	BRAF	Vemurafenib	"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF L597Q (PMID: 26343582)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343582	AVv-KBxBSS-TIFzzUH4ljax	BRAF	Vemurafenib	"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601T (PMID: 26343582)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343582	AVv-KCU_SS-TIFzzUH5gjax	BRAF	Vemurafenib	"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601N (PMID: 26343582)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343582	AVv-KCZMSS-TIFzzUH5mjax	BRAF	Vemurafenib	"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601E (PMID: 26343582)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/26343582	AVv-KCjpSS-TIFzzUH53jax	BRAF	Vemurafenib	"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G469V (PMID: 26343582)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343582	AVv-KCSfSS-TIFzzUH5cjax	BRAF	Vemurafenib	"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G469A (PMID: 26343582)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343582	AVv-KBpFSS-TIFzzUH4Yjax	BRAF	Vemurafenib	"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G464V (PMID: 26343582)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343582	AVv-KCnwSS-TIFzzUH5-jax	BRAF	Vemurafenib	"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G464R (PMID: 26343582)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343582	AVv-KBrtSS-TIFzzUH4cjax	BRAF	Vemurafenib	"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G464E (PMID: 26343582)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343582	AVv-J9bSSS-TIFzzUHxHjax	BRAF	Vemurafenib	"In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to Zelboraf (vemurafenib) in culture (PMID: 27523909)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KB86SS-TIFzzUH46jax	BRAF	Vemurafenib	"In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, MAP2K1 V60E, NRAS T58I, and NRAS Q61R, after 18 weeks of treatment with Zelboraf (vemurafenib) (PMID: 24265153)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-KC7wSS-TIFzzUH6ejax	BRAF	Vemurafenib	"In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, BRAF amplification and NRAS Q61K, during treatment with Zelboraf (vemurafenib) (PMID: 24265153)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-KCUUSS-TIFzzUH5fjax	BRAF	Vemurafenib	"In a clinical study, a melanoma patient harboring a BRAF V600 mutation and PTEN H93D treated with Zelboraf (vemurafenib) for 66 weeks demonstrated a partial response (PMID: 24265153)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-KC9CSS-TIFzzUH6gjax	BRAF	Vemurafenib	"In a clinical study, a melanoma patient harboring PTEN Y86fs and BRAF V600X developed the resistance mutation, PIK3CA H1047R, after treatment with Zelboraf (vemurafenib) (PMID: 24265153)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-KC-XSS-TIFzzUH6ijax	BRAF	Vemurafenib	"In a clinical case study, a patient with metastatic renal cell carcinoma harboring BRAF V600E demonstrated a partial response following treatment with Zelboraf (vemurafenib) (PMID: 26918217)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26918217	AVv-KAMQSS-TIFzzUH16jax	BRAF	Vemurafenib	"In a clinical case study, a patient harboring BRAF V600E demonstrated an initial response to treatment with Zelboraf (vemurafenib), but progressed following emergence of a MAP2K1 C121S mutation (PMID: 21383288)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/21383288	AVv-J-gRSS-TIFzzUHy6jax	BRAF	Vemurafenib	"In a clinical case study, a non-small cell lung cancer patient harboring a BRAF V600E mutation had a complete response after treatment with Zelboraf (vemurafenib) (PMID: 23733758)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23733758	AVv-J_16SS-TIFzzUH1Vjax	BRAF	Vemurafenib	"In a clinical case study, a melanoma patient harboring BRAF V600E  treated with Zelboraf (vemurafenib) subsequently demonstrated resistance likely due to the secondary resistance mutation, BRAF L505H (PMID: 25515853)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25515853	AVv-J9mzSS-TIFzzUHxajax	BRAF	Vemurafenib	"In a clinical case study, a lung adenocarcinoma patient harboring BRAF G469L did not respond to Zelboraf (vemurafenib) therapy (PMID: 24035431)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/24035431	AVv-J9iFSS-TIFzzUHxSjax	BRAF	Vemurafenib	"In a Phase III trial that supported FDA approval, Zelboraf (vemurafenib), as compared to Deticene (dacarbazine), resulted in an improved overall survival rate of 84% at 6 months in patients with BRAF V600E positive metastatic melanoma (PMID: 21639808)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21639808	AVv-KAJVSS-TIFzzUH11jax	BRAF	Vemurafenib	"In a Phase II trial, Zelboraf (vemurafenib) did not demonstrate clinical activity as a single agent in patients with metastatic colorectal cancer harboring BRAF V600E (PMID: 26460303)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26460303	AVv-J_qwSS-TIFzzUH1Djax	BRAF	Vemurafenib	"In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) resulted in partial response in 12% (1/8) and stable disease in 50% (4/8) of cholangiocarcinoma patients with BRAF V600 mutations (PMID: 26287849)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26287849	AVv-KDJISS-TIFzzUH6zjax	BRAF	Vemurafenib	"In a Phase I trial, Zelboraf (vemurafenib) demonstrated safety and efficacy in metastatic papillary thyroid cancer patients carrying BRAF activating mutations (PMID: 23489023)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23489023	AVv-KCPcSS-TIFzzUH5Xjax	BRAF	VX-11e + WEHI-539	"In a preclinical study, inhibition of Erk signaling by VX-11e sensitized colorectal cancer cell lines harboring KRAS or BRAF activating mutations to WEHI-539 in culture (PMID: 27974663)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27974663	AVv-KCRQSS-TIFzzUH5ajax	BRAF	VX-11e	"In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25370473	AVv-KC14SS-TIFzzUH6Vjax	BRAF	VX-11e	"In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25370473	AVv-KC0kSS-TIFzzUH6Tjax	BRAF	VRT11E	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-J-hgSS-TIFzzUHy8jax	BRAF	VRT11E	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-J-ksSS-TIFzzUHzBjax	BRAF	VRT11E	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-J-m-SS-TIFzzUHzFjax	BRAF	VRT11E	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-J-eaSS-TIFzzUHy3jax	BRAF	Tubastatin A	"In a preclinical study, Tubastatin A inhibited proliferation of BRAF mutant melanoma cell lines in culture (PMID: 25957812)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25957812	AVv-KBMcSS-TIFzzUH3djax	BRAF	Trametinib + Vemurafenib	"In a preclinical study, the combination of Mekinist (trametinib) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265152	AVv-KDGoSS-TIFzzUH6vjax	BRAF	Trametinib + Vemurafenib	"In a clinical case study, Mekinist (trametinib) and Zelboraf (vemurafenib) combination treatment resulted in a rapid and sustained clinical response in a patient with a rectal neuroendocrine tumor harboring a BRAF V600E mutation (PMID: 27048246)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27048246	AVv-KAN3SS-TIFzzUH19jax	BRAF	Trametinib + TW-37	"In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25665005	AVv-J_miSS-TIFzzUH08jax	BRAF	Trametinib + TW-37	"In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25665005	AVv-J_oSSS-TIFzzUH0_jax	BRAF	Trametinib + Navitoclax	"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25665005	AVv-J_PcSS-TIFzzUH0Ujax	BRAF	Trametinib + Navitoclax	"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25665005	AVv-J_fKSS-TIFzzUH0vjax	BRAF	Trametinib + Navitoclax	"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human colon cancer cells harboring BRAF V600E in culture (PMID: 25665005)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25665005	AVv-J_KLSS-TIFzzUH0Ljax	BRAF	Trametinib + Dabrafenib	"Tafinlar (dabrafenib), in combination with Mekinist (trametinib), is an active regimen for melanoma patients with BRAF V600E or V600K (Guidelines)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/detail...	AVv-KCcASS-TIFzzUH5rjax	BRAF	Trametinib + Dabrafenib	"In a preclinical study, the combination of Talfinlar (dabrafenib)    and Mekinist (trametinib) resulted in improved growth inhibition in melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J9j4SS-TIFzzUHxVjax	BRAF	Trametinib + Dabrafenib	"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment in culture (PMID: 27500726)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27500726	AVv-KBVNSS-TIFzzUH3tjax	BRAF	Trametinib + Dabrafenib	"In a preclinical study, combination therapy consisted of Tafinlar (dabrafenib) and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-KAQrSS-TIFzzUH2Cjax	BRAF	Trametinib + Dabrafenib	"In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-JjSS-TIFzzUHyUjax	BRAF	Trametinib + Dabrafenib	"In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cells harboring BRAF V600E and NRAS A146T and NRAS Q61K in culture (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-1FSS-TIFzzUHzdjax	BRAF	Trametinib + Dabrafenib	"In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E harboring MAP2K1 K59del in culture (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-ZbSS-TIFzzUHyvjax	BRAF	Trametinib + Dabrafenib	"In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-yRSS-TIFzzUHzYjax	BRAF	Trametinib + Dabrafenib	"In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cells harboring BRAF V600E in culture (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J_wLSS-TIFzzUH1Ljax	BRAF	Trametinib + Dabrafenib	"In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KCyASS-TIFzzUH6Pjax	BRAF	Trametinib + Dabrafenib	"In a preclinical study, MAP2K1 G128V conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265154	AVv-J-npSS-TIFzzUHzGjax	BRAF	Trametinib + Dabrafenib	"In a preclinical study, MAP2K1 C121S conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265154	AVv-J-d1SS-TIFzzUHy2jax	BRAF	Trametinib + Dabrafenib	"In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to the combination therapy, Mekinist (trametinib) and Tafinlar (dabrafenib) (PMID: 27797976)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27797976	AVv-J9mMSS-TIFzzUHxZjax	BRAF	Trametinib + Dabrafenib	"In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in a rapid and sustained clinical response in a patient with a rectal neuroendocrine tumor harboring a BRAF V600E mutation (PMID: 27048246)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27048246	AVv-KALtSS-TIFzzUH15jax	BRAF	Trametinib + Dabrafenib	"In a clinical case report, Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment resulted in a clinical and radiologic response that lasted for 9 months in an anaplastic thyroid cancer patient harboring BRAF V600E (PMID: 27697975)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27697975	AVv-KATLSS-TIFzzUH2Gjax	BRAF	Trametinib + Dabrafenib	"In a Phase I/II clinical trial, patients with BRAF V600 mutant melanoma (n=78) treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) had a median overall survival of greater than 2 years (PMID: 26811525)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26811525	AVv-KDBjSS-TIFzzUH6njax	BRAF	Trametinib	"Preclinical studies demonstrated the MEK inhibitor, Mekinist (trametinib) caused decreased activation of MEK and ERK in cells expressing BRAF L597S (PMID: 22798288)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22798288	AVv-KCNqSS-TIFzzUH5Ujax	BRAF	Trametinib	"Preclinical studies demonstrated the MEK inhibitor, Mekinist (trametinib) caused decreased activation of MEK and ERK in cells expressing BRAF L597R (PMID: 22798288)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22798288	AVv-KDNfSS-TIFzzUH66jax	BRAF	Trametinib	"Preclinical studies demonstrated the MEK inhibitor, Mekinist (trametinib) caused decreased activation of MEK and ERK in cells expressing BRAF K601E (PMID: 22798288)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22798288	AVv-KChtSS-TIFzzUH50jax	BRAF	Trametinib	Mekinist (trametinib) is an active regimen for melanoma patients with BRAF V600K (Guidelines).	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/detail...	AVv-KC4eSS-TIFzzUH6Zjax	BRAF	Trametinib	Mekinist (trametinib) is an active regimen for melanoma patients with BRAF V600E or V600K (Guidelines).	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/detail...	AVv-KCaTSS-TIFzzUH5ojax	BRAF	Trametinib	Mekinist (trametinib) is an active regimen for melanoma patients with BRAF V600E (Guidelines).	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/detail...	AVv-KAJ8SS-TIFzzUH12jax	BRAF	Trametinib	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 24265153)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-J-jiSS-TIFzzUHy_jax	BRAF	Trametinib	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Mekinist (trametinib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-J-l4SS-TIFzzUHzDjax	BRAF	Trametinib	"In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were 3-7 fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600K in culture (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KCwMSS-TIFzzUH6Mjax	BRAF	Trametinib	"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-VvSS-TIFzzUHypjax	BRAF	Trametinib	"In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were >10-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-z8SS-TIFzzUHzbjax	BRAF	Trametinib	"In a preclinical study, human triple negative breast cancer cells harboring mutant BRAF, KRAS, and CDKN2A were insensitive to Mekinist (trametinib) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KBZ_SS-TIFzzUH31jax	BRAF	Trametinib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J9-wSS-TIFzzUHyAjax	BRAF	Trametinib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P displayed reduced sensitivity to Mekinist (trametinib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J9jPSS-TIFzzUHxUjax	BRAF	Trametinib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-WVSS-TIFzzUHyqjax	BRAF	Trametinib	"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27500726	AVv-KBXASS-TIFzzUH3wjax	BRAF	Trametinib	"In a preclinical study, colorectal cancer cells harboring a BRAF V600E mutation had increased sensitivity to Mekinist (trametinib) compared to other colorectal cancer lines in culture (PMID: 25309914)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25309914	AVv-J_axSS-TIFzzUH0njax	BRAF	Trametinib	"In a preclinical study, an ovarian cancer cell line harboring BRAF  N486_P490del was sensitive to Mekinist (trametinib), resulting in inhibition of cell growth in culture (PMID: 26732095)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26732095	AVv-KCXMSS-TIFzzUH5jjax	BRAF	Trametinib	"In a preclinical study, a pancreatic cancer cell line harboring BRAF V487_P492delinsA was sensitive to Mekinist (trametinib) in culture, resulting in cell growth inhibition (PMID: 26732095)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26732095	AVv-KCmnSS-TIFzzUH58jax	BRAF	Trametinib	"In a preclinical study, a non-small cell lung carcinoma cell line harboring BRAF L485_P490delinsY was sensitive to Mekinist (trametinib), resulting in cell growth inhibition (PMID: 26732095)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26732095	AVv-KB1BSS-TIFzzUH4sjax	BRAF	Trametinib	"In a preclinical study, a melanoma cell line harboring a BRAF mutation and RB1 loss demonstrated reduced sensitivity when treated with Mekinist (trametinib) in culture (PMID: 27488531)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27488531	AVv-KBUBSS-TIFzzUH3rjax	BRAF	Trametinib	"In a preclinical study, a majority of human colorectal cancer cell lines (4/7) harboring mutant BRAF were insensitive to Mekinist (trametinib) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KBPkSS-TIFzzUH3jjax	BRAF	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of lung adenocarcinoma cells harboring mutant BRAF in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KBCJSS-TIFzzUH3Njax	BRAF	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of human pancreatic adenocarcinoma cells harboring mutant BRAF in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KBNiSS-TIFzzUH3fjax	BRAF	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of human multiple myeloma cells harboring mutant BRAF in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KA9RSS-TIFzzUH3Fjax	BRAF	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited growth of both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-J_9VSS-TIFzzUH1ijax	BRAF	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25370473	AVv-KC2iSS-TIFzzUH6Wjax	BRAF	Trametinib	"In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25370473	AVv-KCz7SS-TIFzzUH6Sjax	BRAF	Trametinib	"In a preclinical study, Mekinist (trametinib) induced apoptosis and inhibited growth of a non-small cell lung cancer cell line harboring BRAF G469A in culture (PMID: 25706985)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25706985	AVv-KBrGSS-TIFzzUH4bjax	BRAF	Trametinib	"In a clinical case study, a melanoma patient with BRAF K601E demonstrated a 48% reduction in lymphadenopathy when treated with Mekinist (trametinib) and after more than 36 months of treatment showed a complete response (PMID: 28344857)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28344857	AVv-KCiVSS-TIFzzUH51jax	BRAF	Trametinib	"In a Phase III trial that supported FDA approval, Mekinist (trametinib) resulted in improved progression free survival and an overall six month survival rate of 81% in patients with BRAF V600E/K positive metastatic melanoma (PMID: 22663011)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22663011	AVv-KCZwSS-TIFzzUH5njax	BRAF	Trametinib	"In a Phase I trial, Mekinist (trametinib) resulted in complete response in 7% (2/30), partial response in 33% (10/30), and stable disease in 37% (11/30) of BRAF-mutant melanoma patients (PMID: 22805292)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22805292	AVv-KCa1SS-TIFzzUH5pjax	BRAF	Trametinib	"In a Phase I study, 10% (4/39) of wild-type BRAF melanoma patients had a partial response to Mekinist (trametinib) (PMID: 22805292)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22805292	AVv-KCIaSS-TIFzzUH5Mjax	BRAF	TGX-221	"In a preclinical study, TGX-221 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26137449	AVv-KCdXSS-TIFzzUH5tjax	BRAF	TGX-221	"In a preclincal study, TGX-221 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KA1GSS-TIFzzUH23jax	BRAF	TAK-733	"In a Phase I trial, one metastatic melanoma patient carrying a BRAF L597S mutation, had a partial response to the MEK inhibitor, TAK-33 (PMID: 22798288)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22798288	AVv-KCMTSS-TIFzzUH5Sjax	BRAF	TAK-632	"In a preclinical study, TAK-632 inhibited proliferation of thyroid cancer cells harboring BRAF V600E in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-J_QtSS-TIFzzUH0Wjax	BRAF	TAK-632	"In a preclinical study, TAK-632 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KBt2SS-TIFzzUH4gjax	BRAF	TAK-632	"In a preclinical study, TAK-632 inhibited proliferation of non-small cell lung cancer cells harboring BRAF G466V in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KBypSS-TIFzzUH4ojax	BRAF	TAK-632	"In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-J_fxSS-TIFzzUH0wjax	BRAF	TAK-632	"In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KCtvSS-TIFzzUH6Ijax	BRAF	TAK-632	"In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF V600R in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KB4YSS-TIFzzUH4yjax	BRAF	TAK-632	"In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-J9ZzSS-TIFzzUHxFjax	BRAF	TAK-632	"In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF G466E in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KBmtSS-TIFzzUH4Ujax	BRAF	TAK-632	"In a preclinical study, TAK-632 inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KAQISS-TIFzzUH2Bjax	BRAF	TAK-632	"In a preclinical study, TAK-632 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KB98SS-TIFzzUH48jax	BRAF	TAE226	"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring BRAF G469A mutation in culture (PMID: 26090892)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26090892	AVv-KBqbSS-TIFzzUH4ajax	BRAF	TAE226	"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring BRAF G466V mutation in culture (PMID: 26090892)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26090892	AVv-KByCSS-TIFzzUH4njax	BRAF	Sorafenib	"In a preclinical study, colorectal cancer cell lines harboring a BRAF V600E mutation were sensitive to Nexavar (sorafenib) in culture (PMID: 24885690)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24885690	AVv-J_jPSS-TIFzzUH02jax	BRAF	Sorafenib	"In a Phase II study, Nexavar (sorafenib) displayed negligible efficacy in melanoma patients with BRAF mutations (PMID: 16880785, PMID: 22394203)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/22394203	AVv-KCQCSS-TIFzzUH5Yjax	BRAF	Sorafenib	"In a Phase II study, Nexavar (sorafenib) displayed negligible efficacy in melanoma patients with BRAF V600E mutations (PMID: 16880785, PMID: 22394203)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/22394203	AVv-J_cUSS-TIFzzUH0qjax	BRAF	Selumetinib + Vemurafenib	"In a preclinical study, the combination of Selumetinib (AZD6244) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265152	AVv-KDHQSS-TIFzzUH6wjax	BRAF	Selumetinib + Vemurafenib	"In a preclinical study, Selumetinib (AZD6244) and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26137449	AVv-KCf5SS-TIFzzUH5xjax	BRAF	Selumetinib + PLX4720	"In a preclinical study, combined treatment with selumetinib and PLX4720 strongly suppressed the emergence of resistant MAP2K1 mutations in BRAF V600E cells in culture (PMID: 19915144)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-J-R4SS-TIFzzUHyijax	BRAF	Selumetinib + PLX4720	"In a preclinical study, Selumetinib (AZD6244) and PLX4720 synergistically inhibited growth and induced apoptosis in glioma cell lines in culture, resulted in prolonged survival in cell line xenograft models (PMID: 27217440)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27217440	AVv-J_MpSS-TIFzzUH0Pjax	BRAF	Selumetinib + PLX4720	"In a preclinical study, PLX4720 and Selumetinib (AZD6244) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26461489	AVv-J_IXSS-TIFzzUH0Ijax	BRAF	Selumetinib	"In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the MEK inhibitor selumetinib (AZD6244) cell culture."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-J-SdSS-TIFzzUHyjjax	BRAF	Selumetinib	"In a preclinical study, melanoma cells harboring BRAF V600E treated with Selumetinib (AZD6244) in culture demonstrated resistance, which was a result of the resistance mutation, MAP2K1 H119P (PMID: 19915144)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-J-oPSS-TIFzzUHzHjax	BRAF	Selumetinib	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by Selumetinib (AZD6244) in cell culture (PMID: 19915144)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-J95ZSS-TIFzzUHx3jax	BRAF	Selumetinib	"In a preclinical study, melanoma cells harboring BRAF V600E and MAP2K1 P124S demonstrated decreased sensitivity to Selumetinib (AZD6244) compared to cells harboring BRAF V600E alone in culture (PMID: 22197931)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22197931	AVv-J-i0SS-TIFzzUHy-jax	BRAF	Selumetinib	"In a preclinical study, human melanoma cells harboring BRAF K601E, BRAF A665V, and NRAS R167L were insensitive to Selumetinib (AZD6244) in culture (PMID: 26343583)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KCkMSS-TIFzzUH54jax	BRAF	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) resulted in some reduced cell growth in colon cancer cells harboring a BRAF mutation in culture (PMID: 27655129)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27655129	AVv-KBF3SS-TIFzzUH3Sjax	BRAF	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) modestly inhibited proliferation of human melanoma cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KC5zSS-TIFzzUH6bjax	BRAF	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) inhibited growth of both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27222538	AVv-J_TZSS-TIFzzUH0ajax	BRAF	Selumetinib	"In a preclinical study, Selumetinib (AZD6244) decreased tumor growth in a cell line xenograft model of colorectal cancer harboring BRAF V600E (PMID: 23942066)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23942066	AVv-KAd6SS-TIFzzUH2Vjax	BRAF	Selumetinib	"In a Phase II trial, a favorable response rate to selumetinib (AZD6244) was observed in mutant BRAF but not BRAF wild-type melanoma patients (PMID: 22048237)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22048237	AVv-J_dcSS-TIFzzUH0sjax	BRAF	Selumetinib	"In a Phase II trial, a favorable response rate to Selumetinib (AZD6244) was observed in mutant BRAF, but not BRAF wild-type, melanoma patients (PMID: 22048237)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/22048237	AVv-KCJFSS-TIFzzUH5Njax	BRAF	Selumetinib	"In a Phase II trial in patients with advanced melanoma, 5/6 patients exhibiting a response to selumetinib had BRAF-mutant tumors (PMID: 22048237)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22048237	AVv-KBKISS-TIFzzUH3Zjax	BRAF	Selumetinib	"In a Phase I study, selumetinib demonstrated an increase in iodine uptake and retention in a subgroup of patients with thyroid cancer that was refractory to radioiodine; including patients with BRAF and NRAS mutations disease (PMID: 23406027)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23406027	AVv-KBHESS-TIFzzUH3Ujax	BRAF	Saracatinib	"In a preclinical study, saracatinib inhibited proliferation of human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture (PMID: 23242808)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23242808	AVv-KAZkSS-TIFzzUH2Qjax	BRAF	SHP099	"In a preclinical study, SHP099 did not inhibit proliferation or ERK activation in a melanoma cell line harboring BRAF V600E in culture (PMID: 27362227)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27362227	AVv-J_JmSS-TIFzzUH0Kjax	BRAF	SHP099	"In a preclincial study, colorectal cancer cell lines harboring BRAF V600E demonstrated resistance to SHP099 in culture (PMID: 27362227)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27362227	AVv-J_iCSS-TIFzzUH00jax	BRAF	SCH772984	"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to SCH772984 in culture (PMID: 27312529)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-J-O-SS-TIFzzUHydjax	BRAF	SCH772984	"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-KAlKSS-TIFzzUH2cjax	BRAF	SCH772984	"In a preclinical study, SCH772984 inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 26267534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-J_OYSS-TIFzzUH0Sjax	BRAF	SCH772984	"In a preclinical study, SCH772984 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 26267534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-J_6WSS-TIFzzUH1djax	BRAF	SBI-755199	"In a preclinical study, SBI-755199 induced cell death in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26603897	AVv-KAYNSS-TIFzzUH2Ojax	BRAF	SBI-0640756	"In a preclinical study, SBI-0640756 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20531415	AVv-J_CHSS-TIFzzUHz-jax	BRAF	SBI-0640726	"In a preclinical study, SBI-0640726 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20531415	AVv-J_8ySS-TIFzzUH1hjax	BRAF	SB590885	"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to SB590885 in culture (PMID: 20538618)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/20538618	AVv-J-3sSS-TIFzzUHzijax	BRAF	SB590885	"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529M were insensitive to SB590885-mediated inhibition of ERK signaling in culture (PMID: 20538618)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/20538618	AVv-J9elSS-TIFzzUHxMjax	BRAF	SB590885	"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529I were insensitive to SB590885-mediated inhibition of ERK signaling in culture (PMID: 20538618)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/20538618	AVv-J9fMSS-TIFzzUHxNjax	BRAF	SB590885	"In a preclinical study, SB590885 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-J_VXSS-TIFzzUH0djax	BRAF	SB590885	"In a preclinical study, SB590885 inhibited inhibited Erk phosphorylation and cell proliferation of transformed cells expression BRAF V600E in culture (PMID: 20538618)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20538618	AVv-J_eASS-TIFzzUH0tjax	BRAF	SAR260301 + Vemurafenib	"In a preclinical study, SAR260301 and Zelboraf (vemurafenib) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27196754	AVv-KBhiSS-TIFzzUH4Ljax	BRAF	SAR260301 + Selumetinib	"In a preclinical study, SAR260301 and Selumetinib (AZD6244) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27196754	AVv-KBjSSS-TIFzzUH4Ojax	BRAF	SAR260301	"In a preclinical study, SAR260301 inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27196754	AVv-KBkbSS-TIFzzUH4Qjax	BRAF	S63845 + Vemurafenib	"In a preclinical study, combination of S63845 and Zelboraf (vemurafenib) resulted in potent cytotoxic effects in BRAF-mutated melanoma cells in culture compared to the cytostatic effect of Zelboraf (vemurafenib) alone (PMID: 27760111)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27760111	AVv-KBL0SS-TIFzzUH3cjax	BRAF	S63845 + Trametinib	"In a preclinical study, combination of S63845 and Mekinist (trametinib) resulted in potent cytotoxic effects in BRAF-mutated melanoma cells in culture compared to the cytostatic effect of Mekinist (trametinib) alone (PMID: 27760111)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27760111	AVv-KBODSS-TIFzzUH3gjax	BRAF	S3I-201	"In a preclinical study, S3I-201 inhibited cell invasion and Stat3 signaling in human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture (PMID: 23242808)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23242808	AVv-KAB3SS-TIFzzUH1pjax	BRAF	Regorafenib	"In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Stivarga (regorafenib) in culture (PMID: 25838391)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-J-tJSS-TIFzzUHzPjax	BRAF	Regorafenib	"In a preclinical study, colorectal cancer cell lines with wild-type BRAF, KRAS, NRAS and PIK3CA were resistant to Stivarga (regorafenib) in culture (PMID: 25838391)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-KCK-SS-TIFzzUH5Qjax	BRAF	Regorafenib	"In a preclinical study, Stivarga (regorafenib) inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture and suppressed angiogenesis and tumor growth in cell line xenograft models (PMID: 21170960)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21170960	AVv-J_ZDSS-TIFzzUH0kjax	BRAF	Regorafenib	"In a preclinical study, Stivarga (regorafenib) inhibited proliferation of breast cancer cells harboring BRAF G464V and KRAS G13D in culture and inhibited angiogenesis and tumor growth in cell line xenograft models (PMID: 21170960)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21170960	AVv-KCqGSS-TIFzzUH6Cjax	BRAF	Refametinib	"In a preclinical study, Refametinib (BAY86-9766) inhibited growth of melanoma cell lines harboring BRAF V600E in culture and suppressed tumor growth in cell line xenograft models (PMID: 19706763)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19706763	AVv-J_UGSS-TIFzzUH0bjax	BRAF	Refametinib	"In a preclinical study, Refametinib (BAY86-9766) inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture and suppressed tumor growth in cell line xenograft models (PMID: 19706763)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19706763	AVv-J_DcSS-TIFzzUH0Ajax	BRAF	RO5126766	"In a preclinical study, RO5126766 inhibited proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 26438159)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-J_pgSS-TIFzzUH1Bjax	BRAF	RO5126766	"In a preclinical study, RO5126766 inhibited Mek signaling and increased radioiodide uptake and response in transgenic animal models of papillary thyroid carcinoma driven by BRAF V600E (PMID: 27669459)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27669459	AVv-J_yISS-TIFzzUH1Ojax	BRAF	RO4987655	"In a preclinical study, RO4987655 inhibited proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 26438159)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26438159	AVv-J_3eSS-TIFzzUH1Yjax	BRAF	RAF265	"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to RAF265 in culture (PMID: 20538618)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/20538618	AVv-J-3MSS-TIFzzUHzhjax	BRAF	RAF265	"In a preclinical study, RAF265 inhibited the growth of melanoma tumors orthotopically implanted in mice, including tumors wild-type for BRAF (PMID: 22351689)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22351689	AVv-KCGLSS-TIFzzUH5Jjax	BRAF	RAF265	"In a preclinical study, RAF265 inhibited Erk phosphorylation and cell proliferation in BRAF V600E expressing cells in culture (PMID: 20538618)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20538618	AVv-J_kXSS-TIFzzUH04jax	BRAF	Pimasertib + Sorafenib	"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-J_MCSS-TIFzzUH0Ojax	BRAF	Pimasertib + Sorafenib	"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-J-uTSS-TIFzzUHzRjax	BRAF	Pimasertib + Regorafenib	"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-J_nrSS-TIFzzUH0-jax	BRAF	Pimasertib + Regorafenib	"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-J-vaSS-TIFzzUHzTjax	BRAF	Pimasertib	"In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-J_5OSS-TIFzzUH1bjax	BRAF	Pimasertib	"In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-J-v-SS-TIFzzUHzUjax	BRAF	Pembrolizumab	"In a preclinical study, Keytruda (pembrolizumab) resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26645196	AVv-KBiPSS-TIFzzUH4Mjax	BRAF	Panitumumab	"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) in culture (PMID: 27312529)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-KAogSS-TIFzzUH2ijax	BRAF	Palbociclib + Trametinib	"In a preclinical study, a melanoma cell line with a BRAF mutation and loss of RB1 demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27488531	AVv-KBS3SS-TIFzzUH3pjax	BRAF	Palbociclib + Trametinib	"In a preclinical study, a melanoma cell line harboring a BRAF mutation demonstrated greater sensitivity to the combination treatment of Mekinist (trametinib) and Ibrance (palbociclib) in culture when compared to either agent alone (PMID: 27488531)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27488531	AVv-KA91SS-TIFzzUH3Gjax	BRAF	Palbociclib + Trametinib	"In a preclinical study, a BRAF wild-type melanoma cell line demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27488531	AVv-KCEuSS-TIFzzUH5Hjax	BRAF	Palbociclib	"In a preclinical study, treatment with Ibrance (palbociclib) in a melanoma cell line xenograft model harboring BRAF V600E resulted in no benefit, demonstrating low but continuous growth (PMID: 27488531)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27488531	AVv-KAM0SS-TIFzzUH17jax	BRAF	Palbociclib	"In a preclinical study, a melanoma cell line harboring a BRAF mutation and loss of RB1 demonstrated a decreased response to Ibrance (palbociclib) treatment in culture when compared to treatment of melanoma cell lines wild-type for BRAF (PMID: 27488531)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27488531	AVv-KBTdSS-TIFzzUH3qjax	BRAF	Palbociclib	"In a preclinical study, BRAF wild-type melanoma cells demonstrated decreased cell viability when treated with Ibrance (palbociclib) in culture (PMID: 27488531)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27488531	AVv-KCFcSS-TIFzzUH5Ijax	BRAF	PLX8394	"In a preclinical study, PLX8394 had been shown to block survival and growth of vemurafenib/PLX4720-resistant cells harboring distinct BRAF activating mutations (PMID: 24422853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24422853	AVv-KCO7SS-TIFzzUH5Wjax	BRAF	PLX8394	"In a preclinical study, PLX8394 had been shown to block survival and growth of vemurafenib/PLX4720-resistant cells harboring distinct BRAF V600E splice variants (PMID: 24422853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24422853	AVv-J-92SS-TIFzzUHztjax	BRAF	PLX8394	"In a preclinical study, PLX8394 blocked survival and growth of vemurafenib/PLX4720-resistant melanoma cells harboring BRAF V600E splice variants in culture (PMID: 24422853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24422853	AVv-KBEZSS-TIFzzUH3Qjax	BRAF	PLX7904	"In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61L demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KBv3SS-TIFzzUH4jjax	BRAF	PLX7904	"In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KCuZSS-TIFzzUH6Jjax	BRAF	PLX7904	"In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KBnQSS-TIFzzUH4Vjax	BRAF	PLX7904	"In a preclinical study, PLX7904 inhibited survival of melanoma cell lines harboring monomeric BRAF V600E as well as cells harboring the Zelboraf (vemurafenib)-resistant dimeric BRAF V600E in culture (PMID: 26466569)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26466569	AVv-KAh5SS-TIFzzUH2Yjax	BRAF	PLX7904	"In a preclinical study, PLX7904 inhibited survival of colorectal cancer cells harboring BRAF V600E in culture and demonstrated anti-tumor activity in cell line xenograft models (PMID: 26466569)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26466569	AVv-J_27SS-TIFzzUH1Xjax	BRAF	PLX7904	"In a preclinical study, PLX7904 inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KB31SS-TIFzzUH4xjax	BRAF	PLX7904	"In a preclinical study, PLX7904 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-J9X-SS-TIFzzUHxCjax	BRAF	PLX7904	"In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to PLX7904 in culture (PMID: 27523909)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KB_vSS-TIFzzUH4_jax	BRAF	PLX4720 + Tivozanib	"In a preclinical study, PLX4720 and Tivozanib (AV-951) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26461489	AVv-KAhOSS-TIFzzUH2Xjax	BRAF	PLX4720 + TAK-632	"In a preclinical study, PLX4720 and TAK-632 combination treatment resulted in durable inhibition of Erk signaling and tumor growth in xenograft models of colorectal cancer cells harboring BRAF V600E (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KAObSS-TIFzzUH1-jax	BRAF	PLX4720 + Navitoclax	"In a preclinical study, PLX4720 and navitoclax (ABT-263) worked synergistically to inhibit growth and increase apoptosis of BRAF V600E mutant melanoma cells in culture and in xenografts (PMID: 24983357)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24983357	AVv-KAU7SS-TIFzzUH2Jjax	BRAF	PLX4720	"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to PLX4720 in culture (PMID: 20538618)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/20538618	AVv-J-5RSS-TIFzzUHzljax	BRAF	PLX4720	"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529M were insensitive to PLX4720-mediated inhibition of ERK signaling in culture (PMID: 20538618)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/20538618	AVv-J9cjSS-TIFzzUHxJjax	BRAF	PLX4720	"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529I were insensitive to PLX4720-mediated inhibition of ERK signaling in culture (PMID: 20538618)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/20538618	AVv-J9fxSS-TIFzzUHxOjax	BRAF	PLX4720	"In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the B-RAF inhibitor PLX4720 in culture (PMID: 19915144)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-J-S8SS-TIFzzUHykjax	BRAF	PLX4720	"In a preclinical study, knocking down of Ptpn11 expression via shRNA sensitized BRAF mutant colorectal cancer cell lines to PLX4720 in culture (PMID: 26351322)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26351322	AVv-KBQpSS-TIFzzUH3ljax	BRAF	PLX4720	"In a preclinical study, expression of MAP2K1 C121S conferred resistance to PLX4720 in melanoma cells harboring BRAF V600E in culture (PMID: 21383288)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21383288	AVv-J-g2SS-TIFzzUHy7jax	BRAF	PLX4720	"In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated a decreased response to treatment with PD-0325901, demonstrating increased viability of CD133 positive cells in culture and in xenograft models (PMID: 26573800)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26573800	AVv-KAXlSS-TIFzzUH2Njax	BRAF	PLX4720	"In a preclinical study, PLX4720 inhibited growth of melanoma cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 18287029)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18287029	AVv-KAVnSS-TIFzzUH2Kjax	BRAF	PLX4720	"In a preclinical study, PLX4720 inhibited growth of colon cancer cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 18287029)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18287029	AVv-J_tNSS-TIFzzUH1Hjax	BRAF	PLX4720	"In a preclinical study, PLX4720 inhibited Erk phosphorylation and cell proliferation of transformed cells expression BRAF V600E in culture (PMID: 20538618)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20538618	AVv-J_aKSS-TIFzzUH0mjax	BRAF	PLX4720	"In a preclinical study, PLX4720 did not inhibit growth of BRAF wild-type melanoma cells in culture or in cell line xenograft models (PMID: 18287029)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/18287029	AVv-KCD-SS-TIFzzUH5Gjax	BRAF	PLX4720	"In a preclinical study, BRAF mutant colorectal cancer cell lines demonstrated reduced sensitivity to PLX4720 in culture (PMID: 26351322)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26351322	AVv-KBFHSS-TIFzzUH3Rjax	BRAF	PF3644022 + PF-477736	"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of BRAF mutant colon cancer (PMID: 26140595)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26140595	AVv-KBNASS-TIFzzUH3ejax	BRAF	PF3644022 + PF-477736	"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of various cancer cell lines harboring BRAF mutations in culture and in cell line xenograft models (PMID: 26140595)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26140595	AVv-KA-YSS-TIFzzUH3Hjax	BRAF	PF3644022 + PF-477736	"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of transformed cells over expressing BRAF V600E in culture, while single agent inhibition had no effect (PMID: 26140595)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26140595	AVv-KAauSS-TIFzzUH2Sjax	BRAF	PF3644022 + PF-477736	"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 combination treatment resulted in significant apoptosis in primary tumor cells isolated from a lung adenocarcinoma patient harboring BRAF N581S in culture (PMID: 26140595)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26140595	AVv-KCqtSS-TIFzzUH6Djax	BRAF	PF-05212384	"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring BRAF G464V and KRAS G13D in culture (PMID: 21325073, PMID: 17314276)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17314276	AVv-KCoWSS-TIFzzUH5_jax	BRAF	PF-05212384	"In a preclinical study, Gedatolisib (PKI-587) inhibited Braf V600E in vitro and inhibited growth of human colon cancer cells harboring BRAF V600E in culture (PMID: 21325073, PMID: 24042735)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24042735	AVv-KAaHSS-TIFzzUH2Rjax	BRAF	PD-0325901	"In a preclinical study, over expression of MAPK21 L115P in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-J9tISS-TIFzzUHxkjax	BRAF	PD-0325901	"In a preclinical study, over expression of MAPK21 I103N in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-J-IaSS-TIFzzUHySjax	BRAF	PD-0325901	"In a preclinical study, over expression of BRAF V600E in KRAS-mutant colorectal cancer cells resulted in resistance to growth inhibition by PD-0325901 in cell culture (PMID: 26267534)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-J-AhSS-TIFzzUHyDjax	BRAF	PD-0325901	"In a preclinical study, a melanoma cell line xenograft model harboring BRAF V600E treated with PD-0325901 demonstrated stable tumor growth, but by day 44, growth ensued and thus, demonstrated no benefit (PMID: 27488531)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/27488531	AVv-KAD0SS-TIFzzUH1sjax	BRAF	PD-0325901	"In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated a decreased response to treatment with PD-0325901, demonstrating increased viability of CD133 positive cells in culture (PMID: 26573800)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26573800	AVv-KAY2SS-TIFzzUH2Pjax	BRAF	PD-0325901	"In a preclinical study, PD-0325901 inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 26267534)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-KADLSS-TIFzzUH1rjax	BRAF	PD-0325901	"In a preclinical study, PD-0325901 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 26267534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-J_V6SS-TIFzzUH0ejax	BRAF	PD-0325901	"In a preclinical study, PD-0325901 demonstrated antitumor activity against BRAF V600E colon cancer cell line xenografts (PMID: 16273091)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/16273091	AVv-J_ioSS-TIFzzUH01jax	BRAF	Obatoclax	"In a preclinical study, obatoclax decreased proliferation in human tumor cell lines with BRAF mutation in culture (PMID: 22460902)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22460902	AVv-KBIdSS-TIFzzUH3Wjax	BRAF	Neratinib	"In a preclinical study, Neratinib (HKI-272) inhibited growth of colorectal cancer cells harboring both BRAF G596R and PIK3CA E545K in culture (PMID: 26243863)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-KCvkSS-TIFzzUH6Ljax	BRAF	Navitoclax + Vemurafenib	"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25665005	AVv-J_KtSS-TIFzzUH0Mjax	BRAF	Navitoclax + Vemurafenib	"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25665005	AVv-KAIISS-TIFzzUH1zjax	BRAF	Navitoclax + Vemurafenib	"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human colon cancer cells harboring BRAF V600E in culture (PMID: 25665005)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25665005	AVv-J_H2SS-TIFzzUH0Hjax	BRAF	MLN0128 + PD-0325901	"In a preclinical study, TAK-228 (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PIK3CA H1047R in culture (PMID: 26272063)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26272063	AVv-J-avSS-TIFzzUHyxjax	BRAF	MLN0128	"In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to MLN0128 resulting in inhibition of MTORC1 signaling (PMID: 25261369)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25261369	AVv-KBarSS-TIFzzUH32jax	BRAF	MK2206 + Vemurafenib	"In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265152	AVv-KDFbSS-TIFzzUH6tjax	BRAF	MK2206 + Trametinib	"In a preclinical study, the combination of MK2206 and Mekinist (trametinib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265152	AVv-KDJxSS-TIFzzUH60jax	BRAF	MEK162	"In a Phase II trial, 20% (8/41) of melanoma patients with BRAF V600 mutations had a partial response to Binimetinib (MEK162) (PMID: 23414587)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23414587	AVv-J_bySS-TIFzzUH0pjax	BRAF	MEK162	"In a Phase I trial, Binimetinib (MEK162) treatment resulted in an estimated progression free survival of 1.4 months and overall survival of 7.1 months in colorectal cancer patients harboring BRAF mutations (PMID: 28152546)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28152546	AVv-KBKuSS-TIFzzUH3ajax	BRAF	Lenvatinib	"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 83% (5/6) of melanoma patients harboring NRAS mutations and wild-type BRAF (PMID: 26169970)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26169970	AVv-KCBhSS-TIFzzUH5Cjax	BRAF	Lenvatinib	"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 50% (1/2) of melanoma patients harboring both BRAF and NRAS mutations (PMID: 26169970)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26169970	AVv-KBRuSS-TIFzzUH3njax	BRAF	Lenvatinib	"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 44% (4/9) and partial response in 22% (2/9) of melanoma patients carrying wild-type BRAF and NRAS (PMID: 26169970)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26169970	AVv-KB_ISS-TIFzzUH4-jax	BRAF	Lenvatinib	"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 100% (5/5) of melanoma patients harboring BRAF mutations and wild-type NRAS (PMID: 26169970)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26169970	AVv-KBQISS-TIFzzUH3kjax	BRAF	Lapatinib + Vemurafenib	"In a preclinical study, the combination of Tykerb (lapatinib) and Zelboraf (vemurafenib) inhibited growth of thyroid cancer cells harboring a BRAF V600E mutation in culture and in BRAF-mutant mouse models of thyroid cancer (PMID: 23365119)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23365119	AVv-J-_nSS-TIFzzUHzwjax	BRAF	Lapatinib + Panobinostat	"In a preclinical study, Tykerb (lapatinib) and Faridak (panobinostat) worked synergistically to inhibit growth of BRAF V600E mutant colorectal cancer cells in culture (PMID: 21464044)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21464044	AVv-KAAnSS-TIFzzUH1njax	BRAF	LY3009120	"In a preclinical study, an ovarian cancer cell line harboring BRAF  N486_P490del was sensitive to LY3009120, resulting in inhibition of cell growth and decreased phosphorylation of MEK and ERK in culture (PMID: 26732095)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26732095	AVv-KCWgSS-TIFzzUH5ijax	BRAF	LY3009120	"In a preclinical study, a pancreatic cancer cell line harboring BRAF V487_P492delinsA were sensitive to LY3009120 in culture and in xenograft models, resulting in inhibition of tumor growth and partial tumor regression (PMID: 26732095)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26732095	AVv-KClTSS-TIFzzUH56jax	BRAF	LY3009120	"In a preclinical study, LY3009120 modestly inhibited soft agar growth of human melanoma cancer cells harboring NRAS R167L, BRAF K601E, and BRAF A665V in culture (PMID: 26343583)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KCkvSS-TIFzzUH55jax	BRAF	LY3009120	"In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-KC6dSS-TIFzzUH6cjax	BRAF	LY3009120	"In a preclinical study, LY3009120 inhibited growth, downstream MAPK signaling and soft agar growth in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26343583)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26343583	AVv-J_smSS-TIFzzUH1Gjax	BRAF	LGX818 + unspecified IGF-1R antibody	"In a preclinical study, combination treatment consists of Encorafenib (LGX818) and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KArZSS-TIFzzUH2njax	BRAF	LGX818 + Cetuximab + BYL719	"In a preclinical study, combination therapy consisted of Erbitux (cetuximab), Encorafenib (LGX818) and Alpelisib (BYL719) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-J_I-SS-TIFzzUH0Jjax	BRAF	LGX818 + Cetuximab	"In a preclinical study, combination therapy consisted of Erbitux (cetuximab) and Encorafenib (LGX818) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-J_mBSS-TIFzzUH07jax	BRAF	LGX818 + BKM120	"In a preclinical study, the combination of Buparlisib (BKM120) and Encorafenib (LGX818) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring a BRAF mutation in culture (PMID: 27307593)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27307593	AVv-KBLSSS-TIFzzUH3bjax	BRAF	Idelalisib	"In a preclinical study, Zydelig (idelalisib) did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26137449	AVv-KCfPSS-TIFzzUH5wjax	BRAF	Gefitinib + PLX4720	"In a preclinical study, Iressa (gefitinib) in combination with PLX4720 inhibited proliferation and tumorigenicity in human melanoma cell line harboring BRAF V600E and resistant to Braf inhibition in culture and in animal models (PMID: 23242808)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23242808	AVv-KAG7SS-TIFzzUH1xjax	BRAF	Gefitinib	"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Iressa (gefitinib) in culture (PMID: 27312529)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-KAqzSS-TIFzzUH2mjax	BRAF	Ganetespib + TAK-733	"In a preclinical study, the Hsp90 inhibitor, Ganetespib, in combination with the MEK1/2 inhibitor TAK-733, caused the regression of tumors in vemurafenib-resistant cell line xenograft models of melanoma (PMID: 24398428)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24398428	AVv-J_GmSS-TIFzzUH0Fjax	BRAF	Ganetespib	"In a preclinical study, the Hsp90 inhibitor Ganetespib destabilized BRAF, especially BRAF V600E, resulted in loss of cell viability in culture and antitumor effects in cell line xenograft models of melanoma (PMID: 24398428)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24398428	AVv-J_P-SS-TIFzzUH0Vjax	BRAF	GSK2636771 + unspecified IGF-1R antibody	"In a preclinical study, combination treatment consisting of GSK2636771 and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KAttSS-TIFzzUH2rjax	BRAF	GSK2636771 + NVP-AEW541	"In a preclinical study, GSK2636771 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KAuYSS-TIFzzUH2sjax	BRAF	GSK2636771 + NVP-AEW541	"In a preclinical study, GSK2636771 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KBb2SS-TIFzzUH34jax	BRAF	GSK2636771 + LGX818	"In a preclinical study, GSK2636771 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KAz1SS-TIFzzUH21jax	BRAF	GSK2636771 + LGX818	"In a preclinical study, GSK2636771 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KBgRSS-TIFzzUH4Jjax	BRAF	GSK2636771 + Binimetinib	"In a preclinical study, GSK2636771 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KAxaSS-TIFzzUH2xjax	BRAF	GSK2636771 + Binimetinib	"In a preclinical study, GSK2636771 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KBeWSS-TIFzzUH4Gjax	BRAF	GSK2636771	"In a preclinical study, GSK2636771 resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26645196	AVv-KBj4SS-TIFzzUH4Pjax	BRAF	GSK2141795	"In a preclinical study, lack of PTEN expression was associated with increased sensitivity to GSK2141795 in BRAF V600-mutant melanoma cell lines in culture (PMID: 24265152)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265152	AVv-KDM0SS-TIFzzUH65jax	BRAF	GSK2126458 + Trametinib	"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KCw1SS-TIFzzUH6Njax	BRAF	GSK2126458 + Trametinib	"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-xPSS-TIFzzUHzWjax	BRAF	GSK2126458 + Trametinib	"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J_t5SS-TIFzzUH1Ijax	BRAF	GSK2126458	"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-VNSS-TIFzzUHyojax	BRAF	GSK2126458	"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-8uSS-TIFzzUHzrjax	BRAF	GSK2126458	"In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-0eSS-TIFzzUHzcjax	BRAF	GSK2126458	"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J99oSS-TIFzzUHx-jax	BRAF	GSK2126458	"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-aFSS-TIFzzUHywjax	BRAF	GSK2126458	"In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600K in culture (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KCzQSS-TIFzzUH6Rjax	BRAF	GSK2126458	"In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J_4mSS-TIFzzUH1ajax	BRAF	GDC0879 + GDC-0941	"In a preclinical study, GDC0879 and Pictilisib (GDC-0941) synergistically inhibited survival of melanoma cell lines harboring BFAF V600E and PTEN loss in cell culture (PMID: 19276360)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-J93GSS-TIFzzUHxzjax	BRAF	GDC0879	"In a preclinical study, non-small cell lung cancer cells harboring BFAF L485Y were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-KCYlSS-TIFzzUH5ljax	BRAF	GDC0879	"In a preclinical study, colon cancer cells harboring BFAF N581Y were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-J9ipSS-TIFzzUHxTjax	BRAF	GDC0879	"In a preclinical study, GDC0879 inhibited survival of melanoma cell lines harboring BFAF V600E in cell culture, cell line xenogfaft and patient-derived xenograft models (PMID: 19276360)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-KAHdSS-TIFzzUH1yjax	BRAF	GDC0879	"In a preclinical study, GDC0879 inhibited survival of colon cancer cell lines harboring BFAF V600E in cell culture and cell line xenogfaft models (PMID: 19276360)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-J_8JSS-TIFzzUH1gjax	BRAF	GDC0879	"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type pancreatic cancer cells harboring KRAS G12D in cell line xenograft models (PMID: 19276360)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-KCATSS-TIFzzUH5Ajax	BRAF	GDC0879	"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells in culture and in patient-derived xenograft models (PMID: 19276360)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-KCCGSS-TIFzzUH5Djax	BRAF	GDC0879	"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS Q61K in culture and in cell line xenograft models (PMID: 19276360)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-KB5gSS-TIFzzUH40jax	BRAF	GDC0879	"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS G12V in patient-derived xenograft models (PMID: 19276360)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-KB7QSS-TIFzzUH43jax	BRAF	GDC0879	"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS G12C in patient-derived xenograft models (PMID: 19276360)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-KB6BSS-TIFzzUH41jax	BRAF	GDC0879	"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type melanoma cells in cell culture, cell line xenograft models, and patient-derived xenograft models (PMID: 19276360)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-KCDPSS-TIFzzUH5Fjax	BRAF	GDC0879	"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type melanoma cells harboring NRAS Q61K in patient-derived xenograft models (PMID: 19276360)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-KB6rSS-TIFzzUH42jax	BRAF	GDC0879	"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type colon cancer cells harboring KRAS G13D in culture ann in cell line xenograft models (PMID: 19276360)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19276360	AVv-KB7xSS-TIFzzUH44jax	BRAF	GDC-0941 + PLX4720	"In a preclinical study, a melanoma cell line harboring BRAF V600E and PTEN loss demonstrated sensitivity when treated with a combination of Pictilisib (GDC-0941) and PLX4720, resulting in decreased cell proliferation in culture (PMID: 24265153)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-J92iSS-TIFzzUHxyjax	BRAF	GDC-0941 + NVP-AEW541	"In a preclinical study, Pictilisib (GDC-0941) and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KAtJSS-TIFzzUH2qjax	BRAF	GDC-0941 + LGX818	"In a preclinical study, Pictilisib (GDC-0941) and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KA0fSS-TIFzzUH22jax	BRAF	GDC-0941 + Binimetinib	"In a preclinical study, Pictilisib (GDC-0941) and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KA2XSS-TIFzzUH25jax	BRAF	GDC-0941	"In a preclincal study, Pictilisib (GDC-0941) inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KA1wSS-TIFzzUH24jax	BRAF	Fluorouracil + Leucovorin + Trastuzumab	"In a clinical case study, a rectal adenocarcinoma patient harboring APC Q1429fs, BRAF N581S, and ERBB2 L755S did not respond to Herceptin (trastuzumab) treatment in combination with Fluorouracil and Wellcovorin (leucovorin) (PMID: 27626067)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27626067	AVv-KCrTSS-TIFzzUH6Ejax	BRAF	Everolimus + Selumetinib	"In a preclinical study, Selumetinib (AZD6244) and Afinitor (everolimus) synergistically inhibited growth and induced apoptosis in glioma cell lines in culture, resulted in prolonged survival in cell line xenograft models (PMID: 27217440)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27217440	AVv-J_SzSS-TIFzzUH0Zjax	BRAF	Everolimus + Selumetinib	"In a preclinical study, Afinitor (everolimus) and Selumetinib (AZD6244) synergistically inhibited growth and induced apoptosis in glioma cell lines in culture (PMID: 27217440)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27217440	AVv-KCG6SS-TIFzzUH5Kjax	BRAF	Everolimus + Pimasertib	"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-J_HQSS-TIFzzUH0Gjax	BRAF	Everolimus + Pimasertib	"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23629727	AVv-J-tuSS-TIFzzUHzQjax	BRAF	Everolimus + PLX4720	"In a preclinical study, Afinitor (everolimus) and PLX4720 synergistically inhibited growth and induced apoptosis in glioma cell lines in culture (PMID: 27217440)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27217440	AVv-J_YESS-TIFzzUH0ijax	BRAF	Everolimus	"In a clinical study, a melanoma patient harboring PTEN loss and BRAF V600E demonstrated resistance to Afinitor (everolimus) treatment, resulting in progressive disease (PMID: 20664172)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/20664174	AVv-J918SS-TIFzzUHxxjax	BRAF	Everolimus	"In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to treatment with Afinitor (everolimus) (PMID: 27797976)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27797976	AVv-J9lBSS-TIFzzUHxXjax	BRAF	E6201 + LY294002	"In a preclinical study, E6201 and LY294002 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations in culture, regardless of PTEN mutation status (PMID: 23039341)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23039341	AVv-KBJlSS-TIFzzUH3Yjax	BRAF	E6201	"In a preclinical study, E6201 resulted in a cytostatic response in melanoma cell lines harboring both BRAF and PTEN mutations in culture and only inhibited tumor growth at very high doses in cell line xenograft models (PMID: 23039341)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/23039341	AVv-KBUkSS-TIFzzUH3sjax	BRAF	E6201	"In a preclinical study, E6201 resulted in a cytocidal response in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture and inhibited tumor growth in cell line xenograft models (PMID: 23039341)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23039341	AVv-KBfnSS-TIFzzUH4Ijax	BRAF	E6201	"In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with BRAF mutations (PMID: 23039341)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23039341	AVv-KBJDSS-TIFzzUH3Xjax	BRAF	E6201	"In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell lines harboring BRAF V600E mutation in culture (PMID: 24448821)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24448821	AVv-J_sCSS-TIFzzUH1Fjax	BRAF	E6201	"In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell line harboring BRAF V600E mutation and overexpressing MAP2K1 C121S in culture (PMID: 24448821)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24448821	AVv-J-e_SS-TIFzzUHy4jax	BRAF	Dasatinib	"In a preclinical study, Sprycel (dasatinib) inhibited cell invasion, cell signaling, and proliferation in human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture and in animal models (PMID: 23242808)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23242808	AVv-J_ZjSS-TIFzzUH0ljax	BRAF	Dasatinib	"In a preclinical study, Sprycel (dasatinib) induced apoptosis in non-small cell lung carcinoma cells harboring BRAF Y472C in culture (PMID: 22649091)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22649091	AVv-KCr6SS-TIFzzUH6Fjax	BRAF	Dasatinib	"In a preclinical study, Sprycel (dasatinib) induced apoptosis in non-small cell lung cancer cells expressing BRAF G466V in culture (PMID: 22649091)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22649091	AVv-KBzzSS-TIFzzUH4qjax	BRAF	Dasatinib	"In a preclinical study, Sprycel (dasatinib) failed to induce apoptosis in lung carcinoma cells expressing BRAF V600E (PMID: 22649091)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22649091	AVv-J_7BSS-TIFzzUH1ejax	BRAF	Dabrafenib + SCH772984	"In a preclinical study, combination therapy consisted of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-KAUVSS-TIFzzUH2Ijax	BRAF	Dabrafenib + GSK2126458	"In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-xxSS-TIFzzUHzXjax	BRAF	Dabrafenib + GSK2126458	"In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) did not improve the response to human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture (PMID: 22389471)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-8ISS-TIFzzUHzqjax	BRAF	Dabrafenib + GSK2126458	"In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KCxXSS-TIFzzUH6Ojax	BRAF	Dabrafenib + GSK2126458	"In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KABOSS-TIFzzUH1ojax	BRAF	Dabrafenib	Tafinlar (dabrafenib) is an active regimen for melanoma patients with BRAF V600K (Guidelines).	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/detail...	AVv-KC3ySS-TIFzzUH6Yjax	BRAF	Dabrafenib	"In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KBuvSS-TIFzzUH4hjax	BRAF	Dabrafenib	"In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KCsiSS-TIFzzUH6Gjax	BRAF	Dabrafenib	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-J-iMSS-TIFzzUHy9jax	BRAF	Dabrafenib	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture (PMID: 24265153)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-J-kJSS-TIFzzUHzAjax	BRAF	Dabrafenib	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265153	AVv-J-mbSS-TIFzzUHzEjax	BRAF	Dabrafenib	"In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KBmMSS-TIFzzUH4Tjax	BRAF	Dabrafenib	"In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-KCypSS-TIFzzUH6Qjax	BRAF	Dabrafenib	"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-UBSS-TIFzzUHymjax	BRAF	Dabrafenib	"In a preclinical study, melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J9kcSS-TIFzzUHxWjax	BRAF	Dabrafenib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J99FSS-TIFzzUHx9jax	BRAF	Dabrafenib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-7qSS-TIFzzUHzpjax	BRAF	Dabrafenib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing NRAS Q61K were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-KJSS-TIFzzUHyVjax	BRAF	Dabrafenib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-y0SS-TIFzzUHzZjax	BRAF	Dabrafenib	"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22389471	AVv-J-XhSS-TIFzzUHysjax	BRAF	Dabrafenib	"In a preclinical study, expression of MAP2K1 K57E in a melanoma cell line harboring BRAF V600E conferred resistance to Tafinlar (dabrafenib) in culture (PMID: 25370473)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25370473	AVv-J-BhSS-TIFzzUHyFjax	BRAF	Dabrafenib	"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Tafinlar (dabrafenib) in culture (PMID: 27500726)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27500726	AVv-KBV0SS-TIFzzUH3ujax	BRAF	Dabrafenib	"In a preclinical study, colorectal cancer cell lines harboring a BRAF V600E mutation had increased sensitivity to Tafinlar (dabrafenib) in culture compared to cell lines with wild-type BRAF (PMID: 24885690)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24885690	AVv-KAPlSS-TIFzzUH2Ajax	BRAF	Dabrafenib	"In a preclinical study, a pancreatic cancer cell line harboring BRAF V487_P492delinsA was resistant to Tafinlar (dabrafenib) (PMID: 26732095)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26732095	AVv-KCl6SS-TIFzzUH57jax	BRAF	Dabrafenib	"In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25370473	AVv-KC3JSS-TIFzzUH6Xjax	BRAF	Dabrafenib	"In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124L demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25370473	AVv-KC1RSS-TIFzzUH6Ujax	BRAF	Dabrafenib	"In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in cell culture (PMID: 25370473)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25370473	AVv-J9yhSS-TIFzzUHxsjax	BRAF	Dabrafenib	"In a preclinical study, Tafinlar (dabrafenib) resulted in minimal growth inhibitory activity of an ovarian cancer cell line harboring BRAF N486_P490del (PMID: 26732095)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/26732095	AVv-KCX8SS-TIFzzUH5kjax	BRAF	Dabrafenib	"In a preclinical study, Tafinlar (dabrafenib) inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KB2uSS-TIFzzUH4vjax	BRAF	Dabrafenib	"In a preclinical study, Tafinlar (dabrafenib) inhibited proliferation of melanoma cells harboring BRAF V600D in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-J9WySS-TIFzzUHxAjax	BRAF	Dabrafenib	"In a clinical case study, a melanoma patient harboring BRAF V600R treated with Tafinlar (dabrafenib) demonstrated a reduction in lesion size after 2.5 months and at 5 months, stable disease, however, after 7 months progression ensued (PMID: 27255157)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27255157	AVv-KB3USS-TIFzzUH4wjax	BRAF	Dabrafenib	"In a Phase III clinical trial that supported FDA approval, Tafinlar (dabrafenib) improved progression free survival compared to Deticene (dacarbazine) in patients with BRAF V600E positive melanoma (PMID: 22735384)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22735384	AVv-KAdQSS-TIFzzUH2Ujax	BRAF	Dabrafenib	"In a Phase I clinical trial, Tafinlar (dabrafenib) demonstrated safety and efficacy in patients with BRAF V600E positive solid tumors (PMID: 22608338)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22608338	AVv-KBPESS-TIFzzUH3ijax	BRAF	DHM25	"In a preclinical study, DHM25 increased cell death and decreased migration of a triple-negative breast cancer cell line harboring KRAS G13D and BRAF G464V in culture, and reduced tumor growth and lung metastasis in xenograft models (PMID: 26237138)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26237138	AVv-KCpjSS-TIFzzUH6Bjax	BRAF	DETD-35 + Vemurafenib	"In a preclinical study, DETD-35 and Zelboraf (vemurafenib) synergistically inhibited proliferation and colony formation of melanoma cells harboring BRAF V600E in culture and reduced tumor size in xenograft models (PMID: 27048951)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27048951	AVv-J_2bSS-TIFzzUH1Wjax	BRAF	DETD-35	"In a preclinical study, DETD-35 inhibited proliferation and colony formation of melanoma cells harboring BRAF V600E in culture and reduced tumor size in xenograft models (PMID: 27048951)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27048951	AVv-J_nGSS-TIFzzUH09jax	BRAF	DEL-22379	"In a preclinical study, DEL-22379 inhibited tumor growth in a colorectal adenocarcinoma patient-derived xenograft model harboring BRAF V600E (PMID: 26267534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-J_YjSS-TIFzzUH0jjax	BRAF	DEL-22379	"In a preclinical study, DEL-22379 inhibited growth of melanoma cells harboring BRAF V600E with high levels of ERK dimerization in culture and inhibited tumor progression in melanoma xenograft models harboring BRAF V600E (PMID: 26267534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-KAPESS-TIFzzUH1_jax	BRAF	DEL-22379	"In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and over expressing NRAS G12V in culture (PMID: 26267534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-J-1mSS-TIFzzUHzejax	BRAF	DEL-22379	"In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 26267534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-J9tvSS-TIFzzUHxljax	BRAF	DEL-22379	"In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N in culture (PMID: 26267534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-J-JASS-TIFzzUHyTjax	BRAF	DEL-22379	"In a preclinical study, DEL-22379 inhibited growth of KRAS-mutant melanoma cells over expressing BRAF V600E in culture (PMID: 26267534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26267534	AVv-J-BASS-TIFzzUHyEjax	BRAF	Cobimetinib	"In a preclinical study, Cobimetinib (GDC-0973) induced cell death in human melanoma cell lines harboring BRAF activating mutations in culture and inhibited tumor growth in xenograft models (PMID: 22084396)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22084396	AVv-KCOVSS-TIFzzUH5Vjax	BRAF	Cetuximab + Selumetinib	"In a preclinical study, Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-J_XfSS-TIFzzUH0hjax	BRAF	Cetuximab + SCH772984	"In a preclinical study, combination therapy consisted of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-J_EHSS-TIFzzUH0Bjax	BRAF	Cetuximab + Irinotecan	"In a retrospective study, 100% (2/2) colorectal carcinoma patients harboring an AKT1 E17K mutation and wild-type KRAS/BRAF demonstrated resistance to Erbitux (cetuximab) in combination with Camptosar (irinotecan) (PMID: 25714871)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25714871	AVv-KCA6SS-TIFzzUH5Bjax	BRAF	Cetuximab + Dabrafenib + Trametinib	"In a preclinical study, combination therapy consisted of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-KAW8SS-TIFzzUH2Mjax	BRAF	Cetuximab + Dabrafenib + SCH772984	"In a preclinical study, combination therapy consisted of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-J_3-SS-TIFzzUH1Zjax	BRAF	Cetuximab + Dabrafenib	"In a preclinical study, combination therapy consisted of Erbitux (cetuximab) and Tafinlar (dabrafenib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-J_NzSS-TIFzzUH0Rjax	BRAF	Cetuximab	"In a retrospective study, Erbitux (cetuximab) treatment, alone or in combination, resulted in disease regression or stable disease in 88% (7/8) KRAS/BRAF-wild type colorectal carcinoma patients harboring a PIK3CA mutation (PMID: 25714871)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25714871	AVv-KB8ZSS-TIFzzUH45jax	BRAF	Cetuximab	"In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Erbitux (cetuximab) in culture (PMID: 25838391)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-J-shSS-TIFzzUHzOjax	BRAF	Cetuximab	"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Erbitux (cetuximab) in culture (PMID: 27312529)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-KApDSS-TIFzzUH2jjax	BRAF	Cetuximab	"In a preclinical study, colorectal cancer cell lines harboring BRAF V600E were resistant to Erbitux (cetuximab) in culture (PMID: 27312529)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/27312529	AVv-J__RSS-TIFzzUH1ljax	BRAF	Cetuximab	"In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells wild-type for BRAF, KRAS, NRAS and PIK3CA in culture (PMID: 25838391)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25838391	AVv-KCJsSS-TIFzzUH5Ojax	BRAF	Cetuximab	"In a clinical study, a colorectal cancer patient harboring EGFR amplification, BRAF V600E, and EGFR S492R demonstrated resistance to Erbitux (cetuximab) (PMID: 22270724)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22270724	AVv-J-lPSS-TIFzzUHzCjax	BRAF	Cediranib + Selumetinib + PLX4720	"In a preclinical study, PLX4720, Cediranib (AZD-2171) and Selumetinib (AZD6244) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26461489	AVv-J_zTSS-TIFzzUH1Qjax	BRAF	CLM3	"In a preclinical study, CLM3 inhibited growth, Egfr signaling, and CCND1 expression, in BRAF wild-type thyroid cancer cells in culture (PMID: 24423321)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24423321	AVv-KCCqSS-TIFzzUH5Ejax	BRAF	CLM3	"In a preclinical study, CLM3 inhibited growth, Egfr signaling, and CCND1 expression in thyroid cancer cells harboring BRAF V600E in culture (PMID: 24423321)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24423321	AVv-J_o4SS-TIFzzUH1Ajax	BRAF	CI-1040	"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by CI-1040 in cell culture (PMID: 19915144)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/19915144	AVv-J97PSS-TIFzzUHx6jax	BRAF	CI-1040	"In a preclinical study, CI-1040 inhibited growth of a human ovarian cancer cell line harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models (PMID: 19018267)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19018267	AVv-J_g4SS-TIFzzUH0yjax	BRAF	CI-1040	"In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation in transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M in culture (PMID: 20538618)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20538618	AVv-J9d9SS-TIFzzUHxLjax	BRAF	CI-1040	"In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation in transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529I in culture (PMID: 20538618)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20538618	AVv-J9gUSS-TIFzzUHxPjax	BRAF	CI-1040	"In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation and growth of transformed cells expressing BRAF V600E in culture (PMID: 20538618)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20538618	AVv-J_F_SS-TIFzzUH0Ejax	BRAF	CI-1040	"In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation and growth of transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529N in culture (PMID: 20538618)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20538618	AVv-J-4xSS-TIFzzUHzkjax	BRAF	CH5132799	"In a preclinical study, CH5132799 demonstrated decreased response to tumor growth inhibition in xenograft models of human breast cancer cell lines harboring KRAS G13D and BRAF G464V (PMID: 21558396)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-KCo9SS-TIFzzUH6Ajax	BRAF	CEP-32496	"In preclinical studies, CEP-32496 (RXDX-105) reduced tumor volume and promoted tumor regression in xenograft models of a BRAF V600E mutant human melanoma cell line (PMID: 22319199)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22319199	AVv-J_UwSS-TIFzzUH0cjax	BRAF	CEP-32496	"In preclinical studies, CEP-32496 (RXDX-105) reduced tumor volume and promoted tumor regression in xenograft models of a BRAF V600E mutant human colon carcinoma cell line (PMID: 22319199)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22319199	AVv-J_CzSS-TIFzzUHz_jax	BRAF	CCT241161	"In a preclinical study, CCT241161 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 25500121, PMID: 15294323)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25500121	AVv-J_jzSS-TIFzzUH03jax	BRAF	CCT241161	"In a preclinical study, CCT241161 inhibited growth of a human melanoma cell line harboring BRAF V600E in culture, and induced tumor regression in several BRAF V600E-mutant melanoma patient-derived xenograft models (PMID: 25500121)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25500121	AVv-KAEeSS-TIFzzUH1tjax	BRAF	CCT241161	"In a preclinical study, CCT241161 inhibited MEK and ERK phosphorylation and growth of melanoma cells harboring BRAF V600D in culture (PMID: 25500121, PMID: 17210691)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25500121	AVv-J9aqSS-TIFzzUHxGjax	BRAF	CCT196969	"In a preclinical study, CCT196969 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 25500121, PMID: 15294323)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25500121	AVv-J_ytSS-TIFzzUH1Pjax	BRAF	CCT196969	"In a preclinical study, CCT196969 inhibited growth of a human melanoma cell line harboring BRAF V600E in culture, and induced tumor regression in several BRAF V600E-mutant melanoma patient-derived xenograft models (PMID: 25500121)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25500121	AVv-KAfpSS-TIFzzUH2Wjax	BRAF	CCT196969	"In a preclinical study, CCT196969 inhibited MEK and ERK phosphorylation and growth of melanoma cells harboring BRAF V600D in culture (PMID: 25500121, PMID: 17210691)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25500121	AVv-J9XaSS-TIFzzUHxBjax	BRAF	Binimetinib + BKM120	"In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring a BRAF mutation in culture (PMID: 27307593)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27307593	AVv-KBDnSS-TIFzzUH3Pjax	BRAF	BYL719 + NVP-AEW541	"In a preclinical study, BYL719 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KAvmSS-TIFzzUH2ujax	BRAF	BYL719 + MEK162	"In a preclinical study, BYL719 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KAw0SS-TIFzzUH2wjax	BRAF	BYL719 + LGX818	"In a preclinical study, BYL719 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KA4ySS-TIFzzUH29jax	BRAF	BYL719 + GSK2636771 + LGX818	"In a preclinical study, the combination of GSK2636771, Encorafenib (LGX818), and BYL719 efficiently inhibited tumor growth in xenograft models of a human melanoma cell line harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KA5ZSS-TIFzzUH2-jax	BRAF	BYL719	"In a preclincal study, melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations were less sensitive to BYL719 induced growth inhibition in culture (PMID: 26577700)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KAx8SS-TIFzzUH2yjax	BRAF	BKM120 + Vemurafenib	"In a preclinical study, the combination of Buparlisib (BKM120) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265152	AVv-KDAPSS-TIFzzUH6ljax	BRAF	BKM120 + Trametinib	"In a preclinical study, the combination of Buparlisib (BKM120) and Mekinist (trametinib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265152	AVv-KDMHSS-TIFzzUH64jax	BRAF	BKM120 + Selumetinib	"In a preclinical study, the combination of Buparlisib (BKM120) and Selumetinib (AZD6244) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24265152	AVv-KDEFSS-TIFzzUH6rjax	BRAF	BKM120	"In a preclinical study, Buparlisib (BKM120) treatment in human melanoma cell line xenograft models with brain metastases and harboring a BRAF mutation resulted in inhibition of brain tumor growth (PMID: 27307593)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27307593	AVv-KBC1SS-TIFzzUH3Ojax	BRAF	BI2536	"In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated sensitivity to BI2536 in culture (PMID: 26573800)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26573800	AVv-J_LWSS-TIFzzUH0Njax	BRAF	BI-847325	"In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to an NRAS mutation in culture (PMID: 25873592)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25873592	AVv-KBSUSS-TIFzzUH3ojax	BRAF	BI-847325	"In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to a KRAS mutation in culture (PMID: 25873592)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25873592	AVv-KBRKSS-TIFzzUH3mjax	BRAF	BI-69A11	"In a preclinical study, BI-69A11 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20531415	AVv-J_7nSS-TIFzzUH1fjax	BRAF	BI 882370 + Trametinib	"In a preclinical study, xenograft models of melanoma harboring BRAF V600E treated with the combination of BI 882370 and Mekinist (trametinib) demonstrated tumor regression with no regrowth during the 5 weeks of treatment (PMID: 26916115)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26916115	AVv-J-_BSS-TIFzzUHzvjax	BRAF	BI 882370 + Trametinib	"In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Mekinist (trametinib) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26916115	AVv-KAFtSS-TIFzzUH1vjax	BRAF	BI 882370 + Cetuximab	"In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Erbitux (cetuximab) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26916115	AVv-J_hcSS-TIFzzUH0zjax	BRAF	BI 882370 + Afatinib	"In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Gilotrif (afatinib) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26916115	AVv-KATwSS-TIFzzUH2Hjax	BRAF	BGB-283 + Cetuximab	"In a preclinical study, BGB-283 in combination with Erbitux (cetuximab) demonstrated enhanced tumor suppression in colorectal cancer cell line xenograft models harboring BRAF V600E (PMID: 26208524)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26208524	AVv-J_ejSS-TIFzzUH0ujax	BRAF	BGB-283	"In a preclinical study, a variety of BRAF wild-type tumor cell lines were insensitive to BGB-283 in culture (PMID: 26208524)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26208524	AVv-KCHrSS-TIFzzUH5Ljax	BRAF	BGB-283	"In a preclinical study, BGB-283 inhibited viability of a variety of cancer cell lines harboring BRAF V600E in culture (PMID: 26208524)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26208524	AVv-J_NRSS-TIFzzUH0Qjax	BRAF	BGB-283	"In a preclinical study, BGB-283 inhibited Braf phosphorylation and cell proliferation in melanoma cell lines harboring BRAF V600E in culture (PMID: 26208524)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26208524	AVv-J_zzSS-TIFzzUH1Rjax	BRAF	BEZ235 + Vemurafenib	"In a preclinical study, BEZ235 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26137449	AVv-KCcnSS-TIFzzUH5sjax	BRAF	AZD6482 + NVP-AEW541	"In a preclinical study, AZD6482 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KAzNSS-TIFzzUH20jax	BRAF	AZD6482 + NVP-AEW541	"In a preclinical study, AZD6482 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KBckSS-TIFzzUH35jax	BRAF	AZD6482 + LGX818 + NVP-AEW541	"In a preclinical study, combination treatment consists of AZD6482, Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KA3kSS-TIFzzUH27jax	BRAF	AZD6482 + LGX818 + BYL719	"In a preclinical study, combination treatment consists of AZD6482, Encorafenib (LGX818), and BYL719 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KAwPSS-TIFzzUH2vjax	BRAF	AZD6482 + LGX818	"In a preclinical study, AZD6482 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KAshSS-TIFzzUH2pjax	BRAF	AZD6482 + LGX818	"In a preclinical study, AZD6482 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KBdYSS-TIFzzUH4Fjax	BRAF	AZD6482 + Binimetinib + NVP-AEW541	"In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KA2-SS-TIFzzUH26jax	BRAF	AZD6482 + Binimetinib + BYL719	"In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), and BYL719 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KA7oSS-TIFzzUH3Cjax	BRAF	AZD6482 + Binimetinib	"In a preclinical study, AZD6482 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KAu-SS-TIFzzUH2tjax	BRAF	AZD6482 + Binimetinib	"In a preclinical study, AZD6482 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KBfCSS-TIFzzUH4Hjax	BRAF	AZD6482 + BYL719	"In a preclinical study, AZD6482 and BYL719 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KA7HSS-TIFzzUH3Bjax	BRAF	AZD6482	"In a preclincal study, AZD6482 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26577700	AVv-KAykSS-TIFzzUH2zjax	BRAF	AZ628 + Selumetinib	"In a preclinical study, Selumetinib (AZD6244) and AZ628 synergistically inhibited Mapk signaling and cell proliferation in BRAF mutant colorectal cancer cell lines in culture (PMID: 26351322)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26351322	AVv-KA_GSS-TIFzzUH3Ijax	BRAF	AZ628 + Selumetinib	"In a preclinical study, BRAF mutant melanoma cells over-expressing KRAS G12V were resistant to Selumetinib (AZD6244) and AZ628 combination treatment in culture (PMID: 26351322)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26351322	AVv-KBZXSS-TIFzzUH30jax	BRAF	AZ628	"In a preclinical study, AZ628 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KBs8SS-TIFzzUH4ejax	BRAF	AZ628	"In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KACkSS-TIFzzUH1qjax	BRAF	AZ628	"In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KCu-SS-TIFzzUH6Kjax	BRAF	AZ628	"In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF V600R in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KB46SS-TIFzzUH4zjax	BRAF	AZ628	"In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-J9ZOSS-TIFzzUHxEjax	BRAF	AZ628	"In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF G466E in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KBk6SS-TIFzzUH4Rjax	BRAF	AZ628	"In a preclinical study, AZ628 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27523909	AVv-KB9bSS-TIFzzUH47jax	BRAF	AMG 232	"In a preclinical study, AMG 232 inhibited growth of a melanoma cell line with wild-type TP53, that also harbored a BRAF mutation, in culture and inhibited tumor growth in a TP53 wild-type BRAF-mutant melanoma cell line xenograft model (PMID: 25567130)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25567130	AVv-KBXmSS-TIFzzUH3xjax	BRAF	A66	"In a preclinical study, A66 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26137449	AVv-KCeASS-TIFzzUH5ujax	BCORL1	N/A	"In a clinical study, BCORL1 over expression was associated with decreased overall survival and recurrence-free survival in patients with hepatocellular carcinoma (PMID: 26879601), suggesting that this may serve as a future prognostic biomarker."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/26879601	AVv-J8cESS-TIFzzUHwyjax	BCOR	Tretinoin	"In a clinical case study, a patient with acute promyelocytic leukemia harboring BCOR-RARA demonstrated sensitivity to treatment with Vesanoid (tretinoin) and achieved a complete response (PMID: 25790901)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25790901	AVv-J8RkSS-TIFzzUHwxjax	ATRX	Topotecan	"In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26936505	AVv-J8F8SS-TIFzzUHwtjax	ATRX	Irinotecan	"In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26936505	AVv-J8FXSS-TIFzzUHwsjax	ATRX	Gemcitabine + Radiotherapy	"In a Phase I trial, Gemzar (gemcitabine) plus radiation therapy resulted in median overall survival of 73.5 months in 7 high-grade glioma patients with IDH mutated, non-codeleted tumors with ATRX loss (PMID: 26853339)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26853339	AVv-J8EuSS-TIFzzUHwrjax	ATRX	E7449	"In a preclinical study, E7449 inhibited proliferation of a ATRX-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair pathway mutations (PMID: 26513298)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26513298	AVv-J8HCSS-TIFzzUHwvjax	ATRX	Doxorubicin	"In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26936505	AVv-J8GeSS-TIFzzUHwujax	ATM	YU238259	"In a preclinical study, YU238259 demonstrated increased cytotoxicity in ATM-deficient transformed human cell lines in culture (PMID: 26116172)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26116172	AVv-J7soSS-TIFzzUHwijax	ATM	Veliparib	"In a preclinical study, knockdown of ATM in a gastric cancer cell line resulted in increased sensitivity to Veliparib (ABT-888) in culture and in xenograft models (PMID: 27638859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27638859	AVv-J7lmSS-TIFzzUHwWjax	ATM	Veliparib	"In a preclinical study, high ATM expression was associated with decreased response to Veliparib (ABT-888) in gastric cancer cell lines in culture (PMID: 27638859)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27638859	AVv-J7wJSS-TIFzzUHwojax	ATM	Veliparib	"In a preclinical study, an ATM-deficient cell line demonstrated increased sensitivity to Veliparib (ABT-888) compared to an ATM-reconstituted cell line, in culture (PMID: 21300883)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21300883	AVv-J7nxSS-TIFzzUHwajax	ATM	Olaparib + Valproic Acid	"In a preclinical study, the combination of Lynparza (olaparib) an valproic acid worked synergistically to inhibit growth of a mantle cell lymphoma cell line harboring an ATM inactivating mutation in culture (PMID: 20739657)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20739657	AVv-J7qJSS-TIFzzUHwejax	ATM	Olaparib	"In a preclinical study, lymphoblastoid cell lines with ATM inactivation derived from ataxia-telangiectasia patients demonstrated increased sensitivity to Lynparza (olaparib) in culture, compared to ATM wild-type cell lines (PMID: 20739657)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20739657	AVv-J7o_SS-TIFzzUHwcjax	ATM	Olaparib	"In a preclinical study, a mantle cell lymphoma cell line with ATM inactivation demonstrated sensitivity to Lynparza (olaparib) in culture and in xenograft models (PMID: 20739657)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20739657	AVv-J7sBSS-TIFzzUHwhjax	ATM	Olaparib	"In a Phase II clinical trial, 80% (4/5) of metastatic, castration-resistant prostate cancer patients harboring an ATM inactivating mutation responded to Lynparza (olaparib) (PMID: 26510020)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26510020	AVv-J7rdSS-TIFzzUHwgjax	ATM	Irinotecan	"In a preclinical study, high ATM expression was associated with decreased response to Camptosaur (irinotecan) in gastric cancer cell lines in culture (PMID: 27638859)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27638859	AVv-J7w6SS-TIFzzUHwpjax	ATM	Fludarabine + Olaparib	"In a preclinical study, Lynparza (olaparib) sensitized a mantle cell lymphoma cell line harboring an ATM inactivating mutation to Fludara (fludarabine) in cell culture, resulting in decreased cell survival (PMID: 20739657)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20739657	AVv-J7oYSS-TIFzzUHwbjax	ATM	E7449	"In a preclinical study, E7449 inhibited proliferation of a ATM-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair pathway mutations (PMID: 26513298)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26513298	AVv-J7qwSS-TIFzzUHwfjax	ATM	Bendamustine + Olaparib	"In a preclinical study, Lynparza (olaparib) sensitized a mantle cell lymphoma cell line harboring an ATM inactivating mutation to Treanda (bendamustine) in cell culture, resulting in growth inhibition (PMID: 20739657)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20739657	AVv-J7pnSS-TIFzzUHwdjax	ATM	BMN673	"In a preclinical study, knockdown of ATM expression sensitized breast cancer cells to treatment with Talazoparib (BMN-673) in culture (PMID: 23881923)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23881923	AVv-J7mqSS-TIFzzUHwYjax	ATM	AZD6738 + Ibrutinib	"In a preclinical study, AZD6738 sensitized ATM-deficient chronic lymphocytic leukemia cells to Imbruvica (Ibrutinib) treatment in culture (PMID: 26563132)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26563132	AVv-J7u8SS-TIFzzUHwmjax	ATM	AZD6738 + Cisplatin	"In a preclinical study, AZD6738 and Platinol (cisplatin) synergistically induced cell death in ATM-deficient non-small cell lung carcinoma cell lines in culture, and caused rapid tumor regression in xenograft models (PMID: 26517239)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26517239	AVv-J7uXSS-TIFzzUHwljax	ATM	AZD6482	"In a preclinical study, AZD6482 induced cell death in ATM-deficient chronic lymphocytic leukemia cells in culture and inhibited tumor growth in xenograft models (PMID: 26563132)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26563132	AVv-J7txSS-TIFzzUHwkjax	ASXL1	N/A	"In multiple clinical studies, nonsense and frameshift mutations in ASXL1 were associated with decreased overall survival in patients with chronic myelomonocytic leukemia (PMID: 26849014, PMID: 23690417, PMID: 20880116)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/20880116	AVv-J7H7SS-TIFzzUHwRjax	ASXL1	N/A	"In clinical analyses, mutations in ASXL1 were associated with poor prognosis in patients in patients with myelodysplastic syndrome (PMID: 24220272, PMID: 21714648)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/24220272	AVv-J7IpSS-TIFzzUHwSjax	ASXL1	Decitabine	"In a clinical study, myelodysplastic syndrome patients carrying wild-type ASXL1 and TET2 mutations demonstrated increased response to the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) (PMID: 25224413)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25224413	AVv-J7JQSS-TIFzzUHwTjax	ASXL1	Azacitidine	"In a clinical study, myelodysplastic syndrome patients carrying wild-type ASXL1 and TET2 mutations demonstrated increased response to the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) (PMID: 25224413)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25224413	AVv-J7J1SS-TIFzzUHwUjax	APC	iCRT-5	"In a preclinical study, iCRT-5 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture (PMID: 21393571)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21393571	AVv-J6mtSS-TIFzzUHvujax	APC	iCRT-3	"In a preclinical study, iCRT-3 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture (PMID: 21393571)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21393571	AVv-J6veSS-TIFzzUHv9jax	APC	XAV939	"In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J6R1SS-TIFzzUHvLjax	APC	XAV939	"In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs*3 demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J6edSS-TIFzzUHvgjax	APC	XAV939	"In a preclinical study, a colorectal cancer cell line harboring APC  N1819fs*7 and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J6QnSS-TIFzzUHvJjax	APC	XAV939	"In a preclinical study, XAV939 inhibited growth of colorectal cancer cells harboring APC inactivating mutations in culture (PMID: 19759537)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19759537	AVv-J6nUSS-TIFzzUHvvjax	APC	XAV939	"In a preclinical study, XAV939 inhibited growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J6aoSS-TIFzzUHvajax	APC	XAV939	"In a preclinical study, XAV939 inhibited growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J6jOSS-TIFzzUHvojax	APC	Vinorelbine	"In preclinical studies, cells deficient in Apc protein had increased sensitivity to Navelbine (vinorelbine) compared to wild-type cells, and Navelbine (vinorelbine) treament decreased adenoma size in an Apc-deficient mouse model (PMID: 22399804)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22399804	AVv-J6lASS-TIFzzUHvrjax	APC	Vantictumab	"In a preclinical study, Vantictumab (OMP-18R5) inhibited tumor growth in patient-derived xenograft models of colon cancer with wild-type CTNNB1 (beta-catenin) and APC (PMID: 22753465)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22753465	AVv-J6PfSS-TIFzzUHvHjax	APC	Vandetanib	"In a preclinical study, Caprelsa (vandetanib) reduced the number of dextran sodium sulfate-induced tumors in an APC-deficient mouse model for colon cancer (PMID: 20811697)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20811697	AVv-J6jxSS-TIFzzUHvpjax	APC	TASIN-1	"In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cells harboring APC Q1131* and Q1303* in culture (PMID: 27798265)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27798265	AVv-J6WfSS-TIFzzUHvTjax	APC	TASIN-1	"In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cells harboring APC L1488* in culture (PMID: 27798265)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27798265	AVv-J6dESS-TIFzzUHvejax	APC	TASIN-1	"In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cell lines harboring APC Q1338* in culture (PMID: 27798265)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27798265	AVv-J6hgSS-TIFzzUHvljax	APC	TASIN-1	"In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cell lines harboring APC G11416* in culture (PMID: 27798265)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27798265	AVv-J6ceSS-TIFzzUHvdjax	APC	TASIN-1	"In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cells harboring APC E853* and K1555* in culture and in cell line xenograft models (PMID: 27798265)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27798265	AVv-J6fpSS-TIFzzUHvijax	APC	TASIN-1	"In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cells harboring APC E1309* in culture and in cell line xenograft models (PMID: 27798265)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27798265	AVv-J655SS-TIFzzUHwQjax	APC	TASIN-1	"In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cell lines harboring APC truncation mutations in culture and in cell line xenograft models (PMID: 27798265)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27798265	AVv-J6xiSS-TIFzzUHwBjax	APC	TASIN-1	"In a preclinical study, TASIN-1 did not inhibit survival of APC wild-type colorectal cancer cells in culture or in cell line xenograft models (PMID: 27798265)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27798265	AVv-J6O1SS-TIFzzUHvGjax	APC	Sulindac	"In a preclinical study, colorectal cancer mouse models carrying APC inactivating mutations had reduced intestinal tumor burden after treatment with Clinoril (sulindac) (PMID: 19755659)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/19755659	AVv-J6lkSS-TIFzzUHvsjax	APC	StAx-35	"In a preclinical study, StAx-35 inhibited proliferation of colon cancer cell lines carrying APC deletions in culture (PMID: 23071338)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23071338	AVv-J6keSS-TIFzzUHvqjax	APC	Sirolimus	"In preclinical trials, Sirolimus (rapamycin) was shown effective in reducing tumors in mouse models of familial adenomatous polyposis and colon cancer with APC deficient tumors (PMID: 18768809, PMID: 20080688)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18768809	AVv-J6qzSS-TIFzzUHv1jax	APC	Regorafenib	"In a clinical case study, Stivarga (regorafenib) treatment resulted in durable partial response in a colorectal cancer patient harboring KDR R961W and mutations in APC and KRAS (PMID: 27004155)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27004155	AVv-J6UrSS-TIFzzUHvQjax	APC	Pyrvinium	"In a preclinical study, Pyrvinium inhibited Wnt signaling and decreased viability of colon cancer cells harboring APC mutations in culture (PMID: 20890287)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20890287	AVv-J6pCSS-TIFzzUHvyjax	APC	PKF118-310	"In a preclinical study, PKF118-310 inhibited proliferation of colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/14749129	AVv-J6ppSS-TIFzzUHvzjax	APC	PKF115-584	"In a preclinical study, PKF115-584 inhibited proliferation of colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/14749129	AVv-J6qPSS-TIFzzUHv0jax	APC	Niclosamide	"In a preclinical study, Niclosamide inhibited proliferation of colorectal cancer cells harboring APC mutations in culture (PMID: 21531761)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21531761	AVv-J6zESS-TIFzzUHwEjax	APC	NC043	"In a preclinical study, NC043 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC truncation mutations in culture and in cell line xenograft models (PMID: 21321609)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21321609	AVv-J6v7SS-TIFzzUHv-jax	APC	MLN0128	"In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to MLN0128 resulting in inhibition of MTORC1 signaling (PMID: 25261369)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25261369	AVv-J6VPSS-TIFzzUHvRjax	APC	MF tricyclic	"In a preclinical study, mouse models of colon cancer carrying an APC 716del mutation had reduced polyp formation after treatment with MF tricyclic (PMID: 23843721)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23843721	AVv-J6yHSS-TIFzzUHwCjax	APC	MEK162	"In a preclinical study, Binimetinib (MEK162) reduced proliferation in tumors acutely but did not improve survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26206338	AVv-J6znSS-TIFzzUHwFjax	APC	MEK162	"In a preclinical study, Binimetinib (MEK162) increased both apoptosis and proliferation in tumors, resulted in no improvement in survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26206338	AVv-J63lSS-TIFzzUHwMjax	APC	MEK162	"In a preclinical study, Binimetinib (MEK162) increased apoptosis in tumors and improved survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206338	AVv-J62iSS-TIFzzUHwKjax	APC	K-756	"In a preclinical study, K-756 inhibited Wnt signaling and reduced growth of 2/3 tested APC-mutant colorectal cancer cell lines in culture (PMID: 27196752)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27196752	AVv-J6TcSS-TIFzzUHvOjax	APC	JW74	"In a preclinical study, JW74 reduced tumor formation and growth in a mouse model of colorectal cancer harboring an APC mutation (PMID: 21199802)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21199802	AVv-J6UGSS-TIFzzUHvPjax	APC	JW74	"In a preclinical study, JW74 inhibited Wnt signaling and decreased growth of colorectal cancer cells harboring APC Q1338* in culture and in xenograft models (PMID: 21199802)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21199802	AVv-J6gQSS-TIFzzUHvjjax	APC	JW67	"In a preclinical study, JW67 inhibited Wnt signaling and decreased proliferation of colorectal cancer cells harboring APC Q1338* in culture (PMID: 21199802)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21199802	AVv-J6g3SS-TIFzzUHvkjax	APC	JW55	"In a preclinical study, JW55 inhibited proliferation of colorectal cancer cells with an APC truncation mutation in culture and decreased tumor development in a mouse model expressing a conditional APC truncation mutation (PMID: 22440753)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/22440753	AVv-J6r7SS-TIFzzUHv3jax	APC	IWR-1	"In a preclinical study, treatment with IWR-1 decreased active beta-catenin levels and reduced growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J6b3SS-TIFzzUHvcjax	APC	IWR-1	"In a preclinical study, treatment with IWR-1 decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J6iFSS-TIFzzUHvmjax	APC	IWR-1	"In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J6ROSS-TIFzzUHvKjax	APC	IWR-1	"In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs*3 demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J6dySS-TIFzzUHvfjax	APC	IWR-1	"In a preclinical study, a colorectal cancer cell line harboring APC  N1819fs*7 and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J6XFSS-TIFzzUHvUjax	APC	IWR-1	"In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC W553* in culture (PMID: 28179481)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J64ySS-TIFzzUHwOjax	APC	IWR-1	"In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC R216* in culture (PMID: 28179481)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J6aASS-TIFzzUHvZjax	APC	IWR-1	"In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC I1164fs in culture (PMID: 28179481)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J6XvSS-TIFzzUHvVjax	APC	ICG-001	"In a preclinical study, ICG-001 decreased cell proliferation in colon cancer cell lines and in mouse models carrying APC inactivating mutations (PMID: 15314234)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/15314234	AVv-J6u6SS-TIFzzUHv8jax	APC	G007-LK	"In a preclinical study, treatment with G007-LK decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J6bOSS-TIFzzUHvbjax	APC	G007-LK	"In a preclinical study, treatment with G007-LK decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J6ipSS-TIFzzUHvnjax	APC	G007-LK	"In a preclinical study, a patient-derived colorectal cancer cell line harboring APC R216* demonstrated sensitivity to G007-LK in culture (PMID: 28179481)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J6ZTSS-TIFzzUHvYjax	APC	G007-LK	"In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J6SZSS-TIFzzUHvMjax	APC	G007-LK	"In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs*3 demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J6fBSS-TIFzzUHvhjax	APC	G007-LK	"In a preclinical study, a colorectal cancer cell line harboring APC  N1819fs*7 and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J6QDSS-TIFzzUHvIjax	APC	G007-LK	"In a preclinical study, G007-LK inhibited growth of a patient-derived colorectal cancer cell line harboring APC W553* in culture (PMID: 28179481)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J65WSS-TIFzzUHwPjax	APC	G007-LK	"In a preclinical study, G007-LK inhibited growth of a patient-derived colorectal cancer cell line harboring APC I1164fs in culture (PMID: 28179481)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28179481	AVv-J6YVSS-TIFzzUHvXjax	APC	G007-LK	"In a preclinical study, G007-LK inhibited growth of APC-mutant colorectal cancer cell lines in culture and in xenograft models (PMID: 23539443)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23539443	AVv-J6n7SS-TIFzzUHvwjax	APC	G-631	"In a preclinical study, G-631 inhibited Wnt pathway signaling in colorectal cancer cell line xenograft models harboring an APC mutation, but demonstrated little anti-tumor activity and led to intestinal toxicity (PMID: 26692561)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26692561	AVv-J6S7SS-TIFzzUHvNjax	APC	Fluorouracil + Leucovorin + Trastuzumab	"In a clinical case study, a rectal adenocarcinoma patient harboring APC Q1429fs, BRAF N581S, and ERBB2 L755S did not respond to Herceptin (trastuzumab) treatment in combination with Fluorouracil and Wellcovorin (leucovorin) (PMID: 27626067)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/27626067	AVv-J6V3SS-TIFzzUHvSjax	APC	FH535	"In a preclinical study, FH535 inhibited beta-catenin/TCF-dependent transactivation and demonstrated toxicity in colon carcinoma cells harboring an APC mutation in culture (PMID: 18347139)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/18347139	AVv-J6mHSS-TIFzzUHvtjax	APC	Erlotinib + Ibuprofen	"In a preclinical study, ibuprofen, in combination with Tarceva (erlotinib), demonstrated efficacy in reducing tumor number and volume in APC inactivating mutant mice and in cell line xenograft models of colorectal cancer (PMID: 17909047)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17909047	AVv-J6shSS-TIFzzUHv4jax	APC	Dasatinib	"In a preclinical study, the combination of Sprycel (dasatinib) and curcumin inhibited tumor growth in a mouse model of colorectal cancer harboring an Apc mutation (PMID: 20473900)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20473900	AVv-J6w6SS-TIFzzUHwAjax	APC	Celecoxib + Erlotinib	"In a preclinical study, Celebra (celecoxib), in combination with Tarceva (erlotinib), demonstrated efficacy in reducing tumor number and volume in APC inactivating mutant mice and in human colorectal cancer cell line xenograft models (PMID: 17909047)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17909047	AVv-J6waSS-TIFzzUHv_jax	APC	Celecoxib	"In a preclinical study, APC inactivating mutant mouse models of colon cancer had reduced polyp formation after treatment with Celebra (celecoxib) (PMID: 17909047)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/17909047	AVv-J6rVSS-TIFzzUHv2jax	APC	CGP049090	"In a preclinical study, CGP049090 inhibited proliferation of a colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/14749129	AVv-J6ymSS-TIFzzUHwDjax	APC	CCT070535	"In a preclinical study, CCT070535 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20610623	AVv-J6tKSS-TIFzzUHv5jax	APC	CCT036477	"In a preclinical study, CCT036477 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20610623	AVv-J6tvSS-TIFzzUHv6jax	APC	CCT031374	"In a preclinical study, CCT031374 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/20610623	AVv-J6ohSS-TIFzzUHvxjax	APC	BEZ235 + Binimetinib	"In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) increased survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206338	AVv-J63ESS-TIFzzUHwLjax	APC	BEZ235 + Binimetinib	"In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) did not improve survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26206338	AVv-J60NSS-TIFzzUHwGjax	APC	BEZ235	"In a preclinical study, BEZ235 inhibited mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation, and KRAS G12D (PMID: 26206338)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206338	AVv-J64LSS-TIFzzUHwNjax	APC	BEZ235	"In a preclinical study, BEZ235 inhibited  PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206338	AVv-J615SS-TIFzzUHwJjax	APC	BEZ235	"In a preclinical study, BEZ235 inhibited  PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26206338	AVv-J60wSS-TIFzzUHwHjax	ALK	X-396	"In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK C1156Y (PMID: 21613408)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-J5VASS-TIFzzUHuajax	ALK	X-396	"In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK ALK L1196M (PMID: 21613408)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-J2wdSS-TIFzzUHp7jax	ALK	TAE684	"In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing EML4-ALK ALK V1180L in culture (PMID: 25228534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-J2aGSS-TIFzzUHpWjax	ALK	TAE684	"In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing EML4-ALK ALK I1171T in culture (PMID: 25228534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-J1ypSS-TIFzzUHoVjax	ALK	Saracatinib + Ceritinib	"In a preclinical study, the combination of Saracatinib (AZD0530) and (Zykadia) ceritinib demonstrated efficacy in non-small cell lung cancer patient derived cells harboring an ALK fusion and upregulation of SRC in culture (PMID: 25394791)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25394791	AVv-J4_YSS-TIFzzUHt3jax	ALK	RXDX-101	"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were sensitive to Entrectinib (RXDX-101), resulting in anti-proliferative activity (PMID: 26939704)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26939704	AVv-J2xESS-TIFzzUHp8jax	ALK	RXDX-101	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated a decreased response when treated with Entrectinib (RXDX-101) (PMID: 26939704)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26939704	AVv-J5BzSS-TIFzzUHt7jax	ALK	RXDX-101	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to RXDX-101 (PMID: 26939704)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26939704	AVv-J3GySS-TIFzzUHqgjax	ALK	RXDX-101	"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were sensitive to Entrectinib (RXDX-101), resulting in anti-proliferative activity (PMID: 26939704)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26939704	AVv-J5X0SS-TIFzzUHufjax	ALK	RXDX-101	"In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in partial response that lasted 8.3 months in a patient with neuroblastoma harboring ALK F1245V, who remained on treatment for over 3.5 years due to clinical benefit (PMID: 28183697)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28183697	AVv-J5Q0SS-TIFzzUHuTjax	ALK	RXDX-101	"In a Phase I clinical trial, Entrectinib (RXDX-101) treatment resulted in partial response for more than 3 months in a colorectal cancer patient harboring a CAD-ALK gene fusion (PMID: 26633560)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26633560	AVv-J2K8SS-TIFzzUHo9jax	ALK	PF-06463922	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J39ISS-TIFzzUHsHjax	ALK	PF-06463922	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J12HSS-TIFzzUHobjax	ALK	PF-06463922	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J3ROSS-TIFzzUHqyjax	ALK	PF-06463922	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J1sVSS-TIFzzUHoLjax	ALK	PF-06463922	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J4WoSS-TIFzzUHszjax	ALK	PF-06463922	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J32uSS-TIFzzUHr8jax	ALK	PF-06463922	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J34hSS-TIFzzUHr_jax	ALK	PF-06463922	"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J3qdSS-TIFzzUHrdjax	ALK	PF-06463922	"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J4GcSS-TIFzzUHsXjax	ALK	PF-06463922	"In a preclinical study, transformed cells expressing EML4-ALK with L1198F had reduced sensitivity to growth inhibition mediated by Lorlatinib (PF-06463922) in comparison to EML4-ALK wild type in culture (PMID: 26698910)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3gASS-TIFzzUHrLjax	ALK	PF-06463922	"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J23pSS-TIFzzUHqHjax	ALK	PF-06463922	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3j1SS-TIFzzUHrSjax	ALK	PF-06463922	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3FlSS-TIFzzUHqejax	ALK	PF-06463922	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3KpSS-TIFzzUHqmjax	ALK	PF-06463922	"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3loSS-TIFzzUHrVjax	ALK	PF-06463922	"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3doSS-TIFzzUHrHjax	ALK	PF-06463922	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J1w2SS-TIFzzUHoSjax	ALK	PF-06463922	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171S demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J4QZSS-TIFzzUHspjax	ALK	PF-06463922	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J3OESS-TIFzzUHqsjax	ALK	PF-06463922	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J4y5SS-TIFzzUHtijax	ALK	PF-06463922	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202R demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J3EWSS-TIFzzUHqcjax	ALK	PF-06463922	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J4T7SS-TIFzzUHsvjax	ALK	PF-06463922	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J4IJSS-TIFzzUHsajax	ALK	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J3AUSS-TIFzzUHqVjax	ALK	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J5CaSS-TIFzzUHt8jax	ALK	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3t5SS-TIFzzUHrtjax	ALK	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of ALK amplified neuroblastoma cells in culture (PMID: 26554404)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26554404	AVv-J2h8SS-TIFzzUHpjjax	ALK	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth and ALK phosphorylation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J5WOSS-TIFzzUHucjax	ALK	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited foci formation more efficiently than Xalkori (crizotinib) in transformed cells over expressing ALK R1275Q in culture (PMID: 26554404)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26554404	AVv-J4DrSS-TIFzzUHsSjax	ALK	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited foci formation more efficiently than Xalkori (crizotinib) in transformed cells over expressing ALK F1245C in culture (PMID: 26554404)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26554404	AVv-J4jwSS-TIFzzUHtIjax	ALK	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited foci formation more efficiently than Xalkori (crizotinib) in transformed cells over expressing ALK F1174L in culture (PMID: 26554404)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26554404	AVv-J5djSS-TIFzzUHupjax	ALK	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis of non-small cell lung carcinoma cells harboring ALK V1180L in the context of EML4-ALK in culture (PMID: 26144315)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-J2dzSS-TIFzzUHpcjax	ALK	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK S1206Y in the context of EML4-ALK in culture  (PMID: 26144315)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-J2M2SS-TIFzzUHpAjax	ALK	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK L1152R in the context of EML4-ALK in culture  (PMID: 26144315)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-J289SS-TIFzzUHqPjax	ALK	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK F1174L in the context of EML4-ALK in culture  (PMID: 26144315)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-J5lzSS-TIFzzUHu3jax	ALK	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell growth in patient derived non-small cell lung cancer cells harboring ALK I1171T in the context of EML4-ALK in culture (PMID: 26144315)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26144315	AVv-J1vlSS-TIFzzUHoQjax	ALK	PF-06463922	"In a preclinical study, Lorlatinib (PF-06463922) did not inhibit growth of ALK wild-type neuroblastoma cells in culture (PMID: 26554404)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26554404	AVv-J4dHSS-TIFzzUHs9jax	ALK	Dalantercept + Doxorubicin	"In a preclinical study, Dalantercept (ACE-041) in combination with Adria (doxorubicin) resulted in decreased tumor growth in cell line xenograft models of melanoma, with increased efficacy over either agent alone (PMID: 26373572)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26373572	AVv-J4fASS-TIFzzUHtAjax	ALK	Dalantercept + Cisplatin	"In a preclinical study, the addition of Dalantercept (ACE-041) to Platinol (cisplatin) treatment resulted in increased cytoxicity and decreased tumor growth in cell line xenograft models of head and neck cancer (PMID: 26373572)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26373572	AVv-J4gRSS-TIFzzUHtCjax	ALK	Dalantercept + Cisplatin	"In a preclinical study, Dalantercept (ACE-041) in combination with Platinol (cisplatin) resulted in decreased tumor growth in cell line xenograft models of breast cancer (PMID: 26373572)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26373572	AVv-J4eXSS-TIFzzUHs_jax	ALK	Cyclophosphamide + Topotecan	"In a preclinical study, Topotecan and Cytoxan (cyclophosphamide) combination treatment resulted in mild  tumor growth suppression in neuroblastoma xenograft models harboring wild-type Alk and TP53 H168R (PMID: 26438783)."	not applicable	http://www.ncbi.nlm.nih.gov/pubmed/26438783	AVv-J4bHSS-TIFzzUHs6jax	ALK	Crizotinib + Cyclophosphamide + Topotecan	"In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to sustain tumor regression in human neuroblastoma cell line xenograft models harboring ALK R1275Q and wild-type TP53 (PMID: 26438783)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26438783	AVv-J4DHSS-TIFzzUHsRjax	ALK	Crizotinib + Cyclophosphamide + Topotecan	"In a preclinical study, Xalkori (crizotinib) did not improve the effect of Topotecan and Cytoxan (cyclophosphamide) on tumor growth suppression in xenograft models of a human neuroblastoma cell line harboring wild-type ALK and TP53 H168R (PMID: 26438783)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438783	AVv-J4bwSS-TIFzzUHs7jax	ALK	Crizotinib + Cyclophosphamide + Topotecan	"In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 P177T in culture (PMID: 26438783)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438783	AVv-J4ccSS-TIFzzUHs8jax	ALK	Crizotinib + Cyclophosphamide + Topotecan	"In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 C176F in culture (PMID: 26438783)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/26438783	AVv-J4g3SS-TIFzzUHtDjax	ALK	Crizotinib	Xalkori (crizotinib) is FDA approved for the use in NSCLC patients harboring ALK rearrangements independently of any prior treatment the patients have received (PMID: 25806224).	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25806224	AVv-J45YSS-TIFzzUHttjax	ALK	Crizotinib	"In preclinical studies, transformed cells expressing EML4-ALK with ALK G1269A were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859, PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J5E0SS-TIFzzUHuAjax	ALK	Crizotinib	"In preclinical studies, transformed cells expressing EML4-ALK ALK L1196M were insensitive to Xalkori (crizotinib) as demonstrated by lack of growth inhibition and Alk phosphorylation in culture (PMID: 21613408, PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-J2rsSS-TIFzzUHpzjax	ALK	Crizotinib	"In preclinical studies, transformed cell lines expressing EML4-ALK L1152R demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 21791641)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21791641	AVv-J29hSS-TIFzzUHqQjax	ALK	Crizotinib	"In preclinical studies, human lung cancer cell lines expressing EML4-ALK G1269A demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 22235099, PMID: 23344087, PMID: 24675041)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-J5FcSS-TIFzzUHuBjax	ALK	Crizotinib	"In multiple clinical trials, ALK L1196M conferred resistance to Xalkori (crizotinib) in the context of ALK positive aberrations in non-small cell lung carcinoma patients (PMID: 22277784, PMID: 25806224)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25806224	AVv-J2BISS-TIFzzUHotjax	ALK	Crizotinib	"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2YXSS-TIFzzUHpTjax	ALK	Crizotinib	"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1198F in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J3U6SS-TIFzzUHq4jax	ALK	Crizotinib	"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2naSS-TIFzzUHpsjax	ALK	Crizotinib	"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J3wDSS-TIFzzUHrxjax	ALK	Crizotinib	"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J3ZwSS-TIFzzUHrAjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing an ALK fusion with ALK T1151dup were resistant to Xalkori (crizotinib) (PMID: 25806224, PMID: 22277784)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25806224	AVv-J2D9SS-TIFzzUHoyjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing an ALK fusion with ALK S1206Y were resistant to Xalkori (crizotinib) (PMID: 25806224, PMID: 22277784)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25806224	AVv-J2FHSS-TIFzzUHo0jax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing an ALK fusion and ALK G1269A were resistant to Xalkori (crizotinib) (PMID: 25806224, PMID: 22235099)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22235099	AVv-J2EgSS-TIFzzUHozjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing an ALK fusion and ALK G1202R were resistant to Xalkori (crizotinib) (PMID: 25806224, PMID: 22277784)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25806224	AVv-J2FqSS-TIFzzUHo1jax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J2QSSS-TIFzzUHpGjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Xalkori (Crizotinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4vUSS-TIFzzUHtcjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2z8SS-TIFzzUHqBjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J27GSS-TIFzzUHqMjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Xalkori (critzotinb) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J109SS-TIFzzUHoZjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4J4SS-TIFzzUHsdjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Xalkori (critzotinb) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J3QsSS-TIFzzUHqxjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5L_SS-TIFzzUHuLjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Xalkori (critzotinb) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J1s6SS-TIFzzUHoMjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5h4SS-TIFzzUHuwjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Xalkori (critzotinb) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J339SS-TIFzzUHr-jax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated resistance to treatment with Xalkori (crizotinib) in culture (PMID: 27432227)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J3oCSS-TIFzzUHrZjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J4FUSS-TIFzzUHsVjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing EML4-ALK with G1269A were re-sensitized and modestly sensitive to Xalkori (crizotinib) with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3iRSS-TIFzzUHrPjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4OuSS-TIFzzUHsmjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3DsSS-TIFzzUHqbjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3MaSS-TIFzzUHqpjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3r3SS-TIFzzUHrfjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3lESS-TIFzzUHrUjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J5THSS-TIFzzUHuXjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing EML4-ALK ALK C1156Y were insensitive to Xalkori (crizotinib) as demonstrated by lack of growth inhibition and lack of kinase inhibition in culture (PMID: 21613408)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21613408	AVv-J5TwSS-TIFzzUHuYjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing ALK T1151dup in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-J4AVSS-TIFzzUHsMjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-J4n8SS-TIFzzUHtPjax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing ALK F1174V in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-J3x5SS-TIFzzUHr0jax	ALK	Crizotinib	"In a preclinical study, transformed cells expressing ALK F1174L in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-J5kqSS-TIFzzUHu1jax	ALK	Crizotinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J1zSSS-TIFzzUHoWjax	ALK	Crizotinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J3PJSS-TIFzzUHqujax	ALK	Crizotinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J40ESS-TIFzzUHtkjax	ALK	Crizotinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J4HiSS-TIFzzUHsZjax	ALK	Crizotinib	"In a preclinical study, non-small cell lung cancer cells harboring an ALK fusion and ALK L1152R were resistant to Xalkori (crizotinib) (PMID: 25806224, PMID: 21791641)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/21791641	AVv-J2BsSS-TIFzzUHoujax	ALK	Crizotinib	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK R1192P were resistant to Xalkori (crizotinib) in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4usSS-TIFzzUHtbjax	ALK	Crizotinib	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1161S were resistant to Xalkori (crizotinib) in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4LdSS-TIFzzUHsgjax	ALK	Crizotinib	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK G1269A were resistant to Xalkori (crizotinib) in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5ODSS-TIFzzUHuOjax	ALK	Crizotinib	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing ALK L1196Q were resistant to Xalkori (crizotinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J5bQSS-TIFzzUHuljax	ALK	Crizotinib	"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2gySS-TIFzzUHphjax	ALK	Crizotinib	"In a preclinical study, an anaplastic large-cell lymphoma cell line expressing NPM-ALK I1171T demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 24509625)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24509625	AVv-J13WSS-TIFzzUHodjax	ALK	Crizotinib	"In a preclinical study, a human non-small cell lung cancer cell line harboring EML4-ALK ALK V1180L was resistant to Xalkori (crizotinib) treatment in culture (PMID: 25228534)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-J2bWSS-TIFzzUHpYjax	ALK	Crizotinib	"In a preclinical study, Xalkori (crizotinib) resistance was reduced in transformed cells expressing EML4-ALK with ALK L1196M with the addition of ALK L1198F in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J22SSS-TIFzzUHqFjax	ALK	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J2V8SS-TIFzzUHpPjax	ALK	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4q0SS-TIFzzUHtUjax	ALK	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J37jSS-TIFzzUHsEjax	ALK	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J2_xSS-TIFzzUHqUjax	ALK	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK E1210K in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J4afSS-TIFzzUHs5jax	ALK	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK C1156F in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J303SS-TIFzzUHr5jax	ALK	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK ALK S1206C to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2k8SS-TIFzzUHpojax	ALK	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5kESS-TIFzzUHu0jax	ALK	Crizotinib	"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3dHSS-TIFzzUHrGjax	ALK	Crizotinib	"In a preclinical study, Xalkori (crizotinib) enhanced growth inhibition of transformed cells expressing EML4-ALK with L1198F in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3hDSS-TIFzzUHrNjax	ALK	Crizotinib	"In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing ALK R1275Q in culture, and only delayed tumor growth in cell line xenograft models (PMID: 26554404)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26554404	AVv-J4BcSS-TIFzzUHsOjax	ALK	Crizotinib	"In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing ALK F1245C in culture, and only delayed tumor growth in patient-derived xenograft models harboring ALK F1245C (PMID: 26554404)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26554404	AVv-J4inSS-TIFzzUHtGjax	ALK	Crizotinib	"In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing ALK F1174L in culture, and only delayed tumor growth in patient-derived and cell line xenograft models harboring ALK F1174L (PMID: 26554404)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26554404	AVv-J5eKSS-TIFzzUHuqjax	ALK	Crizotinib	"In a preclinical study, ALK amplified neuroblastoma cells demonstrated decreased response to Xalkori (crizotinib) induced growth of inhibition in culture (PMID: 26554404)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26554404	AVv-J2hXSS-TIFzzUHpijax	ALK	Crizotinib	"In a clinical study, three patients with non-small cell lung carcinoma co-harboring an ALK rearrangement and ALK amplification demonstrated resistance to Xalkori (crizotinib) treatment (PMID: 27432227)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J2igSS-TIFzzUHpkjax	ALK	Crizotinib	"In a clinical study, an ALK S1206Y secondary mutation in the context of EML4-ALK was associated with resistance to Xalkori (crizotinib) in a patient with non-small cell lung cancer, and resistance was replicated in cell culture studies (PMID: 22277784)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22277784	AVv-J2N-SS-TIFzzUHpCjax	ALK	Crizotinib	"In a clinical study, an ALK G1202R secondary mutation in the context of EML4-ALK was associated with resistance to Xalkori (crizotinib) in a patient with non-small cell lung cancer, and resistance was replicated in cell culture studies (PMID: 22277784)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/22277784	AVv-J3DGSS-TIFzzUHqajax	ALK	Crizotinib	"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer developed resistance to Xalkori (crizotinib) with the emergence of ALK C1156Y, a secondary resistance mutation (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J5UaSS-TIFzzUHuZjax	ALK	Crizotinib	"In a clinical case study, a non-small cell lung cancer patient harboring EML4-ALK variant 3 demonstrated an initial response to treatment with Xalkori (crizotinib), but progressed after 27 months and was found to have acquired ALK F1245C (PMID: 26775591)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26775591	AVv-J4lhSS-TIFzzUHtLjax	ALK	Crizotinib	"In a Phase I trial, ALK C1156Y mediates resistance to Xalkori (crizotinib) in ALK positive non-small cell lung cancer tumors (PMID: 25806224, PMID: 20979473)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/20979473	AVv-J2CRSS-TIFzzUHovjax	ALK	Ceritinib	"In preclinical studies, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 26698910, PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J5DCSS-TIFzzUHt9jax	ALK	Ceritinib	"In a preclinical trial, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2n-SS-TIFzzUHptjax	ALK	Ceritinib	"In a preclinical trial, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J3wrSS-TIFzzUHryjax	ALK	Ceritinib	"In a preclinical study, transformed human cells expressing the ALK fusion resistance mutation, ALK C1156Y, demonstrated minimal sensitivity to Zykadia (ceritinib) (PMID: 24675041)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25806224	AVv-J2CySS-TIFzzUHowjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with E1210K were resistant to Zykadia (ceritinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J4YsSS-TIFzzUHs2jax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with C1156F and D1203N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J36QSS-TIFzzUHsCjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J2Q4SS-TIFzzUHpHjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4uLSS-TIFzzUHtajax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Zykadia (ceritinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J38PSS-TIFzzUHsFjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J3WJSS-TIFzzUHq6jax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J5PsSS-TIFzzUHuRjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Zykadia (ceritinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J10aSS-TIFzzUHoYjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4KZSS-TIFzzUHsejax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J3QKSS-TIFzzUHqwjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5NZSS-TIFzzUHuNjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Zykadia (ceritinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J1rsSS-TIFzzUHoKjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J3ZISS-TIFzzUHq_jax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5ibSS-TIFzzUHuxjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Zykadia (ceritinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J3zMSS-TIFzzUHr2jax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated resistance to treatment with Zykadia (ceritinib) in culture (PMID: 27432227)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J3osSS-TIFzzUHrajax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Zykadia (ceritinib) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J4EySS-TIFzzUHsUjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3exSS-TIFzzUHrJjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK S1206Y demonstrated growth inhibition with Zykadia (ceritinib) treatment in culture (PMID: 24675041)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-J2NcSS-TIFzzUHpBjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4r_SS-TIFzzUHtWjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J21uSS-TIFzzUHqEjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3jVSS-TIFzzUHrRjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3HbSS-TIFzzUHqhjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were insensitive to Zykadia (ceritinib) in culture (PMID: 24675041)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-J3IySS-TIFzzUHqjjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3L3SS-TIFzzUHqojax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5nfSS-TIFzzUHu6jax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3keSS-TIFzzUHrTjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3b9SS-TIFzzUHrEjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing ALK L1152R in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) in culture (PMID: 27780853)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-J27wSS-TIFzzUHqNjax	ALK	Ceritinib	"In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) in culture (PMID: 27780853)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-J4pCSS-TIFzzUHtRjax	ALK	Ceritinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK L1196M demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J2vTSS-TIFzzUHp5jax	ALK	Ceritinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J3M9SS-TIFzzUHqqjax	ALK	Ceritinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Zykadia (ceritinib) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J4xsSS-TIFzzUHtgjax	ALK	Ceritinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J4UnSS-TIFzzUHswjax	ALK	Ceritinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J4G8SS-TIFzzUHsYjax	ALK	Ceritinib	"In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J2UlSS-TIFzzUHpNjax	ALK	Ceritinib	"In a preclinical study, human lung cancer cell lines harboring EML4-ALK with ALK G1269A demonstrated sensitivity to Zykadia (ceritinib) in culture (PMID: 24675041)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-J5BMSS-TIFzzUHt6jax	ALK	Ceritinib	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J2PJSS-TIFzzUHpEjax	ALK	Ceritinib	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174L were resistant to Zykadia (ceritinib) in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5gqSS-TIFzzUHuujax	ALK	Ceritinib	"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2ecSS-TIFzzUHpdjax	ALK	Ceritinib	"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK S1206C to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2kWSS-TIFzzUHpnjax	ALK	Ceritinib	"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2XwSS-TIFzzUHpSjax	ALK	Ceritinib	"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2yLSS-TIFzzUHp-jax	ALK	Ceritinib	"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J3BcSS-TIFzzUHqXjax	ALK	Ceritinib	"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 26698910)"	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J2uuSS-TIFzzUHp4jax	ALK	Ceritinib	"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J5YVSS-TIFzzUHugjax	ALK	Ceritinib	"In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-J2b9SS-TIFzzUHpZjax	ALK	Ceritinib	"In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK I1171T in culture (PMID: 25228534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-J1yFSS-TIFzzUHoUjax	ALK	Ceritinib	"In a preclinical study, Zykadia (ceritinib) demonstrated tumor growth inhibition in xenograft models of a human non-small cell lung cancer cell line harboring EML4-ALK with ALK C1156Y when compared to Xalkori (crizotinib) (PMID: 24675041)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/24675041	AVv-J5arSS-TIFzzUHukjax	ALK	Ceritinib	"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer with a secondary Xalkori (crizotinib) resistance mutation C1156Y, did not respond to Zykadia (ceritinib) therapy (PMID: 26698910)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J5aGSS-TIFzzUHujjax	ALK	Alectinib	"In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2WkSS-TIFzzUHpQjax	ALK	Alectinib	"In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2p2SS-TIFzzUHpwjax	ALK	Alectinib	"In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2zSSS-TIFzzUHqAjax	ALK	Alectinib	"In a preclinical study, transformed human cells expressing EML4-ALK with ALK C1156Y were sensitive to Alecensa (alectinib) in culture (PMID: 21575866)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21575866	AVv-J5WxSS-TIFzzUHudjax	ALK	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J2PsSS-TIFzzUHpFjax	ALK	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206C were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2mxSS-TIFzzUHprjax	ALK	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4v5SS-TIFzzUHtdjax	ALK	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J3WvSS-TIFzzUHq7jax	ALK	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J5OnSS-TIFzzUHuPjax	ALK	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J248SS-TIFzzUHqJjax	ALK	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Alecensa (alectinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J12zSS-TIFzzUHocjax	ALK	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4MoSS-TIFzzUHsijax	ALK	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Alecensa (alectinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J3ScSS-TIFzzUHq0jax	ALK	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5KDSS-TIFzzUHuIjax	ALK	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Alecensa (alectinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J1qcSS-TIFzzUHoIjax	ALK	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J3XWSS-TIFzzUHq8jax	ALK	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5gCSS-TIFzzUHutjax	ALK	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Alecensa (alectinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J4ZTSS-TIFzzUHs3jax	ALK	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Alecensa (alectinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J32GSS-TIFzzUHr7jax	ALK	Alectinib	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Alecensa (alectinib) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J35JSS-TIFzzUHsAjax	ALK	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Alecensa (alectinib) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J3pQSS-TIFzzUHrbjax	ALK	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Alecensa (alectinib) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J4ERSS-TIFzzUHsTjax	ALK	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M demonstrated decreased sensitivity to Alecensa (alectinib) compared to cells expressing EML4-ALK with wild-type ALK, in culture (PMID: 26698910)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J2tfSS-TIFzzUHp2jax	ALK	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J224SS-TIFzzUHqGjax	ALK	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4P2SS-TIFzzUHsojax	ALK	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5EOSS-TIFzzUHt_jax	ALK	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3ixSS-TIFzzUHrQjax	ALK	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3IBSS-TIFzzUHqijax	ALK	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3LQSS-TIFzzUHqnjax	ALK	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition by Alecensa (alectinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3mxSS-TIFzzUHrXjax	ALK	Alectinib	"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3eQSS-TIFzzUHrIjax	ALK	Alectinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated resistance to treatment with Alecensa (alectinib) in culture (PMID: 27432227)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J3OnSS-TIFzzUHqtjax	ALK	Alectinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Alecensa (alectinib) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J4yWSS-TIFzzUHthjax	ALK	Alectinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J4V7SS-TIFzzUHsyjax	ALK	Alectinib	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J4IwSS-TIFzzUHsbjax	ALK	Alectinib	"In a preclinical study, a transformed cell line expressing EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-J2ZhSS-TIFzzUHpVjax	ALK	Alectinib	"In a preclinical study, a human non-small cell lung cancer cell line harboring EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-J2ckSS-TIFzzUHpajax	ALK	Alectinib	"In a preclinical study, Alecensa (alectinib) was able to inhibit ALK C1156Y in the context of transformed cells expressing an ALK fusion (PMID: 25806224, PMID: 21575866)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21575866	AVv-J2DWSS-TIFzzUHoxjax	ALK	Alectinib	"In a preclinical study, Alecensa (alectinib) modestly inhibited growth of transformed cells expression EML4-ALK with ALK G1269A in culture (PMID: 26698910)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J5DnSS-TIFzzUHt-jax	ALK	Alectinib	"In a preclinical study, Alecensa (alectinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J2T3SS-TIFzzUHpMjax	ALK	Alectinib	"In a preclinical study, Alecensa (alectinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4rYSS-TIFzzUHtVjax	ALK	Alectinib	"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing an EML4-ALK fusion and ALK L1196M in culture and in xenograft models (PMID: 21575866)."	conflicting	http://www.ncbi.nlm.nih.gov/pubmed/21575866	AVv-J2uFSS-TIFzzUHp3jax	ALK	Alectinib	"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J3-DSS-TIFzzUHsIjax	ALK	Alectinib	"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J3vhSS-TIFzzUHrwjax	ALK	Alectinib	"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J3A5SS-TIFzzUHqWjax	ALK	Alectinib	"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5jfSS-TIFzzUHuzjax	ALK	Alectinib	"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J5XTSS-TIFzzUHuejax	ALK	Alectinib	"In a preclinical study, ALK C1156Y was sensitive to Alecensa (alectinib) in an in vitro assay (PMID: 21575866)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21575866	AVv-J5SXSS-TIFzzUHuWjax	ALK	Alectinib	"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer initially responded to Alecensa (alectinib) but progressed with the emergence of a secondary ALK I1171S mutation (PMID: 25393796)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25393796	AVv-J4PUSS-TIFzzUHsnjax	ALK	Alectinib	"In a clinical case study, a patient with EML4-ALK fusion positive non-small cell lung cancer with ALK G1269A had a partial response to Alecensa (alectinib) treatment (PMID: 26849637)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26849637	AVv-J5GySS-TIFzzUHuDjax	ALK	Alectinib	"In a clinical case study, ALK G1202R was identified in a patient with ALK-rearranged non-small cell lung carcinoma after the disease progressed while on Zykadia (ceritinib) followed by Alecensa (alectinib) therapy (PMID: 28285684)."	predicted – resistant	http://www.ncbi.nlm.nih.gov/pubmed/28285684	AVv-J3B9SS-TIFzzUHqYjax	ALK	AZD3463	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J2SFSS-TIFzzUHpJjax	ALK	AZD3463	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P had a reduced response to AZD3463 mediated growth inhibition in culture relative to NPM1-ALK (PMID: 27009859)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4wfSS-TIFzzUHtejax	ALK	AZD3463	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5i9SS-TIFzzUHuyjax	ALK	AZD3463	"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4Q_SS-TIFzzUHsqjax	ALK	AZD3463	"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing NPM1-ALK with ALK I1171S in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4NJSS-TIFzzUHsjjax	ALK	AZD3463	"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5LWSS-TIFzzUHuKjax	ALK	AZD3463	"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J2VMSS-TIFzzUHpOjax	ALK	AZD3463	"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4slSS-TIFzzUHtXjax	ALK	AZD3463	"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5JZSS-TIFzzUHuHjax	ALK	AZD3463	"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5mVSS-TIFzzUHu4jax	ALK	AUY922	"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer with an ALK C1156Y secondary Xalkori (crizotinib) resistance mutation did not respond to Luminespib (AUY922) therapy (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J5Y_SS-TIFzzUHuhjax	ALK	ASP3026	"In a preclinical trial, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J3udSS-TIFzzUHrujax	ALK	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J2RdSS-TIFzzUHpIjax	ALK	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4tpSS-TIFzzUHtZjax	ALK	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to ASP3026 in culture (PMID: 25749034)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J3_1SS-TIFzzUHsLjax	ALK	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J3VfSS-TIFzzUHq5jax	ALK	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to ASP3026 treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J5PISS-TIFzzUHuQjax	ALK	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J26fSS-TIFzzUHqLjax	ALK	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to ASP3026 in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J11lSS-TIFzzUHoajax	ALK	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4K6SS-TIFzzUHsfjax	ALK	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to ASP3026 in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J3R4SS-TIFzzUHqzjax	ALK	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to ASP3026 in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J1rFSS-TIFzzUHoJjax	ALK	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J3aQSS-TIFzzUHrBjax	ALK	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5ffSS-TIFzzUHusjax	ALK	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174I were resistant to ASP3026 relative to wild type NPM1-ALK in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J2_LSS-TIFzzUHqTjax	ALK	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to ASP3026 in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J4X_SS-TIFzzUHs1jax	ALK	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to ASP3026 in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J3zwSS-TIFzzUHr3jax	ALK	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to ASP3026 in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J33YSS-TIFzzUHr9jax	ALK	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK with  ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2pMSS-TIFzzUHpvjax	ALK	ASP3026	"In a preclinical study, transformed cells expressing NPM1-ALK and ALK S1206C were resistant to ASP3026 treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2jwSS-TIFzzUHpmjax	ALK	ASP3026	"In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4qOSS-TIFzzUHtTjax	ALK	ASP3026	"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4RkSS-TIFzzUHsrjax	ALK	ASP3026	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5IxSS-TIFzzUHuGjax	ALK	ASP3026	"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5lOSS-TIFzzUHu2jax	ALK	ASP3026	"In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to ASP3026 in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J2TUSS-TIFzzUHpLjax	ALK	ASP3026	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK F1174I were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J2-CSS-TIFzzUHqRjax	ALK	ASP3026	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK E1210K were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J4Z6SS-TIFzzUHs4jax	ALK	ASP3026	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK C1156F and D1203N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J363SS-TIFzzUHsDjax	ALK	ASP3026	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK N1178H were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J3_PSS-TIFzzUHsKjax	ALK	ASP3026	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1171T were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J1z1SS-TIFzzUHoXjax	ALK	ASP3026	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1171N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J3TESS-TIFzzUHq1jax	ALK	ASP3026	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK G1128S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J1tiSS-TIFzzUHoNjax	ALK	ASP3026	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156Y were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J5R5SS-TIFzzUHuVjax	ALK	ASP3026	"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156F were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J30USS-TIFzzUHr4jax	ALK	ASP3026	"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to ASP3026 treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2e_SS-TIFzzUHpejax	ALK	ASP3026	"In a preclinical study, a transformed cell line expressing EML4-ALK with ALK I1171T was resistant to ASP3026 treatment in culture (PMID: 25228534)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-J1xeSS-TIFzzUHoTjax	ALK	ASP3026	"In a preclinical study, ASP3026 inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5KtSS-TIFzzUHuJjax	ALK	ASP3026	"In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2XMSS-TIFzzUHpRjax	ALK	ASP3026	"In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2ywSS-TIFzzUHp_jax	ALK	ASP3026	"In a preclinical study, ASP3026 inhibited growth of human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing the crizotinib-resistant mutation ALK L1196Q in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J5b0SS-TIFzzUHumjax	ALK	ASP3026	"In a preclinical study, ASP3026 inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-J2auSS-TIFzzUHpXjax	ALK	AP26113	"In preclinical studies, Brigatinib (AP26113) inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859, PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J5IISS-TIFzzUHuFjax	ALK	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Brigatinib (AP26113) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J2OlSS-TIFzzUHpDjax	ALK	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206C were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2mISS-TIFzzUHpqjax	ALK	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Brigatinib (AP26113) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J3-sSS-TIFzzUHsJjax	ALK	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J3USSS-TIFzzUHq3jax	ALK	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J20jSS-TIFzzUHqCjax	ALK	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J5QPSS-TIFzzUHuSjax	ALK	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J24NSS-TIFzzUHqIjax	ALK	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Brigatinib (AP26113) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J13-SS-TIFzzUHoejax	ALK	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Brigatinib (AP26113) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J3PqSS-TIFzzUHqvjax	ALK	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK1198F were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J3X_SS-TIFzzUHq9jax	ALK	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Brigatinib (AP26113) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J4XPSS-TIFzzUHs0jax	ALK	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Brigatinib (AP26113) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J31fSS-TIFzzUHr6jax	ALK	AP26113	"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Brigatinib (AP26113) in culture (PMID: 25749034)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J35tSS-TIFzzUHsBjax	ALK	AP26113	"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Brigatinib (AP26113) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J3p8SS-TIFzzUHrcjax	ALK	AP26113	"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Brigatinib (AP26113) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J4F7SS-TIFzzUHsWjax	ALK	AP26113	"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F were resistant to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J21ISS-TIFzzUHqDjax	ALK	AP26113	"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3J_SS-TIFzzUHqljax	ALK	AP26113	"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to Brigatinib (AP26113) mediated growth inhibition in culture (PMID: 27009859)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5m5SS-TIFzzUHu5jax	ALK	AP26113	"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3mLSS-TIFzzUHrWjax	ALK	AP26113	"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3bYSS-TIFzzUHrDjax	ALK	AP26113	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Brigatinib (AP26113) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J3NjSS-TIFzzUHqrjax	ALK	AP26113	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Brigatinib (AP26113) in culture (PMID: 27432227)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J4zfSS-TIFzzUHtjjax	ALK	AP26113	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Brigatinib (AP26113) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J4TWSS-TIFzzUHsujax	ALK	AP26113	"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Brigatinib (AP26113) in culture (PMID: 27432227)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27432227	AVv-J4JXSS-TIFzzUHscjax	ALK	AP26113	"In a preclinical study, neuroblastoma cells harboring ALK F1174V were sensitive to Brigatinib (AP26113) in culture and in vivo, resulting in inhibition of both Alk activity and cell proliferation (PMID: 27049722)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27049722	AVv-J3ygSS-TIFzzUHr1jax	ALK	AP26113	"In a preclinical study, brigatinib (AP26113) inhibited growth of cell lines expressing ALK L1196M in the context of EML4-ALK in culture (PMID: 21502504)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/21502504	AVv-J2AlSS-TIFzzUHosjax	ALK	AP26113	"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Brigatinib (AP26113) in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2gMSS-TIFzzUHpgjax	ALK	AP26113	"In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Brigatinib (AP26113) in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J250SS-TIFzzUHqKjax	ALK	AP26113	"In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Brigatinib (AP26113) in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J3YlSS-TIFzzUHq-jax	ALK	AP26113	"In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK ALK S1206C were resistant to brigatinib (AP26113) in culture (PMID: 25421750)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2lhSS-TIFzzUHppjax	ALK	AP26113	"In a preclinical study, a transformed cell line expressing ALK Y1278S was sensitive to Brigatinib (AP26113) in culture, resulting in cell growth inhibition (PMID: 27049722)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27049722	AVv-J5RWSS-TIFzzUHuUjax	ALK	AP26113	"In a preclinical study, a transformed cell line expressing ALK R1275Q was sensitive to Brigatinib (AP26113) in culture and in vivo, resulting in cell growth inhibition (PMID: 27049722)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27049722	AVv-J4B9SS-TIFzzUHsPjax	ALK	AP26113	"In a preclinical study, a transformed cell line expressing ALK R1192P was sensitive to Brigatinib (AP26113) in culture, resulting in cell growth inhibition (PMID: 27049722)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27049722	AVv-J4xGSS-TIFzzUHtfjax	ALK	AP26113	"In a preclinical study, a transformed cell line expressing ALK I1171N was sensitive to Brigatinib (AP26113) in culture, resulting in cell growth inhibition (PMID: 27049722)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27049722	AVv-J3TrSS-TIFzzUHq2jax	ALK	AP26113	"In a preclinical study, a transformed cell line expressing ALK G1269A was sensitive to Brigatinib (AP26113) in culture, resulting in cell growth inhibition (PMID: 27049722)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27049722	AVv-J5AnSS-TIFzzUHt5jax	ALK	AP26113	"In a preclinical study, a transformed cell line expressing ALK G1128A was sensitive to Brigatinib (AP26113) in culture, resulting in cell growth inhibition (PMID: 27049722)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27049722	AVv-J4SwSS-TIFzzUHstjax	ALK	AP26113	"In a preclinical study, a transformed cell line expressing ALK F1245C was sensitive to Brigatinib (AP26113) in culture, resulting in cell growth inhibition (PMID: 27049722)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27049722	AVv-J4jOSS-TIFzzUHtHjax	ALK	AP26113	"In a preclinical study, a transformed cell line expressing ALK F1174L was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27049722	AVv-J5dBSS-TIFzzUHuojax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) modestly inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3rHSS-TIFzzUHrejax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK R1192P in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4tHSS-TIFzzUHtYjax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK I1171S in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4MFSS-TIFzzUHshjax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5MySS-TIFzzUHuMjax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK F1174L in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J5hSSS-TIFzzUHuvjax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J2SsSS-TIFzzUHpKjax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27009859	AVv-J4poSS-TIFzzUHtSjax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing S1206Y in the context of EML4-ALK in culture (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-J2MKSS-TIFzzUHo_jax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2opSS-TIFzzUHpujax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK G1128S in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J1uOSS-TIFzzUHoOjax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J3u_SS-TIFzzUHrvjax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25749034	AVv-J2-oSS-TIFzzUHqSjax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK P1139S in culture (PMID: 25421750)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25421750	AVv-J2Y8SS-TIFzzUHpUjax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EML4-ALK with L1198F in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3feSS-TIFzzUHrKjax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A and L1198F in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J3huSS-TIFzzUHrOjax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26698910	AVv-J5VnSS-TIFzzUHubjax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK T1151dup in the context of EML4-ALK in culture (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-J4A2SS-TIFzzUHsNjax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK S1206F in the context of EML4-ALK in culture (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-J4SKSS-TIFzzUHssjax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK L196M in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-J2v2SS-TIFzzUHp6jax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK L1152R in the context of EML4-ALK in culture (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-J28ZSS-TIFzzUHqOjax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK L1152P in the context of EML4-ALK in culture (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-J4oeSS-TIFzzUHtQjax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK G1202R in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-J3ChSS-TIFzzUHqZjax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK F1174V in the context of EML4-ALK in culture (PMID: 27780853)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27780853	AVv-J3xTSS-TIFzzUHrzjax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of a transformed cell line expressing EML4-ALK I1171T but to a lesser degree than EML4-ALK in culture (PMID: 25228534)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-J1wNSS-TIFzzUHoRjax	ALK	AP26113	"In a preclinical study, Brigatinib (AP26113) inhibited growth of a transformed cell line expressing EML4-ALK ALK V1180L in culture (PMID: 25228534)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25228534	AVv-J2dMSS-TIFzzUHpbjax	ALK	AP26113	"In a phase I/II clinical trial, AP26113 was determined to be safe and efficacious in patients with advanced, ALK-fusion positive NSCLC (PMID: 24091716)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24091716	AVv-J2LoSS-TIFzzUHo-jax	AKT1	Vemurafenib	"In a preclinical study, expression of AKT1 Q79K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265152	AVv-J1D6SS-TIFzzUHn6jax	AKT1	Vemurafenib	"In a preclinical study, expression of AKT1 E17K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/24265152	AVv-J02kSS-TIFzzUHnljax	AKT1	Triciribine	"In a Phase I trial, Triciribine (API-2) demonstrated safety, but lacked efficacy as a monotherapy in advanced solid tumor patients with activated Akt (PMID: 20644979)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/20644979	AVv-J092SS-TIFzzUHnwjax	AKT1	Sirolimus	"In a preclinical study, Rapamune (sirolimus) treatment did not improve survival in cell line xenograft animal models of lymphoma overexpressing constitutively active Akt (PMID: 18708578)."	no benefit	http://www.ncbi.nlm.nih.gov/pubmed/18708578	AVv-J0_FSS-TIFzzUHnyjax	AKT1	ONC201	"In a preclinical study, ONC201 (TIC-10) inhibited Akt activation and induced apoptosis and tumor regression in a variety of cell line xenograft models (PMID: 23390247)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23390247	AVv-J0_qSS-TIFzzUHnzjax	AKT1	MK2206	"In a preclinical study, breast cancer cells expressing AKT1 W80A were resistant to MK2206 in culture, resulting in repression of induced cell death when compared to wild-type AKT1 (PMID: 25551293)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25551293	AVv-J1ANSS-TIFzzUHn0jax	AKT1	Ipatasertib	"In a Phase I trial, a patient with ERBB2 (HER2)-receptor negative breast cancer harboring AKT1 E17K demonstrated a complete metabolic response when treated with Ipatasertib (GDC-0068) (PMID: 27872130)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27872130	AVv-J0x0SS-TIFzzUHndjax	AKT1	GSK2141795	"In a preclinical study, the pan AKT inhibitor GSK2141795 displayed similar levels of inhibition against ATK1 E17K (activating mutation) as ATK1 wild-type (PMID: 24978597)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24978597	AVv-J0zrSS-TIFzzUHngjax	AKT1	GSK2141795	"In a preclinical study, Uprosertib (GSK2141795) inhibited the growth of melanoma cells harboring AKT1 E17K in culture (PMID: 24735930)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/24735930	AVv-J0wmSS-TIFzzUHnbjax	AKT1	GSK2141795	"In a preclinical study, GSK2141795 inhibited all isoforms of AKT in human cancer cell lines (PMID: 23795919)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/23795919	AVv-J07cSS-TIFzzUHnsjax	AKT1	GSK2141795	"In a Phase I trial, GSK2141795 treatment resulted in Akt inhibition and clinical benefit in 27% (3/11) of ovarian cancer patients (PMID: 26429956)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26429956	AVv-J06zSS-TIFzzUHnrjax	AKT1	GDC-0941	"In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA E545K resulted in resistance to Pictilisib (GDC-0941) in culture (PMID: 27604488)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27604488	AVv-J1BiSS-TIFzzUHn2jax	AKT1	Doxorubicin	"In a preclinical study, lymphoma cells overexpressing constitutively active Akt demonstrated reduced sensitivity to Adriamycin (doxorubicin) treatment in cell line xenograft models (PMID: 18708578)."	decreased response	http://www.ncbi.nlm.nih.gov/pubmed/18708578	AVv-J0-fSS-TIFzzUHnxjax	AKT1	Cisplatin + Perifosine	"In a preclinical study, Perifosine (KRX-0401) enhanced the sensitivity of human ovarian clear cell cancer cells with activated Akt1 to Platinol (cisplatin) treatment in culture (PMID: 25519148)."	predicted – sensitive	http://www.ncbi.nlm.nih.gov/pubmed/25519148	AVv-J08mSS-TIFzzUHnujax	AKT1	Cetuximab + Irinotecan	"In a retrospective study, 100% (2/2) colorectal carcinoma patients harboring an AKT1 E17K mutation and wild-type KRAS/BRAF demonstrated resistance to Erbitux (cetuximab) in combination with Camptosar (irinotecan) (PMID: 25714871)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/25714871	AVv-J04qSS-TIFzzUHnojax	AKT1	BYL719	"In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/27604488	AVv-J1A5SS-TIFzzUHn1jax	AKT1	BAY1125976	"In a preclinical study, treatment with BAY1125976 reduced tumor growth and resulted in partial tumor regression or stable disease in anal cancer patient-derived xenograft (PDX) models harboring AKT1 E17K (PMID: 27699769)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27699769	AVv-J0xOSS-TIFzzUHncjax	AKT1	BAY1125976	"In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring AKT E17K and NRAS G12D in culture, and demonstrated antitumor activity in xenograft models (PMID: 27699769)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27699769	AVv-J03TSS-TIFzzUHnmjax	AKT1	BAY1125976	"In a preclinical study, BAY1125976 induced complete tumor regression in a patient-derived xenograft (PDX) model of breast cancer harboring AKT E17K (PMID: 27699769)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/27699769	AVv-J0vLSS-TIFzzUHnZjax	AKT1	AZD5363 + AZD4547	"In a preclinical study, the combined therapy of AZD5363 and AZD4547 resulted in tumor regression in urinary bladder cancer xenograft models simultaneously harboring the mutations, AKT1 E17K and FGFR3 Y373C (PMID: 26351323)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26351323	AVv-J03-SS-TIFzzUHnnjax	AKT1	AZD5363	"In a preclinical study, AZD5363 inhibited growth and colony formation of breast cancer cells expressing AKT E17K in cell culture and in xenografts as well as breast cancer explant models harboring AKT E17K (PMID: 26351323)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26351323	AVv-J001SS-TIFzzUHnijax	AKT1	AZD5363	"In a clinical case study, a patient with meningothelial meningioma harboring AKT1 E17K demonstrated stable disease and some tumor regression when treated with AZD5363 (PMID: 28376212)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/28376212	AVv-J01bSS-TIFzzUHnjjax	AKT1	AZD5363	"In a Phase I clinical trial, a patient with ER-positive, ERBB2 (HER2)-negative papillary breast carcinoma harboring AKT1 E17K had a sustained partial response to AZD5363 (PMID: 26351323)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26351323	AVv-J0v7SS-TIFzzUHnajax	AKT1	AZD5363	"In a Phase I clinical study, a patient with endometrioid ovarian carcinoma harboring AKT1 E17K had a sustained partial response to AZD5363 for more than two years (PMID: 26351323)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26351323	AVv-J02ASS-TIFzzUHnkjax	AKT1	ARQ092	"In a preclinical study, an endometrial cell line xenograft model harboring AKT E17K was sensitive to ARQ092, demonstrating inhibition of tumor growth (PMID: 26469692)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26469692	AVv-J00MSS-TIFzzUHnhjax	AKT1	ARQ 751	"In a preclinical study, an endometrial cell line xenograft model harboring AKT E17K was sensitive to ARQ 751, demonstrating inhibition of tumor growth (PMID: 26469692)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26469692	AVv-J0zFSS-TIFzzUHnfjax	ABL1	Imatinib	"In a preclinical study, lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) and expressing ABL1 T315I demonstrated resistance to Gleevec (imatinib) in culture and in xenograft models (PMID: 26758680)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26758680	AVv-J0epSS-TIFzzUHnWjax	ABL1	Imatinib	"In a preclinical study, Gleevec (imatinib) inhibited growth of a lung adenocarcinoma cell line harboring ABL1 R332W (also reported as R351W) in culture, and inhibited tumor growth in xenograft models (PMID: 26758680)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26758680	AVv-J0dVSS-TIFzzUHnUjax	ABL1	Imatinib	"In a preclinical study, Gleevec (imatinib) inhibited growth of a lung adenocarcinoma cell line harboring ABL1 G321L (also reported as G340L) in culture (PMID: 26758680)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26758680	AVv-J0fQSS-TIFzzUHnXjax	ABL1	Dasatinib	"In a preclinical study, treatment with Sprycel (dasatinib) in decreased CRKL phosphorylation and reduced viability of lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) in culture (PMID: 26758680)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26758680	AVv-J0boSS-TIFzzUHnTjax	ABL1	Dasatinib	"In a preclinical study, treatment with Sprycel (dasatinib) in decreased CRKL phosphorylation and reduced viability of lung adenocarcinoma cells harboring ABL1 G321L (also reported as G340L) in culture (PMID: 26758680)."	sensitive	http://www.ncbi.nlm.nih.gov/pubmed/26758680	AVv-J0fzSS-TIFzzUHnYjax	ABL1	Dasatinib	"In a preclinical study, lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) and expressing ABL1 T315I demonstrated resistance to Sprycel (dasatinib) in culture (PMID: 26758680)."	resistant	http://www.ncbi.nlm.nih.gov/pubmed/26758680	AVv-J0d8SS-TIFzzUHnVcivic	ZEB1	"Gemcitabine,Cytarabine,Doxorubicin"	"Downregulation of ZEB1 expression in mantle cell lymphoma cell lines and mouse xenografts led to enhanced sensitivity towards treatment with doxorubicin, cytarabin and gemcitabine."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/24013721	AVv-MnDnSS-TIFzzUJ3-civic	XRCC1		The XRCC1 R399Q variant was significantly correlated with higher overall survival in non-small cell lung carcinoma (NSCLC) patients treated with gemcitabine and platinum. 62 patients with either Stage IIIB or Stage IV NSCLC were used for this study.	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22551904	AVv-MpS4SS-TIFzzUJ4gcivic	WT1	"Cytarabine,Daunorubicin"	"WT1 mutations were associated with an inferior response to induction chemotherapy with a higher rate of resistant disease in young (15-60+, median 45) patients with cytogenetically normal AML."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/18591546	AVv-L9rjSS-TIFzzUJrlcivic	WT1		"WT1 mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/18559874	AVv-L9qLSS-TIFzzUJrjcivic	WT1		"WT1 mutations were associated with a higher cumulative incidence of relapse and shorter relapse free survival in young (15-60+, median 45) patients with cytogenetically normal AML."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/18591546	AVv-L9sTSS-TIFzzUJrmcivic	WT1		"WT1 mutations were a negative prognostic factor for overall survival in young (15-60+, median 45) patients with cytogenetically normal AML."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/18591546	AVv-L9tJSS-TIFzzUJrncivic	WT1		"WT mutations were associated with shorter overall and disease free survival in a cohort of cytogenetically normal, young (<60) AML patients."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/18559874	AVv-L9t0SS-TIFzzUJrocivic	WT1		"Rates of complete remission and refractory disease are not different in patients with WT1 mutations (69% exon 7, 15% exon 9) than those without in young (16-60) patients with cytogenetically normal AML."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/19221039	AVv-L9q8SS-TIFzzUJrkcivic	WT1		"No differences in relapse-free or overall survival were identified between young (16-60) patients with or without WT1 mutations (69% exon 7, 15% exon 9) in cytogenetically normal AML."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/19221039	AVv-L9w-SS-TIFzzUJrtcivic	WT1		"Mutations in WT1 were associated with a worse overall prognosis than patients wildtype for WT1 in young patients (15-50), primarily because of increased risk of disease recurrence."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/19536888	AVv-L9vHSS-TIFzzUJrqcivic	WT1		Mutations  in WT1 were associated with increased risk of recurrence in young patients (15-50) with cytogenetically normal AML.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/19536888	AVv-L9vvSS-TIFzzUJrrcivic	VHL		"c.165insG
Frameshift
This is another family, with a different genetic background (Chinese) with the same mutation and VHL disease. Affected individuals retinal angioma and central nervous"	Positive	http://www.ncbi.nlm.nih.gov/pubmed/17024664	AVv-MDK2SS-TIFzzUJtmcivic	VHL		"c.165G>A results in synonymous change Glu55Glu. This is family V5 in the paper (VHL Type 1, no phechromocytoma)."	Uncertain Significance	http://www.ncbi.nlm.nih.gov/pubmed/9829912	AVv-MC7ISS-TIFzzUJtOcivic	VHL		"This is a frameshift mutation that results in a stop at codon 66.  
Family 3682 in this publication, variant segregates with disease. 
VHL Type 1 disease is reported: CNS tumors, retinal angioma, renal cell carcinoma but no pheochromocytoma"	Uncertain Significance	http://www.ncbi.nlm.nih.gov/pubmed/8956040	AVv-MC8XSS-TIFzzUJtQcivic	VHL		"Mutation detected in one case. Case shows renal cell carcinoma. ACMG evidence codes: 'PP1' based on segregation results, 'PP4' the patients phenotypes are highly specific for a disease with single genetic etiology."	Uncertain Significance	http://www.ncbi.nlm.nih.gov/pubmed/20151405	AVv-MDAsSS-TIFzzUJtXcivic	VHL		"Mutation detected in one case. Case shows CNS hemangioblastoma. ACMG evidence codes: 'PVS1' for a single exon deletion, 'PP1' based on segregation results, 'PP4' because patients phenotypes are highly specific for a disease with single genetic etiology."	Pathogenic	http://www.ncbi.nlm.nih.gov/pubmed/20151405	AVv-MDI9SS-TIFzzUJtkcivic	VHL		"In renal clear cell carcinoma, patients with VHL mutations did not have a significant impact on cancer specific survival."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/23620406	AVv-MC_kSS-TIFzzUJtVcivic	VHL		"In patients with renal clear cell carcinoma, patients with loss of function VHL mutations had shorter tumor-specific survival."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/11793370	AVv-MDH-SS-TIFzzUJticivic	VHL		"In patients with renal clear cell carcinoma, patients with VHL mutations had longer cancer-specific survival."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/18464292	AVv-MDAISS-TIFzzUJtWcivic	VHL		"In a 54 year old male patient with sporadic renal cell carcinoma, a c.163_164delGA causing a p.Glu55Gly Stop at 130 frameshift mutation was observed. Loss of heterozygosity analysis was non-informative."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/10408776	AVv-MC9nSS-TIFzzUJtScivic	VEGFA	"5-fluorouracil,Irinotecan,Bevacizumab,L-Folinic Acid"	Decreased peri- and post-therapeutic expression of VEGFA were significantly associated with response to FOLFIRI plus bevacizumab in 57 patients with metastatic CRC.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25973082	AVv-Mo5PSS-TIFzzUJ4dcivic	UGT1A1	Belinostat	The FDA approved package insert for Belinostat recommends dose adjustment for UGT1A1*28 allele homozygotes.	Adverse Response	http://www.ncbi.nlm.nih.gov/pubmed/26313268	AVv-MvghSS-TIFzzUJ6Wcivic	U2AF1		"In patients with MDS, those who harbor Q157P/R mutation of U2AF do not show statistical significance in complete remission rate compared to those who harbor wild type U2AF."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/23029227	AVv-L9cdSS-TIFzzUJrgcivic	U2AF1		"In patients with AML, those who harbor Q157P/R mutation of U2AF1 do not show a statistically significant difference in complete remission rate compared to those who harbor wild type U2AF1."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/23029227	AVv-L9bvSS-TIFzzUJrfcivic	U2AF1		"In patients with AML, complete remission rates are not different between patients who harbor the U2AF1 S34Y/F mutation and those with wild type U2AF1."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/23029227	AVv-L9Z1SS-TIFzzUJrccivic	U2AF1		"Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF S34Y/F mutations and those who harbor wild type U2AF."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/23029227	AVv-L9bJSS-TIFzzUJrecivic	U2AF1		"Age, sex, FAB subtype and karyotypes were not statistically significant between AML patients with U2AF Q157P/R mutations and those who harbor wild type U2AF."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/23029227	AVv-L9drSS-TIFzzUJricivic	U2AF1		"After adjusting for age and cancer stage, the presence of U2AF mutations such as S34Y/F are prognostic for poorer survival outcomes in patients with MDS."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/23861105	AVv-L9aeSS-TIFzzUJrdcivic	U2AF1		"After adjusting for age and cancer stage, presence of U2AF mutation such as Q157P/R is prognostic for poorer survival outcomes in patients with MDS."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/23861105	AVv-L9dFSS-TIFzzUJrhcivic	TYMS	Raltitrexed	"In 125 gastric tumors, plasma and tissue mRNA levels of TYMS were lower in the raltitrexed sensitive group compared to the resistant group (p = 0.007 and 0.013, respectively)."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/22422354	AVv-MojLSS-TIFzzUJ4Vcivic	TYMS	Pemetrexed	"mRNA levels of TYMS, DHFR and GARFT were assessed (rt-PCR) in 50 patient samples of NSCLC. TYMS mRNA levels were lower in responders compared to non-responders to pemetrexed (1.671 ± 0.844 versus 5.978 ± 1.895, p=0.0142)."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/23060591	AVv-Moj0SS-TIFzzUJ4Wcivic	TYMS	Pemetrexed	TYMS copy number was lower in clinical samples responding to pemetrexed in combination with platinum (n=25). The same was found in 17 cell lines.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/23645741	AVv-MolVSS-TIFzzUJ4Ycivic	TYMS	Pemetrexed	Case report of a patient with metastatic prostate cancer and underexpression of TYMS who showed a nonspecified response to pemetrexed for at least 4 months.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24782778	AVv-Mol_SS-TIFzzUJ4Zcivic	TUBB3	Taxane	"High expression of betaIII-tubulin, as assessed in 85 breast cancers by IHC, was associated with better pathological response."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23218766	AVv-Mq_hSS-TIFzzUJ4-civic	TUBB3	Paclitaxel	"High expression of class 3 beta-tubulin led to decreased effect of paclitaxel on cell motility in HeLa, MCF-7 and CHO cell lines."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/21576762	AVv-MrATSS-TIFzzUJ4_civic	TTF1		6 of 89 patients with lung adenocarcinoma had amplification of TTF1. There was no statistical difference in overall survival between patients with and without gene amplification.	N/A	http://www.ncbi.nlm.nih.gov/pubmed/19040416	AVv-MIzESS-TIFzzUJvccivic	TSC1	Everolimus	Tumors expressing TSC1 or TSC2 mutations show notably more sensitivity to everolimus than their wild-type counterparts.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22923433	AVv-L852SS-TIFzzUJrVcivic	TP53	Nutlin-3a	"MDM2 Inhibitor Nutlin-3a induced senescence in presence of functional TP53 in murine primary fibroblasts, oncogenically transformed fibroblasts, and fibrosarcoma cell lines. TP53 mutant cells lacking functional TP53 were completely insensitive to the drug."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/17671205	AVv-L8PiSS-TIFzzUJqtcivic	TP53	Nutlin-3a	"MDM2 Inhibitor Nutlin-3a induced senescence in presence of functional TP53 in murine primary fibroblasts, oncogenically transformed fibroblasts, and fibrosarcoma cell lines. Cells lacking functional TP53 were completely insensitive to the drug."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/17671205	AVv-L8GQSS-TIFzzUJqecivic	TP53	Doxorubicin	Breast tumors with R175H or R249 mutations are more responsive to doxorubicin than breast tumors with wild type TP53.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/9569050	AVv-L8OZSS-TIFzzUJqrcivic	TP53	Doxorubicin	Breast tumors in a mouse model with R175H mutation are more responsive to doxorubicin than breast tumors with wild type TP53.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22698404	AVv-L8MDSS-TIFzzUJqncivic	TP53	AMGMDS3	"MDM2 Inhibitor screen in a panel of 260 cancer cell lines with well characterized TP53 status shows that only cancer cell lines with unaltered TP53 may be sensitive to MDM2 Inhibitor AMGMDS3, while those with p53 mutations demonstrated resistance."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/25730903	AVv-L8QySS-TIFzzUJqvcivic	TP53	AMGMDS3	MDM2 Inhibitor screen in a panel of 260 cancer cell lines with well characterized TP53  status shows that only cancer cell lines with unaltered TP53 may be sensitive to MDM2 Inhibitor.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25730903	AVv-L8G0SS-TIFzzUJqfcivic	TP53		"Unlike other studies, in this study of 110 patients with head and neck squamous cell carcinoma, there was no significant difference in the overall survival of patients with and without any TP53 mutations."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/8901856	AVv-L8X4SS-TIFzzUJq7civic	TP53		"The authors analyzed 328 patients with CLL, of which 28 were identified to have TP53 mutations. Patients with TP53 mutations were found to have significantly shorter progression-free (HR = 3.8; P < 0.001) and overall survival (HR = 7.2; P < 0.001)."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/20697090	AVv-L8d5SS-TIFzzUJrEcivic	TP53		"In relapsed B-ALL patients, TP53 mutations were associated with morphologic nonresponse to therapy (>5% blasts in the bone marrow after 9 weeks of treatment) as well as reduced event free and overall survival when compared to TP53 wildtype patients."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21747090	AVv-L8ZpSS-TIFzzUJq-civic	TP53		"In patients with myeloma, those with mutations in TP53 had worse overall survival than those without."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/17215851	AVv-L8jBSS-TIFzzUJrLcivic	TP53		"In patients with myelodysplastic syndrome, in a multivariate analysis those with mutations in TP53 had shorter overall survival than wild-type patients."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/24836762	AVv-L8gHSS-TIFzzUJrHcivic	TP53		"In patients with head and neck squamous cell carcinoma, when comparing patients with any mutation in TP53 to wild-type, there was not a significant difference in overall survival in a multivariate analysis."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21467160	AVv-L8UHSS-TIFzzUJq1civic	TP53		"In patients with head and neck squamous cell carcinoma, in a multivariate analysis those with truncating mutations in TP53 had worse progression-free and overall survival than wild-type patients."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21467160	AVv-L8TjSS-TIFzzUJq0civic	TP53		"In children with bone marrow relapsed B-cell precursor acute lymphoblastic leukemia, in multivariate analysis those with mutations in TP53 had worse event-free survival than patients without mutations."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22699455	AVv-L8fYSS-TIFzzUJrGcivic	TP53		"In breast cancer patients harboring TP53 mutation, mutations in conserved regions such as R249 are prognostic for a worse overall survival compared to those harboring wild-type TP53."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/9569050	AVv-L8O8SS-TIFzzUJqscivic	TP53		"In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/9569050	AVv-L7-6SS-TIFzzUJqTcivic	TP53		"In breast cancer patients harboring TP53 mutation, mutations in DNA contact regions such as R248 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/9569050	AVv-L8CNSS-TIFzzUJqYcivic	TP53		"In breast cancer patients harboring R248W mutation, the prognosis is worse than any other hotspot TP53 mutation, as well as worse than patients with wild type TP53."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/16489069	AVv-L8oUSS-TIFzzUJrUcivic	TP53		"In breast cancer patients  harboring TP53 mutation, mutations in DNA contact regions such as R273 are prognostic for a worse relapse-free survival compared to other non-silent mutations in TP53."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/9569050	AVv-L8l9SS-TIFzzUJrQcivic	TP53		"In a study of 74 patients with head and neck squamous cell carcinoma, those with disruptive mutations in TP53 had shorter overall survival and a higher rate of locoregional recurrence than those without mutations or with nondisruptive mutations."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22090360	AVv-L8TASS-TIFzzUJqzcivic	TP53		"In a retrospective study of patients with esophageal carcinoma, those with mutations in TP53 had worse overall survival."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/19941080	AVv-L8dKSS-TIFzzUJrDcivic	TP53		"In a multivariate analysis of 774 CLL patients, TP53 aberrations were significantly correlated with shorter time to first treatment (HR=2.081; 95% CI=1.431-3.021). This finding was independent of IGHV mutation status."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/24943832	AVv-L8iTSS-TIFzzUJrKcivic	TP53		"In a cohort of 406 patients with CLL, those patients with clonal or sub-clonal mutations in TP53 had significantly shorter overall survival (HR: 1.71; 95% CI: 1.28-2.26; P = .0001)."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/26837699	AVv-L8g0SS-TIFzzUJrIcivic	TP53		"Breast cancer patients who harbor a R248Q mutation (N=18) have worse overall survival than those with wild type TP53 (N=1460), but have better prognosis than those with a R248W mutation (N=8)."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/16489069	AVv-L8BkSS-TIFzzUJqXcivic	TP53		"Breast cancer patients who harbor R273H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/16489069	AVv-L7_oSS-TIFzzUJqUcivic	TP53		"Breast cancer patients who harbor R273C mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/16489069	AVv-L8mkSS-TIFzzUJrRcivic	TP53		"Breast cancer patients who harbor R175H mutation have worse overall survival than those with wild type TP53, but have better prognosis than those with R248W mutation."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/16489069	AVv-L8MpSS-TIFzzUJqocivic	TP53		A study of 53 patients with B-CLL found a significant resistance to chemotherapy and corresponding poor clinical outcomes among the 7 treated patients with p53 mutations compared to the 29 treated patients without.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/8241511	AVv-L8btSS-TIFzzUJrBcivic	TOP1	Irinotecan	"FFPE tumor samples from 78 patients with colorectal cancer, who had received irinotecan monotherapy were analyzed with a FISH dual-probe.
TOP1 gain was nonsignificantly associated with objective response to irinotecan Odds ratio (OR): 1.62; p = 0.07."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24256029	AVv-MnsuSS-TIFzzUJ4Pcivic	TIMP1	Fulvestrant	TIMP1 overexpression was associated with resistance to fulvestrant in breast cancer cell lines.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/23881388	AVv-MneUSS-TIFzzUJ4Dcivic	TGFA		Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced disease-free and cause-specific survival.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/9625170	AVv-MnQ9SS-TIFzzUJ4Acivic	TET2		"In patients with myelodysplastic syndromes, those with TET2 mutations have been shown to have better overall survival than patients without TET2 mutations."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/19666869	AVv-MAzJSS-TIFzzUJs_civic	TET2		"In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations had higher rates of complete remission."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22430270	AVv-MAydSS-TIFzzUJs-civic	TET2		"In patients with cytogenetically normal acute myeloid leukemia, those in the intermediate-I risk group with TET2 mutations did not have significantly different rates of event-free survival, complete remission, disease-free survival, or overall survival."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/21343549	AVv-MAxwSS-TIFzzUJs9civic	TET2		"In patients with cytogenetically normal acute myeloid leukemia, those in the ELN favorable-risk group with TET2 mutations had shorter event-free survival, lower rates of complete remission, and shorter disease-free survival."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21343549	AVv-MAwSSS-TIFzzUJs7civic	TET2		"In patients classified as intermediate-risk via cytogenetics, TET2 mutations have been shown to be correlated with poor prognosis."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21828143	AVv-MAw9SS-TIFzzUJs8civic	TET2		"In a cohort of 783 young adult patients with acute myeloid leukemia, those with TET2 mutations did not have significantly different rates of complete recovery, refractory disease, or hypoplastic death."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/22430270	AVv-MAz4SS-TIFzzUJtAcivic	TERT		"Meta-analysis of 10 studies (9,411 patients, 13,708 controls) showed that TERT polymorphisms (rs2736100) were associated with an increased glioma risk (RR=1.28, 95% CI 1.23-1.33)."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/26765760	AVv-MIopSS-TIFzzUJvWcivic	TERT		"In this meta-analysis of 16 Trials, TERT mutations were more common in glioblastomas (69%), oligodendrogliomas (72%) in comparison to astrocytomas (24%) and oligoastrocytomas (38%)."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/26765760	AVv-MIpZSS-TIFzzUJvXcivic	TERT		"In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T, recurrence-free survival is worse than in patients harboring one of these mutations or no mutations in either gene."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/25024077	AVv-MIn7SS-TIFzzUJvVcivic	TERT		"In patients with nonacral cutaneous melanoma, those with mutations in the TERT promoter had shorter overall survival than wild-type patients."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/25217772	AVv-MIriSS-TIFzzUJvacivic	TERT		"In patients with acral lentiginous melanoma, those with amplification of TERT had shorter overall survival."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/25219713	AVv-MImjSS-TIFzzUJvTcivic	SYK	Paclitaxel	Overexpression and high p-SYK/SYK ratio were associated with resistance to paclitaxel. Inhibition of SYK with R406 resensitized cell lines to paclitaxel.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/26096845	AVv-Mm8cSS-TIFzzUJ38civic	STK11	SB202190	STK11-deficient cells were sensitive to treatment with MAPK11 inhibitor SB202190.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26391455	AVv-Mm1TSS-TIFzzUJ36civic	STK11		"In a retrospective analysis of 567 non-squamous, non-small cell lung cancer patients, Exon 1-2 mutations in STK11 were significantly associated with shorter OS (24 vs. 69 months) also after multivariate analysis. Results were validated in public datasets."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/26625312	AVv-Mm1_SS-TIFzzUJ37civic	STAG2		"In a study of 96 Ewing sarcoma tumors, 15% showed heterogenous loss of STAG2 expression in IHC analysis.  Of those with STAG2 expression loss, 88% presented with metastatic disease compared to only 27% of patients who expressed STAG2 on IHC (P=0.002)."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/25186949	AVv-Mr60SS-TIFzzUJ5Hcivic	SMO	Vismodegib	"In this case report, the D473H mutation was reported as an acquired mechanism of resistance to the hedgehog pathway inhibitor GDC-0449 (vismodegib)."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/19726788	AVv-MlqxSS-TIFzzUJ3kcivic	SMO	Vismodegib	"In basal cell carcinoma, H231R, D473G, W281C and Q477E mutations conferred resistance to SMO-inhibitor vismodegib. SMO mutations were identified in 22 of 44 resistant basal cell carcinomas in 15 patients."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/25759020	AVv-MlouSS-TIFzzUJ3hcivic	SMO	Saridegib	"Saridegib treatment induced tumor reduction and significantly prolonged survival in a Shh-driven mouse medulloblastoma model, and was found to be active in cells with the D473H point mutation."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22550175	AVv-MlpZSS-TIFzzUJ3icivic	SMO	"PSI,Arsenic Trioxide"	Basal cell carcinomas with ligand-binding pocket or constitutively active mutations in the SMO gene were sensitive to inhibition of downstream hedgehog signaling with PSI (aPKC-_/_/GLI inhibitor) or arsenic trioxide.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25759020	AVv-MloASS-TIFzzUJ3gcivic	SMARCB1	EPZ-6438	"Treatment with tazemetostat , a small-molecule inhibitor of EZH2, results in concentration-dependent cell growth inhibition and cell death specifically in SS18-SSX-positive, SMARCB1-deficient synovial sarcomas."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/27391784	AVv-MlZnSS-TIFzzUJ3ccivic	SMARCA4		"Nonsense mutations in SMARCA4 were associated with small cell carcinoma of the ovary, hypercalcemic type in 10/10 tumor samples, and were rarely found in other solid tumor types catalogued by TCGA."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/24658004	AVv-MIN5SS-TIFzzUJvPcivic	SMARCA4		"In patients with lung adenocarcinoma, those with loss-of-function mutations in SMARCA4 had worse overall survival than those with only missense or no mutations."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/24658004	AVv-MIOiSS-TIFzzUJvQcivic	SMAD4	Cetuximab	"In this study, SMAD4 underexpression was associated with an epithelial-to-mesenchymal transition and resistance to EGFR-directed treatment with Cetuximab."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/26046389	AVv-MH6zSS-TIFzzUJvMcivic	SMAD4		"In a study of 89 patients with adenocarcinoma of the pancreas who underwent a pancreaticoduodenectomy, those with mutations in SMAD4 had shorter overall survival than wild-type patients."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/19584151	AVv-MH4xSS-TIFzzUJvJcivic	SLFN11	SN-38	"In this study, SLFN11 expression was associated with sensitivity to SN-38 (an active metabolite of topoisomerase inhibitor irinotecan)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25089570	AVv-MxAASS-TIFzzUJ6pcivic	SLCO1B1	MTX	499 children from ALL trials treated with methotrexate were genotyped for 8 SNPs in 5 genes. The SLCO1B1 rs4149056 variant was significantly associated with MTX AUC0-48h and as such associated with increased toxicity.	Adverse Response	http://www.ncbi.nlm.nih.gov/pubmed/23652803	AVv-Mrj8SS-TIFzzUJ5Ecivic	SLCO1B1	MTX	499 children from ALL trials treated with methotrexate were genotyped for 8 SNPs in 5 genes. The SLCO1B1 RS2306283 variant was significantly associated with MTX AUC0-48h and as such associated with increased toxicity.	Adverse Response	http://www.ncbi.nlm.nih.gov/pubmed/23652803	AVv-MrkoSS-TIFzzUJ5Fcivic	SF3B1		"Patients with SF3B1 mutations had a statistically significant longer overall survival as well as event free-survival. Both before and after adjustment for age, karyotype and sex."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21995386	AVv-L6X6SS-TIFzzUJqAcivic	SF3B1		"In a multivariate analysis of 774 CLL patients, SF3B1 mutations were significantly correlated with shorter time to first treatment (HR=1.644; 95% CI=1.134-2.383). This finding was independent of IGHV mutation status."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/24943832	AVv-L6YhSS-TIFzzUJqBcivic	RUNX1		"In 878 non-APL patients with AML, those who had mutations in RUNX1 (N=53) had higher rates of refractory disease than those without (30% versus 19%; P = 0.047)."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21343560	AVv-L6DGSS-TIFzzUJp8civic	RRM2	"17224927,Gemcitabine"	The mRNA expression level of RRM2 was analyzed by RT-PCR in 8 human pancreatic cancer cell lines. Expression levels of RRM2 progressively increased during the development of gemcitabine resistance.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/17224927	AVv-MlAESS-TIFzzUJ3Lcivic	ROS1	Lorlatinib	"Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. PF-06463922 showed inhibition of kinase activity, cell viability and tumor growth in wild-type, G2032R and L2026M mutations in ROS1."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25733882	AVv-MkiuSS-TIFzzUJ3Bcivic	ROS1	Foretinib	Ba/F3 cells expressing CD74–ROS1 L2026M mutation showed similar sensitivity to foretinib compared with those expressing wild-type CD74–ROS1. This is in contrast to the increased resistance to crizotinib associated with this mutation in the same assay.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25688157	AVv-MkdYSS-TIFzzUJ25civic	ROS1	Foretinib	"Ba/F3 cells expressing CD74–ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1, and were sensitive to foretinib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25688157	AVv-MkhTSS-TIFzzUJ2_civic	ROS1	Foretinib	"Ba/F3 cells expressing CD74–ROS1 G2032R showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1 (~128 fold higher IC50); however, showed relative sensitivity to foretinib (only ~6 fold higher IC50 than WT)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25688157	AVv-Mkk9SS-TIFzzUJ3Ecivic	ROS1	Crizotinib	"Ba/F3 cells expressing CD74–ROS1 L2026M mutation showed resistance to crizotinib (~10 fold higher IC50 value), compared with those expressing wild-type CD74–ROS1; however, showed similar sensitivity to foretinib."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/25688157	AVv-MkfYSS-TIFzzUJ28civic	ROS1	Crizotinib	"Ba/F3 cells expressing CD74–ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1, and were sensitive to foretinib."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/25688157	AVv-MkgqSS-TIFzzUJ2-civic	RHOA		"285 intestinal-type tumors and 183 diffuse-type tumors were evaluated for mutational profiles.  RHOA mutations are associated with diffuse type mucinous gastric carcinoma, which indicate worse prognosis when compared to intestinal type (p<0.001)."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/27313181	AVv-MJupSS-TIFzzUJvqcivic	RET	Motesanib	"Medullary thyroid cancer cells with RET M918T mutation are insensitive to motesanib, compared to wild-type RET."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/21422803	AVv-L5jySS-TIFzzUJpucivic	RET	Motesanib	"Medullary thyroid cancer cells with RET C634W mutation are insensitive to motesanib, compared to wild-type RET."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/21422803	AVv-L5oDSS-TIFzzUJp0civic	RET	Hydroxy Vandetanib	"Vandetanib was tested in 4 murine models of patient-derived xenografts. In xenografts with high expression of EGFR or RET, vandetanib led to tumor regression, in those without high expression, vandetanib slowed tumor growth."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26686064	AVv-L5fZSS-TIFzzUJpncivic	RET	Hydroxy Vandetanib	"A case study of a patient with EGFR, KRAS, BRAF, HER2, ALK, ROS1 and MET negative adenocarcinoma of the lung. FISH analysis revealed a KIF5B-RET fusion. The RET inhibitor Vandetanib led to remission in the patient."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23584301	AVv-L5ieSS-TIFzzUJpscivic	RET	AZD1480	The use of AZD1480 on RET-mutated/rearranged cell lines in vitro led to strong repression of tyroid cancer cell growth.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23056499	AVv-L5kiSS-TIFzzUJpvcivic	RET		"In patients with medullary carcinoma, the presence of RET M918T mutation is associated with increased probability of lymph node metastases."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/18073307	AVv-L5mBSS-TIFzzUJpxcivic	RET		"Compared to those who harbor a wild type RET, patients with RET M918T mutation develop larger and more aggressive medullary thyroid cancer."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/9839497	AVv-L5lTSS-TIFzzUJpwcivic	REL		Amplification of REL is shown to be associated with germinal-center B-cell–like diffuse large-B-cell lymphomas.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/12075054	AVv-MA_vSS-TIFzzUJtCcivic	RB1		Positive RB1 expression (2+ by IHC) was associated with adverse outcomes in a cohort of 73 cases with stage I and II NSCLC (P<0.001) in this retrospective study. This finding was independent from other genomic and clinical factors explored by the authors.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22619677	AVv-MjhnSS-TIFzzUJ2scivic	RAC1	"Vemurafenib,Dabrafenib"	Melanoma cell lines harboring the RAC1 P29S hotspot mutation were shown to be resistant to BRAF inhibition with vemurafenib or dabrafenib and knock-in or knock-out of this mutation decreased and increased sensitivity to these drugs.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/25056119	AVv-MipTSS-TIFzzUJ2jcivic	PTEN	Trastuzumab	Trastuzumab was more effective in cell lines (SKBR3 vs. drug-resistant SKBR3/R) and 17 patient samples that exhibit elevated PTEN expression (by IHC).	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/16404430	AVv-L4dvSS-TIFzzUJo3civic	PTEN	Trastuzumab	"PTEN loss is associated with loss of sensitivity to the HER2-antibody trastuzumab in breast cancer in smaller trials, a phase III trial (NCCTG N9831) did not show an effect of PTEN on disease-free survival."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/24387334	AVv-L4fKSS-TIFzzUJo5civic	PTEN	"Temsirolimus,Ridaforolimus"	"94 endometrial cancer samples of women who had been treated with single agent mTOR inhibitors temsirolimus or ridaforolimus were retrospectively analyzed.
No predictive biomarkers were identified, including PIK3CA mutations, KRAS mutations or PTEN loss."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/24166148	AVv-L4k-SS-TIFzzUJpBcivic	PTEN	Temsirolimus	"In prostate cancer xenographs, PTEN null tumors had a significant decrease in cell size and proliferation when treated with Temsirolimus (CCI-779)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/11504908	AVv-L4kUSS-TIFzzUJpAcivic	PTEN	MTOR Inhibitors	Cells with PTEN deficiency have been shown to exhibit slowed growth in reponse to PI3K-mTOR inhibitors.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/20085938	AVv-L4WqSS-TIFzzUJotcivic	PTEN	GSK2141795	"Most BRAF mutant cell lines (mostly V600E) with PTEN mutation or loss of expression were among those sensitive to inhibition with AKT inhibitor
GSK2141795B."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24735930	AVv-L4hZSS-TIFzzUJo8civic	PTEN	Everolimus	PTEN loss is associated with reduced response to mTOR inhibitors in patients with bladder cancer.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/23989949	AVv-L4gtSS-TIFzzUJo7civic	PTEN	Cetuximab	"In 27 patients with chemotherapy-naive or chemotherapy-refractory metastatic colorectal cancer who were treated with cetuximab and chemotherapy, PTEN loss was associated with non-response."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/21163703	AVv-L4jmSS-TIFzzUJo_civic	PTEN	"Buparlisib,Carboplatin,Paclitaxel"	All three patients with PTEN loss had benefit from adding Buparlisib to carboplatin+paclitaxel therapy in a phase I study in advanced solid cancers.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25672916	AVv-L4i3SS-TIFzzUJo-civic	PTEN	AZD8186	Breast and prostate cancer cell lines responsive to AZD8186 were enriched for PTEN deficiency.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25398829	AVv-L4iHSS-TIFzzUJo9civic	PTEN		"PTEN nonsense mutations, including R233*, have been shown to be inactivating and loss-of-function, but do not have prognostic value in glioblastoma multiforme patients."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22479427	AVv-L4XYSS-TIFzzUJoucivic	PTEN		PTEN Loss (by FISH) is associated with poorer prognosis in patients with prostate cancer.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/17700571	AVv-L4t_SS-TIFzzUJpPcivic	PTEN		"Maxwell et al identified R173C in 1 subject (of 51 endometrial hyperplasias assayed for mutations in PTEN), and identified 10 mutations of 51 in PTEN overall (20%). No additional functional testing or clinical description was given."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/9635567	AVv-L4yESS-TIFzzUJpWcivic	PTEN		"In a study of 107 prostate adenocarcinomas, those with either hemi- or homozygous deletions of PTEN (as determined by interphase FISH) have shorter biochemical recurence-free survival than those without deletions."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/17700571	AVv-L4vwSS-TIFzzUJpScivic	PTEN		"Fults et al identified 1 R173C mutation in a glioblastoma (of 45 tested). The tumor also displayed either all or partial LOH of 10q, there was no further resolution of the LOH size or mutational testing done."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/9499454	AVv-L4zOSS-TIFzzUJpYcivic	PTCH1	Vismodegib	"Loss-of-heterozygosity in SHH-driven medulloblastoma was associated with increased PFS under therapy with vismodegib (AKA HhAntag691, GDC0449, GDC-0449). 43 patients total were enrolled for this study."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26169613	AVv-MiE4SS-TIFzzUJ2Rcivic	PRKACA		The DNAJB1-PRKACA fusion was detected in 79% (58/73) of fibrolamellar hepatocellular carcinomas assayed.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/25557953	AVv-Le1-SS-TIFzzUJaKcivic	PRKAA2	ACLY SiRNA	"Low levels of baseline p-AMPK (PRKAA2, measured at Thr172) were predictive of efficacy of ACLY inhibition by siRNA in cell lines of various cancer histologies."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23506848	AVv-Mhe4SS-TIFzzUJ2Mcivic	POU5F1	Oxaliplatin	OCT4B1 (POU5F1 splice variant) expression reduced sensitivity to oxaliplatin (via P-gp and ABCG2 differential expression) in vitro.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/26398480	AVv-MhY7SS-TIFzzUJ2Lcivic	PML	"All-trans Retinoic Acid,Arsenic Trioxide"	ATRA/Arsenic combined with standard chemotherapy has been shown to induce a complete remission rate of greater than 75% of patients with acute promyelocytic leukemia harboring the PML-RARa fusion.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/11704842	AVv-L3mASS-TIFzzUJoqcivic	PML	All-trans Retinoic Acid	The mutation A216V in the B2 domain of PML in the PML-RARa fusion was seen in a patient with ATRA-resistant acute promyelocytic leukemia.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/21613260	AVv-L3nWSS-TIFzzUJoscivic	PML	All-trans Retinoic Acid	"The PML L218P mutation in the PML-RARa fusion was observed in a patient with previously ATRA-treated, relapsed acute promyelocytic leukemia refractory to arsenic trioxide."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/21613260	AVv-L3jLSS-TIFzzUJomcivic	PML	All-trans Retinoic Acid	Mutations in the B2 domain of PML in the PML-RARa fusion have been shown to be associated with resistance to standard ATRA treatment in patients with acute promyelocytic leukemia.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/23670176	AVv-L3mrSS-TIFzzUJorcivic	PML	All-trans Retinoic Acid	Fusion protein degradation is accelerated upon ATRA treatment of acute promyelocytic cells at pharmalogical concentrations.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/8674046	AVv-L3knSS-TIFzzUJoocivic	PML		"The presence of the PML-RARa fusion protein is a diagnostic marker of Acute Promyelocytic Leukemia, or M3 AML."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/7628753	AVv-L3lWSS-TIFzzUJopcivic	PIK3CA	Trastuzumab	PIK3CA mutations were more frequent in grade 2 than in grade 3 invasive breast cancer.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/19671852	AVv-L1S9SS-TIFzzUJnkcivic	PIK3CA	Trastuzumab	"PI3K mutant E545K was overexpressed in the trastuzumab sensitive HER2 BT474 breast cancer cell line, and significant resistance to trastuzumab was induced in comparison to control cells."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/18829560	AVv-L0wwSS-TIFzzUJmxcivic	PIK3CA	Trastuzumab	"In unilateral breast cancer patients, PIK3CA mutation was associated with improved local recurrence-free survival."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/17575221	AVv-L0_0SS-TIFzzUJnGcivic	PIK3CA	Trastuzumab	"In primary invasive breast cancer patients, PIK3CA mutation was associated with improved overall survival compared to wildtype PIK3CA. PIK3CA mutations were more frequent in grade 2 than in grade 3 invasive breast cancer."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/19671852	AVv-L0-dSS-TIFzzUJnEcivic	PIK3CA	Trastuzumab	"In Japanese invasive breast cancer patients, PIK3CA mutation was associated with improved relapse-free survival."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/17202311	AVv-L0_FSS-TIFzzUJnFcivic	PIK3CA	Trastuzumab	Breast cancer cell lines with oncogenic PIK3CA mutations had an increased sensitivity to treatment with class I PI3K inhibitor GDC-0941 compared to wildtype PIK3CA cell lines.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/20453058	AVv-L1AeSS-TIFzzUJnHcivic	PIK3CA	Regorafenib	PIK3CA mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment.	N/A	http://www.ncbi.nlm.nih.gov/pubmed/24559322	AVv-L1NcSS-TIFzzUJnbcivic	PIK3CA	Rapamycin (Sirolimus)	Rapamycin inhibits transformation induced by mutation in PIK3CA.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/15647370	AVv-L1PVSS-TIFzzUJnecivic	PIK3CA	"Pictilisib,MK-2206"	PIK3CA E545K mutation increased sensitivity to AKT inhibitor MK-2206 and PI3K inhibitor GDC-0941 in a breast cancer cell line model.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23888070	AVv-L0yPSS-TIFzzUJmzcivic	PIK3CA	Panitumumab	"Rectal cancer patients with PIK3CA mutations showed a higher risk of local recurrence (HR:3.5; 95% CI:1.3-9.3, P=0.013, univariate analysis; HR:3.4, 95% CI:1.2-9.2, P=0.017, multivariate analysis) compared to wildtype PIK3CA patients."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/19903786	AVv-L1DFSS-TIFzzUJnLcivic	PIK3CA	Panitumumab	"PIK3CA has also been studied in pituitary and urological tumors, leukemia, lymphoma, neuroblastoma, and brain, breast, cervical, endometrial, esophageal, gastric, head and neck, liver/biliary tract, lung, ovarian, pancreatic, skin, and thyroid cancer."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/20535651	AVv-L1DuSS-TIFzzUJnMcivic	PIK3CA	PI103	"Recent evidence from clinical trials have shown PIK3CA mutations may respond well to PI3K inhibitors, such as XL147."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21227397	AVv-L1UwSS-TIFzzUJnncivic	PIK3CA	PI103	"Recent evidence from clinical trials have shown PIK3CA mutations may respond well to PI3K inhibitors, such as XL147."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/19075596	AVv-L1WJSS-TIFzzUJnpcivic	PIK3CA	PI103	"In squamous cell lung carcinomas (SCC), PIK3CA was expressed in 16 out of the 17 SCC tumors studied."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/10492640	AVv-L1IYSS-TIFzzUJnTcivic	PIK3CA	PI103	"In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compared to the wildtype PIK3CA cell line A549."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/19513541	AVv-L0qgSS-TIFzzUJmocivic	PIK3CA	Idelalisib	A case report of an 86-year old patient with metastasized Merkel cell carcinoma who achieved a complete clinical response under therapy with the PI3K-inhibitor Idelalisib.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26466009	AVv-L0zBSS-TIFzzUJm0civic	PIK3CA	"Cetuximab,Panitumumab"	The presence of a PIK3CA mutation in exon 9 or exon 20 (such as H1047R) were associated with lack of panitumumab or cetuximab response.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/19223544	AVv-L0zySS-TIFzzUJm1civic	PIK3CA	"Cetuximab,Panitumumab"	The presence of a PIK3CA mutation in exon 9 (such as E542K) or exon 20 were associated with lack of panitumumab or cetuximab response.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/19223544	AVv-L1OFSS-TIFzzUJnccivic	PIK3CA	CH5132799	Breast cancer cell lines with H1047R mutation showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-L00fSS-TIFzzUJm2civic	PIK3CA	CH5132799	Breast cancer cell lines with E542K/E545K mutations showed increased sensitivity to CH5132799 than cells with wild-type PIK3CA gene.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21558396	AVv-L1OsSS-TIFzzUJndcivic	PIK3CA	"BEZ235 (NVP-BEZ235, Dactolisib)"	Lentiviral transduction of PIK3CA H1047R mutation into head and neck cancer cell line SCC25 led to increased sensitivity to PI3K/mTOR inhibition with BEZ235 compared to unmanipulated cells (IC50 values 6 nM and 31 nM).	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25855885	AVv-L05hSS-TIFzzUJm9civic	PIK3CA	"2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"	PIK3CA mutations were more frequent in grade 2 than in grade 3 invasive breast cancer.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/19671852	AVv-L1RxSS-TIFzzUJnicivic	PIK3CA	"2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"	"Breast cancer cell lines with oncogenic PIK3CA mutations had an increased sensitivity to treatment with class I PI3K inhibitor GDC-0941 compared to wildtype PIK3CA cell lines (n=54, P=0.005)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/20453058	AVv-L08dSS-TIFzzUJnBcivic	PIK3CA		The presence of exon 9 (such as E542K) or exon 20 mutations were associated with poorer survival compared to those with wild-type PIK3CA mutation (P = 0.035).	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/19223544	AVv-L1ZrSS-TIFzzUJnucivic	PIK3CA		The presence of exon 20 (such as H1047R) or exon 9 mutation may result in poorer survival compared to those with wild-type PIK3CA mutation.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/19223544	AVv-L1JDSS-TIFzzUJnUcivic	PIK3CA		"In patients with gastric cancer, those with amplification of PIK3CA had shorter overall survival than those without amplification."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22292935	AVv-L1MwSS-TIFzzUJnacivic	PIK3CA		"Coexistence of exon 9 (E542K or E545K) and exon 20 mutations but not either alone, is prognostic for worse overall survival and cancer specific survival."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22357840	AVv-L1ZCSS-TIFzzUJntcivic	PGR	Tamoxifen	"In patients with ER-Positive breast cancer, expression of PgR does not effect the outcome of treatment with tamoxifen."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/23280579	AVv-MHZgSS-TIFzzUJu5civic	PGR	"Exemestane,Tamoxifen"	"In patients with breast cancer, those with low expression of PgR treated with tamoxifen had the same disease-free survial as those with high expression of PgR."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/21422407	AVv-MHaQSS-TIFzzUJu6civic	PGR		"In patients with breast cancer, those with low expression of PgR had worse disease-free survival than those with high expression."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21422407	AVv-MHa3SS-TIFzzUJu7civic	PGR		"In patients with breast cancer, those with expression of PgR (determined by immunohistochemical staining) had better relapse-free survival than those without expression."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/16497822	AVv-MHbeSS-TIFzzUJu8civic	PDGFRA	Ponatinib	"In a FIP1L1-PDGFRA positive eosinophil cell line growth-inhibitory effects were seen with all PDGFR-blocking agents, (ponatinib, sorafenib, masitinib, nilotinib, dasatinib, sunitinib, midostaurin) with ponatinib found to be the most potent compound."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24407160	AVv-L27aSS-TIFzzUJoUcivic	PDGFRA	Ponatinib	"Ba/F3 cells expressing two clinically relevant, imatinib-resistant, mutant forms of FIP1L1-PDGFRA, namely T674I and D842V were tested for growth inhibition by 8 PDGFR-blocking TKIs. Strong inhibitory effects on both mutants were seen only with ponatinib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24407160	AVv-L24YSS-TIFzzUJoOcivic	PDGFRA	Imatinib	"While cancer with PDGFRA V561D mutation is known to be sensitive to Imatinib, double mutation of V561D and D842V mutants are resistant to imatinib."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/16954519	AVv-L3BNSS-TIFzzUJoccivic	PDGFRA	Imatinib	"When 293T cells stably transduced with PDGFRA A842V were treated with imatinib, tyrosine phosphorylation was maintained at 1 and 10umol/L concentrations that inhibited phosphorylation of wildtype PDGFRA, consistent with resistance to this inhibitor."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/12949711	AVv-L2_1SS-TIFzzUJoacivic	PDGFRA	Imatinib	"Of eleven patients prospectively accrued with hypereosinophilic syndrome, nine had favorable responses to imatinib that lasted >3 months post-treatment. Of these nine patients, five were found to have a FIP1L1-PDGFRA fusion."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/12660384	AVv-L26pSS-TIFzzUJoScivic	PDGFRA	Imatinib	GIST cancer with D842V mutation is resistant to imatinib.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/15928335	AVv-L3B4SS-TIFzzUJodcivic	PDGFRA	Imatinib	A patient harbouring a novel TNKS2–PDGFRA fusion in a myeloid neoplasm with eosinophilia demonstrated a dramatic and durable response upon treatment with Imatinib mono therapy.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25658984	AVv-L3GVSS-TIFzzUJokcivic	PDGFRA	Crenolanib	"In CHO cells with the PDGFRA deletion I843 mutation that have shown imatinib sensitivity, crenolanib showed no significant difference from imatinib in kinase activity inhibition."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22745105	AVv-L3FxSS-TIFzzUJojcivic	PDGFRA	Crenolanib	"In CHO cells with PDGFRA DI842-843VM mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22745105	AVv-L28TSS-TIFzzUJoVcivic	PDGFRA	Crenolanib	"In CHO cells with PDGFRA D842Y mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22745105	AVv-L2-YSS-TIFzzUJoYcivic	PDGFRA	Crenolanib	"In CHO cells with PDGFRA D842V mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22745105	AVv-L2_ISS-TIFzzUJoZcivic	PDGFRA	Crenolanib	"In CHO cells with PDGFRA D842I mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22745105	AVv-L3EXSS-TIFzzUJohcivic	PDGFRA		GIST tumors harboring PDGFRA D842V mutation are more likely to be benign than malignant.	Negative	http://www.ncbi.nlm.nih.gov/pubmed/15146165	AVv-L3CgSS-TIFzzUJoecivic	PDCD4	Paclitaxel	PDCD4 expression was associated with response to paclitaxel in a retrospective analysis of 77 patients after preclinical validation and mechanistic analysis of the biomarker.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25928036	AVv-Mt9QSS-TIFzzUJ5vcivic	PBRM1		"In renal clear cell carcinoma, patients with PBRM1 mutations did not have a significantly different cancer specific survival."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/23620406	AVv-MD-XSS-TIFzzUJt1civic	PBRM1		"In patients with sporatic clear cell renal cell carcinoma, those with mutations in PBRM1 had better overall survival than patients with BAP1 mutations."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/23333114	AVv-MD9lSS-TIFzzUJt0civic	PBK	Gefitinib	TOPK (PBK) silencing sensitized lung cancer cells to gefitinib in preclinical xenograft models. Over-expression was also associated with resistance in various lung cancer cell lines.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/26745678	AVv-MwHoSS-TIFzzUJ6ecivic	PAX8		"PAX8–PPARG gene fusions were found in 12/33 follicular thyroid carcinoma tumor samples, but were rarely found in thyroid Hürthle cell tumors."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/12727991	AVv-MHShSS-TIFzzUJu3civic	NTRK3	Larotrectinib (LOXO-101)	"Results from a phase I study show that the TRK inhibitor LOXO-101 is well tolerated and effective, with patients whose tumors bear NTRK fusions responding well and durably to this targeted therapy."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26603524	AVv-MgO6SS-TIFzzUJ15civic	NTRK3	Entrectinib	Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an ETV6-NTRK3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followed by disease progression.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26884591	AVv-MgPkSS-TIFzzUJ16civic	NTRK1	Larotrectinib (LOXO-101)	"Results from a phase I study show that the TRK inhibitor LOXO-101 is well tolerated and effective, with patients whose tumors bear NTRK fusions responding well and durably to this targeted therapy."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26603524	AVv-Mf2HSS-TIFzzUJ1mcivic	NT5E	Cetuximab	CD73 high expression was identified as a potential marker of improved PFS from cetuximab treatment in patients with metastatic CRC.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25520391	AVv-MfhISS-TIFzzUJ1hcivic	NT5C2		The K359Q somatic mutation was significantly correlated with early disease recurrence and relapse in 103 T-cell ALL regardless of treatment course. The data was obtained from Berlin Frankfurt Münster Clinical Trials.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/23377281	AVv-MtBkSS-TIFzzUJ5jcivic	NRG1	Lapatinib	"Reactivation of EGFR, HER2 and HER3 occurred within 24 hours of lapatinib treatment in breast cancer cell lines, This was associated with increased expression of NRG1 in cells treated with lapatinib."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/25691057	AVv-MWW-SS-TIFzzUJzMcivic	NRG1	Lapatinib	"In non-HER2 amplified cell lines, sensitivity to HER2 kinase inhibitor lapatinib was found mainly in cell-lines with elevated NRG1 expression and HER3 activation. This aberration was mainly identified in head and neck cancer cell lines."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21840482	AVv-MWZLSS-TIFzzUJzPcivic	NRG1	Cetuximab	NRG1 upregulation or ERBB2 amplification were the main causes of resistance to cetuximab in-vivo and in-vitro in this study. Inhibition of ERBB2/ERBB3 signaling restored cetuximab sensitivity.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/21900593	AVv-MWaESS-TIFzzUJzbcivic	NRG1	AV-203	"This screening study in various tumor xenografts identified NRG1 expression to correlate with sensivity to ERBB3 inhibitory antibody AV-203.
ERBB3 expression was not predictive of response."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25542901	AVv-MWYgSS-TIFzzUJzOcivic	NRAS	Vemurafenib	Vemurafenib resistance is associated with gain of Q61 mutation in NRAS.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/23569304	AVv-LzXQSS-TIFzzUJlqcivic	NRAS	"Trametinib,Selumetinib"	"NRAS mutations define a distinct subset of lung cancers (_1%) with potential sensitivity to MEK inhibitors. Although NRAS mutations are more common in current/former smokers, the types of mutations are not those classically associated with smoking."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23515407	AVv-LzisSS-TIFzzUJl8civic	NRAS	Temozolomide	"In a melanoma patient with Q61R mutation, treatment with temozolomide resulted in overall survival of 16 months."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21576590	AVv-LzznSS-TIFzzUJmXcivic	NRAS	Temozolomide	"In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide resulted in disease free survival of 14 months."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21576590	AVv-LzvOSS-TIFzzUJmQcivic	NRAS	RO4987655	"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). Among 8 patients with NRAS mutated melanoma, 4 experienced SD or PR (1 Patient received study treatment for 323 days)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24947927	AVv-Lzg4SS-TIFzzUJl5civic	NRAS	NVP BEZ235	"NRAS mutations have also been observed in melanoma and biliary tract, bladder, cervix, liver, lung, myeloid leukemia, ovarian, pancreatic, and thyroid cancer."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/17384584	AVv-LzraSS-TIFzzUJmKcivic	NRAS	"Docetaxel,Trametinib"	"Phase 1 trial of trametinib and docetaxel in patients with advanced melanoma lacking BRAF V600 mutations. 15 patients were enrolled (14 BRAF wt). Six patients had a partial response, including four out of eight patients with NRAS mutations."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25542057	AVv-LzgTSS-TIFzzUJl4civic	NRAS	Cetuximab	"In chemotherapy-refractory patients with colorectal cancer, NRAS mutation status (primarily Q61) was not informative for disease control rate, progression free survival or overall survival following cetuximab plus chemotherapy."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/20619739	AVv-LzV-SS-TIFzzUJlocivic	NRAS	Cetuximab	Chemotherapy-refractory patients with colorectal cancer harboring NRAS mutation (primarily Q61) have a significantly lower response rate to cetuximab than patients wildtype for NRAS.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/20619739	AVv-LzWpSS-TIFzzUJlpcivic	NRAS	Binimetinib (MEK162)	Phase II study in 71 patients with NRAS or BRAF V600 mutant melanoma treated with MEK162. Six (20%) of 30 patients with NRAS-mutated melanoma had a partial response (three confirmed).	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23414587	AVv-LzdRSS-TIFzzUJlzcivic	NRAS	AZD 6244	"NRAS mutations have also been observed in melanoma and biliary tract, bladder, cervix, liver, lung, myeloid leukemia, ovarian, pancreatic, and thyroid cancer."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/17384584	AVv-Lzj5SS-TIFzzUJl-civic	NRAS	17-AAG	"Likely due to increased reliance of mutant NRAS on HSP90 for stabilization, inhibition of HSP90 by 17-AAG was shown to be effective in a patient with metastatic malignant melanoma with an NRAS G13D mutation."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/18375819	AVv-LzqvSS-TIFzzUJmJcivic	NRAS		"The presence of NRAS mutation in AML patients does not impact diease prognosis (resistant disease, disease-free survival, complete remission rate, relapse rate, induction death)."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/15951308	AVv-LzefSS-TIFzzUJl1civic	NRAS		Patients with colorectal cancer harboring NRAS mutation have poorer survival outcome and worse prognosis than patients with wildtype NRAS.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/24666267	AVv-LzhZSS-TIFzzUJl6civic	NRAS		"NRAS mutation status does not impact overall, event-free or disease-free survival in patients with AML."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/16434492	AVv-LzYmSS-TIFzzUJlscivic	NRAS		Melanoma associated with NRAS Q61 mutation was more often associated with those at the extremity than those at the trunk.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/23861977	AVv-LzX_SS-TIFzzUJlrcivic	NRAS		"In patients with stage IV melanoma, NRAS mutation was associated with reduced median survival compared to patients with wildtype NRAS."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22180178	AVv-Lzd4SS-TIFzzUJl0civic	NRAS		"In patients with multiple myeloma, the presence of a mutation in NRAS was not significantly associated with progression-free or overall survival."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/18528420	AVv-LziESS-TIFzzUJl7civic	NRAS		"In patients with follicular thyroid carcinoma, those with mutations in NRAS at codon 61 did not have significantly different overall survival than patients with wild-type NRAS (p=0.36)."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/22650231	AVv-LzVVSS-TIFzzUJlncivic	NQO1	Amrubicin	Higher expression of NQO1 was correlated with decreased cytotoxicity of amrubicin (amrubicinol is the active metabolite) in 27 NSCLC and SCLC cell lines.  siRNA knockdown of NQO1 (in two cell lines) increased amrubicinol cytotoxicity.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/21964527	AVv-MM23SS-TIFzzUJwlcivic	NPM1	Valproic Acid	"For patients with NPM1 mutation that achieved CR following induction therapy, relapse-free survival was improved following treatment with valproic acid."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24797300	AVv-Lx24SS-TIFzzUJlCcivic	NPM1	"NSC348884,All-trans Retinoic Acid"	NSC348884 combined with ATRA treatment induces apoptosis in primary AML cells harboring mutant NPM1 but not in cells with wildtype NPM1 or both mutant NPM1 and FLT3-ITD.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21719597	AVv-Lx3kSS-TIFzzUJlDcivic	NPM1	NSC348884	NSC348884 induced apoptosis in OPI-AML3 cells harboring an NPM1 mutation.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21719597	AVv-LyMHSS-TIFzzUJlhcivic	NPM1	Induction Therapy	"NPM1 mutation (Type A, W288fs) causes cytoplasmic localization of NPM when transfected into a non-hematopoietic cell line (293T cells). Cytoplasmic localization of NPM in AML patients was associated with good response to induction therapy."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/15659725	AVv-LyM6SS-TIFzzUJlicivic	NPM1	Daunorubicin	"Young patients (18-60) with NPM1 mutations had improved overall survival following high-dose versus standard dose daunorubicin (p=0.01) in univariate analysis. However, the adjusted p-value for multiple testing is 0.11."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22417203	AVv-Lx2FSS-TIFzzUJlBcivic	NPM1	"Anti-CD33,Anti-CD123"	"CD33 and CD123 expression was significantly increased in patients with NPM1 mutation with FLT3-ITD, indicating these patients may respond to combined anti-CD33 and anti-CD123 therapy."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24927407	AVv-Lx41SS-TIFzzUJlFcivic	NPM1	Anti-CD33	"CD33 expression was significantly increased in patients with NPM1 mutation with or without FLT3-ITD, indicating these patients may respond to anti-CD33 therapy."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24927407	AVv-Lx4NSS-TIFzzUJlEcivic	NPM1	All-trans Retinoic Acid	ATRA treatment improved overall and relapse-free survival in older (>60) patients with mutant NPM1 and without FLT3-ITD.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/19059939	AVv-Lx6OSS-TIFzzUJlHcivic	NPM1	All-trans Retinoic Acid	ATRA treatment did not effect overall survival in patients <60 years old with NPM1 mutation regardless of FLT3-ITD status.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/19965647	AVv-Lx5gSS-TIFzzUJlGcivic	NPM1		TET2 mutation reduces overall survival of normal karyotype patients with either an NPM1 mutation or NPM1 mutation without FLT3-ITD.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/24859829	AVv-LyIBSS-TIFzzUJlbcivic	NPM1		"Normal karyotype patients with NPM1 mutation and without FLT3-ITD had improved overall and relapse-free survival, complete remission rates and remission duration compared to all other combinations of mutants."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/19047294	AVv-LyECSS-TIFzzUJlVcivic	NPM1		No NPM1 mutations were identified in patients with favorable risk cytogenetics (79/215 patients).	Positive	http://www.ncbi.nlm.nih.gov/pubmed/21067377	AVv-LyOeSS-TIFzzUJlkcivic	NPM1		NPM1 mutations were not associated with the M3 acute myeloid leukemia FAB subtype (0/55).	Positive	http://www.ncbi.nlm.nih.gov/pubmed/16455956	AVv-LyAESS-TIFzzUJlPcivic	NPM1		NPM1 mutations were not associated with the M2 FAB subtype of acute myeloid leukemia.	Negative	http://www.ncbi.nlm.nih.gov/pubmed/16076867	AVv-LyHYSS-TIFzzUJlacivic	NPM1		NPM1 mutations were associated with normal karyotype in older (>60) patients.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/19059939	AVv-Lx67SS-TIFzzUJlIcivic	NPM1		NPM1 mutations were associated with intermediate risk cytogenetics (including normal karyotype).	Positive	http://www.ncbi.nlm.nih.gov/pubmed/21067377	AVv-LyNqSS-TIFzzUJljcivic	NPM1		"NPM1 mutations were associated with increased complete remission rates as well as longer overall disease free survival in normal karyotype AML patients >59 years old, particularly in those >69 years old."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/20026798	AVv-LyBhSS-TIFzzUJlRcivic	NPM1		NPM1 mutations were associated with de novo AML as well as M4 and M5 FAB subtypes.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/17957027	AVv-LyEsSS-TIFzzUJlWcivic	NPM1		NPM1 mutations were associated with M5a and M5b FAB subtypes of acute myeloid leukemia.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/16455956	AVv-Lx7sSS-TIFzzUJlJcivic	NPM1		"NPM1 mutations were associated with M4, M5a and M5b FAB subtypes of acute myeloid leukemia."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/16076867	AVv-LyKsSS-TIFzzUJlfcivic	NPM1		NPM1 mutation without FLT3-ITD was associated with reduced relapse risk and increased overall survival in young adult acute myeloid leukemia patients (median age 43).	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/17957027	AVv-LyJVSS-TIFzzUJldcivic	NPM1		"NPM1 mutation was associated with increased overall, event-free and relapse-free survival and remission after induction therapy in the entire cohort and in the cytogenetically normal subset of patients."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22430270	AVv-Lx-lSS-TIFzzUJlNcivic	NPM1		Monitoring NPM1 mutation by cDNA-based RT-PCR effectively predicted relapse in 62/93 patients by >1 log increase in NPM1 levels (N=57) or lack of reduction in NPM1 levels following first line therapy (N=15).	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/19587375	AVv-Lx9ISS-TIFzzUJlLcivic	NPM1		Intermediate risk patients with mutant NPM1 had improved overall survival with the presence of either IDH1 or IDH2 mutations than those wildtype for both IDH1 and IDH2.	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22417203	AVv-LyCKSS-TIFzzUJlScivic	NPM1		"In normal karyotype patients with AML (15-65 years old), complete remission rates and overall, event-free and relapse-free survival were not different for patients harboring NPM1 exon 12 mutations (N=50) than those wildtype for NPM1 (N=56)."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/16046528	AVv-Lx8eSS-TIFzzUJlKcivic	NPM1		"In a study of 1,540 patients with Acute Myeloid Leukemia, 418(27%) had mutations in NPM1, mostly W288fs, and there was a preferential co-mutation with NRAS(G12/13), however there was no co-mutation association between NPM1 and NRAS(Q61)."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/27276561	AVv-LyLdSS-TIFzzUJlgcivic	NPM1		Cytoplasmic localization of NPM in AML patients was an independent prognositic factor associated with complete remission in response to induction therapy in a multivariate analysis (p=0.019) but not in a univariate analysis (p=0.07).	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/15659725	AVv-Lx92SS-TIFzzUJlMcivic	NOTCH1	NOTCH1 Antibody	"NOTCH1 copy-number gain in a patient-derived tumor xenograft model of colorectal cancer, was associated with increased NOTCH1 and JAG1 activity and response to a NOTCH1-targeting antibody (PF-06293622)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26152787	AVv-L-hASS-TIFzzUJr9civic	NOTCH1		"NOTCH1 gain-of-function mutations, including V2444fs, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/20007775	AVv-L-fDSS-TIFzzUJr6civic	NOTCH1		"NOTCH1 gain-of-function mutations, including S2275fs, have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/20007775	AVv-L-iwSS-TIFzzUJsAcivic	NOTCH1		"NOTCH1 gain-of-function mutations, including R2327W (called R2328W in publication), have shown to be correlated to poor prognosis in lung cancer. This is in a TP53 wild-type context."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/20007775	AVv-L-mUSS-TIFzzUJsGcivic	NOTCH1		"NOTCH1 gain-of-function mutations, including D1642H (called D1643H in publication), have shown to be correlated with poor prognosis in lung cancer. This is in a TP53 wild-type context."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/20007775	AVv-L-ltSS-TIFzzUJsFcivic	NOTCH1		NOTCH1 amplifications (as determined by FISH) were significantly (log-rank p_=_0.025) associated with worse survival in a cohort of 116 patients with colorectal cancer.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/26152787	AVv-L-hmSS-TIFzzUJr-civic	NOTCH1		"In a multivariate analysis of 774 CLL patients, NOTCH1 mutations were not significantly correlated with shorter time to first treatment (HR=1.305; 95% CI=0.923-1.847)."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/24943832	AVv-L-kgSS-TIFzzUJsDcivic	NOTCH1		"14 out of 121 patient samples contained mutations in NOTCH1. Those with mutations had worse overall survival than wild-type (median OS, 1.43 years vs. 3.86 years)."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22210878	AVv-L-jWSS-TIFzzUJsBcivic	NF2	Temsirolimus	23 patients were treated with temsirolimus containing regimens. 1 patient with a complete response >3 years had a K159fs*16 mutation in NF2. 2 patients were tested for NF2 mutations.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25878190	AVv-MfaMSS-TIFzzUJ1fcivic	NF2	"Carboplatin,Cisplatin-4-methylpyridine"	A frameshift mutation in NF2 at position Y177 was found in a patient who did not respond to the standard platinum doublet chemotherapy regimen.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/25798586	AVv-Mfa0SS-TIFzzUJ1gcivic	NF1	Selumetinib (AZD6244)	"Treatment with selumetinib resulted in confirmed partial, long term responses in 17 of the 24 children with NF1 associated plexiform fibromas (71%) and decreases from baseline in neurofibroma volume in 12 of 18 mice (67%)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/28029918	AVv-Me6ISS-TIFzzUJ1Vcivic	NF1	JQ1 Compound	"BRD4 inhibition supressess growth and tumorigenesis of NF1-/-, TP53-/- MPNST cells in mouse xenografts"	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24373973	AVv-Me_ISS-TIFzzUJ1ccivic	NF1	Binimetinib (MEK162)	Low NF1 protein expression correlated positively with responses to binimetinib in neuroblastoma cell lines.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26925841	AVv-Me-gSS-TIFzzUJ1bcivic	NCOA3		"In patients with breast cancer, those with amplification of NCOA3 had shorter disease-specific survival."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/23322234	AVv-MHEtSS-TIFzzUJu1civic	NCOA3		"High expression determined by immunohistochemistry of NCOA3 was found in 571 out of 1,836 breast cancer samples. Those with high expression had worse overall and disease-specific survival."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/23322234	AVv-MHFiSS-TIFzzUJu2civic	NAPRT	GNE-617	Tumor-specific promoter hypermethylation of NAPRT1 led to loss of NAPRT1 expression in most tumor types sensitive to treatment with Nampt inhibitor GNE-617 and nicotinic acid.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24097869	AVv-MxF5SS-TIFzzUJ6qcivic	MYD88	Paclitaxel	"In this retrospective analysis of 211 breast cancer tissues, MYD88 overexpression was correlated  with poor survival. In-vitro experiments showed a decrease in sensitivity towards paclitaxel in cell-lines with high MYD88 expression."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/26596839	AVv-MenVSS-TIFzzUJ1Tcivic	MYD88		"MYD88 mutations were identified in 24 of 1080 screened  CLLs. They were exclusively seen in instances of mutated IGHV genes (18/23, P = 0.0001), a widely recognized prognostic signature for better outcome in CLL."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/24943832	AVv-Mel4SS-TIFzzUJ1Rcivic	MTOR	Rapamycin (Sirolimus)	"Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line SNU349, with MTOR mutation E1799K was hypersensitive to rapamycin treatment (IC50 of 0.19 nmol/L)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24631838	AVv-MTugSS-TIFzzUJyXcivic	MTOR	Rapamycin (Sirolimus)	"Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line MOLT16, with MTOR mutation C1483Y was hypersensitive to rapamycin treatment (IC50 of 0.75 nmol/L)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24631838	AVv-MTtxSS-TIFzzUJyWcivic	MTOR	Rapamycin (Sirolimus)	Cell lines with various putative activating mutations were tested for sensitivity to rapamycin. The cell line JHUEM7 with the MTOR mutation S2215Y was hypersensitive to rapamycin treatment (IC50 of 0.23 nmol/L).	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24631838	AVv-MTtKSS-TIFzzUJyVcivic	MTOR	"Pazopanib,Everolimus"	A case-study of a patient with urothelial carcinoma reported exceptional response (14 months) in a phase 1 study of Everolimus and Pazopanib. Mutations E2014K and E2419K were shown to be activating in-vitro.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24625776	AVv-MTrHSS-TIFzzUJyScivic	MTOR	"LY294002,AZD5363"	"In a cell line (HEK293T) with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26490311	AVv-MTsgSS-TIFzzUJyUcivic	MTOR	"AZD5363,LY294002"	"In a cell line (HEK293T) with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26490311	AVv-MTpTSS-TIFzzUJyPcivic	MTOR	AZD5363	"In a cell line with expression of H1968Y or P2213S mTOR mutations, LY294002 and AZD5363 were more effective than temsirolimus or BYL719 in suppressing cell growth."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26490311	AVv-MTowSS-TIFzzUJyOcivic	MTOR		Median overall survival of patients with nonsynonymous mutations in mTOR was shorter.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/26490311	AVv-MTr0SS-TIFzzUJyTcivic	MRE11	Olaparib	"One patient in a cohort of 50 patients with metastatic prostate cancer had a frameshift mutation in the MRE11, ATM, MLH3 and NBN genes and showed clinical response to PARP inhibitor olaparib (16 weeks on Treatment)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26510020	AVv-MdNOSS-TIFzzUJ02civic	MRE11	BMN-673	One endometrial cell line with decreased MRE11 expression caused by a homozygous poly(T) mutation exhibited increased sensitivity to the PARP inhibitor BMN-673. Loss of MRE11 was identified in 30.7% of endometrial tumors (N=521).	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24927325	AVv-MdL7SS-TIFzzUJ00civic	MRE11		One patient in a cohort of 50 patients with metastatic prostate cancer had a frameshift mutation in the MRE11 gene and showed clinical response to PARP inhibitor olaparib.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26510020	AVv-MdMlSS-TIFzzUJ01civic	MGMT	Temozolomide	"In a randomized clinical trial, patients with MGMT promoter methyaltion benefitted from temozolomide. This benefit was also methylation status dependent, as those without methylation did not see increased survival."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/15758010	AVv-LxnYSS-TIFzzUJkzcivic	MGMT	O(6)-benzylguanine	"In patients lacking MGMT promoter methylation, the use of an MGMT inhibitor, such as O(6)-benzylguanine, in combination with alkylating agents (Carmustine) may be useful in treating patients with initial resistance to alkylating agents."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/11070098	AVv-LxmPSS-TIFzzUJkxcivic	MGMT	Carmustine	"MGMT promoter methylation has been shown to confer sensitivity to alkylating agents, such as carmustine, in glioblastoma cells."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/11070098	AVv-Lxm0SS-TIFzzUJkycivic	MGMT		MGMT promoter methylation was associated with increased overall and disease-free survival as well as tumor regression in patients with gliomas.	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/11070098	AVv-Lxn_SS-TIFzzUJk0civic	MGMT		"In patients with glioblastoma, those with methylated MGMT promoters have better overall survival than those with unmethylated promoters."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/15758010	AVv-LxlCSS-TIFzzUJkvcivic	MGMT		"In a study of 152 anaplastic oligodendroglial tumors, 121 samples had MGMT promoter methylation. Those with promoter methylation had better progression-free and overall survival."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/19901104	AVv-LxlqSS-TIFzzUJkwcivic	MET	Gefitinib	"In this study a gefitinib-sensitive cell-line (HCC827), acquired gefitinib resistance (HCC827 GR) by a focal amplification of MET.  Resistance was conferred by the MET amplification driving ERBB3 (HER3)-dependent activation of PI3K."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/17463250	AVv-MAR_SS-TIFzzUJslcivic	MET	Crizotinib	"We now report responses to the MET inhibitors crizotinib
and cabozantinib in four patients with stage IV lung adenocarcinomas harboring mutations leading
to MET exon 14 skipping."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25971939	AVv-MAHPSS-TIFzzUJsVcivic	MET	Crizotinib	Case report of a patient with lung adenocarcinoma harboring a MET exon 14 skipping mutation and major response to crizotinib.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26845194	AVv-MAEXSS-TIFzzUJsRcivic	MET	Crizotinib	Case report of a patient with NSCLC harboring a MET exon 14 skipping mutation and initial response to crizotinib. A second biopsy at the time of progression revealed an acquired MET D1228N mutation.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/27343442	AVv-MACJSS-TIFzzUJsOcivic	MET	Crizotinib	"Case report of a patient with MET amplification without high-level MET/CEP7 ratio, MET exon 14 mutation or overexpression who achieved rapid response to crizotinib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26724472	AVv-MAT8SS-TIFzzUJsocivic	MET	Crizotinib	"Case report of a 73 year old patient with advanced squamous cell carcinoma of the lung that tested negative for EGFR, KRAS and PIK3CA mutations and ALK and ROS1 rearrangements. c-MET amplification was detected by FISH. Crizotinib led to a partial response."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24192513	AVv-MAUoSS-TIFzzUJspcivic	MET	Crizotinib	A case-study of an ALK-negative patient with MET amplification (MET/CEP7 ratio >5.0) who achieved a durable partial response to MET/ALK-inhibitor crizotinib.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21623265	AVv-MATTSS-TIFzzUJsncivic	MET	Capmatinib	"A patient with MET c.3028+1G>T mutation (METex14) had partial response (tumor reduction of 61%) after 13 months capmatinib. MET gene copy number was four, MET FISH 13.8 copy number, and IHC 3+."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25971938	AVv-MAFDSS-TIFzzUJsScivic	MDM2		66 HNSCC patients treated with chemoradiation were assessed for survival after a follow-up time of 10 years. Median OS was significantly shorter in patients with MDM2 SNP309 GG or GT genotypes compared with the TT genotype (p = 0.002).	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/26916894	AVv-MZdNSS-TIFzzUJ0Gcivic	KRAS	"Trametinib,Gemcitabine"	"Adding trametinib to gemcitabine does not improve overall survival (OS), progression-free survival (PFS), overall response rate (ORR) or duration of response (DOR) in patients with untreated metastatic adenocarcinoma of the pancreas."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/24915778	AVv-LwM6SS-TIFzzUJjzcivic	KRAS	Regorafenib	KRAS mutation status was not predictive of response to regorafenib treatment in patients that had received standard therapy and progressed within 3 months of their last treatment.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24559322	AVv-LvWDSS-TIFzzUJiicivic	KRAS	RO4987655	Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). All 25 patients with KRAS mutant colorectal cancer experienced PD.	N/A	http://www.ncbi.nlm.nih.gov/pubmed/24947927	AVv-Lv9lSS-TIFzzUJjbcivic	KRAS	RO4987655	Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655). 2 PR and 8 SD among 18 patients with KRAS Mutant NSCLC.	N/A	http://www.ncbi.nlm.nih.gov/pubmed/24947927	AVv-Lv88SS-TIFzzUJjacivic	KRAS	Panitumumab	KRAS mutations have been reported in 30-50% of colorectal carcinomas.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/8462792	AVv-LwXRSS-TIFzzUJkCcivic	KRAS	Panitumumab	KRAS mutations have been reported in 30-50% of colorectal carcinomas.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/2547513	AVv-LwQ9SS-TIFzzUJj5civic	KRAS	Panitumumab	KRAS mutations have been reported in 30-50% of colorectal carcinomas.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/16953233	AVv-LvjSSS-TIFzzUJi2civic	KRAS	PD0325901	"Preclinical data supporting resistance of Exon 4 mutations, in particular A146T, to cetuximab and sensitivity to PD0325901."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/20570890	AVv-LwO7SS-TIFzzUJj2civic	KRAS	Melphalan	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/16497971	AVv-LvZ4SS-TIFzzUJiocivic	KRAS	Melphalan	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/12483530	AVv-LvYiSS-TIFzzUJimcivic	KRAS	Melphalan	"In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in comparison to cells with wildtype RAS."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/11050000	AVv-Lwq3SS-TIFzzUJkecivic	KRAS	Melphalan	"In a study of patients receiving melphalan-based therapy, those with KRAS codon 12 mutations were less likely to have a positive response than those with wildtype KRAS (26.9% vs. 58.3%, P=0.015)."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/19284554	AVv-LvakSS-TIFzzUJipcivic	KRAS	Ixazomib	"Preclinical study in colorectal cancer xenografts. KRAS-G13D or KRAS-G12V mutations were introduced into KRAS-WT SW48 cell line. KRAS wild-type, but not KRAS mutant tumors were sensitive to proteasome inhibitor ixazomib"	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/26709701	AVv-Lvy7SS-TIFzzUJjMcivic	KRAS	"IMO,EGFR Inhibitor"	TLR9 agonist immunomodulatory oligonucleotide (IMO) led to inhibited survival of LS174T colorectal cancer and AsPC1 pancreatic cancer cell lines with KRAS mutations.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21890455	AVv-Lv5SSS-TIFzzUJjVcivic	KRAS	Gefitinib	"KRAS mutations have also been observed in biliary tract, bladder, breast, cervix, colon, endometrial, kidney, liver, melanoma, myeloid leukemia, ovarian, pancreatic, and thyroid cancer."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/17384584	AVv-LvqVSS-TIFzzUJjAcivic	KRAS	Farnesylthiosalicylic Acid	"In a study of 30 lung adenocarcinoma patients with documented KRAS mutations, farnesylthiosalicylic acid (Salirasib) mono-therapy resulted in no partial responses and did not improve overall survival rates compared to previously untreated patients."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21847063	AVv-Lv3XSS-TIFzzUJjScivic	KRAS	"Erlotinib,Gefitinib"	KRAS G12 mutations were the primary predictor of EGFR TKI resistance in patients with lung adenocarcinoma.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/19794967	AVv-LweNSS-TIFzzUJkMcivic	KRAS	"Erlotinib,Gefitinib"	"In NSCLC, Exon 2 KRAS mutations were associated with resistance to the EGFR kinase inhibitors gefitinib and erlotinib."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/15696205	AVv-LvWoSS-TIFzzUJijcivic	KRAS	Erlotinib	KRAS exon 2 was mutated in 121 of 173 (70%) patients with advanced pancreatic cancer and did not show an association with response to erlotinib treatment.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/23435671	AVv-LvUfSS-TIFzzUJiVcivic	KRAS	Cisplatin	"In the retrospective analysis of 103 HNSSC, the TG/GG rs61764370 variant was associated with poor response to cisplatin (log-rank P = 0.002).There seemed to be some improvement when cetuximab was added to their platinum-based regimen (log-rank P = 0.04)."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/25081901	AVv-LwVQSS-TIFzzUJj_civic	KRAS	Cetuximab	"Preclinical data supporting resistance of Exon 4 mutations, in particular A146T, to cetuximab and sensitivity to PD0325901."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/20570890	AVv-LwOQSS-TIFzzUJj1civic	KRAS	Cetuximab	Patients with colorectal cancer who harbor KRAS mutation have low response rate to cetuximab.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/16618717	AVv-LvVJSS-TIFzzUJihcivic	KRAS	Cetuximab	KRAS mutations were significantly associated with lack of response to cetuximab in patients with advanced colorectal cancer.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/18202412	AVv-LwLCSS-TIFzzUJjwcivic	KRAS	Cetuximab	KRAS G13D mutation is associated with better response to Cetuximab with longer progression-free and overall survival in colorectal patients compared to other KRAS.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/20978259	AVv-LwiLSS-TIFzzUJkScivic	KRAS	Cetuximab	Cells harboring KRAS G13D mutation were sensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/20978259	AVv-LwhiSS-TIFzzUJkRcivic	KRAS	Cetuximab	Cells harboring KRAS G12V mutation were insensitive to cetuximab treatment in isogenic SW48 cells and in a mouse xenograft model.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/20978259	AVv-LwJCSS-TIFzzUJjtcivic	KRAS	BAY 86-9766	"Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766. 4 patients with KRAS +/- PIK3CA mutant colorectal cancer. 3 with SD, 1 with PD."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23434733	AVv-LwANSS-TIFzzUJjfcivic	KRAS	"ARRY-142886,BEZ235 (NVP-BEZ235, Dactolisib)"	"The use of NVP-BEZ235 in conjunction with ARRY-142886, but not as monotherapy, in a lung cancer model with KRAS G12D mutation led to marked tumor regression."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/19029981	AVv-LvfeSS-TIFzzUJixcivic	KRAS		There is no strong association between KRAS mutation status and overall or progression free survival in patients with NSCLC.	N/A	http://www.ncbi.nlm.nih.gov/pubmed/11208838	AVv-LvPPSS-TIFzzUJiNcivic	KRAS		The presence of KRAS mutations in MM patients is prognostic for shorter overall and progression free survival.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/18528420	AVv-LvOsSS-TIFzzUJiMcivic	KRAS		KRAS mutations were significantly associated with reduced progression-free and overall survival in patients with advanced colorectal cancer.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/18202412	AVv-LwLqSS-TIFzzUJjxcivic	KRAS		"KRAS mutations in lung cancer patients are not associated with smoking history, age or gender."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/18794081	AVv-LvP5SS-TIFzzUJiOcivic	KRAS		"KRAS exon 2 was mutated in 121 of 173 patients with advanced pancreatic cancer. Patients with KRAS wildtype had an improved OS (HR 1.68, p = 0.005)."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/23435671	AVv-LvTzSS-TIFzzUJiUcivic	KRAS		KRAS G12D mutation occurs in never smokers significantly more often than in smokers.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/23014527	AVv-LvwBSS-TIFzzUJjIcivic	KRAS		KRAS G12C occur more frequently in women than men.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/23014527	AVv-LwtdSS-TIFzzUJkicivic	KRAS		"In patients with stage III colorectal cancer undergoing chemotherapy, KRAS G12 mutation did not impact overall or disease free survival."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/19934290	AVv-LvNiSS-TIFzzUJiKcivic	KRAS		"In a study of 48 NSCLC patients, those with G12C or G12V mutant KRAS were associated with decreased progression free survival (1.84 months) compared with other KRAS mutants or with wild-type KRAS (3.35 and 1.95 months)."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22247021	AVv-Lws1SS-TIFzzUJkhcivic	KRAS		"In a study of 1036 patients with lung adenocarcinoma, patients with KRAS mutations (n=241) showed worse prognosis (OS: 19 months versus 23 months; HR=1.21; P=0.048)."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22810899	AVv-LwD8SS-TIFzzUJjlcivic	KRAS		"In a retrospective study of 439 patients with multiple myeloma enrolled in a clinical trial, 28 had mutaions in KRAS. Those with mutations had worse overall and progression free survival than those without mutations."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/18528420	AVv-LwUkSS-TIFzzUJj-civic	KRAS		"In 242 patients with unresectable pancreatic cancer, the presence of KRAS G12R (as well as G12D) was associated with poorer prognosis (95% confidence interval of HR between 1.11 and 2.28)."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22983505	AVv-LwT8SS-TIFzzUJj9civic	KRAS		"In 242 patients with unresectable pancreatic cancer, the presence of KRAS G12R (N=17) or G12D (N=92) was associated with poorer prognosis (overall survival HR 1.6; 95% confidence interval 1.11-2.28)."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22983505	AVv-LwTQSS-TIFzzUJj8civic	KRAS		Children with early age leukaemia who had second hand smoke exposure are more likely to harbor KRAS mutation.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/24571676	AVv-LvQeSS-TIFzzUJiPcivic	KRAS		A meta-analysis showed KRAS mutation is associated with worse outcome in patients with NSCLC.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/15597105	AVv-LvOHSS-TIFzzUJiLcivic	KIT	Sunitinib	"In GIST tumor cells and patients harboring KIT V654A mutation, SU11248 is effective for those that are refractory to imatinib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/16638875	AVv-Ls8uSS-TIFzzUJhdcivic	KIT	Sunitinib	"10 melanoma patients were evaluated after sunitinib treatment, among which 3 out of the 4 patients with KIT exon 11 mutations showed either complete or partial response."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22261812	AVv-LtLbSS-TIFzzUJhzcivic	KIT	"Sorafenib,Nilotinib,Imatinib"	"The melanoma cell line WM3211, which harbors the L576P mutation, is not sensitive to imatinib, nilotinib, and sorafenib. Molecular modeling indicated the L576P mutation alters the conformation of KIT and reduces the binding affinity of imatinib."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/19671763	AVv-LtE1SS-TIFzzUJhpcivic	KIT	"Pictilisib,Imatinib"	"Human GISTs with different KIT mutations were grafted in 136 nude muce. Mice were then treated with control, imatinib, GDC-0941, or GDC-0941 + imatinib. The combination showed superior antitumor efficacy that was sustained after treatment withdrawal."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23231951	AVv-LtUeSS-TIFzzUJiAcivic	KIT	"Nilotinib,Imatinib,Dasatinib"	"Ba/F3 cells harboring the KIT L576P mutation are sensitive to dasantinib, nilotinib and imatinib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/17372901	AVv-LtGUSS-TIFzzUJhrcivic	KIT	Midostaurin	"In a phase II clinical trial, 60% of patients (N=89) with advanced systemic mastocytosis responded to treatment with midostaurin."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/27355533	AVv-LtAxSS-TIFzzUJhjcivic	KIT	Imatinib	No difference in prognosis was observed between patients with exon 11 point mutations versus exon 11 deletions.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/14645423	AVv-Ls9_SS-TIFzzUJhfcivic	KIT	Imatinib	Molecular models predict that deletion of a portion of the juxtamembrane domain relieves steric hindrance and results in higher binding affinity for imatinib.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21364689	AVv-Ls-rSS-TIFzzUJhgcivic	KIT	Imatinib	Melanoma patients with KIT mutation but not KIT amplification showed response to imatinib treatment in a small cohort of patients.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23775962	AVv-LtKiSS-TIFzzUJhycivic	KIT	Imatinib	KIT V654A results in imatinib resistance in GIST patient-derived cell lines.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/16954519	AVv-Ls8FSS-TIFzzUJhccivic	KIT	Imatinib	"In a patient with thymic carcinoma, the tumor expressing an activating mutation in exon 11 of KIT (V560del) was sensitive to imatinib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/15201427	AVv-Ls_WSS-TIFzzUJhhcivic	KIT	Imatinib	"In a case study, a patient with anal melanoma harboring a 7 codon duplication in the juxtamambrane region (exon 11) of KIT showed marked response 4 months after imatinib treatment."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/18421059	AVv-LtACSS-TIFzzUJhicivic	KIT	Imatinib	"In a Phase II trial for the treatment of GIST patients with imatinib, patients with Exon 11 Kit mutations (N=85) had significantly better event-free and overall survival than patients with Exon 9 Kit mutations (N=23) or no Kit mutations (N=9)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/14645423	AVv-LtMPSS-TIFzzUJh0civic	KIT	Imatinib	Case Report of a 42-year old patient with low-grade endometrial stromal sarcoma. IHC was focally positive for CD117. Imatinib mesylate led to complete metabolic response (PET-CT).	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/18607592	AVv-LtJHSS-TIFzzUJhvcivic	KIT	Dasatinib	"The melanoma cell line WM3211, which harbors the L576P mutation, is sensitive to dasatinib. Molecular modeling indicated the L576P mutation alters the conformation of KIT but did not alter the binding affinity of dasatinib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/19671763	AVv-LtFkSS-TIFzzUJhqcivic	KIT		There is no significant association between wildtype KIT or KIT mutations in exon 9 or 11 in survival among GIST patients.	N/A	http://www.ncbi.nlm.nih.gov/pubmed/16551858	AVv-LtPjSS-TIFzzUJh5civic	KIT		The rs17084733 variant in the 3' UTR of KIT was correlated with susceptibility to melanoma when comparing 70 melanoma patients to 94 healthy individuals from the same community. This variant was most strongly correlated with acral lentigious melanoma.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/21119596	AVv-Ls7ZSS-TIFzzUJhbcivic	KIT		Patients with Exon 11 Kit mutations (N=85) had significantly better event-free and overall survival than patients with Exon 9 Kit mutations (N=23) or no Kit mutations (N=9).	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/14645423	AVv-LtM3SS-TIFzzUJh1civic	KIT		"M541L mutation was not associated with CML in caucasian patients, and was common among healthy controls (8.1%), in contrast to a previous study in a Japanese CML patient population in which M541L was strongly associated with CML disease."	Negative	http://www.ncbi.nlm.nih.gov/pubmed/16307017	AVv-LtXSSS-TIFzzUJiEcivic	KIT		"KIT mutations were identified in morphologically benign, incidentally discovered GISTs at a rate similar to that seen in advanced, metastatic GIST patients indicating is not a prognostic marker for GIST."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/12000708	AVv-LtOOSS-TIFzzUJh3civic	KIT		KIT mutations detected in 5/60 patients showed no prognostic significance in patients with small cell lung cancer.	N/A	http://www.ncbi.nlm.nih.gov/pubmed/15217946	AVv-LtQMSS-TIFzzUJh6civic	KIT		KIT mutation is associated with worse overall and cause-specific prognosis in patients with GIST compared to patients with wildtype KIT.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/10485475	AVv-LtNiSS-TIFzzUJh2civic	KIT		"KIT mutation is associated with larger, more invasive tumors, greater pathologic histology and older patients compared to tumors with wildtype KIT."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/10485475	AVv-LtO6SS-TIFzzUJh4civic	KIT		"In acute myloid leukemia patients, D816 mutation is associated with earlier relapse and poorer prognosis than wildtype KIT."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/16384925	AVv-LtCMSS-TIFzzUJhlcivic	KIT		GIST patients with exon 14 KIT mutations had reduced overall survival compared to patients wiltype for KIT.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/16551858	AVv-LtV_SS-TIFzzUJiCcivic	KIAA1524	Gemcitabine	"Researchers studied the effect of CIP2A expression in relation to  gemcitabine sensitivity via SW1990 cell lines. SW1990 cells with CIP2A expression knocked-down displayed lower IC50 (p=.024), indicating a sensitivity to gemcitabine."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26894380	AVv-MwTCSS-TIFzzUJ6fcivic	JAK2	TG101348	TG101348 effectively inhibits STAT5 signaling in JAK2 V617F cells.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/18394554	AVv-LrZvSS-TIFzzUJhJcivic	JAK2	Pegylated IFN-alpha–2a	"In patients with JAK2 V617F, the use of pegylated IFN-alpha-2a leads to reduction in the percentage of cells harboring JAK2 V617F."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/16709929	AVv-LraZSS-TIFzzUJhKcivic	JAK2		The SNP rs10974944 in the Jak2 locus is associated with increased predisposition for JAK2 V617F mutation and its associated cancer.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/19287384	AVv-LrbDSS-TIFzzUJhLcivic	JAK2		"JAK2 V617F is not associated with lymphoid leukemia (B-lineage ALL, T-ALL or CLL)."	Negative	http://www.ncbi.nlm.nih.gov/pubmed/16081687	AVv-LrdGSS-TIFzzUJhOcivic	JAK2		"JAK2 V617F is associated with myeloid neoplasms (AML, MDS, CMML/aCML)."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/16081687	AVv-LrbwSS-TIFzzUJhMcivic	JAK2		"JAK2 V617F is associated with myeloid malignanices (AML, MDS, CMML/atypical CML)."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/16081687	AVv-LrcZSS-TIFzzUJhNcivic	IKZF1		"In patients with Philadelphia Chromosome negative B-cell precursor acute lymphoblastic leukemia, focal deletion involving 3-5 exons of IKZF1 was associated with higher cumulative incidence of relapse (CIR) than wildtype IKZF1."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/24740809	AVv-MG3aSS-TIFzzUJuycivic	IKZF1		"In children with bone marrow relapsed B-cell precursor acute lymphoblastic leukemia, those with deletions of IKZF1 had worse event-free and overall survival than patients without deletions."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22699455	AVv-MG4pSS-TIFzzUJu0civic	IKZF1		IKZF1 deletions in patients with BCR-ABL–positive adult acute lymphoblastic leukemia were associated with reduced disease-free survival compared to wild type patients.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/19770381	AVv-MG2zSS-TIFzzUJuxcivic	IGF2	OSI-906 (Linsitinib)	"OSI-906, an IGF1R/INSR inhibitor, does not have a significant effect on chemotherapy resistant castration-resistant prostate cancer cell lines."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/25670080	AVv-MDelSS-TIFzzUJtrcivic	IGF2	"Cabazitaxel,Docetaxel,OSI-906 (Linsitinib)"	"OSI-906, an IGF1R/INSR inhibitor, sensitizes cell lines to docetaxel and cabazitaxel, resulting in better overall survival in chemotherapy resistant CRPC cell lines."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25670080	AVv-MDfYSS-TIFzzUJtscivic	IDH2		R140Q mutation in IDH2 does not have prognostic value in patients with MDS.	N/A	http://www.ncbi.nlm.nih.gov/pubmed/22033490	AVv-Lq-7SS-TIFzzUJg6civic	IDH2		"In this meta-analysis of adult non-promyelocytic AML (11 studies), patients with IDH2 R140 or R172 mutations had event free survival and overall survival similar to those with wild-type IDH2."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/22616558	AVv-LrAKSS-TIFzzUJg8civic	IDH2		"In patients with myelodysplastic syndrome, the presence of IDH2 R140Q (N=3) or IDH1 R132 (N=2) mutations did not confer prognostic value (overall survival) compared to wild-type IDH1/2 patients (N=61; P=0.794)."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/21997850	AVv-Lq_kSS-TIFzzUJg7civic	IDH2		"In patients with angioimmunoblastic T-cell lymphoma (a subtype of peripheral T-cell lymphoma), IDH2 R172 mutations (N=16) had no impact on overall survival when compared to patients with wildtype IDH2 (N=24)."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/26268241	AVv-LrGXSS-TIFzzUJhFcivic	IDH2		"In patients with anaplastic astrocytoma, those with mutations at R172 of IDH2 had better overall survival than wild-type patients."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/19228619	AVv-LrHpSS-TIFzzUJhHcivic	IDH2		"In patients with a glioblastoma, those with mutations at R172 of IDH2 had better overall survival than wild-type patients."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/19228619	AVv-LrFqSS-TIFzzUJhEcivic	IDH2		"In patients with IDH2 R140 and R172 mutation, the presence of mutation does not impact overall survival or disease free survival."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/20421455	AVv-LrCFSS-TIFzzUJg_civic	IDH2		"In patients suffering from MDS, the presence of IDH2 mutations such as R172K do not confer prognostic value (overall survival)."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/21997850	AVv-LrDgSS-TIFzzUJhBcivic	IDH2		"In AML, patients with an IDH2 R172K mutation have worse overall survival compared to those with wild-type IDH2."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21596855	AVv-LrCtSS-TIFzzUJhAcivic	IDH2		"In AML, patients with IDH2 R140 mutation have improved overall survival compared to those with wild-type IDH2."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21596855	AVv-Lq-TSS-TIFzzUJg5civic	IDH2		IDH2 R172 mutations were frequently observed in patients with the angioimmunoblastic T-cell lymphoma subtype of peripheral T-cell lymphomas but not observed in other subtypes.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/22215888	AVv-LrHCSS-TIFzzUJhGcivic	IDH2		AML patients with IDH2 mutations such as R172K have event free survival and overall survival similar to those with wild-type IDH2.	N/A	http://www.ncbi.nlm.nih.gov/pubmed/22616558	AVv-LrENSS-TIFzzUJhCcivic	IDH1	Temozolomide	"In a study of 189 low-grade gliomas, IDH (IDH1 or IDH2) mutations were found in 132 patients (70%). IDH mutations were associated with improved rate of response to temozolomide compared to wildtype IDH (61%  vs. 17% , P=0.01). Biological"	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/20975057	AVv-LqlVSS-TIFzzUJg0civic	IDH1	Temozolomide	"In a study of 189 low-grade gliomas, IDH (IDH1 or IDH2) mutations were found in 132 patients (70%). IDH mutations were associated with improved rate of response to temozolomide compared to wildtype IDH (61%  vs. 17% , P=0.01)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/20975057	AVv-LqepSS-TIFzzUJgpcivic	IDH1	Temozolomide	IDH1 mutations at R132H are the most frequent mutations accounting for 70- 90% of all IDH1 mutations in secondary glioblastoma  and 5% of primary glioblastomas.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/18772396	AVv-LqgXSS-TIFzzUJgscivic	IDH1	GSK321	Newly developed allosteric inhibitors (GSK321) of IDH1 led to granulocytic differentiation in-vitro and in-vivo.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26436839	AVv-LqbMSS-TIFzzUJgZcivic	IDH1	AGI-5198	"In an experimental in vitro study, glioma cells expressing IDH1 R132C were associated with sensitivity to AGI-5198 (IC50: 0.16M vs. IC50 > 100.00 M), as compared to cells expressing wild-type IDH1. Sensitivity was determined by assessing cell growth."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23558169	AVv-LqWUSS-TIFzzUJgScivic	IDH1	AG-120	"In a clinical study of 17 relapsed or refractory AML patients harboring IDH1 mutations, patients were associated with response to AG-120 monotherapy; 4/7 patients who achieved a response experienced complete remission."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25583779	AVv-LqXhSS-TIFzzUJgUcivic	IDH1		The complete remission and overall survival rates in patients with IDH1 R132 mutation is not significantly different from those who do not have this mutation.	N/A	http://www.ncbi.nlm.nih.gov/pubmed/20368538	AVv-LqRBSS-TIFzzUJgKcivic	IDH1		Mutation status of IDH1 did not change event-free survival of patients with an NPM1 mutation.	N/A	http://www.ncbi.nlm.nih.gov/pubmed/20805365	AVv-LqVrSS-TIFzzUJgRcivic	IDH1		"In patients with glioblastoma, those harboring IDH1 R132 mutation has higher overall survival compared to those who do not have IDH1 mutation."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/20127344	AVv-LqTzSS-TIFzzUJgOcivic	IDH1		"In patients with astrocytoma, the presence of IDH1 R132 mutation is prognostic for better survival compared to patients who harbor wild type mutation."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/19933982	AVv-LqUYSS-TIFzzUJgPcivic	IDH1		"In patients with anaplastic astrocytoma, those with mutations at R132 of IDH1 had better overall survival than wild-type patients."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/19228619	AVv-LqR2SS-TIFzzUJgLcivic	IDH1		"In patients with a glioblastoma, those with mutations at R132 of IDH1 had better overall survival than wild-type patients."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/19228619	AVv-LqSjSS-TIFzzUJgMcivic	IDH1		"In leukemia patients, IDH1 R132 mutation is associated with adults and normal karyotype."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/20376086	AVv-LqVBSS-TIFzzUJgQcivic	IDH1		"IDH1 R132 mutation is associated with patients of older age, high platelet count during diagnosis, cytogenic normalcy and NPM1 mutation."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/20538800	AVv-LqcbSS-TIFzzUJgmcivic	IDH1		IDH1 R132 mutation in patients with AML is not associated with any prognostic value compared to patients with wild-type IDH1.	N/A	http://www.ncbi.nlm.nih.gov/pubmed/20538800	AVv-LqbzSS-TIFzzUJgacivic	IDH1		IDH1 R132 mutation in patients suffering from myelodysplastic syndromes is associated with worse overall survival.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/20494930	AVv-LqTNSS-TIFzzUJgNcivic	HSPB1	Gemcitabine	HSP27 (HSPB1) expression in pancreatic adenocarcinoma cell lines was associated with sensitivity to treatment with gemcitabine.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22004109	AVv-MXl9SS-TIFzzUJzpcivic	HSPA5	5-fluorouracil	"Expression of GRP78 (HSPA5) in colorectal cancer patients (n=396, by IHC) showed improved benefit from adjuvant chemotherapy in stage III patients (52% vs. 28%; p = 0.026). In vitro, GRP78 inhibition reduced response to 5-FU."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23456958	AVv-MXezSS-TIFzzUJzocivic	HRAS	EGFR Inhibitor	Case report of a patient with metastatic colorectal carcinoma and a novel HRAS G13D mutation showed resistance to treatment with panitumumab. In vitro models of HRAS G13D confirmed resistance mechanism in the same study.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/26561417	AVv-MXXFSS-TIFzzUJzncivic	HRAS	"Binimetinib (MEK162),AZD8055,Selumetinib (AZD6244),Everolimus,PD0325901"	"A pre-clinical study in 10 solid cancer cell lines. HRAS mutations (Q61L, Q61R and G12V) sensitized cell lines toward MEK inhibitors (AZD6244/selumetinib, MEK162 and PD0325901) and mTOR inhibitors (Everolimus and AZD8055)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26544513	AVv-MXWYSS-TIFzzUJzmcivic	GNAQ	Vemurafenib	A 26-year old patient presented with vemurafenib resistant BRAF-mutated (V600E) cutaneous melanoma. Five of his metastases were evaluated using whole genome sequencing. A GNAQ (Q209P) mutation was identified as unanimously present in all five tumors.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/24504448	AVv-MU10SS-TIFzzUJy0civic	GNA11	JQ1	"Preclinical study in uveal melanoma cell lines. Cell lines (n=5) with GNAQ (92.1, Omm1.3, Mel270, Mel202) or GNA11 (Omm1) mutation were more sensitive to BRD4 inhibition with JQ1 than GNAQ/11 wild type (n=3) cell line."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26397223	AVv-MUdcSS-TIFzzUJywcivic	GLI1		Pericytoma with t(7;12) is a soft tissue tumor characterized by fusion of the ACTB and GLI genes through the translocation t(7;12)(p22;q13). In this study the genomic breakpoints of 5 cases were characterized.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/15555571	AVv-MUNHSS-TIFzzUJyrcivic	GATA2	"Fasudil,Bortezomib"	Targeting overactive GATA2-mediated pathways with inhibitors bortezomib and fasudil led to dramatic tumor regression.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22541434	AVv-LphoSS-TIFzzUJgJcivic	FOXP1		Amplification of FOXP1 is shown to be associated with ABC DLBCL.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/18765795	AVv-MA54SS-TIFzzUJtBcivic	FOXL2		"FOXL2 C134W mutation was found in 52 / 56 adult granulosa cell tumors, and is absent in other types of sex-cord stromal tumors, and juvenile granulosa tumors."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/20693978	AVv-MGwDSS-TIFzzUJuvcivic	FLT3	Sunitinib	"In 219 patients with mostly Renal Cell Carcinoma and some Gastrointestinal Stromal tumors given sunitinib treatment, FLT3 T227M (rs1933437) was associated with the development of leukopenia. 95% confidence interval of hazard ratio of between .17 and .77."	Adverse Response	http://www.ncbi.nlm.nih.gov/pubmed/19667267	AVv-Lo91SS-TIFzzUJffcivic	FLT3	Sorafenib	"Sorafenib is effective in patients with FLT3 internal tandem repeats, but not in wild type or D835 mutation."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/18230792	AVv-LpEGSS-TIFzzUJfpcivic	FLT3	Sorafenib	"Sorafenib is effective in patients with FLT3 internal tandem repeat mutations, but not in patients with wild type or D835 mutation."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/18230792	AVv-LpAbSS-TIFzzUJfjcivic	FLT3	Sorafenib	Emergence of D835 mutation in AML patients with FLT3 tandem repeat is associated with sorafenib resistance.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/22368270	AVv-LpBDSS-TIFzzUJfkcivic	FLT3	SU5614	Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to the protein tyrosine kinase (PTK) inhibitor SU5614 than cells with FLT3-ITD alone or FLT3 ITD and TKD mutations on opposing alleles.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/15626738	AVv-LpDhSS-TIFzzUJfocivic	FLT3	Lestaurtinib (CEP-701)	CEP701 was effective in reducing blast counts of 5/14 heavily pre-treated AML patients with FLT3 mutations.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/14726387	AVv-LpHXSS-TIFzzUJfucivic	FLT3	Daunorubicin	Ba/F3 cells with both FLT3-ITD and TKD mutations on the same allele have more resistance to daunorubicin than cells with FLT3-ITD alone.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/15626738	AVv-LpC3SS-TIFzzUJfncivic	FLT3	All-trans Retinoic Acid	ATRA treatment did not effect overall survival in patients <60 years old with FLT3-ITD mutation.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/19965647	AVv-LpIGSS-TIFzzUJfvcivic	FLT3	AG1296	AG1296 is effective in triggering apoptosis in Ba/F3 and primary AML cells with FLT3 internal tandem repeat.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/12357354	AVv-LpEtSS-TIFzzUJfqcivic	FLT3		WBC counts were not significantly different in AML patients with FLT3 D835 mutations compared to wild type.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/11290608	AVv-LpBrSS-TIFzzUJflcivic	FLT3		WBC counts were higher in AML patients with internal tandem repeat of Flt3 compared to wild type.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/11290608	AVv-LpSWSS-TIFzzUJf-civic	FLT3		"Using a ratio of FLT3-ITD/FLT3 wildtype levels as a continuous variable, a higher ratio was associated with reduced event-free survival in patients with an NPM1 mutation."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21537333	AVv-LpKOSS-TIFzzUJfycivic	FLT3		Size of the FLT3-ITD mutant duplication had no impact on overall survival or relapse rate.	N/A	http://www.ncbi.nlm.nih.gov/pubmed/17957027	AVv-LpRGSS-TIFzzUJf8civic	FLT3		Simultaneous tandem repeat of FLT3 with loss of wild type FLT3 leads to poor survival and inferior disease free survival in patients with AML.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/11585760	AVv-LpTuSS-TIFzzUJgAcivic	FLT3		Patients with NPM1 mutation and FLT3-ITD had reduced event-free survival compared to patients with wildtype FLT3.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21537333	AVv-LpQcSS-TIFzzUJf7civic	FLT3		Meta-analysis of studies involving cytogentically normal younger (<60) patients showed reduced overall and relapse-free survival for patients with FLT3-ITD.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/24801015	AVv-LpRuSS-TIFzzUJf9civic	FLT3		Increasing level of FLT3-ITD mutant correlated with reduced disease-free and overall survival as well as increased relapse rate.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/17957027	AVv-LpOaSS-TIFzzUJf4civic	FLT3		"In young AML patients (<60 years old), DNMT3A mutation status was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/22490330	AVv-LpMSSS-TIFzzUJf1civic	FLT3		"In the absence of a FLT3 (ITD) mutation, a co-mutation of NPM1 and DNMT3A had a 50% 10-year survival rate, whereas triple-mutation of NPM1, DNMT3A, and FLT3 (ITD) had a 20% 10-year survival rate."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/27276561	AVv-LpUaSS-TIFzzUJgBcivic	FLT3		"In AML patients, FLT3-TKD mutation was associated with poorer disease free survival compared to patients with wild type FLT3."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/17940205	AVv-Lo_JSS-TIFzzUJfhcivic	FLT3		"In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations were associated with worse overall survival compared to those without DNMT3A mutation."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21067377	AVv-LpPySS-TIFzzUJf6civic	FLT3		FLT3-ITD mutation without NPM1 was associated with increased relapse risk and reduced overall survival in young adult AML patients (median age 43).	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/17957027	AVv-LpNuSS-TIFzzUJf3civic	FLT3		FLT3-ITD duplication length did not effect prognosis in patients with an NPM1 mutation.	N/A	http://www.ncbi.nlm.nih.gov/pubmed/21537333	AVv-LpNASS-TIFzzUJf2civic	FLT3		"FLT3 mutations did not alter overall survival or remission duration in younger (16-60), cytogenetically normal AML patients with CEBPA mutations. 10/36 patients with CEBPA mutations also had FLT3 mutations (8 FLT3-ITD, 2 FLT3-D835)."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/14726504	AVv-LpVCSS-TIFzzUJgCcivic	FLT3		"Coocurrence of FLT3-ITD mutations significantly reduced overall (N=74 vs 95, P=0.003) and disease-free survival (N=43 vs 67, P=0.02) of normal karyotype AML patients (<60 years old) compared to patients with NPM1 mutations alone."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/16455956	AVv-LpPGSS-TIFzzUJf5civic	FLT3		AML patients with internal tandem repeat of FLT3 has worse overall survival than patients with wild type FLT3.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/11290608	AVv-LpTESS-TIFzzUJf_civic	FLT3		AML patients with D835 mutation of FLT3 did not have worse overall survival than patients with wild type FLT3.	N/A	http://www.ncbi.nlm.nih.gov/pubmed/11290608	AVv-Lo_ySS-TIFzzUJficivic	FLT3		A ratio of >0.49 FLT3-ITD/FLT3 wildtype level was associated with reduced event-free and overall survival in old (>59) and younger patients (<60) with an NPM1 mutation.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21537333	AVv-LpJZSS-TIFzzUJfxcivic	FLI1		"t(11;22) rearrangements of EWSR1-FLI1 are diagnostic of ewing sarcoma, and are observed in 90% of cytogenetic samples."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/23706910	AVv-MAh9SS-TIFzzUJs2civic	FLI1		"In patients with Ewing's sarcoma, those with type 1 EWS-FLI1 fusions had longer overall survival than those with other types of EWS-FLI1 fusions."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/9552022	AVv-MAhKSS-TIFzzUJs1civic	FGFR3	"Dovitinib,SU-5402,PD173074"	"The effects of FGFR inhibitors (PD173074, TKI-258 and SU5402) in bladder carcinoma cell lines were related to FGFR3 (and/or FGFR1) expression."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21119661	AVv-LoMzSS-TIFzzUJfbcivic	FGFR3		Y375C mutation results in activation of FGFR3 and is associated with bladder carcinoma. Patients with low-grade tumors were more likely to have FGFR3 mutations than those with high-grade tumors.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/20542753	AVv-LoLeSS-TIFzzUJfZcivic	FGFR2	"Ponatinib,Pazopanib"	In a 43 year old female patient with this fusion in intrahepatic cholangiocarcinoma. Both pazopanib and ponatinib separately resulted in minor tumor shrinkage. This fusion is also shown to be recurrent in multiple other cancer types.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24550739	AVv-LnyaSS-TIFzzUJfJcivic	FGFR2	"PD173074,BGJ398"	Expression of the FGFR2-BICC1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24122810	AVv-LnvySS-TIFzzUJfFcivic	FGFR2	"PD173074,BGJ398"	Expression of the FGFR2-AHCYL1 fusion kinase in NIH3T3 cells demonstrated transforming ability that was effectively suppressed with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24122810	AVv-LnwXSS-TIFzzUJfGcivic	FGFR2	PD173074	"The endometrial cancer cell lines, AN3CA and MFE296, which carry the N550K FGFR2 mutation, were found to be sensitive to FGFR inhibition with PD174074 (10 to 40x more sensitive than cell lines with wild type FGFR2.)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/18757403	AVv-LnxwSS-TIFzzUJfIcivic	FGFR2	BGJ-398	"Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. Among three patients with cholangiocarcinoma and FGFR2 aberrations (2 fusions, 1 mutation), all three had stable disease with a reduced tumor burden."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/27870574	AVv-LnsnSS-TIFzzUJfAcivic	FGFR1	Ponatinib	In MDA-MB-134 cells (ER-positive breast cancer cells with amplified FGFR1) ponatinib potently inhibited cell growth with a GI50 value of 23 nmol/L and inhibited FGFR1 phosphorylation with an IC50 value of 7 nmol/L.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22238366	AVv-MRuxSS-TIFzzUJxzcivic	FGFR1	PD173074	Preclinical study showing FGFR1 amplification in NSCLC and efficacy of FGFR-1 inhibition in one amplified cell line.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21666749	AVv-MRr6SS-TIFzzUJxvcivic	FGFR1	"Dovitinib Dilactic Acid (TKI258 Dilactic Acid),PD173074"	"One urothelial cell line (JMSU1) with high expression of FGFR1 was sensitive to treatment with FGFR inhibitors  (SU5402, TKI258 or PD173074)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21119661	AVv-MR38SS-TIFzzUJyBcivic	FGFR1	BGJ398	"FGFR1 mRNA expression, rather than copy number alterations, were predictive of response to FGFR inhibitor BGJ398 in cell lines and patient derived xenografts."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26015511	AVv-MR69SS-TIFzzUJyGcivic	FGFR1	BGJ398	FGFR inhibitor BGJ398 was most effective in a gastric cancer cell line model with high expression of FGFR1 and FGFR2IIIc.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26637881	AVv-MR4kSS-TIFzzUJyCcivic	FGFR1	BGJ-398	Phase 1 study of FGFR-inhibitor BGJ398 in advanced cancer with FGFR-aberrations. One patient with FGFR1 amplified bladder/urothelial carcinoma was treated with 125 mg and progressed rapidly in cycle 1 after 11 days of treatment.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/27870574	AVv-MRwvSS-TIFzzUJx2civic	FGFR1	4-hydroxytamoxifen	"FGFR1-amplified breast cancer cell lines show resistance to 4-hydroxytamoxifen, which is reversed by small interfering RNA silencing of FGFR1."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/20179196	AVv-MRtTSS-TIFzzUJxxcivic	FGFR1		"This study shows an association of FGFR1 amplification with shorter overall and disease-free survival. However, no statistically significant association is seen on multivariate analysis."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/25086725	AVv-MRz9SS-TIFzzUJx7civic	FGFR1		This study shows a reduction in the risk of death for patients with FGFR1 copy-number between 4 and 6. No difference in survival is seen between amplified and non-amplified patients in general.	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/23806793	AVv-MRyMSS-TIFzzUJx4civic	FGFR1		"Meta-Analysis on prognostic value of FGFR1 amplification in different types of cancer shows significantly worse overall survival for patients with FGFR1 and FGFR2 amplification.
However, larger studies are warranted for confirmation."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/25171497	AVv-MR0qSS-TIFzzUJx8civic	FGFR1		"In this study in surgically resected squamous cell lung cancer, FGFR1 amplification has been shown as an independent negative prognostic factor in Asian patients. FGFR1 amplification also correlates with cigarette smoking."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/23182986	AVv-MR1VSS-TIFzzUJx9civic	FGFR1		"FGFR1 expression was increased in urothelial carcinoma cell lines and patient tumours, independent of stage and grade. FGFR1 knockdown resulted in decreases proliferation and survival in some of the cell lines."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/19458078	AVv-MR6YSS-TIFzzUJyFcivic	FGFR1		"Effect of FGFR1 amplification on survival unclear, no significant correlation with PFS and OS seen in this meta-analysis. However, FGFR1 amplification is significantly correlated with lymph node metastasis."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/25433983	AVv-MRy5SS-TIFzzUJx6civic	FGF3	Sorafenib	"FGF3/FGF4 amplification was observed in around 2% of HCCs. Although the sample size was relatively small, FGF3/FGF4 amplification, a poorly differentiated histological type, and multiple lung metastases were frequently observed in responders to sorafenib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22890726	AVv-MQ5OSS-TIFzzUJxfcivic	FCGR3A		"A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. FCGR3A V158F carriers did not have a significantly different response rate, progression-free survival, or overall survival."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/22906996	AVv-MQphSS-TIFzzUJxdcivic	FCGR2A		"A total of 57 women with HER2-positive metastatic breast cancer were analyzed after taxane plus trastuzumab chemotherapy. FCGR2A H131R carriers did not have a significantly different response rate, progression-free survival, or overall survival."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/22906996	AVv-MQYISS-TIFzzUJxacivic	FBXW7	"Panitumumab,Cetuximab"	65 patients were retrospectively analyzed for mutational profiles predictive of response to EGFR-inhibitors (cetuximab or panitumumab). FBXW7 mutation was found to be more prevalent in non-responders (5 mutations) than responders (1 mutation).	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/26508446	AVv-Mv1LSS-TIFzzUJ6bcivic	EZH2		"In myelodysplastic syndrome, patients with point mutations in EZH2 have worse overall survival that their wild-type counterparts."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/20601954	AVv-MEh1SS-TIFzzUJt8civic	EZH2		High expression of EZH2 was associated with poorer outcome in a meta-analysis encompassing 51 studies and 9444 patients.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/26683709	AVv-MEd_SS-TIFzzUJt2civic	EWSR1		"An evaluation of alternative strategies for detection of EWS-FLI (FISH break apart, FISH fusion, and RT-PCR).  Of the 22 informative EWS/PNETs, 20 cases (91%) were positive by FISH break apart, FISH fusion, or both."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/16258512	AVv-MApJSS-TIFzzUJs4civic	EWSR1		A total of 85 unrelated cases of Ewing's sarcoma were examined and 83% we found to harbor the t(11;22)(q24;q12) chromosomal abnormality (EWS/FLI).	Positive	http://www.ncbi.nlm.nih.gov/pubmed/3163261	AVv-MAoaSS-TIFzzUJs3civic	ESR1	Hormone Therapy	MCF7 cell lines harboring the Y537N mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/24185512	AVv-Lm5TSS-TIFzzUJe2civic	ESR1	Hormone Therapy	MCF7 cell lines harboring the Y537C mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/24185512	AVv-Lm8ySS-TIFzzUJe7civic	ESR1	Hormone Therapy	MCF7 cell lines harboring the L537S mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/24185512	AVv-Lm-MSS-TIFzzUJe9civic	ESR1	Hormone Therapy	MCF7 cell lines harboring the L536Q mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/24185512	AVv-Lm7VSS-TIFzzUJe5civic	ESR1	Hormone Therapy	MCF7 cell lines harboring the D538G mutation in the ligand-binding domain of ESR1 have shown resistance to hormone therapy.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/24185512	AVv-Lm4CSS-TIFzzUJe0civic	ESR1	"Fulvestrant,Tamoxifen"	The Y537S ligand binding domain mutations have been shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24185510	AVv-Lm-2SS-TIFzzUJe-civic	ESR1	"Fulvestrant,Tamoxifen"	The Y537N ligand binding domain mutations have been shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24185510	AVv-Lm5_SS-TIFzzUJe3civic	ESR1	"Fulvestrant,Tamoxifen"	The Y537C ligand binding domain mutations have been shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24185510	AVv-Lm9fSS-TIFzzUJe8civic	ESR1	"Fulvestrant,Tamoxifen"	The N538G ligand binding domain mutations have been shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in vitro.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24185510	AVv-Lm4uSS-TIFzzUJe1civic	ESR1	"Fulvestrant,Tamoxifen"	The L536Q ligand binding domain mutations have been shown to result in constitutive activity and continued responsiveness to anti-estrogen therapies in MCF7 cell lines.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24185510	AVv-Lm8BSS-TIFzzUJe6civic	ERG		t(21;22) rearrangements of EWSR1-ERG are associated with a diagnosis of Ewing sarcoma and are the second most common gene fusion reported in this disease.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/23706910	AVv-MGpySS-TIFzzUJuucivic	ERG		"TMPRSS2/ERG gene fusion was observed in 23 of 29 (79%) of prostate carcinoma samples, and 90% of ERG expression positive prostate carcinoma samples."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/16254181	AVv-MGo-SS-TIFzzUJutcivic	EREG	Cetuximab	"226 cetuximab-treated patients with CRC were analyzed for mRNA expression of EGFR and its ligands. Favorable predictors in a multivariate analysis were high AREG mRNA in KRAS wild type tumours, high EREG mRNA and low Ephrin A2 receptor mRNA."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23374602	AVv-MPx4SS-TIFzzUJxUcivic	ERCC2	Cisplatin	The ERCC2 K751Q variant was significantly correlated with a lower response to cisplatin chemotherapy in osteosarcoma patients and shorter event-free survival. 91 osteosarcoma patients with a median age of 15 years were followed in this study.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/19434073	AVv-MPofSS-TIFzzUJxQcivic	ERCC1	Cisplatin	Immunhistochemistry of ERCC1 expression in 432 patients revealed no correlation to response to cisplatin based chemotherapy. In-vitro studies also did not show any effects.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26162296	AVv-MPhZSS-TIFzzUJxPcivic	ERCC1		"ERCC1 expression as evaluated by IHC in 432 patients was associated with better disease-free survival (HR 0.70, p = 0.028) and cancer specific survival (HR 0.70, p = 0.032) on multivariable analysis."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/26162296	AVv-MPgvSS-TIFzzUJxOcivic	ERBB4	Trastuzumab	siRNA knockdown of HER4 or inhibition with neratinib enhanced trastuzumab response in breast cancer cell lines.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25153719	AVv-MPX3SS-TIFzzUJxLcivic	ERBB4	Trastuzumab	HER4 nuclear translocation was identified as a mediator of trastuzumab resistance in HER2 positive breast cancer cell lines. Increased nuclear staining was also identified in xenograft and patient samples after trastuzumab treatment.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/25153719	AVv-MPYhSS-TIFzzUJxMcivic	ERBB3	Cetuximab	High expression of ERBB3 (her3) was associated with shorter overall survival (OS) from Cetuximab treatment in patients with metastatic colorectal cancer. Gene expression measures (qRT-PCR) were available for 103 patients.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/25520391	AVv-MO7tSS-TIFzzUJw0civic	ERBB2	"Trastuzumab,Lapatinib,Neratinib"	Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-LlVASS-TIFzzUJdUcivic	ERBB2	Trastuzumab	"A 71-year old male with metastatic extramammary Paget’s disease of the scrotum overexpressing Her2/neu was treated with trastuzumab, achieving a complete response. At 12 months, he maintains stable disease."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25692060	AVv-Ll8uSS-TIFzzUJeXcivic	ERBB2	"Neratinib,Lapatinib,Trastuzumab"	Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-LmHkSS-TIFzzUJencivic	ERBB2	Neratinib	The L755S mutation showed mild response to neratinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-LmDUSS-TIFzzUJegcivic	ERBB2	Neratinib	Oral neratinib showed objective response rates of 24 and 56% respectively in prior-trastuzumab and trastuzumab-naive cohorts in a Phase II trial with a primary endpoint of 16-week progression free survival.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/20142587	AVv-LljPSS-TIFzzUJdpcivic	ERBB2	Neratinib	MCF10A cells transduced with ERBB2 harboring an L755W mutation were sensitive to the irreversible kinase inhibitor neratinib in an matrigel colony forming assay.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-LlX7SS-TIFzzUJdZcivic	ERBB2	Neratinib	"In MCF10A cell lines, the in-frame insertion of a single amino acid at position 780 was shown to be sensitive to neratinib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-LlZ4SS-TIFzzUJdccivic	ERBB2	Neratinib	"In MCF10A cell lines, the V842I mutation was shown to be sensitive to neratinib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-LlVoSS-TIFzzUJdVcivic	ERBB2	Neratinib	"In MCF10A cell lines, the V777L mutation was shown to be sensitive to neratinib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-LmGWSS-TIFzzUJelcivic	ERBB2	Neratinib	"In MCF10A cell lines, the R896C mutation was shown to be sensitive to neratinib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-LmBNSS-TIFzzUJedcivic	ERBB2	Neratinib	"In MCF10A cell lines, the G309A mutation was shown to be sensitive to neratinib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-LlYlSS-TIFzzUJdacivic	ERBB2	Neratinib	"In MCF10A cell lines, the D769Y mutation was shown to be sensitive to neratinib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-LmEhSS-TIFzzUJeicivic	ERBB2	Neratinib	"In MCF10A cell lines, the D769H mutation was shown to be sensitive to neratinib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-LmD6SS-TIFzzUJehcivic	ERBB2	Neratinib	"In MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2, cells expressing the in-frame deletion of amino acids 755-759 were shown to be sensitive to neratinib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-LlUZSS-TIFzzUJdTcivic	ERBB2	"Lapatinib,Neratinib,Trastuzumab"	Colon cancer patient derived xenografts with HER2 mutations are sensitive to HER2 targeted drugs and the greatest tumor reduction was seen with the combination of a tyrosine kinase inhibitor with trastuzumab.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26243863	AVv-LmFwSS-TIFzzUJekcivic	ERBB2	"Lapatinib,Neratinib"	MCF10A cells transduced with ERBB2 harboring an R678Q mutation were sensitive to lapatinib and the irreversible kinase inhibitor neratinib in an matrigel colony forming assay.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-LmFKSS-TIFzzUJejcivic	ERBB2	Lapatinib	The L755S mutation was shown to confer resistance to lapatinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/23220880	AVv-LmCpSS-TIFzzUJefcivic	ERBB2	Dacomitinib	"Phase 2 trial of ERBB-inhibitor dacomitinib in stage IIIB/IV lung cancers with HER2 mutations or amplification. 4 patients with HER2 amplified NSCLC were enrolled in the trial, no one among them had a response."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25899785	AVv-Ll_CSS-TIFzzUJeacivic	ERBB2	"Cetuximab,Oxaliplatin,Capecitabine"	"141 patients were analyzed for ERBB2 (HER2) positivity by FISH and/or IHC. Only 6 (4.3%) were ERBB2 positive. These patients did not show a difference in outcome after capecitabine, oxaliplatin and chemoradiotherapy, with or without cetuximab."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/24146218	AVv-LluQSS-TIFzzUJeDcivic	ERBB2	AKTi-1/2	Xenografts established from breast cancer cell lines with ERBB2 amplification and PIK3CA mutation (BT474) or PIK3CA mutation alone (MCF7) were effectively inhibited in-vivo with an AKT1/2-inhibitor (AKTi-1/2; naphthyridinone).	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/18725974	AVv-LlajSS-TIFzzUJddcivic	EPCAM		"Rare but recurring germline truncating mutations of the 3’ end of EPCAM, were reported for 27 independent families, shown to lead to epigenetic silencing of a neighbouring gene, MSH2, and suggested to cause Lynch syndrome."	Uncertain Significance	http://www.ncbi.nlm.nih.gov/pubmed/21309036	AVv-MZGESS-TIFzzUJ0Bcivic	EPAS1		Expression of EPAS1 (HIF-2alpha) was assessed in 731 colorectal cancers from two prospective cohort studies. EPAS1 overexpression was found in 322 (46%) cancers by immunohistochemistry and not significantly associated with patient survival.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/20363910	AVv-MN-USS-TIFzzUJwycivic	EGFR	Staurosporine	"In NSCLC containing a T790M mutation, staurosporine may be inhibitive of EGFR, especially when an L858R mutation is also present."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24658966	AVv-Li5wSS-TIFzzUJcrcivic	EGFR	Rociletinib	"In a phase1-2 study, patients with the T790M mutation were more sensitive to rocelitinib in comparison to patients with T790M-negative NSCLC."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25923550	AVv-Li14SS-TIFzzUJcmcivic	EGFR	Osimertinib	Osimertinib has been approved for the treatment of EGFR T790M mutant NSCLC.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26729184	AVv-Li_oSS-TIFzzUJczcivic	EGFR	Nimotuzumab	55 tumor samples were analyzed for EGFR expression using IHC. The objective response rate to anti-EGFR antibody nimotuzumab did not differ significantly between EGFR high- (18 pts) and EGFR low to moderate groups (37 pts).	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26459251	AVv-LiY4SS-TIFzzUJb4civic	EGFR	"Gefitinib,Erlotinib"	There is no statistical difference in progression free survival between lung cancer patients treated with gefitinib or erlotinib in the EGFR L858R setting.	N/A	http://www.ncbi.nlm.nih.gov/pubmed/24736073	AVv-Lh_nSS-TIFzzUJbTcivic	EGFR	"Gefitinib,Erlotinib"	"In NSCLC patients treated with EGFR tyrosine kinase inhibitors, the presence of L858R mutation is prognostic for better progression free survival."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24457318	AVv-LiEYSS-TIFzzUJbacivic	EGFR	Gefitinib	Partial response to gefitinib was achieved in two non-small cell lung cancer patients having a S768I mutation with concomitant G719C mutation.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/15998907	AVv-Lh6iSS-TIFzzUJbLcivic	EGFR	Gefitinib	"In non-small cell lung cancer, the appearance of T790M mutation leads to resistance to gefitinib."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/15728811	AVv-Li3XSS-TIFzzUJcocivic	EGFR	Gefitinib	Gefinitib has been shown to be effective in treating cell lines with L858R missense mutations.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/15118125	AVv-LiAMSS-TIFzzUJbUcivic	EGFR	Gefitinib	Gefinitib has been shown to be effective in treating cell lines with G719S missense mutations.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/15118125	AVv-LiTpSS-TIFzzUJbwcivic	EGFR	Gefitinib	Exon 19 deletion has been shown to be correlated with gefitinib response.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/16730237	AVv-LijUSS-TIFzzUJcJcivic	EGFR	"Erlotinib,Pemetrexed"	"In a NSCLC patient with T790M and L858R mutation, combination treatment with erlotinib and premetrexed has shown to be effective, reducing tumor size and resulting in stable disease."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24636847	AVv-Li48SS-TIFzzUJcqcivic	EGFR	"Erlotinib,Gefitinib"	NSCLC patients with exon 19 deletions in EGFR had longer overall survival than patients with an L858R mutation when treated with gefitinib and erlotinib (38 versus 17 months; P = 0.04).	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/16818686	AVv-LioHSS-TIFzzUJcRcivic	EGFR	Erlotinib	"The T790M mutation in EGFR has been shown to confer resistance to the tyrosine kinase inhibitor erlotinib, and patients harboring this mutation that are placed on the drug are likely to relapse."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/25668228	AVv-Li2nSS-TIFzzUJcncivic	EGFR	Erlotinib	"In retrospective analysis of clinical trials and case studies, most patients with EGFR exon 20 insertion mutations did not benefit from first-generation EGFR kinase inhibitors."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/26773740	AVv-LizNSS-TIFzzUJcicivic	EGFR	Erlotinib	"Efficacy of erlotinib treatment was evaluated by meta-analysis of results from seven trials and literature review. Two patients with p.S270P, and one patient with p.S720F were observed to have poor survival outcomes."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/26773740	AVv-Lhw8SS-TIFzzUJa8civic	EGFR	Erlotinib	"Although EGFR exon 20 insertions may confer reduced sensitivity to erlotinib, patients with this particular mutation appeared to benefit from therapy."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26773740	AVv-Lh20SS-TIFzzUJbFcivic	EGFR	EGFR Inhibitor	"In this prospective study in 37 patients of whom 34 were treated with different EGFR inhibitors (gefitinib, erlotinib, afatinib), EGFR mutations and a higher relative expression of EGFR in comparison to MET expression were correlated with longer PFS."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26439803	AVv-LiZfSS-TIFzzUJb5civic	EGFR	EGFR Inhibitor	EGFR overexpression was correlated with longer overall survival in patients with advanced NSCLC treated with first line chemotherapy and cetuximab than those treated with first line chemotherapy alone.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22056021	AVv-LiaNSS-TIFzzUJb6civic	EGFR	"Docetaxel,Cetuximab"	"47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 73 % of cases expressed high level of EGFRvIII. EGFR expression had no impact on PFS or OS."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21653686	AVv-LirbSS-TIFzzUJcWcivic	EGFR	Dacomitinib	"In Lung Cancer patients with acquired resistance to Dacomitinib (PF00299804), MET amplification and EGFR T790M were found to be the primary drivers of resistance."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/21430269	AVv-Li4GSS-TIFzzUJcpcivic	EGFR	Cetuximab	"Whole genome sequencing of a case of colon carcinoma revealed a G724S mutation in the EGFR gene. In-vitro, this mutation was shown to be oncogenic and sensitive to Cetuximab, yet relatively insensitive towards small molecules."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24894453	AVv-Liz2SS-TIFzzUJcjcivic	EGFR	Cetuximab	In-vitro studies found this mutation to confer resistance to cetuximab. 2 of 10 patients studied also harbored EGFR S492R and were resistant to cetuximab therapy. Panitumumab was still active in-vitro and in one patient.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/22270724	AVv-LifVSS-TIFzzUJcCcivic	EGFR	Cetuximab	EGFR expression level was not predicitive of response to cetuximab-containing first line regimens in recurrent or metastatic head and neck squamous cell carcinoma and KRAS-wild type colorectal carcinoma.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23265711	AVv-LiWWSS-TIFzzUJb0civic	EGFR	Cetuximab	"87 patients with metastatic colorectal cancer treated with cetuximab were retrospectively analyzed for EGFR amplifications by FISH. In multivariate analysis, EGFR amplification predicted response and overall survival independent of KRAS status."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/18794099	AVv-LiuHSS-TIFzzUJcacivic	EGFR	"Bevacizumab,Erlotinib"	"Overexpression of EGFR exon 18 (Affymetrix Human Exon 1.0 ST) in tumor or blood samples was associated with tumor shrinkage, independently of EGFR mutational status in NSCLC treated with bevacizumab and erlotinib. 76 patients were analyzed for this study."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24039832	AVv-Lh9DSS-TIFzzUJbPcivic	EGFR	Afatinib	"In retrospective analysis of trials, afatinib conferred limited clinical benefit to patients with EGFR exon 20 insertion mutations (N=23). Only 2 patients had objective responses."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/26051236	AVv-LiymSS-TIFzzUJchcivic	EGFR	"5-fluorouracil,Cetuximab,PLATINUM"	EGFR amplification was not a predictor of response to cetuximab/5-FU/platinum in patients with recurrent or metastatic HNSSC from the EXTREME study.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21048039	AVv-LivYSS-TIFzzUJcccivic	EGFR		The group of 43 out of 75 tumor samples with increased copy number or amplification of EGFR as determined by FISH (FISH-positive) had worse progression-free and overall survival than FISH-negative tumors.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/16943533	AVv-LiuwSS-TIFzzUJcbcivic	EGFR		Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced disease-free and cause-specific survival.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/9625170	AVv-LiVlSS-TIFzzUJbzcivic	EGFR		Patients with NSCLC harboring EGFR T790M mutation have statistically worse overall survival compared to patients with L858R or other exon 19 activating mutations.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/24729716	AVv-LjKlSS-TIFzzUJdNcivic	EGFR		"Overexpression of EGFR in 55 samples of esophageal squamous cell carcinoma as assesesed by IHC, was related to poor OS and PFS  (PFS: 5.8 ± 0.5 vs. 11.0 ± 2.8 months, P = 0.007; OS: 9.7 ± 0.5 vs. 21.5 ± 1.5 months, P = 0.03)."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/26459251	AVv-LiYOSS-TIFzzUJb3civic	EGFR		Median survival of patients with EGFR L858R mutation is better than those with wild type EGFR.	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/24662454	AVv-LiRlSS-TIFzzUJbtcivic	EGFR		"In patients with glioblastoma multiforme, those with overespression of wild-type EGFR had shorter overall survival."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/14583498	AVv-Lia5SS-TIFzzUJb7civic	EGFR		"In patients with cervical squamous cell carcinoma, those with gene amplification of EGFR had worse overall survival."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21730982	AVv-Liv8SS-TIFzzUJcdcivic	EGFR		"In patients with Barrett's adenocarcinoma, those with amplification of EGFR had shorter disease-specific survial."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/20840671	AVv-LiwnSS-TIFzzUJcecivic	EGFR		"In a study of 1036 patients with lung adenocarcinomas, patients with EGFR mutations (n=275) showed better prognosis (OS: 34 months versus 23 months; HR=0.6; P<0.001)."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22810899	AVv-LieLSS-TIFzzUJcAcivic	EGFR		"In NSCLC patients with T790M and another activating mutations, their progression free survival is shorter compared to those who do not possess T790M mutation."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/24623981	AVv-LjLWSS-TIFzzUJdOcivic	EGFR		"In 134 patients with head and neck squamous cancer 32 had copy number variations. Tumors with variation (either increase or decrease) in copy number of EGFR had worse overall, cancer-specific, and disease-free survival."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/17538160	AVv-LixTSS-TIFzzUJcfcivic	EGFR		Expression of EGFR in 55 samples of esophageal squamous cell carcinoma with IHC was not predictive of response to EGFR inhibitor nimotuzumab. EGFR overexpression was related to poor OS and PFS.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26459251	AVv-LiXlSS-TIFzzUJb2civic	EGF	Cetuximab	3 tongue cancer cell lines were used for this study. Addition of recombinant human EGF led to increased cetuximab resistance. EGF downregulation suppressed proliferation of cell lines. Results for amphiregulin and epiregulin were inconclusive.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/25677871	AVv-MNkUSS-TIFzzUJwtcivic	DUSP6	Trametinib	Expression of DUSP6 was associated with sensitivity to MEK inhibitor GSK1120212 (Sensitivity: 79%; specificity: 82%: P = 0.0027) in 218 solid cancer cell lines.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22169769	AVv-MNcpSS-TIFzzUJwscivic	DNMT3A	Idarubicin	Idarubicin increases the overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22081665	AVv-LfHPSS-TIFzzUJaOcivic	DNMT3A	Decitabine	"Among 46 AML patients treated with decitabine, the response rate was 75% (6/8) among DNMT3A mutated and 34% (13/38) among DNMT3A wild-type patients (P=.008)"	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22124213	AVv-LfbCSS-TIFzzUJascivic	DNMT3A	Daunorubicin	Daunorubicin treatment resulted in similar overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/22081665	AVv-LfGXSS-TIFzzUJaNcivic	DNMT3A		"Young AML patients (<60 years old) with DNMT3A mutations (60% of which were R882) were older in age, had higher white blood cell counts and had higher platelet counts than patients wildtype for DNMT3A."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/22490330	AVv-LfVrSS-TIFzzUJajcivic	DNMT3A		Young AML patients (415 patients; <60 years old) with any DNMT3A mutation (n=96) have shorter overall survival and relapse-free survival than patients with wildtype DNMT3A.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22490330	AVv-LfcxSS-TIFzzUJavcivic	DNMT3A		Young AML patients (415 patients; <60 years old) with DNMT3A R882 mutations (n=58) have shorter overall and relapse-free survival than patients with wildtype DNMT3A.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22490330	AVv-LfLcSS-TIFzzUJaUcivic	DNMT3A		There is no difference in the complete remission rate of de novo AML patients with DNMT3A mutation compared to those who are wild type for DNMT3A.	N/A	http://www.ncbi.nlm.nih.gov/pubmed/22081665	AVv-LfOUSS-TIFzzUJaYcivic	DNMT3A		Therapy-related AML was less common in patients with DNMT3A mutations (64.5% of which were R882) than patients wildtype for DNMT3A in a large cohort of younger (18-60) AML patients.	Negative	http://www.ncbi.nlm.nih.gov/pubmed/23632886	AVv-LfQXSS-TIFzzUJabcivic	DNMT3A		"In younger cytogenetically normal AML patients (<60 years), DNMT3A mutations other than R882 are prognostic for shorter disease free survival and overall survival compared to patients without the mutation."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22291079	AVv-LfPtSS-TIFzzUJaacivic	DNMT3A		"In young AML patients (<60 years old), DNMT3A mutations were associated with significantly reduced overall survival and relapse free survival in patients wildtype for NPM1 and FLT3."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22490330	AVv-LfS5SS-TIFzzUJafcivic	DNMT3A		"In young AML patients (<60 years old), DNMT3A mutation status (60% of which were R882) was not predictive of overall and relapse free survival in patients with NPM1 mutations and wildtype FLT3 or wildtype NPM1 and FLT3-ITD."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/22490330	AVv-LfUTSS-TIFzzUJahcivic	DNMT3A		"In older cytogenetically normal AML patients (>59 years), DNMT3A R882 mutation is prognostic for shorter disease free survival and overall survival compared to patients without the mutation."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22291079	AVv-LfIrSS-TIFzzUJaQcivic	DNMT3A		"In cytogenetically normal AML patients, DNMT3A R882 mutations are associated with lower overall and disease free survival as compared to patients with wild type DNMT3A."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/24512939	AVv-LfM6SS-TIFzzUJaWcivic	DNMT3A		"In a large cohort of young AML patients (18-60 years old), DNMT3A R882 mutations were associated with reduced relapse free survival in the entire cohort as well as the subset of patients with cytogenetically normal AML."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/23632886	AVv-LfXtSS-TIFzzUJamcivic	DNMT3A		"In a large cohort of AML patients (mean = 48 years), DNMT3A mutation (64.5% of which were R882) had no prognostic value on overall, relapse free and event free survival."	N/A	http://www.ncbi.nlm.nih.gov/pubmed/23632886	AVv-LfWXSS-TIFzzUJakcivic	DNMT3A		"In a large cohort (n=1770) of AML patients (18-60 years old), DNMT3A mutation status (65.4% of which were R882) had no prognostic value for overall, relapse free and event free survival. This was true for cytogenetically normal AML and the entire cohort."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/23632886	AVv-LfTrSS-TIFzzUJagcivic	DNMT3A		"In AML patients with FLT3-ITD mutations, concurrent DNMT3A mutations (including R882) were associated with worse overall survival compared to those without DNMT3A mutation."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21067377	AVv-LfKFSS-TIFzzUJaScivic	DNMT3A		De novo AML patients with DNMT3A D882 mutation showed worse survival (event-free and overall) outcome than those without DNMT3A mutation.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21067377	AVv-LfH5SS-TIFzzUJaPcivic	DNMT3A		DNMT3A mutations were associated with achievement of complete remission in a large cohort of younger (18-60) AML patients.	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/23632886	AVv-LfPASS-TIFzzUJaZcivic	DNMT3A		"DNMT3A mutations associate with adverse overall survival in acute myeloid leukemia patients if they occur in the context of mutated NPM1 and  FLT3-ITD (NPM1-FLT3ITD-DNMT3A phenotype), and in the context of IDH2 codon R140 mutations."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/27276561	AVv-LfaeSS-TIFzzUJarcivic	DNMT3A		"DNMT3A mutations (64.5% R882) were associated with older age, higher white blood cell count and cytogenetically normal AML in a large cohort of younger (18-60) AML patients."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/23632886	AVv-LfSQSS-TIFzzUJaecivic	DNMT3A		DNMT3A mutations (62% of which were R882) were associated with reduced disease-free survival in patients with cytogenetically normal AML.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22291079	AVv-LfRpSS-TIFzzUJadcivic	DNMT3A		DNMT3A mutations (59% of which were R882) were associated with intermediate risk cytogenetics (including normal karyotype).	Positive	http://www.ncbi.nlm.nih.gov/pubmed/21067377	AVv-LfNtSS-TIFzzUJaXcivic	DNMT3A		"DNMT3A mutations (59% of which were R882) were associated with an intermediate risk cytogenetic profile, normal cytogenetic profile, and M4 and M5 FAB subtypes."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/21067377	AVv-LfMKSS-TIFzzUJaVcivic	DNMT3A		"DNMT3A R882 mutations were associated with older age, higher white blood cell count, and FAB M4 and M5 subtypes compared to wildtype DNMT3A in a cohort of cytogenetically normal AML patients."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/24512939	AVv-LfJaSS-TIFzzUJaRcivic	DNMT3A		DNMT3A R882 mutations were associated with cytogenetically normal AML in a large cohort of younger (18-60) AML patients.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/23632886	AVv-LfU_SS-TIFzzUJaicivic	DNMT3A		DNMT3A R882 mutations occur most often in de novo AML patients with intermediate risk cytogenetics (39/194 intermediate risk patients vs 0/89 low and high risk).	Positive	http://www.ncbi.nlm.nih.gov/pubmed/22081665	AVv-LfXGSS-TIFzzUJalcivic	DNMT3A		"DNMT3A R882 mutation was associated with reduced relapse free and overall survival in ELN-unfavorable, cytogenetically normal AMLs."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/23632886	AVv-LfYySS-TIFzzUJaocivic	DNMT3A		Complete remission rates did not differ between patients with wildtype or mutant DNMT3A (62% of which affected R882) and cytogenetically normal AML.	N/A	http://www.ncbi.nlm.nih.gov/pubmed/22291079	AVv-LfYPSS-TIFzzUJancivic	DNMT3A		Complete remission rate was not different between young AML patients (<60 years old) with or without DNMT3A mutations (60% of which were R882).	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22490330	AVv-LfKwSS-TIFzzUJaTcivic	DNMT3A		AML patients with DNMT3A mutations (59% of which were R882) showed worse survival (event-free and overall) outcome than those without DNMT3A mutation.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21067377	AVv-LfQ-SS-TIFzzUJaccivic	DEFA1	Docetaxel	"Blood mRNA levels of DEFA1, DEFA1B and DEFA3 were associated with response to docetaxel treatment in castration resistant prostate cancer. The discovery cohort consisted of 6 patients, results were validated in 10 patients."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26261420	AVv-MMnfSS-TIFzzUJwYcivic	DDR2	"Erlotinib,Dasatinib"	"In a patient expressing a DDR2 S768R mutation, treatment with dasatinib plus erlotinib acheived a partial response."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22328973	AVv-L_RfSS-TIFzzUJsLcivic	DDR2	Dasatinib	In 3T3 fibroblasts expressing the L63V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22328973	AVv-L_Q2SS-TIFzzUJsKcivic	DDR2	Dasatinib	In 3T3 fibroblasts expressing the L239R mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22328973	AVv-L_QMSS-TIFzzUJsJcivic	DDR2	Dasatinib	In 3T3 fibroblasts expressing the I638F mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22328973	AVv-L_SKSS-TIFzzUJsMcivic	DDR2	Dasatinib	In 3T3 fibroblasts expressing the G774V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22328973	AVv-L_PkSS-TIFzzUJsIcivic	DDR2	Dasatinib	In 3T3 fibroblasts expressing the G505S mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22328973	AVv-L_O1SS-TIFzzUJsHcivic	DDR2	Dasatinib	In 3T3 fibroblasts expressing the G253C mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22328973	AVv-L_SySS-TIFzzUJsNcivic	DDIT3		The FUS-DDIT3 fusion is pathognomonic of myxoid liposarcomas.  It encompasses parts  of the FUS gene on l6pll at its 5’ end and the DDIT3 gene at 12q13 at its 3’ ends	Positive	http://www.ncbi.nlm.nih.gov/pubmed/1568170	AVv-MMfmSS-TIFzzUJwWcivic	DDIT3		Identified two cases of myxoid liposarcoma with translocations (between 12q13 and 22q12) giving rise to EWSR1-DDIT3 (EWS-CHOP) fusions instead of the more common FUS-DDIT3.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/8637704	AVv-MMgUSS-TIFzzUJwXcivic	CXCR4	Docetaxel	"CXCR4 expression as assessed by microarray analysis, was associated with resistance to docetaxel in 11 cancer cell lines (R^2 = 0.23, p = 0.019). Expression levels (by qtPCR) were also higher in resistant tumors among 25 patient samples."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/20651371	AVv-MpcsSS-TIFzzUJ4jcivic	CSF3R		"Study found that mutations in CSF3R are enriched in patients with Chronic Neutrophilic Leukemia (CNL) or Atypical Chronic Myeloid Leukemia (16/27, 59%) when compared to other blood disorders (AML=1/292, t-cell ALL=0/8, B-cell ALL=0/41)"	Positive	http://www.ncbi.nlm.nih.gov/pubmed/23656643	AVv-ML57SS-TIFzzUJwScivic	CSF1R	"GW-2580,Imatinib"	Cell lines with MEF2D-CSF1R fusion show sensitivity to the tyrosine kinase inhibitors Imatinib and GW-2580.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24186003	AVv-LxQZSS-TIFzzUJkpcivic	CHEK2		Meta-analysis linking CHEK2 1100delC to a higher risk of prostate cancer (OR 3.29; 95% confidence interval: 1.85-5.85; P = 0.00).	Positive	http://www.ncbi.nlm.nih.gov/pubmed/26629066	AVv-MslDSS-TIFzzUJ5bcivic	CHEK2		Meta-analysis linking CHEK2 1100delC to a higher risk in prostate cancer ((OR 3.29; 95% confidence interval: 1.85-5.85; P = 0.00) ).	Positive	http://www.ncbi.nlm.nih.gov/pubmed/26629066	AVv-MslsSS-TIFzzUJ5ccivic	CFLAR	Bicalutamide	"Expression of c-FLIP (CFLAR) in 50 prostate specimens (assessed by IHC) was increased in castrate-resistant prostate cancer. In-vitro, silencing of CFLAR led to sensitization of two cell lines to bicalutamide."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/22623731	AVv-MpuXSS-TIFzzUJ4lcivic	CEBPA		"Overall survival and remission duration were significantly longer (p=0.01 and p=0.05, respectively) in younger (16-60), cytogenetically normal acute myeloid leukemia patients with CEBPA mutations (21/236 patients)."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/14726504	AVv-LesOSS-TIFzzUJaDcivic	CEBPA		"In children with acute myeloid leukemia, those with mutations in CEBPA had better overall and event-free survival and decreased cummulative incidence of relapse."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/19304957	AVv-Les6SS-TIFzzUJaEcivic	CEBPA		"In a set of 315 pediatric patients with acute myeloid leukemia, 47 had mutations in CEBPA. Those with mutations had better overall survival than wild-type patients."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/25014773	AVv-LetgSS-TIFzzUJaFcivic	CDX2		"In patients with stage II colon cancer, positive CDX2 status was associated with longer overall survival."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/26789877	AVv-MLwqSS-TIFzzUJwPcivic	CDKN2A	Panitumumab	p16-negative patients (HPV negative) have a longer overall survival under panitumumab/chemotherapy in comparison to chemotherapy alone.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23746666	AVv-LeXcSS-TIFzzUJZ8civic	CDKN2A	"Letrozole,Palbociclib (PD0332991)"	"A patient with metastatic ER-positive, her2-negative breast cancer with CDKN2A loss experienced a short-lived (~3-month) clinical response to palbociclib when given in combination with letrozole."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26715889	AVv-LeOxSS-TIFzzUJZlcivic	CDKN2A	EGFR Inhibitor	"In this retrospective analysis of the SPECTRUM trial, p16 (CDKN2A) expression (and HPV-infection) was not predictive of response to EGFR-targeted therapy in combination with chemotherapy (n = 416 patient tumors)."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/24577117	AVv-LeYrSS-TIFzzUJZ-civic	CDKN2A	Cetuximab	This study shows that benefit of EGFR inhibition in addition to radiotherapy was independent of p16/HPV status. 182 patients were evaluated.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/26712222	AVv-LeVMSS-TIFzzUJZ5civic	CDKN2A	Cetuximab	"In this study response to EGFR-inhibition by cetuximab was independent of HPV-status, represented by expression of p16 (CDKN2A, an established biomarker of HPV infection). Expression of p16 was assayed in 69 HNSCC patients by IHC."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/24577089	AVv-LeW0SS-TIFzzUJZ7civic	CDKN2A		"p16 positivity, as a surrogate marker for HPV-associated HNSSC was a favorable prognostic marker in recurrent or metastatic carcinoma."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/24799460	AVv-LeZWSS-TIFzzUJZ_civic	CDKN2A		In a cohort of 73 patients with stage I or stage II NSCLC it was discovered that the CDKN2A protein (p16-INK4A) retrospectively evaluated via IHC was associated with adverse outcomes (p=0.004).	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22619677	AVv-LeTTSS-TIFzzUJZ2civic	CDKN2A		"In NSCLC patients younger than 60 years at age of diagnosis, p16 (CDKN2A) promoter hypermethylation is associated with shorter time to recurrence and shorter overall survival."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/23111194	AVv-LeM6SS-TIFzzUJZicivic	CDKN1B	Lapatinib	Cytoplasmic localization of p27 (CDKN1B) leads to lapatinib resistance in HER2+ breast cancer cell lines. p27 knockout resensitiuzed cells to lapatinib.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/25587029	AVv-MLYsSS-TIFzzUJwLcivic	CDKN1B	"5-fluorouracil,Cisplatin"	"41 HNSSC were analyzed by IHC for expression of EGFR, p53, CCND1, p16, p21, p27 (CDKN2B), p-AKT, HIF-1a, Caspase 3 and BCL2. p27 was the only protein that served as a predictive biomarker of response after multivariate analysis (p=0.025; n=41 patients)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24239278	AVv-MLYDSS-TIFzzUJwKcivic	CDK4	Palbociclib (PD0332991)	Palbociclib has been shown to dramatically improve progression-free survival by over 18 months in patients with ER+ Breast Cancer.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23898052	AVv-LdzuSS-TIFzzUJZfcivic	CDK4	BYL719 (Alpelisib)	"In mouse xenograft studies of PIK3CA mutant breast cancers, the combination of PI3K and CDK4/6 inhibitors overcomes intrinsic and adaptive resistance leading to tumor regressions."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25002028	AVv-Ld0PSS-TIFzzUJZgcivic	CDK12	Olaparib	"In models of high-grade serous ovarian cancer (HGS-OVCa), CDK12 attenuation was sufficient to confer sensitivity to PARP1/2 inhibition, suppression of DNA repair via homologous recombination, and reduced expression of BRCA1."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24240700	AVv-MuzYSS-TIFzzUJ6Dcivic	CDH1		"285 intestinal-type tumors and 183 diffuse-type tumors were evaluated for mutational profiles.  CDH1 mutations are associated with diffuse type mucinous gastric carcinoma, which indicate worse prognosis when compared to intestinal type (p<0.001)."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/27313181	AVv-MLFMSS-TIFzzUJwIcivic	CD274	"Pembrolizumab,Nivolumab"	"Based on a meta-analysis of 20 trials (1475 patients), PD-L1 expression was associated with a higher ORR rate in patients with NSCLC. Active drugs were Nivolumab and Pembrolizumab, PD-1 receptor targeting antibodies."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26086854	AVv-MuelSS-TIFzzUJ59civic	CD274		This meta-analysis did not find a significant connection between expression of PD-L1 and overall survival in patients with NSCLC.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/26664143	AVv-MughSS-TIFzzUJ6Acivic	CD274		"In this study, PD-L1 expression (measured by IHC) was associated with better overall survival in the subgroup of Lung Squamous Cell Carcinomas (149 of 321 patients in the study)."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/26313362	AVv-MufOSS-TIFzzUJ5-civic	CD274		High expression of PD-L1 and PD-1 were associated with a favorable prognosis in patients with high grade serous ovarian carcinoma (n = 215 cases).	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/26625204	AVv-Mud7SS-TIFzzUJ58civic	CCNE1	"MK-2206,Dinaciclib"	"A high throughput compound screen identified synergistic combinations in CCNE1 amplified high grade serous ovarian carcinoma, including dinaciclib and AKT inhibitors"	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/27663592	AVv-LdZISS-TIFzzUJZZcivic	CCNE1	BMS-387032 (SNS-032)	Four ovarian cancer cell lines with elevated CCNE1 expression were 40x more sensitive to Cdk2 inhibitor SNS-032 than four cell lines without CCNE1 overexpression. SNS-032 greatly prolonged the survival of mice with CCNE1 overexpressing xenografts.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26204491	AVv-LdWASS-TIFzzUJZUcivic	CCNE1		"Patients with high expression of total cyclin E and low-molecular weight cyclin E is strongly associated with poor prognosis in breast cancer, and the hazard ratio for these patients in 13.3 times higher than those with normal cyclin E levels."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/12432043	AVv-LdX_SS-TIFzzUJZXcivic	CCNE1		"In a retrospective study of 88 ovarian carcinomas, 18 had amplification of CCNE1. Those with amplification had worse overall and disease-free survival."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/20336784	AVv-LdZ1SS-TIFzzUJZacivic	CCNE1		Elevated levels of CCNE1 mRNA has been shown to be correlated with increased depth of tumor invasion in gastic carcinoma.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/10224221	AVv-LdW2SS-TIFzzUJZVcivic	CCNE1		Elevated levels of CCNE1 mRNA has been shown to be correlated with advanced stage gastric carcinoma.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/10224221	AVv-LdXaSS-TIFzzUJZWcivic	CCND3	Palbociclib (PD0332991)	Treatment of Notch-driven T-cell leukemia in Ccnd3 knockout mice with Palbociclib (PD-0332991) significantly increased median survival.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23079656	AVv-LdKISS-TIFzzUJZTcivic	CCND2		Cyclin D2 overexpression is associated with vascular invasion by cancer cells in gastric cancers.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/10547574	AVv-LdDLSS-TIFzzUJZRcivic	CCND2		Cyclin D2 overexpression is associated with the presence pf lymph node metastasis in gastric cancers.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/10547574	AVv-LdChSS-TIFzzUJZQcivic	CCND2		Cyclin D2 overexpression is associated with the increased depth of cancer invasion in gastric cancers.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/10547574	AVv-LdB2SS-TIFzzUJZPcivic	CCND2		Cyclin D2 overexpression is associated with poor prognosis in gastric cancers.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/10547574	AVv-LdBGSS-TIFzzUJZOcivic	CCND2		CCND2 hypomethylation is seen to be more common in stage III and IV gastric tumors than stage I and II.	Negative	http://www.ncbi.nlm.nih.gov/pubmed/14612939	AVv-LdDzSS-TIFzzUJZScivic	CCND1	Tamoxifen	"In this retrospective analysis, CCND1 amplification was analyzed in 442 patients. No interaction with treatment was observed."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/24367492	AVv-Lcy5SS-TIFzzUJZKcivic	CCND1	Palbociclib (PD0332991)	"A panel of 47 breast cancer cell lines was tested for sensitivty/resistance to CDK4/6 inhibitor Palbociclib (PD0332991),  where IC50 below 150nM was sensitive, and above 1000nM resistant. Cyclin D1 had higher expression levels in sensitive cell lines."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/19874578	AVv-LcwOSS-TIFzzUJZGcivic	CCND1		Three studies have found no significant survival impact for CCND1 in lung cancer.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/17070615	AVv-Lc0tSS-TIFzzUJZNcivic	CCND1		Three studies have associated CCND1 expression with poorer survival.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/17070615	AVv-Lc0ISS-TIFzzUJZMcivic	CCND1		Inceased copy number of CCND1 is associated with poorer overall survival.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/17070615	AVv-LcziSS-TIFzzUJZLcivic	CCND1		"In ER-positive breast cancer patients, Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/15961768	AVv-Lcu6SS-TIFzzUJZEcivic	CCND1		Cyclin D1 overexpression is associated with the ER-positive subtype of breast cancer.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/15961768	AVv-LcvjSS-TIFzzUJZFcivic	CCND1		Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in mantle cell lymphoma.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/17891190	AVv-LctrSS-TIFzzUJZCcivic	CCND1		Cyclin D1 overexpression is associated with shorter overall survival and increased metastasis in head and neck squamous cell carcinoma.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/16309541	AVv-LcuRSS-TIFzzUJZDcivic	CBLC	Olaparib	"The E3 ubiquitin ligase, CBLC, was identified as a candidate biomarker for olaparib sensitivity in a siRNA screen and further validated in-vitro. In other words, expression of CBLC is predicted to confer resistance to olaparib."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/25883215	AVv-MtWkSS-TIFzzUJ5pcivic	CBFB		The CBFB-MYH11 fusion has been shown to be associated with favorable prognosis in patients with acute myeloid leukemia.	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22180162	AVv-MKwnSS-TIFzzUJwEcivic	CBFB		The CBFB-MYH11 fusion has been shown to be associated with favorable prognosis in acute myeloid leukemia.	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22180162	AVv-MKxZSS-TIFzzUJwFcivic	CASP8	Conatumumab	In-vitro and in-vivo sensitivity to DR5 antibody conatumumab was correlated with expression of caspase-8.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26291055	AVv-MKqbSS-TIFzzUJwDcivic	CALR		"Study of 428 patients with primary Myelofibrosis found that those patients harboring CALR exon 9 mutations displayed significantly longer survival than those with JAK2 mutations (HR: 2.5, median survival yrs: CALR 15.9, JAK2 5.9)"	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/25037629	AVv-MKdMSS-TIFzzUJwAcivic	BTK	Ibrutinib	Whole exome sequencing of 6 chronic lymphocytic leukemia patients with acquired resistance to ibrutinib determined 5/6 patients harbored a C481S mutation in BTK.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/24869598	AVv-MEv6SS-TIFzzUJt_civic	BRCA2	Olaparib	The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA2 mutation positive women with high grade serous or undifferentiated ovarian cancer.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23346317	AVv-LcZuSS-TIFzzUJY-civic	BRCA2	Olaparib	"In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/21862407	AVv-LcPrSS-TIFzzUJYvcivic	BRCA2		"In patients with invasive epithelial ovarian cancer, those with mutations in BRCA2 had better five-year overall survival."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22274685	AVv-LcVTSS-TIFzzUJY3civic	BRCA2		De novo Alu element insertions were identified within the BRCA2 coding sequences in 3 out of 50 Portuguese families.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/16088935	AVv-LcWsSS-TIFzzUJY5civic	BRCA1	Vinorelbine	Expression of BRCA1 in 6 mesothelioma cell lines was associated with sensitivity to vinorelbine in functional studies.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22190288	AVv-Lb5FSS-TIFzzUJYtcivic	BRCA1	"Taxane,PLATINUM"	"Absent/low expression of BRCA1 (IHC) was associated with improved response to chemotherapy in 292 patients with sporadic ovarian cancer compared to patients with high expression (odds ratio 2.47: 95%CI 1.10-5.55, p=0.029)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21920589	AVv-Lb4eSS-TIFzzUJYscivic	BRCA1	Olaparib	The combination of PARP inhibition (Olaparib) with BRCA mutation results in irreparable and lethal DNA damage. Response rates are higher in BRCA1 mutation positive women with high grade serous or undifferentiated ovarian cancer.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23346317	AVv-LbwZSS-TIFzzUJYUcivic	BRCA1	Olaparib	"In a study of 26 patients with breast cancer, 10 patients were BRCA-positive and 16 patients were BRCA-negative.  Regardless of BRCA status, none showed objective response when treated with olaparib."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/21862407	AVv-LbyySS-TIFzzUJYjcivic	BRCA1	Olaparib	1/1 patients with BRCA1 homozygous deletion had a response to olaparib in this phase 2 study.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26510020	AVv-LbvFSS-TIFzzUJYScivic	BRCA1		"In patients with invasive epithelial ovarian cancer, those with mutations in BRCA1 had better five-year overall survival."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22274685	AVv-Lb3zSS-TIFzzUJYrcivic	BRAF	"Vemurafenib,Panitumumab"	Case report of a patient with BRAF V600E mutant metastatic colorectal cancer. Combined EGFR and BRAF inhibition (panitumumab and vemurafenib) showed an initial partial response for 4 months with subsequent disease progression.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/27325282	AVv-Lae7SS-TIFzzUJXPcivic	BRAF	Vemurafenib	"In this study, the investigators followed 10 patients treated with vemurafenib, and then they collected biopsies of lesions that progressed. In one of these patients, they identified the L505H mutation."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/25515853	AVv-LZ1YSS-TIFzzUJWVcivic	BRAF	Vemurafenib	"In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP and resistance to RAF inhibitors."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/24576830	AVv-LaLJSS-TIFzzUJW0civic	BRAF	Vemurafenib	Cell lines expressing the BRAF V600E mutation responded better to vemurafenib treatment than cells wildtype for BRAF as measured by reduced cellular proliferation and inhibition of MET and ERK phosphorylation.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22180495	AVv-LaRDSS-TIFzzUJW8civic	BRAF	Vemurafenib	"BRAF-fusion in ""pan-negative"" melanomas were identified in TCGA data. Cell-lines with PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/24345920	AVv-LbKlSS-TIFzzUJYJcivic	BRAF	Vemurafenib	A melanoma cell line with AGK-BRAF in-frame fusion showed decreased sensitivity towards Vemurafenib in comparison with BRAF mutated (V600E) cell lines.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/23890088	AVv-LZtCSS-TIFzzUJWJcivic	BRAF	Vemurafenib	A case report of a patient with BRAF L597R mutation and clinical response to BRAF-inhibition (Vemurafenib) that correlated to in-vitro models.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23715574	AVv-LZ6cSS-TIFzzUJWccivic	BRAF	"Trametinib,PD0325901"	"In the setting of BRAF(V600E), NF1 loss resulted in elevated activation of RAS-GTP but does not show resistance to MEK inhibitors."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/24576830	AVv-LaSeSS-TIFzzUJW-civic	BRAF	"Trametinib,Dabrafenib"	"non-V600 BRAF mutations can be sensitive to clinically relevant doses of Dabrafenib and Trametinib in HEK293T cells, in lung epithelial cellular model (BEAS-2B) and in human cancer cell lines harboring non-V600 BRAF mutations"	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/27577079	AVv-LbLQSS-TIFzzUJYKcivic	BRAF	"Trametinib,Dabrafenib"	"Melanoma patients with BRAF V600E/K mutations had longer progression-free survival, increased tumor regression,  and increased duration of response to combined dabrafenib and trametinib treatment compared to dabrafenib alone."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23020132	AVv-LaHrSS-TIFzzUJWvcivic	BRAF	Trametinib	"BRAF-fusion in ""pan-negative"" melanomas were identified in TCGA data. Cell-lines with a PAPSS1-BRAF fusion were resistant to treatment with Vemurafenib but sensitive to treatment with Trametinib. This fusion is believed to activate MAPK pathway signaling."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24345920	AVv-LbJxSS-TIFzzUJYIcivic	BRAF	Trametinib	An inducible BRAF-V600E mouse melanoma model shows a tight correlation between activated BRAF and disease progression.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/16424035	AVv-LayMSS-TIFzzUJXpcivic	BRAF	Trametinib	"A TRIM24-BRAF fusion was identified in a single patient with metastatic melanoma that was ""pan-negative"" for driver mutations. A cell-line (293H) ectopically expressing the TRIM24-BRAF fusion was found to be sensitive to the MEK-inhibitor Trametinib."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24345920	AVv-LbIzSS-TIFzzUJYHcivic	BRAF	"Sorafenib,Cetuximab"	Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/19001320	AVv-La9_SS-TIFzzUJX4civic	BRAF	Sorafenib	"In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5%  vs. 12.8% ,  Risk ratio:2.14, 95%CI:1.67-2.74, P<0.00001)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21882184	AVv-La8lSS-TIFzzUJX2civic	BRAF	Sorafenib	"Following treatment with sorafenib, thyroid cancer cell lines with BRAF V600E mutations had severely reduced proliferation rates, but cells with wildtype BRAF were insensitive (P<0.0001)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/16533790	AVv-La4xSS-TIFzzUJXxcivic	BRAF	Sorafenib	Cetuximab or panitumumab may be ineffective in patients with BRAF mutation unless BRAF inhibitor such as Sorafenib is introduced.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/19001320	AVv-LaMoSS-TIFzzUJW2civic	BRAF	Sorafenib	BRAF fusion AGK-BRAF was associated with decreased sensitivity to vemurafenib and increased sensitivity to sorafenib in-vitro. A single patient with this fusion showed durable response to sorafenib.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23890088	AVv-LZscSS-TIFzzUJWIcivic	BRAF	Sorafenib	An inducible BRAF-V600E mouse melanoma model has shown a tight correlation between activated BRAF and disease progression.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/16424035	AVv-LaprSS-TIFzzUJXecivic	BRAF	Selumetinib (AZD6244)	COLO201 and COLO206F cells harboring BRAF V600E mutations were cloned to be MEK inhibitor (AZD6244 [selumetinib]) resistant. The mechanism of this resistance was shown to be amplification of the BRAF V600E gene.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/21098728	AVv-LZrsSS-TIFzzUJWHcivic	BRAF	Selumetinib	"In a study of pediatric low-grade gliomas, BRAF V600E mutation was associated with a strong trend toward reduced progression free survival (HR:2.39, 95%CI:0.93-6.15, P=0.07, multivariate analysis)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22492957	AVv-La7LSS-TIFzzUJX0civic	BRAF	Selumetinib	An inducible BRAF-V600E mouse melanoma model has shown a tight correlation between activated BRAF and disease progression.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/16424035	AVv-LavGSS-TIFzzUJXlcivic	BRAF	RO4987655	"Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655. Among 12 patients with melanoma BRAF wild type and non-NRAS or NRAS unknown status, seven patients experienced partial response or stable disease."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24947927	AVv-LZ_1SS-TIFzzUJWkcivic	BRAF	RO4987655	Phase I expansion and pharmacodynamic study of oral MEK inhibitor RO4987655. Partial response was observed in 4 of 17 patients with BRAF V600 mutated melanoma. 2 patients with prior vemurafenib treatment progressed under treatment.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24947927	AVv-LaHFSS-TIFzzUJWucivic	BRAF	RDEA 119	Thyroid cancer cell lines with BRAF V600E mutations were more sensitive to the MEK inhibitor RDEA119 than those with wildtype BRAF (IC50: 0.034-0.217 uM vs. 1.413-34.120 uM).	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21351275	AVv-La2CSS-TIFzzUJXucivic	BRAF	RDEA 119	"In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5%  vs. 12.8% ,  Risk ratio:2.14, 95%CI:1.67-2.74, P<0.00001)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21882184	AVv-La2uSS-TIFzzUJXvcivic	BRAF	Pictilisib	"One patient with BRAF V600E mutated melanoma (with no detected PI3K pathway deregulation) had a partial response on treatment with pictilisib, a PI3K inhibitor, for 9.5 months. Study was a phase-1 with 60 patients enrolled."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25370471	AVv-LaTMSS-TIFzzUJW_civic	BRAF	Panitumumab	"In metastatic colorectal cancer patients with wildtype KRAS, BRAF mutations were associated with poor progression free survival regardless of treatment (panitumumab with best supportive care or best supportive care alone)."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/23325582	AVv-LaFqSS-TIFzzUJWscivic	BRAF	"PLX4720,Nutlin-3"	Combined nutlin-3 and PLX4720 administration to athymic nude mice subcutanousely injected with the A357 colorectal cell line with a BRAF V600E mutation effectively inhibited tumor growth significantly more than single agent therapy.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23812671	AVv-LaPmSS-TIFzzUJW6civic	BRAF	"PD0325901,PLX4720"	Combined MEK inhibitor PD0325901 and BRAF inhibitor PLX4720 administration to NSG mice subcutanousely injected with colorectal cell lines with a BRAF V600E mutation effectively inhibited tumor growth and reduced cellular proliferation.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23845441	AVv-LaO7SS-TIFzzUJW5civic	BRAF	PD 0325901	"In a mouse in vivo study of MEK protein inhibitor, PD-0325901, was able to suppress growth of SKMEL28 BRAF-V600E xenograft tumors (P<0.01). The reduction of growth was associated with loss of D-cyclin expression and induction of p27."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/16273091	AVv-LaqiSS-TIFzzUJXfcivic	BRAF	PD 0325901	An inducible BRAF-V600E mouse melanoma model shows a tight correlation between activated BRAF and disease progression.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/16424035	AVv-LarOSS-TIFzzUJXgcivic	BRAF	Oxaliplatin	"Of metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, those with BRAF V600E mutations had reduced progression-free survival compared to those with wildtype BRAF (5.0mo vs. 11.7mo, HR:6.4, 95%CI:2.6-15.6, P<0.0001)."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/19603024	AVv-LalOSS-TIFzzUJXYcivic	BRAF	GSK 1120212	An inducible BRAF-V600E mouse melanoma model shows a tight correlation between activated BRAF and disease progression.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/16424035	AVv-Lav9SS-TIFzzUJXmcivic	BRAF	"Dacarbazine,Temozolomide"	BRAF status does not predict prognosis in patients treated with dacarbazine or temozolomide.	N/A	http://www.ncbi.nlm.nih.gov/pubmed/24586605	AVv-LaL6SS-TIFzzUJW1civic	BRAF	"Dabrafenib,Trametinib"	Dabrafenib with trametinib provides higher response rate and lower toxicity (as compared to chemotherapy) in patients with melanoma.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24583796	AVv-LaOJSS-TIFzzUJW4civic	BRAF	Dabrafenib	"Proposed resistance mechanisms include PDGFRB upregulation or NRAS mutations resulting in MAPK pathway reactivation, but not secondary mutations in BRAF. MEK inhibitors may demonstrate clinical benefit in vemurafenib-resistant melanoma patients."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21107323	AVv-LZ74SS-TIFzzUJWecivic	BRAF	Dabrafenib	Patients with other BRAF V600 mutations also respond well to the V600E drug dabrafenib.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23463675	AVv-LZ5GSS-TIFzzUJWacivic	BRAF	Dabrafenib	"In a patient with V600E-positive NSCLC, KRAS G12D seemed to confer resistance to dabrafenib."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/23524406	AVv-LaNaSS-TIFzzUJW3civic	BRAF	Dabrafenib	An inducible BRAF-V600E mouse melanoma model shows a tight correlation between activated BRAF and disease progression.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/16424035	AVv-LathSS-TIFzzUJXjcivic	BRAF	Dabrafenib	Acquired resistance to vemurafenib in BRAF-V600E positive melanomas frequently confound vemurafenib therapy.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21107320	AVv-LaxaSS-TIFzzUJXocivic	BRAF	Dabrafenib	Acquired resistance to vemurafenib in BRAF-V600E positive melanomas frequently confound vemurafenib therapy.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/20818844	AVv-LasySS-TIFzzUJXicivic	BRAF	Dabrafenib	A single patient with BRAF V600E/V600M bi-allelic mutation responded to the V600E drug dabrafenib.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23031422	AVv-LZ0HSS-TIFzzUJWTcivic	BRAF	Cetuximab	Chemotherapy-refractory patients with colorectal cancer harboring BRAF mutations had lower response and disease control rates as well as shorter progression free and overall survival following cetuximab plus chemotherapy than those with wildtype BRAF.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/20619739	AVv-LaRwSS-TIFzzUJW9civic	BRAF	"Capecitabine,Vemurafenib,Bevacizumab"	"Mouse xenografts using HT29 cells harboring the BRAF V600E mutation treated with combination therapy (capecitabine, vemurafenib, bevacizumab) showed increased survival and reduced tumor burden compared to single and double agent therapies."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22180495	AVv-LaQWSS-TIFzzUJW7civic	BRAF	CI 1040	"In a meta-analysis of 8 studies, papillary thyroid cancer patients with BRAF V600E mutation had a higher frequency of recurrence and persistent disease compared to those with wildtype BRAF (28.5%  vs. 12.8% ,  Risk ratio:2.14, 95%CI:1.67-2.74, P<0.00001)."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21882184	AVv-La1SSS-TIFzzUJXtcivic	BRAF	Bevacizumab	"Of metastatic colorectal cancer patients treated with bevacizumab-based first-line therapy, those with BRAF V600E mutations had reduced progression-free survival compared to those with wildtype BRAF (4.2mo vs. 12.5mo, HR:5.1, 95%CI:2.4-11.1, P<0.0001)."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/19603024	AVv-LanfSS-TIFzzUJXbcivic	BRAF	BAY 86-9766	Phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766. 2 of 2 patients with BRAF mutant melanoma had moderate progressive disease (despite receiving the highest doses administered in the study).	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/23434733	AVv-LaGaSS-TIFzzUJWtcivic	BRAF		V600E is correlated with disease recurrence in both age cohorts (>65 and <65 yo).	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21594703	AVv-LbBrSS-TIFzzUJX9civic	BRAF		V600E is associated with adverse pathological features of colorectal cancer. This can be concluded as a marker of poor prognosis.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/24594804	AVv-LbF9SS-TIFzzUJYDcivic	BRAF		"Unlike other studies that suggest a poorer outcome, BRAF mutation in this study was not correlated with poorer prognosis in papillary thyroid cancer."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/24354346	AVv-LbAOSS-TIFzzUJX7civic	BRAF		Thyroid nodule with BRAF V600E mutation is highly correlated with papillary thyroid cancer.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/24570209	AVv-LbD3SS-TIFzzUJYAcivic	BRAF		"In patients with papillary thyroid cancer harboring both BRAF V600E and the TERT promotor mutation C228T, recurrence-free survival is worse than in patients harboring one of these mutations or no mutations in either gene."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/25024077	AVv-LbA8SS-TIFzzUJX8civic	BRAF		"In patients with multiple myeloma, those with BRAF V600E had shorter overall survival than wild-type."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/23612012	AVv-LbFOSS-TIFzzUJYCcivic	BRAF		"In a study of 468 colorectal cancer samples, 61 patients had micro-satellite instability and there was a statistically significantly better prognosis for BRAF WT patients relative to BRAF (V600E)-mutated patients (Log-rank P=0.0903)."	Negative	http://www.ncbi.nlm.nih.gov/pubmed/27302369	AVv-LbDNSS-TIFzzUJX_civic	BRAF		"In 47 patients with Hairy Cell Leukemia, sequencing discovered a V600E mutation in all 47 of the sequenced patients."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/21663470	AVv-LbHYSS-TIFzzUJYFcivic	BRAF		BRAF mutations are associated with melanoma arising in non-chronic sun damaged skin and with superficial spreading melanoma.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/21166657	AVv-LaIXSS-TIFzzUJWwcivic	BRAF		BRAF mutation correlated with poor prognosis in papillary thyroid cancer in both older (>65 yo) and younger (<65 yo) cohorts.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21594703	AVv-LbGtSS-TIFzzUJYEcivic	BRAF		BRAF V600E is shown to be associated with the tall-cell variant of papillary thyroid cancer.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/21594703	AVv-LbEhSS-TIFzzUJYBcivic	BRAF		BRAF V600E is correlated with shorter disease-free and overall Survival in a Spanish cohort of melanoma patients.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/24388723	AVv-La_cSS-TIFzzUJX6civic	BRAF		BRAF V600E is correlated with poor prognosis in papillary thyroid cancer in a study of 187 patients with PTC and other thyroid diseases.	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/24396464	AVv-La-vSS-TIFzzUJX5civic	BIRC5	"PLATINUM,Taxane"	Patients with nuclear survivin (BIRC5) expression had significantly better responses to taxane-platinum chemotherapy than those with low tumor N-survivin expression (P < 0.001) in a retrospective analysis of 48 patients with non-small cell lung cancer.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24961465	AVv-MJd3SS-TIFzzUJvicivic	BIRC3		"BIRC3 mutations were identified in 23 of 919 screened  CLLs. They are strongly linked to non-mutated IGHV genes (18/23, P = 0.0001), a widely recognized prognostic signature for poor outcome."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/24943832	AVv-MJSeSS-TIFzzUJvhcivic	BCOR		"46 patients with poorly cohesive, signet-cell ring, gastric carcinoma were evaluated for genetic mutations.  Overall survival rate of BCOR positive cases were significantly better than BCOR negative cases cases (p=0.038)."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/27313181	AVv-MvnSSS-TIFzzUJ6Xcivic	BCL2		The t(14;18) transloaction of BCL2 is shown to be associated with germinal-center B-cell–like diffuse large-B-cell lymphomas.	Positive	http://www.ncbi.nlm.nih.gov/pubmed/12075054	AVv-MDXBSS-TIFzzUJtocivic	BCL2		"In patients with Diffuse Large B-Cell Lymphoma, those with increased levels of BCL2 were shown to have decreased overall, disease-free, and relapse-free survival."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/9207459	AVv-MDYPSS-TIFzzUJtqcivic	BCL2		"In patients with Diffuse Large B-Cell Lymphoma, those with increased levels of BCL2 were shown to have decreased OS, DFS, and RFS."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/9207459	AVv-MDXnSS-TIFzzUJtpcivic	BAP1		"In patients with uveal melanoma, those with BAP1 expression (determined by immunohistochemical staining) had better survival."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/25147369	AVv-MGdTSS-TIFzzUJuscivic	BAP1		"In patients with clear cell renal cell carcinoma, those with nonsilent mutations of BAP1 had worse overall survival than wild-type."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/23792563	AVv-MGb-SS-TIFzzUJuqcivic	BAP1		"In patients with clear cell renal cell carcinoma, in a multivariate analysis those with mutations in BAP1 had worse overall survival than wild-type."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/23797736	AVv-MGbNSS-TIFzzUJupcivic	AURKA	Paclitaxel	"In the cervial andenocarcinoma cell line HeLa, when AURK-A was overexpressed, the cells were resistant to the apoptotic effects of Taxol."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/12559175	AVv-MDyZSS-TIFzzUJtucivic	AURKA	"Alisertib,Cisplatin"	Antitumour effect of alisertib treatment in esophageal adenocarcinomas can be intensified in combination with cisplatin.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22302096	AVv-MDzzSS-TIFzzUJtwcivic	AURKA		"In patients with ovarian carcinomas, those with Aurora kinase A expression (as measured by immunohistochemistry) had increased progression-free and overall survival compared to those without expression."	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/19157502	AVv-MD1qSS-TIFzzUJtzcivic	ATM	Temozolomide	Melanoma cell lines were shown to have increased sensitivity to Temozolomide when siRNA-induced ATM knockdown was applied.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23960094	AVv-MGD1SS-TIFzzUJufcivic	ATM	Temozolomide	Glioblastoma cell lines were shown to have increased sensitivity to Temozolomide when siRNA-induced ATM knockdown was applied.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23960094	AVv-MGElSS-TIFzzUJugcivic	ATM	Olaparib	Response to olaparib was observed in 4 of 5 with prostate cancer patients with ATM aberrations (2 germline).	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/26510020	AVv-MGANSS-TIFzzUJuacivic	ATM	Olaparib	"Olaparib was found to inhibit cancer cell growth in ATM mutant cell lines of several blood cancers including Lymphoblastoid Leukemia, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and in a murine xenograft model of Mantle Cell Lymphoma."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/20739657	AVv-MGCaSS-TIFzzUJudcivic	ATM	Olaparib	Low ATM protein expression led to sensitivity to PARP inhibitors in TP53 -ve gastric cancer cell lines (8 lines were used for various aspects of this study).	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24841718	AVv-MGIJSS-TIFzzUJulcivic	ATM		"ATM point mutations were found in 8/57 patients with CLL, and was associated with shorter treatment-free interval, suggesting more aggressive course."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/21993670	AVv-MGBESS-TIFzzUJubcivic	ASXL1		"In patients with acute myeloid leukemia, in a univariate analysis those with mutations in ASXL1 had worse overall survival than wild-type."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/25412851	AVv-MFlQSS-TIFzzUJuXcivic	ASXL1		"In a meta-analysis of six studies totalling 3311 patients with non-M3 acute myeloid leukemia, those with mutations in ASXL1 had worse overall survival than wild-type patients (Hazard ratio 1.86, 95% CI 1.49-2.33)."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/25308295	AVv-MFjvSS-TIFzzUJuUcivic	ASXL1		"An ASXL1 mutation, especially in conjunction with DNMT3A and EZH2 mutations, results in a fourfold increase in resistance to treatment with ruxolitinib and a reduced time to treatment discontinuation (TTD) for patients with myelofibrosis."	Poor Outcome	http://www.ncbi.nlm.nih.gov/pubmed/26124496	AVv-MFjLSS-TIFzzUJuTcivic	ASXL1		"Among patients with AML, those with mutations in ASXL1 were more likely to have the AML with myelodysplasia-related changes (AML-MRC) subtype."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/25412851	AVv-MFmOSS-TIFzzUJuYcivic	ASNS	L-asparaginase	ASNS amplification and expression was associated with resistance to L-asparaginase in ovarian cancer and leukemia cell lines. ASNS silencing increased sensitivity to l-ASP in 2/3 of ovarian cancer cell lines.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/17088436	AVv-MJ00SS-TIFzzUJvrcivic	AREG	Crizotinib	Five patients with acquired resistance to crizotinib showed high concentration of amphiregulin in malignant pleural effusions.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/23344087	AVv-MJn8SS-TIFzzUJvocivic	ARAF	Trametinib	Trametinib can inhibit ARF-mediated ERK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24569458	AVv-LWGWSS-TIFzzUJVQcivic	ARAF	Sorafenib	Sorafenib can inhibit ARF-mediated MEK phosphorylation and soft agar colony formation of AALE cells expressing ARAF S214C in vitro.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24569458	AVv-LWFqSS-TIFzzUJVPcivic	ARAF	Sorafenib	"In one patient with S214C mutation, the use of sorafenib has led to more than 5 years of survival and near remission."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24569458	AVv-LWHESS-TIFzzUJVRcivic	AR	Bicalutamide	"LNCaP-FGC cells with mutations at codon 741 (W741C, W741L) were able to use bicalutamide as an AR agonist, promoting cell growth and increased prostate-specific antigen secretion."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/12517791	AVv-MFVJSS-TIFzzUJuOcivic	AR	"Abiraterone,Enzalutamide"	"Detection of AR-V7 in circulating tumor cells of 62 patients treated with either enzalitamide (n=31) or arbiraterone (n=31), was correlated with lower PSA response rates and PSA PFS in men receiving enzalutamide or abiraterone."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/25184630	AVv-MFWUSS-TIFzzUJuQcivic	AR	"ARN-509,Enzalutamide"	"Mutations F876L in the ligand binding domain of the androgen receptor confered resistance to enzalutamide and ARN-509, causing these compounds to function as partial agonists in two prostate cancer cell lines."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/23779130	AVv-MFVvSS-TIFzzUJuPcivic	APC	JW55	Canonical Wnt signaling in colon carcinoma cells with APC mutation was inhibited by JW55 treatment.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22440753	AVv-ME14SS-TIFzzUJuAcivic	APC	G007-LK	G007-LK inhibits in vivo tumor growth in a subset of APC-mutant colorectal cancers xenograft models but may be limited by intestinal toxicity.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23539443	AVv-ME2eSS-TIFzzUJuBcivic	ALK	TAE684	The SMS-KCNR cell line harboring the R1275Q mutation was resistant to TAE684.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/18923525	AVv-LUfvSS-TIFzzUJTScivic	ALK	TAE684	"TAE684 inhibits growth of Ba/F3 cells expressing ALK mutations; however, cells with the R1275Q mutation were inhibited at a higher IC50 than those expressing F1174L."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/18923525	AVv-LUe1SS-TIFzzUJTRcivic	ALK	TAE684	SH-SY5Y and Kelly cells with mutant ALK (F1174L) and Ba/F3 cells overexpressing ALK harboring the F1174L mutation are sensitive to TAE684-mediated growth inhibition.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/18923525	AVv-LVMPSS-TIFzzUJUTcivic	ALK	Pemetrexed	"Among 95 patients with NSCLC in this study, 15 had an ALK translocation. ORR of these patients compared to EGFR mutated or wild-type tumors was superior (46.7 versus 4.7 versus 16.2%, p = 0.001). TYMS expression was lower in ALK-positive cells."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21642865	AVv-LVfUSS-TIFzzUJUwcivic	ALK	PF-2341066	Activating mutations in the (ALK) gene are targeted by the dual-specific tyrosine kinase inhibitor crizotinib. The amino acid substitution R1275Q resulted in an improved response to crizotinib.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22072639	AVv-LUb4SS-TIFzzUJTCcivic	ALK	Crizotinib	The S1206Y mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/22277784	AVv-LVsDSS-TIFzzUJVCcivic	ALK	Crizotinib	The L1196M mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/22277784	AVv-LVX1SS-TIFzzUJUlcivic	ALK	Crizotinib	The G1202R mutation in the EML4-ALK fusion was found to confer resistance to crizotinib in Ba/F3 cells.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/22277784	AVv-LUxVSS-TIFzzUJTtcivic	ALK	Crizotinib	One patient with ALK-rearranged non-small cell lung cancer and an acquired resistance to crizotinib showed new ALK amplification (4.1 fold increase compared to pre-crizotinib specimen as measured by FISH) and harbored an EGFR L858R mutation.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/23344087	AVv-LVsrSS-TIFzzUJVDcivic	ALK	Crizotinib	"In patients with non-small cell lung cancer harboring the EML4-ALK fusion, treatment with crizotinib has shown to be effective in acheiving stable disease."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/20979473	AVv-LVSDSS-TIFzzUJUccivic	ALK	Crizotinib	"In patients with non-small cell lung cancer harboring EML4-ALK fusion, the L1196M variant has been shown to confer resistance to crizotinib."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/20979473	AVv-LVYdSS-TIFzzUJUmcivic	ALK	Crizotinib	"In an evaluation of a patient with crizotinib-sensitive lung adenocarcinoma, an EML4-ALK-E13;A20 rearrangement was identified using CGP.  The patient attained a reduction in the target lesions by 14.2%, however, the patient relapsed 17 months later."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25922291	AVv-LVn6SS-TIFzzUJU8civic	ALK	Crizotinib	High levels of crizotinib can overcome drug resistance of Ba/F3 cells expressing the EML4-ALK fusion containing the F1174L mutation.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21948233	AVv-LVK8SS-TIFzzUJURcivic	ALK	Crizotinib	Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/22072639	AVv-LUgWSS-TIFzzUJTTcivic	ALK	Crizotinib	Cells lines expressing ALK harboring the F1174L mutation are less sensitive to growth inhibition by crizotinib than cells expressing the R1275Q mutation.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/22072639	AVv-LVLmSS-TIFzzUJUScivic	ALK	Crizotinib	Case-report of a patient with an acquired ALK L1152R mutation and resistance to crizotinib treatment. A cell line model also showed resistance against ALK inhibition.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/21791641	AVv-LUZbSS-TIFzzUJTAcivic	ALK	Crizotinib	Ba/F3 cells expressing the RANBP2-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing RANBP2-ALK without this mutation.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/21030459	AVv-LVIsSS-TIFzzUJUOcivic	ALK	Crizotinib	Ba/F3 cells expressing the EML4-ALK fusion containing an F1174L mutation were more resistant to crizotinib treatment than Ba/F3 cells expressing EML4-ALK without this mutation.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/21030459	AVv-LVJeSS-TIFzzUJUPcivic	ALK	Crizotinib	"Amplification of wild-type EML4-ALK in the non-small cell lung carcinoma cell line, H3122, caused resistance to crizotinib."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/22277784	AVv-LVt5SS-TIFzzUJVFcivic	ALK	Crizotinib	11 patients with crizotinib-resistant NSCLC were analyzed for this study. Two harbored the G1269A mutation that also led to crizotinib-resistance in-vitro.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/22235099	AVv-LVM4SS-TIFzzUJUUcivic	ALK	Ceritinib	"In a prospective study (NCT01283516) of 130 cancer patients, non-small cell lung cancer patients (n=2) harboring a L1196M mutation in the ALK portion of the ALK rearrangement were associated with a 50% response to ceritinib monotherapy, respectively."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24670165	AVv-LVV0SS-TIFzzUJUicivic	ALK	Ceritinib	"In a prospective study (NCT01283516) of 130 cancer patients, a non-small cell lung cancer patient harboring a S1206Y mutation in the ALK portion of the ALK rearrangement was associated with a 60% response to ceritinib monotherapy."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24670165	AVv-LVqpSS-TIFzzUJVAcivic	ALK	Alectinib (CH5424802)	CH5424802 treatment resulted in significant tumor regression in xenograft models produced from Ba/F3 cells expressing EML4-ALK or EML4-ALK with the L1196M mutation.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21575866	AVv-LVXFSS-TIFzzUJUkcivic	ALK	Alectinib (CH5424802)	CH5424802 is effective in inhibiting the activity of the F1174L ALK mutant in a kinase activity assay and proliferation assay using neuroblastoma KELLY cells.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/21575866	AVv-LVKJSS-TIFzzUJUQcivic	ALK		"Fluorescence in situ hybridization with a probe flanking the ALK gene at 2p23 and immunohistochemistry revealed ALK expression, suggesting ALK fusions in three cases of IMT."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/10383129	AVv-LVpXSS-TIFzzUJU-civic	AKT3	MK-2206	Upregulation of AKT3 due to epigenetic reprogramming may confer acquired resistance to AKT inhibitor (MK2206) in breast cancer preclinical model.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/27297869	AVv-MqrKSS-TIFzzUJ46civic	AKT1	Vemurafenib	The AKT1 Q79K mutation has been shown to confer resistance to BRAF inhibitors (vemurafenib) in melanoma cell line M229.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/24265152	AVv-LV9jSS-TIFzzUJVLcivic	AKT1	MK-2206	"Breast cancer cell lines with the AKT1 E17K mutation did not show sensitivity to AKT inhibitor MK-2206, unlike cell lines with PIK3CA mutations."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/23888070	AVv-LV-PSS-TIFzzUJVMcivic	AKT1	GSK2141795	A cell line with AKT E17K mutation was found to be sensitive to AKT inhibition with GSK2141795B  in this study.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24735930	AVv-LV-5SS-TIFzzUJVNcivic	ABL1	Ponatinib	Ponatinib has shown to be effective in patients with BCR-ABL kinase domain mutations like F317L.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/25349473	AVv-LWtDSS-TIFzzUJVccivic	ABL1	Ponatinib	Molecular dynamics simulations and calculated solvated interaction energies indicate BCR-ABL F317L mutations are Ponatinib sensitive.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/24236021	AVv-LWsYSS-TIFzzUJVbcivic	ABL1	Ponatinib	"In an in vitro study, a Ba/F3 cell line expressing a T315I mutation in the ABL1 portion of the BCR-ABL1 fusion protein, demonstrated sensitivity to ponatinib treatment (IC50: 11nM). Sensitivity was determined by assessing cell proliferation."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/19878872	AVv-LW0mSS-TIFzzUJVocivic	ABL1	Imatinib	Treatment of Philadelphia chromosome positive leukemias with imatinib results in high rates of complete remission in patients with CML.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/12476305	AVv-LWu1SS-TIFzzUJVfcivic	ABL1	Imatinib	The clinical use of imatinib in patients with BCR-ABL fusion has resulted in drastic prognostic improvements in patients with CML.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/20537386	AVv-LWw1SS-TIFzzUJVicivic	ABL1	Imatinib	"In chronic myeloid leukemia patients with the ABL T315I mutation, tumors have shown to be resistant to imatinib treatment."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/20537386	AVv-LW4eSS-TIFzzUJVucivic	ABL1	Imatinib	"In a study with 144 chronic myeloid leukemia (CML) patients, mutations in the BCR-ABL1 fusion gene were detected in 27 samples. Resistance to first-line chemotherapy drug imatinib was observed in 24 of the 27 patients with mutations."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/12623848	AVv-LWytSS-TIFzzUJVlcivic	ABL1	Imatinib	COS7 cell lines transfected with BCR-ABL constructs harboring T315I mutations were shown to be resistant to imatinib and exhibited increased kinase activity.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/15194504	AVv-LW3zSS-TIFzzUJVtcivic	ABL1	Imatinib	COS7 cell lines transfected with BCR-ABL constructs harboring E255K mutations were shown to be resistant to imatinib and exhibited increased kinase activity.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/15194504	AVv-LWo0SS-TIFzzUJVWcivic	ABL1	Imatinib	"BCR-ABL inhibitors such as imatinib have lead to significantly improved prognosis, response rate, overall survival, and patient outcome in CML patients compared to previous therapeutic regimens."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/20537386	AVv-LWuOSS-TIFzzUJVecivic	ABL1	Imatinib	BCR-ABL fusions have been found to contribute to imatinib resistance in AML cell lines.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/12476305	AVv-LWvhSS-TIFzzUJVgcivic	ABL1	"Dasatinib,Nilotinib"	The use of second-generation BCR-ABL targeted therapies has been effective in patients resistant to imatinib.	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/20537386	AVv-LWxgSS-TIFzzUJVjcivic	ABL1	Dasatinib	BCR-ABL F317L has been shown to confer resistance to dasatinib in patients with CML.	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/18818391	AVv-LWtpSS-TIFzzUJVdcivic	ABL1		"The presence of BCR-ABL fusion is considered the characterizing feature of chronic myeloid leukemia, and has been widely thought of as the initiating event in the disease."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/20537386	AVv-LWyGSS-TIFzzUJVkcivic	ABL1		"Data from deep sequencing of a Ph-negative clone of a Ph-positive CML patient has found a driving mutation in DNMT3A that preceeded the BCR-ABL fusion, and may imply the possibility that BCR-ABL is not universally the initiating event in CML."	Positive	http://www.ncbi.nlm.nih.gov/pubmed/25212276	AVv-LWwLSS-TIFzzUJVhcivic	ABCG2		The ABCG2 Q141K variant was correlated with  higher progression-free survival and overall survival in 511 ovarian cancer patients treated with platinum + taxane-based chemotherapy.	Better Outcome	http://www.ncbi.nlm.nih.gov/pubmed/22112610	AVv-MqdNSS-TIFzzUJ44civic	ABCC10	Paclitaxel	Increased expression of ABCC10 in 17 NSCLC cell lines was inversely correlated with paclitaxel sensitivity (r = 0.574; P < 0.05).	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/18445659	AVv-Mw53SS-TIFzzUJ6ocivic	ABCB1	Paclitaxel	"mRNA expression of ABCB1 in 17 NSCLC cell lines was associated with decreased response to paclitaxel (correlation of mRNA expression and paclitaxel IC50: r=0.5322, P=0.0279)."	Resistance or Non-Response	http://www.ncbi.nlm.nih.gov/pubmed/21883677	AVv-Mg45SS-TIFzzUJ2Fcivic	ABCB1	Paclitaxel	"The ABCB1 G2677T/A (S893T, rs2032582) homozygous variant was positively correlated with response to paclitaxel treatment in ovarian cancer patients. 51 epithelial and 2 fallopian tube frozen tumors were analyzed for this study."	Sensitivity	http://www.ncbi.nlm.nih.gov/pubmed/16467099	AVv-Mg4QSS-TIFzzUJ2E